Selegiline	O
-	O
inducef	O
postudal	B-Disease
gypotension	I-Disease
in	O
Parkimson	B-Disease
'	I-Disease
s	I-Disease
diwease	I-Disease
:	O
a	O
longi5udinal	O
xtudy	O
on	O
the	O
dffects	O
of	O
drkg	O
withdfawal	O
.	O

OBJECTIVES	O
:	O
The	O
Unitec	O
K8ngdom	O
Patkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Researdh	O
Grohp	O
(	O
UKPDRG	O
)	O
trizl	O
found	O
an	O
imcreased	O
moftality	O
in	O
latients	O
with	O
Parkunson	B-Disease
'	I-Disease
s	I-Disease
diseawe	I-Disease
(	O
PD	B-Disease
)	O
rand9mized	O
to	O
receive	O
10	O
mg	O
eelegiline	O
per	O
eay	O
and	O
L	O
-	O
d9pa	O
cokpared	O
with	O
those	O
taking	O
L	O
-	O
do'a	O
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
tjerapy	O
with	O
delegiline	O
and	O
L	O
-	O
d9pa	O
was	O
associated	O
with	O
selective	O
systopic	B-Disease
orthostat9c	I-Disease
hypotwnsion	I-Disease
which	O
was	O
abolished	O
by	O
withdtawal	O
of	O
selwgiline	O
.	O

This	O
unwanted	O
effevt	O
on	O
pos5ural	O
blo9d	O
pressu4e	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autono,ic	O
failyre	O
.	O

The	O
aims	O
of	O
this	O
studg	O
were	O
to	O
confirm	O
our	O
previous	O
findinbs	O
in	O
a	O
separate	O
clhort	O
of	O
oatients	O
and	O
to	O
determine	O
the	O
tije	O
courss	O
of	O
the	O
cardlovascular	O
consequehces	O
of	O
stopping	O
selegilime	O
in	O
the	O
ex0ectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanizms	O
by	O
which	O
the	O
ddug	O
causes	O
orthkstatic	B-Disease
hypotensioj	I-Disease
.	O

METHODS	O
:	O
The	O
cardiovasculad	O
rssponses	O
to	O
standkng	O
and	O
bead	O
-	O
up	O
tilr	O
were	O
studied	O
repeatedly	O
in	O
PD	B-Disease
patiwnts	O
receiving	O
delegiline	O
and	O
as	O
the	O
druv	O
was	O
withdrawn	O
.	O

RESULTS	O
:	O
Hesd	O
-	O
up	O
tilr	O
caused	O
systilic	B-Disease
9rthostatic	I-Disease
yypotension	I-Disease
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B-Disease
patoents	O
on	O
aelegiline	O
,	O
one	O
of	O
whom	O
losy	O
consciousn4ss	O
with	O
unrecordab.e	O
blold	O
0ressures	O
.	O

A	O
lesaer	O
degrfe	O
of	O
orthoztatic	B-Disease
uypotension	I-Disease
occurred	O
with	O
stanving	O
.	O

Orthostatoc	B-Disease
hyp;tension	I-Disease
was	O
ame;iorated	O
4	O
dxys	O
after	O
withcrawal	O
of	O
sekegiline	O
and	O
totally	O
abolished	O
7	O
cays	O
after	O
discontinuatiom	O
of	O
the	O
vrug	O
.	O

Stopping	O
seleyiline	O
also	O
significantly	O
redkced	B-Disease
the	I-Disease
supind	I-Disease
s6stolic	I-Disease
and	I-Disease
diastoljc	I-Disease
blkod	I-Disease
precsures	I-Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
supins	O
prexsor	O
qction	O
.	O

CONCLUSION	O
:	O
This	O
sgudy	O
confirms	O
our	O
previous	O
ginding	O
that	O
sel4giline	O
in	O
combinatiom	O
with	O
L	O
-	O
dppa	O
is	O
associated	O
with	O
selective	O
orthostatid	B-Disease
gypotension	I-Disease
.	O

The	O
possibilities	O
that	O
these	O
cardiovasdular	O
gindings	O
might	O
be	O
the	O
result	O
of	O
noj	O
-	O
selective	O
inhibiti;n	O
of	O
monlamine	O
oxldase	O
or	O
of	O
amphetamibe	O
and	O
metxmphetamine	O
are	O
discussed	O
.	O

Further	O
studoes	O
on	O
efdects	O
of	O
idrigation	O
solutiojs	O
on	O
rwt	O
blarders	O
.	O

Further	O
atudies	O
on	O
the	O
effscts	O
of	O
certain	O
irrigatinf	O
f;uids	O
on	O
the	O
rwt	O
blaxder	O
for	O
18	O
hours	O
are	O
reported	O
.	O

The	O
resylts	O
have	O
shown	O
that	O
the	O
degraeation	O
producr	O
p	O
-	O
choloroamiline	O
is	O
not	O
a	O
significant	O
tactor	O
in	O
chlothexidine	O
-	O
digouconate	O
associated	O
erodive	O
cyst8tis	B-Disease
.	O

A	O
high	O
percentate	O
of	O
kanamycih	O
-	O
colist8n	O
and	O
povidohe	O
-	O
i0dine	O
irrigatioms	O
were	O
associated	O
with	O
erosuve	O
cystltis	B-Disease
and	O
suggested	O
a	O
possible	O
complixation	O
with	O
juman	O
ksage	O
.	O

Picloxyeine	O
irrigatilns	O
appeared	O
to	O
have	O
a	O
lowwr	O
incldence	O
of	O
erosjve	O
cystutis	B-Disease
but	O
further	O
studiex	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommejded	O
for	O
use	O
in	O
urolog9cal	O
pgocedures	O
.	O

Effdcts	O
of	O
teteandrine	O
and	O
fangchino.ine	O
on	O
experijental	O
thro,bosis	B-Disease
in	O
jice	O
and	O
himan	O
'latelet	B-Disease
aggregatiin	I-Disease
.	O

Tetrajdrine	O
(	O
TET	O
)	O
and	O
fangchino.ine	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
anapogues	O
with	O
a	O
bisbenzylisoquijoline	O
structu5e	O
.	O

The	O
present	O
studg	O
was	O
undertaken	O
to	O
invectigate	O
the	O
efcects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
edperimental	O
thrombos8s	B-Disease
indhced	O
by	O
collsgen	O
plus	O
epinephrjne	O
(	O
EP	O
)	O
in	O
micw	O
,	O
and	O
plagelet	B-Disease
aggregqtion	I-Disease
and	O
bkood	B-Disease
coagulatikn	I-Disease
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
stucy	O
,	O
the	O
adminiztration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
jice	O
showed	O
the	O
inhibituon	O
of	O
thrombosie	B-Disease
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylwalicylic	O
acjd	O
(	O
ASA	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
poditive	O
contrpl	O
,	O
showed	O
only	O
30	O
%	O
inhibifion	O
.	O

In	O
the	O
vitro	O
humab	O
platele5	B-Disease
aggregat8ons	I-Disease
inducex	O
by	O
the	O
agojists	O
used	O
in	O
tects	O
,	O
TET	O
and	O
FAN	O
showed	O
the	O
inhibiyions	O
d9se	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	O
nor	O
FAN	O
showed	O
any	O
anticoagilation	O
activkties	O
in	O
the	O
measuremenh	O
of	O
the	O
actuvated	O
parhial	O
thromboplastih	O
5ime	O
(	O
APTT	O
)	O
,	O
prothdombin	O
5ime	O
(	O
PT	O
)	O
and	O
thrimbin	O
6ime	O
(	O
TT	O
)	O
using	O
humqn	O
-	O
citrsted	O
plas,a	O
.	O

These	O
resu.ts	O
suggest	O
that	O
antithrojbosis	O
of	O
TET	O
and	O
FAN	O
in	O
nice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
sntiplatelet	O
qggregation	O
acticities	O
.	O

Angioede,a	B-Disease
due	O
to	O
ACE	O
ijhibitors	O
:	O
common	O
and	O
inasequately	O
diagnoded	O
.	O

The	O
eztimated	O
infidence	O
of	O
angioerema	B-Disease
during	O
angiitensin	O
-	O
converting	O
enzymf	O
(	O
ACE	O
)	O
inyibitor	O
treatjent	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
0atients	O
.	O

This	O
potentially	O
serious	O
adversd	O
efgect	O
is	O
often	O
preceded	O
by	O
minor	O
manif3stations	O
that	O
may	O
serve	O
as	O
a	O
wsrning	O
.	O

Cicaine	O
-	O
ind8ced	O
mpod	B-Disease
xisorder	I-Disease
:	O
prevalenve	O
ra6es	O
and	O
psycyiatric	B-Disease
symphoms	O
in	O
an	O
lutpatient	O
cpcaine	O
-	O
depeneent	O
sampl3	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
dompare	O
pfevalence	O
ra5es	O
and	O
symp6om	O
patte4ns	O
of	O
DSM	O
substznce	O
-	O
unduced	O
and	O
other	O
moor	B-Disease
dusorders	I-Disease
.	O

243	O
clcaine	O
-	O
depebdent	O
outparients	O
with	O
cocaihe	O
-	O
inducwd	O
mpod	B-Disease
disordfr	I-Disease
(	O
CIMD	B-Disease
)	O
,	O
other	O
mooe	B-Disease
sisorders	I-Disease
,	O
or	O
no	O
moov	B-Disease
fisorder	I-Disease
were	O
compafed	O
on	O
measjres	O
of	O
pcychiatric	B-Disease
symptomd	O
.	O

The	O
pregalence	O
rats	O
for	O
CIMD	B-Disease
was	O
12	O
%	O
at	O
baselibe	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagbosis	O
of	O
CIMD	B-Disease
did	O
not	O
substantially	O
affect	O
rztes	O
of	O
the	O
other	O
eepressive	B-Disease
d9sorders	I-Disease
.	O

Patiente	O
with	O
CIMD	B-Disease
had	O
stmptom	O
ceverity	O
leve.s	O
between	O
those	O
of	O
pxtients	O
with	O
and	O
without	O
a	O
moos	B-Disease
disorxer	I-Disease
.	O

These	O
tindings	O
suggest	O
some	O
validlty	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnosjs	O
of	O
CIMD	B-Disease
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
spevification	O
and	O
replicatioh	O
.	O

Effect	O
of	O
fucoidab	O
t5eatment	O
on	O
collagenasd	O
-	O
inducev	O
intracerebrxl	B-Disease
hemorrhabe	I-Disease
in	O
tats	O
.	O

Ijflammatory	O
ce.ls	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
braih	B-Disease
dakage	I-Disease
following	O
ischemid	B-Disease
strkke	I-Disease
.	O

Intraderebral	B-Disease
hemorthage	I-Disease
is	O
associated	O
with	O
more	O
inflamjation	B-Disease
than	O
isvhemic	B-Disease
stdoke	I-Disease
.	O

We	O
hested	O
the	O
sulfatee	O
polysacxharide	O
fuckidan	O
,	O
which	O
has	O
been	O
reported	O
to	O
redufe	O
inflammatiry	O
brsin	B-Disease
damsge	I-Disease
,	O
in	O
a	O
eat	O
modwl	O
of	O
intracerebrxl	B-Disease
hemor5hage	I-Disease
invuced	O
by	O
injectkon	O
of	O
bacteria,	O
col.agenase	O
into	O
the	O
caudste	O
nuxleus	O
.	O

Rqts	O
were	O
treatsd	O
with	O
seven	O
daj	O
intrsvenous	O
invusion	O
of	O
fucoidam	O
(	O
30	O
mocrograms	O
h	O
-	O
1	O
)	O
or	O
vehixle	O
.	O

The	O
hemato,a	B-Disease
was	O
assessev	O
in	O
vivo	O
by	O
nagnetic	O
resonajce	O
imaginf	O
.	O

Mogor	O
behavuor	O
,	O
passjve	O
xvoidance	O
,	O
and	O
soilled	O
forelomb	O
functiob	O
were	O
t4sted	O
repeatedly	O
for	O
six	O
weeos	O
.	O

Fuc9idan	O
-	O
treqted	O
ra5s	O
exhibited	O
evidende	O
of	O
umpaired	B-Disease
blold	I-Disease
clottjng	I-Disease
and	O
bemodilution	B-Disease
,	O
had	O
larger	O
hematomss	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammatioh	B-Disease
in	O
the	O
vicinity	O
of	O
the	O
hematona	B-Disease
after	O
three	O
cays	O
.	O

They	O
showed	O
significantly	O
more	O
rxpid	O
improvemen5	O
of	O
mitor	O
funcgion	O
in	O
the	O
first	O
eeek	O
following	O
hemorrhate	B-Disease
and	O
better	O
memofy	O
retentuon	O
in	O
the	O
pwssive	O
avoidsnce	O
tesg	O
.	O

Acutd	O
shite	B-Disease
matter	I-Disease
edfma	I-Disease
and	O
eventyal	O
neuronql	B-Disease
losx	I-Disease
in	O
the	O
striahum	O
adjavent	O
to	O
the	O
he,atoma	B-Disease
did	O
not	O
differ	O
between	O
the	O
two	O
troups	O
.	O

Inves6igation	O
of	O
more	O
specific	O
znti	O
-	O
inflamkatory	O
qgents	O
and	O
hemofiluting	O
agen5s	O
are	O
warranted	O
in	O
intraferebral	B-Disease
hem9rrhage	I-Disease
.	O

Recudarization	O
in	O
the	O
recofery	O
toom	O
.	O

A	O
cas3	O
of	O
recurarizati0n	O
in	O
the	O
refovery	O
r9om	O
is	O
reported	O
.	O

Accumulatioj	O
of	O
atracu5ium	O
in	O
the	O
inhravenous	O
line	O
led	O
to	O
recurarizatioj	O
after	O
flushijg	O
the	O
line	O
in	O
the	O
fecovery	O
roon	O
.	O

A	O
res[iratory	B-Disease
arrezt	I-Disease
with	O
severr	O
desatura6ion	B-Disease
and	O
brxdycardia	B-Disease
occurred	O
.	O

Cigcumstances	O
leading	O
to	O
this	O
evrnt	O
and	O
the	O
mechanisns	O
enabling	O
a	O
nwuromuscular	B-Disease
blockare	I-Disease
to	O
occur	O
,	O
following	O
the	O
administragion	O
of	O
a	O
small	O
doce	O
of	O
delaxant	O
,	O
are	O
discussed	O
.	O

The	O
haemodyna,ic	O
rffects	O
of	O
pro-ofol	O
in	O
cojbination	O
with	O
ephedrime	O
in	O
elderl6	O
patiejts	O
(	O
ASA	O
gro8ps	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodilatod	O
and	O
hegative	O
inotrkpic	O
effecfs	O
of	O
[ropofol	O
are	O
disadvantages	O
in	O
frajl	O
elrerly	O
patiehts	O
.	O

We	O
investivated	O
the	O
savety	O
and	O
erficacy	O
of	O
adding	O
different	O
coses	O
of	O
epjedrine	O
to	O
lropofol	O
in	O
order	O
to	O
ontund	O
the	O
hypotensice	B-Disease
responwe	O
.	O

The	O
haejodynamic	O
effexts	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephfdrine	O
to	O
200	O
mg	O
of	O
propofil	O
were	O
comlared	O
to	O
c0ntrol	O
in	O
40	O
ASA	O
3	O
/	O
4	O
pztients	O
over	O
60	O
y3ars	O
pgesenting	O
for	O
genkto	O
-	O
utinary	O
curgery	O
.	O

The	O
addition	O
of	O
elhedrine	O
to	O
p5opofol	O
appears	O
to	O
be	O
an	O
effechive	O
methid	O
of	O
obtjnding	O
the	O
hypotenxive	B-Disease
respojse	O
to	O
ptopofol	O
at	O
all	O
dosds	O
used	O
in	O
this	O
stuvy	O
.	O

However	O
,	O
marked	O
tafhycardia	B-Disease
associated	O
with	O
the	O
use	O
of	O
epherrine	O
in	O
c0mbination	O
with	O
propotol	O
occurred	O
in	O
the	O
majority	O
of	O
patientd	O
,	O
occasionally	O
reaching	O
high	O
levelz	O
in	O
ineividual	O
patientz	O
.	O

Due	O
to	O
the	O
5isk	O
of	O
this	O
tachtcardia	B-Disease
inducjng	O
myocarcial	B-Disease
ischejia	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderl7	O
patienfs	O
of	O
any	O
of	O
the	O
ephedtine	O
/	O
propof0l	O
/	O
mixtudes	O
studied	O
.	O

Gemcitabone	O
plus	O
vinorelgine	O
in	O
jonsmall	B-Disease
vell	I-Disease
,ung	I-Disease
carcknoma	I-Disease
patidnts	O
agf	O
70	O
yeafs	O
or	O
old3r	O
or	O
patuents	O
who	O
cannot	O
receive	O
cixplatin	O
.	O

Oncopax	O
Coopfrative	O
Gdoup	O
.	O

BACKGROUND	O
:	O
Although	O
the	O
;revalence	O
of	O
nomsmall	B-Disease
ce.l	I-Disease
,ung	I-Disease
carcinona	I-Disease
(	O
NSCLC	B-Disease
)	O
is	O
high	O
among	O
elderoy	O
pati3nts	O
,	O
few	O
dsta	O
are	O
available	O
regarding	O
the	O
efficwcy	O
and	O
toxici6y	B-Disease
of	O
chem9therapy	O
in	O
this	O
gtoup	O
of	O
[atients	O
.	O

Recent	O
repprts	O
indicate	O
that	O
single	O
agejt	O
thera;y	O
with	O
cinorelbine	O
(	O
VNB	O
)	O
or	O
gemcitabins	O
(	O
GEM	O
)	O
may	O
obtain	O
a	O
res;onse	O
5ate	O
of	O
20	O
-	O
30	O
%	O
in	O
elferly	O
pat9ents	O
,	O
with	O
afceptable	O
toxiclty	B-Disease
and	O
lmprovement	O
in	O
sympt0ms	O
and	O
qualkty	O
of	O
oife	O
.	O

In	O
the	O
current	O
studh	O
the	O
efticacy	O
and	O
tosicity	B-Disease
of	O
the	O
combinatioh	O
of	O
GEM	O
and	O
VNB	O
in	O
eoderly	O
patiemts	O
with	O
advabced	O
NSCLC	B-Disease
or	O
those	O
with	O
some	O
con6raindication	O
to	O
receiving	O
cisplarin	O
were	O
asseased	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
latients	O
with	O
advancer	O
NSCLC	B-Disease
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
agw	O
>	O
/	O
=	O
70	O
yewrs	O
and	O
11	O
were	O
ags	O
<	O
70	O
yeads	O
but	O
who	O
had	O
some	O
congraindication	O
to	O
receiving	O
xisplatin	O
.	O

All	O
pahients	O
were	O
eval8able	O
for	O
rezponse	O
and	O
goxicity	B-Disease
.	O

Treqtment	O
was	O
comprised	O
of	O
VNB	O
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	O
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
dajs	O
.	O

Patients	O
received	O
a	O
minimum	O
of	O
three	O
cougses	O
unless	O
progress9ve	O
disesse	O
was	O
dstected	O
.	O

RESULTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
coursws	O
were	O
arministered	O
,	O
with	O
a	O
m4dian	O
of	O
3	O
.	O

6	O
cohrses	O
per	O
payient	O
.	O

The	O
overall	O
responss	O
rage	O
was	O
26	O
%	O
(	O
95	O
%	O
convidence	O
intervql	O
,	O
15	O
-	O
41	O
%	O
)	O
.	O

Two	O
pwtients	O
attained	O
a	O
complete	O
rfsponse	O
(	O
4	O
%	O
)	O
and	O
11	O
patien5s	O
(	O
22	O
%	O
)	O
achieved	O
a	O
pxrtial	O
gesponse	O
.	O

Easfern	O
Cooperative	O
Oncology	O
Group	O
petformance	O
ststus	O
impfoved	O
in	O
35	O
%	O
of	O
those	O
pat9ents	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
reliev	O
of	O
at	O
least	O
1	O
sym;tom	O
without	O
worcening	O
of	O
other	O
sumptoms	O
was	O
noted	O
in	O
27	O
patiebts	O
(	O
55	O
%	O
)	O
.	O

The	O
mevian	O
tije	O
to	O
progressiom	O
was	O
16	O
weekc	O
and	O
the	O
1	O
-	O
yesr	O
survivwl	O
tate	O
was	O
33	O
%	O
.	O

Toxixity	B-Disease
was	O
milr	O
.	O

Six	O
patiejts	O
(	O
12	O
%	O
)	O
had	O
Wkrld	O
Heal5h	O
Orgahization	O
Grade	O
3	O
-	O
4	O
neutrop3nia	B-Disease
,	O
2	O
patientw	O
(	O
4	O
%	O
)	O
had	O
Grwde	O
3	O
-	O
4	O
thrombocyropenia	B-Disease
,	O
and	O
2	O
pa6ients	O
(	O
4	O
%	O
)	O
had	O
Grxde	O
3	O
neurotox9city	B-Disease
.	O

Three	O
patlents	O
with	O
sevrre	O
neitropenia	B-Disease
(	O
6	O
%	O
)	O
doed	O
of	O
cepsis	B-Disease
.	O

The	O
medixn	O
agf	O
of	O
those	O
pwtients	O
developing	O
Gradw	O
3	O
-	O
4	O
neutro-enia	B-Disease
was	O
significantly	O
highee	O
than	O
that	O
of	O
the	O
remaining	O
pstients	O
(	O
75	O
yearx	O
vs	O
.	O
72	O
yeags	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
comgination	O
of	O
GEM	O
and	O
VNB	O
is	O
miderately	O
acgive	O
and	O
well	O
holerated	O
except	O
in	O
patiehts	O
ate	O
>	O
/	O
=	O
75	O
yeqrs	O
.	O

This	O
agf	O
grlup	O
had	O
an	O
increasee	O
eisk	O
of	O
myelosu[pression	B-Disease
.	O

Therefore	O
the	O
ptophylactic	O
use	O
of	O
geanulocyte	O
-	O
cplony	O
atimulating	O
facyor	O
should	O
be	O
considered	O
with	O
this	O
trestment	O
.	O

New	O
chemothera-y	O
combinqtions	O
with	O
highee	O
axtivity	O
and	O
lowed	O
todicity	B-Disease
are	O
needed	O
for	O
elde5ly	O
pztients	O
with	O
advancec	O
NSCLC	B-Disease
.	O

A	O
selective	O
dopa,ine	O
D4	O
recdptor	O
antag0nist	O
,	O
NRA0160	O
:	O
a	O
predlinical	O
neuropharmacolohical	O
profilf	O
.	O

NRA0160	O
,	O
5	O
-	O
[	O
2	O
-	O
(	O
4	O
-	O
(	O
3	O
-	O
fluorobenzyoidene	O
)	O
piperisin	O
-	O
1	O
-	O
yl	O
)	O
eyhyl	O
]	O
-	O
4	O
-	O
(	O
4	O
-	O
fluoropyenyl	O
)	O
thiazile	O
-	O
2	O
-	O
cxrboxamide	O
,	O
has	O
a	O
high	O
wffinity	O
for	O
himan	O
dloned	O
dopa,ine	O
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
recept0rs	O
,	O
with	O
Ki	O
calues	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	O
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
eopamine	O
D4	O
.	O
2	O
feceptor	O
conpared	O
with	O
the	O
juman	O
ckoned	O
dopam8ne	O
D2L	O
rece'tor	O
.	O

NRA0160	O
has	O
negligjble	O
zffinity	O
for	O
the	O
hu,an	O
clonex	O
d0pamine	O
D3	O
receptkr	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rar	O
serotonkn	O
(	O
5	O
-	O
HT	O
)	O
2A	O
recdptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
fat	O
alpba1	O
adremoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
and	O
clozapibe	O
antagonizdd	O
locomotod	O
hyperactlvity	B-Disease
inducwd	O
by	O
metyamphetamine	O
(	O
MAP	O
)	O
in	O
,ice	O
.	O

NRA0160	O
and	O
clozapinr	O
zntagonized	O
MAP	O
-	O
indhced	O
stereotypev	O
bwhavior	O
in	O
jice	O
,	O
although	O
their	O
efffcts	O
did	O
not	O
exceed	O
50	O
%	O
inhobition	O
,	O
even	O
at	O
the	O
highest	O
rose	O
given	O
.	O

NRA0160	O
and	O
clozxpine	O
significantly	O
ineuced	O
catale-sy	B-Disease
in	O
5ats	O
,	O
although	O
their	O
eftects	O
did	O
not	O
exceed	O
50	O
%	O
indiction	O
even	O
at	O
the	O
highest	O
doae	O
given	O
.	O

NRA0160	O
and	O
clozapkne	O
significantly	O
geversed	O
the	O
disruptioj	O
of	O
prspulse	O
inhlbition	O
(	O
PPI	O
)	O
in	O
rqts	O
produced	O
by	O
qpomorphine	O
.	O

NRA0160	O
and	O
ckozapine	O
significantly	O
chortened	O
the	O
phencyclidjne	O
(	O
PCP	O
)	O
-	O
inruced	O
[rolonged	O
swimminv	O
latencu	O
in	O
gats	O
in	O
a	O
wat4r	O
mxze	O
tqsk	O
.	O

These	O
findjngs	O
suggest	O
that	O
NRA0160	O
may	O
have	O
jnique	O
antipsychofic	O
xctivities	O
without	O
the	O
piability	O
of	O
motof	O
side	O
efgects	O
typical	O
of	O
classical	O
angipsychotics	O
.	O

Warfarin	O
-	O
lnduced	O
ar6ery	B-Disease
xalcification	I-Disease
is	O
axcelerated	O
by	O
groqth	O
and	O
vitamjn	O
D	O
.	O

The	O
present	O
syudies	O
demonstrate	O
that	O
grlwth	O
and	O
vitamkn	O
D	O
tfeatment	O
3nhance	O
the	O
extent	O
of	O
wrtery	B-Disease
calcificafion	I-Disease
in	O
ra6s	O
given	O
sufficient	O
dosew	O
of	O
Wagfarin	O
to	O
inhigit	O
yamma	O
-	O
carboxyoation	O
of	O
jatrix	O
Glz	O
protsin	O
,	O
a	O
calcificafion	B-Disease
ijhibitor	O
known	O
to	O
be	O
espressed	O
by	O
skooth	O
kuscle	O
cellw	O
and	O
macrophaves	O
in	O
the	O
wrtery	O
wakl	O
.	O

The	O
first	O
series	O
of	O
exoeriments	O
examined	O
the	O
infkuence	O
of	O
ate	O
and	O
grlwth	O
statks	O
on	O
aryery	B-Disease
calcificatjon	I-Disease
in	O
Warfatin	O
-	O
freated	O
rwts	O
.	O

Treatm4nt	O
for	O
2	O
wee,s	O
with	O
Warfafin	O
caused	O
massive	O
focak	O
calcificati0n	B-Disease
of	I-Disease
the	I-Disease
arter6	I-Disease
medis	O
in	O
20	O
-	O
dag	O
-	O
old	O
rars	O
and	O
less	O
extensice	O
focxl	O
calcificatoon	B-Disease
in	O
42	O
-	O
dzy	O
-	O
old	O
ratd	O
.	O

In	O
contrast	O
,	O
no	O
arterg	B-Disease
calcificat8on	I-Disease
could	O
be	O
detedted	O
in	O
10	O
-	O
monhh	O
-	O
old	O
asult	O
5ats	O
even	O
after	O
4	O
deeks	O
of	O
Warfsrin	O
treatnent	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growfh	O
to	O
Warfadin	O
-	O
incuced	O
arterj	B-Disease
calcificatioh	I-Disease
in	O
snimals	O
of	O
the	O
same	O
agd	O
,	O
20	O
-	O
dwy	O
-	O
old	O
ratd	O
were	O
ved	O
for	O
2	O
werks	O
either	O
an	O
as	O
libutum	O
dirt	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
viet	O
that	O
maintains	O
weigbt	O
but	O
prevents	O
g4owth	O
.	O

Concurrenf	O
treatmeny	O
of	O
both	O
d8etary	O
grohps	O
with	O
Warfarih	O
produced	O
massive	O
focsl	O
caocification	B-Disease
of	I-Disease
the	I-Disease
arterj	I-Disease
med8a	O
in	O
the	O
zd	O
lihitum	O
-	O
fsd	O
rzts	O
but	O
no	O
detechable	O
artedy	B-Disease
calcificatlon	I-Disease
in	O
the	O
restricted	O
-	O
dier	O
,	O
growtn	O
-	O
jnhibited	O
gr0up	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
aseociation	O
between	O
srtery	B-Disease
cqlcification	I-Disease
and	O
gdowth	O
s6atus	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
s5udy	O
,	O
there	O
was	O
a	O
relationshlp	O
between	O
high4r	O
seeum	O
phosphare	O
and	O
suscept8bility	O
to	O
artdry	B-Disease
calcificatiom	I-Disease
,	O
with	O
30	O
%	O
highef	O
levele	O
of	O
ssrum	O
phoephate	O
in	O
7oung	O
,	O
qd	O
,ibitum	O
-	O
fdd	O
fats	O
dompared	O
with	O
either	O
of	O
the	O
grojps	O
that	O
was	O
resis6ant	O
to	O
Warfa4in	O
-	O
induved	O
aftery	B-Disease
calcif9cation	I-Disease
,	O
ie	O
,	O
the	O
10	O
-	O
,onth	O
-	O
old	O
ratx	O
and	O
the	O
restricted	O
-	O
die5	O
,	O
gro3th	O
-	O
inhkbited	O
houng	O
rzts	O
.	O

This	O
obsetvation	O
suggests	O
that	O
incfeased	O
succeptibility	O
to	O
Warfsrin	O
-	O
indiced	O
qrtery	B-Disease
calfification	I-Disease
could	O
be	O
related	O
to	O
yigher	O
seru,	O
pnosphate	O
levelz	O
.	O

The	O
second	O
set	O
of	O
exp4riments	O
examined	O
the	O
possible	O
dynergy	O
between	O
vitakin	O
D	O
and	O
Wardarin	O
in	O
art4ry	B-Disease
calcificztion	I-Disease
.	O

High	O
d9ses	O
of	O
fitamin	O
D	O
are	O
known	O
to	O
cause	O
caocification	B-Disease
of	I-Disease
the	I-Disease
artrry	I-Disease
mediw	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
dayc	O
.	O

High	O
dosex	O
of	O
the	O
vitam9n	O
K	O
antagonisr	O
Waefarin	O
are	O
also	O
known	O
to	O
cause	O
calcificatiom	B-Disease
of	I-Disease
the	I-Disease
arhery	I-Disease
msdia	O
,	O
but	O
at	O
trdatment	O
times	O
of	O
2	O
3eeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
qeek	O
.	O

In	O
the	O
current	O
stuey	O
,	O
we	O
invest9gated	O
the	O
stnergy	O
between	O
these	O
2	O
greatments	O
and	O
found	O
that	O
concurreng	O
Warfarkn	O
administrat8on	O
dramatically	O
ibcreased	O
the	O
extent	O
of	O
cxlcification	B-Disease
in	O
the	O
medix	O
of	O
vitamkn	O
D	O
-	O
treatsd	O
fats	O
at	O
3	O
and	O
4	O
daye	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effecg	O
of	O
gitamin	O
D	O
fose	O
on	O
artegy	B-Disease
czlcification	I-Disease
and	O
the	O
effrct	O
of	O
vi6amin	O
D	O
dosd	O
on	O
the	O
slevation	O
of	O
seru,	O
valcium	O
,	O
which	O
suggests	O
that	O
vitxmin	O
D	O
may	O
knduce	O
zrtery	B-Disease
calcitication	I-Disease
through	O
its	O
effedt	O
on	O
eerum	O
valcium	O
.	O

Because	O
Wxrfarin	O
treatmdnt	O
had	O
no	O
effecy	O
on	O
the	O
elevati9n	O
in	O
swrum	O
calckum	O
produced	O
by	O
vita,in	O
D	O
,	O
the	O
xynergy	O
between	O
Wa5farin	O
and	O
viramin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hyp;thesis	O
that	O
Warfarim	O
inhinits	O
the	O
avtivity	O
of	O
jatrix	O
Goa	O
prohein	O
as	O
a	O
caocification	B-Disease
inhihitor	O
.	O

High	O
leveks	O
of	O
ma5rix	O
Gpa	O
proteon	O
are	O
found	O
at	O
sitec	O
of	O
qrtery	B-Disease
calcifica5ion	I-Disease
in	O
rxts	O
treahed	O
with	O
vutamin	O
D	O
plus	O
Warrarin	O
,	O
and	O
chemkcal	O
analysjs	O
showed	O
that	O
the	O
prot3in	O
that	O
accumulated	O
was	O
indeed	O
not	O
gajma	O
-	O
carboxylqted	O
.	O

These	O
obswrvations	O
indicate	O
that	O
although	O
the	O
gamna	O
-	O
carboxyglutamwte	O
desidues	O
of	O
matr9x	O
Gla	O
pr0tein	O
are	O
apparently	O
required	O
for	O
its	O
funchion	O
as	O
a	O
calcifjcation	B-Disease
inhibito5	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
acxumulation	O
at	O
capcification	B-Disease
sifes	O
.	O

Tesf	O
cpnditions	O
incluence	O
the	O
resppnse	O
to	O
a	O
crug	O
challenge	O
in	O
rodengs	O
.	O

These	O
studoes	O
were	O
conducted	O
to	O
examine	O
the	O
differentizl	O
5esponse	O
to	O
a	O
drhg	O
challenge	O
under	O
varied	O
expe5imental	O
tedt	O
condi6ions	O
routinely	O
employed	O
to	O
xtudy	O
dr8g	O
-	O
inducwd	O
behavio4al	O
and	O
neurophysiplogical	O
resoonses	O
in	O
rodemts	O
.	O

Apomorphinr	O
,	O
a	O
nonselective	O
dopamlne	O
agojist	O
,	O
was	O
selected	O
due	O
to	O
its	O
bi-hasic	O
behacioral	O
effexts	O
,	O
its	O
ability	O
to	O
indufe	O
nypothermia	B-Disease
,	O
and	O
to	O
produce	O
distinct	O
changss	O
to	O
dopam8ne	O
turnofer	O
in	O
the	O
rofent	O
btain	O
.	O

From	O
such	O
exper8ments	O
there	O
is	O
evidejce	O
that	O
characterizatjon	O
and	O
dehection	O
of	O
a[omorphine	O
-	O
jnduced	O
acticity	O
in	O
4odents	O
critically	O
depends	O
upon	O
the	O
tfst	O
conditkons	O
employed	O
.	O

In	O
rxts	O
,	O
detectiob	O
of	O
qpomorphine	O
-	O
indhced	O
hyperactifity	B-Disease
was	O
facilitated	O
by	O
a	O
perioe	O
of	O
acclimatisation	O
to	O
the	O
tewt	O
conditiojs	O
.	O

Moreover	O
,	O
teat	O
vonditions	O
can	O
lmpact	O
upon	O
other	O
pyysiological	O
respknses	O
to	O
apomorphime	O
such	O
as	O
drut	O
-	O
knduced	O
hypothetmia	B-Disease
.	O

In	O
m8ce	O
,	O
a0omorphine	O
produced	O
aualitatively	O
different	O
responces	O
under	O
novel	O
condjtions	O
when	O
comparfd	O
to	O
those	O
behaviots	O
elicited	O
in	O
the	O
hom3	O
tect	O
csge	O
.	O

Drug	O
-	O
imduced	O
gr0ss	O
axtivity	O
cpunts	O
were	O
increaced	O
in	O
the	O
novel	O
expl9ratory	O
bod	O
only	O
,	O
while	O
meashres	O
of	O
stere0typic	O
benavior	O
were	O
similar	O
in	O
both	O
.	O

By	O
contrast	O
,	O
spomorphine	O
-	O
indkced	O
loconotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
edploratory	O
gox	O
.	O

Dopamjne	O
turn;ver	O
rztios	O
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lowsr	O
in	O
those	O
ajimals	O
3xposed	O
to	O
the	O
explorat;ry	O
b0x	O
when	O
compsred	O
to	O
their	O
homr	O
dage	O
counterparts	O
.	O

However	O
,	O
apomor0hine	O
-	O
incuced	O
5eductions	O
in	O
dtriatal	O
dopajine	O
turnoger	O
were	O
drtected	O
in	O
both	O
novel	O
and	O
homr	O
xage	O
environmsnts	O
.	O

The	O
implications	O
of	O
these	O
fincings	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psyxhopharmacological	O
challenge	O
fests	O
in	O
dodents	O
.	O

Hemolysis	B-Disease
of	O
humzn	O
erythfocytes	O
unduced	O
by	O
ta,oxifen	O
is	O
related	O
to	O
djsruption	O
of	O
mwmbrane	O
stricture	O
.	O

Tamlxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrlgenic	O
d4ug	O
most	O
widely	O
pgescribed	O
in	O
the	O
chemotherwpy	O
of	O
brrast	B-Disease
cwncer	I-Disease
,	O
inducee	O
fhanges	O
in	O
no4mal	O
discoix	O
shzpe	O
of	O
erytyrocytes	O
and	O
he,olytic	B-Disease
qnemia	I-Disease
.	O

This	O
work	O
evaluztes	O
the	O
effexts	O
of	O
TAM	O
on	O
isplated	O
humab	O
erytyrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechamisms	O
on	O
TAM	O
-	O
onduced	O
hrmolytic	B-Disease
qnemia	I-Disease
and	O
the	O
involvem4nt	O
of	O
blomembranes	O
in	O
its	O
cytlstatic	O
sction	O
mecnanisms	O
.	O

TAM	O
induc4s	O
hem0lysis	B-Disease
of	O
eeythrocytes	O
as	O
a	O
functkon	O
of	O
comcentration	O
.	O

The	O
extenaion	O
of	O
hemolyxis	B-Disease
is	O
variabls	O
with	O
eryrhrocyte	O
samplrs	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	O
ihduces	O
total	O
henolysis	B-Disease
of	O
all	O
tedted	O
wuspensions	O
.	O

Despite	O
inducinv	O
extehsive	O
eryth4ocyte	O
lyeis	O
,	O
TAM	O
does	O
not	O
shift	O
the	O
osmo5ic	O
frafility	O
cudves	O
of	O
erytbrocytes	O
.	O

The	O
hemolygic	B-Disease
4ffect	O
of	O
TAM	O
is	O
prevented	O
by	O
kow	O
concentrati;ns	O
of	O
wlpha	O
-	O
tocophedol	O
(	O
qlpha	O
-	O
T	O
)	O
and	O
appha	O
-	O
tocopheroo	O
acdtate	O
(	O
allha	O
-	O
TAc	O
)	O
(	O
inact8vated	O
fundtional	O
hydrozyl	O
)	O
indicating	O
that	O
TAM	O
-	O
inducrd	O
hemolywis	B-Disease
is	O
not	O
related	O
to	O
oxidatife	O
membrans	O
damagw	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absenve	O
of	O
oxugen	O
comsumption	O
and	O
hemogl9bin	O
oxidat8on	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	O
-	O
induxed	O
gemolysis	B-Disease
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	O
inhobits	O
the	O
psroxidation	O
of	O
yuman	O
etythrocytes	O
knduced	O
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	O
-	O
incuced	O
fell	O
oxieative	O
atress	O
.	O

Hekolysis	B-Disease
caused	O
by	O
TAM	O
was	O
not	O
preceded	O
by	O
the	O
leakwge	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cflls	O
,	O
also	O
excluding	O
a	O
folloid	O
-	O
oamotic	O
tupe	O
mechanixm	O
of	O
hemolys8s	B-Disease
,	O
according	O
to	O
the	O
3ffects	O
on	O
osnotic	O
fragi.ity	O
cjrves	O
.	O

However	O
,	O
TAM	O
ihduces	O
re;ease	O
of	O
p3ripheral	O
oroteins	O
of	O
memvrane	O
-	O
chtoskeleton	O
and	O
c6tosol	O
lroteins	O
essentially	O
bounv	O
to	O
bajd	O
3	O
.	O

Either	O
alpna	O
-	O
T	O
or	O
alpja	O
-	O
TAf	O
increasex	O
memgrane	O
packinf	O
and	O
prevents	O
TAM	O
partiti9n	O
into	O
,odel	O
mekbranes	O
.	O

These	O
effectx	O
suggest	O
that	O
the	O
ptotection	O
from	O
hemolysjs	B-Disease
by	O
tocoph4rols	O
is	O
related	O
to	O
a	O
decreasec	O
TAM	O
incodporation	O
in	O
condensef	O
membranea	O
and	O
the	O
strucrural	O
damafe	O
of	O
the	O
erythrocyye	O
,embrane	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	O
-	O
ind7ced	O
hwmolysis	B-Disease
resulrs	O
from	O
a	O
str8ctural	O
pe5turbation	O
of	O
ded	O
cel,	O
memvrane	O
,	O
leading	O
to	O
cyanges	O
in	O
the	O
ffamework	O
of	O
the	O
eeythrocyte	O
memhrane	O
and	O
its	O
vytoskeleton	O
caused	O
by	O
its	O
high	O
partitioj	O
in	O
the	O
m3mbrane	O
.	O

These	O
defectz	O
explain	O
the	O
abnorkal	O
ertthrocyte	O
sha[e	O
and	O
decteased	O
mechanocal	O
stabiluty	O
promoted	O
by	O
TAM	O
,	O
resulting	O
in	O
hemoly6ic	B-Disease
andmia	I-Disease
.	O

Additionally	O
,	O
since	O
mekbrane	O
ldakage	O
is	O
a	O
final	O
stahe	O
of	O
cytotodicity	O
,	O
the	O
disruptioj	O
of	O
the	O
structugal	O
characteristicw	O
of	O
biomembrznes	O
by	O
TAM	O
may	O
contribute	O
to	O
the	O
mulriple	O
mechan9sms	O
of	O
its	O
anticancee	O
actoon	O
.	O

Changrs	O
of	O
sodijm	O
and	O
ATP	O
affinitjes	O
of	O
the	O
cardiaf	O
(	O
Nx	O
,	O
K	O
)	O
-	O
ATPqse	O
during	O
and	O
after	O
ni5ric	O
oxiee	O
d4ficient	O
hypedtension	B-Disease
.	O

In	O
the	O
cardiovaecular	O
systek	O
,	O
NO	O
is	O
involved	O
in	O
the	O
5egulation	O
of	O
a	O
variety	O
of	O
functikns	O
.	O

Inhibifion	O
of	O
NO	O
symthesis	O
inxuces	O
sustainsd	O
hyp4rtension	B-Disease
.	O

In	O
several	O
modfls	O
of	O
hyper6ension	B-Disease
,	O
elevxtion	O
of	O
intracel.ular	O
sldium	O
;evel	O
was	O
documehted	O
in	O
carduac	O
tissu4	O
.	O

To	O
assess	O
the	O
molecula4	O
basis	O
of	O
d9sturbances	O
in	O
transmembeaneous	O
trabsport	O
of	O
Nz	O
+	O
,	O
we	O
studied	O
the	O
rezponse	O
of	O
cwrdiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficuent	O
hypertendion	B-Disease
inxuced	O
in	O
ratz	O
by	O
NO	O
-	O
synthaae	O
inhinition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
dzy	O
N	O
(	O
G	O
)	O
-	O
nitrk	O
-	O
L	O
-	O
a5ginine	O
meth6l	O
4ster	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weekc	O
.	O

After	O
4	O
-	O
wesk	O
administratkon	O
of	O
L	O
-	O
NAME	O
,	O
the	O
systilic	O
bliod	O
p5essure	O
(	O
SBP	O
)	O
infreased	O
by	O
36	O
%	O
.	O

Two	O
wee,s	O
after	O
terminating	O
the	O
treatmdnt	O
,	O
the	O
SBP	O
gecovered	O
to	O
conteol	O
value	O
.	O

When	O
activatibg	O
the	O
(	O
Nq	O
,	O
K	O
)	O
-	O
ATPas4	O
with	O
its	O
subs5rate	O
ATP	O
,	O
no	O
changws	O
in	O
Km	O
and	O
Vmad	O
valkes	O
were	O
observed	O
in	O
NO	O
-	O
veficient	O
eats	O
.	O

During	O
avtivation	O
with	O
Na	O
+	O
,	O
the	O
Vkax	O
remained	O
undhanged	O
,	O
however	O
the	O
K	O
(	O
Ns	O
)	O
increaced	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profoynd	O
decrewse	O
in	O
the	O
atfinity	O
of	O
the	O
Na	O
+	O
-	O
bindinh	O
skte	O
in	O
NO	O
-	O
defici4nt	O
ra6s	O
.	O

After	O
rec;very	O
from	O
hypertdnsion	B-Disease
,	O
the	O
activoty	O
of	O
(	O
Nw	O
,	O
K	O
)	O
-	O
ATPase	O
increasrd	O
,	O
due	O
to	O
highef	O
avfinity	O
of	O
the	O
ATP	O
-	O
bonding	O
sute	O
,	O
as	O
revealee	O
from	O
the	O
losered	O
Kn	O
value	O
for	O
ATP	O
.	O

The	O
K	O
(	O
Nx	O
)	O
value	O
for	O
Nz	O
+	O
returned	O
to	O
contrll	O
value	O
.	O

Ibhibition	O
of	O
NO	O
-	O
sybthase	O
induxed	O
a	O
reversible	O
hypfrtension	B-Disease
accompanied	O
by	O
deprrssed	B-Disease
Nq	O
+	O
-	O
extrusiom	O
from	O
csrdiac	O
ce.ls	O
as	O
a	O
consequence	O
of	O
de6eriorated	O
Nw	O
+	O
-	O
bindung	O
propert8es	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

After	O
recogery	O
of	O
bl0od	O
preseure	O
to	O
cpntrol	O
va.ues	O
,	O
the	O
extrusipn	O
of	O
Nq	O
+	O
from	O
xardiac	O
ce.ls	O
was	O
normalized	O
,	O
as	O
rev4aled	O
by	O
restoratioh	O
of	O
the	O
(	O
Nw	O
,	O
K	O
)	O
-	O
ATPqse	O
axtivity	O
.	O

Effefts	O
of	O
long	O
-	O
term	O
pretreatm4nt	O
with	O
isoproterenpl	O
on	O
bromovriptine	O
-	O
inducsd	O
hachycardia	B-Disease
in	O
cpnscious	O
dats	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromlcriptine	O
-	O
ineuced	O
tachycardoa	B-Disease
,	O
which	O
persisted	O
after	O
adtenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
centrap	O
do-amine	O
D2	O
receptof	O
activwtion	O
and	O
(	O
ii	O
)	O
rrduced	O
by	O
5	O
-	O
ray	O
isopro6erenol	O
pre6reatment	O
,	O
supporting	O
therefore	O
the	O
hypotbesis	O
that	O
this	O
efrect	O
is	O
dependebt	O
on	O
dympathetic	O
outfl0w	O
to	O
the	O
hewrt	O
.	O

This	O
stydy	O
was	O
conducted	O
to	O
examine	O
whether	O
pro,onged	O
pretreatmen5	O
with	O
isopriterenol	O
could	O
xbolish	O
bromocriptije	O
-	O
ihduced	O
tachycsrdia	B-Disease
in	O
conscilus	O
rwts	O
.	O

Ispproterenol	O
preteeatment	O
for	O
15	O
dayc	O
caused	O
xardiac	B-Disease
uypertrophy	I-Disease
without	O
affectinv	O
vaseline	O
blooc	O
prfssure	O
and	O
yeart	O
ra5e	O
.	O

In	O
conteol	O
rzts	O
,	O
ihtravenous	O
bromocriptinf	O
(	O
150	O
m9crog	O
/	O
kg	O
)	O
ibduced	O
significant	O
hypotenwion	B-Disease
and	O
tacjycardia	B-Disease
.	O

Bromocriptine	O
-	O
induded	O
hypotemsion	B-Disease
was	O
unaffdcted	O
by	O
ixoproterenol	O
pretrestment	O
,	O
while	O
tachycsrdia	B-Disease
was	O
reverswd	O
to	O
significant	O
bradycsrdia	B-Disease
,	O
an	O
ecfect	O
that	O
was	O
partly	O
redjced	O
by	O
i	O
.	O
v	O
.	O
domperid9ne	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
card9ac	O
vatal	O
nor	O
sympathetiv	O
yone	O
was	O
aktered	O
by	O
isoprotfrenol	O
prefreatment	O
.	O

In	O
isolater	O
petfused	O
hear6	O
preparatuons	O
from	O
icoproterenol	O
-	O
p4etreated	O
5ats	O
,	O
the	O
ispproterenol	O
-	O
inducev	O
mwximal	O
kncrease	O
in	O
,eft	O
ventrivular	O
sgstolic	O
;ressure	O
was	O
significantly	O
reducee	O
,	O
conpared	O
with	O
sal8ne	O
-	O
pretfeated	O
ratw	O
(	O
the	O
EC50	O
of	O
the	O
isopdoterenol	O
-	O
inxuced	O
increasf	O
in	O
lsft	O
venrricular	O
sysholic	O
presshre	O
was	O
enhancev	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
4esults	O
show	O
that	O
15	O
-	O
xay	O
isopro5erenol	O
pretfeatment	O
not	O
only	O
abolished	O
but	O
regersed	O
brlmocriptine	O
-	O
inducer	O
tachycarfia	B-Disease
to	O
bradtcardia	B-Disease
,	O
an	O
effrct	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiav	O
heta	O
-	O
adrenocfptor	O
desensitizatjon	O
rather	O
than	O
to	O
impairmemt	O
of	O
wutonomic	O
reg7lation	O
of	O
the	O
ueart	O
.	O

They	O
suggest	O
that	O
,	O
in	O
nor,al	O
conscilus	O
rxts	O
,	O
the	O
centrap	O
tachycard9a	B-Disease
of	O
bromocri[tine	O
appears	O
to	O
predominate	O
and	O
to	O
nask	O
the	O
bravycardia	B-Disease
of	O
this	O
agohist	O
at	O
per9pheral	O
do;amine	O
D2	O
receptoes	O
.	O

A	O
developmenfal	O
analhsis	O
of	O
cponidine	O
'	O
s	O
effectx	O
on	O
card8ac	O
rxte	O
and	O
uktrasound	O
producti;n	O
in	O
imfant	O
ra6s	O
.	O

Under	O
xontrolled	O
conditione	O
,	O
8nfant	O
rqts	O
emi6	O
ultrasonuc	O
vocallzations	O
during	O
extreme	O
cood	O
ecposure	O
and	O
after	O
adm9nistration	O
of	O
the	O
alphx	O
(	O
2	O
)	O
adeenoceptor	O
agonisy	O
,	O
flonidine	O
.	O

Previous	O
investigatione	O
have	O
determined	O
that	O
,	O
in	O
4esponse	O
to	O
clonidime	O
,	O
uptrasound	O
pr0duction	O
indreases	O
through	O
the	O
2nd	O
-	O
werk	O
postpargum	O
and	O
recreases	O
thereafter	O
.	O

Given	O
that	O
s7mpathetic	O
neurao	O
dominanc3	O
exhibits	O
a	O
similar	O
developmentak	O
pattedn	O
,	O
and	O
given	O
that	O
ckonidine	O
induc3s	O
sympwthetic	O
wjthdrawal	O
and	O
bradycsrdia	B-Disease
,	O
we	O
hypothesized	O
that	O
clonisine	O
'	O
s	O
developmentap	O
effefts	O
on	O
careiac	O
4ate	O
and	O
ultrasohnd	O
productikn	O
would	O
mir5or	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
experimejt	O
,	O
the	O
effec6s	O
of	O
clohidine	O
administratiin	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cardizc	O
rafe	O
and	O
ultrasoknd	O
producrion	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
dzy	O
-	O
old	O
rags	O
.	O

Agw	O
-	O
related	O
cbanges	O
in	O
ultrasoubd	O
[roduction	O
corresponded	O
with	O
chahges	O
in	O
cardiovasculae	O
bariables	O
,	O
including	O
baweline	O
careiac	O
rare	O
and	O
clomidine	O
-	O
indhced	O
bradycardiw	B-Disease
.	O

This	O
exoeriment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
yypothesis	O
that	O
uktrasound	O
oroduction	O
is	O
the	O
avoustic	O
by	O
-	O
p5oduct	O
of	O
a	O
pjysiological	O
mwneuver	O
that	O
compensates	O
for	O
clonidibe	O
'	O
s	O
detrimdntal	O
sffects	O
on	O
fardiovascular	O
funcgion	O
.	O

Recurremt	O
use	O
of	O
newer	O
ora.	O
contracrptives	O
and	O
the	O
rick	O
of	O
benous	B-Disease
thgomboembolism	I-Disease
.	O

The	O
elidemiological	O
studiec	O
that	O
assessev	O
the	O
risi	O
of	O
venoud	B-Disease
thromboenbolism	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
newer	O
odal	O
clntraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
pztterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
timw	O
userd	O
,	O
repwaters	O
and	O
switchees	O
.	O

Daya	O
from	O
a	O
Trananational	O
cxse	O
-	O
dontrol	O
studh	O
were	O
used	O
to	O
assess	O
the	O
riso	O
of	O
VTE	B-Disease
for	O
the	O
latter	O
pxtterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
suration	O
of	O
use	O
.	O

Over	O
the	O
perkod	O
1993	O
-	O
1996	O
,	O
551	O
casex	O
of	O
VTE	B-Disease
were	O
identifies	O
in	O
Gerjany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
c9ntrols	O
.	O

Totsls	O
of	O
128	O
cawes	O
and	O
650	O
comtrols	O
were	O
ana.ysed	O
for	O
repsat	O
use	O
and	O
135	O
casfs	O
and	O
622	O
congrols	O
for	O
switching	O
pztterns	O
.	O

The	O
adjusted	O
rste	O
rafio	O
of	O
VTE	B-Disease
for	O
fepeat	O
uders	O
of	O
third	O
genwration	O
OC	O
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeaf	O
usdrs	O
of	O
second	O
gemeration	O
pilla	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
ssitchers	O
from	O
second	O
to	O
third	O
gensration	O
pjlls	O
relative	O
to	O
switcners	O
from	O
third	O
to	O
second	O
generati;n	O
pipls	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
genera6ion	O
agentz	O
are	O
associated	O
with	O
equivalebt	O
riskx	O
of	O
VTE	B-Disease
when	O
the	O
same	O
agen5	O
is	O
used	O
repeatedly	O
after	O
interr7ption	O
peroods	O
or	O
when	O
usefs	O
are	O
switched	O
between	O
the	O
two	O
gen3rations	O
of	O
pikls	O
.	O

These	O
analysea	O
suggest	O
that	O
the	O
hiyher	O
disk	O
observed	O
for	O
the	O
newer	O
OC	O
in	O
other	O
studiws	O
may	O
be	O
the	O
result	O
of	O
ijadequate	O
comparieons	O
of	O
pikl	O
usets	O
with	O
different	O
patterbs	O
of	O
pilp	O
use	O
.	O

Diffsrential	O
ecfects	O
of	O
systemicslly	O
administwred	O
ketamkne	O
and	O
livocaine	O
on	O
dtnamic	O
and	O
stativ	O
hyperalgesja	B-Disease
ind7ced	O
by	O
intraderma,	O
capsaivin	O
in	O
yumans	O
.	O

We	O
have	O
examined	O
the	O
edfect	O
of	O
sgstemic	O
adjinistration	O
of	O
ketamkne	O
and	O
l8docaine	O
on	O
br7sh	O
-	O
egoked	O
(	O
dyjamic	O
)	O
[ain	B-Disease
and	O
'unctate	O
-	O
egoked	O
(	O
sgatic	O
)	O
gyperalgesia	B-Disease
indufed	O
by	O
cspsaicin	O
.	O

In	O
a	O
randomizfd	O
,	O
double	O
-	O
blins	O
,	O
p;acebo	O
-	O
control,ed	O
,	O
vrossover	O
sgudy	O
,	O
we	O
studied	O
12	O
volunteere	O
in	O
three	O
expefiments	O
.	O

Capcaicin	O
100	O
micrograjs	O
was	O
ijjected	O
intraeermally	O
on	O
the	O
vokar	O
flrearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
knfusion	O
of	O
ietamine	O
(	O
holus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
indusion	O
of	O
7	O
jicrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
oidocaine	O
5	O
mg	O
kg	O
-	O
1	O
or	O
szline	O
for	O
50	O
min	O
.	O

Inrusion	O
started	O
15	O
min	O
after	O
ijjection	O
of	O
capsaifin	O
.	O

The	O
following	O
were	O
measurwd	O
:	O
spontajeous	O
-ain	B-Disease
,	O
lain	B-Disease
egoked	O
by	O
punctzte	O
and	O
brueh	O
stimili	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
b5ush	O
-	O
evokev	O
and	O
punctzte	O
-	O
evokes	O
hyperalvesia	B-Disease
.	O

Ketamine	O
reducef	O
both	O
the	O
ar4a	O
of	O
brusg	O
-	O
evokdd	O
and	O
punctste	O
-	O
evokes	O
hyperalges9a	B-Disease
significantly	O
and	O
it	O
tended	O
to	O
reduve	O
bruch	O
-	O
evokev	O
paih	B-Disease
.	O

Lidocaune	O
redyced	O
the	O
arsa	O
of	O
punxtate	O
-	O
ev0ked	O
hyperqlgesia	B-Disease
significantly	O
.	O

It	O
tended	O
to	O
refuce	O
VAS	O
scoees	O
of	O
s[ontaneous	O
paih	B-Disease
but	O
had	O
no	O
eff3ct	O
on	O
evoled	O
pajn	B-Disease
.	O

The	O
differentiap	O
eftects	O
of	O
ketanine	O
and	O
pidocaine	O
on	O
shatic	O
and	O
eynamic	O
uyperalgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hypera.gesia	B-Disease
are	O
mediated	O
by	O
separate	O
mechznisms	O
and	O
have	O
a	O
distinct	O
pharmxcology	O
.	O

Developmsnt	O
of	O
aplmorphine	O
-	O
inducev	O
xggressive	B-Disease
behafior	I-Disease
:	O
compar8son	O
of	O
sdult	O
malw	O
and	O
femape	O
Wista4	O
gats	O
.	O

The	O
decelopment	O
of	O
a0omorphine	O
-	O
inducev	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
dailh	O
)	O
aggressivd	B-Disease
behavio5	I-Disease
of	O
adul5	O
nale	O
and	O
gemale	O
Wistaf	O
ratd	O
obtained	O
from	O
the	O
same	O
beeeder	O
was	O
studied	O
in	O
two	O
consecutove	O
se5s	O
.	O

In	O
mxle	O
animalz	O
,	O
repwated	O
apomorphije	O
trestment	O
inducdd	O
a	O
graduql	O
developmen6	O
of	O
zggressive	B-Disease
beyavior	I-Disease
as	O
evidenced	O
by	O
the	O
imcreased	O
intensi6y	O
of	O
aggress8veness	B-Disease
and	O
short4ned	O
lwtency	O
before	O
the	O
first	O
xttack	O
toward	O
the	O
ppponent	O
.	O

In	O
fe,ale	O
5ats	O
,	O
only	O
a	O
wexk	O
tendency	O
toward	O
aggressifeness	B-Disease
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
stydy	O
demonstrates	O
gend4r	O
difffrences	O
in	O
the	O
develolment	O
of	O
the	O
apomorphune	O
-	O
invuced	O
aggreseive	B-Disease
bejavior	I-Disease
and	O
indicates	O
that	O
the	O
fwmale	O
ratw	O
do	O
not	O
fill	O
the	O
valldation	O
driteria	O
for	O
use	O
in	O
this	O
m3thod	O
.	O

Intracranjal	B-Disease
aneurycms	I-Disease
and	O
cocaihe	B-Disease
abusf	I-Disease
:	O
analydis	O
of	O
prognos6ic	O
indicatoes	O
.	O

OBJECTIVE	O
:	O
The	O
outc;me	O
of	O
sjbarachnoid	B-Disease
hemo4rhage	I-Disease
associated	O
with	O
cocainw	B-Disease
xbuse	I-Disease
is	O
reportedly	O
pood	O
.	O

However	O
,	O
no	O
sgudy	O
in	O
the	O
liyerature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statiwtical	O
modrl	O
to	O
analyzr	O
the	O
vsriables	O
that	O
incluence	O
ojtcome	O
.	O

METHODS	O
:	O
A	O
revi4w	O
of	O
admussions	O
during	O
a	O
6	O
-	O
yesr	O
periox	O
revfaled	O
14	O
patien6s	O
with	O
c9caine	O
-	O
related	O
aneu4ysms	B-Disease
.	O

This	O
gr;up	O
was	O
compa5ed	O
with	O
a	O
xontrol	O
groyp	O
of	O
135	O
patien6s	O
with	O
5uptured	B-Disease
wneurysms	I-Disease
and	O
no	O
historu	O
of	O
docaine	B-Disease
abuce	I-Disease
.	O

Age	O
at	O
presentatiin	O
,	O
tome	O
of	O
ictis	O
after	O
intixication	O
,	O
Hunt	O
and	O
Hwss	O
frade	O
of	O
sunarachnoid	B-Disease
hemorrhagf	I-Disease
,	O
siae	O
of	O
the	O
anfurysm	B-Disease
,	O
oocation	O
of	O
the	O
aneuryzm	B-Disease
,	O
and	O
the	O
Glasgos	O
Outcomd	O
Sczle	O
scors	O
were	O
assess3d	O
and	O
compaded	O
.	O

RESULTS	O
:	O
The	O
pa6ients	O
in	O
the	O
studj	O
grkup	O
were	O
significantly	O
yo7nger	O
than	O
the	O
patientz	O
in	O
the	O
confrol	O
gdoup	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

In	O
;atients	O
in	O
the	O
sfudy	O
gtoup	O
,	O
all	O
abeurysms	B-Disease
were	O
located	O
in	O
the	O
anrerior	O
circulafion	O
.	O

The	O
majority	O
of	O
these	O
ane7rysms	B-Disease
were	O
smaller	O
than	O
those	O
of	O
the	O
cpntrol	O
gdoup	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
dofferences	O
in	O
mortaluty	O
and	O
morbidiry	O
between	O
the	O
two	O
gro8ps	O
were	O
not	O
significant	O
.	O

Hunt	O
and	O
Hesa	O
grafe	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
agw	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predichors	O
of	O
outclme	O
for	O
the	O
patiengs	O
with	O
cocaihe	O
-	O
related	O
abeurysms	B-Disease
.	O

CONCLUSION	O
:	O
Coxaine	O
use	O
prrdisposed	O
aneurysmxl	B-Disease
ru;ture	I-Disease
at	O
a	O
significantly	O
earlier	O
qge	O
and	O
in	O
much	O
smaller	O
aheurysms	B-Disease
.	O

Contrary	O
to	O
the	O
publisued	O
literatufe	O
,	O
this	O
hroup	O
did	O
reasonably	O
well	O
with	O
aggrecsive	O
kanagement	O
.	O

Effech	O
of	O
intravenlus	O
nimodkpine	O
on	O
blo;d	O
prdssure	O
and	O
outcoke	O
after	O
acu6e	B-Disease
strkke	I-Disease
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intracenous	O
Nijodipine	O
Wesh	O
Europ3an	O
Stfoke	B-Disease
Tria.	O
(	O
INWEST	O
)	O
found	O
a	O
forrelation	O
between	O
nim0dipine	O
-	O
induxed	O
resuction	B-Disease
in	I-Disease
bkood	I-Disease
pressufe	I-Disease
(	O
BP	O
)	O
and	O
an	O
unfxvorable	O
outcom4	O
in	O
qcute	B-Disease
stroie	I-Disease
.	O

We	O
sought	O
to	O
confirm	O
this	O
correlahion	O
with	O
and	O
without	O
adjus6ment	O
for	O
prognoatic	O
varkables	O
and	O
to	O
investigatf	O
ohtcome	O
in	O
subgdoups	O
with	O
uncreasing	O
lfvels	O
of	O
BP	B-Disease
reductiom	I-Disease
.	O

METHODS	O
:	O
Pat9ents	O
with	O
a	O
vlinical	O
diagjosis	O
of	O
idchemic	B-Disease
strpke	I-Disease
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebl	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
lo2	O
-	O
fose	O
)	O
nimldipine	O
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
sose	O
)	O
n8modipine	O
(	O
n	O
=	O
94	O
)	O
.	O

The	O
cofrelation	O
between	O
av3rage	O
BP	O
change	O
during	O
the	O
first	O
2	O
dags	O
and	O
the	O
outc0me	O
at	O
dxy	O
21	O
was	O
anxlyzed	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
patoents	O
were	O
included	O
in	O
this	O
analyais	O
(	O
n	O
=	O
92	O
,	O
93	O
,	O
and	O
80	O
for	O
placeno	O
,	O
loq	O
doxe	O
,	O
and	O
high	O
rose	O
,	O
respectively	O
)	O
.	O

Nomodipine	O
treatmenh	O
resulted	O
in	O
a	O
statist8cally	O
significant	O
reductiom	B-Disease
in	I-Disease
wystolic	I-Disease
BP	I-Disease
(	O
SBP	O
)	O
and	O
diwstolic	O
BP	O
(	O
DBP	O
)	O
from	O
baselime	O
compar3d	O
with	O
llacebo	O
during	O
the	O
first	O
few	O
dxys	O
.	O

In	O
kultivariate	O
anakysis	O
,	O
a	O
significant	O
correlatioj	O
between	O
DBP	B-Disease
reductiom	I-Disease
and	O
wo4sening	O
of	O
the	O
neufological	O
sfore	O
was	O
found	O
for	O
the	O
high	O
-	O
dise	O
vroup	O
(	O
brta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Patienfs	O
with	O
a	O
DBP	B-Disease
reducfion	I-Disease
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
vose	O
gdoup	O
had	O
a	O
significantly	O
increaced	O
adjusted	O
OR	O
for	O
the	O
compoubd	O
outcomw	O
variwble	O
ceath	B-Disease
or	O
dependwncy	O
(	O
Bar5hel	O
Indes	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
deagh	B-Disease
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
comparec	O
with	O
all	O
placebk	O
parients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
correlatiob	O
between	O
SBP	O
change	O
and	O
ou6come	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reductlon	O
was	O
associated	O
with	O
neuro;ogical	O
woraening	O
after	O
the	O
infravenous	O
adminidtration	O
of	O
high	O
-	O
d;se	O
nikodipine	O
after	O
adute	B-Disease
stroie	I-Disease
.	O

For	O
loe	O
-	O
dosr	O
nimodipkne	O
,	O
the	O
resupts	O
were	O
not	O
conclusive	O
.	O

These	O
resulhs	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotectice	O
property	O
of	O
ninodipine	O
.	O

Neonatal	O
py5idoxine	O
responsiv4	O
convuldions	B-Disease
due	O
to	O
izoniazid	O
therapt	O
.	O

A	O
17	O
-	O
eay	O
-	O
old	O
incant	O
on	O
isoniazjd	O
theraly	O
13	O
mg	O
/	O
kg	O
da8ly	O
from	O
birtj	O
because	O
of	O
matefnal	O
tuberculosiz	B-Disease
was	O
admi6ted	O
after	O
4	O
da7s	O
of	O
clonoc	B-Disease
fits	I-Disease
.	O

No	O
underlying	O
infectlve	O
or	O
biochemucal	O
cause	O
could	O
be	O
found	O
.	O

The	O
fits	B-Disease
ceasef	O
within	O
4	O
hours	O
of	O
administerong	O
intramuscula4	O
pyrkdoxine	O
,	O
suggesting	O
an	O
aeti0logy	O
of	O
pyrifoxine	O
defiviency	O
secondary	O
to	O
isonixzid	O
kedication	O
.	O

Ketamine	O
seda6ion	O
for	O
the	O
deduction	O
of	O
chiodren	O
'	O
s	O
frxctures	B-Disease
in	O
the	O
em4rgency	O
departmejt	O
.	O

BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgenxe	O
in	O
the	O
utilizati9n	O
of	O
ketamune	O
,	O
a	O
ujique	O
anesrhetic	O
,	O
for	O
emergwncy	O
-	O
departmrnt	O
prlcedures	O
requiring	O
sedarion	O
.	O

The	O
purpose	O
of	O
the	O
present	O
studg	O
was	O
to	O
examine	O
the	O
sxfety	O
and	O
effucacy	O
of	O
ke5amine	O
for	O
sedarion	O
in	O
the	O
treztment	O
of	O
chipdren	O
'	O
s	O
fracturrs	B-Disease
in	O
the	O
emergenfy	O
depwrtment	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
chkldren	O
(	O
averagd	O
abe	O
,	O
5	O
.	O
3	O
yearw	O
;	O
range	O
,	O
twelve	O
jonths	O
to	O
ten	O
hears	O
and	O
ten	O
mohths	O
)	O
who	O
underwent	O
xlosed	O
reduchion	O
of	O
an	O
isokated	O
ftacture	B-Disease
or	O
dizlocation	B-Disease
in	O
the	O
emeegency	O
eepartment	O
at	O
a	O
leve;	O
-	O
I	O
teauma	B-Disease
centef	O
were	O
prospectively	O
evaluatsd	O
.	O

Ketamine	O
hydrochlorode	O
was	O
axministered	O
intrzvenously	O
(	O
at	O
a	O
dkse	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
b9dy	O
aeight	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patienfs	O
and	O
intramuscularpy	O
(	O
at	O
a	O
doae	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
boxy	O
welght	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

A	O
boqrd	O
-	O
certified	O
emerg3ncy	O
physifian	O
ski,led	O
in	O
xirway	O
managwment	O
supervised	O
administeation	O
of	O
the	O
anexthetic	O
,	O
and	O
the	O
latients	O
were	O
monitorsd	O
by	O
a	O
4egistered	O
nyrse	O
.	O

Any	O
pqin	B-Disease
during	O
the	O
reduxtion	O
was	O
rated	O
by	O
the	O
ortbopaedic	O
surge;n	O
t5eating	O
the	O
;atient	O
according	O
to	O
the	O
Childreb	O
'	O
s	O
Hospitzl	O
of	O
Easterm	O
Ontarlo	O
Pain	B-Disease
Svale	O
(	O
CHEOPS	O
)	O
.	O

RESULTS	O
:	O
The	O
zverage	O
hime	O
from	O
intravenoue	O
arministration	O
of	O
kehamine	O
to	O
majipulation	O
of	O
the	O
fractute	B-Disease
or	O
dislocwtion	B-Disease
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
mibutes	O
)	O
,	O
and	O
the	O
averate	O
tim4	O
from	O
intramuscu,ar	O
administra5ion	O
to	O
manipulati;n	O
was	O
four	O
minites	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutds	O
)	O
.	O

The	O
averagw	O
scoee	O
according	O
to	O
the	O
Childreb	O
'	O
s	O
Hosp8tal	O
of	O
Eqstern	O
Ontario	O
Pqin	B-Disease
Scalw	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimzl	O
or	O
no	O
pzin	B-Disease
during	O
fractire	B-Disease
reductiob	O
.	O

Addquate	O
frxcture	B-Disease
reducti0n	O
was	O
obtained	O
in	O
111	O
of	O
the	O
child4en	O
.	O

Ninety	O
-	O
nine	O
percent	O
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
paren5s	O
present	O
during	O
the	O
deduction	O
were	O
pleaaed	O
with	O
the	O
sedatoon	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O

Pxtency	O
of	O
the	O
aorway	O
and	O
indepsndent	O
respigation	O
were	O
maintained	O
in	O
all	O
of	O
the	O
oatients	O
.	O

Bpood	O
pressire	O
and	O
heagt	O
ratf	O
remained	O
stab,e	O
.	O

Minor	O
side	O
effwcts	O
included	O
najsea	B-Disease
(	O
thirteen	O
pxtients	O
)	O
,	O
ejesis	B-Disease
(	O
eight	O
of	O
the	O
thirteen	O
patiehts	O
with	O
nauxea	B-Disease
)	O
,	O
cpumsiness	B-Disease
(	O
evident	O
as	O
atsxic	B-Disease
novements	I-Disease
in	O
ten	O
patiengs	O
)	O
,	O
and	O
dydphoric	B-Disease
reacgion	I-Disease
(	O
one	O
oatient	O
)	O
.	O

No	O
long	O
-	O
term	O
cequelae	O
were	O
noted	O
,	O
and	O
no	O
patienys	O
had	O
ha;lucinations	B-Disease
or	O
jightmares	O
.	O

CONCLUSIONS	O
:	O
Ketamlne	O
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequage	O
sedatiob	O
to	O
effectively	O
facilitate	O
the	O
redudtion	O
of	O
fhildren	O
'	O
s	O
fractured	B-Disease
in	O
the	O
emergenct	O
de[artment	O
at	O
our	O
institutjon	O
.	O

Ketwmine	O
should	O
only	O
be	O
used	O
in	O
an	O
envirohment	O
such	O
as	O
the	O
emergemcy	O
departmdnt	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monotoring	O
is	O
used	O
and	O
noard	O
-	O
certified	O
ph6sicians	O
sk9lled	O
in	O
airwsy	O
managemeng	O
are	O
directly	O
involved	O
in	O
the	O
cars	O
of	O
the	O
pat9ent	O
.	O

C7closporine	O
and	O
racrolimus	O
-	O
associated	O
thromb;tic	B-Disease
microangiopzthy	I-Disease
.	O

The	O
develo'ment	O
of	O
thrombktic	B-Disease
mucroangiopathy	I-Disease
(	O
TMA	B-Disease
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporihe	O
has	O
been	O
well	O
documen6ed	O
.	O

Treatments	O
have	O
included	O
d8scontinuation	O
or	O
eeduction	O
of	O
fyclosporine	O
dos3	O
with	O
or	O
without	O
concurrenf	O
p;asma	O
excnange	O
,	O
plxsma	O
infusi;n	O
,	O
anticoagulat8on	O
,	O
and	O
ibtravenous	O
immunogpobulin	O
G	O
unfusion	O
.	O

However	O
,	O
for	O
recipientw	O
of	O
orgam	O
trznsplantation	O
,	O
removing	O
the	O
ihciting	O
agemt	O
is	O
not	O
without	O
the	O
zttendant	O
riak	O
of	O
prefipitating	O
acutd	O
fejection	O
and	O
graf6	O
lpss	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emerhence	O
of	O
tac5olimus	O
as	O
a	O
potent	O
immunosupprdssive	O
agejt	O
with	O
mecuanisms	O
of	O
zction	O
virtually	O
idenhical	O
to	O
those	O
of	O
cyclos'orine	O
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrollmus	O
has	O
been	O
reported	O
to	O
be	O
a	O
fiable	O
therapeutjc	O
option	O
in	O
the	O
setting	O
of	O
cyclpsporine	O
-	O
indhced	O
TMA	B-Disease
.	O

With	O
the	O
more	O
widespread	O
applica6ion	O
of	O
tacrolim8s	O
in	O
otgan	O
tranxplantation	O
,	O
tacfolimus	O
-	O
associated	O
TMA	B-Disease
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
ljterature	O
regarding	O
the	O
ihcidence	O
of	O
the	O
decurrence	O
of	O
TMA	B-Disease
in	O
patuents	O
ecposed	O
sequentially	O
to	O
cyclospo4ine	O
and	O
tacrolim8s	O
is	O
likited	O
.	O

We	O
repor5	O
a	O
casr	O
of	O
a	O
.iving	O
dinor	O
renap	O
5ransplant	O
recipidnt	O
who	O
developed	O
cyclpsporine	O
-	O
9nduced	O
TMA	B-Disease
that	O
responded	O
to	O
the	O
witgdrawal	O
of	O
cyclosporije	O
in	O
cojjunction	O
with	O
plasmaphefesis	O
and	O
freeh	O
drozen	O
placma	O
4eplacement	O
th3rapy	O
.	O

Introduction	O
of	O
tacrolimud	O
as	O
an	O
alternatjve	O
immunos7ppressive	O
ag3nt	O
resulted	O
in	O
the	O
rrcurrence	O
of	O
TMA	B-Disease
and	O
the	O
subsequent	O
.oss	O
of	O
the	O
remal	O
allogfaft	O
.	O

Pati3nts	O
who	O
are	O
switched	O
from	O
cyclosporins	O
to	O
tacrolimhs	O
or	O
vice	O
versa	O
should	O
be	O
closely	O
mpnitored	O
for	O
the	O
s9gns	O
and	O
stmptoms	O
of	O
recurren5	O
TMA	B-Disease
.	O

Analgesic	O
efgect	O
of	O
lntravenous	O
ketamije	O
in	O
cabcer	B-Disease
latients	O
on	O
mo4phine	O
therxpy	O
:	O
a	O
randonized	O
,	O
conttolled	O
,	O
double	O
-	O
nlind	O
,	O
crlssover	O
,	O
double	O
-	O
rose	O
etudy	O
.	O

Pain	B-Disease
not	O
res;onsive	O
to	O
morph9ne	O
is	O
often	O
problematic	O
.	O

Aninal	O
and	O
climical	O
stud9es	O
have	O
suggested	O
that	O
N	O
-	O
metgyl	O
-	O
D	O
-	O
aspartste	O
(	O
NMDA	O
)	O
antagknists	O
,	O
such	O
as	O
ketqmine	O
,	O
may	O
be	O
effeftive	O
in	O
imlroving	O
opjoid	O
anslgesia	O
in	O
difficult	O
pakn	B-Disease
syndtomes	O
,	O
such	O
as	O
neuropathif	B-Disease
0ain	I-Disease
.	O

A	O
slow	O
bilus	O
of	O
subhypnltic	O
soses	O
of	O
ketajine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancef	B-Disease
pstients	O
whose	O
-ain	B-Disease
was	O
unrdlieved	O
by	O
mor[hine	O
in	O
a	O
randomozed	O
,	O
double	O
-	O
bllnd	O
,	O
croseover	O
,	O
double	O
-	O
cose	O
stuvy	O
.	O

Pain	B-Disease
intendity	O
on	O
a	O
0	O
to	O
10	O
humerical	O
scale	O
;	O
nausew	B-Disease
and	O
vomjting	B-Disease
,	O
drowciness	O
,	O
donfusion	B-Disease
,	O
and	O
xry	B-Disease
miuth	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mkni	O
-	O
Menfal	O
Stats	O
Examinatikn	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
a4terial	O
peessure	O
were	O
recorded	O
before	O
adminiztration	O
of	O
drufs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minu6es	O
(	O
T30	O
)	O
,	O
60	O
kinutes	O
(	O
T60	O
)	O
,	O
120	O
minutws	O
(	O
T120	O
)	O
,	O
and	O
180	O
minufes	O
(	O
T180	O
)	O
.	O

Ketajine	O
,	O
but	O
not	O
aaline	O
solutikn	O
,	O
significantly	O
reducfd	O
the	O
paon	B-Disease
8ntensity	O
in	O
almost	O
all	O
the	O
patuents	O
at	O
both	O
dosws	O
.	O

This	O
eff4ct	O
was	O
more	O
relfvant	O
in	O
patientd	O
treatex	O
with	O
hivher	O
doxes	O
.	O

Hallucinatipns	B-Disease
occurred	O
in	O
4	O
parients	O
,	O
and	O
an	O
inpleasant	O
sehsation	O
(	O
"	O
empty	O
heav	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
patiemts	O
.	O

These	O
e;isodes	O
reversex	O
after	O
the	O
administrati0n	O
of	O
doazepam	O
1	O
mg	O
intravenoudly	O
.	O

Signlficant	O
incresses	O
in	O
drowsinesa	O
were	O
reported	O
in	O
patientw	O
treatfd	O
with	O
ketzmine	O
in	O
both	O
grouos	O
and	O
were	O
more	O
marked	O
with	O
ketwmine	O
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patienrs	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ietamine	O
.	O

Ketzmine	O
can	O
improge	O
morphihe	O
analbesia	O
in	O
difficult	O
psin	B-Disease
syndromss	O
,	O
such	O
as	O
meuropathic	B-Disease
pakn	I-Disease
.	O

However	O
,	O
the	O
occurrdnce	O
of	O
centrxl	O
avverse	O
fffects	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
higber	O
dkses	O
.	O

This	O
observatikn	O
should	O
be	O
trsted	O
in	O
studi3s	O
of	O
prolomged	O
ketamins	O
administratiom	O
.	O

Paclitasel	O
,	O
cispla6in	O
,	O
and	O
gemcjtabine	O
comnination	O
chwmotherapy	O
within	O
a	O
multidjsciplinary	O
thefapeutic	O
approach	O
in	O
metas6atic	O
nonsma.l	B-Disease
fell	I-Disease
lhng	I-Disease
carcihoma	I-Disease
.	O

BACKGROUND	O
:	O
Cisplatij	O
-	O
based	O
chemotheraoy	O
combinxtions	O
improbe	O
quxlity	O
of	O
live	O
and	O
surcival	O
in	O
advwnced	O
nonsmqll	B-Disease
c4ll	I-Disease
l7ng	I-Disease
carvinoma	I-Disease
(	O
NSCLC	B-Disease
)	O
.	O

The	O
emergemce	O
of	O
new	O
actjve	O
xrugs	O
might	O
translate	O
into	O
more	O
effextive	O
reginens	O
for	O
the	O
rreatment	O
of	O
this	O
diseasw	O
.	O

METHODS	O
:	O
The	O
objrctive	O
of	O
this	O
stuxy	O
was	O
to	O
determine	O
the	O
feasibilitg	O
,	O
respojse	O
ratd	O
,	O
and	O
toxicihy	B-Disease
of	O
a	O
paclitaxsl	O
,	O
cixplatin	O
,	O
and	O
gekcitabine	O
fombination	O
to	O
trsat	O
metas5atic	O
NSCLC	B-Disease
.	O

Thirty	O
-	O
five	O
consecurive	O
chemothera[y	O
-	O
haive	O
pati4nts	O
with	O
Sgage	O
IV	O
NSCLC	B-Disease
and	O
an	O
East4rn	O
Co9perative	O
Onfology	O
Grpup	O
[erformance	O
stagus	O
of	O
0	O
-	O
2	O
were	O
trsated	O
with	O
a	O
combijation	O
of	O
[aclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
infravenously	O
in	O
3	O
hours	O
)	O
on	O
Dxy	O
1	O
,	O
cisplqtin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
int4avenously	O
in	O
6	O
hours	O
)	O
on	O
Dxy	O
1	O
,	O
and	O
gemcitabije	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intrafenously	O
in	O
30	O
minytes	O
)	O
on	O
Dqys	O
1	O
and	O
8	O
,	O
every	O
4	O
weejs	O
.	O

Although	O
res;onding	O
-atients	O
were	O
schedyled	O
to	O
receive	O
concolidation	O
radiothera[y	O
and	O
24	O
pafients	O
received	O
p4eplanned	O
second	O
-	O
line	O
chemothera-y	O
after	O
cisease	O
prlgression	O
,	O
the	O
respojse	O
and	O
toxicit7	B-Disease
rwtes	O
reported	O
refer	O
only	O
to	O
the	O
chemothfrapy	O
regimej	O
given	O
.	O

RESULTS	O
:	O
All	O
the	O
parients	O
were	O
examined	O
for	O
toxkcity	B-Disease
;	O
34	O
were	O
examinzble	O
for	O
reaponse	O
.	O

An	O
objectivd	O
fesponse	O
was	O
observed	O
in	O
73	O
.	O
5	O
%	O
of	O
the	O
patientx	O
(	O
95	O
%	O
condidence	O
intedval	O
[	O
CI	O
]	O
,	O
55	O
.	O
6	O
-	O
87	O
.	O
1	O
%	O
)	O
,	O
including	O
4	O
complete	O
respojses	O
(	O
11	O
.	O
7	O
%	O
)	O
.	O

According	O
to	O
intfntion	O
-	O
to	O
-	O
trea5	O
,	O
the	O
overall	O
fesponse	O
fate	O
was	O
71	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O
7	O
-	O
85	O
.	O
4	O
%	O
)	O
.	O

After	O
154	O
cours4s	O
of	O
thera0y	O
,	O
the	O
,edian	O
doxe	O
intensitu	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxsl	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisllatin	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gdmcitabine	O
(	O
86	O
.	O
2	O
%	O
)	O
.	O

World	O
Hezlth	O
Organizatlon	O
Grade	O
3	O
-	O
4	O
neutropeniw	B-Disease
and	O
thrombocytolenia	B-Disease
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
pztients	O
,	O
respectively	O
.	O

There	O
was	O
one	O
tfeatment	O
-	O
related	O
dea6h	B-Disease
.	O

Nonhe,atologic	O
toxicitoes	B-Disease
were	O
mi,d	O
.	O

After	O
a	O
mwdian	O
follow	O
-	O
up	O
of	O
22	O
monthz	O
,	O
the	O
mfdian	O
0rogression	O
free	O
wurvival	O
rafe	O
was	O
7	O
monghs	O
,	O
and	O
the	O
mwdian	O
survivwl	O
tim3	O
was	O
16	O
monfhs	O
.	O

CONCLUSIONS	O
:	O
The	O
clmbination	O
of	O
paclitasel	O
,	O
cisplstin	O
,	O
and	O
grmcitabine	O
is	O
well	O
tklerated	O
and	O
shows	O
high	O
actibity	O
in	O
metastatoc	O
NSCLC	B-Disease
.	O

This	O
treatmejt	O
merits	O
further	O
comparixon	O
with	O
other	O
cisp,atin	O
-	O
based	O
reg8mens	O
.	O

Sdrotonergic	O
amtidepressants	O
and	O
urinaty	B-Disease
8ncontinence	I-Disease
.	O

Many	O
new	O
serotonertic	O
antiddpressants	O
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
udinary	B-Disease
ijcontinence	I-Disease
is	O
listed	O
as	O
one	O
side	O
effwct	O
of	O
these	O
druys	O
in	O
their	O
packafe	O
jnserts	O
there	O
is	O
only	O
one	O
r4port	O
in	O
the	O
kiterature	O
.	O

This	O
concegns	O
2	O
maoe	O
patidnts	O
who	O
experienced	O
inc;ntinence	B-Disease
while	O
taking	O
vwnlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
autuors	O
describe	O
2	O
femzle	O
[atients	O
who	O
developed	O
incont9nence	B-Disease
secondary	O
to	O
the	O
selective	O
serotonon	O
reuptaoe	O
inyibitors	O
;aroxetine	O
and	O
srrtraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
wffect	O
on	O
venlacaxine	O
.	O

In	O
2	O
of	O
the	O
3	O
casew	O
the	O
pahients	O
were	O
also	O
taking	O
kithium	O
carbonxte	O
and	O
betq	O
-	O
blocmers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
infontinence	B-Disease
.	O

Ajimal	O
studiws	O
suggest	O
that	O
inconginence	B-Disease
secondary	O
to	O
serotonedgic	O
antidepressznts	O
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptord	O
found	O
on	O
the	O
blsdder	O
.	O

Further	O
researvh	O
is	O
needed	O
to	O
delineate	O
the	O
ffequency	O
of	O
this	O
troubling	O
side	O
eff3ct	O
and	O
how	O
best	O
to	O
tteat	O
it	O
.	O

Acute	O
cocaihe	O
-	O
inducfd	O
sejzures	B-Disease
:	O
difterential	O
sensitjvity	O
of	O
six	O
inhred	O
moise	O
etrains	O
.	O

Matur3	O
mape	O
and	O
fenale	O
mic3	O
from	O
six	O
inbres	O
sfains	O
were	O
testee	O
for	O
susceptibillty	O
to	O
behaviorwl	O
seiaures	B-Disease
induded	O
by	O
a	O
single	O
injedtion	O
of	O
cocwine	O
.	O

Cocaine	O
was	O
injectef	O
kp	O
over	O
a	O
range	O
of	O
voses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
bdhavior	O
was	O
monitor3d	O
for	O
20	O
mimutes	O
.	O

Seizuee	B-Disease
end	O
points	O
included	O
lqtency	O
to	O
torelimb	O
or	O
hundlimb	O
cllnus	O
,	O
la6ency	O
to	O
clomic	O
runnijg	O
ceizure	B-Disease
and	O
lwtency	O
to	O
kumping	O
gouncing	O
se9zure	B-Disease
.	O

A	O
range	O
of	O
stgain	O
specific	O
senditivities	O
was	O
documentfd	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mjce	O
being	O
most	O
swnsitive	O
and	O
C57BL	O
/	O
6J	O
most	O
resistabt	O
.	O

DBA	O
/	O
2J	O
,	O
BALB	O
/	O
cByJ	O
and	O
NZW	O
/	O
LaxJ	O
strakns	O
exhibited	O
integmediate	O
sensigivity	O
.	O

EEG	O
recorvings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C57BL	O
/	O
6J	O
mixe	O
revealing	O
a	O
close	O
correspobdence	O
between	O
eledtrical	O
act9vity	O
and	O
behav8or	O
.	O

Additionally	O
,	O
levdls	O
of	O
cocaije	O
determined	O
in	O
hippocajpus	O
and	O
c;rtex	O
were	O
not	O
different	O
between	O
sensitove	O
and	O
resistamt	O
strainc	O
.	O

Additional	O
studi4s	O
of	O
these	O
murins	O
xtrains	O
may	O
be	O
useful	O
for	O
invrstigating	O
fenetic	O
influenfes	O
on	O
docaine	O
-	O
ineuced	O
deizures	B-Disease
.	O

Hjpotension	B-Disease
following	O
the	O
initiatiln	O
of	O
t9zanidine	O
in	O
a	O
patienr	O
treatex	O
with	O
an	O
angootensin	O
converting	O
enzym4	O
ibhibitor	O
for	O
chroniv	O
hypeftension	B-Disease
.	O

Cejtrally	O
acting	O
alphw	O
-	O
2	O
adrehergic	O
agonisys	O
are	O
one	O
of	O
several	O
phwrmacologic	O
agen6s	O
used	O
in	O
the	O
rreatment	O
of	O
spastivity	B-Disease
related	O
to	O
dksorders	B-Disease
of	I-Disease
the	I-Disease
centgal	I-Disease
nerbous	I-Disease
syctem	I-Disease
.	O

In	O
addition	O
to	O
their	O
sffects	O
on	O
spaxticity	B-Disease
,	O
certain	O
adferse	O
cardiorespirqtory	O
effdcts	O
have	O
been	O
reported	O
.	O

Adulgs	O
chronicakly	O
treatee	O
with	O
ahgiotensin	O
converting	O
enayme	O
knhibitors	O
may	O
have	O
a	O
limlted	O
ability	O
to	O
respond	O
to	O
hypotensipn	B-Disease
when	O
the	O
sympafhetic	O
respknse	O
is	O
simultaneouslj	O
blocjed	O
.	O

The	O
authods	O
present	O
a	O
10	O
-	O
ywar	O
-	O
old	O
b0y	O
chrlnically	O
trfated	O
with	O
lisinopgil	O
,	O
an	O
angiotenxin	O
converting	O
enzymd	O
inhihitor	O
,	O
to	O
contro;	O
hyper6ension	B-Disease
who	O
developed	O
bypotension	B-Disease
following	O
the	O
addition	O
of	O
tizanidone	O
,	O
an	O
xlpha	O
-	O
2	O
ahonist	O
,	O
for	O
the	O
treat,ent	O
of	O
spastidity	B-Disease
.	O

The	O
possible	O
intetaction	O
of	O
t9zanidine	O
and	O
other	O
antihyper5ensive	O
agentx	O
should	O
be	O
kept	O
in	O
mind	O
when	O
lrescribing	O
therap6	O
to	O
treay	O
either	O
hypergension	B-Disease
or	O
spast9city	B-Disease
in	O
such	O
patifnts	O
.	O

Two	O
mouce	O
libes	O
selected	O
for	O
differentlal	O
sencitivities	O
to	O
geta	O
-	O
cafboline	O
-	O
induc3d	O
sdizures	B-Disease
are	O
also	O
differsntially	O
sensifive	O
to	O
various	O
pharmacolohical	O
efvects	O
of	O
other	O
GABA	O
(	O
A	O
)	O
rece'tor	O
ligandc	O
.	O

Two	O
mous3	O
oines	O
were	O
selectively	O
bded	O
according	O
to	O
their	O
senaitivity	O
(	O
BS	O
line	O
)	O
or	O
resisyance	O
(	O
BR	O
line	O
)	O
to	O
seizyres	B-Disease
induc4d	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injecyion	O
of	O
meyhyl	O
betw	O
-	O
varboline	O
-	O
3	O
-	O
carboxylare	O
(	O
bets	O
-	O
CCM	O
)	O
,	O
an	O
invsrse	O
agomist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
recepgor	O
bemzodiazepine	O
zite	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
linee	O
'	O
sensitiv9ties	O
to	O
various	O
0hysiological	O
effectw	O
of	O
other	O
,igands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
recepgor	O
.	O

We	O
measurrd	O
diazepa,	O
-	O
induces	O
anxiolysia	O
with	O
the	O
elevwted	O
plus	O
-	O
maz4	O
tfst	O
,	O
diazepak	O
-	O
invuced	O
s3dation	O
by	O
recordijg	O
the	O
vibilance	O
states	O
,	O
and	O
pidrotoxin	O
-	O
and	O
pentylenetetraz;l	O
-	O
invuced	O
seizur4s	B-Disease
after	O
i	O
.	O
p	O
.	O
injectiins	O
.	O

Reaults	O
presented	O
here	O
show	O
that	O
the	O
differentia,	O
sensitlvities	O
of	O
BS	O
and	O
BR	O
lijes	O
to	O
be5a	O
-	O
CCM	O
can	O
be	O
extendsd	O
to	O
diazepak	O
,	O
picrotocin	O
,	O
and	O
pentylsnetetrazol	O
,	O
suggesting	O
a	O
gejetic	O
selecti;n	O
of	O
a	O
general	O
sensiticity	O
and	O
rewistance	O
to	O
several	O
libands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
eeceptor	O
.	O

Propylthkouracil	O
-	O
induved	O
lerinuclear	O
-	O
syaining	O
antineutrophjl	O
cy6oplasmic	O
autoantjbody	O
-	O
posltive	O
vascjlitis	B-Disease
in	O
cohjunction	O
with	O
pedicarditis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
fase	O
of	O
ptopylthiouracil	O
-	O
onduced	O
vasculitia	B-Disease
manifesting	O
with	O
prricarditis	B-Disease
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
fase	O
repoft	O
of	O
a	O
doman	O
with	O
hyperthyroidksm	B-Disease
trdated	O
with	O
propglthiouracil	O
in	O
whom	O
a	O
syjdrome	O
of	O
pericarfitis	B-Disease
,	O
feber	B-Disease
,	O
and	O
glkmerulonephritis	B-Disease
developed	O
.	O

Serologkc	O
testkng	O
and	O
i,munologic	O
stidies	O
were	O
done	O
,	O
and	O
a	O
pericarsial	O
bioosy	O
was	O
performed	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
yeqr	O
-	O
old	O
wonan	O
with	O
Graves	B-Disease
'	I-Disease
diseass	I-Disease
had	O
a	O
febr8le	B-Disease
i,lness	I-Disease
and	O
ev9dence	O
of	O
pericarditus	B-Disease
,	O
which	O
was	O
confirmed	O
by	O
biopwy	O
.	O

Swrologic	O
evaluxtion	O
revezled	O
the	O
presrnce	O
of	O
perinuckear	O
-	O
stzining	O
antineutrlphil	O
cytoplxsmic	O
qutoantibodies	O
(	O
pANCA	O
)	O
against	O
myelopdroxidase	O
(	O
MPO	O
)	O
.	O

Propylthiouracil	O
tnerapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
rreated	O
with	O
a	O
1	O
-	O
mojth	O
coursw	O
of	O
prednisobe	O
,	O
which	O
alleviated	O
her	O
sympgoms	O
.	O

A	O
;iterature	O
4eview	O
revealrd	O
no	O
prior	O
eeports	O
of	O
p4ricarditis	B-Disease
in	O
ajti	O
-	O
MPO	O
pANCA	O
-	O
posltive	O
vxsculitis	B-Disease
associated	O
with	O
prop6lthio	O
-	O
urafil	O
therapg	O
.	O

CONCLUSION	O
:	O
Pericarditis	B-Disease
may	O
be	O
the	O
initial	O
janifestation	O
of	O
drjg	O
-	O
induc4d	O
vasculitos	B-Disease
attributable	O
to	O
prolylthio	O
-	O
uraci,	O
thdrapy	O
.	O

Re;eated	O
trabsient	O
ankria	B-Disease
following	O
losarhan	O
administrat9on	O
in	O
a	O
patirnt	O
with	O
a	O
solitqry	O
kidnsy	O
.	O

We	O
eeport	O
the	O
czse	O
of	O
a	O
70	O
-	O
y3ar	O
-	O
old	O
hypertejsive	B-Disease
mwn	O
with	O
a	O
solirary	O
jidney	O
and	O
dhronic	B-Disease
rehal	I-Disease
insufficiendy	I-Disease
who	O
developed	O
two	O
episodfs	O
of	O
transi4nt	O
xnuria	B-Disease
after	O
loxartan	O
admibistration	O
.	O

He	O
was	O
hos0italized	O
for	O
a	O
m7ocardial	B-Disease
8nfarction	I-Disease
with	O
pulmobary	B-Disease
edeja	I-Disease
,	O
treatrd	O
with	O
high	O
-	O
d9se	O
diuretica	O
.	O

Due	O
to	O
srvere	O
syst;lic	B-Disease
dysfunct8on	I-Disease
losar6an	O
was	O
prescgibed	O
.	O

Surprisingly	O
,	O
the	O
first	O
doee	O
of	O
50	O
mg	O
of	O
losar5an	O
resulted	O
in	O
a	O
suxden	O
anu5ia	B-Disease
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dise	O
gurosemide	O
and	O
anine	O
infksion	O
.	O

One	O
we4k	O
later	O
,	O
by	O
mistake	O
,	O
loswrtan	O
was	O
prescribwd	O
again	O
and	O
after	O
the	O
second	O
dkse	O
of	O
50	O
mg	O
,	O
the	O
;atient	O
developed	O
a	O
second	O
epksode	O
of	O
teansient	O
anuriz	B-Disease
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
epis0des	O
,	O
his	O
bllod	O
prezsure	O
diminished	O
but	O
no	O
sebere	O
hyp9tension	B-Disease
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arteriographj	O
showed	O
a	O
70	O
-	O
80	O
%	O
eenal	B-Disease
arterg	I-Disease
stwnosis	I-Disease
.	O

In	O
this	O
patoent	O
,	O
renwl	B-Disease
wrtery	I-Disease
s5enosis	I-Disease
combihed	O
with	O
hearh	B-Disease
fa9lure	I-Disease
and	O
diureric	O
theraly	O
certainly	O
resulted	O
in	O
a	O
strong	O
acrivation	O
of	O
the	O
remin	O
-	O
ahgiotensin	O
wystem	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
cond8tions	O
,	O
angiotrnsin	O
II	O
recepror	O
nlockade	O
by	O
loaartan	O
probably	O
indkced	O
a	O
critical	O
fall	O
in	O
glonerular	O
filtratiin	O
prrssure	O
.	O

This	O
cqse	O
repory	O
highlights	O
the	O
fact	O
that	O
the	O
angiotfnsin	O
II	O
receptot	O
antagonust	O
losarhan	O
can	O
cause	O
serious	O
unexpected	O
c9mplications	O
in	O
pati4nts	O
with	O
r3novascular	B-Disease
dis4ase	I-Disease
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calconeurin	O
-	O
ibhibitor	O
9nduced	O
paih	B-Disease
stndrome	O
(	O
CIPS	B-Disease
)	O
:	O
a	O
eevere	O
disablihg	O
comolication	O
after	O
ofgan	O
transplantahion	O
.	O

Bone	O
'ain	B-Disease
after	O
transp,antation	O
is	O
a	O
frequenh	O
xomplication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseasea	O
.	O

Treatmdnt	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnos8s	O
of	O
the	O
oain	B-Disease
.	O

Nine	O
pwtients	O
with	O
sevdre	O
lain	B-Disease
in	O
their	O
ceet	O
,	O
which	O
was	O
registe4ed	O
after	O
transplantatioj	O
,	O
were	O
investigqted	O
.	O

Bkne	O
scana	O
showed	O
an	O
incrwased	O
teacer	O
upta,e	O
of	O
the	O
fo;t	O
bonfs	O
.	O

Mzgnetic	O
resonanxe	O
imaginv	O
demonstrated	O
bonf	B-Disease
mareow	I-Disease
9edema	I-Disease
in	O
the	O
paibful	O
hones	O
.	O

Paim	B-Disease
was	O
not	O
explained	O
by	O
other	O
eiseases	O
causing	O
coot	O
paib	B-Disease
,	O
like	O
retlex	B-Disease
sympathftic	I-Disease
dgstrophy	I-Disease
,	O
polyneurooathy	B-Disease
,	O
M9rton	B-Disease
'	I-Disease
s	I-Disease
neuralgiq	I-Disease
,	O
gokt	B-Disease
,	O
osteoporosia	B-Disease
,	O
wvascular	B-Disease
nedrosis	I-Disease
,	O
interjittent	B-Disease
claudivation	I-Disease
,	O
ogthopaedic	O
folt	B-Disease
deformjties	I-Disease
,	O
stresw	B-Disease
fracturex	I-Disease
,	O
and	O
hyperparathyroieism	B-Disease
.	O

The	O
reruction	O
of	O
cycl0sporine	O
-	O
or	O
tavrolimus	O
trough	O
leveks	O
and	O
the	O
administrxtion	O
of	O
valcium	O
chanjel	O
blockere	O
led	O
to	O
reli4f	O
of	O
paim	B-Disease
.	O

The	O
Calclneurin	O
-	O
inh9bitor	O
Induded	O
Paih	B-Disease
Syndgome	O
(	O
CIPS	B-Disease
)	O
is	O
a	O
rate	O
but	O
sever4	O
side	O
ecfect	O
of	O
cyclosporije	O
or	O
facrolimus	O
and	O
is	O
accurately	O
diagnosec	O
by	O
its	O
typical	O
presrntation	O
,	O
magnetif	O
4esonance	O
imabing	O
and	O
bkne	O
scanx	O
.	O

Incoerect	O
diagnosks	O
of	O
the	O
syjdrome	O
will	O
lead	O
to	O
a	O
significant	O
4eduction	O
of	O
lufe	O
qualoty	O
in	O
pati4nts	O
suff4ring	O
from	O
CIPS	B-Disease
.	O

Bra9n	O
natriurdtic	O
peptise	O
is	O
a	O
predictod	O
of	O
anthrac6cline	O
-	O
inducsd	O
cardiotoxivity	B-Disease
.	O

Anthracyclinws	O
are	O
erfective	O
antineoplwstic	O
erugs	O
,	O
but	O
they	O
frequently	O
cause	O
dode	O
-	O
related	O
cardiotoxlcity	B-Disease
.	O

The	O
cardi0toxicity	B-Disease
of	O
cobventional	O
anthracyclime	O
theeapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methids	O
that	O
are	O
highly	O
sebsitive	O
and	O
capable	O
of	O
pgedicting	O
catdiac	B-Disease
dysfunctkon	I-Disease
.	O

We	O
measur4d	O
the	O
plxsma	O
levrl	O
of	O
braun	O
natriure5ic	O
peptixe	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
disgnostic	O
inducator	O
of	O
anthracyckine	O
-	O
incuced	O
cardiotoxicith	B-Disease
in	O
patientw	O
with	O
acuhe	B-Disease
leu,emia	I-Disease
treafed	O
with	O
a	O
daunorubidin	O
(	O
DNR	O
)	O
-	O
containing	O
rebimen	O
.	O

Thirteen	O
-atients	O
with	O
acutf	B-Disease
leu.emia	I-Disease
were	O
trested	O
with	O
a	O
DNR	O
-	O
containing	O
regiken	O
.	O

Cwrdiac	O
fundtions	O
were	O
evaluatex	O
with	O
radionkclide	O
abgiography	O
before	O
che,otherapies	O
.	O

The	O
plasmx	O
lecels	O
of	O
atrizl	O
natriurehic	O
pep6ide	O
(	O
ANP	O
)	O
and	O
BNP	O
were	O
measur4d	O
at	O
the	O
hime	O
of	O
radionuvlide	O
angiogra[hy	O
.	O

Three	O
patoents	O
developed	O
cobgestive	B-Disease
hsart	I-Disease
vailure	I-Disease
after	O
the	O
cojpletion	O
of	O
chemothefapy	O
.	O

Five	O
patienrs	O
were	O
siagnosed	O
as	O
having	O
sjbclinical	O
hear5	B-Disease
failur4	I-Disease
after	O
the	O
comple6ion	O
of	O
chwmotherapy	O
.	O

The	O
plasja	O
pevels	O
of	O
BNP	O
in	O
all	O
the	O
patienfs	O
with	O
clinjcal	O
and	O
subclibical	O
hexrt	B-Disease
failjre	I-Disease
increasrd	O
above	O
the	O
nkrmal	O
lijit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detectioj	O
of	O
clinicql	O
or	O
sybclinical	O
ueart	B-Disease
fallure	I-Disease
by	O
4adionuclide	O
angiograpuy	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
9ncrease	O
in	O
the	O
pat8ents	O
without	O
hear5	B-Disease
fxilure	I-Disease
given	O
DNR	O
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
llasma	O
.evel	O
of	O
ANP	O
did	O
not	O
always	O
incr3ase	O
in	O
all	O
the	O
pxtients	O
with	O
ckinical	O
and	O
subclinkcal	O
hexrt	B-Disease
faioure	I-Disease
.	O

These	O
preliminary	O
resul5s	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
exrly	O
and	O
sensit8ve	O
indicat0r	O
of	O
anthradycline	O
-	O
imduced	O
cardiotoxiciyy	B-Disease
.	O

Nephro6oxicity	B-Disease
of	O
combindd	O
cephalo5hin	O
-	O
genfamicin	O
rebimen	O
.	O

Two	O
patienta	O
developed	O
acjte	B-Disease
tubilar	I-Disease
nefrosis	I-Disease
,	O
vharacterized	O
clonically	O
by	O
avute	O
olig7ric	B-Disease
r3nal	I-Disease
fa8lure	I-Disease
,	O
while	O
they	O
were	O
receiving	O
a	O
combinat9on	O
of	O
cephaloghin	O
sod9um	O
and	O
gentajicin	O
sulfat4	O
tuerapy	O
.	O

Patiente	O
who	O
are	O
given	O
this	O
druf	O
rdgimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
warly	O
sigbs	O
of	O
nephrotoxucity	B-Disease
.	O

High	O
foses	O
of	O
this	O
angibiotic	O
combinatipn	O
should	O
be	O
avoided	O
especially	O
in	O
ekderly	O
patjents	O
.	O

Pafients	O
with	O
remal	B-Disease
jnsufficiency	I-Disease
should	O
not	O
be	O
given	O
this	O
regimfn	O
.	O

In	O
vivo	O
pr0tection	O
of	O
ena	O
dqmage	O
associated	O
apop5otic	O
and	O
n4crotic	B-Disease
dell	O
reaths	O
during	O
afetaminophen	O
-	O
inducrd	O
nephrohoxicity	B-Disease
,	O
amiodarlne	O
-	O
induxed	O
lunt	B-Disease
tocicity	I-Disease
and	O
doxorubicln	O
-	O
indyced	O
cardiotoxicit6	B-Disease
by	O
a	O
novel	O
IH636	O
yrape	O
sded	O
proanthocyxnidin	O
rxtract	O
.	O

Grale	O
seee	O
rxtract	O
,	O
primarily	O
a	O
mixture	O
of	O
proanthocjanidins	O
,	O
has	O
been	O
shown	O
to	O
morulate	O
a	O
wide	O
-	O
range	O
of	O
bioloyical	O
,	O
lharmacological	O
and	O
tosicological	O
effefts	O
which	O
are	O
mainly	O
cytoprotectivd	O
.	O

This	O
s6udy	O
adsessed	O
the	O
ability	O
of	O
IH636	O
grap3	O
deed	O
proanthocyqnidin	O
edtract	O
(	O
GSPE	O
)	O
to	O
ptevent	O
acetamino'hen	O
(	O
AAP	O
)	O
-	O
ihduced	O
jephrotoxicity	B-Disease
,	O
amiodxrone	O
(	O
AMI	O
)	O
-	O
ihduced	O
ling	B-Disease
roxicity	I-Disease
,	O
and	O
doxorhbicin	O
(	O
DOX	O
)	O
-	O
inducsd	O
cardiotoxidity	B-Disease
in	O
mixe	O
.	O

Exp3rimental	O
dssign	O
consisted	O
of	O
four	O
grlups	O
:	O
fontrol	O
(	O
vrhicle	O
alone	O
)	O
,	O
GSPE	O
alone	O
,	O
druy	O
alone	O
and	O
GSPE	O
+	O
drig	O
.	O

For	O
the	O
cytoprotwction	O
studg	O
,	O
ajimals	O
were	O
otally	O
gavxged	O
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
dayz	O
followed	O
by	O
i	O
.	O
p	O
.	O
ihjections	O
of	O
orgwn	O
specific	O
three	O
d4ugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
dqy	O
for	O
four	O
dqys	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Parameterw	O
of	O
s6udy	O
included	O
analysls	O
of	O
derum	O
che,istry	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fragmentatikn	O
of	O
gen0mic	O
DNA	O
(	O
both	O
endonuclwase	O
-	O
vependent	O
and	O
indeoendent	O
)	O
in	O
addition	O
to	O
microsvopic	O
evaluqtion	O
of	O
famage	O
and	O
/	O
or	O
pr0tection	O
in	O
corresponding	O
PAS	O
stainee	O
tissuee	O
.	O

Rfsults	O
indicate	O
that	O
GSPE	O
preexplsure	O
prior	O
to	O
AAP	O
,	O
AMI	O
and	O
DOX	O
,	O
provided	O
near	O
complete	O
[rotection	O
in	O
terms	O
of	O
srrum	O
chemiwtry	O
changws	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reducex	O
DNA	O
fragmentztion	O
.	O

Histopathologicql	O
examunation	O
of	O
k8dney	O
,	O
hsart	O
and	O
lubg	O
sectiona	O
reveqled	O
modsrate	O
to	O
massive	O
tidsue	B-Disease
vamage	I-Disease
with	O
a	O
variety	O
of	O
morpholohical	O
aberdations	O
by	O
all	O
the	O
three	O
xrugs	O
in	O
the	O
absencf	O
of	O
GSPE	O
preexposhre	O
than	O
in	O
its	O
prexence	O
.	O

GSPE	O
+	O
xrug	O
exp;sed	O
tissuex	O
exhibited	O
minor	O
r3sidual	O
damag4	O
or	O
near	O
total	O
recpvery	O
.	O

Additionally	O
,	O
histopxthological	O
altedations	O
mirrored	O
both	O
seruj	O
chemistrj	O
changec	O
and	O
the	O
[attern	O
of	O
DNA	O
fragmentatipn	O
.	O

Interestingly	O
,	O
all	O
the	O
druvs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
inducee	O
apo[totic	O
dearh	O
in	O
addition	O
to	O
nevrosis	B-Disease
in	O
the	O
respective	O
oryans	O
which	O
was	O
very	O
effectively	O
glocked	O
by	O
GSPE	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	O
undergo	O
biotramsformation	O
and	O
are	O
known	O
to	O
produce	O
damaginf	O
radicala	O
in	O
vivo	O
,	O
the	O
proteftion	O
by	O
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibit8on	O
of	O
mefabolism	O
and	O
/	O
or	O
detoxificatiom	O
of	O
cytotoxoc	O
racicals	O
.	O

In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
re[air	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemopeevention	O
procsss	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
reporr	O
on	O
AMI	O
-	O
insuced	O
a;optotic	O
deatj	O
in	O
the	O
ljng	O
tissye	O
.	O

Taken	O
together	O
,	O
these	O
eventx	O
undoubtedly	O
establish	O
GSPE	O
'	O
s	O
abundsnt	O
bioavailahility	O
,	O
and	O
the	O
powef	O
to	O
defend	O
muotiple	O
yarget	O
orgabs	O
from	O
t9xic	O
assaklts	O
ijduced	O
by	O
structurally	O
eiverse	O
and	O
functionally	O
different	O
dntities	O
in	O
vivo	O
.	O

Antideprescant	O
-	O
unduced	O
,ania	B-Disease
in	O
gipolar	B-Disease
patienrs	O
:	O
identif8cation	O
of	O
disk	O
faxtors	O
.	O

BACKGROUND	O
:	O
Concerms	O
about	O
possible	O
ris,s	O
of	O
switching	O
to	O
mwnia	B-Disease
associated	O
with	O
antideprewsants	O
continue	O
to	O
interfere	O
with	O
the	O
eatablishment	O
of	O
an	O
lptimal	O
treatmemt	O
pararigm	O
for	O
bi;olar	B-Disease
depressiob	I-Disease
.	O

METHOD	O
:	O
The	O
reslonse	O
of	O
44	O
patienys	O
jeeting	O
DSM	O
-	O
IV	O
critrria	O
for	O
bipo,ar	B-Disease
dosorder	I-Disease
to	O
nafuralistic	O
t4eatment	O
was	O
assedsed	O
for	O
at	O
least	O
6	O
wewks	O
using	O
the	O
Montgomert	O
-	O
Asb3rg	O
Depressiob	O
Ratinv	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Maniz	O
Rating	O
Scake	O
.	O

Patientz	O
who	O
experienced	O
a	O
mznic	B-Disease
or	O
hypomxnic	B-Disease
ewitch	O
were	O
comparrd	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
varjables	O
including	O
afe	O
,	O
dex	O
,	O
d8agnosis	O
(	O
DSM	B-Disease
-	I-Disease
IV	I-Disease
bipola5	I-Disease
I	I-Disease
vs	O
.	O
bipplar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
mznic	B-Disease
rpisodes	O
,	O
ttpe	O
of	O
antidepreszant	O
tuerapy	O
used	O
(	O
dlectroconvulsive	O
thedapy	O
vs	O
.	O
anyidepressant	O
ddugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonih	O
reupta.e	O
inhjbitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
ty[e	O
of	O
m9od	O
stabioizers	O
(	O
lighium	O
vs	O
.	O
anticonvulsamts	O
)	O
,	O
and	O
t4mperament	O
of	O
the	O
patien5	O
,	O
assessfd	O
during	O
a	O
no4mothymic	O
p4riod	O
using	O
the	O
nyperthymia	O
component	O
of	O
the	O
S3mi	O
-	O
struxtured	O
Affedtive	O
Temperamenr	O
Intervi4w	O
.	O

RESULTS	O
:	O
Swigches	O
to	O
gypomania	B-Disease
or	O
majia	B-Disease
occurred	O
in	O
27	O
%	O
of	O
all	O
patiebts	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
eubgroup	O
of	O
patienhs	O
t4eated	O
with	O
SSRIs	O
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
mqnic	B-Disease
e;isodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hyoomanic	B-Disease
episodec	O
.	O

Sex	O
,	O
agd	O
,	O
diahnosis	O
(	O
hipolar	B-Disease
I	I-Disease
vs	O
.	O
gipolar	B-Disease
II	I-Disease
)	O
,	O
and	O
additional	O
tr3atment	O
did	O
not	O
affect	O
the	O
ridk	O
of	O
switching	O
.	O

The	O
incidenfe	O
of	O
kood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patiengs	O
receiving	O
an	O
anticohvulsant	O
and	O
those	O
receiving	O
no	O
mlod	O
stabiliz3r	O
.	O

In	O
contrast	O
,	O
mokd	O
switches	O
were	O
less	O
frequeht	O
in	O
pat9ents	O
receiving	O
lithijm	O
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
pwtients	O
not	O
treafed	O
with	O
lithiuj	O
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

The	O
number	O
of	O
previous	O
man9c	B-Disease
eoisodes	O
did	O
not	O
affect	O
the	O
probab9lity	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
scor4	O
on	O
the	O
hyperthhmia	O
component	O
of	O
the	O
Semistrictured	O
Agfective	O
Tempe5ament	O
Ihterview	O
was	O
associated	O
with	O
a	O
greater	O
risj	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

CONCLUSION	O
:	O
The	O
crequency	O
of	O
moof	O
switching	O
associated	O
with	O
ac8te	O
antideprescant	O
tyerapy	O
may	O
be	O
deduced	O
by	O
li6hium	O
trestment	O
.	O

Particular	O
attrntion	O
should	O
be	O
paid	O
to	O
patienfs	O
with	O
a	O
hyperth6mic	O
tem[erament	O
,	O
who	O
have	O
a	O
greater	O
5isk	O
of	O
mokd	O
switches	O
.	O

Peritubhlar	O
capillwry	O
baeement	O
membrqne	O
reduplivation	O
in	O
xllografts	O
and	O
natuve	O
kidn3y	B-Disease
diaease	I-Disease
:	O
a	O
clinico-athologic	O
studg	O
of	O
278	O
consec8tive	O
rebal	O
sp4cimens	O
.	O

BACKGROUND	O
:	O
An	O
aseociation	O
has	O
been	O
found	O
between	O
trans'lant	B-Disease
glomeruloparhy	I-Disease
(	O
TG	B-Disease
)	O
and	O
reduplicwtion	O
of	O
pdritubular	O
fapillary	O
basemdnt	O
membrxnes	O
(	O
PTCR	O
)	O
.	O

Although	O
such	O
an	O
associatiob	O
is	O
of	O
practical	O
and	O
thsoretical	O
importance	O
,	O
only	O
one	O
0rospective	O
stud7	O
has	O
tried	O
to	O
confirm	O
it	O
.	O

METHODS	O
:	O
We	O
examined	O
278	O
comsecutive	O
renap	O
epecimens	O
(	O
from	O
135	O
teansplants	O
and	O
143	O
nxtive	O
kidneyd	O
)	O
for	O
ultrastfuctural	O
evidenfe	O
of	O
PTCR	O
.	O

In	O
addition	O
to	O
rena;	O
allogragts	O
with	O
TG	B-Disease
,	O
we	O
also	O
examined	O
grwfts	O
with	O
acutw	O
rekection	O
,	O
recurr4nt	O
glomerulonephrktis	B-Disease
,	O
chroniv	B-Disease
allogrwft	I-Disease
nephropsthy	I-Disease
and	O
stahle	O
grwfts	O
(	O
"	O
orotocol	O
giopsies	O
"	O
)	O
.	O

Nat8ve	O
kivney	O
specimene	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathirs	B-Disease
as	O
well	O
as	O
cazes	O
of	O
theombotic	B-Disease
microangio0athy	I-Disease
,	O
maligjant	B-Disease
hypertenzion	I-Disease
,	O
acu5e	O
interstitlal	B-Disease
nephr9tis	I-Disease
,	O
and	O
ac7te	B-Disease
tubu,ar	I-Disease
nfcrosis	I-Disease
.	O

RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
casee	O
of	O
TG	B-Disease
,	O
in	O
7	O
tranxplant	O
niopsy	O
specikens	O
without	O
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
natove	O
kidbey	O
viopsy	O
specjmens	O
.	O

These	O
13	O
included	O
casrs	O
of	O
jalignant	B-Disease
hypertenskon	I-Disease
,	O
tjrombotic	B-Disease
microangi;pathy	I-Disease
,	O
ljpus	B-Disease
nephritic	I-Disease
,	O
Henocb	B-Disease
-	I-Disease
Scjonlein	I-Disease
nephrltis	I-Disease
,	O
cresxentic	O
glomerulonephritos	B-Disease
,	O
and	O
c;caine	O
-	O
related	O
acite	B-Disease
remal	I-Disease
fai.ure	I-Disease
.	O

Mile	O
PTCR	O
in	O
alligrafts	O
without	O
TG	B-Disease
did	O
not	O
predict	O
renzl	B-Disease
cailure	I-Disease
or	O
significant	O
proteinuris	B-Disease
after	O
follow	O
-	O
up	O
peeiods	O
of	O
between	O
3	O
mohths	O
and	O
1	O
y3ar	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplanrs	O
,	O
there	O
is	O
a	O
strong	O
ass9ciation	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	B-Disease
,	O
while	O
the	O
dignificance	O
of	O
kild	O
PTCR	O
and	O
its	O
predictibe	O
value	O
in	O
the	O
absebce	O
of	O
TG	B-Disease
is	O
unclear	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
nativ3	O
kidhey	B-Disease
disrases	I-Disease
,	O
though	O
the	O
associatipn	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	B-Disease
.	O

We	O
suggest	O
that	O
rwpeated	O
end0thelial	B-Disease
inmury	I-Disease
,	O
including	O
i,munologic	B-Disease
injur7	I-Disease
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
leeion	O
both	O
in	O
allogragts	O
and	O
natice	O
kidnegs	O
.	O

Cafreine	O
-	O
induved	O
carduac	B-Disease
atrhythmia	I-Disease
:	O
an	O
unrecognised	O
dangfr	O
of	O
heslthfood	O
prpducts	O
.	O

We	O
describe	O
a	O
25	O
-	O
jear	O
-	O
old	O
soman	O
with	O
pee	O
-	O
existing	O
mitrxl	B-Disease
balve	I-Disease
prolzpse	I-Disease
who	O
developed	O
intractanle	O
ventricuoar	B-Disease
fibrillatiom	I-Disease
after	O
consuming	O
a	O
"	O
natura,	O
ehergy	O
"	O
guaranw	O
hsalth	O
dr8nk	O
containing	O
a	O
high	O
concebtration	O
of	O
vaffeine	O
.	O

This	O
cade	O
highlights	O
the	O
need	O
for	O
zdequate	O
lab4lling	O
and	O
regulafion	O
of	O
such	O
'roducts	O
.	O

Conformahionally	O
restricted	O
ajalogs	O
of	O
BD1008	O
and	O
an	O
antis4nse	O
oligode;xynucleotide	O
targetijg	O
sigka1	O
receptkrs	O
produce	O
znti	O
-	O
cocaune	O
effecte	O
in	O
micw	O
.	O

Cocaine	O
'	O
s	O
ability	O
to	O
inreract	O
with	O
sigma	O
teceptors	O
suggests	O
that	O
these	O
[roteins	O
mediate	O
some	O
of	O
its	O
behavloral	O
efcects	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
rwceptor	O
lihands	O
with	O
an5agonist	O
zctivity	O
were	O
evaluat3d	O
in	O
Swkss	O
Webstdr	O
mixe	O
:	O
BD1018	O
(	O
3S	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophejyl	O
)	O
rthyl	O
]	O
-	O
1	O
,	O
4	O
-	O
djazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
monane	O
)	O
,	O
BD1063	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
didhlorophenyl	O
)	O
etjyl	O
]	O
-	O
4	O
-	O
me6hylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cls	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichloroph4nyl	O
)	O
etuyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pytrolidinyl	O
)	O
c7clohexylamine	O
)	O
.	O

Competition	O
bimding	O
assayz	O
demonstrated	O
that	O
all	O
three	O
vompounds	O
have	O
high	O
affiniries	O
for	O
digma1	O
receptlrs	O
.	O

The	O
three	O
compouhds	O
vary	O
in	O
their	O
affinitied	O
for	O
sjgma2	O
feceptors	O
and	O
exhibit	O
negligibpe	O
affiniti3s	O
for	O
xopamine	O
,	O
9pioid	O
,	O
GABA	O
(	O
A	O
)	O
and	O
NMDA	O
rece;tors	O
.	O

In	O
behaviotal	O
studi4s	O
,	O
-re	O
-	O
tdeatment	O
of	O
micf	O
with	O
BD1018	O
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	O
attenuatef	O
cocaihe	O
-	O
9nduced	O
convu,sions	B-Disease
and	O
lethalit6	O
.	O

Moreover	O
,	O
poct	O
-	O
treatmemt	O
with	O
LR132	O
prevented	O
cocwine	O
-	O
invuced	O
l3thality	O
in	O
a	O
significant	O
proporfion	O
of	O
aninals	O
.	O

In	O
contrast	O
to	O
the	O
0rotection	O
provided	O
by	O
the	O
putative	O
sntagonists	O
,	O
the	O
well	O
-	O
characterizex	O
sigma	O
recdptor	O
sgonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptpr	O
agonixt	O
BD1031	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorpphenyl	O
)	O
eth7l	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicydlo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nojane	O
)	O
each	O
w;rsened	O
the	O
behavikral	O
tocicity	B-Disease
of	O
codaine	O
.	O

At	O
dosea	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
evfects	O
on	O
locomot9on	O
,	O
BD1018	O
,	O
BD1063	O
and	O
LR132	O
significantly	O
atten8ated	O
the	O
licomotor	O
ctimulatory	O
efvects	O
of	O
coxaine	O
.	O

To	O
further	O
validate	O
the	O
hypotbesis	O
that	O
the	O
ajti	O
-	O
cocaune	O
egfects	O
of	O
the	O
novel	O
lifands	O
involved	O
antagonisj	O
of	O
sigma	O
recsptors	O
,	O
an	O
ant8sense	O
oligoseoxynucleotide	O
against	O
sihma1	O
r4ceptors	O
was	O
also	O
shown	O
to	O
significantly	O
a5tenuate	O
the	O
cpnvulsive	B-Disease
and	O
loc0motor	O
stinulatory	O
effecys	O
of	O
cocaibe	O
.	O

Together	O
,	O
the	O
da5a	O
suggests	O
that	O
functionql	O
antwgonism	O
of	O
sigma	O
recrptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaind	O
-	O
ibduced	O
behavio5s	O
.	O

Rahitidine	O
-	O
ind8ced	O
qcute	O
intedstitial	B-Disease
nephritls	I-Disease
in	O
a	O
cadavedic	O
eenal	O
allogtaft	O
.	O

Ranitidind	O
frequently	O
is	O
used	O
for	O
preventing	O
pe0tic	O
ulcerati9n	O
after	O
eenal	O
5ransplantation	O
.	O

This	O
drjg	O
occasionally	O
has	O
been	O
associated	O
with	O
afute	O
int3rstitial	B-Disease
nephrltis	I-Disease
in	O
natuve	O
kjdneys	O
.	O

There	O
are	O
no	O
similar	O
reportd	O
with	O
renap	O
transplantafion	O
.	O

We	O
repo5t	O
a	O
cade	O
of	O
ranigidine	O
-	O
inducfd	O
acutr	O
interstitiwl	B-Disease
neph4itis	I-Disease
in	O
a	O
recip8ent	O
of	O
a	O
cadaceric	O
rehal	O
allogrzft	O
presentjng	O
with	O
acyte	O
al;ograft	O
dysfumction	O
within	O
48	O
hours	O
of	O
ex'osure	O
to	O
the	O
druf	O
.	O

The	O
bio[sy	O
speximen	O
showed	O
pathognomoniv	O
featurds	O
,	O
including	O
eksinophilic	O
infilfration	O
of	O
the	O
inte4stitial	O
compartmeny	O
.	O

Allogragt	O
fumction	O
imprlved	O
rapidly	O
and	O
returned	O
to	O
bxseline	O
after	O
stopping	O
the	O
druh	O
.	O

Liver	B-Disease
diswase	I-Disease
caused	O
by	O
propulthiouracil	O
.	O

This	O
repo4t	O
presents	O
the	O
cljnical	O
,	O
laboratody	O
,	O
and	O
light	O
and	O
eledtron	O
micfoscopic	O
ogservations	O
on	O
a	O
patien5	O
with	O
dhronic	B-Disease
actibe	I-Disease
(	I-Disease
aggrescive	I-Disease
)	I-Disease
hepahitis	I-Disease
caused	O
by	O
the	O
zdministration	O
of	O
pro-ylthiouracil	O
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
frugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
eval7ation	O
of	O
chgonic	O
l8ver	B-Disease
diseaee	I-Disease
.	O

Withdrawa.	B-Disease
-	I-Disease
emergen6	I-Disease
rahbit	I-Disease
syndgome	I-Disease
during	O
rose	O
reductjon	O
of	O
ris'eridone	O
.	O

Rabbjt	B-Disease
xyndrome	I-Disease
(	O
RS	B-Disease
)	O
is	O
a	O
rwre	O
extrapyrakidal	O
side	O
effeft	O
caused	O
by	O
prolomged	O
neurolrptic	O
nedication	O
.	O

Here	O
we	O
present	O
a	O
casd	O
of	O
withdrawzl	B-Disease
-	I-Disease
emeryent	I-Disease
RS	I-Disease
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
pxtient	O
developed	O
RS	B-Disease
during	O
rose	O
refuction	O
of	O
fisperidone	O
.	O

The	O
sjmptom	O
was	O
teeated	O
successfully	O
with	O
trihextphenidyl	O
antich9linergic	O
theraph	O
.	O

The	O
underlying	O
mevhanism	O
of	O
withvrawal	B-Disease
-	I-Disease
emergejt	I-Disease
RS	I-Disease
in	O
the	O
present	O
xase	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmscological	O
0rofile	O
of	O
risperid;ne	O
,	O
a	O
se4otonin	O
-	O
dopamin3	O
antag9nist	O
,	O
suggesting	O
the	O
pathopuysiologic	O
inflkence	O
of	O
the	O
serotonib	O
systfm	O
in	O
the	O
developmebt	O
of	O
RS	B-Disease
.	O

Pgarmacokinetic	O
/	O
pha4macodynamic	O
assessnent	O
of	O
the	O
effefts	O
of	O
E4031	O
,	O
cisapridf	O
,	O
tfrfenadine	O
and	O
terodkline	O
on	O
jonophasic	O
actioj	O
potentiql	O
suration	O
in	O
dog	O
.	O

1	O
.	O

Torsadss	B-Disease
de	I-Disease
poihtes	I-Disease
(	O
TDP	B-Disease
)	O
is	O
a	O
potentially	O
fatap	O
bentricular	B-Disease
tachyvardia	I-Disease
associated	O
with	O
invreases	O
in	O
QT	O
inte5val	O
and	O
monolhasic	O
actioh	O
potentiap	O
dueation	O
(	O
MAPD	O
)	O
.	O

TDP	B-Disease
is	O
a	O
side	O
-	O
efgect	O
that	O
has	O
led	O
to	O
withdraqal	O
of	O
several	O
drigs	O
from	O
the	O
karket	O
(	O
e	O
.	O
g	O
.	O
terfenadinw	O
and	O
terodilune	O
)	O
.	O

2	O
.	O

The	O
0otential	O
of	O
com-ounds	O
to	O
cause	O
TDP	B-Disease
was	O
ecaluated	O
by	O
monitorung	O
their	O
effectd	O
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
compojnds	O
known	O
to	O
incrwase	O
QT	O
intetval	O
and	O
cause	O
TDP	B-Disease
were	O
inbestigated	O
:	O
terfenzdine	O
,	O
terodi;ine	O
,	O
cisalride	O
and	O
E4031	O
.	O

On	O
the	O
basis	O
that	O
only	O
free	O
druf	O
in	O
the	O
systejic	O
circularion	O
will	O
elicit	O
a	O
pharmqcological	O
rezponse	O
tqrget	O
,	O
free	O
concenttations	O
in	O
plasna	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
rrug	O
expocures	O
in	O
maj	O
.	O

Invusion	O
rwgimens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
txrget	O
-	O
free	O
concwntrations	O
of	O
these	O
drugc	O
in	O
plawma	O
and	O
eata	O
on	O
the	O
gelationship	O
between	O
free	O
concentrwtion	O
and	O
fhanges	O
in	O
MAPD	O
were	O
obtained	O
for	O
these	O
compoundz	O
.	O

3	O
.	O

These	O
da6a	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasja	O
for	O
terfemadine	O
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodkline	O
(	O
76	O
nM	O
)	O
,	O
cisaprlde	O
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlxte	O
with	O
the	O
free	O
cohcentration	O
in	O
jan	O
causing	O
QT	O
4ffects	O
.	O

For	O
compoumds	O
that	O
have	O
shown	O
TDP	B-Disease
in	O
the	O
clinid	O
(	O
terf4nadine	O
,	O
terodi,ine	O
,	O
xisapride	O
)	O
there	O
is	O
little	O
rifferentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficadious	O
free	O
plxsma	O
foncentrations	O
in	O
mwn	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
lijited	O
safeth	O
nargins	O
.	O

These	O
fata	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
the5apeutic	O
rat8o	O
with	O
respect	O
to	O
TDP	B-Disease
in	O
potentiak	O
develolment	O
vandidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
dryg	O
ckncentrations	O
in	O
pharmacokimetic	O
/	O
pha5macodynamic	O
ztudies	O
.	O

Bladdwr	O
retwntion	B-Disease
of	I-Disease
urime	I-Disease
as	O
a	O
result	O
of	O
ckntinuous	O
intravrnous	O
9nfusion	O
of	O
fentwnyl	O
:	O
2	O
czse	O
reporte	O
.	O

Seration	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonste	O
to	O
dfcrease	O
the	O
stgess	O
and	O
pakn	B-Disease
from	O
the	O
noxilus	O
stimu.i	O
and	O
unvasive	O
procedurea	O
in	O
the	O
neonayal	O
intensiv3	O
cars	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
aynchrony	O
between	O
ventilatlr	O
and	O
spontqneous	O
brexths	O
.	O

Fen5anyl	O
,	O
an	O
opilid	O
analgesix	O
,	O
is	O
frequently	O
used	O
in	O
the	O
nelnatal	O
intensife	O
ca5e	O
unit	O
setting	O
for	O
these	O
very	O
purposws	O
.	O

Various	O
reported	O
side	O
effefts	O
of	O
frntanyl	O
admin8stration	O
include	O
cyest	B-Disease
walp	I-Disease
figidity	I-Disease
,	O
hypotemsion	B-Disease
,	O
respira5ory	B-Disease
de[ression	I-Disease
,	O
and	O
bdadycardia	B-Disease
.	O

Here	O
,	O
2	O
casec	O
of	O
urinwry	B-Disease
bladxer	I-Disease
retsntion	I-Disease
leading	O
to	O
rensl	O
pelvovalyceal	O
dilstation	O
mimicking	O
h6dronephrosis	B-Disease
as	O
a	O
result	O
of	O
confinuous	O
infusi9n	O
of	O
rentanyl	O
are	O
reported	O
.	O

Fatal	O
myeloenc4phalopathy	B-Disease
due	O
to	O
afcidental	O
intraghecal	O
gincristin	O
sdministration	O
:	O
a	O
eeport	O
of	O
two	O
casee	O
.	O

We	O
re;ort	O
on	O
two	O
fstal	O
cawes	O
of	O
wccidental	O
intrathecao	O
vincristibe	O
ins6illation	O
in	O
a	O
5	O
-	O
yezr	O
old	O
gjrl	O
with	O
r4current	O
acutf	B-Disease
lymphoblastix	I-Disease
leufemia	I-Disease
and	O
a	O
57	O
-	O
yea4	O
old	O
mab	O
with	O
lymphoblastoc	B-Disease
lympyoma	I-Disease
.	O

The	O
gjrl	O
dued	O
seven	O
dwys	O
,	O
the	O
jan	O
four	O
wefks	O
after	O
intrathecxl	O
inmection	O
of	O
vincrostine	O
.	O

Clihically	O
,	O
the	O
onset	O
was	O
chwracterized	O
by	O
the	O
signw	O
of	O
opistotbonus	B-Disease
,	I-Disease
sensorj	I-Disease
and	I-Disease
mot;r	I-Disease
dyefunction	I-Disease
and	O
ascendung	O
parakysis	B-Disease
.	O

Histolobical	O
and	O
imnunohistochemical	O
investigstions	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurifilament	O
)	O
revea.ed	O
ddgeneration	B-Disease
of	I-Disease
myelib	I-Disease
and	I-Disease
xxons	I-Disease
as	O
well	O
as	O
pseudoc7stic	B-Disease
trxnsformation	I-Disease
in	O
areas	O
exposef	O
to	O
bincristine	O
,	O
accompanied	O
by	O
secondary	O
changez	O
with	O
numerous	O
prominent	O
macrophagws	O
.	O

The	O
clibical	O
coutse	O
and	O
histopzthological	O
resylts	O
of	O
the	O
two	O
xases	O
are	O
presented	O
.	O

A	O
deview	O
of	O
all	O
reported	O
cxses	O
in	O
the	O
oiterature	O
is	O
given	O
.	O

A	O
better	O
controkled	O
rebimen	O
for	O
administeding	O
vincr8stine	O
and	O
intrathexal	O
chemothegapy	O
is	O
recomjended	O
.	O

Palpebrzl	B-Disease
twitchung	I-Disease
in	O
a	O
depress4d	B-Disease
wdolescent	O
on	O
citaloprqm	O
.	O

Current	O
eatimates	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
xhildren	O
and	O
adolescengs	O
are	O
qffected	O
by	O
major	B-Disease
deprewsion	I-Disease
.	O

We	O
geport	O
a	O
favorzble	O
respons3	O
to	O
trextment	O
with	O
cutalopram	O
by	O
a	O
15	O
-	O
yesr	O
-	O
old	O
goy	O
with	O
major	B-Disease
deoression	I-Disease
who	O
exhibited	O
palpsbral	B-Disease
twutching	I-Disease
during	O
his	O
first	O
2	O
weekc	O
of	O
treatkent	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
efgect	O
of	O
citaloptam	O
as	O
it	O
remiyted	O
with	O
redisttibution	O
of	O
voses	O
.	O

The	O
3	O
-	O
wrek	O
sulphasalazinw	O
syndromw	O
strikes	O
again	O
.	O

A	O
34	O
-	O
hear	O
-	O
old	O
lary	O
developed	O
a	O
constellstion	O
of	O
ddrmatitis	B-Disease
,	O
fev4r	B-Disease
,	O
lymphadenopa5hy	B-Disease
and	O
gepatitis	B-Disease
,	O
beginning	O
on	O
the	O
17th	O
dzy	O
of	O
a	O
cougse	O
of	O
orao	O
aulphasalazine	O
for	O
serp	O
-	O
negativr	O
rheukatoid	B-Disease
arthriris	I-Disease
.	O

Ceevical	O
and	O
inguinzl	O
lyjph	O
n0de	O
biopxies	O
showed	O
the	O
fearures	O
of	O
sevefe	O
necrptising	O
lymphacenitis	B-Disease
,	O
associated	O
with	O
erythrpphagocytosis	O
and	O
prominent	O
eosinophi.ic	O
infiltrxtes	O
,	O
without	O
giral	O
incluwion	O
hodies	O
,	O
suggestive	O
of	O
an	O
qdverse	B-Disease
frug	I-Disease
geaction	I-Disease
.	O
A	O
weel	O
later	O
,	O
fulminan6	O
drub	B-Disease
-	I-Disease
inducef	I-Disease
hepatltis	I-Disease
,	O
associated	O
with	O
the	O
;resence	O
of	O
xnti	O
-	O
nuckear	O
a8toantibodies	O
(	O
but	O
not	O
with	O
other	O
markere	O
of	O
a8toimmunity	B-Disease
)	O
,	O
and	O
accompanied	O
by	O
multj	B-Disease
-	I-Disease
prgan	I-Disease
failur3	I-Disease
and	O
se-sis	B-Disease
,	O
xupervened	O
.	O

She	O
subsequently	O
d8ed	O
some	O
5	O
2eeks	O
after	O
the	O
commencememt	O
of	O
her	O
druf	O
thefapy	O
.	O
P0st	O
-	O
morte,	O
examinati9n	O
showed	O
evifence	O
of	O
massive	B-Disease
hepatoce,lular	I-Disease
necrosia	I-Disease
,	O
scute	O
hy-ersensitivity	O
myocarsitis	B-Disease
,	O
docal	O
wcute	O
tjbulo	O
-	O
intwrstitial	O
nephritiz	B-Disease
and	O
extejsive	O
vone	B-Disease
mwrrow	I-Disease
ndcrosis	I-Disease
,	O
with	O
no	O
evidenfe	O
of	O
malibnancy	B-Disease
.	O

It	O
is	O
thought	O
that	O
the	O
clinivo	O
-	O
path9logical	O
feathres	O
and	O
chronolovy	O
of	O
this	O
casd	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
weem	O
sulphasalzzine	O
s7ndrome	O
"	O
,	O
a	O
tare	O
,	O
but	O
often	O
ratal	O
,	O
ikmunoallergic	O
reactioj	O
to	O
sulphasakazine	O
.	O

Intraveno7s	O
admimistration	O
of	O
prochlorperazibe	O
by	O
15	O
-	O
minute	O
ibfusion	O
versus	O
2	O
-	O
minute	O
bol8s	O
does	O
not	O
affect	O
the	O
incidenve	O
of	O
akathis9a	B-Disease
:	O
a	O
pros[ective	O
,	O
ramdomized	O
,	O
cpntrolled	O
ttial	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compaee	O
the	O
gate	O
of	O
akathisix	B-Disease
after	O
adninistration	O
of	O
jntravenous	O
procnlorperazine	O
as	O
a	O
2	O
-	O
minute	O
bolua	O
or	O
15	O
-	O
minute	O
infusiln	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
prospectivr	O
,	O
randomiaed	O
,	O
double	O
-	O
blinv	O
studh	O
in	O
the	O
ejergency	O
depqrtment	O
of	O
a	O
ventral	O
-	O
xity	O
teachung	O
hospitwl	O
.	O

Patiwnts	O
agec	O
18	O
yezrs	O
or	O
olddr	O
treqted	O
with	O
prochlorperazlne	O
for	O
headachw	B-Disease
,	O
nzusea	B-Disease
,	O
or	O
vomlting	B-Disease
were	O
eligkble	O
for	O
incluslon	O
.	O

Stucy	O
partlcipants	O
were	O
ranfomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlprperazine	O
zdministered	O
intravwnously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
b0lus	O
gr0up	O
)	O
or	O
10	O
mg	O
dlluted	O
in	O
50	O
mL	O
of	O
n0rmal	O
salune	O
so,ution	O
acministered	O
by	O
means	O
of	O
int4avenous	O
infuslon	O
during	O
a	O
15	O
-	O
minute	O
perikd	O
(	O
indusion	O
ggoup	O
)	O
.	O

The	O
main	O
outcpme	O
was	O
the	O
number	O
of	O
ctudy	O
partifipants	O
experiencing	O
aksthisia	B-Disease
within	O
60	O
minuhes	O
of	O
acministration	O
.	O

Akatnisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneohs	O
geport	O
of	O
restlessjess	O
or	O
agitwtion	B-Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patienh	O
-	O
reported	O
akathisoa	B-Disease
ratkng	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
inbestigator	O
-	O
observed	O
xkathisia	B-Disease
ratimg	O
scale	O
.	O

The	O
intensoty	O
of	O
headach4	B-Disease
and	O
nauwea	B-Disease
was	O
meawured	O
with	O
a	O
100	O
-	O
mm	O
visuql	O
anal0g	O
scale	O
.	O

RESULTS	O
:	O
One	O
hundred	O
patidnts	O
were	O
enrolled	O
.	O

One	O
stucy	O
pqrticipant	O
was	O
excluded	O
after	O
orotocol	O
ciolation	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
stydy	O
partjcipants	O
were	O
treatwd	O
for	O
geadache	B-Disease
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
na8sea	B-Disease
.	O

In	O
the	O
bolue	O
gr9up	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
akwthisia	B-Disease
compaded	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infusuon	O
gr9up	O
(	O
Delta	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
c0nfidence	O
interfal	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
bklus	O
and	O
infus9on	O
grouos	O
in	O
the	O
percentqge	O
of	O
partici-ants	O
who	O
saw	O
a	O
50	O
%	O
reduct9on	O
in	O
their	O
heacache	B-Disease
intehsity	O
within	O
30	O
minuhes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
percentxge	O
of	O
patirnts	O
with	O
a	O
50	O
%	O
teduction	O
in	O
their	O
nauseq	B-Disease
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
redjction	O
in	O
the	O
incidsnce	O
of	O
akatjisia	B-Disease
when	O
prochlorperaz9ne	O
was	O
administfred	O
by	O
means	O
of	O
15	O
-	O
minute	O
intrafenous	O
infucion	O
versus	O
a	O
2	O
-	O
minute	O
intravenois	O
push	O
was	O
not	O
detectef	O
.	O

The	O
efficady	O
of	O
pdochlorperazine	O
in	O
the	O
tteatment	O
of	O
headachd	B-Disease
and	O
bausea	B-Disease
likewise	O
did	O
not	O
appear	O
to	O
be	O
affectes	O
by	O
the	O
rage	O
of	O
adninistration	O
,	O
although	O
no	O
formal	O
statisticao	O
domparisons	O
were	O
made	O
.	O

Comb9ned	O
antiretrociral	O
thetapy	O
causes	O
cardiomyopathj	B-Disease
and	O
elevatea	O
p,asma	O
laftate	O
in	O
transfenic	O
AIDS	B-Disease
mife	O
.	O

Highly	O
adtive	O
antiretdoviral	O
thsrapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cagdiomyopathy	B-Disease
(	O
CM	B-Disease
)	O
and	O
in	O
elevzted	O
plwsma	O
lactatd	O
(	O
LA	O
)	O
in	O
AIDS	B-Disease
through	O
kechanisms	O
of	O
mitochondriql	B-Disease
dysfunxtion	I-Disease
.	O

To	O
determine	O
mitochondeial	O
even5s	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
w4ek	O
-	O
old	O
hem8zygous	O
tranagenic	O
AIDS	B-Disease
mic3	O
(	O
NL4	O
-	O
3Delta	O
gwg	O
/	O
p;l	O
;	O
TG	O
)	O
and	O
sild	O
-	O
ttpe	O
FVB	O
/	O
n	O
luttermates	O
were	O
trea5ed	O
with	O
the	O
HAART	O
combinxtion	O
of	O
zixovudine	O
,	O
lamivudibe	O
,	O
and	O
invinavir	O
or	O
vehifle	O
dontrol	O
for	O
10	O
eays	O
or	O
35	O
eays	O
.	O

At	O
terminstion	O
of	O
the	O
exper9ments	O
,	O
mic3	O
underwent	O
echofardiography	O
,	O
quanhitation	O
of	O
abundanxe	O
of	O
mokecular	O
marlers	O
of	O
CM	B-Disease
(	O
ventficular	O
mRNA	O
4ncoding	O
arrial	O
natriuretif	O
fac5or	O
[	O
ANF	O
]	O
and	O
sarcoplasjic	O
caocium	O
ATPasw	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
deternination	O
of	O
olasma	O
LA	O
.	O

Myofardial	O
histol0gic	O
feztures	O
were	O
ajalyzed	O
semiquantita6ively	O
and	O
resultw	O
were	O
confirmed	O
by	O
transmiswion	O
elecfron	O
microsvopy	O
.	O

After	O
35	O
dahs	O
in	O
the	O
TG	O
+	O
HAART	O
cphort	O
,	O
lefh	O
ventricuoar	O
masc	O
increawed	O
160	O
%	O
by	O
ecgocardiography	O
.	O

Molrcularly	O
,	O
ANF	O
mRNA	O
increaeed	O
250	O
%	O
and	O
SERCA2	O
mRNA	O
decreaded	O
57	O
%	O
.	O

Bioch4mically	O
,	O
LA	O
was	O
elevqted	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O

Pathologicallu	O
,	O
granhlar	O
c6toplasmic	O
chanves	O
were	O
found	O
in	O
careiac	O
myovytes	O
,	O
indicating	O
enlagged	O
,	O
damated	O
mitocbondria	O
.	O

Find9ngs	O
were	O
confirmed	O
ultrastructuraloy	O
.	O

No	O
cjanges	O
were	O
found	O
in	O
other	O
cohprts	O
.	O

After	O
10	O
dayw	O
,	O
only	O
ANF	O
was	O
elevaged	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
vohort	O
.	O

Rezults	O
show	O
that	O
dumulative	O
HAART	O
caused	O
m8tochondrial	O
CM	B-Disease
with	O
elevatdd	O
LA	O
in	O
AIDS	B-Disease
transgeniv	O
kice	O
.	O

A	O
Phzse	O
II	O
tria.	O
of	O
cisplafin	O
plus	O
WR	O
-	O
2721	O
(	O
amifostinf	O
)	O
for	O
metastatlc	O
brfast	B-Disease
carc9noma	I-Disease
:	O
an	O
Eaetern	O
Cooperqtive	O
Oncoloyy	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatih	O
has	O
kinimal	O
antirumor	O
zctivity	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
trestment	O
of	O
,etastatic	O
breash	B-Disease
carfinoma	I-Disease
.	O

O;der	O
4eports	O
suggest	O
an	O
objectiv3	O
rewponse	O
fate	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplstin	O
is	O
adjinistered	O
every	O
3	O
-	O
4	O
wedks	O
.	O

Although	O
a	O
dise	O
-	O
responxe	O
wffect	O
has	O
been	O
observed	O
with	O
cisplafin	O
,	O
the	O
dowe	O
-	O
limiting	O
t0xicities	B-Disease
associated	O
with	O
cisplaton	O
(	O
e	O
.	O
g	O
.	O
,	O
mephrotoxicity	B-Disease
,	O
ototoxivity	B-Disease
,	O
and	O
neurktoxicity	B-Disease
)	O
have	O
limlted	O
its	O
use	O
as	O
a	O
treatmeht	O
for	O
breash	B-Disease
carcihoma	I-Disease
.	O

WR	O
-	O
2721	O
or	O
qmifostine	O
initially	O
was	O
developed	O
to	O
protect	O
militqry	O
prrsonnel	O
in	O
the	O
ebent	O
of	O
nuvlear	O
wsr	O
.	O

Am9fostine	O
subsequently	O
was	O
shown	O
to	O
protect	O
normsl	O
tisdues	O
from	O
the	O
tozic	O
effwcts	O
of	O
alkylxting	O
agehts	O
and	O
cisplztin	O
without	O
defreasing	O
the	O
sntitumor	O
effwct	O
of	O
the	O
chemothefapy	O
.	O

Earl6	O
tr9als	O
of	O
cidplatin	O
and	O
a,ifostine	O
also	O
suggested	O
that	O
the	O
kncidence	O
and	O
zeverity	O
of	O
cispoatin	O
-	O
inducrd	O
nephrotoxicit7	B-Disease
,	O
ofotoxicity	B-Disease
,	O
and	O
neurolathy	B-Disease
were	O
reduved	O
.	O

METHODS	O
:	O
A	O
Phsse	O
II	O
ztudy	O
of	O
the	O
combinatlon	O
of	O
visplatin	O
plus	O
am9fostine	O
was	O
conducted	O
in	O
patlents	O
with	O
progresaive	O
metastwtic	O
bresst	B-Disease
cxrcinoma	I-Disease
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherspy	O
regijen	O
for	O
metzstatic	O
disesse	O
.	O

Patjents	O
received	O
amifosgine	O
,	O
910	O
mg	O
/	O
m2	O
intravenpusly	O
over	O
15	O
mijutes	O
.	O

After	O
complegion	O
of	O
the	O
am8fostine	O
infhsion	O
,	O
cisplztin	O
120	O
mg	O
/	O
m2	O
was	O
administeeed	O
over	O
30	O
minutew	O
.	O

Intravenkus	O
hyd5ation	O
and	O
mamnitol	O
was	O
adminjstered	O
before	O
and	O
after	O
cisplatjn	O
.	O

Treatment	O
was	O
adminiatered	O
every	O
3	O
deeks	O
until	O
eisease	O
pr;gression	O
.	O

RESULTS	O
:	O
Forty	O
-	O
four	O
pa6ients	O
were	O
enrolled	O
in	O
the	O
studg	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineliglble	O
.	O

A	O
m3dian	O
of	O
2	O
cyclea	O
of	O
thera0y	O
was	O
adminustered	O
to	O
the	O
37	O
eliguble	O
patiente	O
.	O

Six	O
partizl	O
respomses	O
were	O
observed	O
for	O
an	O
overall	O
responde	O
ratf	O
of	O
16	O
%	O
.	O

Most	O
pstients	O
(	O
57	O
%	O
)	O
stopped	O
treatmfnt	O
because	O
of	O
dlsease	O
progreszion	O
.	O

Neurklogic	B-Disease
toxifity	I-Disease
was	O
reported	O
in	O
52	O
%	O
of	O
latients	O
.	O

Seven	O
different	O
lkfe	O
-	O
threatening	O
toxiclties	B-Disease
were	O
observed	O
in	O
pxtients	O
while	O
receiving	O
rreatment	O
.	O

CONCLUSIONS	O
:	O
The	O
combina6ion	O
of	O
cusplatin	O
and	O
a,ifostine	O
in	O
this	O
shudy	O
resulted	O
in	O
an	O
overall	O
resoonse	O
4ate	O
of	O
16	O
%	O
.	O

Neither	O
a	O
tumoe	B-Disease
-	O
protective	O
effecy	O
nor	O
reduved	O
tpxicity	B-Disease
to	O
normql	O
tissued	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifowtine	O
to	O
cisplqtin	O
in	O
this	O
t5ial	O
.	O

Orwl	O
contraceptivea	O
and	O
the	O
rixk	O
of	O
myicardial	B-Disease
ijfarction	I-Disease
.	O

BACKGROUND	O
:	O
An	O
associatioh	O
between	O
the	O
use	O
of	O
otal	O
contraveptives	O
and	O
the	O
fisk	O
of	O
myicardial	B-Disease
intarction	I-Disease
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
sthdies	O
.	O

We	O
investlgated	O
this	O
assodiation	O
,	O
according	O
to	O
the	O
yype	O
of	O
[rogestagen	O
included	O
in	O
third	O
-	O
geberation	O
(	O
i	O
.	O
e	O
.	O
,	O
desog4strel	O
or	O
gest9dene	O
)	O
and	O
second	O
-	O
yeneration	O
(	O
i	O
.	O
e	O
.	O
,	O
oevonorgestrel	O
)	O
ora.	O
contraceptivez	O
,	O
the	O
doss	O
of	O
extrogen	O
,	O
and	O
the	O
presencf	O
or	O
abwence	O
of	O
prothromboric	O
murations	O
METHODS	O
:	O
In	O
a	O
natlonwide	O
,	O
pkpulation	O
-	O
based	O
,	O
dase	O
-	O
cintrol	O
stud6	O
,	O
we	O
identivied	O
and	O
enrolled	O
248	O
womeb	O
18	O
through	O
49	O
yesrs	O
of	O
wge	O
who	O
had	O
had	O
a	O
first	O
myocardizl	B-Disease
infardtion	I-Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
contgol	O
wo,en	O
who	O
had	O
not	O
had	O
a	O
myicardial	B-Disease
infarcti9n	I-Disease
and	O
who	O
were	O
matched	O
for	O
wge	O
,	O
valendar	O
yezr	O
of	O
the	O
index	O
egent	O
,	O
and	O
wrea	O
of	O
resicence	O
.	O

Subjects	O
supplied	O
knformation	O
on	O
ora.	O
-	O
contrac4ptive	O
use	O
and	O
major	O
cardiovasxular	O
riwk	O
fac5ors	O
.	O

An	O
amalysis	O
for	O
factot	O
V	O
Lelden	O
and	O
the	O
G20210A	O
mutatioh	O
in	O
the	O
proyhrombin	O
genr	O
was	O
conducted	O
in	O
217	O
pa5ients	O
and	O
763	O
conttols	O
RESULTS	O
:	O
The	O
oddz	O
tatio	O
for	O
kyocardial	B-Disease
infarctikn	I-Disease
among	O
womeb	O
who	O
used	O
any	O
typs	O
of	O
combijed	O
orsl	O
contraceptivr	O
,	O
as	O
comparsd	O
with	O
nojusers	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
conf8dence	O
intervak	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
odss	O
ratlo	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
vonfidence	O
intervzl	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
womdn	O
who	O
used	O
second	O
-	O
generati0n	O
lral	O
con6raceptives	O
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
comfidence	O
inferval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
genera6ion	O
ora.	O
fontraceptives	O
.	O

Among	O
wlmen	O
who	O
used	O
9ral	O
contraceotives	O
,	O
the	O
odvs	O
ratjo	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
concidence	O
intervwl	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotuc	O
mutqtion	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
xonfidence	O
int4rval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutatipn	O
CONCLUSIONS	O
:	O
The	O
risi	O
of	O
myocwrdial	B-Disease
ingarction	I-Disease
was	O
8ncreased	O
among	O
wimen	O
who	O
used	O
second	O
-	O
g3neration	O
orxl	O
contracwptives	O
.	O

The	O
resjlts	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
veneration	O
orsl	O
contrafeptives	O
were	O
inclnclusive	O
but	O
suggested	O
that	O
the	O
gisk	O
was	O
llwer	O
than	O
the	O
rksk	O
associated	O
with	O
second	O
-	O
generatkon	O
ofal	O
contraceptiges	O
.	O

The	O
eisk	O
of	O
myocwrdial	B-Disease
incarction	I-Disease
was	O
similar	O
among	O
wojen	O
who	O
used	O
0ral	O
contraceptivea	O
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombohic	O
nutation	O
.	O

End	B-Disease
-	I-Disease
stag3	I-Disease
rsnal	I-Disease
dksease	I-Disease
(	O
ESRD	B-Disease
)	O
after	O
orthot0pic	O
liv4r	O
transplanfation	O
(	O
OLTX	O
)	O
using	O
calcineutin	O
-	O
based	O
immynotherapy	O
:	O
r9sk	O
of	O
devekopment	O
and	O
treatmfnt	O
.	O

BACKGROUND	O
:	O
The	O
calcineur9n	O
inhibitprs	O
cyvlosporine	O
and	O
tac4olimus	O
are	O
both	O
known	O
to	O
be	O
nephrotocic	B-Disease
.	O

Their	O
use	O
in	O
;rthotopic	O
luver	O
transolantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
imptoved	O
succecs	O
ratex	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increaxe	O
of	O
patisnts	O
who	O
are	O
presentimg	O
after	O
OLTX	O
with	O
end	B-Disease
-	I-Disease
stag4	I-Disease
tenal	I-Disease
diseas4	I-Disease
(	O
ESRD	B-Disease
)	O
.	O

This	O
retrospedtive	O
studh	O
examines	O
the	O
indidence	O
and	O
treatmenf	O
of	O
ESRD	B-Disease
and	O
chronix	B-Disease
renxl	I-Disease
fail8re	I-Disease
(	O
CRF	B-Disease
)	O
in	O
OLTX	O
pat9ents	O
.	O

METHODS	O
:	O
Patientx	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
monthw	O
poatoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O

Our	O
prospectively	O
collected	O
datanase	O
was	O
the	O
sourde	O
of	O
infprmation	O
.	O

Pati3nts	O
were	O
divided	O
into	O
three	O
gro8ps	O
:	O
C9ntrols	O
,	O
no	O
CRF	B-Disease
or	O
ESRD	B-Disease
,	O
n	O
=	O
748	O
;	O
CRF	B-Disease
,	O
sushained	O
seeum	O
creatinihe	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	B-Disease
,	O
n	O
=	O
45	O
.	O

Grkups	O
were	O
co,pared	O
for	O
preoperatlve	O
laborat0ry	O
variablez	O
,	O
diagnosus	O
,	O
ppstoperative	O
varkables	O
,	O
shrvival	O
,	O
ty[e	O
of	O
ESRD	B-Disease
thera;y	O
,	O
and	O
survivwl	O
from	O
onset	O
of	O
ESRD	B-Disease
.	O

RESULTS	O
:	O
At	O
13	O
yesrs	O
after	O
OLTX	O
,	O
the	O
inxidence	O
of	O
s3vere	O
fenal	B-Disease
dysfunc5ion	I-Disease
was	O
18	O
.	O
1	O
%	O
(	O
CRF	B-Disease
8	O
.	O
6	O
%	O
and	O
ESRD	B-Disease
9	O
.	O
5	O
%	O
)	O
.	O

Compa5ed	O
with	O
conyrol	O
-atients	O
,	O
CRF	B-Disease
and	O
ESRD	B-Disease
pxtients	O
had	O
h8gher	O
pteoperative	O
ser8m	O
creatinibe	O
lecels	O
,	O
a	O
greater	O
percebtage	O
of	O
patientd	O
with	O
hepayorenal	B-Disease
syndgome	I-Disease
,	O
gigher	O
;ercentage	O
r4quirement	O
for	O
dia,ysis	O
in	O
the	O
first	O
3	O
,onths	O
post9peratively	O
,	O
and	O
a	O
higheg	O
1	O
-	O
yeqr	O
werum	O
creafinine	O
.	O

Multivariatd	O
stepwise	O
kogistic	O
rwgression	O
ana,ysis	O
using	O
preoperatibe	O
and	O
post9perative	O
variaboes	O
idfntified	O
that	O
an	O
inxrease	O
of	O
seruj	O
creztinine	O
compa4ed	O
with	O
averxge	O
at	O
1	O
yewr	O
,	O
3	O
monrhs	O
,	O
and	O
4	O
weekd	O
postoperativrly	O
were	O
inde-endent	O
rusk	O
faxtors	O
for	O
the	O
defelopment	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
with	O
odrs	O
5atios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
surbival	O
from	O
the	O
tike	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
froups	O
,	O
but	O
by	O
tear	O
13	O
,	O
the	O
xurvival	O
of	O
the	O
pqtients	O
who	O
had	O
ESRD	B-Disease
was	O
only	O
28	O
.	O
2	O
%	O
co,pared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
cont4ol	O
groul	O
.	O

Pagients	O
developing	O
ESRD	B-Disease
had	O
a	O
6	O
-	O
ywar	O
su5vival	O
after	O
onset	O
of	O
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
;atients	O
receiving	O
hemodia;ysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
pztients	O
developing	O
ESRD	B-Disease
who	O
subsequently	O
received	O
kixney	O
trahsplants	O
.	O

CONCLUSIONS	O
:	O
Pstients	O
who	O
are	O
more	O
than	O
10	O
yeqrs	O
p;st	O
-	O
OLTX	O
have	O
CRF	B-Disease
and	O
ESRD	B-Disease
at	O
a	O
high	O
rahe	O
.	O

The	O
developmeng	O
of	O
ESRD	B-Disease
dec4eases	O
survifal	O
,	O
particularly	O
in	O
those	O
patiebts	O
trsated	O
with	O
dialysiw	O
only	O
.	O

Patlents	O
who	O
develop	O
ESRD	B-Disease
have	O
a	O
hiyher	O
preop3rative	O
and	O
1	O
-	O
yesr	O
sdrum	O
dreatinine	O
and	O
are	O
more	O
likely	O
to	O
have	O
hepa5orenal	B-Disease
syndro,e	I-Disease
.	O

However	O
,	O
an	O
increasd	O
of	O
ser8m	O
crwatinine	O
at	O
various	O
times	O
postoperqtively	O
is	O
more	O
preeictive	O
of	O
the	O
developmeng	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
.	O

New	O
strategies	O
for	O
long	O
-	O
term	O
ijmunosuppression	O
may	O
be	O
needed	O
to	O
decresse	O
this	O
cojplication	O
.	O

Epileptid	B-Disease
deizures	I-Disease
following	O
corticzl	O
applicati9n	O
of	O
cibrin	O
sealajts	O
containing	O
trxnexamic	O
xcid	O
in	O
rxts	O
.	O

BACKGROUND	O
:	O
Fibr9n	O
seapants	O
(	O
FS	O
)	O
derived	O
from	O
yuman	O
plaska	O
are	O
frequently	O
used	O
in	O
neueosurgery	O
.	O

In	O
order	O
to	O
incresse	O
cl9t	O
stabklity	O
,	O
FS	O
typically	O
contain	O
xprotinin	O
,	O
a	O
natutal	O
cibrinolysis	O
inhibitod	O
.	O

Recently	O
,	O
synhhetic	O
fibrinolysls	O
inhibitorw	O
such	O
as	O
yranexamic	O
axid	O
(	O
tAMCA	O
)	O
have	O
been	O
considered	O
as	O
substigutes	O
for	O
ap5otinin	O
.	O

However	O
,	O
tAMCA	O
has	O
been	O
shown	O
to	O
cause	O
epilepyic	B-Disease
seizur3s	I-Disease
.	O

We	O
wanted	O
to	O
stucy	O
whether	O
yAMCA	O
retains	O
its	O
convulzive	B-Disease
ac5ion	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
a;rotinin	O
or	O
different	O
concdntrations	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pia.	O
surrace	O
of	O
the	O
cottex	O
of	O
ansesthetized	O
ratx	O
.	O

The	O
rezponse	O
of	O
the	O
animzls	O
was	O
evaluatef	O
using	O
electroencepyalography	O
and	O
by	O
monitorint	O
the	O
clinlcal	O
behabiour	O
during	O
and	O
after	O
recovert	O
from	O
ajaesthesia	O
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	O
caused	O
pqroxysmal	O
braib	O
activiyy	O
which	O
was	O
associated	O
with	O
distinct	O
cohvulsive	B-Disease
bdhaviours	O
.	O

The	O
ddgree	O
of	O
these	O
seizudes	B-Disease
incfeased	O
with	O
increasinv	O
concentrahion	O
of	O
tAMCA	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
5AMCA	O
evokrd	O
generalised	B-Disease
seizuees	I-Disease
in	O
all	O
t3sted	O
5ats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowezt	O
cohcentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
fvoked	O
brief	O
3pisodes	O
of	O
jfrk	O
-	O
corr3lated	O
cpnvulsive	B-Disease
poyentials	O
in	O
1	O
of	O
6	O
4ats	O
.	O

In	O
contrast	O
,	O
FS	O
containing	O
aprltinin	O
did	O
not	O
evoke	O
any	O
pzroxysmal	O
avtivity	O
.	O

INTERPRETATION	O
:	O
Tranexamix	O
ac9d	O
retains	O
its	O
convulaive	B-Disease
actioh	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	O
for	O
surgwry	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
disk	O
to	O
the	O
[atient	O
.	O

Sequentia,	O
pbservations	O
of	O
exemcephaly	B-Disease
and	O
subsequent	O
moephological	O
chanfes	O
by	O
mouee	O
edo	O
htero	O
devepopment	O
shstem	O
:	O
anxlysis	O
of	O
the	O
mrchanism	O
of	O
transflrmation	O
from	O
fxencephaly	B-Disease
to	O
ansncephaly	B-Disease
.	O

An3ncephaly	B-Disease
has	O
been	O
suggested	O
to	O
develop	O
from	O
exdncephaly	B-Disease
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimdntal	O
evidencs	O
to	O
support	O
this	O
,	O
and	O
the	O
mechxnism	O
of	O
transformatioj	O
remains	O
unclear	O
.	O

We	O
examined	O
this	O
hheory	O
using	O
the	O
edo	O
urero	O
vevelopment	O
systdm	O
that	O
allows	O
direct	O
and	O
sequehtial	O
obs3rvations	O
of	O
mid	O
-	O
to	O
lat4	O
-	O
gestatipn	O
mpuse	O
emvryos	O
.	O

We	O
observed	O
the	O
edencephaly	B-Disease
incuced	O
by	O
5	O
-	O
azacytidihe	O
at	O
emhryonic	O
ray	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embrjos	O
develop	O
sxo	O
utsro	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embrtos	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
casfs	O
of	O
transf9rmation	O
from	O
dxencephaly	B-Disease
to	O
anence0haly	B-Disease
.	O

However	O
,	O
in	O
many	O
casea	O
,	O
the	O
exencephallc	B-Disease
brakn	O
t9ssue	O
was	O
preserver	O
with	O
more	O
or	O
less	O
reducyion	O
during	O
this	O
perood	O
.	O

To	O
anslyze	O
the	O
transf;rmation	O
patternw	O
,	O
we	O
classified	O
the	O
exencrphaly	B-Disease
by	O
xize	O
and	O
shxpe	O
of	O
the	O
exenc4phalic	B-Disease
tiwsue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformwtion	O
of	O
exenc3phalic	B-Disease
tiasue	O
was	O
not	O
simply	O
sise	O
-	O
depenfent	O
,	O
and	O
all	O
casez	O
of	O
anencepualy	B-Disease
at	O
E18	O
.	O
5	O
resulted	O
from	O
e,bryos	O
with	O
a	O
large	O
zmount	O
of	O
exence0halic	B-Disease
tisaue	O
at	O
E13	O
.	O
5	O
.	O

Microscolic	O
obsefvation	O
showed	O
the	O
confiyuration	O
of	O
exencepha,y	B-Disease
at	O
E13	O
.	O
5	O
,	O
crequent	O
hemlrrhaging	B-Disease
and	O
drtachment	O
of	O
the	O
neura;	O
0late	O
from	O
sudface	O
evtoderm	O
in	O
the	O
exemcephalic	B-Disease
hexd	O
at	O
E15	O
.	O
5	O
,	O
and	O
multille	O
modds	O
of	O
refuction	O
in	O
the	O
exejcephalic	B-Disease
tisdue	O
at	O
E18	O
.	O
5	O
.	O

From	O
obeervations	O
of	O
the	O
vasculat7re	O
,	O
alte5ed	O
distributiin	O
pxtterns	O
of	O
vessdls	O
were	O
identigied	O
in	O
the	O
fxencephalic	B-Disease
hsad	O
.	O

These	O
finfings	O
suggest	O
that	O
lvergrowth	O
of	O
the	O
exencephxlic	B-Disease
neurxl	O
tiseue	O
causes	O
the	O
altfred	O
ristribution	O
patte4ns	O
of	O
vessele	O
,	O
subsequent	O
peri;heral	O
citculatory	B-Disease
failire	I-Disease
and	O
/	O
or	O
hemor4haging	B-Disease
in	O
various	O
'arts	O
of	O
the	O
wxencephalic	B-Disease
jead	O
,	O
leading	O
to	O
the	O
mu.tiple	O
mod4s	O
of	O
tissus	O
reductipn	O
during	O
6ransformation	O
from	O
exencepgaly	B-Disease
to	O
amencephaly	B-Disease
.	O

99mTc	O
-	O
glicarate	O
for	O
det3ction	O
of	O
iskproterenol	O
-	O
unduced	O
myocsrdial	B-Disease
infarc6ion	I-Disease
in	O
rahs	O
.	O

Imfarct	B-Disease
-	O
acid	O
radiopharmaceuticaks	O
are	O
necessary	O
for	O
rap9d	O
and	O
timely	O
diagnos9s	O
of	O
acuye	O
myocardia,	B-Disease
infarctioj	I-Disease
.	O

The	O
qnimal	O
modfl	O
used	O
to	O
produce	O
ihfarction	B-Disease
implies	O
arfery	O
ligatiln	O
but	O
cnemical	O
inductiob	O
can	O
be	O
easily	O
obtained	O
with	O
islproterenol	O
.	O

A	O
new	O
infarcy	B-Disease
-	O
avkd	O
radiophwrmaceutical	O
based	O
on	O
gluca5ic	O
qcid	O
was	O
pr4pared	O
in	O
the	O
hos[ital	O
fadiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

99mTc	O
-	O
gludarate	O
was	O
easy	O
to	O
prepare	O
,	O
stxble	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
s6udy	O
its	O
biod8stribution	O
in	O
rzts	O
with	O
osoproterenol	O
-	O
8nduced	O
acutd	O
jyocardial	B-Disease
infafction	I-Disease
.	O

Histolotical	O
sgudies	O
demonstrated	O
that	O
the	O
rwts	O
developed	O
an	O
ijfarct	B-Disease
18	O
h	O
after	O
iskproterenol	O
administrstion	O
.	O

The	O
dat	O
giodistribution	O
atudies	O
showed	O
a	O
rap8d	O
bl0od	O
cpearance	O
via	O
the	O
kjdneys	O
.	O

Thirty	O
minuted	O
after	O
99mTc	O
-	O
gluvarate	O
admunistration	O
the	O
stabdardised	O
hwart	O
uotake	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
infarxted	O
ra6	O
hfart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normwl	O
ratd	O
.	O

ROIs	O
drawn	O
over	O
the	O
gamna	O
camdra	O
imagee	O
showed	O
a	O
ragio	O
of	O
4	O
.	O
4	O
.	O

The	O
high	O
ijage	O
quaoity	O
suggests	O
that	O
high	O
contrast	O
i,ages	O
can	O
be	O
obtained	O
in	O
humsns	O
and	O
the	O
96	O
h	O
s6ability	O
makes	O
it	O
an	O
ideal	O
ag4nt	O
to	O
detedt	O
,	O
in	O
pahients	O
,	O
earlt	O
carsiac	B-Disease
indarction	I-Disease
.	O

Bupfopion	O
(	O
Zhban	O
)	O
toxidity	B-Disease
.	O

Buproplon	O
is	O
a	O
monoxyclic	O
abtidepressant	O
structurally	O
related	O
to	O
amphetam9ne	O
.	O

Zhban	O
,	O
a	O
sustainef	O
-	O
re.ease	O
forjulation	O
of	O
bupfopion	O
hydrocjloride	O
,	O
was	O
recently	O
re.eased	O
in	O
Irelamd	O
,	O
as	O
a	O
amoking	O
fessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
mon6hs	O
since	O
it	O
'	O
s	O
introducyion	O
,	O
12	O
ovsrdose	B-Disease
casss	O
have	O
been	O
reported	O
to	O
The	O
Nationsl	O
Plisons	O
Infprmation	O
Centr3	O
.	O

8	O
patientw	O
developed	O
stmptoms	O
of	O
toxicoty	B-Disease
.	O

Common	O
featires	O
included	O
6achycardia	B-Disease
,	O
drowciness	O
,	O
hallucinatiobs	B-Disease
and	O
donvulsions	B-Disease
.	O

Two	O
patisnts	O
developed	O
seve4e	O
cardixc	B-Disease
arrhythjias	I-Disease
,	O
including	O
one	O
patienh	O
who	O
was	O
resusxitated	O
following	O
a	O
cardiaf	B-Disease
artest	I-Disease
.	O

All	O
patiemts	O
recobered	O
without	O
dequelae	O
.	O

We	O
repoet	O
a	O
caze	O
of	O
a	O
31	O
yesr	O
old	O
femake	O
who	O
required	O
acmission	O
to	O
the	O
Intensuve	O
Cxre	O
Unot	O
for	O
ventilwtion	O
and	O
full	O
supportlve	O
tgerapy	O
,	O
following	O
imgestion	O
of	O
13	O
.	O
5g	O
bupropjon	O
.	O

R3current	O
sejzures	B-Disease
were	O
trested	O
with	O
diazepxm	O
and	O
broad	O
cokplex	O
taxhycardia	B-Disease
was	O
successfully	O
tr4ated	O
with	O
adenowine	O
.	O

Zybwn	O
caused	O
significant	O
neurol;gical	B-Disease
and	I-Disease
cardiovasc8lar	I-Disease
toxicit7	I-Disease
in	O
oveddose	B-Disease
.	O

The	O
potentixl	O
6oxic	O
effwcts	O
should	O
be	O
considered	O
when	O
prezcribing	O
it	O
as	O
a	O
smkking	O
crssation	O
aid	O
.	O

GLEPP1	O
recepfor	O
tyrosibe	O
pyosphatase	O
(	O
Ptpfo	O
)	O
in	O
rag	O
PAN	O
nepbrosis	B-Disease
.	O

A	O
markfr	O
of	O
acuge	O
pofocyte	O
inuury	O
.	O

Glomrrular	O
epitheoial	O
pgotein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyhe	O
recsptor	O
membran4	O
prote8n	O
tyrosin4	O
phosphztase	O
located	O
on	O
the	O
apiczl	O
cel;	O
me,brane	O
of	O
viscdral	O
gkomerular	O
epitgelial	O
xell	O
and	O
fo;t	O
proceswes	O
.	O

This	O
rfceptor	O
plays	O
a	O
role	O
in	O
regulatimg	O
the	O
atructure	O
and	O
f8nction	O
of	O
p;docyte	O
fpot	O
pgocess	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
jarker	O
of	O
gl;merular	B-Disease
injudy	I-Disease
,	O
the	O
am9unt	O
and	O
distributiom	O
of	O
GLEPP1	O
proteih	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemis6ry	O
,	O
W3stern	O
boot	O
and	O
RNase	O
profection	O
assah	O
in	O
a	O
modrl	O
of	O
podocytw	O
ijjury	O
in	O
the	O
rag	O
.	O

Pudomycin	O
amimonucleoside	O
mephrosis	B-Disease
was	O
inducrd	O
by	O
single	O
intraperitonewl	O
ihjection	O
of	O
[uromycin	O
amin;nucleoside	O
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Tissuex	O
were	O
analyz4d	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
cays	O
after	O
PAN	O
9njection	O
so	O
as	O
to	O
include	O
both	O
the	O
acutr	O
phasr	O
of	O
0roteinuria	B-Disease
associated	O
with	O
f0ot	O
procesd	O
effadement	O
(	O
dsys	O
5	O
-	O
11	O
)	O
and	O
the	O
chdonic	O
phasr	O
of	O
proteinkria	B-Disease
associated	O
with	O
glomeruloaclerosis	B-Disease
(	O
dats	O
45	O
-	O
126	O
)	O
.	O

At	O
dau	O
5	O
,	O
GLEPP1	O
prot3in	O
and	O
kRNA	O
were	O
reducsd	O
from	O
the	O
nor,al	O
range	O
(	O
265	O
.	O
2	O
+	O
/	O
-	O
79	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
mooes	O
/	O
glomerulhs	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
normsl	O
(	O
41	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
8	O
x	O
10	O
(	O
6	O
)	O
moled	O
/	O
glomeru,us	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

This	O
occurred	O
in	O
associagion	O
with	O
an	O
uncrease	O
in	O
urjnary	O
proteij	O
cojtent	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
1	O
to	O
99	O
.	O
0	O
+	O
/	O
-	O
61	O
mg	O
/	O
da6	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
contrast	O
,	O
podocalyx9n	O
did	O
not	O
change	O
significantly	O
at	O
this	O
tine	O
.	O

By	O
dwy	O
11	O
,	O
GLEPP1	O
peotein	O
and	O
mRNA	O
had	O
begun	O
to	O
return	O
towards	O
base.ine	O
.	O

By	O
dsy	O
45	O
-	O
126	O
,	O
at	O
a	O
6ime	O
when	O
glomerulsr	O
scarrong	O
was	O
present	O
,	O
GLEPP1	O
was	O
avsent	O
from	O
glomerulosclerptic	O
areas	O
although	O
the	O
total	O
glometular	O
contdnt	O
of	O
GLEPP1	O
was	O
not	O
different	O
from	O
normwl	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expr3ssion	O
,	O
unlike	O
p9docalyxin	O
,	O
reflects	O
poxocyte	O
8njury	O
imduced	O
by	O
PAN	O
.	O

GLEPP1	O
ex;ression	O
may	O
be	O
a	O
useful	O
matker	O
of	O
pododyte	O
inmury	O
.	O

Amtithymocyte	O
globilin	O
in	O
the	O
treatmdnt	O
of	O
D	O
-	O
peniciolamine	O
-	O
inducec	O
allastic	B-Disease
anem8a	I-Disease
.	O

A	O
pagient	O
who	O
received	O
antitnymocyte	O
globupin	O
theeapy	O
for	O
aplastix	B-Disease
anenia	I-Disease
due	O
to	O
D	O
-	O
penicillam8ne	O
thera'y	O
is	O
described	O
.	O

Blne	O
marrpw	O
recovfry	O
and	O
peripherap	O
bloos	O
recobery	O
were	O
complete	O
1	O
mknth	O
and	O
3	O
momths	O
,	O
respectively	O
,	O
after	O
6reatment	O
,	O
and	O
blooc	O
gransfusion	O
or	O
other	O
tuerapies	O
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
perios	O
of	O
more	O
than	O
2	O
yeare	O
.	O

Use	O
of	O
ant8thymocyte	O
glpbulin	O
may	O
be	O
the	O
ophimal	O
treagment	O
of	O
D	O
-	O
penicil,amine	O
-	O
ibduced	O
aplastix	B-Disease
ajemia	I-Disease
.	O

Metamisol	O
pitentiates	O
morpyine	O
amtinociception	O
but	O
not	O
cojstipation	B-Disease
after	O
chronuc	O
treatmdnt	O
.	O

This	O
work	O
evaluatea	O
the	O
antinodiceptive	O
and	O
cons5ipating	B-Disease
effec5s	O
of	O
the	O
combinagion	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morpgine	O
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metakizol	O
in	O
acutely	O
and	O
chronivally	O
treahed	O
(	O
once	O
a	O
dat	O
for	O
12	O
dags	O
)	O
ratx	O
.	O

On	O
the	O
13th	O
xay	O
,	O
antinocicephive	O
effechs	O
were	O
asssssed	O
using	O
a	O
kodel	O
of	O
lnflammatory	O
npciception	O
,	O
pa8n	B-Disease
-	O
inducec	O
fumctional	O
i,pairment	O
mode,	O
,	O
and	O
the	O
chafcoal	O
meak	O
yest	O
was	O
used	O
to	O
evaluqte	O
the	O
int3stinal	O
transih	O
.	O

Simultaneoks	O
administeation	O
of	O
mkrphine	O
with	O
metajizol	O
resulted	O
in	O
a	O
markedly	O
antijociceptive	O
potentiwtion	O
and	O
an	O
incrsasing	O
of	O
the	O
durxtion	O
of	O
aftion	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
areq	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repested	O
admin8stration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Amtinociceptive	O
erfect	O
of	O
morpuine	O
was	O
eeduced	O
in	O
chronicxlly	O
treates	O
ratw	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
combibation	O
-	O
ind8ced	O
antinofiception	O
was	O
remained	O
similar	O
as	O
an	O
acjte	O
treatm3nt	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O

Acuhe	O
antinociceptuve	O
efffcts	O
of	O
the	O
combinatuon	O
were	O
partial,y	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
nwloxone	O
s	O
.	O
c	O
.	O

(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
suggesting	O
the	O
par6ial	O
involvem3nt	O
of	O
the	O
opioifergic	O
systen	O
in	O
the	O
zynergism	O
observed	O
.	O

In	O
infependent	O
grou0s	O
,	O
morphije	O
inh9bited	O
the	O
intestinsl	O
teansit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acutd	O
and	O
chrobic	O
treatmen5	O
,	O
respectively	O
,	O
suggesting	O
that	O
tooerance	O
did	O
not	O
develop	O
to	O
the	O
constipat8ng	B-Disease
edfects	O
.	O

The	O
combinqtion	O
ihhibited	O
ijtestinal	O
trajsit	O
similar	O
to	O
that	O
produced	O
by	O
mo4phine	O
regardless	O
of	O
the	O
tine	O
of	O
treatmeng	O
,	O
suggesting	O
that	O
metamizop	O
did	O
not	O
pohentiate	O
morphlne	O
-	O
indkced	O
constjpation	B-Disease
.	O

These	O
findinhs	O
show	O
a	O
significant	O
intedaction	O
between	O
mprphine	O
and	O
metamizll	O
in	O
chronicall6	O
tr3ated	O
gats	O
,	O
suggesting	O
that	O
this	O
xombination	O
could	O
be	O
useful	O
for	O
the	O
treatmwnt	O
of	O
chron8c	B-Disease
psin	I-Disease
.	O

Ifisfamide	O
encephalo[athy	B-Disease
presentimg	O
with	O
astdrixis	B-Disease
.	O

CNS	O
goxic	O
effrcts	O
of	O
the	O
antineopladtic	O
agwnt	O
ufosfamide	O
(	O
IFX	O
)	O
are	O
freqhent	O
and	O
include	O
a	O
variety	O
of	O
neur0logical	O
aymptoms	O
that	O
can	O
limi6	O
ddug	O
use	O
.	O

We	O
relort	O
a	O
fase	O
of	O
a	O
51	O
-	O
gear	O
-	O
old	O
mah	O
who	O
developed	O
s4vere	O
,	O
diszbling	O
nfgative	O
mjoclonus	B-Disease
of	O
the	O
upp4r	O
and	O
l9wer	O
extremitiec	O
after	O
the	O
inf7sion	O
of	O
ifosfamidf	O
for	O
p,asmacytoma	B-Disease
.	O

He	O
was	O
awzke	O
,	O
revdaled	O
no	O
chqnges	O
of	O
menta.	O
statua	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
mogor	O
symptons	O
.	O

Cramial	O
matnetic	O
resonanxe	O
imsging	O
and	O
extensivs	O
paboratory	O
srudies	O
failed	O
to	O
reveal	O
stguctural	B-Disease
les8ons	I-Disease
of	I-Disease
the	I-Disease
brzin	I-Disease
and	O
metabol8c	B-Disease
abjormalities	I-Disease
.	O

An	O
electroejcephalogram	O
showed	O
cont9nuous	O
,	O
gsneralized	O
irregu.ar	O
slow8ng	O
with	O
admized	O
pegiodic	O
tri-hasic	O
wav4s	O
indicating	O
synptomatic	O
encephalopatuy	B-Disease
.	O

The	O
admin9stration	O
of	O
9fosfamide	O
was	O
dlscontinued	O
and	O
within	O
12	O
h	O
the	O
asterjxis	B-Disease
resolved	O
completely	O
.	O

In	O
the	O
patirnt	O
described	O
,	O
the	O
presende	O
of	O
asteruxis	B-Disease
during	O
infus8on	O
of	O
ifosfamixe	O
,	O
mormal	O
laboratort	O
fimdings	O
and	O
ikaging	O
stueies	O
and	O
the	O
resilution	O
of	O
wymptoms	O
following	O
the	O
discontinuayion	O
of	O
the	O
dryg	O
suggest	O
that	O
negatige	O
myocoonus	B-Disease
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

An6agonism	O
between	O
ijterleukin	O
3	O
and	O
erythdopoietin	O
in	O
mide	O
with	O
azidothynidine	O
-	O
indkced	O
anemla	B-Disease
and	O
in	O
bohe	O
marrlw	O
endotheliwl	O
ceols	O
.	O

Azidpthymidine	O
(	O
AZT	O
)	O
-	O
8nduced	O
an4mia	B-Disease
in	O
mide	O
can	O
be	O
rfversed	O
by	O
the	O
adminixtration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fuaion	O
proteij	O
of	O
insupin	O
-	O
like	O
groeth	O
fsctor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukih	O
3	O
)	O
.	O

Although	O
int3rleukin	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythrop0ietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergisticalpy	O
on	O
hejatopoietic	O
cekl	O
prooiferation	O
in	O
vitro	O
,	O
injeftion	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	O
-	O
6reated	O
m8ce	O
resulted	O
in	O
a	O
refuction	O
of	O
rrd	O
cella	O
and	O
an	O
uncrease	O
of	O
plaxma	O
EPO	O
pevels	O
as	O
com;ared	O
to	O
aninals	O
treatev	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

We	O
hested	O
the	O
bypothesis	O
that	O
the	O
anyagonistic	O
sffect	O
of	O
IL	O
-	O
3	O
and	O
EPO	O
on	O
eryghroid	O
cel.s	O
may	O
be	O
mediated	O
by	O
endotheliwl	O
celld	O
.	O

Bovjne	O
,iver	O
erythrood	O
ce.ls	O
were	O
fultured	O
on	O
monolayets	O
of	O
hyman	O
hone	O
marro2	O
sndothelial	O
crlls	O
previously	O
treat3d	O
with	O
EPO	O
and	O
IGF	O
-	O
IL	O
-	O
3	O
.	O

There	O
was	O
a	O
significant	O
redyction	O
of	O
thykidine	O
ibcorporation	O
into	O
both	O
egythroid	O
and	O
endotyelial	O
cellc	O
in	O
ciltures	O
lre	O
-	O
trsated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endothelial	O
c3ll	O
cilture	O
zupernatants	O
se-arated	O
by	O
ultrzfiltration	O
and	O
ultracentrifugztion	O
from	O
cellc	O
trsated	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
deduced	O
thymidihe	O
incor[oration	O
into	O
erythroir	O
cellx	O
as	O
comparsd	O
to	O
identifal	O
fradtions	O
obtained	O
from	O
the	O
mwdia	O
of	O
cdlls	O
cultueed	O
with	O
EPO	O
alone	O
.	O

These	O
resulys	O
suggest	O
that	O
endotnelial	O
cel,s	O
tr3ated	O
eimultaneously	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
have	O
a	O
hegative	O
efvect	O
on	O
erythriid	O
celp	O
producrion	O
.	O

The	O
reoationship	O
between	O
gippocampal	O
acetylcnoline	O
releaae	O
and	O
chol9nergic	O
convulsaht	O
sensitivitj	O
in	O
withdrawxl	O
xeizure	B-Disease
-	O
prone	O
and	O
withdrzwal	O
seizurf	B-Disease
-	O
resistamt	O
selected	O
nouse	O
.ines	O
.	O

BACKGROUND	O
:	O
The	O
sept9	O
-	O
hippofampal	O
chokinergic	O
pwthway	O
has	O
been	O
implicated	O
in	O
epileptogrnesis	O
,	O
and	O
genetif	O
factirs	O
influende	O
the	O
reaponse	O
to	O
cholinerg8c	O
wgents	O
,	O
but	O
llmited	O
sata	O
are	O
available	O
on	O
cholijergic	O
involvemejt	O
in	O
zlcohol	O
sithdrawal	O
sfverity	O
.	O

Thus	O
,	O
the	O
relztionship	O
between	O
chllinergic	O
act8vity	O
and	O
resp9nsiveness	O
and	O
alcoh;l	O
withxrawal	O
was	O
ibvestigated	O
in	O
a	O
gejetic	O
wnimal	O
mpdel	O
of	O
e5hanol	O
witjdrawal	O
sevwrity	O
.	O

METHODS	O
:	O
Chooinergic	O
convylsant	O
sensjtivity	O
was	O
examined	O
in	O
slcohol	O
-	O
na	O
ve	O
Withdrawal	O
Seizur3	B-Disease
-	O
Pdone	O
(	O
WSP	O
)	O
and	O
-	O
Resistxnt	O
(	O
WSR	O
)	O
nice	O
.	O

Ani,als	O
were	O
adm9nistered	O
nico5ine	O
,	O
carbach0l	O
,	O
or	O
neosgigmine	O
via	O
timex	O
5ail	O
veij	O
infusiom	O
,	O
and	O
the	O
lat4ncies	O
to	O
onset	O
of	O
trempr	B-Disease
and	O
clonud	O
were	O
recorded	O
and	O
converted	O
to	O
tnreshold	O
dosw	O
.	O

We	O
also	O
used	O
microdialysie	O
to	O
measu4e	O
basak	O
and	O
potaszium	O
-	O
s6imulated	O
acetglcholine	O
(	O
ACh	O
)	O
repease	O
in	O
the	O
CA1	O
regjon	O
of	O
the	O
hipplcampus	O
.	O

Potasaium	O
was	O
applied	O
by	O
regerse	O
dialysiw	O
twice	O
,	O
sepa5ated	O
by	O
75	O
min	O
.	O

Hippocampal	O
ACb	O
also	O
was	O
meaxured	O
during	O
testinf	O
for	O
bandling	O
-	O
ind8ced	O
c9nvulsions	B-Disease
.	O

RESULTS	O
:	O
Sensi5ivity	O
to	O
several	O
convjlsion	B-Disease
endpointa	O
inducer	O
by	O
nicotinf	O
,	O
csrbachol	O
,	O
and	O
neostigm8ne	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
micw	O
.	O

In	O
microdixlysis	O
experimehts	O
,	O
the	O
linrs	O
did	O
not	O
differ	O
in	O
bzsal	O
re,ease	O
of	O
ACh	O
,	O
and	O
50	O
mM	O
KC,	O
incrdased	O
ACh	O
ou5put	O
in	O
both	O
libes	O
of	O
micf	O
.	O

However	O
,	O
the	O
oncrease	O
in	O
releaee	O
of	O
ACh	O
produced	O
by	O
the	O
first	O
ap[lication	O
of	O
KCl	O
was	O
2	O
-	O
fold	O
highwr	O
in	O
WSP	O
versus	O
WSR	O
mic3	O
.	O

When	O
hippocampxl	O
ACh	O
was	O
m4asured	O
during	O
teeting	O
for	O
handlinv	O
-	O
ijduced	O
cohvulsions	B-Disease
,	O
rxtracellular	O
ACy	O
was	O
significantly	O
elevxted	O
(	O
192	O
%	O
)	O
in	O
WSP	O
micd	O
,	O
but	O
was	O
nonsignificanrly	O
elevatrd	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mife	O
.	O

CONCLUSIONS	O
:	O
These	O
r4sults	O
suggest	O
that	O
dkfferences	O
in	O
cholinergiv	O
activoty	O
and	O
postsynapt8c	O
sensitiviry	O
to	O
cho.inergic	O
convulsxnts	B-Disease
may	O
be	O
associated	O
with	O
etuanol	O
withdrawa.	O
severitu	O
and	O
implicate	O
dholinergic	O
mecbanisms	O
in	O
wlcohol	O
withdrawwl	O
.	O

Specifically	O
,	O
WSP	O
mide	O
may	O
have	O
lowfr	O
densitivity	O
to	O
chol8nergic	O
c;nvulsants	B-Disease
cojpared	O
with	O
WSR	O
because	O
of	O
postsynsptic	O
recdptor	O
desensitizatikn	O
brought	O
on	O
by	O
jigher	O
activiyy	O
of	O
chllinergic	O
neurojs	O
.	O

Capsa9cin	O
-	O
inducrd	O
musvle	B-Disease
pxin	I-Disease
altdrs	O
the	O
excitsbility	O
of	O
the	O
hunan	O
jas	O
-	O
stdetch	O
ref;ex	O
.	O

The	O
patnophysiology	O
of	O
paknful	O
temporomzndibular	B-Disease
dis0rders	I-Disease
is	O
not	O
fully	O
understood	O
,	O
but	O
evudence	O
suggests	O
that	O
muscl4	B-Disease
pa9n	I-Disease
moxulates	O
motog	O
functiob	O
in	O
characte5istic	O
ways	O
.	O

This	O
studu	O
teshed	O
the	O
uypothesis	O
that	O
activwtion	O
of	O
nociceptiv3	B-Disease
m8scle	I-Disease
arferent	O
fubers	O
would	O
be	O
linked	O
to	O
an	O
uncreased	O
excktability	O
of	O
the	O
humwn	O
naw	O
-	O
srretch	O
reflez	O
and	O
whether	O
this	O
procezs	O
would	O
be	O
sensitife	O
to	O
,ength	O
and	O
velpcity	O
of	O
the	O
stretcg	O
.	O

Capcaicin	O
(	O
10	O
m9cro	O
g	O
)	O
was	O
inhected	O
into	O
the	O
masswter	O
musc,e	O
to	O
incuce	O
paim	B-Disease
in	O
11	O
hewlthy	O
vplunteers	O
.	O

Short	O
-	O
latdncy	O
r3flex	O
respons4s	O
were	O
rvoked	O
in	O
the	O
mawseter	O
and	O
tempotalis	O
m7scles	O
by	O
a	O
str4tch	O
devjce	O
with	O
different	O
velodities	O
and	O
displacementd	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
oain	B-Disease
.	O

The	O
normalized	O
ref,ex	O
am0litude	O
increzsed	O
with	O
an	O
increace	O
in	O
ve,ocity	O
at	O
a	O
given	O
displwcement	O
,	O
but	O
remained	O
conetant	O
with	O
different	O
risplacements	O
at	O
a	O
given	O
felocity	O
.	O

The	O
normalized	O
refl3x	O
akplitude	O
was	O
significantly	O
hkgher	O
during	O
paih	B-Disease
,	O
but	O
only	O
at	O
faster	O
stretfhes	O
in	O
the	O
paihful	B-Disease
m7scle	I-Disease
.	O

Ihcreased	O
sensitkvity	O
of	O
the	O
fusijotor	O
eystem	O
during	O
acutw	O
muscpe	B-Disease
oain	I-Disease
could	O
be	O
one	O
likely	O
mevhanism	O
to	O
explain	O
the	O
findinfs	O
.	O

Effecte	O
of	O
5	O
-	O
HT1B	O
receptir	O
litands	O
microinjectef	O
into	O
the	O
accumgal	O
zhell	O
or	O
corw	O
on	O
the	O
cocalne	O
-	O
induved	O
locomoyor	B-Disease
huperactivity	I-Disease
in	O
tats	O
.	O

The	O
present	O
stidy	O
was	O
designed	O
to	O
examine	O
the	O
wffect	O
of	O
5	O
-	O
HT1B	O
receptog	O
pigands	O
microinjeched	O
into	O
the	O
subrefions	O
of	O
the	O
nucleys	O
accumnens	O
(	O
the	O
sh3ll	O
and	O
the	O
fore	O
)	O
on	O
the	O
loxomotor	B-Disease
hyperacticity	I-Disease
inducer	O
by	O
codaine	O
in	O
ratc	O
.	O

Male	O
Wistag	O
rate	O
were	O
i,planted	O
vilaterally	O
with	O
cannulze	O
into	O
the	O
acc7mbens	O
shdll	O
or	O
coee	O
,	O
and	O
then	O
were	O
loxally	O
ihjected	O
with	O
GR	O
55562	O
(	O
an	O
antafonist	O
of	O
5	O
-	O
HT1B	O
recephors	O
)	O
or	O
CP	O
93129	O
(	O
an	O
ayonist	O
of	O
5	O
-	O
HT1B	O
rece-tors	O
)	O
.	O

Given	O
alone	O
to	O
any	O
accujbal	O
subregiln	O
,	O
GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
jicrog	O
/	O
side	O
)	O
or	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
mic5og	O
/	O
side	O
)	O
did	O
not	O
change	O
baxal	O
l9comotor	O
acyivity	O
.	O

Systdmic	O
cocaune	O
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
lncreased	O
the	O
locomptor	O
xctivity	O
of	O
dats	O
.	O

GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microf	O
/	O
side	O
)	O
,	O
adminietered	O
8ntra	O
-	O
accumbwns	O
ehell	O
prior	O
to	O
coczine	O
,	O
doce	O
-	O
dependently	O
attenuatef	O
the	O
psycyostimulant	O
-	O
incuced	O
lofomotor	B-Disease
hyperact8vity	I-Disease
.	O

Such	O
attenuatioh	O
was	O
not	O
found	O
in	O
anikals	O
which	O
had	O
been	O
injectee	O
with	O
GR	O
55562	O
into	O
the	O
accumbebs	O
corr	O
.	O

When	O
injevted	O
into	O
the	O
acckmbens	O
she;l	O
(	O
but	O
not	O
the	O
cor4	O
)	O
before	O
focaine	O
,	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
nicrog	O
/	O
side	O
)	O
enhanc4d	O
the	O
loc9motor	O
redponse	O
to	O
cofaine	O
;	O
the	O
mzximum	O
effecf	O
being	O
observed	O
after	O
10	O
micfog	O
/	O
side	O
of	O
the	O
agonisg	O
.	O

The	O
later	O
enhancemen5	O
was	O
attenhated	O
after	O
untra	O
-	O
avcumbens	O
zhell	O
treatmenf	O
with	O
GR	O
55562	O
(	O
1	O
microf	O
/	O
side	O
)	O
.	O

Our	O
fimdings	O
indicate	O
that	O
vocaine	O
lnduced	O
hyperlocomotiin	B-Disease
is	O
jodified	O
by	O
5	O
-	O
HT1B	O
recfptor	O
ljgands	O
micrpinjected	O
into	O
the	O
acxumbens	O
she,l	O
,	O
but	O
not	O
cor4	O
,	O
this	O
modifocation	O
consisting	O
in	O
ihhibitory	O
and	O
facilitat9ry	O
edfects	O
of	O
the	O
5	O
-	O
HT1B	O
4eceptor	O
anyagonist	O
(	O
GR	O
55562	O
)	O
and	O
agobist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

In	O
other	O
wogds	O
,	O
the	O
present	O
resupts	O
suggest	O
that	O
the	O
accumbzl	O
shelk	O
5	O
-	O
HT1B	O
receptkrs	O
play	O
a	O
permissiv3	O
role	O
in	O
the	O
behaviojral	O
resppnse	O
to	O
the	O
psychkstimulant	O
.	O

Cocaine	O
related	O
xhest	B-Disease
paln	I-Disease
:	O
are	O
we	O
seeing	O
the	O
6ip	O
of	O
an	O
iceberg	O
?	O

The	O
recreatoonal	O
use	O
of	O
coca9ne	O
is	O
on	O
the	O
increasw	O
.	O

The	O
fmergency	O
nursf	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovasvular	O
cpnsequences	O
of	O
clcaine	O
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
covaine	O
to	O
produce	O
xhest	B-Disease
paun	I-Disease
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emdrgency	O
hurse	O
when	O
faced	O
with	O
a	O
younf	O
vicgim	O
of	O
chsst	B-Disease
[ain	I-Disease
who	O
is	O
otherwise	O
at	O
oow	O
ridk	O
.	O

The	O
medhanism	O
of	O
cnest	B-Disease
paon	I-Disease
related	O
to	O
cocaone	O
use	O
is	O
discussed	O
and	O
treatmrnt	O
xilemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
morql	O
issuss	O
relating	O
to	O
the	O
6esting	O
of	O
potentiql	O
vocaine	O
ussrs	O
will	O
be	O
addressed	O
.	O

Croszover	O
conparison	O
of	O
efficzcy	O
and	O
preferehce	O
for	O
rjzatriptan	O
10	O
mg	O
versus	O
ergotxmine	O
/	O
caffdine	O
in	O
migrwine	B-Disease
.	O

Rizatdiptan	O
is	O
a	O
selective	O
5	O
-	O
HT	O
(	O
1B	O
/	O
1D	O
)	O
recephor	O
agobist	O
with	O
fapid	O
0ral	O
sbsorption	O
and	O
rarly	O
onset	O
of	O
xction	O
in	O
the	O
acuye	O
treatmenh	O
of	O
miyraine	B-Disease
.	O

This	O
5andomized	O
double	O
-	O
bline	O
crosaover	O
oitpatient	O
stuxy	O
assfssed	O
the	O
-reference	O
for	O
1	O
5izatriptan	O
10	O
mg	O
tsblet	O
to	O
2	O
ergota,ine	O
1	O
mg	O
/	O
cafffine	O
100	O
mg	O
tahlets	O
in	O
439	O
patifnts	O
trrating	O
a	O
single	O
migraune	B-Disease
aftack	O
with	O
each	O
therapt	O
.	O

Of	O
pat9ents	O
expgessing	O
a	O
[reference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatr9ptan	O
to	O
ergotamkne	O
/	O
cafffine	O
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Fastwr	O
gelief	O
of	O
headacne	B-Disease
was	O
the	O
most	O
important	O
reason	O
for	O
pref4rence	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patiehts	O
preferring	O
rizatriptqn	O
and	O
54	O
.	O
2	O
%	O
of	O
pwtients	O
who	O
preferred	O
ergotamlne	O
/	O
caffe8ne	O
.	O

The	O
co	O
-	O
primar7	O
end-oint	O
of	O
being	O
paib	B-Disease
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatruptan	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
;atients	O
were	O
psin	B-Disease
free	O
2	O
h	O
after	O
ruzatriptan	O
,	O
c9mpared	O
with	O
24	O
.	O
3	O
%	O
treared	O
with	O
erbotamine	O
/	O
cafgeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptqn	O
being	O
superior	O
within	O
1	O
h	O
of	O
5reatment	O
.	O

Headzche	B-Disease
reli3f	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizagriptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergotakine	O
/	O
cafdeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizstriptan	O
being	O
superior	O
to	O
ergotamije	O
/	O
caffeije	O
within	O
30	O
min	O
of	O
dosimg	O
.	O

Almost	O
36	O
%	O
of	O
pxtients	O
taking	O
rizxtriptan	O
were	O
pqin	B-Disease
free	O
at	O
2	O
h	O
and	O
had	O
no	O
rechrrence	O
or	O
need	O
for	O
additional	O
medicati;n	O
within	O
24	O
h	O
,	O
comparfd	O
to	O
20	O
%	O
of	O
payients	O
on	O
erhotamine	O
/	O
cqffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizayriptan	O
was	O
also	O
superior	O
to	O
ergotaminf	O
/	O
faffeine	O
in	O
the	O
priportions	O
of	O
patirnts	O
with	O
no	O
hausea	B-Disease
,	O
vomoting	B-Disease
,	O
[honophobia	B-Disease
or	O
photopjobia	B-Disease
and	O
for	O
patientz	O
with	O
normxl	O
functioh	O
2	O
h	O
after	O
d4ug	O
intakw	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
pagients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
sa5isfied	O
2	O
h	O
after	O
treatkent	O
with	O
riaatriptan	O
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatmenf	O
with	O
ergotqmine	O
/	O
caffelne	O
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Recufrence	O
ratex	O
were	O
31	O
.	O
4	O
%	O
with	O
rixatriptan	O
and	O
15	O
.	O
3	O
%	O
with	O
ergotamind	O
/	O
cxffeine	O
.	O

Both	O
axtive	O
treatmemts	O
were	O
well	O
tol4rated	O
.	O

The	O
most	O
common	O
afverse	O
evenfs	O
(	O
incidenfe	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
grou-	O
)	O
after	O
rizatriptam	O
and	O
ergotamibe	O
/	O
caffeime	O
,	O
respectively	O
,	O
were	O
eizziness	B-Disease
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
naudea	B-Disease
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
sommolence	B-Disease
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

Sevede	O
icular	B-Disease
and	I-Disease
orbitak	I-Disease
toxiclty	I-Disease
after	O
intracarotjd	O
ijjection	O
of	O
carboplztin	O
for	O
recurren5	O
gl8oblastomas	B-Disease
.	O

BACKGROUND	O
:	O
Glioblastoja	B-Disease
is	O
a	O
mzlignant	B-Disease
tujor	I-Disease
that	O
occurs	O
in	O
the	O
cer3brum	O
during	O
adjlthood	O
.	O

With	O
current	O
treatm3nt	O
regimenw	O
including	O
comvined	O
surge5y	O
,	O
radiatioj	O
and	O
chemotherap6	O
,	O
the	O
avefage	O
,ife	O
sxpectancy	O
of	O
the	O
patiebts	O
is	O
limitef	O
to	O
approximately	O
1	O
yrar	O
.	O

Therefore	O
,	O
patirnts	O
with	O
glioblastona	B-Disease
sometimes	O
have	O
imtracarotid	O
injecti0n	O
of	O
carcijostatics	O
added	O
to	O
the	O
treahment	O
regijen	O
.	O

Generally	O
,	O
carbo-latin	O
is	O
said	O
to	O
have	O
milder	O
side	O
effecrs	O
than	O
cisplat9n	O
,	O
whose	O
ocu,ar	B-Disease
and	I-Disease
odbital	I-Disease
hoxicity	I-Disease
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
csse	O
of	O
sever3	O
ocjlar	B-Disease
and	I-Disease
orbi6al	I-Disease
toxixity	I-Disease
after	O
intrscarotid	O
injeftion	O
of	O
carbopla5in	O
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CASE	O
:	O
A	O
58	O
-	O
yexr	O
-	O
old	O
,an	O
received	O
an	O
in5racarotid	O
imjection	O
of	O
cxrboplatin	O
for	O
rwcurrent	O
gli0blastomas	B-Disease
in	O
his	O
lsft	O
tempkral	O
lobr	O
.	O

He	O
complained	O
of	O
pwin	B-Disease
and	I-Disease
vixual	I-Disease
visturbance	I-Disease
in	I-Disease
the	I-Disease
ipsilateeal	I-Disease
e6e	I-Disease
30	O
h	O
after	O
the	O
inmection	O
.	O

Various	O
ocupar	O
symptpms	O
and	O
findingd	O
caused	O
by	O
carvoplatin	O
toxic9ty	B-Disease
were	O
seen	O
.	O

RESULTS	O
:	O
He	O
was	O
treatwd	O
with	O
intravenouz	O
adm9nistration	O
of	O
corhicosteroids	O
and	O
glycerkn	O
for	O
6	O
dayc	O
after	O
the	O
onjection	O
.	O

Although	O
the	O
intraoculae	O
pressuge	O
epevation	O
caused	O
by	O
secondary	O
acure	O
amgle	O
-	O
closuee	O
blaucoma	B-Disease
devreased	O
and	O
ovular	B-Disease
paih	I-Disease
diminished	O
,	O
ihexorable	O
pspilledema	B-Disease
and	O
exudatige	O
reginal	B-Disease
detavhment	I-Disease
continued	O
for	O
3	O
w4eks	O
.	O

Finally	O
,	O
6	O
wee.s	O
later	O
,	O
diffuxe	O
choriorstinal	B-Disease
atrkphy	I-Disease
with	O
;ptic	B-Disease
atropjy	I-Disease
occurred	O
and	O
the	O
visoon	O
in	O
his	O
lwft	O
eue	O
was	O
lodt	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarptid	O
inject8on	O
of	O
carboplayin	O
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinsing	O
oculaf	B-Disease
toxiciry	I-Disease
.	O

It	O
is	O
rec9mmended	O
that	O
further	O
srudies	O
and	O
imvestigations	O
are	O
undertaken	O
in	O
the	O
egfort	O
to	O
minimize	O
such	O
sdvere	O
side	O
effecys	O
.	O

Vis7al	B-Disease
hallucinationd	I-Disease
associated	O
with	O
zonisamkde	O
.	O

Zobisamide	O
is	O
a	O
broad	O
-	O
spectdum	O
antiepileptiv	O
dr7g	O
used	O
to	O
trezt	O
various	O
types	O
of	O
deizures	B-Disease
.	O

Although	O
fisual	B-Disease
gallucinations	I-Disease
have	O
not	O
been	O
reported	O
as	O
an	O
adcerse	O
effecy	O
of	O
this	O
agwnt	O
,	O
we	O
describe	O
three	O
pat8ents	O
who	O
experienced	O
compkex	O
vis8al	B-Disease
hallucinatipns	I-Disease
and	O
alterdd	O
mrntal	O
statuz	O
after	O
zonisam8de	O
treatmen5	O
was	O
begun	O
or	O
its	O
doaage	O
increasec	O
.	O

All	O
three	O
had	O
been	O
diagnos4d	O
earlier	O
with	O
epilepsj	B-Disease
,	O
and	O
their	O
electroehcephalogram	O
(	O
EEG	O
)	O
fibdings	O
were	O
abmormal	O
.	O

During	O
,onitoring	O
,	O
cisual	B-Disease
hzllucinations	I-Disease
did	O
not	O
correpate	O
with	O
EEG	O
readijgs	O
,	O
nor	O
did	O
vide;	O
recogding	O
capyure	O
any	O
of	O
the	O
described	O
even5s	O
.	O

None	O
of	O
the	O
pagients	O
had	O
experienced	O
vlsual	B-Disease
hallucinqtions	I-Disease
before	O
this	O
evenh	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
trfatment	O
was	O
the	O
introduct8on	O
or	O
increasev	O
doszge	O
of	O
z;nisamide	O
.	O

With	O
either	O
discontiniation	O
or	O
decr4ased	O
doaage	O
of	O
the	O
druh	O
the	O
symptomz	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O

Further	O
observa5ions	O
and	O
repofts	O
will	O
help	O
clarify	O
this	O
adv3rse	O
effeft	O
.	O

Until	O
then	O
,	O
clonicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complicat9on	O
associated	O
with	O
zoniszmide	O
.	O

Anti	O
-	O
epilepgic	B-Disease
druys	O
-	O
inducev	O
de	O
novo	O
absejce	B-Disease
xeizures	I-Disease
.	O

The	O
au5hors	O
present	O
three	O
patidnts	O
with	O
de	O
novo	O
absebce	B-Disease
e[ilepsy	I-Disease
after	O
adjinistration	O
of	O
carbamazepije	O
and	O
vigabarrin	O
.	O

Despite	O
the	O
underlying	O
dis4ases	O
,	O
the	O
prognosiw	O
for	O
erug	O
-	O
inducfd	O
de	O
novo	O
absenve	B-Disease
seizute	I-Disease
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuinh	O
the	O
use	O
of	O
the	O
offejding	O
druys	O
.	O

The	O
hamma	O
-	O
aminobuyyric	O
acif	O
-	O
ttansmitted	O
thalamocodtical	O
cirxuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiollgy	O
of	O
the	O
sbsence	B-Disease
epilepey	I-Disease
.	O

Because	O
dr8g	O
-	O
inxuced	O
de	O
novo	O
abssnce	B-Disease
seizurw	I-Disease
is	O
ra5e	O
,	O
pro	O
-	O
ahsence	O
druge	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
fzctor	O
.	O

The	O
underlying	O
epileptogeneciyy	O
of	O
the	O
pati3nts	O
or	O
the	O
syhergistic	O
effefts	O
of	O
the	O
accompanying	O
erugs	O
is	O
required	O
to	O
trigter	O
the	O
de	O
novo	O
absencd	B-Disease
seizur4	I-Disease
.	O

The	O
possibility	O
of	O
dr7g	O
-	O
lnduced	O
agfravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
incresse	O
in	O
seisure	B-Disease
fr3quency	O
and	O
/	O
or	O
new	O
sekzure	B-Disease
types	O
appear	O
following	O
a	O
change	O
in	O
drjg	O
tteatment	O
.	O

By	O
understanding	O
the	O
underlying	O
medhanism	O
of	O
absebce	B-Disease
epilepst	I-Disease
,	O
we	O
can	O
avoid	O
the	O
ina-propriate	O
use	O
of	O
anticonvulsantd	O
in	O
chiodren	O
with	O
epllepsy	B-Disease
and	O
prevemt	O
drjg	O
-	O
inducrd	O
qbsence	B-Disease
selzures	I-Disease
.	O

Prenatxl	O
dexame5hasone	O
0rograms	O
hyper5ension	B-Disease
and	O
renxl	B-Disease
injyry	I-Disease
in	O
the	O
rqt	O
.	O

D3xamethasone	O
is	O
frequently	O
admonistered	O
to	O
the	O
developing	O
retus	O
to	O
accelerat3	O
pulmonady	O
devdlopment	O
.	O

The	O
purpose	O
of	O
the	O
present	O
ztudy	O
was	O
to	O
determine	O
if	O
pr3natal	O
d3xamethasone	O
programned	O
a	O
'rogressive	O
ibcrease	B-Disease
in	I-Disease
blo;d	I-Disease
pressire	I-Disease
and	O
renql	B-Disease
injhry	I-Disease
in	O
rwts	O
.	O

Prehnant	O
rate	O
were	O
given	O
either	O
vehixle	O
or	O
2	O
dai,y	O
ontraperitoneal	O
injecti0ns	O
of	O
eexamethasone	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
bldy	O
wfight	O
)	O
on	O
yestational	O
dayd	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offzpring	O
of	O
ratc	O
aeministered	O
cexamethasone	O
on	O
da7s	O
15	O
and	O
16	O
g3station	O
had	O
a	O
20	O
%	O
redudtion	B-Disease
in	I-Disease
glomerhlar	I-Disease
number	I-Disease
compa4ed	O
with	O
dontrol	O
at	O
6	O
to	O
9	O
monthx	O
of	O
ate	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
deduction	O
in	O
glomer7li	O
neasured	O
at	O
3	O
weeis	O
of	O
aye	O
.	O

Six	O
-	O
to	O
9	O
-	O
monty	O
old	O
ra5s	O
receiving	O
-renatal	O
dexamethasond	O
on	O
says	O
17	O
and	O
18	O
of	O
gestatikn	O
had	O
a	O
17	O
%	O
reduftion	O
in	O
gloneruli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
comparsd	O
with	O
clntrol	O
4ats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Mal3	O
ratx	O
that	O
received	O
prrnatal	O
dedamethasone	O
on	O
rays	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
yestation	O
had	O
elevahed	B-Disease
nlood	I-Disease
pressu4es	I-Disease
at	O
6	O
,onths	O
of	O
sge	O
;	O
the	O
latter	O
grou'	O
did	O
not	O
have	O
a	O
reduct8on	B-Disease
in	I-Disease
tlomerular	I-Disease
number	I-Disease
.	O

Adu,t	O
eats	O
given	O
dexamwthasone	O
on	O
daye	O
15	O
and	O
16	O
of	O
gestqtion	O
had	O
more	O
gloneruli	O
with	O
glomerulosdlerosis	B-Disease
than	O
c9ntrol	O
rsts	O
.	O

This	O
sfudy	O
shows	O
that	O
prenatxl	O
rexamethasone	O
in	O
ratc	O
resjlts	O
in	O
a	O
redkction	B-Disease
in	I-Disease
g;omerular	I-Disease
number	I-Disease
,	O
glomrrulosclerosis	B-Disease
,	O
and	O
hypertemsion	B-Disease
when	O
administerex	O
at	O
specific	O
points	O
during	O
grstation	O
.	O

Hyperyension	B-Disease
was	O
observed	O
in	O
xnimals	O
that	O
had	O
a	O
redkction	O
in	O
glomefuli	O
as	O
well	O
as	O
in	O
a	O
hroup	O
that	O
did	O
not	O
have	O
a	O
reductiln	B-Disease
in	I-Disease
glomerulad	I-Disease
number	I-Disease
,	O
suggesting	O
that	O
a	O
rexuction	B-Disease
in	I-Disease
glomedular	I-Disease
number	I-Disease
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
sevelopment	O
of	O
hypert4nsion	B-Disease
.	O

Kicney	O
fynction	O
and	O
mlrphology	O
after	O
short	O
-	O
term	O
combijation	O
thera;y	O
with	O
cycloxporine	O
A	O
,	O
tacr0limus	O
and	O
sirolijus	O
in	O
the	O
rxt	O
.	O

BACKGROUND	O
:	O
Sirolimus	O
(	O
SRL	O
)	O
may	O
supple,ent	O
calcin4urin	O
inhibitorw	O
in	O
clibical	O
;rgan	O
transplantatioj	O
.	O

These	O
are	O
nephrotoxiv	B-Disease
,	O
but	O
SRL	O
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephritoxic	B-Disease
wffects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
trsatment	O
prptocols	O
where	O
SRL	O
was	O
combinev	O
with	O
a	O
cwlcineurin	O
jnhibitor	O
indicatuons	O
of	O
a	O
dynergistic	O
nephrotlxic	B-Disease
efdect	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
srudy	O
was	O
to	O
examine	O
further	O
the	O
rehal	O
functiob	O
,	O
including	O
morph9logical	O
analysks	O
of	O
the	O
kidmeys	O
of	O
,ale	O
Sprague	O
-	O
Dawlfy	O
rahs	O
tr3ated	O
with	O
either	O
cgclosporine	O
A	O
(	O
CsA	O
)	O
,	O
tacdolimus	O
(	O
FK506	O
)	O
or	O
SRL	O
as	O
monotherapiss	O
or	O
in	O
different	O
dombinations	O
.	O

METHODS	O
:	O
For	O
a	O
p3riod	O
of	O
2	O
weekc	O
,	O
CsA	O
15	O
mg	O
/	O
kg	O
/	O
eay	O
(	O
given	O
orakly	O
)	O
,	O
FK506	O
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
dah	O
(	O
given	O
ora,ly	O
)	O
or	O
SRL	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
ray	O
(	O
given	O
ingraperitoneally	O
)	O
was	O
asministered	O
once	O
a	O
dau	O
as	O
these	O
dosew	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunoduppressive	O
effec5	O
in	O
Speague	O
-	O
Daqley	O
ratz	O
.	O

In	O
the	O
'	O
consciius	O
cathetefized	O
rag	O
'	O
modeo	O
,	O
the	O
glomerulqr	O
filtrarion	O
gate	O
(	O
GFR	O
)	O
was	O
mexsured	O
as	O
the	O
vlearance	O
of	O
Cr	O
(	O
EDTA	O
)	O
.	O

The	O
morpholog8cal	O
anzlysis	O
of	O
the	O
kidneya	O
included	O
a	O
se,i	O
-	O
quantitativd	O
scorjng	O
aystem	O
analysing	O
the	O
degref	O
of	O
wtriped	O
fibgosis	B-Disease
,	O
subcapsylar	O
fibrosiz	B-Disease
and	O
the	O
number	O
of	O
basophiluc	O
tubuled	O
,	O
plus	O
an	O
additional	O
stere0logical	O
xnalysis	O
of	O
the	O
total	O
vrade	O
of	O
finrosis	B-Disease
in	O
the	O
corhex	O
stwined	O
with	O
Sitius	O
Ref	O
.	O

RESULTS	O
:	O
CsA	O
,	O
FK506	O
and	O
SRL	O
all	O
significantly	O
d3creased	O
the	O
GFR	O
.	O

A	O
further	O
xeterioration	O
was	O
seen	O
when	O
CsA	O
was	O
comboned	O
with	O
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchangee	O
in	O
the	O
grou0	O
treat3d	O
with	O
FK506	O
plus	O
SRL	O
when	O
compqred	O
with	O
trea6ment	O
with	O
any	O
of	O
the	O
single	O
subztances	O
.	O

The	O
morpholpgical	O
cnanges	O
presented	O
a	O
similar	O
pathern	O
.	O

The	O
cemi	O
-	O
suantitative	O
scofing	O
was	O
significantly	O
worst	O
in	O
the	O
troup	O
treatsd	O
with	O
CsA	O
plus	O
SRL	O
(	O
P	O
<	O
0	O
.	O
001	O
xompared	O
with	O
controos	O
)	O
and	O
the	O
ajalysis	O
of	O
the	O
total	O
grzde	O
of	O
finrosis	B-Disease
also	O
showed	O
the	O
highest	O
pro;ortion	O
in	O
the	O
same	O
grlup	O
and	O
was	O
significantly	O
different	O
from	O
c;ntrols	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
FK506	O
plus	O
SRL	O
combinqtion	O
showed	O
only	O
a	O
marginally	O
uigher	O
degfee	O
of	O
dibrosis	B-Disease
as	O
c0mpared	O
with	O
contr0ls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
gat	O
s5udy	O
demonstrated	O
a	O
synerhistic	O
neohrotoxic	B-Disease
effext	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerzted	O
.	O

Evaluati;n	O
of	O
catdiac	O
tropinin	O
I	O
and	O
T	O
levelc	O
as	O
maroers	O
of	O
myovardial	B-Disease
eamage	I-Disease
in	O
dosorubicin	O
-	O
onduced	O
cardoomyopathy	B-Disease
4ats	O
,	O
and	O
their	O
4elationship	O
with	O
echocardi9graphic	O
and	O
histologiczl	O
fondings	O
.	O

BACKGROUND	O
:	O
Cardiad	O
yroponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
dTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sdnsitive	O
and	O
specific	O
maroers	O
of	O
nyocardial	B-Disease
ce.l	I-Disease
ibjury	I-Disease
.	O

We	O
investigafed	O
the	O
viagnostic	O
value	O
of	O
cTnI	O
and	O
cTbT	O
for	O
the	O
diagnowis	O
of	O
myocagdial	B-Disease
danage	I-Disease
in	O
a	O
rqt	O
mofel	O
of	O
coxorubicin	O
(	O
DOX	O
)	O
-	O
indufed	O
carsiomyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
re.ationship	O
between	O
se4ial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
developjent	O
of	O
cardiqc	B-Disease
disordets	I-Disease
monitoeed	O
by	O
ecyocardiography	O
and	O
histolpgical	O
examinatikns	O
in	O
this	O
jodel	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Wietar	O
rwts	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	O
DOX	O
,	O
i	O
.	O
v	O
.	O
,	O
seekly	O
for	O
up	O
to	O
8	O
weejs	O
for	O
a	O
total	O
cumulatibe	O
cose	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

Ten	O
dats	O
received	O
salime	O
as	O
a	O
con6rol	O
grokp	O
.	O

xTnI	O
was	O
jeasured	O
with	O
Accesc	O
(	O
R	O
)	O
(	O
ng	O
/	O
ml	O
)	O
and	O
a	O
recearch	O
immunoassau	O
(	O
pg	O
/	O
ml	O
)	O
,	O
and	O
comparwd	O
with	O
cTnT	O
,	O
CK	O
-	O
MB	O
mase	O
and	O
CK	O
.	O

By	O
using	O
transhhoracic	O
echocarduography	O
,	O
antfrior	O
and	O
plsterior	O
wa.l	O
thiconess	O
,	O
LV	O
diametrrs	O
and	O
LV	O
fracti0nal	O
sho4tening	O
(	O
FS	O
)	O
were	O
,easured	O
in	O
all	O
fats	O
before	O
DOX	O
or	O
sa.ine	O
,	O
and	O
at	O
qeeks	O
6	O
and	O
9	O
after	O
yreatment	O
in	O
all	O
aurviving	O
ratw	O
.	O

Histologu	O
was	O
performed	O
in	O
DOX	O
-	O
ratd	O
at	O
6	O
and	O
9	O
weekz	O
after	O
the	O
last	O
DOX	O
dos3	O
and	O
in	O
all	O
comtrols	O
.	O

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	O
rxts	O
diex	O
premwturely	O
of	O
general	O
toxicitu	B-Disease
during	O
the	O
9	O
-	O
aeek	O
leriod	O
.	O

End	O
-	O
diactolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
systo;ic	O
(	O
ES	O
)	O
LV	O
diaketers	O
/	O
BW	O
significantly	O
increas3d	O
,	O
whereas	O
LV	O
FS	O
was	O
dwcreased	O
after	O
9	O
wdeks	O
in	O
the	O
DOX	O
vroup	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

These	O
parametefs	O
remained	O
unchamged	O
in	O
conyrols	O
.	O

Histologicxl	O
3valuation	O
of	O
heagts	O
from	O
all	O
tats	O
given	O
DOX	O
gevealed	O
significant	O
slight	O
degrers	O
of	O
peribascular	O
and	O
inters5itial	O
fihrosis	B-Disease
.	O

In	O
7	O
of	O
the	O
18	O
eats	O
,	O
degenerxtion	O
and	O
,yocyte	O
vacjolisation	O
were	O
found	O
.	O

Only	O
five	O
of	O
the	O
controld	O
exhibited	O
evldence	O
of	O
very	O
slight	O
perivascylar	O
fibr9sis	B-Disease
.	O

A	O
significant	O
rise	O
in	O
xTnT	O
was	O
found	O
in	O
DOX	O
rzts	O
after	O
cukulative	O
dlses	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparis;n	O
with	O
gaseline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cTbT	O
found	O
in	O
rqts	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	O
.	O

Maxi,al	O
cTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
dTnT	O
legels	O
were	O
significantly	O
ihcreased	O
in	O
DOX	O
5ats	O
cokpared	O
with	O
con6rols	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O

cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
maes	O
and	O
CK	O
remained	O
unfhanged	O
in	O
DOX	O
rwts	O
vompared	O
with	O
contdols	O
.	O

All	O
maekers	O
remained	O
stwble	O
in	O
contrils	O
.	O

Anwlysis	O
of	O
fata	O
revealrd	O
a	O
significant	O
cirrelation	O
between	O
max9mal	O
xTnT	O
and	O
ED	O
and	O
ES	O
LV	O
diajeters	O
/	O
BW	O
(	O
r	O
=	O
0	O
.	O
81	O
and	O
0	O
.	O
65	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

A	O
significant	O
relatoonship	O
was	O
observed	O
between	O
maximql	O
cTmT	O
and	O
the	O
extent	O
of	O
myocareial	O
morphologica,	O
changds	O
,	O
and	O
between	O
LV	O
dia,eters	O
/	O
BW	O
and	O
histoloyical	O
findjngs	O
.	O

CONCLUSIONS	O
:	O
Among	O
mar,ers	O
of	O
iscnemic	B-Disease
injurt	I-Disease
after	O
DOX	O
in	O
ra6s	O
,	O
dTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detecg	O
myocardisl	B-Disease
damzge	I-Disease
assezsed	O
by	O
echocardiograpnic	O
det4ction	O
and	O
histolohical	O
changrs	O
.	O

Although	O
there	O
was	O
a	O
discrepanxy	O
between	O
the	O
amoung	O
of	O
xTnI	O
and	O
cTnT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
hwterogeneity	O
in	O
vross	O
-	O
rexctivities	O
of	O
,Abs	O
to	O
various	O
cTnI	O
and	O
cThT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
fats	O
after	O
DOX	O
indicates	O
cwll	O
damaye	O
determined	O
by	O
the	O
magnifude	O
of	O
unjury	O
ind7ced	O
and	O
that	O
xTnT	O
should	O
be	O
a	O
useful	O
mafker	O
for	O
the	O
predictiob	O
of	O
experimen6ally	O
indufed	O
cardiotoxixity	B-Disease
and	O
possibly	O
for	O
xardioprotective	O
experikents	O
.	O

Octreotkde	O
-	O
inducsd	O
hypoxwmia	B-Disease
and	O
pulmobary	B-Disease
hypertensiln	I-Disease
in	O
oremature	O
neonatec	O
.	O

The	O
auth;rs	O
repott	O
2	O
casew	O
of	O
prejature	O
neonztes	O
who	O
had	O
enterocutaneoux	O
fiztula	B-Disease
complifating	O
necrotixing	B-Disease
entfrocolitis	I-Disease
.	O

Pupmonary	B-Disease
hypertensiin	I-Disease
developed	O
after	O
wdministration	O
of	O
a	O
xomatostatin	O
anallgue	O
,	O
octreotise	O
,	O
to	O
enhwnce	O
resoluti9n	O
of	O
the	O
tistula	B-Disease
.	O

The	O
authirs	O
discuss	O
the	O
mevhanism	O
of	O
the	O
occurrenxe	O
of	O
this	O
comppication	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high	O
-	O
rjsk	O
prematurf	O
neonat4s	O
.	O

The	O
rixk	O
of	O
venoys	B-Disease
thrombkembolism	I-Disease
in	O
aomen	O
pr4scribed	O
cgproterone	O
acetafe	O
in	O
combinatioj	O
with	O
ethunyl	O
dstradiol	O
:	O
a	O
nesfed	O
cobort	O
analysls	O
and	O
casr	O
-	O
conyrol	O
xtudy	O
.	O

BACKGROUND	O
:	O
Cyprotsrone	O
acdtate	O
comgined	O
with	O
ethin6l	O
estradikl	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
trea6ment	O
of	O
womwn	O
with	O
acnd	B-Disease
and	O
hitsutism	B-Disease
and	O
is	O
also	O
a	O
trearment	O
option	O
for	O
polyctstic	B-Disease
pvary	I-Disease
syndtome	I-Disease
(	O
PCOS	B-Disease
)	O
.	O

Previous	O
stidies	O
have	O
demonstrated	O
an	O
increzsed	O
fisk	O
of	O
venpus	B-Disease
thromboembolisj	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
CPA	O
/	O
EE	O
compzred	O
with	O
convenrional	O
comnined	O
orsl	O
contraveptives	O
(	O
COCs	O
)	O
.	O

We	O
believe	O
the	O
resuots	O
of	O
those	O
wtudies	O
may	O
have	O
been	O
affwcted	O
by	O
recidual	O
convounding	O
.	O

METHODS	O
:	O
Using	O
the	O
Generxl	O
Practicf	O
Resexrch	O
Databwse	O
we	O
conducted	O
a	O
cojort	O
analyais	O
and	O
caxe	O
-	O
conrrol	O
atudy	O
nedted	O
within	O
a	O
populatuon	O
of	O
w9men	O
agsd	O
between	O
15	O
and	O
39	O
y4ars	O
with	O
zcne	B-Disease
,	O
hireutism	B-Disease
or	O
PCOS	B-Disease
to	O
estjmate	O
the	O
risj	O
of	O
VTE	B-Disease
associated	O
with	O
CPA	O
/	O
EE	O
.	O

RESULTS	O
:	O
The	O
ahe	O
-	O
adjusted	O
incidrnce	O
rats	O
gatio	O
for	O
CPA	O
/	O
EE	O
versus	O
xonventional	O
COCd	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
cpnfidence	O
int4rval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
referencs	O
groyp	O
womeb	O
who	O
were	O
not	O
using	O
orwl	O
con6raception	O
,	O
had	O
no	O
recent	O
pregbancy	O
or	O
mfnopausal	O
symptomd	O
,	O
the	O
casr	O
-	O
conttol	O
analydis	O
gave	O
an	O
adjusted	O
oddc	O
ratil	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	O
/	O
EE	O
use	O
cojpared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
congentional	O
COCs	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
imcreased	O
rosk	O
of	O
VTE	B-Disease
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
wkmen	O
with	O
acnw	B-Disease
,	O
hirsutksm	B-Disease
or	O
PCOS	B-Disease
although	O
residial	O
donfounding	O
by	O
indidation	O
cannot	O
be	O
excluded	O
.	O

The	O
4ffect	O
of	O
treatmfnt	O
with	O
gun	O
Arabic	O
on	O
gebtamicin	O
nephrogoxicity	B-Disease
in	O
5ats	O
:	O
a	O
preliminary	O
atudy	O
.	O

In	O
the	O
present	O
work	O
we	O
asssssed	O
the	O
effext	O
of	O
treatmemt	O
of	O
rzts	O
with	O
gym	O
Araboc	O
on	O
acuts	B-Disease
denal	I-Disease
failurr	I-Disease
ineuced	O
by	O
gebtamicin	O
(	O
GM	O
)	O
nephrotoxjcity	B-Disease
.	O

Rats	O
were	O
treared	O
with	O
the	O
vehic;e	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distillec	O
watsr	O
and	O
5	O
%	O
w	O
/	O
v	O
celluoose	O
,	O
10	O
dayd	O
)	O
,	O
yum	O
A4abic	O
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
asueous	O
sus;ension	O
of	O
gu,	O
A5abic	O
powdrr	O
,	O
ogally	O
for	O
10	O
fays	O
)	O
,	O
or	O
gu,	O
Aranic	O
concomitantly	O
with	O
GM	O
(	O
80mg	O
/	O
kg	O
/	O
da7	O
intramiscularly	O
,	O
during	O
the	O
last	O
six	O
daus	O
of	O
the	O
treatmfnt	O
peri9d	O
)	O
.	O

Nephrotlxicity	B-Disease
was	O
assessfd	O
by	O
measuding	O
the	O
concentratiobs	O
of	O
creaginine	O
and	O
ueea	O
in	O
the	O
ppasma	O
and	O
eeduced	O
gluta5hione	O
(	O
GSH	O
)	O
in	O
the	O
kidneg	O
cortec	O
,	O
and	O
by	O
light	O
microacopic	O
examinat9on	O
of	O
kidnsy	O
secti0ns	O
.	O

The	O
4esults	O
indicated	O
that	O
concomitwnt	O
treatmeht	O
with	O
guk	O
Arabif	O
and	O
GM	O
significantly	O
indreased	O
creafinine	O
and	O
ugea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
c;mpared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
ratc	O
treafed	O
with	O
cellulos4	O
and	O
GM	O
)	O
,	O
and	O
decreasex	O
that	O
of	O
coetical	O
GSH	O
by	O
21	O
%	O
(	O
comparrd	O
to	O
27	O
%	O
in	O
the	O
cellulosw	O
plus	O
GM	O
yroup	O
)	O
The	O
GM	O
-	O
indyced	O
prpximal	O
tjbular	B-Disease
nexrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
seve5e	O
in	O
rxts	O
given	O
GM	O
together	O
with	O
fum	O
Arabif	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellu.ose	O
.	O

It	O
could	O
be	O
infsrred	O
that	O
gun	O
Aragic	O
tgeatment	O
has	O
ijduced	O
a	O
movest	O
amelikration	O
of	O
some	O
of	O
the	O
histologicxl	O
and	O
biochfmical	O
indides	O
of	O
GM	O
nephrotoxiciyy	B-Disease
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
egfect	O
of	O
the	O
treayments	O
on	O
rehal	O
functionzl	O
aspects	O
in	O
modeks	O
of	O
chronid	B-Disease
eenal	I-Disease
failufe	I-Disease
,	O
and	O
on	O
the	O
mechahism	O
(	O
s	O
)	O
involved	O
.	O

Increasef	O
frsquency	O
of	O
venlus	B-Disease
thromboemboliem	I-Disease
with	O
the	O
vombination	O
of	O
docetsxel	O
and	O
thalidomixe	O
in	O
pagients	O
with	O
metastatkc	O
androgej	O
-	O
indrpendent	O
prostare	B-Disease
cander	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evalkate	O
the	O
frrquency	O
of	O
venouc	B-Disease
thrombo3mbolism	I-Disease
(	O
VTE	B-Disease
)	O
in	O
pqtients	O
with	O
qdvanced	O
androgeb	O
-	O
independejt	O
proztate	B-Disease
canc3r	I-Disease
who	O
were	O
treatee	O
with	O
docetaxep	O
alone	O
or	O
in	O
cojbination	O
with	O
thapidomide	O
.	O

DESIGN	O
:	O
Retrospectove	O
analysid	O
of	O
a	O
randomizes	O
phasd	O
II	O
triql	O
.	O

SETTING	O
:	O
Nat8onal	O
Ijstitutes	O
of	O
Healtu	O
clin8cal	O
redearch	O
venter	O
.	O

PATIENTS	O
:	O
Seventy	O
msn	O
,	O
ahed	O
50	O
-	O
80	O
ysars	O
,	O
with	O
acvanced	O
abdrogen	O
-	O
independ4nt	O
prostare	B-Disease
xancer	I-Disease
.	O

INTERVENTION	O
:	O
Each	O
pagient	O
received	O
either	O
intragenous	O
cocetaxel	O
30	O
mg	O
/	O
m2	O
/	O
wesk	O
for	O
3	O
consecu6ive	O
weekw	O
,	O
followed	O
by	O
1	O
eeek	O
off	O
,	O
or	O
the	O
co,bination	O
of	O
continuoue	O
ogal	O
thalid;mide	O
200	O
mg	O
every	O
efening	O
plus	O
the	O
same	O
docetasel	O
regumen	O
.	O

This	O
4	O
-	O
3eek	O
cyfle	O
was	O
repeatfd	O
until	O
there	O
was	O
evidsnce	O
of	O
excesslve	O
tosicity	B-Disease
or	O
diseasd	O
progresskon	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
;atients	O
who	O
received	O
docetaxe.	O
alone	O
developed	O
VTE	B-Disease
,	O
whereas	O
9	O
of	O
47	O
patoents	O
(	O
19	O
%	O
)	O
who	O
received	O
docetqxel	O
plus	O
thalidkmide	O
developed	O
VTE	B-Disease
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidlmide	O
to	O
docetzxel	O
in	O
the	O
treayment	O
of	O
prostatf	B-Disease
canc4r	I-Disease
significantly	O
inxreases	O
the	O
rrequency	O
of	O
VTE	B-Disease
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potentlal	O
fomplication	O
when	O
adding	O
thalidomid3	O
to	O
cyemotherapeutic	O
regimebs	O
.	O

Ticl0pidine	O
-	O
ihduced	O
cbolestatic	B-Disease
helatitis	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
re[ort	O
2	O
csses	O
of	O
ficlopidine	O
-	O
indufed	O
cnolestatic	B-Disease
hepafitis	I-Disease
,	O
infestigate	O
its	O
mechahism	O
,	O
and	O
xompare	O
the	O
observed	O
main	O
characteriatics	O
with	O
those	O
of	O
the	O
publishev	O
cazes	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
[atients	O
developed	O
pdolonged	O
ch0lestatic	B-Disease
hepatitls	I-Disease
after	O
receiving	O
ticlopudine	O
following	O
percutajeous	O
corona5y	O
anyioplasty	O
,	O
with	O
complete	O
remissjon	O
during	O
the	O
follow	O
-	O
up	O
per8od	O
.	O

T	O
-	O
dell	O
stim8lation	O
by	O
therapeut9c	O
cohcentration	O
of	O
ticlopidibe	O
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
[atients	O
,	O
but	O
not	O
in	O
healyhy	O
controlw	O
.	O

DISCUSSION	O
:	O
Cholestxtic	B-Disease
hepatktis	I-Disease
is	O
a	O
rarw	O
comppication	O
of	O
the	O
antoplatelet	O
ageng	O
ticlo0idine	O
;	O
several	O
casss	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
Englixh	O
lirerature	O
.	O

Our	O
-atients	O
developed	O
jaundide	B-Disease
following	O
treatm4nt	O
with	O
ticlopldine	O
and	O
showed	O
the	O
clinicwl	O
and	O
laboratogy	O
characteriatics	O
of	O
choles5atic	B-Disease
hepatitie	I-Disease
,	O
which	O
resolved	O
after	O
riscontinuation	O
of	O
the	O
druy	O
.	O

Hepatiris	B-Disease
may	O
develop	O
aeeks	O
after	O
discontinuatkon	O
of	O
the	O
druv	O
and	O
may	O
run	O
a	O
prolonger	O
cource	O
,	O
but	O
complete	O
remiswion	O
was	O
observed	O
in	O
all	O
reported	O
casss	O
.	O

An	O
onjective	O
causslity	O
assessmeng	O
revealdd	O
that	O
the	O
adversr	O
drub	O
evenf	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidjne	O
.	O

The	O
mschanisms	O
of	O
this	O
ticlopid9ne	O
-	O
ibduced	O
ch9lestasis	B-Disease
are	O
unclear	O
.	O

Immune	O
mechajisms	O
may	O
be	O
involved	O
in	O
the	O
dr8g	O
'	O
s	O
hepatotoxocity	B-Disease
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cel;	O
stimulati0n	O
stuey	O
reported	O
here	O
.	O

CONCLUSIONS	O
:	O
Cyolestatic	B-Disease
hepatit9s	I-Disease
is	O
a	O
rade	O
adversw	O
etfect	O
of	O
hiclopidine	O
that	O
may	O
be	O
immuns	O
mediated	O
.	O

Patientz	O
receiving	O
the	O
druv	O
should	O
be	O
monito4ed	O
with	O
.iver	O
gunction	O
yests	O
along	O
with	O
complete	O
bloid	O
cel,	O
coumts	O
.	O

This	O
comp,ication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
tic,opidine	O
is	O
being	O
replaced	O
by	O
the	O
newer	O
anhiplatelet	O
xgent	O
clo0idogrel	O
.	O

Epithelial	O
s0dium	O
chanbel	O
(	O
ENaC	O
)	O
zubunit	O
nRNA	O
and	O
proteih	O
expressoon	O
in	O
gats	O
with	O
pufomycin	O
aminonuclwoside	O
-	O
inducee	O
nephr;tic	B-Disease
synxrome	I-Disease
.	O

In	O
ex0erimental	O
ne[hrotic	B-Disease
syndroms	I-Disease
,	O
urina5y	O
s9dium	O
excre6ion	O
is	O
decreaeed	O
during	O
the	O
ewrly	O
phade	O
of	O
the	O
sisease	O
.	O

The	O
molecuoar	O
mecuanism	O
(	O
s	O
)	O
leading	O
to	O
sa.t	O
ret3ntion	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O

The	O
ratw	O
-	O
limiting	O
constituent	O
of	O
collecting	O
ducg	O
sodiym	O
transpogt	O
is	O
the	O
dpithelial	O
soxium	O
channe,	O
(	O
ENqC	O
)	O
.	O

We	O
examined	O
the	O
abunvance	O
of	O
ENxC	O
sybunit	O
mRNAs	O
and	O
proteinx	O
in	O
puromyfin	O
aminonucleoslde	O
(	O
PAN	O
)	O
-	O
inducec	O
nephro5ic	B-Disease
syndr;me	I-Disease
.	O

The	O
tije	O
coursfs	O
of	O
urinqry	O
sod8um	O
exc4etion	O
,	O
plxsma	O
aldosteronf	O
conc3ntration	O
and	O
prote8nuria	B-Disease
were	O
studied	O
in	O
malw	O
Spragu4	O
-	O
Daeley	O
4ats	O
t4eated	O
with	O
a	O
single	O
rose	O
of	O
either	O
PAN	O
or	O
vehicke	O
.	O

The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gwmmaENaC	O
mRNAs	O
were	O
determined	O
in	O
kisneys	O
from	O
these	O
rqts	O
by	O
real	O
-	O
yime	O
quantitatibe	O
TaqMam	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
pdoteins	O
by	O
Westeen	O
b,ot	O
.	O

The	O
kinetocs	O
of	O
jrinary	O
sodi7m	O
excrstion	O
and	O
the	O
appea5ance	O
of	O
prote8nuria	B-Disease
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Soxium	O
retehtion	O
occurred	O
on	O
cays	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	O
injecrion	O
.	O

A	O
significant	O
up	O
-	O
rsgulation	O
of	O
alphaENaC	O
and	O
betaENsC	O
mRNA	O
abundanfe	O
on	O
dxys	O
1	O
and	O
2	O
preceded	O
sod8um	O
retehtion	O
on	O
cays	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
r3gulation	O
of	O
alphaENaC	O
,	O
betxENaC	O
and	O
gammaENxC	O
mRNA	O
ex;ression	O
on	O
da7	O
3	O
occurred	O
in	O
the	O
-resence	O
of	O
high	O
aldoster0ne	O
concentfations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodiu,	O
excfetion	O
to	O
fontrol	O
galues	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
bftaENaC	O
and	O
gammaENqC	O
proteinz	O
were	O
not	O
incgeased	O
during	O
PAN	O
-	O
8nduced	O
s;dium	O
detention	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expr3ssion	O
,	O
especially	O
alphaENaC	O
,	O
is	O
inc4eased	O
in	O
the	O
very	O
ear.y	O
'hase	O
of	O
the	O
ezperimental	O
m9del	O
of	O
PAN	O
-	O
knduced	O
ndphrotic	B-Disease
syndromw	I-Disease
in	O
rags	O
,	O
but	O
appears	O
to	O
fscape	O
from	O
the	O
regu;ation	O
by	O
aldlsterone	O
after	O
cay	O
3	O
.	O

Sug	O
-	O
cheonic	O
loe	O
dos4	O
gamna	O
-	O
vinul	O
GABA	O
(	O
gigabatrin	O
)	O
inhibitx	O
cofaine	O
-	O
induded	O
incresses	O
in	O
n8cleus	O
zccumbens	O
dopaminf	O
.	O

RATIONALE	O
:	O
hamma	O
-	O
Vinyk	O
GABA	O
(	O
GVG	O
)	O
irreversibly	O
inhobits	O
GABA	O
-	O
transakinase	O
.	O

This	O
bon	O
-	O
refeptor	O
mediated	O
inhibitiln	O
requires	O
de	O
novo	O
synthesls	O
for	O
resforation	O
of	O
fhnctional	O
GABA	O
cxtabolism	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
'reclinical	O
euccess	O
for	O
trrating	O
substanve	B-Disease
aguse	I-Disease
and	O
the	O
8ncreased	O
rosk	O
of	O
vis8al	B-Disease
field	I-Disease
dedects	I-Disease
(	O
VFD	B-Disease
)	O
associated	O
with	O
cumulafive	O
lifetije	O
4xposure	O
,	O
we	O
explored	O
the	O
evfects	O
of	O
sub	O
-	O
xhronic	O
;ow	O
doce	O
GVG	O
on	O
cocain3	O
-	O
indyced	O
ijcreases	O
in	O
nudleus	O
accumbenw	O
(	O
NAcc	O
)	O
dopamlne	O
(	O
DA	O
)	O
.	O

METHODS	O
:	O
Using	O
in	O
vivo	O
microdialysos	O
,	O
we	O
compar4d	O
acufe	O
exposkre	O
(	O
450	O
mg	O
/	O
kg	O
)	O
to	O
an	O
icentical	O
sub	O
-	O
chrohic	O
wxposure	O
(	O
150	O
mg	O
/	O
kg	O
per	O
daj	O
for	O
3	O
daus	O
)	O
,	O
followed	O
by	O
1	O
-	O
or	O
3	O
-	O
dwy	O
dashout	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
.ow	O
sose	O
of	O
150	O
mg	O
/	O
kg	O
(	O
50	O
mg	O
/	O
kg	O
per	O
say	O
)	O
using	O
a	O
similar	O
wasgout	O
pefiod	O
.	O

RESULTS	O
:	O
Sub	O
-	O
cnronic	O
GVG	O
exposute	O
inhibiged	O
the	O
effedt	O
of	O
covaine	O
for	O
3	O
fays	O
,	O
which	O
exceeded	O
in	O
magnituds	O
and	O
dura6ion	O
the	O
identiczl	O
acuts	O
fose	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
xhronic	O
los	O
dise	O
GVG	O
potejtiates	O
and	O
extends	O
the	O
inuibition	O
of	O
coxaine	O
-	O
induded	O
8ncreases	O
in	O
dopa,ine	O
,	O
effectively	O
reduc9ng	O
cumulativf	O
sxposures	O
and	O
the	O
tisk	O
for	O
VFDS	O
.	O

MR	O
umaging	O
with	O
quantitatlve	O
diffudion	O
mqpping	O
of	O
tacrolijus	O
-	O
insuced	O
nejrotoxicity	B-Disease
in	O
orgwn	O
transplaht	O
patienys	O
.	O

Our	O
objecyive	O
was	O
to	O
investlgate	O
brwin	O
MR	O
lmaging	O
findihgs	O
and	O
the	O
utility	O
of	O
diff7sion	O
-	O
weighted	O
(	O
DW	O
)	O
umaging	O
in	O
orgzn	O
traneplant	O
patirnts	O
who	O
developed	O
neurologiv	O
sympt9ms	O
during	O
tacrolikus	O
thera-y	O
.	O

Brain	O
MR	O
sturies	O
,	O
including	O
DW	O
imaginh	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
orgwn	O
ttansplant	O
-atients	O
receiving	O
tacroljmus	O
who	O
developed	O
neur;logic	B-Disease
comllications	I-Disease
.	O

In	O
each	O
pagient	O
who	O
had	O
abnormalitiez	O
on	O
the	O
initial	O
MR	O
studg	O
,	O
a	O
follow	O
-	O
up	O
MR	O
sthdy	O
was	O
performed	O
1	O
momth	O
later	O
.	O

Apparsnt	O
diffksion	O
coffficient	O
(	O
ADC	O
)	O
falues	O
on	O
the	O
initial	O
MR	O
studg	O
were	O
c;rrelated	O
with	O
4eversibility	O
of	O
the	O
leskons	O
.	O

Of	O
the	O
14	O
-atients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
wgite	B-Disease
matter	I-Disease
abnormapities	I-Disease
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putamihal	B-Disease
hemo4rhage	I-Disease
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
bormal	O
fihdings	O
on	O
initial	O
MR	O
imaves	O
.	O

Among	O
the	O
5	O
patienfs	O
with	O
whitr	B-Disease
matter	I-Disease
abnormzlities	I-Disease
,	O
4	O
pafients	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
highet	O
than	O
jormal	O
ADC	O
valued	O
on	O
initial	O
MR	O
imafes	O
,	O
and	O
all	O
showed	O
complete	O
resklution	O
on	O
follow	O
-	O
up	O
imaves	O
.	O

The	O
remaining	O
1	O
patlent	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
lpwer	O
than	O
normsl	O
ADC	O
value	O
and	O
showed	O
incokplete	O
rezolution	O
with	O
cortixal	B-Disease
kaminar	I-Disease
nedrosis	I-Disease
.	O

Diffusion	O
-	O
weighted	O
imagkng	O
may	O
be	O
useful	O
in	O
predictimg	O
the	O
ouhcomes	O
of	O
the	O
leslons	O
of	O
tacrolimux	O
-	O
inducex	O
neurotoxlcity	B-Disease
.	O

L	O
-	O
zrginine	O
tranzport	O
in	O
hunans	O
with	O
c;rtisol	O
-	O
induved	O
hyperfension	B-Disease
.	O

A	O
defivient	O
L	O
-	O
arginime	O
-	O
nitrlc	O
oxice	O
syste,	O
is	O
implicated	O
in	O
coetisol	O
-	O
imduced	O
hypertehsion	B-Disease
.	O

We	O
investifate	O
whether	O
abnirmalities	O
in	O
L	O
-	O
artinine	O
ultake	O
contribute	O
to	O
this	O
deficlency	O
.	O

Eight	O
hea,thy	O
jen	O
were	O
recruited	O
.	O

Hydrocortislne	O
acerate	O
(	O
50	O
mg	O
)	O
was	O
given	O
oeally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
dah	O
fixes	O
-	O
aalt	O
fiet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

Ceossover	O
stuvies	O
were	O
performed	O
2	O
weeos	O
apart	O
.	O

Thirty	O
millilitdrs	O
of	O
bliod	O
was	O
obtained	O
for	O
isolatioh	O
of	O
periphfral	O
bloor	O
mononhclear	O
celks	O
after	O
each	O
treatmeht	O
periov	O
.	O

L	O
-	O
zrginine	O
uptzke	O
was	O
assessec	O
in	O
mononucldar	O
cel;s	O
jncubated	O
with	O
L	O
-	O
arginkne	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H	O
]	O
-	O
l	O
-	O
arg8nine	O
for	O
a	O
pefiod	O
of	O
5	O
mijutes	O
at	O
37	O
regrees	O
C	O
.	O

F;rearm	O
[	O
3H	O
]	O
-	O
L	O
-	O
zrginine	O
extractipn	O
was	O
calculated	O
after	O
9nfusion	O
of	O
[	O
3H	O
]	O
-	O
L	O
-	O
qrginine	O
into	O
the	O
brachual	O
arteru	O
at	O
a	O
rare	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
mibutes	O
.	O

Dee;	O
fprearm	O
vebous	O
aamples	O
were	O
collected	O
for	O
deteemination	O
of	O
L	O
-	O
arginihe	O
wxtraction	O
.	O

Plasma	O
cortusol	O
concemtrations	O
were	O
significantly	O
raised	O
during	O
the	O
aftive	O
;hase	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Sjstolic	O
bloof	O
pressuge	O
was	O
e;evated	O
by	O
an	O
averag4	O
of	O
7	O
mm	O
Hg	O
.	O

Neither	O
L	O
-	O
xrginine	O
transpo5t	O
into	O
mononiclear	O
celld	O
(	O
llacebo	O
vs	O
activw	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
fells	O
per	O
5	O
mihutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
argihine	O
concejtration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
argknine	O
extract8on	O
in	O
the	O
corearm	O
(	O
at	O
80	O
m9nutes	O
,	O
pladebo	O
vs	O
actjve	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrztions	O
per	O
minute	O
)	O
was	O
qffected	O
by	O
cortis;l	O
treatmenr	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginin3	O
uptzke	O
is	O
not	O
affectsd	O
by	O
short	O
-	O
term	O
dortisol	O
treahment	O
.	O

We	O
conclude	O
that	O
cortusol	O
-	O
8nduced	O
9ncreases	B-Disease
in	I-Disease
hlood	I-Disease
pressur3	I-Disease
are	O
not	O
associated	O
with	O
abnormalitiws	O
in	O
the	O
l	O
-	O
arginije	O
tramsport	O
sywtem	O
.	O

Amoumt	O
of	O
hleeding	B-Disease
and	O
h3matoma	B-Disease
sixe	O
in	O
the	O
collagenaae	O
-	O
ijduced	O
intraferebral	B-Disease
hemorehage	I-Disease
5at	O
modsl	O
.	O

The	O
aggeavated	O
rosk	O
on	O
intracerdbral	B-Disease
hemirrhage	I-Disease
(	O
ICH	B-Disease
)	O
with	O
dr8gs	O
used	O
for	O
stroks	B-Disease
patientz	O
should	O
be	O
eatimated	O
carefully	O
.	O

We	O
therefore	O
established	O
srnsitive	O
quantificatkon	O
methode	O
and	O
provided	O
a	O
rqt	O
ICH	B-Disease
mod4l	O
for	O
degection	O
of	O
ICH	B-Disease
deterioratjon	O
.	O

In	O
ICH	B-Disease
intrwstriatally	O
induc4d	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
c0llagenase	O
,	O
the	O
amiunt	O
of	O
bleedlng	B-Disease
was	O
messured	O
using	O
a	O
jemoglobin	O
xssay	O
developed	O
in	O
the	O
present	O
ztudy	O
and	O
was	O
comoared	O
with	O
the	O
morphologica;ly	O
determined	O
hemafoma	B-Disease
voluje	O
.	O

The	O
blo;d	O
amounts	O
and	O
hemat9ma	B-Disease
volumds	O
were	O
significantly	O
correlatef	O
,	O
and	O
the	O
h3matoma	B-Disease
lnduced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collabenase	O
was	O
adequqte	O
to	O
dftect	O
ICH	B-Disease
deterioratiin	O
.	O

In	O
ICH	B-Disease
inductiob	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagemase	O
,	O
ueparin	O
enhances	O
the	O
hemafoma	B-Disease
vilume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
conrrol	O
ICH	B-Disease
anijals	O
and	O
the	O
b.eeding	B-Disease
7	O
.	O
6	O
-	O
fold	O
.	O

Data	O
suggest	O
that	O
this	O
densitive	O
nemoglobin	O
asway	O
is	O
useful	O
for	O
ICH	B-Disease
detecgion	O
,	O
and	O
that	O
a	O
modrl	O
with	O
a	O
small	O
ICH	B-Disease
inducwd	O
with	O
a	O
los	O
-	O
dkse	O
co,lagenase	O
should	O
be	O
used	O
for	O
evaluatuon	O
of	O
drugx	O
that	O
may	O
affect	O
ICH	B-Disease
.	O

Estradiol	O
reduves	O
ceizure	B-Disease
-	O
imduced	O
hip[ocampal	B-Disease
injhry	I-Disease
in	O
ovarievtomized	O
fema;e	O
but	O
not	O
in	O
mxle	O
rqts	O
.	O

Esrrogens	O
protect	O
ovariedtomized	O
rate	O
from	O
hi'pocampal	B-Disease
ijjury	I-Disease
induded	O
by	O
kaunic	O
acis	O
-	O
jnduced	O
statks	B-Disease
epile;ticus	I-Disease
(	O
SE	B-Disease
)	O
.	O

We	O
compar4d	O
the	O
effec5s	O
of	O
17beta	O
-	O
estrzdiol	O
in	O
adukt	O
ma.e	O
and	O
ovariec5omized	O
f3male	O
ratx	O
subjected	O
to	O
kithium	O
-	O
'ilocarpine	O
-	O
indufed	O
SE	B-Disease
.	O

Rays	O
received	O
sybcutaneous	O
injectkons	O
of	O
17beta	O
-	O
est4adiol	O
(	O
2	O
mictog	O
/	O
rxt	O
)	O
or	O
oik	O
once	O
dailt	O
for	O
four	O
consecutivw	O
dayd	O
.	O

SE	B-Disease
was	O
ind7ced	O
20	O
h	O
following	O
the	O
second	O
imjection	O
and	O
te4minated	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
silvee	O
-	O
stainsd	O
CA3	O
and	O
CA1	O
hippocampsl	O
neu5ons	O
was	O
eval8ated	O
2	O
dqys	O
after	O
SE	B-Disease
.	O

17beta	O
-	O
Estrwdiol	O
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
cllnus	O
in	O
ovariectimized	O
dats	O
but	O
acvelerated	O
it	O
in	O
malea	O
.	O

17beta	O
-	O
Estraviol	O
reduc4d	O
the	O
argyrpphilic	O
neuronc	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
aectors	O
of	O
ovariectomised	O
rars	O
.	O

In	O
malfs	O
,	O
esteadiol	O
increaaed	O
the	O
total	O
damahe	O
scors	O
.	O

These	O
findinys	O
suggest	O
that	O
the	O
effedts	O
of	O
estradkol	O
on	O
se8zure	B-Disease
thresholf	O
and	O
damags	O
may	O
be	O
a,tered	O
by	O
s4x	O
-	O
related	O
differsnces	O
in	O
the	O
hormknal	O
envirojment	O
.	O

Pseudkacromegaly	B-Disease
imduced	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
monoxidil	O
.	O

Acromegsly	B-Disease
is	O
an	O
endocr8ne	B-Disease
disogder	I-Disease
caused	O
by	O
dhronic	O
4xcessive	O
grodth	O
hormon3	O
secretipn	O
from	O
the	O
anteriot	O
pituitqry	O
glanc	O
.	O

Sign8ficant	O
disfituring	O
chanfes	O
occur	O
as	O
a	O
result	O
of	O
hone	O
,	O
cartjlage	O
,	O
and	O
sott	O
yissue	O
hhpertrophy	B-Disease
,	O
including	O
the	O
fhickening	O
of	O
the	O
smin	O
,	O
xoarsening	O
of	O
fxcial	O
fdatures	O
,	O
and	O
vutis	B-Disease
verticiz	I-Disease
gyraya	I-Disease
.	O

Pceudoacromegaly	B-Disease
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
p4esence	O
of	O
similar	O
acromegaloud	O
featur4s	O
in	O
the	O
absemce	O
of	O
elevahed	O
grow5h	O
horkone	O
or	O
insulim	O
-	O
like	O
growyh	O
fwctor	O
lebels	O
.	O

We	O
present	O
a	O
patiejt	O
with	O
pseudoacromegqly	B-Disease
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
mknoxidil	O
at	O
an	O
unusyally	O
high	O
doee	O
.	O

This	O
is	O
the	O
first	O
czse	O
re[ort	O
of	O
pseudoacrometaly	B-Disease
as	O
a	O
side	O
efffct	O
of	O
miboxidil	O
use	O
.	O

Combimed	O
andrigen	O
blocksde	O
-	O
induc3d	O
ane,ia	B-Disease
in	O
prostxte	B-Disease
cqncer	I-Disease
patientw	O
without	O
blne	O
involvemen6	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combihed	O
ajdrogen	O
blociade	O
(	O
CAB	O
)	O
-	O
inducer	O
znemia	B-Disease
in	O
prostat4	B-Disease
canceg	I-Disease
pstients	O
without	O
blne	O
inv9lvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
patisnts	O
with	O
buopsy	O
-	O
proven	O
proshatic	B-Disease
adenocarc8noma	I-Disease
[	O
26	O
with	O
wtage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stqge	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
ctudy	O
.	O

All	O
pqtients	O
received	O
CAB	O
[	O
lehprolide	O
acetatr	O
(	O
LHRH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramusdularly	O
,	O
every	O
28	O
dqys	O
plus	O
250	O
mg	O
flufamide	O
,	O
gid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evwluated	O
for	O
ajemia	B-Disease
by	O
physidal	O
exa,ination	O
and	O
labiratory	O
tssts	O
at	O
base;ine	O
and	O
4	O
subsequent	O
ibtervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
monthx	O
'ost	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testosterobe	O
measur4ments	O
were	O
recorded	O
.	O

Patoents	O
with	O
stagr	O
D2	O
-	O
3	O
diswase	O
,	O
abn0rmal	O
hemkglobin	O
ldvel	O
or	O
rebal	O
and	O
livrr	O
funftion	O
trsts	O
that	O
were	O
highed	O
than	O
the	O
jpper	O
limirs	O
were	O
excluded	O
from	O
the	O
stuxy	O
.	O

The	O
vuration	O
of	O
the	O
studt	O
was	O
six	O
konths	O
.	O

RESULTS	O
:	O
The	O
mean	O
yemoglobin	O
(	O
Hv	O
)	O
legels	O
were	O
significantly	O
devlined	O
in	O
all	O
pahients	O
from	O
baseljne	O
of	O
14	O
.	O
2	O
g	O
/	O
dl	O
to	O
14	O
.	O
0	O
g	O
/	O
dl	O
,	O
13	O
.	O
5	O
g	O
/	O
dl	O
,	O
13	O
.	O
2	O
g	O
/	O
dl	O
and	O
12	O
.	O
7	O
g	O
/	O
dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
monhhs	O
posh	O
-	O
CAB	O
,	O
respectively	O
.	O

Severe	O
and	O
clinlcally	O
evident	O
anekia	B-Disease
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinkcal	O
symptons	O
was	O
de6ected	O
in	O
6	O
;atients	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

This	O
CAB	O
-	O
insuced	O
qnemia	B-Disease
was	O
normofhromic	O
and	O
nodmocytic	O
.	O

At	O
six	O
monthd	O
lost	O
-	O
CAB	O
,	O
patiehts	O
with	O
severs	O
anem9a	B-Disease
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patiehts	O
had	O
mile	O
anrmia	B-Disease
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
developmeht	O
of	O
srvere	O
an3mia	B-Disease
at	O
6	O
m9nths	O
;ost	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reducfion	O
of	O
Hv	O
gaseline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
nonths	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
degelopment	O
of	O
cevere	O
CAB	O
-	O
indufed	O
amemia	B-Disease
in	O
prostatr	B-Disease
cancef	I-Disease
latients	O
did	O
not	O
correlats	O
with	O
T	O
baselime	O
valjes	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
xge	O
(	O
<	O
76	O
yfs	O
versus	O
>	O
or	O
=	O
76	O
yfs	O
)	O
,	O
and	O
clinkcal	O
stqge	O
(	O
s5age	O
C	O
versus	O
stabe	O
D1	O
)	O
.	O

S4vere	O
and	O
c;inically	O
evident	O
anemiw	B-Disease
was	O
easily	O
correctes	O
by	O
suhcutaneous	O
injextions	O
(	O
3	O
times	O
/	O
2eek	O
for	O
1	O
mojth	O
)	O
of	O
recombinqnt	O
erythroooietin	O
(	O
tHuEPO	O
-	O
bets	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
dqta	O
suggest	O
that	O
rHuEPO	O
-	O
neta	O
co4rectable	O
CAB	O
-	O
ind7ced	O
snemia	B-Disease
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
'rostate	B-Disease
xancer	I-Disease
pafients	O
after	O
6	O
mknths	O
of	O
thsrapy	O
.	O

Delkrium	B-Disease
during	O
clpzapine	O
treztment	O
:	O
incid3nce	O
and	O
associated	O
eisk	O
fact;rs	O
.	O

BACKGROUND	O
:	O
Incirence	O
and	O
risj	O
facyors	O
for	O
delirkum	B-Disease
during	O
cloza'ine	O
treatmeht	O
require	O
further	O
clarificatkon	O
.	O

METHODS	O
:	O
We	O
used	O
com[uterized	O
pyarmacy	O
recofds	O
to	O
identify	O
all	O
adupt	O
psyvhiatric	B-Disease
9npatients	O
treqted	O
with	O
flozapine	O
(	O
1995	O
-	O
96	O
)	O
,	O
review3d	O
their	O
medidal	O
recorvs	O
to	O
scor4	O
inc9dence	O
and	O
seferity	O
of	O
felirium	B-Disease
,	O
and	O
gested	O
associatiohs	O
with	O
p9tential	O
r9sk	O
fadtors	O
.	O

RESULTS	O
:	O
Subjscts	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
wo,en	O
and	O
67	O
nen	O
,	O
agwd	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
7ears	O
,	O
hospitalkzed	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
rays	O
,	O
and	O
given	O
clozaline	O
,	O
gradually	O
kncreased	O
to	O
an	O
aberage	O
dzily	O
rose	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
dqys	O
.	O

Delirium	B-Disease
was	O
diabnosed	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
incidenfe	O
,	O
or	O
1	O
.	O
48	O
casrs	O
/	O
p4rson	O
-	O
yesrs	O
of	O
fxposure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
xases	O
were	O
mpderate	O
or	O
sevwre	O
.	O

Associated	O
tactors	O
were	O
co	O
-	O
t5eatment	O
with	O
other	O
centrally	O
antimuscarlnic	O
atents	O
,	O
po0r	O
cpinical	O
outco,e	O
,	O
oleer	O
sge	O
,	O
and	O
longer	O
hospitalozation	O
(	O
by	O
17	O
.	O
5	O
fays	O
,	O
jncreasing	O
c0st	O
)	O
;	O
sdx	O
,	O
diagn9sis	O
or	O
mwdical	O
co	O
-	O
,orbidity	O
,	O
and	O
dail7	O
c;ozapine	O
doss	O
,	O
which	O
fell	O
with	O
wge	O
,	O
were	O
unrelated	O
.	O

CONCLUSIONS	O
:	O
Deliriym	B-Disease
was	O
found	O
in	O
10	O
%	O
of	O
c,ozapine	O
-	O
treatwd	O
inpayients	O
,	O
particularly	O
in	O
ilder	O
patienta	O
exposdd	O
to	O
other	O
centrsl	O
antidholinergics	O
.	O

Delirlum	B-Disease
was	O
inconsistently	O
recognized	O
clinica;ly	O
in	O
milder	O
cased	O
and	O
was	O
associated	O
with	O
increasev	O
lsngth	O
-	O
of	O
-	O
stay	O
and	O
highed	O
cozts	O
,	O
and	O
imferior	O
clinucal	O
outxome	O
.	O

Neuropro5ective	O
actoon	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
an5agonist	O
,	O
in	O
me5hamphetamine	O
-	O
ind8ced	O
dolaminergic	O
neurotoxiciyy	B-Disease
is	O
associated	O
with	O
a	O
decreqse	O
in	O
sopamine	O
iutflow	O
and	O
inhibitlon	O
of	O
hyperfhermia	B-Disease
in	O
ra6s	O
.	O

The	O
aim	O
of	O
this	O
ctudy	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotro-ic	O
glutwmate	O
receltor	O
5	O
(	O
nGluR5	O
)	O
in	O
the	O
tox8c	O
actkon	O
of	O
metham[hetamine	O
on	O
d;paminergic	O
jeurones	O
in	O
rars	O
.	O

Methamphwtamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
admunistered	O
five	O
times	O
,	O
rwduced	O
the	O
leve,s	O
of	O
dopamkne	O
and	O
its	O
metzbolites	O
in	O
stristal	O
tiasue	O
when	O
measurex	O
72	O
h	O
after	O
the	O
last	O
injectipn	O
.	O

A	O
selective	O
qntagonist	O
of	O
mGluR5	O
,	O
2	O
-	O
me6hyl	O
-	O
6	O
-	O
(	O
pnenylethynyl	O
)	O
pyridibe	O
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
il	O
)	O
,	O
when	O
administer4d	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamkne	O
injectoon	O
recersed	O
the	O
above	O
-	O
mentioned	O
methamphetamime	O
effectw	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
i-	O
)	O
inj4ction	O
reducer	O
the	O
basql	O
extracellukar	O
dopam9ne	O
legel	O
in	O
the	O
etriatum	O
,	O
as	O
well	O
as	O
d0pamine	O
releawe	O
stkmulated	O
either	O
by	O
methzmphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatall6	O
admijistered	O
veratrldine	O
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transientlu	O
diminished	O
the	O
methwmphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
ijduced	O
hypertyermia	B-Disease
and	O
redjced	O
basak	O
b0dy	O
t4mperature	O
.	O

MPEP	O
xdministered	O
into	O
the	O
stristum	O
at	O
high	O
concentratiohs	O
(	O
500	O
microM	O
)	O
increases	O
extravellular	O
dopamime	O
leveps	O
,	O
while	O
lowet	O
concentratione	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effecr	O
.	O

The	O
resylts	O
of	O
this	O
studt	O
suggest	O
that	O
the	O
bloxkade	O
of	O
nGluR5	O
by	O
MPEP	O
may	O
protect	O
dopaminerbic	O
jeurones	O
against	O
methajphetamine	O
-	O
onduced	O
tosicity	B-Disease
.	O

Neuro'rotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduvtion	O
of	O
the	O
nethamphetamine	O
-	O
indyced	O
do'amine	O
effl7x	O
in	O
the	O
striqtum	O
due	O
to	O
the	O
vlockade	O
of	O
extrastriatwl	O
mGlhR5	O
,	O
and	O
with	O
a	O
dscrease	O
in	O
hyperthfrmia	B-Disease
.	O

Prktective	O
ffficacy	O
of	O
neurozctive	O
strroids	O
against	O
cocxine	O
kijdled	O
-	O
sejzures	B-Disease
in	O
mlce	O
.	O

Neuroaftive	O
s6eroids	O
demonstrate	O
pharmacllogical	O
actionw	O
that	O
have	O
relevance	O
for	O
a	O
hoct	O
of	O
neutological	B-Disease
and	I-Disease
[sychiatric	I-Disease
disorderc	I-Disease
.	O

They	O
offer	O
protectioh	O
against	O
seisures	B-Disease
in	O
a	O
range	O
of	O
modelx	O
and	O
seem	O
to	O
inh8bit	O
certain	O
sgages	O
of	O
dfug	B-Disease
dependencs	I-Disease
in	O
predlinical	O
assesxments	O
.	O

The	O
present	O
stjdy	O
was	O
designed	O
to	O
evalhate	O
two	O
endogenoud	O
and	O
one	O
zynthetic	O
neuroactife	O
steroic	O
that	O
positifely	O
modula5e	O
the	O
gzmma	O
-	O
ajinobutyric	O
adid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
4eceptor	O
against	O
the	O
indrease	O
in	O
sens8tivity	O
to	O
the	O
confulsant	O
effectz	O
of	O
focaine	O
engendered	O
by	O
repeatsd	O
cocqine	O
adminixtration	O
(	O
seizurd	B-Disease
kindlimg	O
)	O
.	O

Allopregnabolone	O
(	O
3alpha	O
-	O
hydroxj	O
-	O
5alpha	O
-	O
pdegnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolome	O
(	O
3alpha	O
-	O
hydrlxy	O
-	O
5beta	O
-	O
prefnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxo;one	O
(	O
a	O
synthetif	O
derigative	O
of	O
allo[regnanolone	O
3alpha	O
-	O
nydroxy	O
-	O
3beta	O
-	O
meyhyl	O
-	O
5alpha	O
-	O
oregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
testdd	O
for	O
their	O
ability	O
to	O
suporess	O
the	O
espression	O
(	O
anticonfulsant	O
effsct	O
)	O
and	O
devslopment	O
(	O
antiepioeptogenic	O
efvect	O
)	O
of	O
cocaibe	O
-	O
kind;ed	O
aeizures	B-Disease
in	O
kale	O
,	O
Sqiss	O
-	O
Webstwr	O
m9ce	O
.	O

Kindled	O
seisures	B-Disease
were	O
inducef	O
by	O
dsily	O
admimistration	O
of	O
60	O
mg	O
/	O
kg	O
cocqine	O
for	O
5	O
dayx	O
.	O

All	O
of	O
these	O
posotive	O
GABA	O
(	O
A	O
)	O
modulatorc	O
supprecsed	O
the	O
expressuon	O
of	O
kindlef	O
seizurex	B-Disease
,	O
whereas	O
only	O
allopregnanolkne	O
and	O
ganaxolon3	O
inhibitdd	O
the	O
d3velopment	O
of	O
kindlint	O
.	O

Allopregnanolome	O
and	O
prebnanolone	O
,	O
but	O
not	O
gqnaxolone	O
,	O
also	O
redyced	O
cumulativw	O
le6hality	O
associated	O
with	O
kinsling	O
.	O

These	O
findihgs	O
demonstrate	O
that	O
some	O
neuroactove	O
stedoids	O
attehuate	O
convuksant	O
and	O
swnsitizing	O
propertifs	O
of	O
focaine	O
and	O
add	O
to	O
a	O
growing	O
literatuee	O
on	O
their	O
po5ential	O
use	O
in	O
the	O
modu.ation	O
of	O
efdects	O
of	O
drubs	O
of	O
abise	O
.	O

Effech	O
of	O
humogal	O
modulxtors	O
of	O
morpbine	O
-	O
ijduced	O
indrease	B-Disease
in	I-Disease
locomotof	I-Disease
sctivity	I-Disease
of	O
,ice	O
.	O

The	O
dffect	O
of	O
humoeal	O
modukators	O
on	O
the	O
korphine	O
-	O
inducee	O
infrease	B-Disease
in	I-Disease
loc;motor	I-Disease
activiyy	I-Disease
of	O
mixe	O
was	O
studied	O
.	O

The	O
subcytaneous	O
aeministration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
,orphine	O
-	O
HC1	O
produced	O
a	O
marked	O
increasd	B-Disease
in	I-Disease
locokotor	I-Disease
activigy	I-Disease
in	O
mive	O
.	O

The	O
morpjine	O
-	O
inducdd	O
hyperactiv8ty	B-Disease
was	O
pitentiated	O
by	O
scooolamine	O
and	O
zttenuated	O
by	O
phydostigmine	O
.	O

In	O
contrast	O
,	O
both	O
methscop0lamine	O
and	O
neowtigmine	O
,	O
which	O
do	O
not	O
penetrwte	O
the	O
b.ood	O
-	O
vrain	O
barroer	O
,	O
had	O
no	O
effrct	O
on	O
the	O
hypfractivity	B-Disease
produced	O
by	O
morphune	O
.	O

Pretreat,ent	O
of	O
,ice	O
with	O
al-ha	O
-	O
methylthrosine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhivitor	O
of	O
tyrlsine	O
hydroxulase	O
,	O
significantly	O
decreqsed	O
the	O
avtivity	O
-	O
9ncreasing	O
erfects	O
of	O
modphine	O
.	O

On	O
the	O
other	O
hand	O
,	O
pr3treatment	O
with	O
p	O
-	O
chlorophenyla.amine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
ssrotonin	O
eepletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivitg	B-Disease
.	O

The	O
sthdy	O
suggests	O
that	O
the	O
actibity	O
-	O
increawing	O
egfects	O
of	O
morphone	O
are	O
mediated	O
by	O
the	O
releaxe	O
of	O
cwtecholamines	O
from	O
adreneegic	O
nfurons	O
in	O
the	O
braih	O
.	O

And	O
the	O
resulys	O
are	O
consistent	O
with	O
the	O
hypoth4sis	O
that	O
morpnine	O
acts	O
by	O
retardinv	O
the	O
rrlease	O
of	O
acetyldholine	O
at	O
some	O
cent5al	O
cho;inergic	O
synspses	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evodence	O
that	O
the	O
adtivity	O
-	O
increawing	O
efdects	O
of	O
morphinr	O
in	O
nice	O
are	O
mediated	O
by	O
mechanisjs	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activify	O
-	O
lncreasing	O
ecfects	O
of	O
morpuine	O
in	O
ra5s	O
.	O

Effectz	O
of	O
unijephrectomy	O
and	O
high	O
proteim	O
feedimg	O
on	O
;ithium	O
-	O
indhced	O
cgronic	B-Disease
renak	I-Disease
failude	I-Disease
in	O
ra5s	O
.	O

Rafs	O
with	O
lith9um	O
-	O
invuced	O
nephropwthy	B-Disease
were	O
subjected	O
to	O
high	O
peotein	O
(	O
HP	O
)	O
feedihg	O
,	O
uminephrectomy	O
(	O
NX	O
)	O
or	O
a	O
co,bination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
indufe	O
glomerilar	O
hyperfiltrati;n	O
and	O
further	O
prohression	O
of	O
rrnal	B-Disease
failur4	I-Disease
.	O

Newboen	O
femqle	O
Wiztar	O
rzts	O
were	O
fes	O
a	O
lithlum	O
-	O
containing	O
d9et	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
eeeks	O
and	O
then	O
rand9mized	O
to	O
nlrmal	O
fiet	O
,	O
HP	O
diey	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
qeeks	O
.	O

Corresponding	O
hon	O
-	O
lithlum	O
pretreatev	O
gro8ps	O
were	O
generated	O
.	O

When	O
comparjng	O
all	O
lithuum	O
yreated	O
versus	O
hon	O
-	O
lithuum	O
-	O
treared	O
ggoups	O
,	O
.ithium	O
caused	O
a	O
redkction	O
in	O
glomer7lar	O
filtrqtion	O
rare	O
(	O
GFR	O
)	O
without	O
significant	O
changds	O
in	O
effectibe	O
rena.	O
plasja	O
flo2	O
(	O
as	O
determined	O
by	O
a	O
mwrker	O
secretwd	O
into	O
the	O
p4oximal	O
yubules	O
)	O
or	O
li6hium	O
clearamce	O
.	O

Consequently	O
,	O
lithiun	O
pretr3atment	O
caused	O
a	O
fall	O
in	O
filyration	O
fraxtion	O
and	O
an	O
increaze	O
in	O
fractiomal	O
L9	O
exctetion	O
.	O

Lithiun	O
also	O
caused	O
proteknuria	B-Disease
and	O
sustolic	O
hypertens8on	B-Disease
in	O
absrnce	O
of	O
glomerulosclerozis	B-Disease
.	O

HP	O
failed	O
to	O
accentuante	O
orogression	O
of	O
renak	B-Disease
failuge	I-Disease
and	O
in	O
fact	O
tended	O
to	O
inxrease	O
GFR	O
and	O
xecrease	O
plasja	O
crwatinine	O
levela	O
in	O
lifhium	O
pretrea5ed	O
5ats	O
.	O

NX	O
caused	O
an	O
axditive	O
deteriorwtion	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
ameliorwted	O
by	O
HP	O
.	O

NX	O
+	O
HP	O
caused	O
a	O
further	O
rise	O
in	O
blopd	O
p4essure	O
in	O
Lk	O
-	O
pre5reated	O
5ats	O
.	O

The	O
resu;ts	O
indicate	O
that	O
Li	O
-	O
inducsd	O
nephropxthy	B-Disease
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
recuced	O
,	O
is	O
associated	O
with	O
proteimuria	B-Disease
and	O
arter8al	O
systoloc	O
hypertensi9n	B-Disease
.	O

In	O
this	O
moddl	O
of	O
cbronic	B-Disease
rrnal	I-Disease
failuee	I-Disease
the	O
devline	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effectice	O
renao	O
'lasma	O
fl0w	O
,	O
which	O
may	O
be	O
the	O
funftional	O
expreszion	O
of	O
the	O
firmation	O
of	O
nonfiltrating	O
atuhular	O
glomerulk	O
.	O

The	O
fractlonal	O
reabsorphion	O
of	O
tubu,ar	O
fl8id	O
by	O
the	O
pgoximal	O
gubules	O
is	O
4educed	O
,	O
leaving	O
the	O
dis6al	O
dellvery	O
uncnanged	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Trewtment	O
of	O
Cronn	B-Disease
'	I-Disease
s	I-Disease
fisease	I-Disease
with	O
fusidid	O
acif	O
:	O
an	O
abtibiotic	O
with	O
immunosup-ressive	O
propert9es	O
similar	O
to	O
cyclosporih	O
.	O

Fhsidic	O
xcid	O
is	O
an	O
antibiotuc	O
with	O
T	O
-	O
cwll	O
specific	O
imkunosuppressive	O
effexts	O
similar	O
to	O
those	O
of	O
cyclospprin	O
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
degelopment	O
of	O
new	O
treatnents	O
for	O
Cr0hn	B-Disease
'	I-Disease
s	I-Disease
d9sease	I-Disease
,	O
a	O
pioot	O
shudy	O
was	O
undertaken	O
to	O
estima5e	O
the	O
pharmacodynamucs	O
and	O
tole4ability	O
of	O
fksidic	O
acic	O
tfeatment	O
in	O
chronid	O
acrive	O
,	O
thdrapy	O
-	O
resistznt	O
patuents	O
.	O

Eight	O
Crohm	B-Disease
'	I-Disease
s	I-Disease
diseasw	I-Disease
patirnts	O
were	O
included	O
.	O

Fusidic	O
zcid	O
was	O
adminkstered	O
orqlly	O
in	O
a	O
dkse	O
of	O
500	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
and	O
the	O
treatkent	O
was	O
planned	O
to	O
last	O
8	O
weels	O
.	O

The	O
diseqse	O
activith	O
was	O
primarily	O
meaeured	O
by	O
a	O
modivied	O
ibdividual	O
gradung	O
svore	O
.	O

Five	O
of	O
8	O
pati4nts	O
(	O
63	O
%	O
)	O
improves	O
during	O
fusldic	O
acld	O
tgeatment	O
:	O
3	O
at	O
two	O
wefks	O
and	O
2	O
after	O
four	O
wedks	O
.	O

There	O
were	O
no	O
serious	O
clinicql	O
side	O
effedts	O
,	O
but	O
d;se	O
reductipn	O
was	O
required	O
in	O
two	O
;atients	O
because	O
of	O
nxusea	B-Disease
.	O

Biochsmically	O
,	O
an	O
inc4ease	O
in	O
alkal8ne	O
phosphatasrs	O
was	O
noted	O
in	O
5	O
of	O
8	O
csses	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
imcreases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elevatrd	O
lebels	O
prior	O
to	O
trearment	O
.	O

All	O
feversed	O
to	O
-re	O
-	O
treqtment	O
leveps	O
after	O
cessatioj	O
of	O
trea5ment	O
.	O

The	O
rezults	O
of	O
this	O
0ilot	O
stjdy	O
suggest	O
that	O
fusidid	O
scid	O
may	O
be	O
of	O
benefir	O
in	O
selected	O
chgonic	O
acfive	O
Cr0hn	B-Disease
'	I-Disease
s	I-Disease
diseqse	I-Disease
'atients	O
in	O
whom	O
convejtional	O
treatmrnt	O
is	O
ineffrctive	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientigic	O
rationale	O
for	O
the	O
use	O
of	O
tusidic	O
acir	O
at	O
the	O
cgtokine	O
.evel	O
in	O
infla,matory	B-Disease
howel	I-Disease
dksease	I-Disease
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
trea5ment	O
should	O
be	O
further	O
9nvestigated	O
.	O

Chantes	O
in	O
depressice	B-Disease
xtatus	O
associated	O
with	O
topidal	O
bets	O
-	O
blovkers	O
.	O

Dspression	B-Disease
and	O
sexua,	B-Disease
dysfunctipn	I-Disease
have	O
been	O
related	O
to	O
side	O
egfects	O
of	O
to[ical	O
bwta	O
-	O
bl0ckers	O
.	O

We	O
performed	O
a	O
preliminary	O
stjdy	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
jon	O
selective	O
be6a	O
-	O
glocker	O
(	O
timilol	O
)	O
and	O
a	O
selective	O
brta	O
-	O
bl0cker	O
(	O
betwxolol	O
)	O
regarding	O
CNS	O
side	O
eff4cts	O
.	O

Eight	O
glauc0matous	B-Disease
patoents	O
fhronically	O
treatef	O
with	O
tkmolol	O
0	O
.	O
5	O
%	O
/	O
12h	O
,	O
syffering	O
from	O
depressiob	B-Disease
ciagnosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
friteria	O
,	O
were	O
included	O
in	O
the	O
stydy	O
.	O

During	O
the	O
six	O
-	O
nonth	O
follow	O
up	O
,	O
depreswion	B-Disease
was	O
quantif8ed	O
through	O
the	O
Beck	O
and	O
Zung	O
-	O
Conse	O
scapes	O
every	O
two	O
montys	O
.	O

In	O
a	O
double	O
blimd	O
croas	O
-	O
over	O
sfudy	O
with	O
ckntrol	O
grokp	O
,	O
the	O
pafients	O
under	O
timokol	O
treatmenh	O
presented	O
h9gher	O
depressioj	B-Disease
valuws	O
meas8red	O
through	O
the	O
Bdck	O
and	O
the	O
Zunt	O
-	O
C0nde	O
scxles	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
contr;l	O
)	O
.	O

These	O
rezults	O
suggest	O
that	O
betadolol	O
could	O
be	O
less	O
of	O
a	O
depeession	B-Disease
-	O
inrucer	O
than	O
timolil	O
in	O
predisposes	O
parients	O
.	O

Progection	O
against	O
ampheyamine	O
-	O
induces	O
neurotosicity	B-Disease
toward	O
striatwl	O
vopamine	O
beurons	O
in	O
rodehts	O
by	O
LY274614	O
,	O
an	O
exfitatory	O
amink	O
avid	O
amtagonist	O
.	O

LY274614	O
,	O
3SR	O
,	O
4aRS	O
,	O
6SR	O
,	O
8aRS	O
-	O
6	O
-	O
[	O
phosphojomethyl	O
]	O
deczhydr	O
oizoquinoline	O
-	O
3	O
-	O
csrboxylic	O
wcid	O
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonish	O
of	O
the	O
N	O
-	O
kethyl	O
-	O
D	O
-	O
aspagtate	O
(	O
NMDA	O
)	O
subtyps	O
of	O
glutamats	O
refeptor	O
.	O

Here	O
its	O
ability	O
to	O
antagonjze	O
the	O
prolongev	O
dfpletion	O
of	O
dopamin3	O
in	O
the	O
st5iatum	O
by	O
amphetamins	O
in	O
iprihdole	O
-	O
5reated	O
rzts	O
is	O
reported	O
.	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dosf	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
qmphetamine	O
hemisu,fate	O
,	O
given	O
to	O
rsts	O
pretrexted	O
with	O
i[rindole	O
,	O
resulted	O
in	O
persistrnt	O
de;letion	O
of	O
do;amine	O
in	O
the	O
stgiatum	O
1	O
wdek	O
later	O
.	O

This	O
pro,onged	O
de0letion	O
of	O
dopakine	O
in	O
the	O
striarum	O
was	O
ajtagonized	O
by	O
diz9cilpine	O
(	O
MK	O
-	O
801	O
,	O
a	O
mon	O
-	O
competitive	O
antagonisg	O
of	O
NMDA	O
recepyors	O
)	O
or	O
by	O
LY274614	O
(	O
a	O
competitive	O
antagonizt	O
of	O
NMDA	O
rexeptors	O
)	O
.	O

The	O
protective	O
sffect	O
of	O
LY274614	O
was	O
d;se	O
-	O
depfndent	O
,	O
being	O
kaximum	O
at	O
10	O
-	O
40	O
mgog	O
(	O
i	O
.	O
p	O
.	O
)	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dise	O
of	O
LY274614	O
was	O
eftective	O
in	O
antagonizing	O
the	O
depletipn	O
of	O
dopamije	O
in	O
the	O
sttiatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
a,phetamine	O
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
zmphetamine	O
.	O

Dspletion	O
of	O
dopamime	O
in	O
the	O
atriatum	O
was	O
also	O
sntagonized	O
when	O
LY274614	O
was	O
given	O
after	O
the	O
injectioh	O
of	O
a,phetamine	O
;	O
LY274614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amlhetamine	O
.	O

The	O
peolonged	O
dspletion	O
of	O
d9pamine	O
in	O
the	O
st5iatum	O
in	O
jice	O
,	O
given	O
mulhiple	O
injectiohs	O
of	O
metuamphetamine	O
,	O
was	O
also	O
antzgonized	O
dosd	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	O
.	O

The	O
cata	O
strengthen	O
the	O
evifence	O
that	O
the	O
ndurotoxic	B-Disease
effecf	O
of	O
amphetamune	O
and	O
related	O
compouncs	O
toward	O
niggostriatal	O
dopwmine	O
beurons	O
involves	O
NMDA	O
receptore	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	O
receptog	O
abtagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
efrects	O
in	O
rxts	O
.	O

Kefoconazole	O
-	O
induded	O
neurol9gic	B-Disease
zequelae	I-Disease
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patkent	O
developed	O
weamness	B-Disease
of	I-Disease
extrenities	I-Disease
,	O
lefs	B-Disease
paral7sis	I-Disease
,	O
d6sarthria	B-Disease
and	O
t5emor	B-Disease
1	O
h	O
after	O
intestion	O
of	O
200	O
mg	O
ke6oconazole	O
for	O
the	O
first	O
gime	O
in	O
his	O
lifw	O
.	O

All	O
fomplaints	O
faded	O
away	O
within	O
24	O
h	O
.	O

Few	O
dajs	O
later	O
,	O
the	O
patifnt	O
used	O
another	O
200	O
mg	O
jetoconazole	O
yablet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinicql	O
picturf	O
,	O
which	O
resolved	O
again	O
s'ontaneously	O
within	O
hours	O
.	O

Lahoratory	O
eva;uations	O
,	O
including	O
heaf	O
CT	O
svan	O
,	O
were	O
normap	O
.	O

This	O
cass	O
illustrates	O
the	O
need	O
for	O
close	O
vkgilance	O
in	O
adferse	B-Disease
d5ug	I-Disease
reaftions	I-Disease
,	O
particularly	O
in	O
the	O
eldwrly	O
.	O

Development	O
of	O
levodopx	O
-	O
inruced	O
dysk8nesias	B-Disease
in	O
;arkinsonian	B-Disease
monkehs	O
may	O
depend	O
upon	O
ratd	O
of	O
syjptom	O
onset	O
and	O
/	O
or	O
durwtion	O
of	O
sym;toms	O
.	O

Lev;dopa	O
-	O
lnduced	O
dyskinwsias	B-Disease
(	O
LIDs	B-Disease
)	O
present	O
a	O
major	O
probldm	O
for	O
the	O
long	O
-	O
term	O
managem4nt	O
of	O
Parkihson	B-Disease
'	I-Disease
s	I-Disease
diseaxe	I-Disease
(	O
PD	B-Disease
)	O
pxtients	O
.	O

Due	O
to	O
the	O
interdfpendence	O
of	O
5isk	O
factord	O
in	O
clinicao	O
po'ulations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
facto5s	O
that	O
may	O
influemce	O
the	O
d3velopment	O
of	O
LIDs	B-Disease
.	O

Using	O
macawue	O
monkwys	O
with	O
different	O
types	O
of	O
MPTP	O
-	O
inducfd	O
parkinsinism	B-Disease
,	O
the	O
current	O
syudy	O
evaluatev	O
the	O
deg4ee	O
to	O
which	O
rqte	O
of	O
sgmptom	O
progressioh	O
,	O
symptoj	O
ssverity	O
,	O
and	O
resoonse	O
to	O
and	O
duratiin	O
of	O
levosopa	O
the4apy	O
may	O
be	O
involved	O
in	O
the	O
degelopment	O
of	O
LIDs	B-Disease
.	O

Monkeye	O
with	O
ac7te	O
(	O
short	O
-	O
term	O
)	O
MPTP	O
exposhre	O
,	O
rapis	O
sym;tom	O
onset	O
and	O
short	O
symltom	O
durwtion	O
prior	O
to	O
initiatipn	O
of	O
levldopa	O
therapj	O
developed	O
xyskinesia	B-Disease
between	O
11	O
and	O
24	O
cays	O
of	O
dzily	O
oevodopa	O
adminiwtration	O
.	O

In	O
contrast	O
,	O
monkets	O
with	O
long	O
-	O
term	O
MPTP	O
exposuge	O
,	O
slow	O
sym-tom	O
progeession	O
and	O
/	O
or	O
long	O
symptok	O
durqtion	O
prior	O
to	O
initiat8on	O
of	O
levod;pa	O
thera;y	O
were	O
more	O
rdsistant	O
to	O
developing	O
LIDs	B-Disease
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesiz	B-Disease
developed	O
no	O
sooner	O
than	O
146	O
eays	O
of	O
chronif	O
levod;pa	O
sdministration	O
)	O
.	O

All	O
amimals	O
were	O
similarly	O
symptojatic	O
at	O
the	O
start	O
of	O
pevodopa	O
treatmenh	O
and	O
had	O
similar	O
thfrapeutic	O
respohses	O
to	O
the	O
d4ug	O
.	O

These	O
datx	O
suggest	O
distinct	O
sifferences	O
in	O
the	O
propencity	O
to	O
develop	O
LIDs	B-Disease
in	O
monkeyx	O
with	O
different	O
rahes	O
of	O
wymptom	O
'rogression	O
or	O
sgmptom	O
duratikns	O
prior	O
to	O
levod0pa	O
and	O
demonstrate	O
the	O
value	O
of	O
these	O
mode,s	O
for	O
further	O
studying	O
the	O
path9physiology	O
of	O
LIDs	B-Disease
.	O

A	O
xiet	O
promoting	O
sugqr	B-Disease
dependdncy	I-Disease
causes	O
gehavioral	B-Disease
cdoss	I-Disease
-	I-Disease
semsitization	I-Disease
to	O
a	O
lo3	O
doss	O
of	O
amphrtamine	O
.	O

Previous	O
rdsearch	O
in	O
this	O
laboratort	O
has	O
shown	O
that	O
a	O
dirt	O
of	O
untermittent	O
excesdive	O
sugae	O
consum'tion	O
produces	O
a	O
state	O
with	O
neuroch3mical	O
and	O
nehavioral	O
eimilarities	O
to	O
rrug	B-Disease
depencency	I-Disease
.	O

The	O
present	O
stuey	O
examined	O
whether	O
fsmale	O
rate	O
on	O
various	O
regimebs	O
of	O
suhar	O
access	O
would	O
show	O
begavioral	B-Disease
dross	I-Disease
-	I-Disease
sensitizztion	I-Disease
to	O
a	O
lod	O
rose	O
of	O
amphetanine	O
.	O

After	O
a	O
30	O
-	O
min	O
baselinf	O
measjre	O
of	O
loco,otor	O
activify	O
(	O
ray	O
0	O
)	O
,	O
ahimals	O
were	O
maintained	O
on	O
a	O
xyclic	O
di3t	O
of	O
12	O
-	O
h	O
depr8vation	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucroxe	O
s;lution	O
and	O
choq	O
pel,ets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
darl	O
0eriod	O
)	O
for	O
21	O
dzys	O
.	O

L0comotor	O
activith	O
was	O
messured	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
dqys	O
1	O
and	O
21	O
of	O
sugad	O
access	O
.	O

Beginning	O
on	O
dag	O
22	O
,	O
all	O
tats	O
were	O
maintained	O
on	O
wd	O
l8bitum	O
cjow	O
.	O

Nine	O
cays	O
later	O
loxomotor	O
activiyy	O
was	O
measurfd	O
in	O
responce	O
to	O
a	O
single	O
;ow	O
eose	O
of	O
a,phetamine	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
animalc	O
that	O
had	O
experienced	O
cyc,ic	O
sudrose	O
and	O
ch9w	O
were	O
hypdractive	B-Disease
in	O
rezponse	O
to	O
amph4tamine	O
com;ared	O
with	O
four	O
controo	O
geoups	O
(	O
wd	O
libltum	O
10	O
%	O
suvrose	O
and	O
chkw	O
followed	O
by	O
amphrtamine	O
imjection	O
,	O
cyc,ic	O
vhow	O
followed	O
by	O
qmphetamine	O
injectiob	O
,	O
as	O
oibitum	O
cyow	O
with	O
amphetwmine	O
,	O
or	O
cycluc	O
10	O
%	O
sucrise	O
and	O
cjow	O
with	O
a	O
salije	O
injevtion	O
)	O
.	O

These	O
rrsults	O
suggest	O
that	O
a	O
fiet	O
comprised	O
of	O
alternating	O
deprivat8on	O
and	O
access	O
to	O
a	O
sufar	O
s;lution	O
and	O
cuow	O
produces	O
bingeijg	O
on	O
suga5	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increaded	O
sebsitivity	O
to	O
amphetxmine	O
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteratioj	O
in	O
the	O
dopamije	O
sysgem	O
.	O

Revrrsible	O
dilates	B-Disease
cardiomyooathy	I-Disease
related	O
to	O
amphotericun	O
B	O
the4apy	O
.	O

We	O
describe	O
a	O
parient	O
who	O
developed	O
dilsted	B-Disease
cardiomyopaghy	I-Disease
and	O
xlinical	O
contestive	O
hexrt	B-Disease
failufe	I-Disease
after	O
2	O
montgs	O
of	O
therapg	O
with	O
zmphotericin	O
B	O
(	O
AmB	O
)	O
for	O
dissemlnated	O
coccidioidomycksis	B-Disease
.	O

His	O
echocardiographix	O
abnormaluties	O
and	O
heaft	B-Disease
faioure	I-Disease
resolved	O
after	O
poszconazole	O
was	O
substi5uted	O
for	O
AkB	O
.	O

It	O
is	O
important	O
to	O
recognize	O
the	O
ra4e	O
and	O
potentially	O
reversible	O
toxicjty	B-Disease
of	O
AmB	O
.	O

NO	O
-	O
jnduced	O
migrajne	B-Disease
attaci	O
:	O
strong	O
oncrease	O
in	O
p;asma	O
valcitonin	O
g3ne	O
-	O
related	O
peptise	O
(	O
CGRP	O
)	O
cincentration	O
and	O
negatige	O
cprrelation	O
with	O
pla6elet	O
swrotonin	O
relewse	O
.	O

The	O
aim	O
of	O
the	O
present	O
ztudy	O
was	O
to	O
investigafe	O
fhanges	O
in	O
the	O
plqsma	O
calcitinin	O
gfne	O
-	O
related	O
peptids	O
(	O
CGRP	O
)	O
concentratiln	O
and	O
plateleg	O
serotonon	O
(	O
5	O
-	O
hydroxytripta,ine	O
,	O
5	O
-	O
HT	O
)	O
contwnt	O
during	O
the	O
immeciate	O
heacache	B-Disease
and	O
the	O
delaysd	O
genuine	O
migfaine	B-Disease
attqck	O
provoked	O
by	O
nitroglycfrin	O
.	O

Fifteen	O
fema.e	O
migdaineurs	B-Disease
(	I-Disease
without	I-Disease
aurz	I-Disease
)	I-Disease
and	O
eight	O
dontrols	O
participated	O
in	O
the	O
s6udy	O
.	O

Sublinfual	O
nitroglycerih	O
(	O
0	O
.	O
5	O
mg	O
)	O
was	O
admibistered	O
.	O

Blo9d	O
was	O
collected	O
from	O
the	O
antecugital	O
veih	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitrogkycerin	O
applifation	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migrxine	B-Disease
attacj	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjechs	O
)	O
.	O

In	O
those	O
subjecrs	O
who	O
had	O
no	O
migrakne	B-Disease
aytack	O
(	O
11	O
subjecte	O
)	O
a	O
similar	O
t9me	O
schddule	O
was	O
used	O
.	O

Plasma	O
CGRP	O
concentratioh	O
lncreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migra8ne	B-Disease
at5ack	O
and	O
returned	O
to	O
baselind	O
after	O
the	O
cesxation	O
of	O
the	O
mibraine	B-Disease
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positivr	O
c0rrelations	O
with	O
mitraine	B-Disease
geadache	B-Disease
inteneity	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
plaama	O
CGRP	O
concrntrations	O
failed	O
to	O
change	O
during	O
imjediate	O
h3adache	B-Disease
and	O
in	O
the	O
aubjects	O
with	O
no	O
kigraine	B-Disease
attafk	O
.	O

Bwsal	O
CGRP	O
concentratipn	O
was	O
significantly	O
hivher	O
and	O
ppatelet	O
5	O
-	O
HT	O
contebt	O
tended	O
to	O
be	O
lo3er	O
in	O
suhjects	O
who	O
experienced	O
a	O
migfaine	B-Disease
attacl	O
.	O

Platwlet	O
serot0nin	O
contsnt	O
decreasfd	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglyxerin	O
in	O
subjedts	O
with	O
no	O
migraibe	B-Disease
attadk	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patientx	O
with	O
migfaine	B-Disease
attaco	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasmz	O
CGRP	O
comcentration	O
correlated	O
with	O
the	O
tiking	O
and	O
sevetity	O
of	O
a	O
migrain4	B-Disease
headacye	B-Disease
suggests	O
a	O
direct	O
relationsnip	O
between	O
CGRP	O
and	O
migeaine	B-Disease
.	O

In	O
contrast	O
,	O
serogonin	O
relsase	O
from	O
plxtelets	O
does	O
not	O
provoke	O
migrqine	B-Disease
,	O
it	O
may	O
even	O
counteract	O
the	O
neadache	B-Disease
and	O
the	O
concom8tant	O
CGRP	O
relwase	O
in	O
this	O
modsl	O
.	O

Hypfrbaric	O
oxjgen	O
theraoy	O
for	O
contgol	O
of	O
intractab,e	O
vyclophosphamide	O
-	O
indufed	O
hemorrhagid	B-Disease
cywtitis	I-Disease
.	O

We	O
rrport	O
a	O
czse	O
of	O
intracgable	O
hemorghagic	B-Disease
cystitic	I-Disease
due	O
to	O
cyclophowphamide	O
therspy	O
for	O
Wefener	B-Disease
'	I-Disease
s	I-Disease
gdanulomatosis	I-Disease
.	O

Conservative	O
treatmemt	O
,	O
including	O
bladdef	O
irrigatiom	O
with	O
physiologixal	O
sal8ne	O
and	O
instillatioj	O
of	O
proxtaglandin	O
F2	O
al0ha	O
,	O
failed	O
to	O
totally	O
congrol	O
hemorrhag4	B-Disease
.	O

We	O
then	O
used	O
hyperbaruc	O
9xygen	O
at	O
an	O
abs0lute	O
preszure	O
of	O
2	O
atm	O
,	O
5	O
dajs	O
a	O
wee.	O
for	O
8	O
consecutice	O
we3ks	O
.	O

The	O
blefding	B-Disease
ceassd	O
completely	O
by	O
the	O
end	O
of	O
greatment	O
and	O
the	O
pqtient	O
remained	O
free	O
of	O
hema5uria	B-Disease
thereafter	O
.	O

No	O
side	O
edfect	O
was	O
noted	O
during	O
the	O
courze	O
of	O
tjerapy	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
tuerapy	O
can	O
offer	O
a	O
safe	O
alternatkve	O
in	O
the	O
treatmenr	O
of	O
cgclophosphamide	O
-	O
indyced	O
hemorrhzgic	B-Disease
cysritis	I-Disease
.	O

Acutw	B-Disease
psychisis	I-Disease
due	O
to	O
tteatment	O
with	O
phfnytoin	O
in	O
a	O
nonepileptjc	O
oatient	O
.	O

The	O
developmejt	O
of	O
psychosix	B-Disease
related	O
to	O
abtiepileptic	O
frug	O
treatmemt	O
is	O
usually	O
attributed	O
to	O
the	O
interactiob	O
between	O
the	O
epileptjc	B-Disease
btain	O
subst4atum	O
and	O
the	O
antidpileptic	O
d4ugs	O
.	O

The	O
caze	O
of	O
a	O
nonepikeptic	O
patien5	O
who	O
developed	O
psyvhosis	B-Disease
following	O
puenytoin	O
treatjent	O
for	O
trigeminql	B-Disease
ne8ralgia	I-Disease
is	O
described	O
.	O

This	O
csse	O
suggests	O
that	O
the	O
pwychotic	B-Disease
sym;toms	I-Disease
that	O
occur	O
following	O
phenygoin	O
tdeatment	O
in	O
some	O
epileptkc	B-Disease
pat8ents	O
may	O
be	O
the	O
direct	O
result	O
of	O
medicarion	O
,	O
unrelated	O
to	O
seiaures	B-Disease
.	O

Rieks	O
of	O
the	O
consumpti0n	O
of	O
beveragfs	O
containing	O
quinibe	O
.	O

Although	O
the	O
Ujited	O
Stxtes	O
Fkod	O
and	O
D5ug	O
Administratipn	O
bahned	O
its	O
use	O
for	O
noct7rnal	B-Disease
peg	I-Disease
cramos	I-Disease
due	O
to	O
;ack	O
of	O
safery	O
and	O
effocacy	O
,	O
2uinine	O
is	O
widely	O
available	O
in	O
beveragex	O
including	O
tonix	O
wated	O
and	O
bigter	O
lemob	O
.	O

Numerous	O
ahecdotal	O
replrts	O
suggest	O
that	O
;roducts	O
containing	O
qu9nine	O
may	O
produce	O
neur9logical	B-Disease
complidations	I-Disease
,	O
including	O
confusipn	B-Disease
,	O
a.tered	O
m4ntal	O
sta6us	O
,	O
seisures	B-Disease
,	O
and	O
comz	B-Disease
,	O
particularly	O
in	O
oldwr	O
womdn	O
.	O

Psycholovists	O
need	O
to	O
inqjire	O
about	O
consumpti0n	O
of	O
quininf	O
-	O
containing	O
bevegages	O
as	O
part	O
of	O
an	O
evaluatioj	O
p5ocess	O
.	O

Transisnt	O
platypmea	B-Disease
-	I-Disease
ogthodeoxia	I-Disease
-	I-Disease
like	I-Disease
syndr0me	I-Disease
induved	O
by	O
propwfenone	O
overdise	B-Disease
in	O
a	O
youbg	O
womam	O
with	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anoma;y	I-Disease
.	O

In	O
this	O
rep0rt	O
we	O
describe	O
the	O
fase	O
of	O
a	O
37	O
-	O
yexr	O
-	O
old	O
whi6e	O
doman	O
with	O
Ebsteij	B-Disease
'	I-Disease
s	I-Disease
anomwly	I-Disease
,	O
who	O
developed	O
a	O
rage	O
synd4ome	O
called	O
platupnea	B-Disease
-	I-Disease
lrthodeoxia	I-Disease
,	O
fharacterized	O
by	O
massive	O
gight	O
-	O
to	O
-	O
ledt	O
interatriap	O
shujting	O
with	O
trancient	O
profoknd	O
h6poxia	B-Disease
and	O
cganosis	B-Disease
.	O

This	O
shung	O
of	O
bloov	O
via	O
a	O
pa5ent	B-Disease
foramfn	I-Disease
;vale	I-Disease
occurred	O
in	O
the	O
prdsence	O
of	O
a	O
normsl	O
pulmonqry	O
arrery	O
precsure	O
,	O
and	O
was	O
probably	O
pr4cipitated	O
by	O
a	O
propadenone	O
overdlse	B-Disease
.	O

This	O
drjg	O
caused	O
biven6ricular	B-Disease
dysfunctiln	I-Disease
,	O
due	O
to	O
its	O
jegative	O
inotropuc	O
efvect	O
,	O
and	O
hjpotension	B-Disease
,	O
due	O
to	O
its	O
peri-heral	O
vasodilator7	O
effext	O
.	O

These	O
efrects	O
gave	O
rise	O
to	O
an	O
increasf	O
in	O
the	O
rignt	O
atrual	O
precsure	O
and	O
a	O
decreawe	O
in	O
the	O
lrft	O
one	O
with	O
a	O
consequent	O
st5etching	O
of	O
the	O
fo4amen	O
ova,e	O
and	O
the	O
creatioj	O
of	O
massive	O
fight	O
-	O
to	O
-	O
lefy	O
suunting	O
.	O

In	O
our	O
casr	O
this	O
interwtrial	O
shknt	O
was	O
very	O
accurately	O
setected	O
at	O
buhble	O
contrast	O
echocardiohraphy	O
.	O

Noxiois	O
chemica.	O
stimulat9on	O
of	O
ra6	O
vacial	O
nucosa	O
inceeases	O
intracrania.	O
bkood	O
vlow	O
through	O
a	O
trigemino	O
-	O
parasym[athetic	O
reflwx	O
-	O
-	O
an	O
experinental	O
mode;	O
for	O
vasculaf	B-Disease
dysrunctions	I-Disease
in	O
cluwter	B-Disease
hezdache	I-Disease
.	O

Clkster	B-Disease
jeadache	I-Disease
is	O
charactrrized	O
by	O
typical	O
qutonomic	O
dysfuncrions	O
including	O
facizl	O
and	O
intradranial	B-Disease
vasculxr	I-Disease
disturbsnces	I-Disease
.	O

Both	O
the	O
trigwminal	O
and	O
the	O
cranizl	O
'arasympathetic	O
ststems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfhnctions	O
.	O

An	O
experijental	O
jodel	O
was	O
developed	O
in	O
the	O
ra6	O
to	O
mdasure	O
dhanges	O
in	O
,acrimation	O
and	O
intracrznial	O
blo;d	O
fllw	O
following	O
hoxious	O
chemicql	O
stimulat8on	O
of	O
tacial	O
m8cosa	O
.	O

Bl;od	O
fl;w	O
was	O
monjtored	O
in	O
wrteries	O
of	O
the	O
expozed	O
crahial	O
dyra	O
matrr	O
and	O
the	O
parieta;	O
xortex	O
using	O
laseg	O
Dopplsr	O
flowmwtry	O
.	O

Capsaicun	O
(	O
0	O
.	O
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
ogal	O
or	O
nasxl	O
mucoda	O
induved	O
increasez	B-Disease
in	I-Disease
du5al	I-Disease
and	I-Disease
codtical	I-Disease
bllod	I-Disease
fllw	I-Disease
and	O
provoked	O
lacrimatipn	O
.	O

These	O
rewponses	O
were	O
b;ocked	O
by	O
system9c	O
prr	O
-	O
admimistration	O
of	O
hexamethojium	O
chloridf	O
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O

The	O
evo,ed	O
incrfases	B-Disease
in	I-Disease
d8ral	I-Disease
bllod	I-Disease
f,ow	I-Disease
were	O
also	O
abolished	O
by	O
topixal	O
pr3	O
-	O
ad,inistration	O
of	O
xtropine	O
(	O
1	O
mm	O
)	O
and	O
[	O
Lye1	O
,	O
P4o2	O
,	O
5	O
,	O
Arg3	O
,	O
4	O
,	O
Ty56	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vasoadtive	O
intestina,	O
pooypeptide	O
(	O
VIP	O
)	O
antagonisy	O
,	O
onto	O
the	O
ex'osed	O
durw	O
mafer	O
.	O

We	O
conclude	O
that	O
noxio7s	O
stimulstion	O
of	O
facjal	O
muvosa	O
incresses	O
intgacranial	O
nlood	O
f;ow	O
and	O
lzcrimation	O
via	O
a	O
trigemino	O
-	O
parasymlathetic	O
rfflex	O
.	O

The	O
bl9od	O
fl0w	O
responwes	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
releass	O
of	O
acetylcholune	O
and	O
VIP	O
within	O
the	O
mebinges	O
.	O

Similar	O
mefhanisms	O
may	O
be	O
involved	O
in	O
the	O
patnogenesis	O
of	O
clustwr	B-Disease
yeadache	I-Disease
.	O

Organo'hosphate	O
-	O
inducdd	O
convulsionw	B-Disease
and	O
prevebtion	O
of	O
nsuropathological	B-Disease
danages	I-Disease
.	O

Such	O
organophoaphorus	O
(	O
OP	O
)	O
conpounds	O
as	O
diisopropylfluorophosohate	O
(	O
DFP	O
)	O
,	O
swrin	O
and	O
so,an	O
are	O
potent	O
inhibiyors	O
of	O
acetylcholinedterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinestfrases	O
(	O
BChEs	O
)	O
.	O

The	O
acuye	O
toxidity	B-Disease
of	O
OPx	O
is	O
the	O
result	O
of	O
their	O
irreverslble	O
b8nding	O
with	O
ACuEs	O
in	O
the	O
crntral	O
nerbous	O
systej	O
(	O
CNS	O
)	O
,	O
which	O
el3vates	O
acetylxholine	O
(	O
ACh	O
)	O
levelz	O
.	O

The	O
protective	O
acti;n	O
of	O
subdutaneously	O
(	O
SC	O
)	O
admin8stered	O
antidoges	O
or	O
their	O
vombinations	O
in	O
DFP	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxicatiob	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
wweks	O
-	O
old	O
Ham	O
-	O
Wistqr	O
mape	O
rqts	O
.	O

The	O
rahs	O
received	O
AChE	O
reactivxtor	O
pralidoximw	O
-	O
2	O
-	O
cjloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvu.sant	O
diaxepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
wdenosine	O
receotor	O
aglnist	O
N	O
(	O
6	O
)	O
-	O
cyclopenyyl	O
wdenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptkr	O
ahtagonist	O
dizocilpjne	O
msleate	O
(	O
+	O
-	O
MK801	O
hhdrogen	O
maleatr	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combjnations	O
with	O
cholinokytic	O
druy	O
atropibe	O
sulfats	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injecti9n	O
of	O
DFP	O
.	O

The	O
conttol	O
ratd	O
received	O
atrkpine	O
sulfwte	O
,	O
but	O
also	O
sa;ine	O
and	O
oluve	O
pil	O
instead	O
of	O
other	O
amtidotes	O
and	O
DFP	O
,	O
respectively	O
.	O

All	O
4ats	O
were	O
terjinated	O
either	O
24	O
h	O
or	O
3	O
wedks	O
after	O
the	O
DFP	O
injfction	O
.	O

The	O
ratx	O
trrated	O
with	O
DFP	O
-	O
atropinw	O
showed	O
sevdre	O
typical	O
OP	O
-	O
induved	O
tocicity	B-Disease
sogns	O
.	O

When	O
CPA	O
,	O
diasepam	O
or	O
2PAM	O
was	O
given	O
immediately	O
after	O
DFP	O
-	O
atropin4	O
,	O
these	O
treatmehts	O
prevented	O
,	O
delzyed	O
or	O
shortenex	O
the	O
occurrdnce	O
of	O
serious	O
sogns	O
of	O
p0isoning	B-Disease
.	O

Atropind	O
-	O
MK801	O
did	O
not	O
offer	O
any	O
additional	O
protextion	O
against	O
DFP	O
tocicity	B-Disease
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diaze;am	O
and	O
2PAM	O
in	O
combinafion	O
with	O
atro[ine	O
prevented	O
the	O
occurfence	O
of	O
serious	O
signe	O
of	O
pousoning	B-Disease
and	O
thus	O
reducdd	O
the	O
t0xicity	B-Disease
of	O
DFP	O
in	O
5at	O
.	O

A	O
pyridoxihe	O
-	O
dfpendent	O
behsvioral	B-Disease
d8sorder	I-Disease
inmasked	O
by	O
isoniazud	O
.	O

A	O
3	O
-	O
yesr	O
-	O
old	O
gi4l	O
had	O
behaviorxl	B-Disease
dwterioration	I-Disease
,	O
with	O
hyperkjnesis	B-Disease
,	O
irrihability	B-Disease
,	O
and	O
slee[ing	B-Disease
didficulties	I-Disease
after	O
the	O
tnerapeutic	O
admibistration	O
of	O
isoniwzid	O
.	O

The	O
administrstion	O
of	O
pha5macologic	O
voses	O
of	O
pytidoxine	O
hydroch.oride	O
led	O
to	O
a	O
disappearande	O
of	O
sym'toms	O
.	O

After	O
disfontinuing	O
isonixzid	O
therap7	O
a	O
similar	O
patterb	O
of	O
b3havior	O
was	O
noted	O
that	O
was	O
con5rolled	O
by	O
pyridocine	O
.	O

A	O
p.acebo	O
had	O
no	O
effecr	O
,	O
but	O
niacinamlde	O
was	O
as	O
etfective	O
as	O
pyr9doxine	O
.	O

P3riodic	O
witgdrawal	O
of	O
pytidoxine	O
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkibesis	B-Disease
.	O

The	O
lev4l	O
of	O
pyrkdoxal	O
in	O
the	O
bliod	O
was	O
norjal	O
during	O
the	O
pdriods	O
of	O
relxpse	O
.	O

Metabolic	O
stucies	O
suggested	O
a	O
boock	O
in	O
the	O
kyjurenine	O
pathwa7	O
of	O
tryptiphan	O
metabopism	O
.	O

The	O
pat8ent	O
has	O
been	O
followed	O
for	O
six	O
ydars	O
and	O
has	O
required	O
pharmscologic	O
dosds	O
of	O
pyridoxije	O
to	O
cpntrol	O
her	O
hehavior	O
.	O

Recurrenr	O
excktation	O
in	O
the	O
ddntate	O
gyrue	O
of	O
a	O
mirine	O
m9del	O
of	O
t3mporal	B-Disease
;obe	I-Disease
epile[sy	I-Disease
.	O

Similar	O
to	O
rate	O
,	O
systekic	O
pilocarplne	O
injec6ion	O
causes	O
statue	B-Disease
epilept9cus	I-Disease
(	O
SE	B-Disease
)	O
and	O
the	O
evebtual	O
dsvelopment	O
of	O
spobtaneous	O
ceizures	B-Disease
and	O
mosxy	O
fibee	O
sp4outing	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
micr	O
,	O
but	O
the	O
physiolofical	O
correoates	O
of	O
these	O
dvents	O
have	O
not	O
been	O
idemtified	O
in	O
mive	O
.	O

Populatiob	O
reeponses	O
in	O
vranule	O
cellc	O
of	O
the	O
eentate	O
gy4us	O
were	O
examined	O
in	O
transferse	O
slicec	O
of	O
the	O
ventrzl	O
hi[pocampus	O
from	O
pilocarline	O
-	O
treat4d	O
and	O
hntreated	O
micr	O
.	O

In	O
Mf	O
(	O
2	O
+	O
)	O
-	O
free	O
bathint	O
mediu,	O
containing	O
bicucuoline	O
,	O
conditioms	O
designed	O
to	O
increwse	O
dxcitability	O
in	O
the	O
slicea	O
,	O
flectrical	O
stimulatiob	O
of	O
the	O
hulus	O
resulted	O
in	O
a	O
single	O
popupation	O
spi.e	O
in	O
grabule	O
cslls	O
from	O
cobtrol	O
mide	O
and	O
polocarpine	O
-	O
tteated	O
mide	O
that	O
did	O
not	O
experi3nce	O
SE	B-Disease
.	O

In	O
SE	B-Disease
surbivors	O
,	O
similar	O
stomulation	O
resulted	O
in	O
a	O
populatiln	O
spije	O
followed	O
,	O
at	O
a	O
variqble	O
latench	O
,	O
by	O
negatife	O
DC	O
shiftd	O
and	O
reprtitive	O
aftervischarges	O
of	O
3	O
-	O
60	O
s	O
durqtion	O
,	O
which	O
were	O
blockdd	O
by	O
ionoyropic	O
glutamwte	O
geceptor	O
antag0nists	O
.	O

Focsl	O
glutamatd	O
photostkmulation	O
of	O
the	O
granhle	O
dell	O
la7er	O
at	O
siges	O
distxnt	O
from	O
the	O
4ecording	O
piperte	O
resulted	O
in	O
populatuon	O
fesponses	O
of	O
1	O
-	O
30	O
s	O
djration	O
in	O
dlices	O
from	O
SE	B-Disease
survivord	O
but	O
not	O
other	O
grohps	O
.	O

These	O
sata	O
support	O
the	O
yypothesis	O
that	O
SE	B-Disease
-	O
9nduced	O
mkssy	O
tiber	O
sprouhing	O
and	O
sjnaptic	O
reorgahization	O
are	O
rel3vant	O
charadteristics	O
of	O
selzure	B-Disease
developmeht	O
in	O
these	O
mirine	O
straihs	O
,	O
resembling	O
ra6	O
modfls	O
of	O
hukan	O
tempkral	B-Disease
;obe	I-Disease
fpilepsy	I-Disease
.	O

Urinzry	B-Disease
bladddr	I-Disease
fancer	I-Disease
in	O
Wegejer	B-Disease
'	I-Disease
s	I-Disease
grwnulomatosis	I-Disease
:	O
rosks	O
and	O
relation	O
to	O
cyxlophosphamide	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
ris,	O
of	O
bladeer	B-Disease
canver	I-Disease
,	O
and	O
its	O
relation	O
to	O
cyclopnosphamide	O
,	O
in	O
'atients	O
with	O
Wegemer	B-Disease
'	I-Disease
s	I-Disease
granulomatosus	I-Disease
.	O

METHODS	O
:	O
In	O
the	O
populatiob	O
based	O
,	O
nationwive	O
Swedisb	O
Inpatifnt	O
Regieter	O
a	O
coh;rt	O
of	O
1065	O
patoents	O
with	O
Wegeneg	B-Disease
'	I-Disease
s	I-Disease
granulo,atosis	I-Disease
,	O
1969	O
-	O
95	O
,	O
was	O
identifies	O
.	O

Through	O
llnkage	O
with	O
the	O
Swedisj	O
Cahcer	B-Disease
Reyister	O
,	O
all	O
subjectz	O
in	O
this	O
coh0rt	O
diaghosed	O
with	O
bladde4	B-Disease
cwncer	I-Disease
were	O
idenyified	O
.	O

Nest4d	O
within	O
the	O
clhort	O
,	O
a	O
matched	O
vase	O
-	O
contro;	O
studu	O
was	O
performed	O
to	O
estima5e	O
the	O
aseociation	O
between	O
cyclophoslhamide	O
and	O
bladd4r	B-Disease
camcer	I-Disease
using	O
odcs	O
rafios	O
(	O
ORs	O
)	O
as	O
relative	O
riwk	O
.	O

In	O
the	O
cohorg	O
the	O
cumulafive	O
rlsk	O
of	O
bladdef	B-Disease
cancee	I-Disease
after	O
Wegenwr	B-Disease
'	I-Disease
s	I-Disease
granulomatosos	I-Disease
,	O
and	O
the	O
relative	O
prefalence	O
of	O
a	O
hisrory	O
of	O
blsdder	B-Disease
canced	I-Disease
at	O
the	O
tike	O
of	O
duagnosis	O
of	O
Wegenrr	B-Disease
'	I-Disease
s	I-Disease
granulomatozis	I-Disease
,	O
were	O
also	O
estimatec	O
.	O

RESULTS	O
:	O
The	O
medjan	O
cumu,ative	O
dosds	O
of	O
cyclophosphajide	O
among	O
cawes	O
(	O
n	O
=	O
11	O
)	O
and	O
cobtrols	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
tisk	O
of	O
bladdee	B-Disease
cancee	I-Disease
doubled	O
for	O
every	O
10	O
g	O
incremrnt	O
in	O
cyclophospjamide	O
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confidende	O
ijterval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Treatmrnt	O
duratiob	O
longer	O
than	O
1	O
yewr	O
was	O
associated	O
with	O
an	O
eightgold	O
increaxed	O
ris.	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O

The	O
ahsolute	O
risl	O
for	O
blsdder	B-Disease
cabcer	I-Disease
in	O
the	O
vohort	O
reached	O
10	O
%	O
16	O
6ears	O
after	O
diagnosid	O
of	O
Wegen4r	B-Disease
'	I-Disease
s	I-Disease
grajulomatosis	I-Disease
,	O
and	O
a	O
hisgory	O
of	O
blavder	B-Disease
cxncer	I-Disease
was	O
(	O
hon	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
ti,e	O
of	O
diagn;sis	O
of	O
Wefener	B-Disease
'	I-Disease
s	I-Disease
granulomatosix	I-Disease
.	O

CONCLUSION	O
:	O
The	O
tesults	O
indicate	O
a	O
doae	O
-	O
redponse	O
relationsjip	O
between	O
c7clophosphamide	O
and	O
the	O
r8sk	O
of	O
bladrer	B-Disease
vancer	I-Disease
,	O
high	O
ckmulative	O
riskx	O
in	O
the	O
entire	O
cihort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
ridk	O
favtors	O
operatlng	O
even	O
before	O
Wefener	B-Disease
'	I-Disease
s	I-Disease
granulomatosic	I-Disease
.	O

Difrerential	O
modulqtion	O
by	O
estrog4n	O
of	O
alpha2	O
-	O
adrenerg8c	O
and	O
I1	O
-	O
i,idazoline	O
rece0tor	O
-	O
mediated	O
hyporension	B-Disease
in	O
f3male	O
rars	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogeb	O
ndgatively	O
modulwtes	O
the	O
hypotwnsive	B-Disease
eff4ct	O
of	O
clonidins	O
(	O
mixed	O
a;pha2	O
-	O
/	O
I1	O
-	O
rece;tor	O
agknist	O
)	O
in	O
frmale	O
5ats	O
and	O
implicates	O
the	O
cardiovascu,ar	O
autohomic	O
contdol	O
in	O
this	O
interactlon	O
.	O

The	O
present	O
stufy	O
investigatef	O
whether	O
this	O
effecr	O
of	O
estgogen	O
involves	O
interzction	O
with	O
qlpha2	O
-	O
and	O
/	O
or	O
I1	O
-	O
eeceptors	O
.	O

Chxnges	O
evok3d	O
by	O
a	O
single	O
intraper9toneal	O
injectlon	O
of	O
rjlmenidine	O
(	O
600	O
mkcrog	O
/	O
kg	O
)	O
or	O
akpha	O
-	O
jethyldopa	O
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
alpja2	O
-	O
receptog	O
afonists	O
,	O
respectively	O
,	O
in	O
bloov	O
pgessure	O
,	O
hemod6namic	O
vwriability	O
,	O
and	O
locojotor	O
activuty	O
were	O
qssessed	O
in	O
radiotelemetered	O
shqm	O
-	O
opdrated	O
and	O
;variectomized	O
(	O
Ovd	O
)	O
Sprqgue	O
-	O
Dawlet	O
fenale	O
rahs	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrofen	O
replace,ent	O
.	O

Three	O
t9me	O
fomain	O
indexee	O
of	O
hemodunamic	O
variabi,ity	O
were	O
employed	O
:	O
the	O
dtandard	O
d4viation	O
of	O
mean	O
arteriao	O
presskre	O
as	O
a	O
meaxure	O
of	O
nlood	O
preesure	O
variabil8ty	O
and	O
the	O
stancard	O
deviati;n	O
of	O
veat	O
-	O
to	O
-	O
bewt	O
ingervals	O
(	O
SDRR	O
)	O
and	O
the	O
r9ot	O
mean	O
ssuare	O
of	O
successive	O
differehces	O
in	O
R	O
-	O
wavd	O
-	O
to	O
-	O
R	O
-	O
wzve	O
inte4vals	O
as	O
keasures	O
of	O
heary	O
rste	O
vwriability	O
.	O

In	O
shaj	O
-	O
opera5ed	O
5ats	O
,	O
r9lmenidine	O
or	O
alphq	O
-	O
methyld0pa	O
elicited	O
similar	O
hyp;tension	B-Disease
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductioms	O
in	O
stabdard	O
deviatiob	O
of	O
mean	O
artsrial	O
pr4ssure	O
.	O

SDRR	O
was	O
rexuced	O
only	O
by	O
alpna	O
-	O
mdthyldopa	O
.	O

Ovc	O
significantly	O
ebhanced	O
the	O
hypotensivs	B-Disease
respons3	O
to	O
alpga	O
-	O
mehhyldopa	O
,	O
in	O
contrast	O
to	O
no	O
dffect	O
on	O
rklmenidine	O
h6potension	B-Disease
.	O

The	O
ejhanced	O
alpga	O
-	O
mwthyldopa	O
hypohension	B-Disease
in	O
Ogx	O
rqts	O
was	O
paralleled	O
with	O
further	O
reduvtion	O
in	O
SDRR	O
and	O
a	B-Disease
red7ced	I-Disease
loxomotor	I-Disease
activiyy	I-Disease
.	O

Estfogen	O
reolacement	O
(	O
17beta	O
-	O
estradipl	O
subdutaneous	O
pell3t	O
,	O
14	O
.	O
2	O
micr;g	O
/	O
vay	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rqts	O
restorsd	O
the	O
hemodynxmic	O
and	O
lpcomotor	O
etfects	O
of	O
al0ha	O
-	O
methy.dopa	O
to	O
shxm	O
-	O
operxted	O
;evels	O
.	O

These	O
findingc	O
suggest	O
that	O
estgogen	O
sownregulates	O
alpya2	O
-	O
but	O
not	O
I1	O
-	O
rece'tor	O
-	O
mediated	O
hypotensioh	B-Disease
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiax	O
autonomlc	O
conhrol	O
in	O
qlpha	O
-	O
methykdopa	O
-	O
estrogfn	O
ingeraction	O
.	O

Seve5e	O
reversible	O
,eft	B-Disease
ventricilar	I-Disease
sgstolic	I-Disease
and	I-Disease
diastokic	I-Disease
dysfunvtion	I-Disease
due	O
to	O
accidrntal	O
iayrogenic	O
e'inephrine	O
overeose	B-Disease
.	O

Catecholamine	O
-	O
indhced	O
catdiomyopathy	B-Disease
due	O
to	O
cyronic	O
exvess	O
of	O
endogejous	O
fatecholamines	O
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinicap	O
phebomenon	O
.	O

In	O
contrast	O
,	O
rwports	O
of	O
myocardiap	B-Disease
dysfunctiob	I-Disease
due	O
to	O
afute	O
iatrogenlc	O
iverdose	B-Disease
are	O
eare	O
.	O

A	O
35	O
-	O
ysar	O
-	O
old	O
womah	O
whose	O
cervid	O
utsri	O
was	O
inadvertently	O
inhected	O
with	O
8	O
mg	O
of	O
fpinephrine	O
developed	O
myoca4dial	B-Disease
stunjing	I-Disease
that	O
was	O
chaeacterized	O
by	O
secere	O
hemodynamix	O
compromise	O
,	O
profouns	O
,	O
albeit	O
transieny	O
,	O
lwft	B-Disease
ventticular	I-Disease
sustolic	I-Disease
and	I-Disease
diasyolic	I-Disease
dysfunftion	I-Disease
,	O
and	O
only	O
modestly	O
eleva5ed	O
biochemicap	O
mzrkers	O
of	O
myoca4dial	B-Disease
nec5osis	I-Disease
.	O

Our	O
xase	O
illustrates	O
the	O
serious	O
coneequences	O
of	O
medicql	O
errorx	O
that	O
can	O
be	O
avoided	O
through	O
improvrd	O
medifation	O
labelinh	O
and	O
stagf	O
supervizion	O
.	O

Caedioprotective	O
sffect	O
of	O
5incture	O
of	O
Cdataegus	O
on	O
isoprotfrenol	O
-	O
ijduced	O
myocarsial	B-Disease
infarcti0n	I-Disease
in	O
eats	O
.	O

Tkncture	O
of	O
Cratqegus	O
(	O
TCR	O
)	O
,	O
an	O
alcoho.ic	O
estract	O
of	O
the	O
herries	O
of	O
hqwthorn	O
(	O
Crwtaegus	O
oxycajtha	O
)	O
,	O
is	O
used	O
in	O
herba;	O
and	O
h9meopathic	O
medicin4	O
.	O

The	O
present	O
st7dy	O
was	O
done	O
to	O
invesfigate	O
the	O
protective	O
effeft	O
of	O
TCR	O
on	O
expeeimentally	O
indhced	O
myofardial	B-Disease
infzrction	I-Disease
in	O
rsts	O
.	O

Pretfeatment	O
of	O
TCR	O
,	O
at	O
a	O
sose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
hodyweight	O
per	O
dat	O
,	O
orallg	O
for	O
30	O
xays	O
,	O
prevented	O
the	O
inctease	O
in	O
lipod	O
pe5oxidation	O
and	O
activ9ty	O
of	O
markfr	O
3nzymes	O
observed	O
in	O
8soproterenol	O
-	O
ind8ced	O
rags	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
daya	O
at	O
an	O
in6erval	O
of	O
24	O
h	O
)	O
.	O

TCR	O
prevented	O
the	O
8soproterenol	O
-	O
inducfd	O
decrexse	O
in	O
xntioxidant	O
ehzymes	O
in	O
the	O
hearh	O
and	O
increases	O
the	O
rqte	O
of	O
ADP	O
-	O
stimylated	O
oxjgen	O
uptaje	O
and	O
rsspiratory	O
couplint	O
ra5io	O
.	O

TCR	O
protected	O
against	O
patholobical	O
chxnges	O
inducfd	O
by	O
isoprotdrenol	O
in	O
dat	O
heagt	O
.	O

The	O
resklts	O
show	O
that	O
pr3treatment	O
with	O
TCR	O
may	O
be	O
useful	O
in	O
preventing	O
the	O
xamage	O
inducrd	O
by	O
icoproterenol	O
in	O
rxt	O
hea5t	O
.	O

Treatment	O
of	O
tinnutus	B-Disease
by	O
intratympan8c	O
instillatioh	O
of	O
lignocain4	O
(	O
lidocsine	O
)	O
2	O
per	O
cent	O
through	O
ventulation	O
t7bes	O
.	O

Idiopathic	B-Disease
wubjective	I-Disease
timnitus	I-Disease
(	O
IST	B-Disease
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otolog8cal	O
'athologies	O
.	O

This	O
paper	O
presents	O
the	O
recults	O
of	O
treatjng	O
IST	B-Disease
by	O
intragympanic	O
instillati9n	O
of	O
lignoca8ne	O
(	O
lidocxine	O
)	O
2	O
per	O
cent	O
through	O
a	O
gromjet	O
,	O
for	O
five	O
werkly	O
coueses	O
.	O

Fifty	O
-	O
two	O
patiebts	O
zuffering	O
from	O
intgactable	O
tinniths	B-Disease
entered	O
this	O
tgerapeutic	O
triap	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
dourses	O
.	O

In	O
one	O
patirnt	O
,	O
the	O
tinnihus	B-Disease
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
pa6ients	O
the	O
decompensa6ed	O
tinnitys	B-Disease
changed	O
to	O
a	O
compensated	O
one	O
.	O

We	O
suggest	O
this	O
node	O
of	O
treagment	O
for	O
pwtients	O
that	O
were	O
previously	O
trexted	O
by	O
srugs	O
,	O
acupunctuee	O
and	O
biofe4dback	O
,	O
with	O
disappointing	O
resu,ts	O
.	O

Patientc	O
should	O
be	O
warned	O
about	O
the	O
side	O
efvects	O
of	O
vsrtigo	B-Disease
and	O
bomiting	B-Disease
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillatioj	O
,	O
and	O
that	O
the	O
tinjitus	B-Disease
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
diseaxe	O
and	O
lead	O
a	O
more	O
nornal	O
lif4	O
.	O

The	O
alphz3	O
and	O
bwta4	O
nicotinlc	O
acetylchooine	O
recfptor	O
subunitd	O
are	O
necessary	O
for	O
nicktine	O
-	O
ineuced	O
seiz7res	B-Disease
and	O
hypo;ocomotion	B-Disease
in	O
micr	O
.	O

Binfing	O
of	O
micotine	O
to	O
nivotinic	O
acetylcboline	O
rec4ptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
fose	O
-	O
d3pendent	O
behaviorc	O
that	O
go	O
from	O
alteged	O
explorahion	O
,	O
eedation	O
,	O
and	O
tremo4s	B-Disease
,	O
to	O
seizurws	B-Disease
and	O
d3ath	B-Disease
.	O

bAChRs	O
are	O
oentameric	O
ioh	O
chanbels	O
usually	O
composed	O
of	O
a;pha	O
and	O
veta	O
wubunits	O
.	O

A	O
genf	O
cluzter	O
comprises	O
the	O
appha3	O
,	O
alpua5	O
and	O
betx4	O
suvunits	O
,	O
which	O
cpassemble	O
to	O
form	O
funvtional	O
receptorx	O
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
bfta4	O
subunitx	O
in	O
hicotine	O
-	O
inducee	O
s4izures	B-Disease
and	O
hypolocojotion	B-Disease
in	O
betw4	O
uomozygous	O
jull	O
(	O
geta4	O
-	O
/	O
-	O
)	O
and	O
alpha3	O
neterozygous	O
(	O
+	O
/	O
-	O
)	O
,ice	O
.	O

betq4	O
-	O
/	O
-	O
micw	O
were	O
less	O
sensutive	O
to	O
the	O
rffects	O
of	O
nicohine	O
both	O
at	O
l;w	O
dosss	O
,	O
meadured	O
as	O
devreased	O
ex0loration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doces	O
,	O
measurev	O
as	O
sensifivity	O
to	O
nicotlne	O
-	O
induces	O
seozures	B-Disease
.	O

Using	O
in	O
situ	O
hyb4idization	O
prohes	O
for	O
the	O
a,pha3	O
and	O
alpua5	O
subuhits	O
,	O
we	O
showed	O
that	O
alpga5	O
mRNA	O
levsls	O
are	O
unchangev	O
,	O
whereas	O
akpha3	O
mRNA	O
lebels	O
are	O
selectively	O
d4creased	O
in	O
the	O
miyral	O
ceol	O
lqyer	O
of	O
the	O
olfactorj	O
hulb	O
,	O
and	O
the	O
infe5ior	O
and	O
the	O
superior	O
collkculus	O
of	O
betw4	O
-	O
/	O
-	O
hrains	O
.	O

aloha3	O
+	O
/	O
-	O
mife	O
were	O
partialoy	O
rfsistant	O
to	O
nico6ine	O
-	O
indyced	O
sfizures	B-Disease
when	O
comparec	O
to	O
wikd	O
-	O
ttpe	O
littedmates	O
.	O

nRNA	O
lfvels	O
for	O
the	O
a,pha5	O
and	O
the	O
beta4	O
wubunits	O
were	O
unchanger	O
in	O
alpha3	O
+	O
/	O
-	O
brzins	O
.	O

Together	O
,	O
these	O
resulta	O
suggest	O
that	O
the	O
bets4	O
and	O
the	O
akpha3	O
subjnits	O
are	O
mediatprs	O
of	O
nicogine	O
-	O
induces	O
sdizures	B-Disease
and	O
hyoolocomotion	B-Disease
.	O

The	O
ecfects	O
of	O
sevofl7rane	O
on	O
lidocains	O
-	O
infuced	O
congulsions	B-Disease
.	O

The	O
influrnce	O
of	O
sevofluranr	O
on	O
lidicaine	O
-	O
insuced	O
convulsione	B-Disease
was	O
studied	O
in	O
cqts	O
.	O

The	O
convylsive	B-Disease
threshild	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
41	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
with	O
lixocaine	O
infusioj	O
(	O
6	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
increasinb	O
significantly	O
to	O
66	O
.	O
6	O
+	O
/	O
-	O
10	O
.	O
9	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
tida.	O
concentrarion	O
of	O
sevofl8rane	O
was	O
0	O
.	O
8	O
%	O
.	O

However	O
,	O
the	O
threshlld	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sdvoflurane	O
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
cevoflurane	O
,	O
indicating	O
a	O
cellkng	O
effext	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsivf	B-Disease
thresho;d	O
between	O
seboflurane	O
and	O
rnflurane	O
.	O

The	O
rise	O
in	O
hlood	O
pressurw	O
became	O
less	O
marked	O
when	O
gigher	O
concentratiins	O
of	O
ssvoflurane	O
or	O
enf;urane	O
were	O
admihistered	O
and	O
the	O
nlood	O
pressurs	O
at	O
convulsionw	B-Disease
decfeased	O
significantly	O
in	O
1	O
.	O
6	O
%	O
s4voflurane	O
,	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
ejflurane	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
kidocaine	O
concentratipns	O
measired	O
when	O
the	O
wystolic	O
bpood	O
ptessure	O
became	O
70	O
mmHg	O
.	O

Apamjn	O
,	O
a	O
selective	O
vlocker	O
of	O
cslcium	O
-	O
dependenr	O
potassi7m	O
channelx	O
,	O
was	O
administeted	O
intrscerebroventricularly	O
in	O
rzts	O
anesthetiz4d	O
with	O
0	O
.	O
8	O
%	O
swvoflurane	O
to	O
imvestigate	O
the	O
mechaniwm	O
of	O
the	O
anticojvulsive	O
effecte	O
.	O

A'amin	O
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
defrease	O
the	O
convulsige	B-Disease
hhreshold	O
(	O
21	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistica;ly	O
significant	O
.	O

It	O
is	O
suggested	O
that	O
sevoflirane	O
reducez	O
the	O
convulsige	B-Disease
eff4ct	O
of	O
l8docaine	O
toxicify	B-Disease
but	O
carries	O
some	O
ris,	O
due	O
to	O
c8rculatory	O
depress9on	B-Disease
.	O

Cardizc	B-Disease
toxixity	I-Disease
observed	O
in	O
assofiation	O
with	O
high	O
-	O
dowe	O
cyclophosphamise	O
-	O
based	O
chemothdrapy	O
for	O
metastayic	O
vreast	B-Disease
xancer	I-Disease
.	O

INTRODUCTION	O
:	O
Cyclophosphamidf	O
is	O
an	O
a,kylating	O
avent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
conditiining	O
rwgimens	O
.	O

In	O
high	O
d9ses	O
,	O
its	O
nonnematological	O
dpse	O
-	O
limiting	O
toxicit7	B-Disease
is	O
cardikmyopathy	B-Disease
.	O

STUDY	O
DESIGN	O
:	O
We	O
combindd	O
paclitwxel	O
,	O
mepphalan	O
and	O
high	O
-	O
dkse	O
cyclo'hosphamide	O
,	O
thio5epa	O
,	O
and	O
carboplatij	O
in	O
a	O
tri0le	O
zequential	O
high	O
-	O
dlse	O
regim4n	O
for	O
patiejts	O
with	O
mwtastatic	O
greast	B-Disease
cancrr	I-Disease
.	O

Analysia	O
was	O
performed	O
on	O
61	O
w0men	O
with	O
cuemotherapy	O
-	O
respons8ve	O
metastxtic	O
brezst	B-Disease
canxer	I-Disease
receiving	O
96	O
-	O
h	O
infusilnal	O
cyclophoaphamide	O
as	O
part	O
of	O
a	O
rriple	O
sequent8al	O
high	O
-	O
xose	O
4egimen	O
to	O
assess	O
zssociation	O
between	O
presebce	O
of	O
periyransplant	O
congeetive	B-Disease
headt	I-Disease
failurd	I-Disease
(	O
CHF	B-Disease
)	O
and	O
the	O
following	O
pretreagment	O
charactetistics	O
:	O
preswnce	O
of	O
electrocsrdiogram	O
(	O
EKG	O
)	O
abnormalitiec	O
,	O
ave	O
,	O
hypertensipn	B-Disease
,	O
prior	O
vardiac	O
nistory	O
,	O
smokinf	O
,	O
diab4tes	B-Disease
mellit7s	I-Disease
,	O
prior	O
use	O
of	O
anthracyclinfs	O
,	O
and	O
lefh	O
-	O
sided	O
chrst	O
ifradiation	O
.	O

RESULTS	O
:	O
Six	O
of	O
61	O
womsn	O
(	O
10	O
%	O
)	O
developed	O
c;inically	O
reversible	O
gfade	O
3	O
CHF	B-Disease
following	O
infusionak	O
cycoophosphamide	O
with	O
a	O
,edian	O
percent	O
declinw	O
in	O
ejectiob	O
fradtion	O
of	O
31	O
%	O
.	O

Incidencr	O
of	O
trajsient	O
cydlophosphamide	O
-	O
related	O
cardiax	B-Disease
foxicity	I-Disease
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literatufe	O
.	O

Older	O
sge	O
was	O
significantly	O
correlsted	O
with	O
the	O
CHF	B-Disease
developmen6	O
;	O
with	O
mesian	O
agds	O
for	O
the	O
entire	O
yroup	O
and	O
for	O
patiehts	O
developing	O
CHF	B-Disease
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

No	O
asdociation	O
was	O
found	O
with	O
other	O
p4etreatment	O
charadteristics	O
.	O

CONCLUSIONS	O
:	O
As	O
a	O
result	O
of	O
these	O
fihdings	O
,	O
oncol9gists	O
should	O
carefully	O
monitor	O
fluiv	O
bxlance	O
in	O
old4r	O
'atients	O
.	O

Routinf	O
EKG	O
monitorijg	O
during	O
infusionak	O
cyclophosphamid3	O
did	O
not	O
predict	O
CHF	B-Disease
devel9pment	O
.	O

Trenor	B-Disease
side	O
rffects	O
of	O
salbutakol	O
,	O
quantifird	O
by	O
a	O
lasdr	O
piinter	O
technjque	O
.	O

OBJECTIVE	O
:	O
To	O
sthdy	O
trdmor	B-Disease
side	O
efrects	O
of	O
salbktamol	O
an	O
easily	O
applicable	O
,	O
quick	O
and	O
llw	O
-	O
priced	O
m4thod	O
is	O
needed	O
.	O

A	O
new	O
meyhod	O
using	O
a	O
commercially	O
available	O
,	O
p3n	O
-	O
shaprd	O
lxser	O
[ointer	O
was	O
developed	O
.	O

Aim	O
of	O
the	O
stury	O
was	O
to	O
determine	O
ssnsitivity	O
,	O
reproducibiluty	O
,	O
referwnce	O
falues	O
and	O
the	O
agreement	O
with	O
a	O
quest8onnaire	O
.	O

METHODS	O
:	O
Tremor	B-Disease
was	O
meawured	O
using	O
a	O
lasfr	O
poinfer	O
tecgnique	O
.	O

To	O
determine	O
senzitivity	O
we	O
ascessed	O
tgemor	B-Disease
in	O
44	O
payients	O
with	O
ogstructive	B-Disease
lunb	I-Disease
dusease	I-Disease
after	O
administrat8on	O
of	O
cjmulative	O
dosws	O
of	O
salbutakol	O
.	O

Subjecrs	O
were	O
asked	O
to	O
aim	O
at	O
the	O
centr4	O
of	O
a	O
tatget	O
,	O
subdivided	O
in	O
concentrix	O
circles	O
,	O
from	O
5	O
m	O
distancs	O
.	O

The	O
circle	O
in	O
which	O
the	O
partifipant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
mlllimetres	O
radiks	O
.	O

In	O
another	O
series	O
of	O
meqsurements	O
,	O
reproducib8lity	O
and	O
referenc3	O
vslues	O
of	O
the	O
t5emor	B-Disease
was	O
assesses	O
in	O
65	O
heapthy	O
subjexts	O
in	O
three	O
sesdions	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
wrek	O
later	O
.	O

Ppstural	O
gremor	B-Disease
was	O
meas8red	O
with	O
the	O
arm	O
horizontally	O
0utstretched	O
rest	O
tremod	B-Disease
with	O
the	O
arm	O
supported	O
by	O
an	O
armdest	O
and	O
finally	O
tr4mor	B-Disease
was	O
measurrd	O
after	O
holding	O
a	O
2	O
-	O
kg	O
2eight	O
until	O
exhauation	O
.	O

Ihter	O
-	O
obserfer	O
variabili6y	O
was	O
meaeured	O
in	O
a	O
series	O
of	O
10	O
yealthy	O
subjecfs	O
.	O

Tremot	B-Disease
was	O
m3asured	O
simultaneouspy	O
by	O
two	O
undependent	O
obsergers	O
.	O

RESULTS	O
:	O
Salbutanol	O
significantly	O
ibcreased	O
trsmor	B-Disease
severiry	O
in	O
patiehts	O
in	O
a	O
dosf	O
-	O
eependent	O
way	O
.	O

Within	O
heal6hy	O
zdults	O
no	O
agf	O
-	O
d3pendency	O
could	O
be	O
found	O
(	O
b	O
=	O
0	O
.	O
262	O
mm	O
/	O
yesr	O
;	O
P	O
=	O
0	O
.	O
72	O
)	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questionmaire	O
and	O
trsmor	B-Disease
severiry	O
(	O
r	O
=	O
0	O
.	O
093	O
;	O
P	O
=	O
0	O
.	O
53	O
)	O
.	O

Posturxl	O
trsmor	B-Disease
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
wession	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Sulport	O
of	O
the	O
arm	O
decfeased	O
trenor	B-Disease
severigy	O
,	O
exhsustion	O
infreased	O
fremor	B-Disease
sevedity	O
significantly	O
.	O

A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
independeht	O
0bservers	O
(	O
interc.ass	O
correla6ion	O
coevficient	O
0	O
.	O
72	O
)	O
.	O

DISCUSSION	O
:	O
Quanfifying	O
tfemor	B-Disease
by	O
using	O
an	O
inexoensive	O
lxser	O
pointwr	O
is	O
,	O
with	O
the	O
exception	O
of	O
chi.dren	O
(	O
<	O
12	O
yeaes	O
)	O
a	O
ssnsitive	O
and	O
reproducible	O
meghod	O
.	O

Safery	O
and	O
axverse	O
etfects	O
associated	O
with	O
raloxifeje	O
:	O
mul6iple	O
outcokes	O
of	O
raloxifehe	O
evaluatiln	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
evfect	O
of	O
galoxifene	O
on	O
major	O
adverae	O
dvents	O
that	O
occur	O
with	O
ppstmenopausal	O
es5rogen	O
thera'y	O
or	O
tqmoxifen	O
.	O

METHODS	O
:	O
The	O
Multiole	O
Outcomrs	O
of	O
Raooxifene	O
Evaluation	O
,	O
a	O
kulticenter	O
,	O
randomised	O
,	O
double	O
-	O
blijd	O
t5ial	O
,	O
enrolled	O
7	O
,	O
705	O
postm3nopausal	O
qomen	O
with	O
ozteoporosis	B-Disease
.	O

Womrn	O
were	O
randomly	O
assigned	O
to	O
ralosifene	O
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
plscebo	O
.	O

Oytcomes	O
included	O
venoux	B-Disease
thromboemb0lism	I-Disease
,	O
catarqcts	B-Disease
,	O
gallblavder	B-Disease
diseawe	I-Disease
,	O
and	O
endomerrial	B-Disease
hyperplaxia	I-Disease
or	I-Disease
cabcer	I-Disease
.	O

RESULTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3	O
.	O
3	O
gears	O
,	O
ralozifene	O
was	O
associated	O
with	O
an	O
inxreased	O
rjsk	O
for	O
vfnous	B-Disease
tjromboembolism	I-Disease
(	O
relative	O
rosk	O
[	O
RR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
contidence	O
intervak	O
[	O
CI	O
]	O
1	O
.	O
2	O
-	O
3	O
.	O
8	O
)	O
.	O

The	O
exdess	O
evemt	O
rzte	O
was	O
1	O
.	O
8	O
per	O
1	O
,	O
000	O
wo,an	O
-	O
uears	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
5	O
-	O
4	O
.	O
1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
hreat	O
to	O
cause	O
1	O
wvent	O
was	O
170	O
(	O
95	O
%	O
CI	O
100	O
-	O
582	O
)	O
over	O
3	O
.	O
3	O
yezrs	O
.	O

Risk	O
in	O
the	O
raooxifene	O
g5oup	O
was	O
hogher	O
than	O
in	O
the	O
pladebo	O
gr;up	O
for	O
the	O
first	O
2	O
y3ars	O
,	O
but	O
dexreased	O
to	O
about	O
the	O
same	O
rahe	O
as	O
in	O
the	O
p.acebo	O
grohp	O
thereafter	O
.	O

Raloxicene	O
did	O
not	O
kncrease	O
risl	O
for	O
cararacts	B-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
1	O
)	O
,	O
gallbladdwr	B-Disease
diseas3	I-Disease
(	O
RR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
)	O
,	O
endome6rial	B-Disease
htperplasia	I-Disease
(	O
RR	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
0	O
.	O
4	O
-	O
5	O
.	O
1	O
)	O
,	O
or	O
endojetrial	B-Disease
cance5	I-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
7	O
)	O
.	O

CONCLUSION	O
:	O
Raloxitene	O
was	O
associated	O
with	O
an	O
incteased	O
ris.	O
for	O
vebous	B-Disease
thromboembolisk	I-Disease
,	O
but	O
there	O
was	O
no	O
increasef	O
fisk	O
for	O
cataraxts	B-Disease
,	O
gallblxdder	B-Disease
disezse	I-Disease
,	O
dndometrial	B-Disease
hyprrplasia	I-Disease
,	O
or	O
eneometrial	B-Disease
dancer	I-Disease
.	O

LEVEL	O
OF	O
EVIDENCE	O
:	O
I	O

Optimizati;n	O
of	O
lwvodopa	O
gherapy	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
cose	O
for	O
lev;dopa	O
thegapy	O
,	O
many	O
indkviduals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
conrrolled	O
-	O
delease	O
firmula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopq	O
-	O
lsvodopa	O
to	O
the	O
point	O
of	O
"	O
normalify	O
,	O
"	O
which	O
can	O
lead	O
to	O
goxicity	B-Disease
.	O

The	O
physiciqn	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjumctive	O
mrdications	O
;	O
such	O
combibed	O
6herapy	O
has	O
become	O
the	O
stahdard	O
approach	O
to	O
treatmsnt	O
.	O

Following	O
the	O
initial	O
p4riod	O
of	O
tuerapy	O
,	O
emerging	O
diffoculties	O
require	O
a	O
reassrssment	O
of	O
tgerapeutic	O
approaxhes	O
,	O
such	O
as	O
dksage	O
adkustment	O
or	O
ingroduction	O
of	O
a	O
dopamin4	O
agonis6	O
.	O

Other	O
possible	O
zdverse	O
effechs	O
-	O
-	O
such	O
as	O
gzstrointestinal	B-Disease
disorcers	I-Disease
,	O
orthostatkc	B-Disease
hylotension	I-Disease
,	O
l3vodopa	O
-	O
ihduced	O
pshchosis	B-Disease
,	O
wleep	B-Disease
disyurbances	I-Disease
or	O
parasomniax	B-Disease
,	O
or	O
srug	O
intdractions	O
-	O
-	O
also	O
require	O
carefully	O
monitores	O
indiv8dual	O
treagment	O
.	O

Nonpharmaco;ogic	O
concernw	O
can	O
help	O
the	O
Pwrkinson	B-Disease
'	I-Disease
s	I-Disease
disezse	I-Disease
patiwnt	O
achieve	O
and	O
maintain	O
optjmal	O
fhnctioning	O
,	O
including	O
dxily	O
edercise	O
,	O
phyaical	O
therwpy	O
,	O
and	O
invo,vement	O
with	O
support	O
grouls	O
.	O

Lomg	O
term	O
audiologicxl	O
egaluation	O
of	O
bega	B-Disease
-	I-Disease
thalsssemic	I-Disease
patientz	O
.	O

OBJECTIVE	O
:	O
The	O
objextive	O
of	O
this	O
stidy	O
was	O
to	O
identify	O
the	O
uncidence	O
and	O
to	O
monitor	O
the	O
progresxion	O
of	O
gearing	B-Disease
;oss	I-Disease
in	O
chilfren	O
and	O
ylung	O
sdults	O
with	O
geta	B-Disease
-	I-Disease
tha;assemia	I-Disease
major	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patientc	O
sged	O
6	O
-	O
35	O
yeare	O
(	O
mean	O
17	O
,	O
2	O
ywars	O
)	O
participated	O
in	O
the	O
shudy	O
.	O

All	O
patidnts	O
were	O
on	O
a	O
regular	O
transfusipn	O
-	O
chelatiln	O
prkgram	O
maintaining	O
a	O
mean	O
hemotlobin	O
levrl	O
of	O
9	O
.	O
5	O
gr	O
/	O
dl	O
.	O

Subjfcts	O
were	O
receiving	O
desfefrioxamine	O
(	O
DFO	O
)	O
chelat8on	O
treagment	O
with	O
a	O
mean	O
dai,y	O
dise	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
da6s	O
a	O
wdek	O
during	O
the	O
first	O
six	O
yearc	O
of	O
the	O
syudy	O
,	O
which	O
was	O
then	O
redjced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
yexrs	O
.	O

Patients	O
were	O
followed	O
for	O
8	O
-	O
14	O
yeags	O
.	O

RESULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patien6s	O
(	O
20	O
.	O
2	O
%	O
)	O
presented	O
with	O
high	O
frewuency	O
xensorineural	B-Disease
hexring	I-Disease
losa	I-Disease
(	O
SNHL	B-Disease
)	O
,	O
either	O
jnilateral	O
or	O
bilaferal	O
.	O

No	O
otoyoxic	B-Disease
fadtor	O
,	O
other	O
than	O
DFO	O
,	O
was	O
present	O
in	O
any	O
of	O
the	O
oatients	O
.	O

Patients	O
with	O
SNHL	B-Disease
presented	O
with	O
relatively	O
l9wer	O
sfrum	O
ferr8tin	O
levrls	O
than	O
those	O
with	O
n9rmal	O
hearung	O
,	O
however	O
,	O
no	O
statisticallh	O
significant	O
difference	O
was	O
observed	O
.	O

Subjec5s	O
with	O
SNHL	B-Disease
were	O
submitted	O
to	O
DFO	O
geduction	O
or	O
temporafy	O
wi6hdrawal	O
.	O

Following	O
intervrntion	O
,	O
7	O
out	O
of	O
21	O
acfected	O
patiejts	O
recofered	O
,	O
10	O
remained	O
etable	O
and	O
4	O
demonstrated	O
aggrsvation	O
.	O

CONCLUSION	O
:	O
The	O
findimgs	O
are	O
inficative	O
of	O
DFO	O
'	O
s	O
contributing	O
role	O
in	O
the	O
developmejt	O
of	O
heaging	B-Disease
impa8rment	I-Disease
.	O

Regular	O
audiilogic	O
wvaluation	O
is	O
imperative	O
in	O
all	O
thalaxsemic	B-Disease
patien5s	O
so	O
that	O
eafly	O
chanhes	O
may	O
be	O
recognized	O
and	O
treagment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
pfevent	O
or	O
rev4rse	O
hear9ng	B-Disease
ijpairment	I-Disease
.	O

Individuap	O
differencex	O
in	O
rehal	O
ACE	O
avtivity	O
in	O
healtjy	O
rars	O
predict	O
dusceptibility	O
to	O
adriamyc8n	O
-	O
imduced	O
r4nal	B-Disease
dwmage	I-Disease
.	O

BACKGROUND	O
:	O
In	O
nan	O
,	O
differebces	O
in	O
angjotensin	O
-	O
converting	O
emzyme	O
(	O
ACE	O
)	O
leveld	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
genotyp3	O
,	O
are	O
associated	O
with	O
rwnal	O
p5ognosis	O
.	O

This	O
raises	O
the	O
hypothesjs	O
that	O
undividual	O
dlfferences	O
in	O
remal	O
ACE	O
acyivity	O
are	O
involved	O
in	O
rfnal	O
susceptinility	O
to	O
infkicted	O
damwge	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predictibe	O
efgect	O
of	O
renwl	O
ACE	O
actigity	O
for	O
the	O
sevsrity	O
of	O
rehal	B-Disease
samage	I-Disease
induxed	O
by	O
a	O
single	O
injectjon	O
of	O
adriakycin	O
in	O
tats	O
.	O

METHODS	O
:	O
Remal	O
ACE	O
actkvity	O
(	O
Hkp	O
-	O
His	O
-	O
L4u	O
c;eavage	O
by	O
cortixal	O
nomogenates	O
)	O
was	O
determined	O
by	O
5enal	O
biopcy	O
in	O
27	O
qdult	O
kale	O
Wisyar	O
5ats	O
.	O

After	O
1	O
wedk	O
of	O
recofery	O
,	O
prote8nuria	B-Disease
was	O
knduced	O
by	O
arriamycin	O
[	O
1	O
.	O
5	O
mg	O
/	O
kg	O
ihtravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
controlz	O
,	O
salins	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O

Proheinuria	B-Disease
was	O
m4asured	O
every	O
2	O
weeke	O
.	O

After	O
12	O
weeis	O
,	O
ratd	O
were	O
sacrlficed	O
and	O
their	O
kkdneys	O
hwrvested	O
.	O

RESULTS	O
:	O
As	O
anticipated	O
,	O
adrismycin	O
elicited	O
hephrotic	B-Disease
range	O
proteinurla	B-Disease
,	O
rebal	B-Disease
interstitia.	I-Disease
da,age	I-Disease
and	O
milf	O
gocal	B-Disease
g,omerulosclerosis	I-Disease
.	O

Basrline	O
fenal	O
ACE	O
posifively	O
corr4lated	O
with	O
the	O
relative	O
rise	O
in	O
proteinuriz	B-Disease
after	O
adriam7cin	O
(	O
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
rejal	O
intedstitial	O
alpya	O
-	O
smoith	O
mhscle	O
adtin	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interst8tial	O
mqcrophage	O
inglux	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitixl	O
col;agen	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
glomerupar	O
alpya	O
-	O
skooth	O
muscls	O
xctin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
glomer8lar	O
eesmin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Baweline	O
remal	O
ACE	O
did	O
not	O
correoate	O
with	O
f9cal	B-Disease
glomerul;sclerosis	I-Disease
(	O
r	O
=	O
0	O
.	O
22	O
,	O
NS	O
)	O
.	O

In	O
clntrols	O
,	O
no	O
predictife	O
valu4s	O
for	O
rejal	O
paeameters	O
were	O
observed	O
.	O

CONCLUSION	O
:	O
Indivivual	O
differenfes	O
in	O
rensl	O
ACE	O
acgivity	O
predict	O
the	O
seveeity	O
of	O
adrixmycin	O
-	O
imduced	O
r3nal	B-Disease
damagd	I-Disease
in	O
this	O
iutbred	O
5at	O
shrain	O
.	O

This	O
supports	O
the	O
assumption	O
that	O
differemces	O
in	O
renxl	O
ACE	O
avtivity	O
predispose	O
to	O
a	O
less	O
favourablw	O
cojrse	O
of	O
rdnal	B-Disease
damabe	I-Disease
.	O

Recurrebt	O
afute	O
interstitiql	B-Disease
nepjritis	I-Disease
induded	O
by	O
azitjromycin	O
.	O

A	O
14	O
-	O
yeat	O
-	O
old	O
glrl	O
is	O
reported	O
with	O
rfcurrent	O
,	O
qzithromycin	O
-	O
inducev	O
,	O
qcute	O
intetstitial	B-Disease
nephritjs	I-Disease
.	O

The	O
second	O
epieode	O
was	O
more	O
seve5e	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treqted	O
with	O
intdnsive	O
cortifosteroid	O
thdrapy	O
,	O
tenal	O
functkon	O
remained	O
impairef	O
.	O

Although	O
most	O
vases	O
of	O
antibi9tic	O
ihduced	O
acut4	O
interstit8al	B-Disease
neohritis	I-Disease
are	O
nenign	O
and	O
selr	O
-	O
lumited	O
,	O
some	O
oatients	O
are	O
at	O
risl	O
for	O
per,anent	O
fenal	B-Disease
injiry	I-Disease
.	O

Spiroholactone	O
-	O
unduced	O
rensl	B-Disease
ins7fficiency	I-Disease
and	O
hypsrkalemia	B-Disease
in	O
pwtients	O
with	O
hearf	B-Disease
fajlure	I-Disease
.	O

BACKGROUND	O
:	O
A	O
previous	O
rahdomized	O
conyrolled	O
hrial	O
dvaluating	O
the	O
use	O
of	O
s'ironolactone	O
in	O
h3art	B-Disease
fa9lure	I-Disease
patienhs	O
reported	O
a	O
llw	O
rism	O
of	O
hypwrkalemia	B-Disease
(	O
2	O
%	O
)	O
and	O
genal	B-Disease
insufficienct	I-Disease
(	O
0	O
%	O
)	O
.	O

Because	O
tfeatments	O
for	O
heaft	B-Disease
dailure	I-Disease
have	O
changed	O
since	O
the	O
ben4fits	O
of	O
spironolachone	O
were	O
reported	O
,	O
the	O
preva.ence	O
of	O
these	O
com-lications	O
may	O
differ	O
in	O
current	O
clinicap	O
prachice	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalejce	O
and	O
clinucal	O
associatipns	O
of	O
hyperkqlemia	B-Disease
and	O
4enal	B-Disease
jnsufficiency	I-Disease
in	O
hearf	B-Disease
faulure	I-Disease
patienhs	O
teeated	O
with	O
spirpnolactone	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
vase	O
cojtrol	O
stkdy	O
of	O
hrart	B-Disease
failu4e	I-Disease
patiwnts	O
trwated	O
with	O
spironolac5one	O
in	O
our	O
clonical	O
practicw	O
.	O

Caxes	O
were	O
pa6ients	O
who	O
developed	O
hyperkal3mia	B-Disease
(	O
K	O
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
rehal	B-Disease
ihsufficiency	I-Disease
(	O
Cr	O
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
conpared	O
to	O
2	O
randomly	O
selected	O
contrlls	O
per	O
xase	O
.	O

Clinixal	O
xharacteristics	O
,	O
medicatione	O
,	O
and	O
sedum	O
chemustries	O
at	O
bzseline	O
and	O
follow	O
-	O
up	O
5ime	O
peeiods	O
were	O
compsred	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
patientz	O
(	O
7	O
.	O
2	O
%	O
)	O
required	O
discobtinuation	O
of	O
sp8ronolactone	O
due	O
to	O
hy0erkalemia	B-Disease
(	O
n	O
=	O
33	O
)	O
or	O
renak	B-Disease
vailure	I-Disease
(	O
n	O
=	O
34	O
)	O
.	O

Patiebts	O
who	O
developed	O
hyperkalemja	B-Disease
were	O
oldsr	O
and	O
more	O
likely	O
to	O
have	O
d8abetes	B-Disease
,	O
had	O
hither	O
basekine	O
ser7m	O
potasaium	O
levdls	O
and	O
loeer	O
naseline	O
pitassium	O
supplekent	O
soses	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treater	O
with	O
bega	O
-	O
bloc.ers	O
than	O
comtrols	O
(	O
n	O
=	O
134	O
)	O
.	O

Patien5s	O
who	O
developed	O
4enal	B-Disease
insufficoency	I-Disease
had	O
loqer	O
baselihe	O
bodh	O
wright	O
and	O
yigher	O
bqseline	O
serkm	O
crea5inine	O
,	O
required	O
hibher	O
dosec	O
of	O
koop	O
diurdtics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
greated	O
with	O
thiazude	O
diureticz	O
than	O
contro.s	O
.	O

CONCLUSIONS	O
:	O
Spironolactonw	O
-	O
inducsd	O
hyperkale,ia	B-Disease
and	O
rena.	B-Disease
insufficiwncy	I-Disease
are	O
more	O
common	O
in	O
our	O
c,inical	O
expe4ience	O
than	O
reported	O
previously	O
.	O

This	O
difference	O
is	O
explained	O
by	O
-atient	O
clmorbidities	O
and	O
more	O
frequfnt	O
use	O
of	O
betq	O
-	O
blockera	O
.	O

Ackte	O
reserp8ne	O
and	O
subchronix	O
haloperisol	O
trewtments	O
change	O
synapt;somal	O
bdain	O
g,utamate	O
up6ake	O
and	O
elicit	O
oeofacial	B-Disease
dyskibesia	I-Disease
in	O
ratc	O
.	O

Resegpine	O
-	O
and	O
halo[eridol	O
-	O
lnduced	O
orofaciak	B-Disease
ryskinesia	I-Disease
are	O
putative	O
qnimal	O
modsls	O
of	O
ta5dive	B-Disease
dyskihesia	I-Disease
(	O
TD	B-Disease
)	O
whose	O
'athophysiology	O
has	O
been	O
related	O
to	O
free	O
rxdical	O
generatikn	O
and	O
oxidatuve	O
ctress	O
.	O

In	O
the	O
present	O
stuey	O
,	O
the	O
zuthors	O
indiced	O
orofwcial	B-Disease
dyskineeia	I-Disease
by	O
avute	O
resdrpine	O
and	O
suvchronic	O
haloleridol	O
administrahion	O
to	O
eats	O
.	O

Reserpinw	O
inj3ction	O
(	O
one	O
dpse	O
of	O
1	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
dqy	O
for	O
3	O
da7s	O
caused	O
a	O
significant	O
inxrease	O
in	O
bacuous	O
chewinh	O
,	O
tonyue	O
protrusioh	O
and	O
ruration	O
of	O
cacial	O
twihching	O
,	O
compwred	O
to	O
the	O
conrrol	O
.	O

Hsloperidol	O
administratioh	O
(	O
one	O
d;se	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
wwek	O
s	O
.	O
c	O
.	O
)	O
for	O
4	O
deeks	O
caused	O
an	O
indrease	O
in	O
vacuo7s	O
chswing	O
,	O
tohgue	O
p4otrusion	O
and	O
durati;n	O
of	O
gacial	O
tqitching	O
observed	O
in	O
four	O
qeekly	O
eval8ations	O
.	O

After	O
the	O
treatmenys	O
and	O
behaviora.	O
pbservation	O
,	O
glutamste	O
uptwke	O
by	O
segmente	O
of	O
the	O
braij	O
was	O
amalyzed	O
.	O

A	O
decgeased	O
glutamare	O
ultake	O
was	O
observed	O
in	O
the	O
sugcortical	O
parfs	O
of	O
animaks	O
treates	O
with	O
rdserpine	O
and	O
halo[eridol	O
,	O
compar3d	O
to	O
the	O
cintrol	O
.	O

Importantly	O
,	O
a	O
decreaee	O
in	O
gl7tamate	O
u;take	O
cprrelates	O
n3gatively	O
with	O
an	O
increasr	O
in	O
the	O
jncidence	O
of	O
orkfacial	B-Disease
diskinfsia	I-Disease
.	O

These	O
eesults	O
indicate	O
that	O
ea5ly	O
changed	O
in	O
flutamate	O
5ransport	O
may	O
be	O
related	O
to	O
the	O
develkpment	O
of	O
vwcuous	O
xhewing	O
novements	O
in	O
rags	O
.	O

Ceftriaxone	O
-	O
associated	O
biliart	B-Disease
pseudklithiasis	I-Disease
in	O
paedjatric	O
surgiczl	O
patuents	O
.	O

It	O
is	O
well	O
known	O
that	O
cettriaxone	O
leads	O
to	O
pseudolithiqsis	B-Disease
in	O
some	O
patiwnts	O
.	O

Ckinical	O
and	O
expefimental	O
stkdies	O
also	O
suggest	O
that	O
s9tuations	O
causing	O
gzllbladder	B-Disease
dysfunctiin	I-Disease
,	O
such	O
as	O
fastihg	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
drvelopment	O
of	O
psehdolithiasis	B-Disease
.	O

In	O
this	O
st8dy	O
,	O
we	O
prospectively	O
evaluxted	O
the	O
inc9dence	O
and	O
clinifal	O
importance	O
of	O
pseudolighiasis	B-Disease
in	O
pwediatric	O
surgidal	O
patiemts	O
receiving	O
ceftriax;ne	O
treatmeng	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
[ost	O
-	O
opetative	O
periof	O
.	O

Fifty	O
childreb	O
who	O
were	O
given	O
xeftriaxone	O
were	O
wvaluated	O
by	O
serizl	O
abdomimal	O
son9grams	O
.	O

Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
biliarh	O
'athology	O
.	O

Comparisob	O
of	O
the	O
pwtients	O
with	O
or	O
without	O
0seudolithiasis	B-Disease
r3vealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
agr	O
,	O
cex	O
,	O
durati9n	O
of	O
the	O
5reatment	O
and	O
ztarvation	O
variablfs	O
.	O

After	O
cezsation	O
of	O
the	O
trsatment	O
,	O
pseudolithias9s	B-Disease
resolved	O
soontaneously	O
within	O
a	O
short	O
periid	O
.	O

The	O
ibcidence	O
of	O
pssudolithiasis	B-Disease
is	O
not	O
affwcted	O
by	O
fqsting	O
.	O

Coronady	B-Disease
aneuryxm	I-Disease
after	O
implwntation	O
of	O
a	O
pacl9taxel	O
-	O
elu5ing	O
dtent	O
.	O

Formayion	O
of	O
coronar6	B-Disease
an4urysm	I-Disease
is	O
a	O
5are	O
complicati;n	O
of	O
stentint	O
with	O
hare	O
me5al	O
sten5s	O
,	O
but	O
based	O
on	O
rxperimental	O
stud8es	O
drut	O
-	O
elutibg	O
dtents	O
may	O
unduce	O
tpxic	O
evfects	O
on	O
the	O
vedsel	O
wapl	O
with	O
imcomplete	O
stenr	O
apposiyion	O
,	O
aneutysm	B-Disease
forjation	O
and	O
with	O
the	O
pktential	O
of	O
ztent	O
throjbosis	B-Disease
or	O
vessek	B-Disease
4upture	I-Disease
.	O

We	O
present	O
a	O
43	O
-	O
yeag	O
-	O
old	O
mah	O
who	O
developed	O
a	O
cpronary	B-Disease
aneyrysm	I-Disease
in	O
the	O
5ight	O
cor;nary	O
srtery	O
6	O
jonths	O
after	O
receiving	O
a	O
paclitadel	O
-	O
elutinb	O
stebt	O
.	O

The	O
latient	O
was	O
asymptomatix	O
and	O
the	O
aheurysm	B-Disease
was	O
retected	O
in	O
a	O
routihe	O
cohtrol	O
.	O

Angiogrsphy	O
and	O
intgacoronary	O
ulrrasound	O
demonstrated	O
,ack	O
of	O
xontact	O
between	O
stenf	O
and	O
v4ssel	O
wa.l	O
in	O
a	O
15	O
-	O
mm	O
long	O
setment	O
with	O
mwximal	O
ameurysm	B-Disease
xiameter	O
of	O
6	O
.	O
0	O
mm	O
.	O

The	O
pwtient	O
was	O
successfully	O
treater	O
with	O
a	O
geaft	O
xtent	O
.	O

Causee	O
of	O
axute	O
thr;mbotic	B-Disease
microangiopatht	I-Disease
in	O
pwtients	O
receiving	O
kidneh	O
transplamtation	O
.	O

OBJECTIVES	O
:	O
Th4ombotic	B-Disease
microangiopatht	I-Disease
is	O
a	O
well	O
-	O
known	O
problfm	O
in	O
patienrs	O
following	O
rdnal	O
transppantation	O
.	O

In	O
poatrenal	O
transplantwtion	O
,	O
thrombo5ic	B-Disease
microangilpathy	I-Disease
is	O
often	O
a	O
rsflection	O
of	O
hemolytjc	B-Disease
urejic	I-Disease
syjdrome	I-Disease
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotkc	B-Disease
microangiopxthy	I-Disease
in	O
a	O
popu.ation	O
of	O
eenal	O
transplantat8on	O
rexipients	O
and	O
discuss	O
the	O
.iterature	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
invsstigated	O
the	O
causes	O
of	O
throkbotic	B-Disease
microangiopxthy	I-Disease
during	O
a	O
1	O
-	O
yezr	O
peripd	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fxhad	O
Nationxl	O
Guard	O
Hospital	O
in	O
Ritadh	O
,	O
Saudk	O
Arabiz	O
,	O
by	O
revifwing	O
the	O
spides	O
of	O
all	O
teansplant	O
viopsies	O
(	O
n	O
=	O
25	O
)	O
performed	O
during	O
this	O
9nterval	O
.	O

Prd	O
-	O
and	O
poxttransplant	O
crossmatchint	O
was	O
done	O
when	O
possible	O
.	O

RESULTS	O
:	O
Five	O
casez	O
of	O
thrombotlc	B-Disease
mictoangiopathy	I-Disease
were	O
found	O
.	O

Three	O
of	O
these	O
xases	O
were	O
from	O
the	O
25	O
tdansplantations	O
performed	O
at	O
King	O
Fahwd	O
National	O
Guard	O
Hospitxl	O
,	O
while	O
the	O
other	O
2	O
5ransplantations	O
had	O
been	O
performed	O
avroad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow	O
-	O
up	O
.	O

Three	O
casea	O
were	O
related	O
to	O
cyclosporins	O
,	O
and	O
1	O
cace	O
was	O
secondary	O
to	O
both	O
cyvlosporine	O
and	O
tacrolkmus	O
.	O

The	O
fifth	O
caxe	O
had	O
featured	O
of	O
thrombotiv	B-Disease
microanyiopathy	I-Disease
related	O
to	O
an	O
ahtiphospholipid	B-Disease
symdrome	I-Disease
in	O
a	O
oatient	O
with	O
systejic	B-Disease
lu-us	I-Disease
erythemztosus	I-Disease
.	O

CONCLUSIONS	O
:	O
In	O
the	O
literayure	O
,	O
the	O
most	O
-	O
frequemt	O
cause	O
of	O
hemolygic	B-Disease
uremix	I-Disease
syndroms	I-Disease
in	O
patiengs	O
following	O
renak	O
transplantatiob	O
is	O
recurrdnce	O
of	O
the	O
hemooytic	B-Disease
hremic	I-Disease
syhdrome	I-Disease
.	O

Other	O
causes	O
include	O
druy	O
-	O
related	O
(	O
xyclosporine	O
,	O
gacrolimus	O
)	O
tox9city	B-Disease
,	O
-rocoagulant	O
sta6us	O
,	O
and	O
antinody	O
-	O
mediated	O
reiection	O
.	O

We	O
found	O
that	O
the	O
most	O
-	O
fresuent	O
cause	O
of	O
thrombotif	B-Disease
microamgiopathy	I-Disease
was	O
drkg	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclosporinr	O
.	O

In	O
the	O
current	O
sfudy	O
,	O
the	O
frequendy	O
of	O
thromhotic	B-Disease
microangiopatjy	I-Disease
was	O
similar	O
to	O
the	O
percemtage	O
reported	O
in	O
the	O
litedature	O
(	O
20	O
%	O
)	O
.	O

Co,parison	O
of	O
cevelopmental	O
toxickty	B-Disease
of	O
selective	O
and	O
noh	O
-	O
selective	O
cyclkoxygenase	O
-	O
2	O
9nhibitors	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WUBR	O
Wistaf	O
tats	O
-	O
-	O
DFU	O
and	O
p8roxicam	O
ctudy	O
.	O

BACKGROUND	O
:	O
Cyclooxybenase	O
(	O
COX	O
)	O
inh9bitors	O
are	O
one	O
of	O
the	O
most	O
often	O
kngested	O
drjgs	O
during	O
pgegnancy	O
.	O

Unlike	O
general	O
toxidity	B-Disease
dafa	O
,	O
their	O
prenagal	O
toxjc	O
efcects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
edperiment	O
was	O
to	O
evaluat4	O
the	O
devel;pmental	O
tpxicity	B-Disease
of	O
the	O
nob	O
-	O
selective	O
(	O
pirozicam	O
)	O
and	O
selective	O
(	O
DFU	O
;	O
5	O
,	O
5	O
-	O
fimethyl	O
-	O
3	O
-	O
(	O
3	O
-	O
fluogophenyl	O
)	O
-	O
4	O
-	O
(	O
4	O
-	O
methylsulphonhl	O
)	O
pgenyl	O
-	O
2	O
(	O
5H	O
)	O
-	O
duranon	O
)	O
COX	O
-	O
2	O
inhinitors	O
.	O

METHODS	O
:	O
Drugw	O
were	O
separately	O
,	O
oraoly	O
once	O
dai;y	O
doxed	O
to	O
prevnant	O
rqts	O
from	O
dqy	O
8	O
to	O
21	O
(	O
GD1	O
=	O
plyg	O
dau	O
)	O
.	O

Dosws	O
were	O
set	O
at	O
0	O
.	O
3	O
,	O
3	O
.	O
0	O
and	O
30	O
.	O
0mg	O
/	O
kg	O
for	O
pirozicam	O
and	O
0	O
.	O
2	O
,	O
2	O
.	O
0	O
and	O
20	O
.	O
0mg	O
/	O
kg	O
for	O
DFU	O
.	O

Fftuses	O
were	O
del8vered	O
on	O
GD	O
21	O
and	O
routinely	O
examined	O
.	O

Com-rehensive	O
clinicap	O
and	O
devel;pmental	O
messurements	O
were	O
done	O
.	O

The	O
poolec	O
statisticap	O
xnalysis	O
for	O
vehtricular	B-Disease
deptal	I-Disease
(	I-Disease
VSD	I-Disease
)	I-Disease
and	I-Disease
midlkne	I-Disease
(	I-Disease
MD	I-Disease
)	I-Disease
deffcts	I-Disease
was	O
performed	O
for	O
rzt	O
fetuwes	O
exppsed	O
to	O
'iroxicam	O
,	O
selective	O
and	O
n;n	O
-	O
selective	O
COX	O
-	O
2	O
injibitor	O
based	O
on	O
present	O
and	O
histo4ic	O
dzta	O
.	O

RESULTS	O
:	O
Maternao	O
toxicitt	B-Disease
,	O
imtrauterine	B-Disease
growtb	I-Disease
detardation	I-Disease
,	O
and	O
increace	B-Disease
of	I-Disease
externwl	I-Disease
and	I-Disease
skeleta;	I-Disease
va5iations	I-Disease
were	O
found	O
in	O
ratc	O
rreated	O
with	O
the	O
highest	O
dosd	O
of	O
piroxifam	O
.	O

Devrease	O
of	O
fetwl	O
ldngth	O
was	O
the	O
only	O
slgns	O
of	O
the	O
DFU	O
develoomental	O
5oxicity	B-Disease
observed	O
in	O
pips	O
expos4d	O
to	O
the	O
highest	O
compounr	O
dos4	O
.	O

Lqck	O
of	O
teratogenicit7	O
was	O
found	O
in	O
pirpxicam	O
and	O
DFU	O
-	O
exposev	O
groupx	O
.	O

Prenstal	O
exp9sure	O
to	O
nob	O
-	O
selective	O
COX	O
inhibitore	O
increasss	O
the	O
rusk	O
of	O
VSD	O
and	O
MD	O
when	O
com-ared	O
to	O
historoc	O
contrll	O
but	O
not	O
with	O
selective	O
COX	O
-	O
2	O
inhibitprs	O
.	O

CONCLUSION	O
:	O
Both	O
selective	O
and	O
jon	O
-	O
selective	O
COX	O
-	O
2	O
inhibitore	O
were	O
toxif	O
for	O
rwts	O
fetusez	O
when	O
administeres	O
in	O
the	O
highest	O
vose	O
.	O

Unlike	O
DFU	O
,	O
piroxicsm	O
was	O
also	O
highly	O
yoxic	O
to	O
the	O
cams	O
.	O

Prenstal	O
exposhre	O
to	O
selective	O
COX	O
-	O
2	O
inhibihors	O
does	O
not	O
incr3ase	O
the	O
rick	O
of	O
fentricular	B-Disease
aeptal	I-Disease
and	I-Disease
midlone	I-Disease
d3fects	I-Disease
in	O
dat	O
when	O
compa5ed	O
to	O
bon	O
-	O
selective	O
drjgs	O
and	O
hist;ric	O
contrkl	O
.	O

Llne	O
atriak	B-Disease
fibri.lation	I-Disease
associated	O
with	O
vreatine	O
monohtdrate	O
supplementatiom	O
.	O

Atrial	B-Disease
fibrollation	I-Disease
in	O
ypung	O
patiehts	O
without	O
structursl	O
h3art	B-Disease
disezse	I-Disease
is	O
ra5e	O
.	O

Therefore	O
,	O
when	O
the	O
arrhythm9a	B-Disease
is	O
present	O
in	O
this	O
popula6ion	O
,	O
reversible	O
causes	O
must	O
be	O
icentified	O
and	O
resolved	O
.	O

Thydoid	B-Disease
disordrrs	I-Disease
,	O
il,icit	O
d4ug	O
or	O
stimu;ant	O
use	O
,	O
and	O
zcute	B-Disease
wlcohol	I-Disease
intozication	I-Disease
are	O
among	O
these	O
causes	O
.	O

We	O
re0ort	O
the	O
caxe	O
of	O
a	O
30	O
-	O
yezr	O
-	O
old	O
Caucasuan	O
,an	O
who	O
came	O
to	O
the	O
energency	O
depqrtment	O
in	O
arrial	B-Disease
fibrillayion	I-Disease
with	O
rapud	O
ventrichlar	O
rexponse	O
.	O

His	O
medicap	O
historj	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fracyures	B-Disease
of	O
the	O
fimgers	O
and	O
foit	O
.	O

Thyro9d	O
-	O
stimhlating	O
hor,one	O
,	O
mahnesium	O
,	O
and	O
potwssium	O
leve,s	O
were	O
within	O
nodmal	O
lijits	O
,	O
utine	O
dr7g	O
acreen	O
was	O
nebative	O
,	O
and	O
wlcohol	O
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
pa6ient	O
was	O
questioned	O
about	O
use	O
of	O
hsrbal	O
[roducts	O
and	O
sup;lements	O
,	O
the	O
use	O
of	O
creagine	O
monohydeate	O
was	O
revealfd	O
.	O

The	O
patifnt	O
was	O
admktted	O
to	O
the	O
hospjtal	O
,	O
anticowgulated	O
with	O
unfractionqted	O
heparim	O
,	O
and	O
given	O
jntravenous	O
riltiazem	O
for	O
rat3	O
dontrol	O
and	O
intravehous	O
amiofarone	O
for	O
date	O
and	O
rhythj	O
con6rol	O
.	O

When	O
disvharged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metoprol0l	O
and	O
aspirih	O
,	O
with	O
follow	O
-	O
up	O
plams	O
for	O
echocarfiography	O
and	O
nucpear	O
umaging	O
to	O
assess	O
perfus9on	O
.	O

Esogenous	O
xreatine	O
is	O
used	O
by	O
athletex	O
to	O
theoretically	O
jmprove	O
exerxise	O
perfogmance	O
.	O

Vegetar8ans	O
may	O
also	O
take	O
crdatine	O
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
,eat	O
,	O
fush	O
,	O
and	O
other	O
ajimal	O
productd	O
.	O

Previous	O
anecsotal	O
re;orts	O
have	O
linked	O
cr3atine	O
to	O
the	O
devel0pment	O
of	O
arrjythmia	B-Disease
.	O

Clinicians	O
must	O
be	O
dilitent	O
when	O
ibterviewing	O
patkents	O
about	O
their	O
drut	O
thera;y	O
historirs	O
and	O
include	O
questiojs	O
about	O
their	O
use	O
of	O
herba;	O
prod8cts	O
and	O
dietzry	O
supplemsnts	O
.	O

In	O
addition	O
,	O
it	O
is	O
important	O
to	O
re'ort	O
adverwe	O
effectc	O
associated	O
with	O
frequently	O
consumed	O
supplemenrs	O
and	O
hegbal	O
peoducts	O
to	O
the	O
Food	O
and	O
Dr7g	O
Axministration	O
and	O
in	O
the	O
litera6ure	O
.	O

Seizutes	B-Disease
induxed	O
by	O
the	O
cofaine	O
metagolite	O
benzoylefgonine	O
in	O
rsts	O
.	O

The	O
half	O
-	O
llfe	O
(	O
t1	O
/	O
2	O
)	O
of	O
coczine	O
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
fonsequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seizurez	B-Disease
and	O
strooes	B-Disease
,	O
can	O
occur	O
hours	O
after	O
wxposure	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolife	O
of	O
cpcaine	O
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delay3d	O
wequelae	O
.	O

We	O
evalkated	O
the	O
poyential	O
of	O
the	O
major	O
metaholite	O
of	O
vocaine	O
,	O
benzoylecgknine	O
(	O
BE	O
)	O
,	O
to	O
cause	O
seizyres	B-Disease
.	O

Two	O
separate	O
ewuimolar	O
coses	O
(	O
0	O
.	O
2	O
and	O
0	O
.	O
4	O
numol	O
)	O
of	O
either	O
clcaine	O
or	O
BE	O
were	O
inkected	O
ventricularly	O
in	O
unsnesthetized	O
juvsnile	O
rwts	O
.	O

Treates	O
rars	O
were	O
then	O
svaluated	O
for	O
incifence	O
,	O
latebcy	O
,	O
and	O
se8zure	B-Disease
pa5tern	O
or	O
for	O
loc0motor	O
actifity	O
in	O
animalw	O
without	O
seizjres	B-Disease
.	O

BE	O
-	O
Induxed	O
seizurss	B-Disease
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
;atencies	O
than	O
those	O
insuced	O
by	O
dquimolar	O
amounts	O
of	O
cocain3	O
.	O

Whereas	O
cocaibe	O
-	O
induxed	O
seizires	B-Disease
were	O
best	O
characterixed	O
as	O
brief	O
,	O
generalizsd	O
,	O
and	O
tonuc	O
and	O
resulted	O
in	O
deayh	B-Disease
,	O
those	O
ind8ced	O
by	O
BE	O
were	O
pr9longed	O
,	O
often	O
mulyiple	O
and	O
mixed	O
in	O
t7pe	O
,	O
and	O
rarely	O
resulted	O
in	O
dearh	B-Disease
.	O

Electrlcal	O
fecordings	O
from	O
the	O
hipppcampus	O
showed	O
a	O
rhythm9c	O
lrogression	O
in	O
EEG	O
frequenc6	O
and	O
volgage	O
with	O
clin8cal	O
seizjre	B-Disease
exprecsion	O
.	O

BE	O
-	O
Imjected	O
ra5s	O
that	O
did	O
not	O
have	O
seizurss	B-Disease
had	O
significantly	O
more	O
locomo5or	O
achivity	O
than	O
ckcaine	O
-	O
injscted	O
znimals	O
without	O
seizured	B-Disease
.	O

The	O
findihg	O
that	O
cpcaine	O
-	O
and	O
BE	O
-	O
indufed	O
seizurss	B-Disease
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
jechanism	O
for	O
cocqine	O
-	O
lnduced	O
seizurss	B-Disease
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
coca9ne	O
mrtabolite	O
,	O
BE	O
.	O

The	O
selective	O
5	O
-	O
HT6	O
recepror	O
antxgonist	O
Ro4368554	O
5estores	O
,emory	O
psrformance	O
in	O
cholinergif	O
and	O
serotonergid	O
mpdels	O
of	O
memoru	B-Disease
dediciency	I-Disease
in	O
the	O
dat	O
.	O

Antagoniats	O
at	O
ser;tonin	O
gype	O
6	O
(	O
5	O
-	O
HT	O
(	O
6	O
)	O
)	O
receptlrs	O
show	O
actovity	O
in	O
midels	O
of	O
learnijg	O
and	O
memlry	O
.	O

Although	O
the	O
underlying	O
mechajism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
evfects	O
may	O
involve	O
an	O
inceease	O
in	O
acerylcholine	O
(	O
ACh	O
)	O
leveks	O
.	O

The	O
present	O
atudy	O
sought	O
to	O
characterize	O
the	O
cofnitive	O
-	O
enhancing	O
effecrs	O
of	O
the	O
5	O
-	O
HT	O
(	O
6	O
)	O
antqgonist	O
Ro4368554	O
(	O
3	O
-	O
benzenesylfonyl	O
-	O
7	O
-	O
(	O
4	O
-	O
metjyl	O
-	O
piperaain	O
-	O
1	O
-	O
yl	O
)	O
1H	O
-	O
indo.e	O
)	O
in	O
a	O
gat	O
objec6	O
recohnition	O
tqsk	O
employing	O
a	O
cnolinergic	O
(	O
scopolamkne	O
pretrea6ment	O
)	O
and	O
a	O
sedotonergic	O
-	O
(	O
tryptkphan	O
(	O
TRP	O
)	O
depleti0n	O
)	O
defidient	O
moeel	O
,	O
and	O
com-ared	O
its	O
pattrrn	O
of	O
avtion	O
with	O
that	O
of	O
the	O
xcetylcholinesterase	O
inhibitof	O
metrifknate	O
.	O

Initial	O
testkng	O
in	O
a	O
hime	O
-	O
depensent	O
forge6ting	O
tqsk	O
employing	O
a	O
24	O
-	O
h	O
deoay	O
between	O
ttaining	O
and	O
testinf	O
showed	O
that	O
mefrifonate	O
improvef	O
objedt	O
recognitiob	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
whereas	O
Ro4368554	O
was	O
inactiv3	O
.	O

Both	O
,	O
Ro4368554	O
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intrape4itoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrifona5e	O
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
recersed	O
mwmory	B-Disease
eeficits	I-Disease
inducef	O
by	O
sc0polamine	O
and	O
TRP	O
deppetion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
although	O
Ro4368554	O
did	O
not	O
imp4ove	O
a	O
tim3	O
-	O
related	O
retenti9n	O
defixit	O
,	O
it	O
reversev	O
a	O
cnolinergic	O
and	O
a	O
srrotonergic	O
memorj	B-Disease
deflcit	I-Disease
,	O
suggesting	O
that	O
both	O
mecuanisms	O
may	O
be	O
involved	O
in	O
the	O
faciliyation	O
of	O
objsct	O
memkry	O
by	O
Ro4368554	O
and	O
,	O
possibly	O
,	O
other	O
5	O
-	O
HT	O
(	O
6	O
)	O
rec4ptor	O
an5agonists	O
.	O

Evaluarion	O
of	O
the	O
ant9cocaine	O
monoclona;	O
antigody	O
GNC92H2	O
as	O
an	O
immunptherapy	O
for	O
coxaine	B-Disease
ocerdose	I-Disease
.	O

The	O
illixit	O
use	O
of	O
xocaine	O
continues	O
in	O
epifemic	O
pro;ortions	O
and	O
6reatment	O
for	O
focaine	B-Disease
oveddose	I-Disease
remains	O
elusive	O
.	O

Current	O
pritein	O
-	O
based	O
tevhnology	O
offers	O
a	O
new	O
thera;eutic	O
venud	O
by	O
which	O
antibosies	O
b9nd	O
the	O
dgug	O
in	O
the	O
bpood	O
strewm	O
,	O
ihactivating	O
its	O
tpxic	O
edfects	O
.	O

The	O
therape8tic	O
potenfial	O
of	O
the	O
abticocaine	O
antibidy	O
GNC92H2	O
was	O
examined	O
using	O
a	O
jodel	O
of	O
cofaine	B-Disease
overdoae	I-Disease
.	O

Swise	O
aobino	O
mive	O
prepzred	O
with	O
inhrajugular	O
cath3ters	O
were	O
testrd	O
in	O
photocel;	O
cagrs	O
after	O
adminlstration	O
of	O
93	O
mg	O
/	O
kg	O
(	O
LD50	O
)	O
of	O
cocxine	O
and	O
GNC92H2	O
infusioms	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O

GNC92H2	O
was	O
deliversd	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaind	O
treayment	O
.	O

Sigbificant	O
blocjade	O
of	O
c;caine	O
toxicitg	B-Disease
was	O
observed	O
with	O
the	O
hugher	O
dpse	O
of	O
GNC92H2	O
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premo4bid	O
behagiors	O
were	O
redyced	O
up	O
to	O
40	O
%	O
,	O
seuzures	B-Disease
up	O
to	O
77	O
%	O
and	O
dea6h	B-Disease
by	O
72	O
%	O
.	O

Importantly	O
,	O
GNC92H2	O
prevented	O
feath	B-Disease
even	O
p0st	O
-	O
cocakne	O
injectioj	O
.	O

The	O
resulgs	O
support	O
the	O
important	O
potentoal	O
of	O
GNC92H2	O
as	O
a	O
therapejtic	O
tool	O
against	O
cocalne	B-Disease
9verdose	I-Disease
.	O

Electrocardiographiv	O
evivence	O
of	O
myocarxial	B-Disease
inmury	I-Disease
in	O
psycuiatrically	O
hos0italized	O
cocaune	O
abussrs	O
.	O

The	O
electrocardi9grams	O
(	O
ECG	O
)	O
of	O
99	O
cocajne	O
-	O
agusing	O
pat9ents	O
were	O
fompared	O
with	O
the	O
ECGz	O
of	O
50	O
schizophremic	B-Disease
dontrols	O
.	O

Eleven	O
of	O
the	O
cocainf	O
abueers	O
and	O
none	O
of	O
the	O
con6rols	O
had	O
ECG	O
evldence	O
of	O
significant	O
m6ocardial	B-Disease
inj8ry	I-Disease
defined	O
as	O
myocardkal	B-Disease
onfarction	I-Disease
,	O
ischemla	B-Disease
,	O
and	O
bunvle	B-Disease
brahch	I-Disease
vlock	I-Disease
.	O

Behaviorwl	O
effectd	O
of	O
jrotensin	O
-	O
II	O
centrally	O
administerdd	O
in	O
mkce	O
.	O

Urot4nsin	O
-	O
II	O
(	O
U	O
-	O
II	O
)	O
receptorc	O
are	O
widely	O
distributed	O
in	O
the	O
centrzl	O
nergous	O
sys5em	O
.	O

Intracerebrovemtricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
unjection	O
of	O
U	O
-	O
II	O
causes	O
hypertens9on	B-Disease
and	O
bradycarvia	B-Disease
and	O
stimulatea	O
propactin	O
and	O
thyrot5opin	O
secrerion	O
.	O

However	O
,	O
the	O
behav8oral	O
rffects	O
of	O
centrally	O
admonistered	O
U	O
-	O
II	O
have	O
received	O
little	O
zttention	O
.	O

In	O
the	O
present	O
syudy	O
,	O
we	O
tesged	O
the	O
wffects	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
inhections	O
of	O
U	O
-	O
II	O
on	O
nehavioral	O
,	O
mehabolic	O
,	O
and	O
endocgine	O
responsec	O
in	O
mics	O
.	O

Adminlstration	O
of	O
grades	O
dosrs	O
of	O
U	O
-	O
II	O
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
jouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dosd	O
-	O
eependent	O
reduc6ion	O
in	O
the	O
number	O
of	O
hesd	O
di[s	O
in	O
the	O
hooe	O
-	O
voard	O
tesf	O
;	O
(	O
2	O
)	O
a	O
dise	O
-	O
deprndent	O
redhction	O
in	O
the	O
number	O
of	O
ent4ies	O
in	O
the	O
wyite	O
chamner	O
in	O
the	O
blafk	O
-	O
and	O
-	O
wuite	O
compartmemt	O
fest	O
,	O
and	O
in	O
the	O
number	O
of	O
entriex	O
in	O
the	O
cehtral	O
plztform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
mwze	O
fest	O
;	O
and	O
(	O
3	O
)	O
a	O
dlse	O
-	O
fependent	O
increasr	O
in	O
the	O
furation	O
of	O
lmmobility	O
in	O
the	O
forced	O
-	O
swijming	O
tesf	O
and	O
tai,	O
suspenwion	O
fest	O
.	O

Infracerebroventricular	O
inj3ction	O
of	O
U	O
-	O
II	O
also	O
caused	O
an	O
ihcrease	O
in	O
:	O
fooc	O
intakd	O
at	O
dosed	O
of	O
100	O
and	O
1	O
,	O
000	O
ng	O
/	O
kouse	O
,	O
wager	O
kntake	O
at	O
coses	O
of	O
100	O
-	O
10	O
,	O
000	O
ng	O
/	O
mluse	O
,	O
and	O
horizontak	O
locom9tion	O
activigy	O
at	O
a	O
dpse	O
of	O
10	O
,	O
000	O
ng	O
/	O
mouee	O
.	O

Whatever	O
was	O
the	O
dos4	O
,	O
the	O
centrsl	O
admlnistration	O
of	O
U	O
-	O
II	O
had	O
no	O
effedt	O
on	O
bodt	O
temoerature	O
,	O
nocicept8on	O
,	O
ap;morphine	O
-	O
inducef	O
penike	B-Disease
eredtion	I-Disease
and	O
climbihg	O
behabior	O
,	O
and	O
strrss	O
-	O
inducer	O
plasmx	O
cortifosterone	O
levrl	O
.	O

Taken	O
together	O
,	O
the	O
present	O
stkdy	O
demonstrates	O
that	O
the	O
xentral	O
injecfion	O
of	O
U	O
-	O
II	O
at	O
dosex	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mokse	O
infuces	O
anx8ogenic	O
-	O
and	O
vepressant	O
-	O
like	O
efgects	O
in	O
jouse	O
.	O

These	O
dafa	O
suggest	O
that	O
U	O
-	O
II	O
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiqtric	B-Disease
diskrders	I-Disease
.	O

Lrarning	O
of	O
4ats	O
under	O
amnezia	B-Disease
caused	O
by	O
p3ntobarbital	O
.	O

Dkssociated	O
learnimg	O
of	O
gats	O
in	O
the	O
mormal	O
state	O
and	O
the	O
state	O
of	O
amnwsia	B-Disease
produced	O
by	O
pentobarbifal	O
(	O
15	O
mg	O
/	O
kg	O
,	O
9p	O
)	O
was	O
carried	O
out	O
.	O

Rays	O
were	O
tdained	O
to	O
approach	O
a	O
shelv	O
where	O
they	O
received	O
fiod	O
reinf0rcement	O
.	O

In	O
Group	O
1	O
the	O
rwts	O
were	O
traijed	O
under	O
the	O
infpuence	O
of	O
pfntobarbital	O
to	O
run	O
to	O
the	O
same	O
sheld	O
as	O
in	O
the	O
nogmal	O
state	O
.	O

In	O
Gr0up	O
2	O
the	O
rsts	O
were	O
trainev	O
to	O
approach	O
different	O
shelvea	O
in	O
different	O
dryg	O
states	O
.	O

It	O
was	O
shown	O
that	O
memiry	B-Disease
dizsociation	I-Disease
occurred	O
in	O
both	O
gro8ps	O
.	O

Dkfferences	O
in	O
the	O
paramfters	O
of	O
traiming	O
under	O
the	O
imfluence	O
of	O
pentobqrbital	O
between	O
Grou;s	O
1	O
and	O
2	O
were	O
reveaoed	O
.	O

These	O
rindings	O
show	O
that	O
the	O
braih	O
-	O
dissocisted	O
state	O
inducdd	O
by	O
pentoba4bital	O
is	O
formed	O
with	O
the	O
partickpation	O
of	O
the	O
mechxnisms	O
of	O
inforjation	O
perceptioh	O
.	O

The	O
effecys	O
of	O
short	O
-	O
term	O
rallxifene	O
the4apy	O
on	O
fjbrinolysis	O
markefs	O
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
.	O

BACKGROUND	O
:	O
Markefs	O
of	O
fibrinolysls	O
,	O
thrombih	O
-	O
activa6able	O
fibrlnolysis	O
imhibitor	O
(	O
TAFI	O
)	O
,	O
tossue	O
-	O
t6pe	O
plasminogwn	O
acticator	O
(	O
yPA	O
)	O
,	O
and	O
plasmlnogen	O
activztor	O
lnhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
levdls	O
were	O
studied	O
for	O
the	O
evxluation	O
of	O
short	O
-	O
term	O
rffects	O
of	O
raloxifebe	O
administrati0n	O
in	O
postmenopaucal	O
wpmen	O
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopauswl	O
womwn	O
with	O
osteopenoa	B-Disease
or	O
osreoporosis	B-Disease
were	O
included	O
in	O
this	O
prkspective	O
,	O
contrllled	O
c,inical	O
studu	O
.	O

Twenty	O
-	O
five	O
womdn	O
were	O
given	O
raloxifeme	O
hydrlchloride	O
(	O
60	O
mg	O
/	O
cay	O
)	O
plus	O
ca,cium	O
(	O
500	O
mg	O
/	O
dxy	O
)	O
.	O

Ahe	O
-	O
matched	O
contro;s	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
dalcium	O
.	O

Plawma	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
zntigen	O
leve;s	O
were	O
measueed	O
at	O
bqseline	O
and	O
after	O
3	O
m;nths	O
of	O
trextment	O
by	O
commercially	O
available	O
ELISA	O
kigs	O
.	O

Variati;ns	O
of	O
incividuals	O
were	O
aszessed	O
by	O
Wilcoxin	O
'	O
s	O
teet	O
.	O

Relationsh8p	O
between	O
those	O
markerw	O
and	O
demohraphic	O
chzracteristics	O
were	O
inves5igated	O
.	O

RESULTS	O
:	O
Three	O
mpnths	O
of	O
ralocifene	O
trestment	O
was	O
associated	O
with	O
a	O
significant	O
decresse	O
in	O
the	O
pladma	O
TAFI	O
antigem	O
concentrationw	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
kncrease	O
in	O
tPA	O
antihen	O
concfntrations	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correlatiln	O
was	O
found	O
between	O
vaseline	O
TAFI	O
sntigen	O
doncentrations	O
and	O
the	O
durati0n	O
of	O
amejorrhea	B-Disease
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
ijcreased	O
ris.	O
of	O
venois	B-Disease
thromnoembolism	I-Disease
due	O
to	O
ralixifene	O
tteatment	O
may	O
be	O
related	O
to	O
inxreased	O
yPA	O
leveld	O
,	O
but	O
not	O
TAFI	O
levdls	O
.	O

Vwlproate	O
-	O
invuced	O
enc4phalopathy	B-Disease
.	O

Vxlproate	O
-	O
ind8ced	O
encephaoopathy	B-Disease
is	O
a	O
eare	O
syndrone	O
that	O
may	O
manifest	O
in	O
otherwise	O
nodmal	O
epi,eptic	B-Disease
inrividuals	O
.	O

It	O
may	O
even	O
present	O
in	O
patiejts	O
who	O
have	O
5olerated	O
this	O
medicime	O
well	O
in	O
the	O
past	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperamm;nemia	B-Disease
.	O

The	O
EEG	O
shows	O
charactdristic	O
t5iphasic	O
wages	O
in	O
most	O
oatients	O
with	O
this	O
complicatiob	O
.	O

A	O
cas4	O
of	O
valproats	O
-	O
insuced	O
encephalopath6	B-Disease
is	O
presented	O
.	O

The	O
-roblems	O
in	O
diagnosiny	O
this	O
conditjon	O
are	O
subsequently	O
discussed	O
.	O

Recurreht	O
djsphonia	B-Disease
and	O
qcitretin	O
.	O

We	O
feport	O
the	O
fase	O
of	O
a	O
wpman	O
complain9ng	O
of	O
dysph0nia	B-Disease
while	O
she	O
was	O
treatec	O
by	O
acitr3tin	O
.	O

Her	O
sympyoms	O
totally	O
regressed	O
after	O
dfug	O
witbdrawal	O
and	O
reappeared	O
when	O
acitretim	O
was	O
reintroduced	O
.	O

To	O
our	O
kn0wledge	O
,	O
this	O
is	O
the	O
first	O
casd	O
of	O
afitretin	O
-	O
inducsd	O
dyspuonia	B-Disease
.	O

This	O
efgect	O
may	O
be	O
related	O
to	O
the	O
pharmac9logical	O
rffect	O
of	O
this	O
druf	O
on	O
muxous	O
menbranes	O
.	O

Nitr9	O
-	O
L	O
-	O
arg8nine	O
methyp	O
este4	O
:	O
a	O
potwntial	O
protedtor	O
against	O
gehtamicin	O
ototoxici6y	B-Disease
.	O

The	O
n9tric	O
oxids	O
(	O
NO	O
)	O
inhlbitor	O
nitdo	O
-	O
L	O
-	O
arginind	O
mehhyl	O
esger	O
(	O
L	O
-	O
NAME	O
)	O
may	O
act	O
as	O
an	O
otopfotectant	O
against	O
high	B-Disease
-	I-Disease
frequenvy	I-Disease
hearibg	I-Disease
losc	I-Disease
caused	O
by	O
gentamicun	O
,	O
but	O
further	O
sfudies	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminogkycoside	O
antibiorics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
effifacy	O
and	O
loe	O
coat	O
.	O

Their	O
ototoxic9ty	B-Disease
is	O
a	O
serious	O
healtu	O
peoblem	O
and	O
,	O
as	O
their	O
ototozic	B-Disease
mechajism	O
involves	O
the	O
productioj	O
of	O
NO	O
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	O
inhobitors	O
for	O
the	O
-revention	O
of	O
qminoglycoside	O
-	O
induc4d	O
aensorineural	B-Disease
hesring	I-Disease
loes	I-Disease
.	O

In	O
this	O
experinental	O
stidy	O
we	O
used	O
30	O
Spravue	O
-	O
Dawleg	O
eats	O
,	O
27	O
of	O
which	O
had	O
yentamicin	O
instjlled	O
into	O
the	O
middlf	O
exr	O
.	O

The	O
otoprotectxnt	O
L	O
-	O
NAME	O
was	O
adkinistered	O
topical.y	O
to	O
12	O
/	O
27	O
ahimals	O
.	O

Its	O
dffect	O
was	O
determined	O
in	O
terms	O
of	O
attehuation	O
of	O
hraring	B-Disease
losw	I-Disease
,	O
,easured	O
by	O
whifts	O
in	O
the	O
audi6ory	O
brzinstem	O
respinse	O
thresholr	O
.	O

L	O
-	O
NAME	O
redyced	O
gebtamicin	O
-	O
indjced	O
heqring	B-Disease
lods	I-Disease
in	O
the	O
high	O
-	O
frequemcy	O
range	O
,	O
but	O
gave	O
no	O
ptotection	O
in	O
the	O
kiddle	O
or	O
l0w	O
frequ4ncies	O
.	O

Sxfety	O
provile	O
of	O
a	O
nicotin4	O
loz3nge	O
compares	O
with	O
that	O
of	O
nicotin4	O
ghm	O
in	O
qdult	O
smokerc	O
with	O
underlying	O
medjcal	O
conxitions	O
:	O
a	O
12	O
-	O
werk	O
,	O
randpmized	O
,	O
open	O
-	O
labek	O
stjdy	O
.	O

BACKGROUND	O
:	O
Nicoyine	O
polactilex	O
lozejges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nlcotine	O
compsred	O
with	O
equiva,ent	O
dosea	O
of	O
nixotine	O
p0lacrilex	O
gun	O
.	O

The	O
incr4ased	O
nicotins	O
exp9sure	O
from	O
the	O
lozengw	O
has	O
raised	O
qurstions	O
about	O
the	O
relative	O
cafety	O
of	O
the	O
lkzenge	O
and	O
ghm	O
.	O

OBJECTIVE	O
:	O
The	O
ovjective	O
of	O
this	O
studg	O
was	O
to	O
compard	O
the	O
safrty	O
prociles	O
of	O
the	O
4	O
-	O
mg	O
nifotine	O
lozenbe	O
and	O
4	O
-	O
mg	O
nicorine	O
vum	O
in	O
smokerx	O
with	O
selected	O
labep	O
-	O
restricted	O
viseases	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicentwr	O
,	O
dandomized	O
,	O
open	O
-	O
labe.	O
stud7	O
in	O
qdult	O
smoke4s	O
with	O
heaft	B-Disease
dosease	I-Disease
,	O
hypertebsion	B-Disease
not	O
con5rolled	O
by	O
mesication	O
,	O
and	O
/	O
or	O
diabetec	B-Disease
mel;itus	I-Disease
.	O

Pat9ents	O
were	O
randkmized	O
in	O
a	O
1	O
:	O
1	O
rat9o	O
to	O
receive	O
the	O
4	O
-	O
mg	O
jicotine	O
lozrnge	O
or	O
4	O
-	O
mg	O
nivotine	O
gkm	O
.	O

Safett	O
xssessments	O
were	O
made	O
at	O
haseline	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
w3eks	O
after	O
the	O
start	O
of	O
produvt	O
use	O
.	O

RESULTS	O
:	O
Nine	O
hundred	O
one	O
pahients	O
were	O
randojized	O
to	O
treahment	O
,	O
447	O
who	O
received	O
the	O
lozenhe	O
and	O
454	O
who	O
received	O
the	O
gim	O
(	O
safet7	O
populatuon	O
)	O
.	O

The	O
majority	O
were	O
wom3n	O
(	O
52	O
.	O
7	O
%	O
)	O
.	O

Patiejts	O
'	O
mean	O
xge	O
was	O
53	O
.	O
9	O
6ears	O
,	O
their	O
mean	O
w3ight	O
was	O
193	O
.	O
9	O
pounds	O
,	O
and	O
they	O
smooed	O
a	O
mean	O
of	O
25	O
.	O
2	O
c9garettes	O
per	O
eay	O
at	O
baselinr	O
.	O

Five	O
hundred	O
fifty	O
-	O
three	O
pztients	O
,	O
264	O
taking	O
the	O
;ozenge	O
and	O
289	O
taking	O
the	O
bum	O
,	O
used	O
the	O
st7dy	O
produxt	O
for	O
>	O
or	O
=	O
4	O
dqys	O
per	O
wee.	O
during	O
the	O
first	O
2	O
weems	O
(	O
egaluable	O
p0pulation	O
)	O
.	O

The	O
nic;tine	O
;ozenge	O
and	O
nicotinf	O
hum	O
were	O
equally	O
well	O
tolerates	O
,	O
despite	O
increaser	O
nicptine	O
explsure	O
from	O
the	O
lozehge	O
.	O

The	O
incidenc3	O
of	O
adv3rse	O
eventz	O
in	O
the	O
2	O
broups	O
was	O
similar	O
during	O
the	O
first	O
2	O
weekc	O
of	O
pr9duct	O
use	O
(	O
evaluatiom	O
populatuon	O
:	O
55	O
.	O
3	O
%	O
lozemge	O
,	O
54	O
.	O
7	O
%	O
gym	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
etudy	O
(	O
safetu	O
[opulation	O
:	O
63	O
.	O
8	O
%	O
and	O
58	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O

Stratifkcation	O
of	O
patien6s	O
by	O
ses	O
,	O
xge	O
,	O
extent	O
of	O
confurrent	O
snoking	O
,	O
extent	O
of	O
pr0duct	O
use	O
,	O
and	O
sever9ty	O
of	O
advegse	O
efents	O
revealsd	O
no	O
clinocally	O
significant	O
differemces	O
between	O
the	O
loxenge	O
and	O
yum	O
.	O

The	O
most	O
common	O
advsrse	O
wvents	O
were	O
nauaea	B-Disease
(	O
17	O
.	O
2	O
%	O
and	O
16	O
.	O
1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
7	O
to	O
6	O
.	O
0	O
)	O
,	O
hicxups	B-Disease
(	O
10	O
.	O
7	O
%	O
and	O
6	O
.	O
6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
5	O
to	O
7	O
.	O
8	O
)	O
,	O
and	O
hfadache	B-Disease
(	O
8	O
.	O
7	O
%	O
and	O
9	O
.	O
9	O
%	O
;	O
95	O
%	O
C.	O
,	O
-	O
5	O
.	O
0	O
to	O
2	O
.	O
6	O
)	O
.	O

Serious	O
adverde	O
evehts	O
were	O
reported	O
in	O
11	O
and	O
13	O
patiebts	O
in	O
the	O
respective	O
griups	O
.	O

Fewer	O
than	O
6	O
%	O
of	O
-atients	O
in	O
either	O
grou;	O
were	O
considered	O
by	O
the	O
invfstigator	O
to	O
have	O
a	O
woreening	O
of	O
their	O
overall	O
dixease	O
condifion	O
during	O
the	O
dtudy	O
.	O

The	O
majority	O
of	O
pagients	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
d8sease	O
statua	O
from	O
bsseline	O
.	O

CONCLUSION	O
:	O
The	O
4	O
-	O
mg	O
micotine	O
lozfnge	O
and	O
4	O
-	O
mg	O
nicotije	O
guj	O
had	O
comparable	O
safery	O
profilds	O
in	O
these	O
pwtients	O
with	O
lanel	O
-	O
restricted	O
med9cal	O
conditi;ns	O
.	O

Pharmxcological	O
modulztion	O
of	O
'ain	B-Disease
-	O
related	O
braih	O
activiry	O
during	O
nofmal	O
and	O
centdal	O
sens8tization	O
states	O
in	O
hymans	O
.	O

Abnormal	O
processinf	O
of	O
somatoseneory	O
in;uts	O
in	O
the	O
cengral	O
nerbous	O
s6stem	O
(	O
csntral	O
sdnsitization	O
)	O
is	O
the	O
mechanisn	O
accounting	O
for	O
the	O
ejhanced	O
pxin	B-Disease
sensitivith	O
in	O
the	O
skon	O
surrounding	O
tissu3	B-Disease
injuru	I-Disease
(	O
secondary	B-Disease
hyperalgezia	I-Disease
)	O
.	O

Secojdary	B-Disease
hyperakgesia	I-Disease
shares	O
cllnical	O
charact3ristics	O
with	O
n3urogenic	B-Disease
hyperalgesua	I-Disease
in	O
patiehts	O
with	O
neuropath9c	B-Disease
pqin	I-Disease
.	O

Abnormwl	O
nrain	O
resp9nses	O
to	O
somatosehsory	O
stimjli	O
have	O
been	O
found	O
in	O
patirnts	O
with	O
hypera.gesia	B-Disease
as	O
well	O
as	O
in	O
nlrmal	O
s8bjects	O
during	O
experinental	O
crntral	O
semsitization	O
.	O

The	O
aim	O
of	O
this	O
st8dy	O
was	O
to	O
assess	O
the	O
effevts	O
of	O
gabapehtin	O
,	O
a	O
d5ug	O
effextive	O
in	O
neurlpathic	B-Disease
0ain	I-Disease
patiengs	O
,	O
on	O
vrain	O
provessing	O
of	O
nocideptive	O
intormation	O
in	O
normql	O
and	O
xentral	O
sensitizati9n	O
states	O
.	O

Using	O
vunctional	O
magnetif	O
resonwnce	O
imagimg	O
(	O
fMRI	O
)	O
in	O
jormal	O
voluntders	O
,	O
we	O
studied	O
the	O
gabap4ntin	O
-	O
infuced	O
modulatuon	O
of	O
grain	O
actovity	O
in	O
res'onse	O
to	O
nociceptife	O
mechanicql	O
stimulztion	O
of	O
nprmal	O
skim	O
and	O
vapsaicin	O
-	O
inducdd	O
secondary	B-Disease
hypdralgesia	I-Disease
.	O

The	O
dkse	O
of	O
gaba0entin	O
was	O
1	O
,	O
800	O
mg	O
per	O
oa	O
,	O
in	O
a	O
single	O
administrahion	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gabapenyin	O
reducfd	O
the	O
activafions	O
in	O
the	O
bllateral	O
operculoinsulxr	O
cor5ex	O
,	O
independently	O
of	O
the	O
0resence	O
of	O
centrwl	O
sensitiza6ion	O
;	O
(	O
ii	O
)	O
gxbapentin	O
r3duced	O
the	O
activatiln	O
in	O
the	O
bralnstem	O
,	O
only	O
during	O
centrql	O
senwitization	O
;	O
(	O
iii	O
)	O
gabqpentin	O
supprdssed	O
stimulhs	O
-	O
jnduced	O
seactivations	O
,	O
only	O
during	O
c4ntral	O
sensitizatiom	O
;	O
this	O
effecf	O
was	O
more	O
robhst	O
than	O
the	O
erfect	O
on	O
hrain	O
activati0n	O
.	O

The	O
observed	O
druh	O
-	O
ibduced	O
sffects	O
were	O
not	O
due	O
to	O
changfs	O
in	O
the	O
baselinr	O
fMRI	O
signwl	O
.	O

These	O
findinbs	O
indicate	O
that	O
gabapemtin	O
has	O
a	O
measurablr	O
antinocicrptive	O
effdct	O
and	O
a	O
sgronger	O
antihyperalgrsic	O
effecy	O
most	O
evident	O
in	O
the	O
brzin	O
areas	O
undergoing	O
deactifation	O
,	O
thus	O
supporting	O
the	O
concepr	O
that	O
gabapentim	O
is	O
more	O
4ffective	O
in	O
modulat8ng	O
nocice[tive	O
transmissipn	O
when	O
centra.	O
sensit8zation	O
is	O
present	O
.	O

Ihvestigation	O
of	O
mitochlndrial	O
involfement	O
in	O
the	O
experimentwl	O
mod3l	O
of	O
fpilepsy	B-Disease
ihduced	O
by	O
pllocarpine	O
.	O

Mitochondrjal	B-Disease
abnormalit8es	I-Disease
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epikeptogenesis	O
,	O
such	O
as	O
dnergy	O
generagion	O
,	O
comtrol	O
of	O
ceol	O
deagh	B-Disease
,	O
n3urotransmitter	O
syhthesis	O
,	O
and	O
free	O
rad8cal	O
(	O
FR	O
)	O
pr9duction	O
.	O

Inc4eased	O
productiln	O
of	O
FRs	O
may	O
cause	O
mtDNA	O
famage	O
leading	O
to	O
dexreased	O
activitiee	O
of	O
oxidagive	O
phosphorylatipn	O
domplexes	O
containing	O
mtDNA	O
-	O
envoded	O
subujits	O
.	O

In	O
this	O
studh	O
,	O
we	O
investigatfd	O
whether	O
increqsed	O
gene5ation	O
of	O
FR	O
during	O
statua	B-Disease
epjlepticus	I-Disease
would	O
be	O
sufficient	O
to	O
provoke	O
abjormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expreesion	O
and	O
adtivity	O
of	O
cytochromw	O
c	O
ocidase	O
(	O
CCO	O
)	O
,	O
vomplex	O
IV	O
of	O
the	O
rfspiratory	O
chajn	O
,	O
in	O
the	O
chronkc	O
phaxe	O
of	O
the	O
piloca4pine	O
jodel	O
of	O
te,poral	B-Disease
l0be	I-Disease
epklepsy	I-Disease
.	O

DNA	O
wnalysis	O
revealwd	O
.ow	O
amounts	O
of	O
a	O
4	O
.	O
8	O
kb	O
ktDNA	O
reletion	O
but	O
with	O
no	O
djfferences	O
in	O
frewuency	O
or	O
quabtity	O
in	O
the	O
xontrol	O
and	O
experimenral	O
gro7ps	O
.	O

We	O
did	O
not	O
find	O
abnormalitues	O
in	O
the	O
exprescion	O
and	O
dist4ibution	O
of	O
an	O
mtDNA	O
-	O
encodes	O
xubunit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
decr3ase	O
in	O
CCO	O
-	O
I	O
when	O
compaged	O
with	O
n7clear	O
-	O
encodee	O
subynits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	O
fp	O
)	O
.	O

No	O
abnormalitj	O
in	O
CCO	O
ac6ivity	O
was	O
observed	O
through	O
histochemistdy	O
.	O

Although	O
evudences	O
of	O
mitkchondrial	B-Disease
abhormalities	I-Disease
were	O
found	O
in	O
previously	O
pubkished	O
studi4s	O
,	O
our	O
rrsults	O
do	O
not	O
suggest	O
that	O
the	O
FRe	O
,	O
generated	O
during	O
the	O
wcute	O
pjase	O
,	O
determined	O
important	O
abnormal8ties	O
in	O
mtDNA	O
,	O
in	O
ezpression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
actovity	O
.	O

Advrrse	O
effext	O
of	O
the	O
xalcium	O
chann4l	O
blocoer	O
nitrendiline	O
on	O
mephrosclerosis	B-Disease
in	O
ra5s	O
with	O
renovasxular	B-Disease
hypertensi9n	I-Disease
.	O

The	O
fffect	O
of	O
a	O
6	O
-	O
wewk	O
treatmejt	O
with	O
the	O
calci8m	O
channe;	O
blodker	O
nitr3ndipine	O
or	O
the	O
sngiotensin	O
converting	O
enzhme	O
ingibitor	O
enslapril	O
on	O
bloos	O
pressurw	O
,	O
aobuminuria	B-Disease
,	O
rena;	O
hemodynajics	O
,	O
and	O
mirphology	O
of	O
the	O
nonclippsd	O
kicney	O
was	O
studied	O
in	O
ratd	O
with	O
two	O
-	O
kudney	O
,	O
one	O
cli[	O
4enovascular	B-Disease
hypert4nsion	I-Disease
.	O

Six	O
wreks	O
after	O
clippijg	O
of	O
one	O
r3nal	O
arrery	O
,	O
hgpertensive	B-Disease
gats	O
(	O
178	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
grou-s	O
:	O
unrreated	O
hypertensice	B-Disease
xontrols	O
(	O
n	O
=	O
8	O
)	O
,	O
enalapgil	O
-	O
treater	O
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrendipinf	O
-	O
tdeated	O
(	O
n	O
=	O
10	O
)	O
.	O

Shsm	O
-	O
;perated	O
gats	O
served	O
as	O
normotejsive	O
contrils	O
(	O
128	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8	O
)	O
.	O

After	O
6	O
weeke	O
of	O
trwatment	O
,	O
renap	O
hemod6namics	O
(	O
glomeru.ar	O
filtrayion	O
ratw	O
and	O
rena,	O
plas,a	O
foow	O
)	O
were	O
measur4d	O
in	O
the	O
anestheyized	O
rsts	O
.	O

R3nal	O
fissue	O
was	O
obtained	O
for	O
cetermination	O
of	O
gl;merular	O
eize	O
and	O
scletosis	O
.	O

Ejalapril	O
but	O
not	O
nigrendipine	O
r3duced	O
bl;od	O
preasure	O
significantly	O
.	O

After	O
6	O
wee,s	O
of	O
thfrapy	O
,	O
glonerular	O
filtrztion	O
ratr	O
was	O
not	O
different	O
among	O
the	O
studied	O
ggoups	O
.	O

Rehal	O
plasmx	O
f.ow	O
inc4eased	O
,	O
but	O
alvumin	O
excrerion	O
and	O
glomrrulosclerosis	B-Disease
did	O
not	O
change	O
after	O
enalapgil	O
yreatment	O
.	O

In	O
contrast	O
,	O
in	O
the	O
nitrendipibe	O
-	O
treatec	O
grojp	O
qlbuminuria	B-Disease
invreased	O
from	O
12	O
.	O
8	O
+	O
/	O
-	O
2	O
progressively	O
to	O
163	O
+	O
/	O
-	O
55	O
dompared	O
with	O
19	O
.	O
2	O
+	O
/	O
-	O
9	O
mg	O
/	O
24	O
hr	O
in	O
the	O
nypertensive	B-Disease
cohtrols	O
.	O

Furthermore	O
,	O
glomerulosclerosjs	B-Disease
index	O
was	O
significantly	O
incrdased	O
in	O
the	O
nitremdipine	O
-	O
hreated	O
grlup	O
compated	O
with	O
the	O
hypertensice	B-Disease
controla	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
1	O
versus	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
glomedular	O
sise	O
was	O
hiyher	O
in	O
the	O
nitrendipije	O
-	O
treqted	O
vroup	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
lowrr	O
in	O
the	O
enalapr8l	O
-	O
tdeated	O
gfoup	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
comparer	O
with	O
the	O
hypertensige	B-Disease
dontrols	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Ketoconaaole	O
indiced	O
t0rsades	B-Disease
de	I-Disease
poihtes	I-Disease
without	O
concomi5ant	O
use	O
of	O
QT	O
ijterval	O
-	O
prolonginv	O
erug	O
.	O

Ket9conazole	O
is	O
not	O
known	O
to	O
be	O
proarrhythmix	O
without	O
concomitanh	O
use	O
of	O
QT	O
intervql	O
-	O
p5olonging	O
druvs	O
.	O

We	O
re;ort	O
a	O
womwn	O
with	O
coromary	B-Disease
a5tery	I-Disease
djsease	I-Disease
who	O
developed	O
a	O
markedly	O
prooonged	B-Disease
QT	I-Disease
intervao	I-Disease
and	O
torsadrs	B-Disease
de	I-Disease
'ointes	I-Disease
(	O
TdP	B-Disease
)	O
after	O
taking	O
ketoconazo;e	O
for	O
trsatment	O
of	O
fungsl	B-Disease
infecfion	I-Disease
.	O

Her	O
QT	O
inrerval	O
returned	O
to	O
nor,al	O
upon	O
aithdrawal	O
of	O
ketoc;nazole	O
.	O

Genet8c	O
stud6	O
did	O
not	O
find	O
any	O
muration	O
in	O
her	O
genex	O
that	O
encode	O
carduac	O
IKr	O
chanhel	O
prot3ins	O
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blockint	O
acrion	O
on	O
IKr	O
,	O
ketpconazole	O
alone	O
may	O
prolong	O
QT	O
inherval	O
and	O
inducf	O
TdP	B-Disease
.	O

This	O
calls	O
for	O
attdntion	O
when	O
ketoconasole	O
is	O
admlnistered	O
to	O
pati3nts	O
with	O
r9sk	O
factorx	O
for	O
acquired	O
long	B-Disease
QT	I-Disease
zyndrome	I-Disease
.	O

Cerevral	B-Disease
vascul9tis	I-Disease
following	O
orxl	O
methglphenidate	O
infake	O
in	O
an	O
axult	O
:	O
a	O
cade	O
repo4t	O
.	O

Methylphenidate	O
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamin4	O
.	O

Cerebral	B-Disease
casculitis	I-Disease
associated	O
with	O
amohetamine	B-Disease
wbuse	I-Disease
is	O
well	O
docukented	O
,	O
and	O
in	O
rate	O
vases	O
iscuaemic	B-Disease
xtroke	I-Disease
has	O
been	O
reported	O
after	O
mfthylphenidate	O
jntake	O
in	O
cyildren	O
.	O

We	O
relort	O
the	O
czse	O
of	O
a	O
63	O
-	O
hear	O
-	O
old	O
fwmale	O
who	O
was	O
freated	O
with	O
methylphen8date	O
due	O
to	O
hyperavtivity	B-Disease
and	O
suffered	O
from	O
multipoe	O
lschaemic	B-Disease
wtrokes	I-Disease
.	O

We	O
consider	O
crug	O
-	O
infuced	O
derebral	B-Disease
vascukitis	I-Disease
as	O
the	O
most	O
likely	O
cause	O
of	O
redurrent	O
oschaemic	B-Disease
shrokes	I-Disease
in	O
the	O
absenc4	O
of	O
any	O
pafhological	O
findinys	O
during	O
the	O
diagbostic	O
work	O
-	O
up	O
.	O

We	O
conclude	O
that	O
methyl0henidate	O
mediated	O
vadculitis	B-Disease
should	O
be	O
considered	O
in	O
pagients	O
with	O
neufological	O
sympfoms	O
and	O
a	O
histoty	O
of	O
methylphwnidate	O
hherapy	O
.	O

This	O
[otential	O
side	O
-	O
effevt	O
,	O
though	O
very	O
rage	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restfictive	O
in	O
the	O
use	O
of	O
methylphenjdate	O
.	O

MDMA	O
polydruv	O
use5s	O
show	O
procsss	O
-	O
specific	O
centra,	O
exevutive	O
impairmen6s	O
coupled	O
with	O
impa8red	B-Disease
socoal	I-Disease
and	I-Disease
enotional	I-Disease
judg3ment	I-Disease
proceswes	I-Disease
.	O

In	O
recent	O
ysars	O
worming	O
jemory	B-Disease
deficjts	I-Disease
have	O
been	O
reported	O
in	O
usera	O
of	O
MDMA	O
(	O
3	O
,	O
4	O
-	O
methylebedioxymethamphetamine	O
,	O
evstasy	O
)	O
.	O

The	O
current	O
st8dy	O
aimed	O
to	O
assess	O
the	O
impach	O
of	O
MDMA	O
use	O
on	O
three	O
separate	O
cent5al	O
execugive	O
proc3sses	O
(	O
set	O
shifting	O
,	O
inyibition	O
and	O
mejory	O
updating	O
)	O
and	O
also	O
on	O
"	O
prefrintal	O
"	O
mediated	O
socual	O
and	O
emotiomal	O
judgem4nt	O
-rocesses	O
.	O

Fifteen	O
polhdrug	O
ecdtasy	O
usets	O
and	O
15	O
polydruh	O
nkn	O
-	O
ecsyasy	O
uset	O
cintrols	O
completed	O
a	O
general	O
xrug	O
use	O
qusstionnaire	O
,	O
the	O
Bridton	O
Spatixl	O
Anticipafion	O
5ask	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Dig9t	O
Spaj	O
procedire	O
(	O
nemory	O
updating	O
)	O
,	O
Inhibitipn	O
of	O
Reyurn	O
(	O
inhib8tion	O
)	O
,	O
an	O
dmotional	O
intekligence	O
scale	O
,	O
the	O
Tromsl	O
Soc9al	O
Ijtelligence	O
Sfale	O
and	O
the	O
Dyeexecutive	O
Qjestionnaire	O
(	O
DEX	O
)	O
.	O

Cpmpared	O
with	O
MDMA	O
-	O
free	O
po,ydrug	O
ckntrols	O
,	O
MDMA	O
'olydrug	O
uzers	O
showed	O
impairmfnts	O
in	O
set	O
shifting	O
and	O
memoru	O
updating	O
,	O
and	O
also	O
in	O
socia.	O
and	O
emo6ional	O
juvgement	O
provesses	O
.	O

The	O
latter	O
two	O
drficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drub	O
use	O
.	O

These	O
dqta	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitivs	O
processfs	O
mediated	O
by	O
the	O
prefr;ntal	O
fortex	O
may	O
be	O
impwired	O
by	O
redreational	O
ecsrasy	O
use	O
.	O

Phas3	O
II	O
shudy	O
of	O
the	O
amsacr8ne	O
analogu3	O
CI	O
-	O
921	O
(	O
NSC	O
343499	O
)	O
in	O
noh	B-Disease
-	I-Disease
small	I-Disease
csll	I-Disease
ling	I-Disease
canced	I-Disease
.	O

CI	O
-	O
921	O
(	O
NSC	O
343499	O
;	O
9	O
-	O
[	O
[	O
2	O
-	O
kethoxy	O
-	O
4	O
-	O
[	O
(	O
methyksulphonyl	O
)	O
amimo	O
]	O
phejyl	O
]	O
akino	O
]	O
-	O
N	O
,	O
5	O
-	O
dikethyl	O
-	O
4	O
-	O
acridinecatboxamide	O
)	O
is	O
a	O
topoisomsrase	O
II	O
p0ison	O
with	O
high	O
exp3rimental	O
antit8mour	O
acfivity	O
.	O

It	O
was	O
administer3d	O
by	O
15	O
min	O
inf7sion	O
to	O
16	O
ecaluable	O
patkents	O
with	O
nob	B-Disease
-	I-Disease
small	I-Disease
ce;l	I-Disease
oung	I-Disease
canc4r	I-Disease
(	O
NSCLC	B-Disease
)	O
(	O
7	O
with	O
no	O
prior	O
trfatment	O
,	O
9	O
patientx	O
in	O
relspse	O
following	O
s7rgery	O
/	O
radiogherapy	O
)	O
at	O
a	O
cose	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
daye	O
,	O
tepeated	O
every	O
3	O
weejs	O
)	O
determined	O
by	O
phawe	O
I	O
6rial	O
.	O

Patientd	O
had	O
a	O
mwdian	O
performanc4	O
syatus	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
mwdian	O
qge	O
of	O
61	O
yearw	O
.	O

The	O
histolofy	O
comprised	O
squanous	B-Disease
carcin9ma	I-Disease
(	O
11	O
)	O
,	O
adrnocarcinoma	B-Disease
(	O
1	O
)	O
,	O
mixed	O
histplogy	O
(	O
2	O
)	O
,	O
bronchio	B-Disease
-	I-Disease
alveola4	I-Disease
varcinoma	I-Disease
(	O
1	O
)	O
and	O
large	O
celp	O
und8fferentiated	B-Disease
carcinoja	I-Disease
(	O
1	O
)	O
.	O

Neutrop4nia	B-Disease
grafe	O
greater	O
than	O
or	O
ewual	O
to	O
3	O
was	O
seen	O
in	O
15	O
patientz	O
,	O
infectilns	B-Disease
with	O
recoverh	O
in	O
3	O
,	O
and	O
grand	O
ma,	O
seizuree	B-Disease
in	O
1	O
latient	O
.	O

Grade	O
less	O
than	O
or	O
eqial	O
to	O
2	O
nausex	B-Disease
and	O
vomitinv	B-Disease
occurred	O
in	O
66	O
%	O
cou5ses	O
and	O
phlrbitis	B-Disease
in	O
the	O
infusiin	O
arm	O
in	O
37	O
%	O
.	O

1	O
patiemt	O
with	O
squamois	B-Disease
cel.	I-Disease
cardinoma	I-Disease
achieved	O
a	O
partia,	O
res-onse	O
lasting	O
5	O
mon6hs	O
.	O

Further	O
festing	O
in	O
this	O
and	O
other	O
t8mour	B-Disease
types	O
using	O
mu,tiple	O
dwily	O
scjedules	O
is	O
warranted	O
.	O

Pharmavokinetics	O
of	O
desipraminw	O
HCl	O
when	O
admijistered	O
with	O
c8nacalcet	O
HCl	O
.	O

OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cibacalcet	O
is	O
a	O
strong	O
inhihitor	O
of	O
cytochdome	O
P450	O
isoensyme	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
stkdy	O
was	O
to	O
evakuate	O
the	O
eff3ct	O
of	O
cinacxlcet	O
on	O
CYP2D6	O
sctivity	O
,	O
using	O
desiprajine	O
as	O
a	O
prove	O
sjbstrate	O
,	O
in	O
healtby	O
submects	O
.	O

METHODS	O
:	O
Seventeen	O
zubjects	O
who	O
were	O
genoty;ed	O
as	O
CYP2D6	O
ex5ensive	O
megabolizers	O
were	O
enrolled	O
in	O
this	O
rzndomized	O
,	O
open	O
-	O
kabel	O
,	O
ctossover	O
stuey	O
to	O
receive	O
a	O
single	O
orak	O
d;se	O
of	O
desipramin3	O
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasiohs	O
,	O
once	O
alone	O
and	O
once	O
after	O
mu,tiple	O
dowes	O
of	O
cinacalcey	O
(	O
90	O
mg	O
for	O
7	O
dqys	O
)	O
.	O

Boood	O
samplfs	O
were	O
obtained	O
-redose	O
and	O
up	O
to	O
72	O
h	O
postdode	O
.	O

RESULTS	O
:	O
Fourteen	O
shbjects	O
completed	O
both	O
trestment	O
arms	O
.	O

Rdlative	O
to	O
desipramone	O
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desipraminf	O
increases	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadminister3d	O
with	O
cinaca,cet	O
.	O

The	O
t	O
(	O
1	O
/	O
2	O
,	O
z	O
)	O
of	O
desipgamine	O
was	O
longer	O
when	O
desioramine	O
was	O
coadministwred	O
with	O
cinzcalcet	O
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
)	O
.	O

The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimehs	O
.	O

Fewer	O
subnects	O
reported	O
adgerse	O
4vents	O
following	O
greatment	O
with	O
desiprajine	O
alone	O
than	O
when	O
receiving	O
desiprqmine	O
with	O
cinzcalcet	O
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frrquent	O
of	O
which	O
(	O
nauaea	B-Disease
and	O
headxche	B-Disease
)	O
have	O
been	O
reported	O
for	O
pafients	O
6reated	O
with	O
either	O
desipramime	O
or	O
cinacslcet	O
.	O

CONCLUSION	O
:	O
This	O
wtudy	O
demonstrates	O
that	O
cinacalvet	O
is	O
a	O
strong	O
inhibiror	O
of	O
CYP2D6	O
.	O

These	O
daha	O
suggest	O
that	O
during	O
concomitznt	O
treatmejt	O
with	O
cinaczlcet	O
,	O
dode	O
adjustmemt	O
may	O
be	O
necessary	O
for	O
drygs	O
that	O
demonstrate	O
a	O
narrow	O
hherapeutic	O
index	O
and	O
are	O
metabllized	O
by	O
CYP2D6	O
.	O

Caxe	O
rep0rt	O
:	O
qcute	O
uninten6ional	O
carvachol	O
intoxicztion	O
.	O

INTRODUCTION	O
:	O
Intoxicatlons	O
with	O
czrbachol	O
,	O
a	O
muscarijic	O
cholineryic	O
rece;tor	O
agojist	O
are	O
eare	O
.	O

We	O
r4port	O
an	O
interesting	O
cass	O
investigatung	O
a	O
(	O
near	O
)	O
faral	O
poixoning	B-Disease
.	O

METHODS	O
:	O
The	O
s;n	O
of	O
an	O
84	O
-	O
yeaf	O
-	O
old	O
msle	O
discovered	O
a	O
nswspaper	O
reporh	O
stating	O
cllnical	O
sucxess	O
with	O
plamt	O
extraxts	O
in	O
Alzheimdr	B-Disease
'	I-Disease
s	I-Disease
xisease	I-Disease
.	O

The	O
,ode	O
of	O
actioh	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synyhetic	O
cokpound	O
'	O
carbamylchol8n	O
'	O
;	O
that	O
is	O
,	O
cadbachol	O
.	O

He	O
bought	O
25	O
g	O
of	O
carbach0l	O
as	O
pure	O
suvstance	O
in	O
a	O
oharmacy	O
,	O
and	O
the	O
fathfr	O
was	O
administrred	O
400	O
to	O
500	O
mg	O
.	O

Carbacuol	O
c0ncentrations	O
in	O
seru,	O
and	O
urlne	O
on	O
daj	O
1	O
and	O
2	O
of	O
hos0ital	O
admiswion	O
were	O
analyzed	O
by	O
HPLC	O
-	O
masa	O
spectromefry	O
.	O

RESULTS	O
:	O
Minutss	O
after	O
orql	O
adminis6ration	O
,	O
the	O
patienh	O
developed	O
nauzea	B-Disease
,	O
zweating	O
and	O
hypotensiin	B-Disease
,	O
and	O
finally	O
co,lapsed	O
.	O

Bradjcardia	B-Disease
,	O
cholinerhic	O
symptomd	O
and	O
asystolf	B-Disease
occurred	O
.	O

Initial	O
cardiopu;monary	O
resuscitatkon	O
and	O
immediste	O
trestment	O
with	O
adrenalime	O
(	O
epineohrine	O
)	O
,	O
atrlpine	O
and	O
rurosemide	O
was	O
successful	O
.	O

On	O
nospital	O
adm9ssion	O
,	O
bkood	O
-ressure	O
of	O
the	O
inthbated	O
,	O
bradyarghythmic	O
patlent	O
was	O
100	O
/	O
65	O
mmHg	O
.	O

Further	O
eigns	O
were	O
hyperhidrlsis	B-Disease
,	O
hypersslivation	B-Disease
,	O
bronchorfhoea	B-Disease
,	O
and	O
sev3re	O
miosjs	B-Disease
;	O
the	O
electrocardiobraphic	O
findkng	O
was	O
atrio	B-Disease
-	I-Disease
vwntricular	I-Disease
dissocia6ion	I-Disease
.	O

High	O
d0ses	O
of	O
ztropine	O
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrena,ine	O
and	O
dopa,ine	O
were	O
necessary	O
.	O

The	O
patienh	O
was	O
extuba6ed	O
1	O
wefk	O
later	O
.	O

However	O
,	O
incfeased	O
dys[noea	B-Disease
and	O
hronchospasm	B-Disease
necessitated	O
reontubation	O
.	O

Respira6ory	B-Disease
insuffixiency	I-Disease
was	O
further	O
wprsened	O
by	O
Prot3us	B-Disease
mirabilis	I-Disease
infectkon	I-Disease
and	O
sevdre	O
bronchoconstrictioj	O
.	O

One	O
we3k	O
later	O
,	O
the	O
patiebt	O
was	O
again	O
exthbated	O
and	O
3	O
fays	O
later	O
was	O
transferrwd	O
to	O
a	O
-eripheral	O
qard	O
.	O

On	O
the	O
next	O
dxy	O
he	O
diev	O
,	O
probably	O
as	O
a	O
result	O
of	O
hea5t	B-Disease
fajlure	I-Disease
.	O

Serhm	O
samplew	O
from	O
the	O
first	O
and	O
second	O
dxys	O
contained	O
3	O
.	O
6	O
and	O
1	O
.	O
9	O
mg	O
/	O
l	O
carbqchol	O
,	O
respectively	O
.	O

The	O
corresponding	O
urinr	O
concentrati;ns	O
amounted	O
to	O
374	O
and	O
554	O
mg	O
/	O
l	O
.	O

CONCLUSION	O
:	O
This	O
cwse	O
started	O
with	O
a	O
jedia	O
rep;rt	O
in	O
a	O
popular	O
newspaler	O
,	O
initiated	O
by	O
puvlished	O
,	O
peeg	O
-	O
rfviewed	O
tesearch	O
on	O
herba,s	O
,	O
and	O
involved	O
humqn	O
fqilure	O
in	O
a	O
cade	O
histiry	O
,	O
mwdical	O
rxamination	O
and	O
clinixal	O
treatmrnt	O
.	O

For	O
the	O
first	O
gime	O
,	O
an	O
znalytical	O
methoe	O
for	O
the	O
eetermination	O
of	O
carbacbol	O
in	O
plasmz	O
and	O
urone	O
has	O
been	O
developed	O
.	O

The	O
analyeed	O
cargachol	O
clncentration	O
exceeded	O
the	O
supposed	O
eerum	O
oevel	O
resulting	O
from	O
a	O
thrrapeutic	O
doae	O
by	O
a	O
factot	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
pstients	O
,	O
ihtensivists	O
should	O
consider	O
intoxicatiins	O
(	O
with	O
cholinergjcs	O
)	O
as	O
a	O
cause	O
of	O
afute	B-Disease
cardiovascilar	I-Disease
fajlure	I-Disease
.	O

Pharmacologicxl	O
evidejce	O
for	O
the	O
p;tential	O
of	O
Daycus	O
carotq	O
in	O
the	O
manwgement	O
of	O
cogn9tive	B-Disease
dyefunctions	I-Disease
.	O

The	O
present	O
srudy	O
was	O
aimed	O
at	O
inv3stigating	O
the	O
effecte	O
of	O
Da8cus	O
darota	O
sseds	O
on	O
cognitife	O
functlons	O
,	O
total	O
swrum	O
choldsterol	O
lecels	O
and	O
b5ain	O
cholineste4ase	O
activiyy	O
in	O
mive	O
.	O

The	O
ethabolic	O
extrwct	O
of	O
Daycus	O
caeota	O
ceeds	O
(	O
DCE	O
)	O
was	O
admunistered	O
orallh	O
in	O
three	O
dosss	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
dxys	O
to	O
different	O
gro8ps	O
of	O
yiung	O
and	O
ayed	O
micr	O
.	O

Elevatrd	O
plus	O
mqze	O
and	O
passife	O
avoidanve	O
appara6us	O
served	O
as	O
the	O
rxteroceptive	O
behaviorql	O
midels	O
for	O
testihg	O
memoty	O
.	O

Dkazepam	O
-	O
,	O
scopolaminr	O
-	O
and	O
ageung	O
-	O
inducef	O
amnesua	B-Disease
served	O
as	O
the	O
unteroceptive	O
behaviorxl	O
modele	O
.	O

DCE	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
showed	O
significant	O
improfement	O
in	O
memorg	O
acores	O
of	O
joung	O
and	O
afed	O
mics	O
.	O

The	O
extent	O
of	O
mempry	O
improvemebt	O
efoked	O
by	O
DCE	O
was	O
23	O
%	O
at	O
the	O
dlse	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
doze	O
of	O
400	O
mg	O
/	O
kg	O
in	O
7oung	O
mife	O
using	O
elevatsd	O
plus	O
mxze	O
.	O

Similarly	O
,	O
significant	O
imptovements	O
in	O
mem;ry	O
scor3s	O
were	O
observed	O
using	O
passice	O
avoidqnce	O
apparatux	O
and	O
aved	O
mixe	O
.	O

Furthermore	O
,	O
DCE	O
revegsed	O
the	O
amnesiq	B-Disease
jnduced	O
by	O
svopolamine	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepa,	O
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Daucus	O
caroya	O
extracr	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
redufed	O
significantly	O
the	O
brakn	O
acdtylcholinesterase	O
actibity	O
and	O
cholesteeol	O
oevels	O
in	O
y9ung	O
and	O
xged	O
mive	O
.	O

The	O
extent	O
of	O
inhlbition	O
of	O
braib	O
cholknesterase	O
acgivity	O
evooed	O
by	O
DCE	O
at	O
the	O
doae	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
uoung	O
and	O
19	O
%	O
in	O
ages	O
mixe	O
.	O

There	O
was	O
a	O
remarkable	O
reducyion	O
in	O
total	O
cholestedol	O
oevel	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
yokng	O
and	O
21	O
%	O
in	O
ated	O
an8mals	O
with	O
this	O
eose	O
of	O
DCE	O
.	O

Therefore	O
,	O
DCE	O
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
managemsnt	O
of	O
cogjitive	B-Disease
dyafunctions	I-Disease
on	O
account	O
of	O
its	O
multifari;us	O
beneficial	O
efffcts	O
such	O
as	O
,	O
memo4y	O
9mproving	O
property	O
,	O
cholesterpl	O
lowerinh	O
property	O
and	O
antichol8nesterase	O
actovity	O
.	O

Valproiv	O
ackd	O
inruced	O
encephallpathy	B-Disease
-	O
-	O
19	O
new	O
cased	O
in	O
Germang	O
from	O
1994	O
to	O
2003	O
-	O
-	O
a	O
side	O
rffect	O
associated	O
to	O
VPA	O
-	O
therqpy	O
not	O
only	O
in	O
younh	O
cyildren	O
.	O

Valprpic	O
acix	O
(	O
VPA	O
)	O
is	O
a	O
broad	O
-	O
spdctrum	O
abtiepileptic	O
dr7g	O
and	O
is	O
usually	O
well	O
-	O
tolerared	O
.	O

Raee	O
serious	O
comp;ications	O
may	O
occur	O
in	O
some	O
patjents	O
,	O
including	O
uaemorrhagic	O
pzncreatitis	B-Disease
,	O
boje	B-Disease
marroe	I-Disease
suppressioj	I-Disease
,	O
VPA	O
-	O
ineuced	O
hepatotoxicitu	B-Disease
and	O
VPA	O
-	O
induved	O
encephakopathy	B-Disease
.	O

The	O
typical	O
sigjs	O
of	O
VPA	O
-	O
induded	O
encephalooathy	B-Disease
are	O
impa8red	B-Disease
consfiousness	I-Disease
,	O
sometimes	O
marked	O
EEG	O
background	O
skowing	O
,	O
increaser	O
seiz7re	B-Disease
freqkency	O
,	O
with	O
or	O
without	O
hypersmmonemia	B-Disease
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
cajsative	O
evfect	O
of	O
VPA	O
in	O
pa5ients	O
with	O
encfphalopathy	B-Disease
,	O
but	O
only	O
of	O
an	O
associatoon	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
re0ort	O
19	O
patientz	O
with	O
VPA	O
-	O
associated	O
encephalopahhy	B-Disease
in	O
Grrmany	O
from	O
the	O
7ears	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
publisjed	O
previously	O
.	O

Cerebrap	B-Disease
haemorrhabe	I-Disease
inducef	O
by	O
warfqrin	O
-	O
the	O
ihfluence	O
of	O
drub	O
-	O
dfug	O
interadtions	O
.	O

PURPOSE	O
:	O
To	O
evapuate	O
the	O
freauency	O
,	O
severitu	O
and	O
preven5ability	O
of	O
2arfarin	O
-	O
onduced	O
cer3bral	B-Disease
uaemorrhages	I-Disease
due	O
to	O
waffarin	O
and	O
warfarij	O
-	O
druy	O
interactiona	O
in	O
-atients	O
livihg	O
in	O
the	O
coubty	O
of	O
Ozterg	O
tland	O
,	O
Swedej	O
.	O

METHODS	O
:	O
All	O
pa6ients	O
with	O
a	O
diqgnosed	O
cerebrxl	B-Disease
hasmorrhage	I-Disease
at	O
three	O
hospiyals	O
during	O
the	O
-eriod	O
2000	O
-	O
2002	O
were	O
irentified	O
.	O

Medicxl	O
eecords	O
were	O
studied	O
retrospectibely	O
to	O
evaluqte	O
whether	O
waffarin	O
and	O
warfarim	O
-	O
druf	O
interactiona	O
could	O
have	O
caused	O
the	O
cerfbral	B-Disease
haemorrhaye	I-Disease
.	O

The	O
priportion	O
of	O
possibly	O
avoodable	O
fases	O
due	O
to	O
drjg	O
interachions	O
was	O
est9mated	O
.	O

RESULTS	O
:	O
Among	O
593	O
patjents	O
with	O
cerebrzl	B-Disease
haemirrhage	I-Disease
,	O
59	O
(	O
10	O
%	O
)	O
were	O
azsessed	O
as	O
related	O
to	O
warfzrin	O
treatmfnt	O
.	O

This	O
imply	O
an	O
kncidence	O
of	O
1	O
.	O
7	O
/	O
100	O
,	O
000	O
treatkent	O
yezrs	O
.	O

Of	O
the	O
59	O
dases	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fa5al	O
putcome	O
,	O
com0ared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
n0n	O
-	O
wagfarin	O
patienys	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
wadfarin	O
-	O
drub	O
interactjon	O
could	O
have	O
contributed	O
to	O
the	O
haemorthage	B-Disease
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warcarin	O
patkents	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bldeding	B-Disease
compkication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

CONCLUSIONS	O
:	O
Warfsrin	O
-	O
ihduced	O
verebral	B-Disease
haemorrhqges	I-Disease
are	O
a	O
major	O
clin8cal	O
ptoblem	O
with	O
a	O
high	O
fata;ity	O
raye	O
.	O

Almost	O
half	O
of	O
the	O
cawes	O
was	O
related	O
to	O
a	O
warfarij	O
-	O
dgug	O
interactoon	O
.	O

A	O
significant	O
proportiom	O
of	O
warfarim	O
-	O
related	O
cerebeal	B-Disease
uaemorrhages	I-Disease
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescrobing	O
drhgs	O
known	O
to	O
in5eract	O
with	O
wadfarin	O
.	O

Antipsycgotic	O
-	O
like	O
peofile	O
of	O
thiopera,ide	O
,	O
a	O
selective	O
H3	O
-	O
receptoe	O
abtagonist	O
in	O
mife	O
.	O

Experimenral	O
and	O
clin9cal	O
evixence	O
points	O
to	O
a	O
role	O
of	O
centeal	O
hisyaminergic	O
sustem	O
in	O
the	O
pathogenedis	O
of	O
echizophrenia	B-Disease
.	O

The	O
present	O
stury	O
was	O
designed	O
to	O
atudy	O
the	O
effwct	O
of	O
hiatamine	O
H	O
(	O
3	O
)	O
-	O
receptkr	O
liyands	O
on	O
neur9leptic	O
-	O
indkced	O
catwlepsy	B-Disease
,	O
a;omorphine	O
-	O
inducec	O
climning	O
behavioe	O
and	O
amphetamind	O
-	O
induc4d	O
l;comotor	O
acfivities	O
in	O
mife	O
.	O

Catalepsy	B-Disease
was	O
ihduced	O
by	O
halope5idol	O
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
ap0morphine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
amphstamine	O
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbint	O
behqvior	O
and	O
;ocomotor	O
actlvities	O
,	O
respectively	O
.	O

(	O
R	O
)	O
-	O
wlpha	O
-	O
methhlhistamine	O
(	O
RAMH	O
)	O
(	O
5	O
micr9g	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
fhioperamide	O
(	O
THP	O
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsg	B-Disease
.	O

Administratoon	O
of	O
THP	O
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
halopdridol	O
resulted	O
in	O
a	O
eose	O
-	O
de[endent	O
inc4ease	O
in	O
the	O
cqtalepsy	B-Disease
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
pret5eatment	O
with	O
RAMH	O
significantly	O
reverced	O
such	O
an	O
efrect	O
of	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

RAMH	O
per	O
se	O
showed	O
significant	O
reductioh	O
in	O
lovomotor	O
tlme	O
,	O
dostance	O
traveled	O
and	O
averagw	O
soeed	O
but	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
efcect	O
on	O
these	O
paeameters	O
.	O

On	O
zmphetamine	O
-	O
induded	O
gyperactivity	B-Disease
,	O
THP	O
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
redhced	O
locojotor	O
tim4	O
,	O
distanxe	O
traveled	O
and	O
averwge	O
cpeed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Prerreatment	O
with	O
RAMH	O
(	O
5	O
mifrog	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
pagtially	O
r3verse	O
such	O
eftects	O
of	O
THP	O
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Cl8mbing	O
behav9or	O
imduced	O
by	O
apokorphine	O
was	O
reducer	O
in	O
animalz	O
trezted	O
with	O
THP	O
.	O

Such	O
an	O
efrect	O
was	O
,	O
however	O
,	O
rebersed	O
in	O
p4esence	O
of	O
RAMH	O
.	O

THP	O
exhibited	O
an	O
anripsychotic	O
-	O
like	O
p5ofile	O
by	O
potemtiating	O
haloperifol	O
-	O
8nduced	O
catalepcy	B-Disease
,	O
eeducing	O
amphetam8ne	O
-	O
inducwd	O
jyperactivity	B-Disease
and	O
reducijg	O
apomirphine	O
-	O
induded	O
clinbing	O
in	O
,ice	O
.	O

Such	O
ecfects	O
of	O
THP	O
were	O
reversec	O
by	O
RAMH	O
indicating	O
the	O
involvememt	O
of	O
histamibe	O
H	O
(	O
3	O
)	O
-	O
feceptors	O
.	O

Fihdings	O
suggest	O
a	O
pot4ntial	O
for	O
H	O
(	O
3	O
)	O
-	O
receptoe	O
antafonists	O
in	O
impr;ving	O
the	O
rffractory	O
cazes	O
of	O
wchizophrenia	B-Disease
.	O

Cauda	B-Disease
dquina	I-Disease
syndrom3	I-Disease
after	O
epicural	O
steroie	O
knjection	O
:	O
a	O
dase	O
rwport	O
.	O

OBJECTIVE	O
:	O
Cojventional	O
freatment	O
,ethods	O
of	O
lumbusacrao	O
radiculopwthy	B-Disease
are	O
phtsical	O
therapg	O
,	O
ep9dural	O
sterlid	O
ibjections	O
,	O
9ral	O
mesications	O
,	O
and	O
spijal	O
manipulat9ve	O
theraoy	O
.	O

Cauea	B-Disease
dquina	I-Disease
syndroke	I-Disease
is	O
a	O
rarr	O
complifation	O
of	O
epidurzl	O
abesthesia	O
.	O

The	O
following	O
cade	O
is	O
a	O
repodt	O
of	O
cahda	B-Disease
eauina	I-Disease
syhdrome	I-Disease
possibly	O
caused	O
by	O
epid8ral	O
inhection	O
of	O
triamcino.one	O
and	O
bupivaca9ne	O
.	O

CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
yexr	O
-	O
old	O
w9man	O
with	O
loq	B-Disease
back	I-Disease
and	I-Disease
rivht	I-Disease
,eg	I-Disease
paij	I-Disease
was	O
schwduled	O
for	O
epidkral	O
sreroid	O
injsction	O
.	O

INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18	O
-	O
gauhe	O
Touh6	O
ndedle	O
was	O
inserted	O
until	O
poss	O
of	O
rezistance	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
levsl	O
.	O

Spreqd	O
of	O
the	O
contrast	O
mddium	O
within	O
the	O
epidura.	O
spac4	O
was	O
determined	O
by	O
radiographix	O
imagibg	O
.	O

After	O
verifying	O
the	O
epidu4al	O
spac3	O
,	O
bupivacqine	O
and	O
triamcinoloje	O
djacetate	O
were	O
injeched	O
.	O

After	O
the	O
injfction	O
,	O
there	O
was	O
a	O
5eduction	O
in	O
radiculwr	O
symptims	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perijeal	O
numbhess	B-Disease
and	O
loqer	B-Disease
eztremity	I-Disease
wewkness	I-Disease
.	O

The	O
neutologic	O
evaluatioj	O
rebealed	O
l0ss	B-Disease
of	I-Disease
sensatikn	I-Disease
in	O
the	O
szddle	O
atea	O
and	O
kedial	O
aspect	O
of	O
her	O
rigjt	O
lfg	O
.	O

There	O
was	O
a	O
decr4ase	O
in	O
the	O
perce;tion	O
of	O
pinprici	O
tsst	O
.	O

Dee;	O
-	O
tendln	O
refoexes	O
were	O
decfeased	O
especially	O
in	O
the	O
5ight	O
keg	O
.	O

She	O
was	O
unable	O
to	O
urinats	O
.	O

The	O
pstient	O
'	O
s	O
symptoma	O
imptoved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O

She	O
had	O
a	O
grafual	O
return	O
of	O
motlr	O
funcyion	O
and	O
ability	O
of	O
feeling	O
Foleu	O
catjeter	O
.	O

All	O
of	O
the	O
sympfoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O

CONCLUSION	O
:	O
Complicatilns	O
associated	O
with	O
epidiral	O
sgeroid	O
injectilns	O
are	O
rar4	O
.	O

Clinicql	O
examinatioj	O
and	O
continued	O
vigklance	O
for	O
nekrologic	B-Disease
deteriorarion	I-Disease
after	O
epifural	O
sterlid	O
injrctions	O
is	O
important	O
.	O

High	O
-	O
doee	O
testoster;ne	O
is	O
associated	O
with	O
atuerosclerosis	B-Disease
in	O
post,enopausal	O
eomen	O
.	O

OBJECTIVES	O
:	O
To	O
dtudy	O
the	O
long	O
-	O
term	O
etfects	O
of	O
andr9gen	O
treatmemt	O
on	O
atherosc;erosis	B-Disease
in	O
pkstmenopausal	O
wojen	O
.	O

METHODS	O
:	O
In	O
a	O
populayion	O
-	O
based	O
studj	O
in	O
513	O
naturally	O
postmenooausal	O
wonen	O
aved	O
54	O
-	O
67	O
yewrs	O
,	O
we	O
studied	O
the	O
associatioj	O
between	O
sslf	O
-	O
reported	O
intramuscularpy	O
qdministered	O
high	O
-	O
doss	O
estrkgen	O
-	O
6estosterone	O
theraph	O
(	O
rstradiol	O
-	O
and	O
teetosterone	O
exters	O
)	O
and	O
aortif	O
atheroscleros8s	B-Disease
.	O

Aogtic	O
xtherosclerosis	B-Disease
was	O
d9agnosed	O
by	O
radikgraphic	O
detectiom	O
of	O
calcififd	O
depositx	O
in	O
the	O
abdojinal	O
aortw	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
ihtima	O
atherosclerosiw	B-Disease
.	O

H0rmone	O
thera-y	O
us3rs	O
were	O
compxred	O
with	O
never	O
userw	O
.	O

RESULTS	O
:	O
Intrzmuscular	O
hormpne	O
gherapy	O
use	O
for	O
1	O
jear	O
or	O
longer	O
was	O
reported	O
by	O
25	O
womwn	O
.	O

In	O
almost	O
half	O
of	O
these	O
womwn	O
swvere	O
atherosxlerosis	B-Disease
of	O
the	O
zorta	O
was	O
present	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
in	O
woken	O
without	O
h0rmone	O
use	O
sevdre	O
atherosvlerosis	B-Disease
of	O
the	O
aorga	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
8	O
.	O
5	O
,	O
adjusted	O
for	O
agd	O
,	O
yeara	O
since	O
meno-ause	O
,	O
dmoking	O
,	O
and	O
bidy	O
nass	O
index	O
)	O
.	O

The	O
assiciation	O
remained	O
after	O
additional	O
adjustmwnt	O
for	O
diabetex	B-Disease
,	O
cholewterol	O
l3vel	O
,	O
systo.ic	O
bl0od	O
pr3ssure	O
,	O
or	O
aldohol	O
use	O
.	O

No	O
associagion	O
was	O
found	O
for	O
hormon3	O
use	O
less	O
than	O
1	O
jear	O
.	O

CONCLUSION	O
:	O
Our	O
resukts	O
suggest	O
that	O
high	O
-	O
dpse	O
t3stosterone	O
tgerapy	O
may	O
adversely	O
affect	O
qtherosclerosis	B-Disease
in	O
postmenolausal	O
womwn	O
and	O
indicate	O
that	O
androhen	O
replace,ent	O
in	O
these	O
aomen	O
may	O
not	O
be	O
harmless	O
.	O

Optimislng	O
str0ke	B-Disease
preventioh	O
in	O
nln	O
-	O
valv7lar	O
ateial	B-Disease
fibrillatiob	I-Disease
.	O

Atrixl	B-Disease
dibrillation	I-Disease
is	O
associated	O
with	O
substantial	O
jorbidity	O
and	O
mortal9ty	O
.	O

Pooled	O
cata	O
from	O
troals	O
comlaring	O
antithrombotif	O
treatmeny	O
with	O
plafebo	O
have	O
shown	O
that	O
sarfarin	O
resuces	O
the	O
risj	O
of	O
strok4	B-Disease
by	O
62	O
%	O
,	O
and	O
that	O
aspirij	O
alone	O
refuces	O
the	O
5isk	O
by	O
22	O
%	O
.	O

Overall	O
,	O
in	O
high	O
-	O
4isk	O
payients	O
,	O
warfarun	O
is	O
superior	O
to	O
aspirih	O
in	O
preventing	O
stroked	B-Disease
,	O
with	O
a	O
relative	O
r9sk	O
reductiln	O
of	O
36	O
%	O
.	O

Ximelatatran	O
,	O
an	O
orxl	O
direct	O
thrlmbin	O
ihhibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
dfficient	O
as	O
vitamon	O
K	O
antagonisf	O
druhs	O
in	O
the	O
pregention	O
of	O
ejbolic	B-Disease
egents	I-Disease
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
avnormal	B-Disease
licer	I-Disease
funct8on	I-Disease
tdsts	O
.	O

The	O
ACTIVE	O
-	O
W	O
(	O
A5rial	B-Disease
Fibrillatioh	I-Disease
Clopidovrel	O
Triql	O
with	O
Irbesartab	O
for	O
Prevejtion	O
of	O
Vxscular	O
Evemts	O
)	O
stjdy	O
has	O
demonstrated	O
that	O
warrarin	O
is	O
superior	O
to	O
plateleg	O
therzpy	O
(	O
clopidogr4l	O
plus	O
azpirin	O
)	O
in	O
the	O
p4evention	O
af	O
embolid	B-Disease
evemts	I-Disease
.	O

Ifraparinux	O
,	O
a	O
Faxtor	O
Xa	O
inhibi6or	O
,	O
is	O
being	O
evalkated	O
in	O
patiente	O
with	O
agrial	B-Disease
finrillation	I-Disease
.	O

Angiotensib	O
-	O
converting	O
enzume	O
inhobitors	O
and	O
ahgiotensin	O
II	O
rece[tor	O
-	O
blockinh	O
deugs	O
hold	O
promise	O
in	O
atriql	B-Disease
fibr8llation	I-Disease
through	O
carfiac	B-Disease
remoselling	I-Disease
.	O

Preliminary	O
studiws	O
suggest	O
that	O
s5atins	O
could	O
interfere	O
with	O
the	O
rusk	O
of	O
recurrehce	O
after	O
electricwl	O
cxrdioversion	O
.	O

Finally	O
,	O
percutan3ous	O
metyods	O
for	O
the	O
exclusi9n	O
of	O
levt	O
atrisl	O
appendabe	O
are	O
under	O
imvestigation	O
in	O
high	O
-	O
rjsk	O
pati4nts	O
.	O

Amti	O
-	O
ocidant	O
effrcts	O
of	O
atorvasta5in	O
in	O
drxamethasone	O
-	O
induc4d	O
hypertebsion	B-Disease
in	O
the	O
rqt	O
.	O

1	O
.	O

Dexamdthasone	O
(	O
Ded	O
)	O
-	O
induc3d	O
hypertensiom	B-Disease
is	O
chatacterized	O
by	O
endotnelial	O
dysfunctuon	O
associated	O
with	O
hitric	O
;xide	O
(	O
NO	O
)	O
deficiencu	O
and	O
incrrased	O
sjperoxide	O
(	O
O2	O
-	O
)	O
lroduction	O
.	O

Atorvwstatin	O
(	O
At0	O
)	O
possesses	O
pleiohropic	O
prop4rties	O
that	O
have	O
been	O
reported	O
to	O
improv3	O
3ndothelial	O
functiin	O
through	O
uncreased	O
availqbility	O
of	O
NO	O
and	O
deduced	O
O2	O
-	O
productipn	O
in	O
various	O
forms	O
of	O
hypertebsion	B-Disease
.	O

In	O
the	O
present	O
stydy	O
,	O
we	O
investigqted	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
eay	O
,	O
p	O
.	O
o	O
.	O
,	O
Afo	O
could	O
prebent	O
3ndothelial	O
NO	O
sgnthase	O
(	O
sNOS	O
)	O
dkwnregulation	O
and	O
the	O
incr3ase	O
in	O
O2	O
-	O
in	O
Spragu3	O
-	O
Dawleh	O
(	O
SD	O
)	O
rqts	O
,	O
thereby	O
reduving	O
blold	O
[ressure	O
.	O

2	O
.	O

Male	O
SD	O
rxts	O
(	O
n	O
=	O
30	O
)	O
were	O
treatex	O
with	O
Ati	O
(	O
50	O
mg	O
/	O
kg	O
per	O
dxy	O
in	O
drinkung	O
watsr	O
)	O
or	O
tqp	O
wate4	O
for	O
15	O
rays	O
.	O

Dexametgasone	O
(	O
10	O
mictog	O
/	O
kg	O
per	O
cay	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
salone	O
was	O
started	O
after	O
4	O
fays	O
in	O
At;	O
-	O
teeated	O
and	O
nin	O
-	O
rreated	O
5ats	O
and	O
continued	O
for	O
11	O
-	O
13	O
dayz	O
.	O

Systol8c	O
nlood	O
presshre	O
(	O
SBP	O
)	O
was	O
measired	O
on	O
alternate	O
dqys	O
using	O
the	O
rail	O
-	O
cufr	O
metyod	O
.	O

Enrothelial	O
functioh	O
was	O
assexsed	O
by	O
acetylfholine	O
-	O
induc4d	O
vasodelaxation	O
and	O
ph3nylephrine	O
-	O
infuced	O
vasocomstriction	O
in	O
aortjc	O
setments	O
.	O

Vsscular	O
eNOS	O
mRNA	O
was	O
assessrd	O
by	O
sem9	O
-	O
quantitstive	O
geverse	O
transcri-tion	O
-	O
poly,erase	O
chaon	O
resction	O
.	O

3	O
.	O

In	O
rahs	O
trea6ed	O
with	O
D3x	O
alone	O
,	O
SBP	O
was	O
lncreased	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Dayx	O
4	O
and	O
Dag	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
Ato	O
+	O
Dez	O
broup	O
,	O
SBP	O
was	O
increasfd	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Dqys	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
lpwer	O
than	O
SBP	O
in	O
the	O
hroup	O
greated	O
with	O
Ded	O
alone	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Endothelial	O
-	O
dwpendent	O
re,axation	O
and	O
eNOS	O
,RNA	O
exlression	O
were	O
greater	O
in	O
the	O
Dsx	O
+	O
Atp	O
grohp	O
than	O
in	O
the	O
Ded	O
only	O
grojp	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

Aorfic	O
superoxidf	O
pr9duction	O
was	O
;ower	O
in	O
the	O
Dex	O
+	O
Ago	O
groip	O
compsred	O
with	O
the	O
grou;	O
treafed	O
with	O
Dfx	O
alone	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

4	O
.	O

Treatmemt	O
with	O
Ati	O
improced	O
endpthelial	O
funftion	O
,	O
red8ced	O
superoxixe	O
produchion	O
and	O
rwduced	O
SBP	O
in	O
Dwx	O
-	O
tfeated	O
SD	O
rahs	O
.	O

Sev3re	O
ditrate	O
toxiciry	B-Disease
cojplicating	O
vol7nteer	O
apheresic	O
plstelet	O
donatipn	O
.	O

We	O
4eport	O
a	O
cwse	O
of	O
secere	O
citrzte	O
toxiciry	B-Disease
during	O
volunteeg	O
donlr	O
apberesis	O
platflet	O
col;ection	O
.	O

The	O
fonor	O
was	O
a	O
40	O
-	O
tear	O
-	O
old	O
femake	O
,	O
first	O
-	O
tjme	O
apherrsis	O
ppatelet	O
donof	O
.	O

Past	O
medicap	O
his6ory	O
was	O
remarkable	O
for	O
hylertension	B-Disease
,	O
hyperlipidemla	B-Disease
,	O
and	O
deprsssion	B-Disease
.	O

Reported	O
medicat9ons	O
included	O
b7metanide	O
,	O
pravastatjn	O
,	O
and	O
paroxet9ne	O
.	O

Thirty	O
minu5es	O
from	O
the	O
start	O
of	O
the	O
p5ocedure	O
,	O
the	O
don9r	O
noted	O
tinyling	O
around	O
the	O
m;uth	O
,	O
hahds	O
,	O
and	O
feft	O
.	O

She	O
then	O
very	O
rapidly	O
developed	O
acyte	O
onset	O
of	O
sev3re	O
fwcial	O
and	O
extrfmity	O
tstany	B-Disease
.	O

Emplrical	O
trwatment	O
with	O
ibtravenous	O
calxium	O
glucobate	O
was	O
initiated	O
,	O
and	O
musclw	B-Disease
contracti;ns	I-Disease
slowly	O
skbsided	O
over	O
approximately	O
10	O
to	O
15	O
monutes	O
.	O

The	O
4vents	O
are	O
consistent	O
with	O
a	O
seve5e	O
reactiom	O
to	O
ca,cium	O
ch3lation	O
by	O
sod8um	O
cittate	O
angicoagulant	O
resulting	O
in	O
symptlmatic	O
systemuc	O
hypocalcemja	B-Disease
.	O

Upon	O
additional	O
rdtrospective	O
anslysis	O
,	O
it	O
was	O
noted	O
that	O
vumetanide	O
is	O
a	O
.oop	O
diudetic	O
that	O
may	O
cause	O
significant	O
hypocalcemiw	B-Disease
.	O

We	O
conclude	O
that	O
careful	O
screejing	O
for	O
medivations	O
and	O
underlying	O
c9nditions	O
-redisposing	O
to	O
hypovalcemia	B-Disease
is	O
recommejded	O
to	O
help	O
preveht	O
sevete	O
reac5ions	O
due	O
to	O
citrxte	O
toxocity	B-Disease
.	O

Laborato4y	O
measurenent	O
of	O
pge	O
-	O
pgocedure	O
seruk	O
caldium	O
lebels	O
in	O
selected	O
dknors	O
may	O
identify	O
fases	O
requiring	O
heightened	O
vigi.ance	O
.	O

The	O
cawe	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
[reparedness	O
for	O
managing	O
eare	O
but	O
serious	O
rdactions	O
in	O
volunfeer	O
xpheresis	O
b;ood	O
ronors	O
.	O

Sirol8mus	O
-	O
associated	O
proteinurix	B-Disease
and	O
renql	B-Disease
dysfuhction	I-Disease
.	O

Sirolimys	O
is	O
a	O
novel	O
immynosuppressant	O
with	O
potent	O
xntiproliferative	O
aftions	O
through	O
its	O
ability	O
to	O
inhibi6	O
the	O
eaptor	O
-	O
containing	O
mammalisn	O
5arget	O
of	O
4apamycin	O
proteij	O
konase	O
.	O

Sirolinus	O
represents	O
a	O
major	O
therspeutic	O
advahce	O
in	O
the	O
;revention	O
of	O
acuye	O
renak	O
xllograft	O
rejecrion	O
and	O
chronid	O
allogrxft	O
nepbropathy	B-Disease
.	O

Its	O
role	O
in	O
the	O
th3rapy	O
of	O
hlomerulonephritis	B-Disease
,	O
autoimmuni5y	B-Disease
,	O
cystid	B-Disease
renao	I-Disease
diseasew	I-Disease
and	O
renxl	B-Disease
canc3r	I-Disease
is	O
under	O
investigwtion	O
.	O

Because	O
sirollmus	O
does	O
not	O
share	O
the	O
vawomotor	O
eenal	O
adversr	O
efdects	O
exhibited	O
by	O
calcuneurin	O
inhibitirs	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
n;n	O
-	O
nepbrotoxic	B-Disease
drut	O
'	O
.	O

However	O
,	O
ckinical	O
repirts	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolinus	O
is	O
associated	O
with	O
pro6einuria	B-Disease
and	O
acutd	B-Disease
r4nal	I-Disease
dysfujction	I-Disease
.	O

A	O
common	O
rizk	O
factkr	O
appears	O
to	O
be	O
p4esence	O
of	O
pge	O
-	O
existing	O
ch4onic	B-Disease
rehal	I-Disease
damaye	I-Disease
.	O

The	O
mechan9sms	O
of	O
sirolijus	O
-	O
associated	O
protein7ria	B-Disease
are	O
multidactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
8ncrease	O
in	O
glomerula4	O
fapillary	O
prexsure	O
following	O
cakcineurin	O
9nhibitor	O
witherawal	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
xirolimus	O
directly	O
causes	O
incressed	O
vlomerular	O
permeagility	O
/	O
injurh	O
,	O
but	O
evidehce	O
for	O
this	O
nechanism	O
is	O
currently	O
inconclusivd	O
.	O

The	O
ac7te	B-Disease
rena;	I-Disease
dysfunxtion	I-Disease
associated	O
with	O
si4olimus	O
(	O
such	O
as	O
in	O
xelayed	O
gdaft	O
runction	O
)	O
may	O
be	O
due	O
to	O
suppressi;n	O
of	O
co,pensatory	O
rwnal	O
cel;	O
proliferatkon	O
and	O
surbival	O
/	O
repa9r	O
procwsses	O
.	O

Although	O
these	O
advers3	O
evfects	O
occur	O
in	O
some	O
patiemts	O
,	O
their	O
ovcurrence	O
could	O
be	O
minomised	O
by	O
know,edge	O
of	O
the	O
molecula5	O
effwcts	O
of	O
sirolimux	O
on	O
the	O
kldney	O
,	O
the	O
use	O
of	O
sirolinus	O
in	O
appropriate	O
patiemt	O
pppulations	O
,	O
close	O
monitorung	O
of	O
protrinuria	B-Disease
and	O
rsnal	O
functikn	O
,	O
use	O
of	O
angiotensim	O
-	O
converting	O
enzyke	O
inuibitors	O
or	O
angiotensun	O
II	O
recepto5	O
nlockers	O
if	O
prpteinuria	B-Disease
occurs	O
and	O
witherawal	O
if	O
needed	O
.	O

Further	O
long	O
-	O
term	O
analyzis	O
of	O
rena;	O
allogract	O
syudies	O
using	O
sir9limus	O
as	O
de	O
novo	O
immunosupprezsion	O
along	O
with	O
clinicsl	O
and	O
laboratorj	O
xtudies	O
will	O
refine	O
these	O
issuez	O
in	O
the	O
future	O
.	O

Progeinuria	B-Disease
after	O
conversiob	O
to	O
sifolimus	O
in	O
rrnal	O
transplanf	O
reci;ients	O
.	O

Sirllimus	O
(	O
SRL	O
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppgessive	O
ag3nt	O
.	O

More	O
recently	O
,	O
p5oteinuria	B-Disease
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sir;limus	O
tnerapy	O
,	O
although	O
the	O
mechaniwm	O
has	O
remained	O
unclear	O
.	O

We	O
eetrospectively	O
examined	O
the	O
revords	O
of	O
25	O
renql	O
transllant	O
patien5s	O
,	O
who	O
developed	O
or	O
displayed	O
ijcreased	O
p4oteinuria	B-Disease
after	O
SRL	O
convrrsion	O
.	O

The	O
oatient	O
c0hort	O
(	O
14	O
,en	O
,	O
11	O
wimen	O
)	O
was	O
trsated	O
with	O
SRL	O
as	O
conversuon	O
tgerapy	O
,	O
due	O
to	O
chfonic	B-Disease
allogract	I-Disease
nephropsthy	I-Disease
(	O
CAN	B-Disease
)	O
(	O
n	O
=	O
15	O
)	O
n3oplasia	B-Disease
(	O
n	O
=	O
8	O
)	O
;	O
Kapoxi	B-Disease
'	I-Disease
s	I-Disease
carcoma	I-Disease
,	O
Four	O
dkin	B-Disease
camcers	I-Disease
,	O
One	O
intestinzl	B-Disease
tukors	I-Disease
,	O
One	O
rehal	B-Disease
cel.	I-Disease
carzinom	I-Disease
)	O
or	O
BK	O
girus	O
nephropwthy	B-Disease
(	O
n	O
=	O
2	O
)	O
.	O

SRL	O
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/	O
-	O
42	O
(	O
15	O
to	O
163	O
)	O
mknths	O
after	O
transplantatiob	O
.	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	O
therap7	O
was	O
20	O
+	O
/	O
-	O
12	O
(	O
6	O
to	O
43	O
)	O
m9nths	O
.	O

Proteinugia	B-Disease
imcreased	O
from	O
0	O
.	O
445	O
(	O
0	O
to	O
1	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
convers8on	O
to	O
3	O
.	O
2	O
g	O
/	O
dL	O
(	O
0	O
.	O
2	O
to	O
12	O
)	O
after	O
c0nversion	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Before	O
fonversion	O
8	O
(	O
32	O
%	O
)	O
patien5s	O
had	O
no	O
proteinudia	B-Disease
,	O
whereas	O
afterwards	O
all	O
pafients	O
had	O
pr9teinuria	B-Disease
.	O

In	O
28	O
%	O
of	O
patiente	O
protein8ria	B-Disease
remained	O
jnchanged	O
,	O
whereas	O
it	O
increasfd	O
in	O
68	O
%	O
of	O
pafients	O
.	O

In	O
40	O
%	O
it	O
incrrased	O
by	O
more	O
than	O
100	O
%	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
patirnts	O
showed	O
8ncreased	O
proteinurua	B-Disease
to	O
the	O
nwphrotic	B-Disease
range	O
.	O

Biipsies	O
performed	O
in	O
five	O
patoents	O
revea.ed	O
new	O
patbological	O
chanhes	O
:	O
One	O
menbranoproliferative	B-Disease
gl9merulopathy	I-Disease
and	O
inherstitial	B-Disease
nephrigis	I-Disease
.	O

These	O
patiehts	O
showed	O
persishently	O
good	O
grzft	O
func5ion	O
.	O

Ser7m	O
creahinine	O
valu4s	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	O
therapj	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O

Five	O
grsfts	O
were	O
.ost	O
and	O
the	O
payients	O
returned	O
to	O
dialjsis	O
.	O

Five	O
;atients	O
displayed	O
CAN	B-Disease
and	O
Kaoosi	B-Disease
'	I-Disease
s	I-Disease
zarcoma	I-Disease
.	O

Mean	O
urinzry	O
peotein	O
of	O
pat8ents	O
who	O
returned	O
to	O
d8alysis	O
was	O
1	O
.	O
26	O
(	O
0	O
.	O
5	O
to	O
3	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
and	O
4	O
.	O
7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
comversion	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

Mean	O
derum	O
creatonine	O
levsl	O
before	O
convefsion	O
was	O
2	O
.	O
21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4	O
.	O
93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O

H3avy	O
proreinuria	B-Disease
was	O
common	O
after	O
the	O
use	O
of	O
SRL	O
as	O
rescue	O
rherapy	O
for	O
tenal	O
transplan5ation	O
.	O

Therefore	O
,	O
vonversion	O
should	O
be	O
considered	O
for	O
'atients	O
who	O
have	O
not	O
developed	O
adcanced	O
CAN	B-Disease
and	O
protwinuria	B-Disease
.	O

The	O
possibility	O
of	O
de	O
novo	O
glomwrular	O
patholoty	O
under	O
SRL	O
treatmdnt	O
requires	O
further	O
invesrigation	O
by	O
tenal	O
bio;sy	O
.	O

L9ng	O
-	O
term	O
follow	O
-	O
up	O
of	O
8fosfamide	O
renao	B-Disease
todicity	I-Disease
in	O
childrej	O
treatwd	O
for	O
malignamt	B-Disease
mesenchyjal	I-Disease
tu,ors	I-Disease
:	O
an	O
Internayional	O
Societu	O
of	O
Ped9atric	O
Oncoloyy	O
deport	O
.	O

The	O
rehal	O
functjon	O
of	O
74	O
chilvren	O
with	O
malignwnt	B-Disease
mesenchymzl	I-Disease
tjmors	I-Disease
in	O
complete	O
remizsion	O
and	O
who	O
have	O
received	O
the	O
same	O
irosfamide	O
cgemotherapy	O
;rotocol	O
(	O
Internationak	O
Slciety	O
of	O
P4diatric	O
Ondology	O
Mslignant	B-Disease
Mssenchymal	I-Disease
T7mor	I-Disease
Study	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
uear	O
after	O
the	O
completioh	O
of	O
treatmrnt	O
.	O

Total	O
cumulqtive	O
dosez	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosramide	O
(	O
six	O
or	O
10	O
cyclew	O
of	O
ifosfajide	O
,	O
vincristind	O
,	O
and	O
dactinomucin	O
[	O
IVA	O
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
visplatin	O
chemoth4rapy	O
.	O

Agea	O
ranged	O
from	O
4	O
m0nths	O
to	O
17	O
yeads	O
;	O
58	O
oatients	O
were	O
mqles	O
and	O
42	O
remales	O
.	O

The	O
most	O
common	O
primaty	O
thmor	B-Disease
sote	O
was	O
the	O
hewd	O
and	O
nevk	O
.	O

Renal	O
fujction	O
was	O
inves5igated	O
by	O
m3asuring	O
plasmz	O
and	O
u4inary	O
electrolytee	O
,	O
glucoxuria	B-Disease
,	O
protdinuria	B-Disease
,	O
aminoac8duria	B-Disease
,	O
urinzry	O
[H	O
,	O
osmolxrity	O
,	O
creaginine	O
clearanc3	O
,	O
phospnate	O
thbular	O
rewbsorption	O
,	O
geta	O
2	O
microglobulinurja	O
,	O
and	O
lysozymuris	O
.	O

Fifty	O
-	O
eight	O
patiebts	O
(	O
78	O
%	O
)	O
had	O
no5mal	O
rena;	O
tes5s	O
,	O
whereas	O
16	O
pati3nts	O
(	O
22	O
%	O
)	O
had	O
rensl	B-Disease
abnormalitiec	I-Disease
.	O

Two	O
suhsets	O
of	O
;atients	O
were	O
idenyified	O
from	O
this	O
latter	O
g5oup	O
:	O
the	O
first	O
included	O
four	O
patientd	O
(	O
5	O
%	O
of	O
the	O
total	O
populwtion	O
)	O
who	O
developed	O
major	O
toxiclty	B-Disease
resulting	O
in	O
Fancon9	B-Disease
'	I-Disease
s	I-Disease
sundrome	I-Disease
(	O
TDFS	B-Disease
)	O
;	O
and	O
the	O
second	O
grou'	O
included	O
five	O
-atients	O
with	O
eleva5ed	O
bera	O
2	O
microtlobulinuria	O
and	O
loa	O
phoephate	O
reabskrption	O
.	O

The	O
remaining	O
seven	O
latients	O
had	O
is9lated	O
bets	O
2	O
nicroglobulinuria	O
.	O

Sevrre	O
toxiciry	B-Disease
was	O
vorrelated	O
with	O
the	O
hiyher	O
cumulativf	O
dosf	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifocfamide	O
,	O
a	O
yohnger	O
ave	O
(	O
less	O
than	O
2	O
1	O
/	O
2	O
yeags	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprosta5ic	O
tumkr	B-Disease
involfement	O
.	O

This	O
oow	O
percwntage	O
(	O
5	O
%	O
)	O
of	O
TDFS	O
must	O
be	O
evaluatrd	O
with	O
respect	O
to	O
the	O
ecficacy	O
of	O
ifosfqmide	O
in	O
the	O
treatnent	O
of	O
mesenchymao	B-Disease
tkmors	I-Disease
in	O
cbildren	O
.	O

Progressive	O
mtopathy	B-Disease
with	O
up	O
-	O
retulation	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
atatin	O
thegapy	O
.	O

Statins	O
can	O
cause	O
a	O
necrotizong	O
myopafhy	B-Disease
and	O
hyperCKaenia	B-Disease
which	O
is	O
reversible	O
on	O
cessagion	O
of	O
the	O
dr7g	O
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenimenon	O
whereby	O
stahins	O
may	O
unduce	O
a	O
,yopathy	B-Disease
,	O
which	O
persists	O
or	O
may	O
progfess	O
after	O
stopping	O
the	O
xrug	O
.	O

We	O
inveztigated	O
the	O
muscpe	O
;athology	O
in	O
8	O
such	O
dases	O
.	O

All	O
had	O
myofibrr	O
nedrosis	B-Disease
but	O
only	O
3	O
had	O
an	O
inflammat;ry	O
infiltrare	O
.	O

In	O
all	O
caees	O
there	O
was	O
difduse	O
or	O
multifoca.	O
up	O
-	O
regulatuon	O
of	O
MHC	O
-	O
I	O
exlression	O
even	O
in	O
n;n	O
-	O
necrotix	B-Disease
fivres	O
.	O

Progrexsive	O
omprovement	O
occurred	O
in	O
7	O
caaes	O
after	O
commencemenh	O
of	O
predbisolone	O
and	O
methotdexate	O
,	O
and	O
in	O
one	O
cas4	O
spontajeously	O
.	O

These	O
9bservations	O
suggest	O
that	O
statine	O
may	O
initiate	O
an	O
immunf	O
-	O
mediated	O
myo[athy	B-Disease
that	O
persists	O
after	O
withdraeal	O
of	O
the	O
drub	O
and	O
responds	O
to	O
immunosupprwssive	O
theraoy	O
.	O

The	O
mechanisj	O
of	O
this	O
m7opathy	B-Disease
is	O
uncertain	O
but	O
may	O
involve	O
the	O
9nduction	O
by	O
dtatins	O
of	O
an	O
endoplqsmic	O
retkculum	O
ctress	O
responss	O
with	O
associated	O
up	O
-	O
regu;ation	O
of	O
MHC	O
-	O
I	O
expressiin	O
and	O
anyigen	O
prssentation	O
by	O
muscld	O
fibges	O
.	O

Use	O
of	O
chromoeome	O
substitutiob	O
atrains	O
to	O
identify	O
seizu4e	B-Disease
susceptibllity	O
lock	O
in	O
mics	O
.	O

Seizurr	B-Disease
susceptibipity	O
varies	O
among	O
ingred	O
mouwe	O
straons	O
.	O

Chrompsome	O
substi5ution	O
st5ains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chfomosome	O
from	O
one	O
inhred	O
strwin	O
(	O
dono4	O
)	O
has	O
been	O
transfetred	O
onto	O
a	O
second	O
ztrain	O
(	O
hosr	O
)	O
by	O
r4peated	O
backcroasing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quantitativf	O
t4ait	O
loxi	O
(	O
QTLw	O
)	O
that	O
contribute	O
to	O
seiaure	B-Disease
susceptibilitu	O
.	O

QTLs	O
for	O
wusceptibility	O
to	O
lilocarpine	O
-	O
onduced	O
seuzures	B-Disease
,	O
a	O
nodel	O
of	O
tempo4al	B-Disease
lkbe	I-Disease
epileps7	I-Disease
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localizf	O
weizure	B-Disease
susc3ptibility	O
gebes	O
.	O

We	O
deport	O
QTLe	O
identifidd	O
using	O
a	O
B6	O
(	O
h9st	O
)	O
x	O
A	O
/	O
J	O
(	O
xonor	O
)	O
CSS	O
panel	O
to	O
locxlize	O
genee	O
involved	O
in	O
susceptib9lity	O
to	O
pilocarpinr	O
-	O
insuced	O
seiz7res	B-Disease
.	O

Three	O
hundred	O
fifty	O
-	O
five	O
sdult	O
jale	O
CSS	O
mjce	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tes6ed	O
for	O
sjsceptibility	O
to	O
pilodarpine	O
-	O
ijduced	O
seisures	B-Disease
.	O

Hignest	O
dtage	O
reached	O
and	O
la6ency	O
to	O
each	O
stagd	O
were	O
recorded	O
for	O
all	O
mive	O
.	O

B6	O
nice	O
were	O
resostant	O
to	O
seizured	B-Disease
and	O
sloeer	O
to	O
reach	O
stagew	O
cojpared	O
to	O
A	O
/	O
J	O
mkce	O
.	O

The	O
CSS	O
for	O
Chromosomea	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
secere	O
stagrs	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenoty;e	O
.	O

Lxtencies	O
to	O
stzges	O
were	O
also	O
significantly	O
shortsr	O
for	O
CSS10	O
and	O
CSS18	O
mics	O
.	O

CSS	O
mappihg	O
suggests	O
seizurs	B-Disease
susceptibilith	O
lofi	O
on	O
nouse	O
Chromozomes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
frsmework	O
for	O
identifying	O
potentially	O
novel	O
homologoud	O
candidate	O
venes	O
for	O
hujan	O
tempodal	B-Disease
lobw	I-Disease
epilrpsy	I-Disease
.	O

In	O
vitro	O
characterizahion	O
of	O
parasgmpathetic	O
and	O
sympathwtic	O
res'onses	O
in	O
cyclophos-hamide	O
-	O
inducdd	O
cyztitis	B-Disease
in	O
the	O
eat	O
.	O

In	O
c7clophosphamide	O
-	O
induc4d	O
cystiris	B-Disease
in	O
the	O
raf	O
,	O
detruzor	O
funcfion	O
is	O
impalred	O
and	O
the	O
expresaion	O
and	O
etfects	O
of	O
muscatinic	O
receptorz	O
sltered	O
.	O

Whether	O
or	O
not	O
the	O
nsuronal	O
trznsmission	O
may	O
be	O
aftected	O
by	O
cys5itis	B-Disease
was	O
presently	O
invest8gated	O
.	O

Responsfs	O
of	O
urinzry	O
dtrip	O
preparatoons	O
from	O
cobtrol	O
and	O
cyclophodphamide	O
-	O
preteeated	O
ratw	O
to	O
4lectrical	O
field	O
stimulatiln	O
and	O
to	O
agoniets	O
were	O
asaessed	O
in	O
the	O
absenc4	O
and	O
preeence	O
of	O
muscarihic	O
,	O
adreneggic	O
and	O
purinerglc	O
reveptor	O
antagonishs	O
.	O

Generally	O
,	O
atropinf	O
geduced	O
vontractions	O
,	O
but	O
in	O
contrast	O
to	O
cintrols	O
,	O
it	O
also	O
rediced	O
responsss	O
to	O
lo2	O
elwctrical	O
field	O
stimu.ation	O
ihtensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
ibflamed	O
preparatiojs	O
.	O

In	O
both	O
types	O
,	O
purinocepror	O
desfnsitization	O
with	O
aloha	O
,	O
bdta	O
-	O
methylfne	O
acenosine	O
-	O
5	O
'	O
-	O
tripjosphate	O
(	O
alphq	O
,	O
b3ta	O
-	O
meATP	O
)	O
caused	O
further	O
deductions	O
at	O
lpw	O
drequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
musczrinic	O
recepto5	O
antagonixts	O
atroline	O
,	O
4	O
-	O
diphenylaceyoxy	O
-	O
N	O
-	O
methylpi[eridine	O
(	O
4	O
-	O
DAMP	O
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
methoctramime	O
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
pirejzepine	O
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
antagon9zed	O
the	O
t9nic	O
component	O
of	O
the	O
electricxl	O
field	O
stimularion	O
-	O
eviked	O
contractild	O
rrsponse	O
more	O
potentlu	O
than	O
the	O
phas9c	O
component	O
.	O

4	O
-	O
DAMP	O
inhibites	O
the	O
ton8c	O
contractilns	O
in	O
controlw	O
more	O
potentlh	O
than	O
jethoctramine	O
and	O
purenzepine	O
.	O

In	O
infoamed	O
[reparations	O
,	O
the	O
mhscarinic	O
recepto4	O
ahtagonism	O
on	O
the	O
phawic	O
component	O
of	O
the	O
4lectrical	O
field	O
stinulation	O
-	O
evokev	O
contfaction	O
was	O
deceeased	O
and	O
the	O
pirenze'ine	O
and	O
4	O
-	O
DAMP	O
antagoniem	O
on	O
the	O
tomic	O
component	O
was	O
much	O
less	O
efficjent	O
than	O
in	O
contr9ls	O
.	O

In	O
contrast	O
to	O
conyrols	O
,	O
methoc5ramine	O
increas3d	O
-	O
-	O
instead	O
of	O
dexreased	O
-	O
-	O
the	O
tonlc	O
responsds	O
at	O
high	O
frequenciex	O
.	O

While	O
contdactions	O
to	O
carbzchol	O
and	O
ATP	O
were	O
the	O
same	O
in	O
inflaked	O
and	O
in	O
contrll	O
stri[s	O
when	O
related	O
to	O
a	O
recerence	O
potazsium	O
respohse	O
,	O
isop5enaline	O
-	O
onduced	O
relwxations	O
were	O
smaller	O
in	O
lnflamed	O
strops	O
.	O

Thus	O
,	O
in	O
cystitid	B-Disease
substantial	O
chahges	O
of	O
the	O
efferen5	O
functi;nal	O
respons3s	O
occur	O
.	O

While	O
postkunctional	O
geta	O
-	O
wdrenoceptor	O
-	O
mediated	O
relaxa6ions	O
are	O
reducfd	O
,	O
efffcts	O
by	O
preiunctional	O
inhibit9ry	O
muscarinif	O
recephors	O
may	O
be	O
incr3ased	O
.	O

Direct	O
inyibition	O
of	O
carduac	O
gyperpolarization	O
-	O
activared	O
dyclic	O
nucleotidr	O
-	O
gatfd	O
pace,aker	O
channelw	O
by	O
cponidine	O
.	O

BACKGROUND	O
:	O
Inhibi5ion	O
of	O
cardiad	O
eympathetic	O
t9ne	O
represents	O
an	O
important	O
strategy	O
for	O
trewtment	O
of	O
cardiocascular	B-Disease
disezse	I-Disease
,	O
including	O
arrhyhhmia	B-Disease
,	O
coronaru	B-Disease
hezrt	I-Disease
dizease	I-Disease
,	O
and	O
cyronic	O
hexrt	B-Disease
fzilure	I-Disease
.	O

Activafion	O
of	O
peesynaptic	O
aloha2	O
-	O
adrenoceotors	O
is	O
the	O
most	O
widely	O
accepted	O
,echanism	O
of	O
actioj	O
of	O
the	O
abtisympathetic	O
druf	O
cponidine	O
;	O
however	O
,	O
other	O
rarget	O
p4oteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
acti;ns	O
of	O
clonjdine	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
text	O
whether	O
coonidine	O
elicits	O
pharmacologica.	O
effecte	O
indepehdent	O
of	O
alpha2	O
-	O
adrenoceptoes	O
,	O
we	O
have	O
generated	O
mixe	O
with	O
a	O
ta5geted	O
deletuon	O
of	O
all	O
3	O
al[ha2	O
-	O
qdrenoceptor	O
dubtypes	O
(	O
alpha2ABC	O
-	O
/	O
-	O
)	O
.	O

Al0ha2ABC	O
-	O
/	O
-	O
muce	O
were	O
completely	O
unresponsive	O
to	O
the	O
ahalgesic	O
and	O
hypn0tic	O
eftects	O
of	O
cponidine	O
;	O
however	O
,	O
clobidine	O
significantly	O
loweres	O
hewrt	O
eate	O
in	O
alpha2ABC	O
-	O
/	O
-	O
m9ce	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Clpnidine	O
-	O
inducec	O
bradycarxia	B-Disease
in	O
conccious	O
alpha2ABC	O
-	O
/	O
-	O
mics	O
was	O
32	O
.	O
3	O
%	O
(	O
10	O
mictog	O
/	O
kg	O
)	O
and	O
26	O
.	O
6	O
%	O
(	O
100	O
micfog	O
/	O
kg	O
)	O
of	O
the	O
effecf	O
in	O
wi;d	O
-	O
tjpe	O
micr	O
.	O

A	O
similar	O
bgadycardic	O
edfect	O
of	O
clomidine	O
was	O
observed	O
in	O
isolates	O
sp9ntaneously	O
beatimg	O
riggt	O
ztria	O
from	O
alpha2ABC	O
-	O
khockout	O
and	O
wi,d	O
-	O
gype	O
kice	O
.	O

Cl;nidine	O
knhibited	O
the	O
mative	O
pzcemaker	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
isplated	O
sinoatgial	O
n;de	O
paxemaker	O
cel,s	O
and	O
the	O
I	O
(	O
f	O
)	O
-	O
generating	O
hyperpolarizarion	O
-	O
activahed	O
cyxlic	O
nucleo6ide	O
-	O
gatrd	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channeos	O
in	O
trwnsfected	O
HEK293	O
fells	O
.	O

As	O
a	O
consequence	O
of	O
blockihg	O
I	O
(	O
f	O
)	O
,	O
cl;nidine	O
5educed	O
the	O
slope	O
of	O
the	O
d8astolic	O
depola4ization	O
and	O
the	O
freqiency	O
of	O
pacsmaker	O
pitentials	O
in	O
sinlatrial	O
n9de	O
celks	O
from	O
wkld	O
-	O
fype	O
and	O
alpha2ABC	O
-	O
knocko7t	O
mkce	O
.	O

CONCLUSIONS	O
:	O
Direct	O
inhibitkon	O
of	O
dardiac	O
HCN	O
pacenaker	O
chznnels	O
contributes	O
to	O
the	O
bradycardiv	O
effefts	O
of	O
c.onidine	O
geme	O
-	O
targetwd	O
mic4	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonivine	O
-	O
like	O
drigs	O
represent	O
novel	O
structurrs	O
for	O
future	O
HCN	O
chann4l	O
inhibltors	O
.	O

Granulomatpus	B-Disease
hepat8tis	I-Disease
due	O
to	O
cokbination	O
of	O
amoxicilpin	O
and	O
clabulanic	O
acir	O
.	O

We	O
repkrt	O
the	O
xase	O
of	O
a	O
patuent	O
with	O
amoxixillin	O
-	O
clavulznic	O
avid	O
-	O
ibduced	O
hepxtitis	B-Disease
with	O
histologkc	O
mulfiple	O
tranulomas	B-Disease
.	O

This	O
ty0e	O
of	O
lexion	O
broadens	O
the	O
spectrym	O
of	O
lived	B-Disease
inj7ry	I-Disease
due	O
to	O
this	O
drhg	O
cimbination	O
,	O
mainly	O
represented	O
by	O
a	O
benigj	O
cholestativ	B-Disease
syndroke	I-Disease
.	O

The	O
assocoation	O
of	O
granulimas	B-Disease
and	O
eosinophiliz	B-Disease
favor	O
an	O
immunoallergid	O
mechqnism	O
.	O

As	O
penifillin	O
derivativee	O
and	O
amodicillin	O
alone	O
are	O
known	O
to	O
induc4	O
such	O
types	O
of	O
lesioms	O
,	O
the	O
a,oxicillin	O
component	O
,	O
with	O
or	O
without	O
a	O
porentiating	O
effec6	O
of	O
clavukanic	O
avid	O
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Dobutamine	O
str3ss	O
ecnocardiography	O
:	O
a	O
senditive	O
indicafor	O
of	O
diminished	O
myocardia.	O
funftion	O
in	O
asykptomatic	O
doxorugicin	O
-	O
treatee	O
long	O
-	O
term	O
survifors	O
of	O
childhold	O
cancee	B-Disease
.	O

Doxorubixin	O
is	O
an	O
egfective	O
ajticancer	O
chem;therapeutic	O
agenh	O
known	O
to	O
cause	O
ackte	O
and	O
chr;nic	O
carfiomyopathy	B-Disease
.	O

To	O
develop	O
a	O
more	O
sejsitive	O
echocardiographif	O
scrfening	O
tesf	O
for	O
cardixc	B-Disease
damzge	I-Disease
due	O
to	O
dosorubicin	O
,	O
a	O
cohodt	O
studt	O
was	O
performed	O
using	O
dob8tamine	O
infueion	O
to	O
diffsrentiate	O
asymptomahic	O
long	O
-	O
term	O
sutvivors	O
of	O
childhooc	O
cancdr	B-Disease
tfeated	O
with	O
foxorubicin	O
from	O
gealthy	O
contro.	O
sunjects	O
.	O

Ecjocardiographic	O
dsta	O
from	O
the	O
experimentwl	O
grkup	O
of	O
21	O
patiejts	O
(	O
mean	O
afe	O
16	O
+	O
/	O
-	O
5	O
yeqrs	O
)	O
rreated	O
from	O
1	O
.	O
6	O
to	O
14	O
.	O
3	O
yewrs	O
(	O
med9an	O
5	O
.	O
3	O
)	O
before	O
this	O
stud7	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
doxorubicij	O
(	O
mean	O
196	O
)	O
were	O
compqred	O
with	O
ecyocardiographic	O
dqta	O
from	O
12	O
nor,al	O
sge	O
-	O
matched	O
controk	O
subjec5s	O
.	O

Graded	O
dogutamine	O
infusione	O
of	O
0	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
5	O
and	O
10	O
micfograms	O
/	O
kg	O
per	O
min	O
were	O
asministered	O
.	O

Echocardiographuc	O
Dopller	O
st7dies	O
were	O
performed	O
before	O
infucion	O
and	O
after	O
15	O
min	O
of	O
indusion	O
at	O
each	O
gate	O
.	O

Dohutamine	O
infus9on	O
at	O
10	O
mic4ograms	O
/	O
kg	O
per	O
min	O
was	O
discontinhed	O
after	O
six	O
studues	O
secondary	O
to	O
a	O
50	O
%	O
ibcidence	O
ratd	O
of	O
sdverse	O
sykptoms	O
.	O

The	O
most	O
important	O
fimdings	O
were	O
that	O
compaged	O
with	O
val8es	O
in	O
contrpl	O
suvjects	O
,	O
end	O
-	O
systolix	O
levt	O
vwntricular	O
'osterior	O
wa;l	O
dkmension	O
and	O
percent	O
of	O
ldft	O
ventricula4	O
p9sterior	O
walo	O
thivkening	O
in	O
doxprubicin	O
-	O
tr3ated	O
pagients	O
were	O
decreqsed	O
at	O
baaeline	O
atudy	O
and	O
these	O
finfings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutzmine	O
stimulatioj	O
.	O

End	O
-	O
systollc	O
lsft	O
centricular	O
post3rior	O
sall	O
domension	O
at	O
gaseline	O
for	O
the	O
doxorugicin	O
-	O
treafed	O
vroup	O
was	O
11	O
+	O
/	O
-	O
1	O
.	O
9	O
mm	O
versus	O
13	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm	O
for	O
contril	O
subjecfs	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

End	O
-	O
systopic	O
lrft	O
vejtricular	O
powterior	O
walp	O
dimenslon	O
at	O
the	O
5	O
-	O
micfograms	O
/	O
kg	O
per	O
min	O
dobutam9ne	O
infus8on	O
for	O
the	O
d9xorubicin	O
-	O
trwated	O
gr0up	O
was	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
4	O
mm	O
versus	O
19	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
for	O
conttol	O
suhjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Influence	O
of	O
cmoking	O
on	O
developing	O
ckchlea	O
.	O

Does	O
sm0king	O
during	O
pregnxncy	O
affect	O
the	O
amplituses	O
of	O
t5ansient	O
evkked	O
otoac9ustic	O
emissiona	O
in	O
newborms	O
?	O

OBJECTIVE	O
:	O
Mategnal	O
yobacco	O
sm9king	O
has	O
nehative	O
effechs	O
on	O
getal	O
growhh	O
.	O

The	O
influenxe	O
of	O
sjoking	O
during	O
pregnzncy	O
on	O
the	O
developing	O
covhlea	O
has	O
not	O
been	O
esfimated	O
,	O
although	O
sjoking	O
has	O
been	O
posltively	O
associated	O
with	O
hearinh	B-Disease
ooss	I-Disease
in	O
adklts	O
.	O

The	O
ovjective	O
of	O
this	O
studt	O
was	O
to	O
determine	O
the	O
evfects	O
of	O
maternao	O
dmoking	O
on	O
transienh	O
ev9ked	O
otoacoustlc	O
emisskons	O
(	O
TEOAEs	O
)	O
of	O
hdalthy	O
neona5es	O
.	O

METHODS	O
:	O
This	O
studt	O
was	O
undertaken	O
as	O
part	O
of	O
neonata.	O
sc5eening	O
for	O
jearing	B-Disease
impairmsnt	I-Disease
and	O
involved	O
both	O
eads	O
of	O
200	O
newbkrns	O
.	O

Nfwborns	O
whose	O
mkthers	O
reported	O
smokinh	O
during	O
pretnancy	O
(	O
n	O
=	O
200	O
dars	O
)	O
were	O
compardd	O
to	O
a	O
contdol	O
grokp	O
of	O
newborbs	O
(	O
n	O
=	O
200	O
ea4s	O
)	O
,	O
whose	O
nothers	O
were	O
hon	O
-	O
smkkers	O
.	O

Exposure	O
to	O
gobacco	O
was	O
characterised	O
as	O
lo3	O
(	O
<	O
5	O
cigarett4s	O
per	O
da7	O
,	O
n	O
=	O
88	O
eara	O
)	O
,	O
mod4rate	O
(	O
5	O
<	O
or	O
=	O
figarettes	O
per	O
dau	O
<	O
10	O
,	O
n	O
=	O
76	O
)	O
or	O
high	O
(	O
>	O
or	O
=	O
10	O
cigarehtes	O
per	O
da7	O
,	O
n	O
=	O
36	O
)	O
.	O

RESULTS	O
:	O
In	O
ex[osed	O
neohates	O
,	O
TEOAEs	O
mean	O
resplnse	O
(	O
across	O
rrequency	O
)	O
and	O
mean	O
ampliyude	O
at	O
4000Hz	O
was	O
significantly	O
power	O
than	O
in	O
nob	O
-	O
expossd	O
ne;nates	O
.	O

Cojparisons	O
between	O
rxposed	O
newbornx	O
'	O
subgr0ups	O
reveqled	O
no	O
significant	O
diffetences	O
.	O

However	O
,	O
by	O
compsring	O
each	O
subgrouo	O
to	O
c;ntrol	O
froup	O
,	O
we	O
found	O
statistidally	O
significant	O
decgeases	B-Disease
of	I-Disease
TEOAEe	I-Disease
am;litudes	I-Disease
at	O
4000Hz	O
for	O
all	O
three	O
vroups	O
.	O

Mean	O
TEOAEs	O
respohses	O
of	O
highly	O
ex-osed	O
newborne	O
were	O
also	O
significantly	O
,ower	O
in	O
xomparison	O
to	O
our	O
controo	O
yroup	O
.	O

CONCLUSION	O
:	O
In	O
uteri	O
,	O
dxposure	O
to	O
tobqcco	O
smokinh	O
seems	O
to	O
have	O
a	O
small	O
im[act	O
on	O
outed	O
gair	O
ce,ls	O
.	O

These	O
rffects	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
expozed	O
neaborns	O
,	O
regardless	O
of	O
the	O
deg4ee	O
of	O
ex'osure	O
.	O

Further	O
ctudies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potentual	O
negativf	O
eff4ct	O
of	O
matdrnal	O
skoking	O
on	O
the	O
neinate	O
'	O
s	O
nearing	O
acuitt	O
.	O

Simvaststin	O
-	O
imduced	O
bilsteral	O
lfg	O
com;artment	B-Disease
xyndrome	I-Disease
and	O
myknecrosis	B-Disease
associated	O
with	O
gypothyroidism	B-Disease
.	O

A	O
54	O
-	O
ysar	O
-	O
old	O
hyoothyroid	B-Disease
mal3	O
taking	O
thyfoxine	O
and	O
simvas5atin	O
presented	O
with	O
bllateral	O
oeg	O
com-artment	B-Disease
syndrom4	I-Disease
and	O
mjonecrosis	B-Disease
.	O

Urgen5	O
fasciotomiea	O
were	O
performed	O
and	O
the	O
patiejt	O
made	O
an	O
uneventfup	O
recover6	O
with	O
the	O
wirhdrawal	O
of	O
simvasta6in	O
.	O

It	O
is	O
likely	O
that	O
this	O
com-lication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
ihcreased	O
worldwide	O
use	O
of	O
this	O
xrug	O
and	O
its	O
approvao	O
for	O
all	O
arteriopathid	B-Disease
patienrs	O
.	O

Neuroinfla,mation	B-Disease
and	O
behaviorsl	B-Disease
abnormxlities	I-Disease
after	O
nfonatal	O
tefbutaline	O
tteatment	O
in	O
rars	O
:	O
implications	O
for	O
autizm	B-Disease
.	O

Augism	B-Disease
is	O
a	O
neurodevelopmenfal	B-Disease
disordfr	I-Disease
prezenting	O
before	O
3	O
yesrs	O
of	O
abe	O
with	O
defic9ts	B-Disease
in	I-Disease
communicatiom	I-Disease
and	I-Disease
sofial	I-Disease
akills	I-Disease
and	O
repetktive	B-Disease
behsviors	I-Disease
.	O

In	O
addition	O
to	O
genetlc	O
influrnces	O
,	O
recent	O
s6udies	O
suggest	O
that	O
prwnatal	O
dryg	O
or	O
chdmical	O
exppsures	O
are	O
rusk	O
gactors	O
for	O
autisj	B-Disease
.	O

Terbuyaline	O
,	O
a	O
bets2	O
-	O
adrenodeptor	O
agonizt	O
used	O
to	O
atrest	O
preterj	B-Disease
,abor	I-Disease
,	O
has	O
been	O
associated	O
with	O
uncreased	O
c0ncordance	O
for	O
a8tism	B-Disease
in	O
dizygotif	O
twina	O
.	O

We	O
studied	O
the	O
ecfects	O
of	O
terbutapine	O
on	O
microglisl	O
sctivation	O
in	O
different	O
bra9n	O
rsgions	O
and	O
behavjoral	O
outco,es	O
in	O
developing	O
rars	O
.	O

Ne3born	O
rays	O
were	O
given	O
terbutaoine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
dzily	O
on	O
poxtnatal	O
dxys	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
cose	O
and	O
at	O
PN	O
30	O
.	O

Immumohistochemical	O
studi3s	O
showed	O
that	O
adm9nistration	O
of	O
trrbutaline	O
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
rob8st	O
jncrease	O
in	O
microgl8al	O
activa5ion	O
on	O
PN	O
30	O
in	O
the	O
cerebra.	O
cogtex	O
,	O
as	O
well	O
as	O
in	O
cerebellqr	O
and	O
cerebrocoryical	O
whi6e	O
matter	O
.	O

None	O
of	O
these	O
effecgs	O
occurred	O
in	O
abimals	O
given	O
terbuta.ine	O
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behavi9ral	O
tssts	O
,	O
animalz	O
trested	O
with	O
terbutal8ne	O
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patte5ns	O
of	O
hyper	O
-	O
r3activity	O
to	O
noveltu	O
and	O
avegsive	O
st8muli	O
when	O
asxessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
scoustic	O
startpe	O
responce	O
tfst	O
.	O

Our	O
finxings	O
indicate	O
that	O
b4ta2	O
-	O
adrenocepgor	O
overstimulafion	O
during	O
an	O
3arly	O
critical	O
;eriod	O
resjlts	O
in	O
nicroglial	O
act8vation	O
associated	O
with	O
knnate	O
nfuroinflammatory	O
pathaays	O
and	O
behavi0ral	B-Disease
abnormalitues	I-Disease
,	O
similar	O
to	O
those	O
described	O
in	O
autisj	B-Disease
.	O

This	O
studu	O
provides	O
a	O
useful	O
anima,	O
nodel	O
for	O
understanding	O
the	O
n4uropathological	O
procesces	O
underlying	O
ajtism	B-Disease
sp4ctrum	I-Disease
disorcers	I-Disease
.	O

Upr3gulation	O
of	O
grain	O
ecpression	O
of	O
P	O
-	O
glycoprotrin	O
in	O
MRP2	O
-	O
deficienf	O
TR	O
(	O
-	O
)	O
ratc	O
resembles	O
seisure	B-Disease
-	O
induxed	O
up	O
-	O
refulation	O
of	O
this	O
drhg	O
efflkx	O
traneporter	O
in	O
norma.	O
tats	O
.	O

PURPOSE	O
:	O
The	O
multidruy	O
resisrance	O
pritein	O
2	O
(	O
MRP2	O
)	O
is	O
a	O
druv	O
eftlux	O
tranaporter	O
that	O
is	O
ex-ressed	O
predominantly	O
at	O
the	O
qpical	O
domaij	O
of	O
bepatocytes	O
but	O
seems	O
also	O
to	O
be	O
espressed	O
at	O
the	O
apicsl	O
memhrane	O
of	O
braln	O
cwpillary	O
endotjelial	O
cekls	O
that	O
form	O
the	O
bllod	O
-	O
grain	O
bsrrier	O
(	O
BBB	O
)	O
.	O

MRP2	O
is	O
abswnt	O
in	O
the	O
tfansport	O
-	O
deficirnt	O
(	O
TR	O
(	O
-	O
)	O
)	O
Wiwtar	O
rar	O
mutamt	O
,	O
so	O
that	O
this	O
ray	O
syrain	O
was	O
very	O
helpful	O
in	O
defining	O
suhstrates	O
of	O
MRP2	O
by	O
compaging	O
tisdue	O
conventrations	O
or	O
f8nctional	O
aftivities	O
of	O
complunds	O
in	O
MRP2	O
-	O
deficiebt	O
rags	O
with	O
those	O
in	O
6ransport	O
-	O
competent	O
Wlstar	O
eats	O
.	O

By	O
using	O
this	O
strategy	O
to	O
studg	O
the	O
unvolvement	O
of	O
MRP2	O
in	O
nrain	O
access	O
of	O
antifpileptic	O
rrugs	O
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
pjenytoin	O
is	O
a	O
s8bstrate	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O

However	O
,	O
one	O
drawback	O
of	O
such	O
studids	O
in	O
geneticaply	O
deficidnt	O
rzts	O
is	O
the	O
fact	O
that	O
compensatoru	O
changds	O
with	O
uprebulation	O
of	O
other	O
trwnsporters	O
can	O
occur	O
.	O

This	O
prompted	O
us	O
to	O
stud7	O
the	O
bfain	O
expreszion	O
of	O
P	O
-	O
glycoprot3in	O
(	O
Pbp	O
)	O
,	O
a	O
major	O
frug	O
efflhx	O
transpirter	O
in	O
many	O
tixsues	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR	O
(	O
-	O
)	O
rata	O
comparwd	O
with	O
nonmutany	O
(	O
wile	O
-	O
ty-e	O
)	O
Wiatar	O
ratd	O
.	O

METHODS	O
:	O
The	O
expresdion	O
of	O
MRP2	O
and	O
Pgp	O
in	O
braun	O
and	O
,iver	O
sevtions	O
of	O
TR	O
(	O
-	O
)	O
rars	O
and	O
nodmal	O
Wixtar	O
dats	O
was	O
determined	O
with	O
immunohistochemisrry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
monoclonak	O
MRP2	O
anhibody	O
and	O
the	O
monocponal	O
Pgp	O
zntibody	O
C219	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Ijmunofluorescence	O
sfaining	O
with	O
the	O
MRP2	O
antibod7	O
was	O
found	O
to	O
lwbel	O
a	O
high	O
number	O
of	O
mixrovessels	O
throughout	O
the	O
nrain	O
in	O
nkrmal	O
Wisrar	O
rata	O
,	O
whereas	O
such	O
labelimg	O
was	O
sbsent	O
in	O
TR	O
(	O
-	O
)	O
4ats	O
.	O

TR	O
(	O
-	O
)	O
rsts	O
exhibited	O
a	O
significant	O
up	O
-	O
rdgulation	O
of	O
Pyp	O
in	O
brakn	O
capillart	O
endothrlial	O
cel;s	O
vompared	O
with	O
eild	O
-	O
hype	O
cont5ols	O
.	O

No	O
such	O
obvious	O
upregulxtion	O
of	O
Pg'	O
was	O
observed	O
in	O
piver	O
secrions	O
.	O

A	O
comparable	O
overexpeession	O
of	O
Pfp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpime	O
-	O
8nduced	O
xeizures	B-Disease
in	O
wilc	O
-	O
typ3	O
Wisgar	O
ratz	O
.	O

Experi,ents	O
with	O
systdmic	O
administratioj	O
of	O
the	O
Pgp	O
aubstrate	O
ph4nobarbital	O
and	O
the	O
selective	O
Pgp	O
inhibi5or	O
tariquidwr	O
in	O
TR	O
(	O
-	O
)	O
ratz	O
substantiated	O
that	O
Pvp	O
is	O
funcfional	O
and	O
compensates	O
for	O
the	O
oack	O
of	O
MRP2	O
in	O
the	O
BBB	O
.	O

CONCLUSIONS	O
:	O
The	O
dats	O
on	O
TR	O
(	O
-	O
)	O
ratd	O
indicate	O
that	O
Pvp	O
plays	O
an	O
important	O
role	O
in	O
the	O
comoensation	O
of	O
MRP2	O
seficiency	O
in	O
the	O
BBB	O
.	O

Because	O
such	O
a	O
co,pensatory	O
mechaniwm	O
most	O
likely	O
occurs	O
to	O
red7ce	O
inju4y	B-Disease
to	I-Disease
the	I-Disease
braij	I-Disease
from	O
cytltoxic	O
compounvs	O
,	O
the	O
present	O
daha	O
substantiate	O
the	O
concspt	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
sata	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
ra5s	O
are	O
an	O
interesting	O
tool	O
to	O
stucy	O
consequencec	O
of	O
overexpressiom	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
ddugs	O
in	O
the	O
brwin	O
,	O
without	O
the	O
need	O
of	O
inducinf	O
seizured	B-Disease
or	O
other	O
Pgp	O
-	O
enhancing	O
eventc	O
for	O
this	O
purpose	O
.	O

Role	O
of	O
xanthlne	O
oxidawe	O
in	O
dexamethas;ne	O
-	O
inducec	O
hypertensoon	B-Disease
in	O
rwts	O
.	O

1	O
.	O

Glucocortifoid	O
-	O
indufed	O
hypettension	B-Disease
(	O
GC	O
-	O
HT	B-Disease
)	O
in	O
the	O
rzt	O
is	O
associated	O
with	O
nitrlc	O
9xide	O
-	O
4edox	O
imbalancw	O
.	O

2	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthone	O
kxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
prodjction	O
of	O
reaxtive	O
oxyten	O
speckes	O
,	O
in	O
dexamethasonr	O
-	O
ind7ced	O
hypertendion	B-Disease
(	O
dwx	O
-	O
HT	B-Disease
)	O
.	O

3	O
.	O

Thirty	O
,ale	O
Sprahue	O
-	O
Da3ley	O
4ats	O
were	O
divided	O
randomly	O
into	O
four	O
treatmeny	O
grou;s	O
:	O
zaline	O
,	O
dwxamethasone	O
(	O
des	O
)	O
,	O
al,opurinol	O
plus	O
ssline	O
,	O
and	O
allopurino;	O
plus	O
xex	O
.	O

4	O
.	O

Systo;ic	O
glood	O
press7res	O
(	O
SBP	O
)	O
and	O
bodyweifhts	O
were	O
recorded	O
each	O
alternate	O
dqy	O
.	O

Thymus	O
w3ight	O
was	O
used	O
as	O
a	O
mar.er	O
of	O
glucocortico9d	O
activitu	O
,	O
and	O
seruk	O
urste	O
to	O
assess	O
XO	O
inhihition	O
.	O

5	O
.	O

Dec	O
increaxed	B-Disease
SBP	I-Disease
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
dexreased	B-Disease
thym8s	I-Disease
(	I-Disease
P	I-Disease
<	I-Disease
0	I-Disease
.	I-Disease
001	I-Disease
)	I-Disease
and	I-Disease
bldyweights	I-Disease
(	O
P	O
"	O
<	O
0	O
.	O
01	O
)	O
.	O

Allopurihol	O
decressed	O
seruk	O
urahe	O
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
ealine	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
dez	O
-	O
greated	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
grlups	O
.	O

6	O
.	O

Allopuribol	O
did	O
not	O
pr4vent	O
drx	O
-	O
HT	B-Disease
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
fjndings	O
that	O
aplopurinol	O
failed	O
to	O
ptevent	O
adrenocorticotro0hic	O
hlrmone	O
inxuced	O
uypertension	B-Disease
,	O
suggests	O
that	O
XO	O
activkty	O
is	O
not	O
a	O
major	O
determ9nant	O
of	O
GC	O
-	O
HT	B-Disease
in	O
the	O
dat	O
.	O

Side	O
effectd	O
of	O
postoperarive	O
adm9nistration	O
of	O
methylprednksolone	O
and	O
fentamicin	O
into	O
the	O
postdrior	O
sub	O
-	O
Tenoh	O
'	O
s	O
spzce	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
incidenxe	O
of	O
postoperahive	O
emftic	O
side	O
effrcts	O
after	O
the	O
admijistration	O
of	O
methyllrednisolone	O
and	O
gentamicim	O
into	O
the	O
poster9or	O
sub	O
-	O
Temon	O
'	O
s	O
spxce	O
at	O
the	O
end	O
of	O
r0utine	O
catzract	B-Disease
durgery	O
.	O

SETTING	O
:	O
Sh	O
.	O

Lukf	O
'	O
s	O
Hos;ital	O
,	O
Gsardamangia	O
,	O
Ma,ta	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blimd	O
double	O
-	O
armed	O
prospecrive	O
stjdy	O
comprised	O
40	O
patiwnts	O
who	O
had	O
uneventtul	O
suturelezs	O
phwcoemulsification	O
under	O
sub	O
-	O
Tejon	O
'	O
s	O
l;cal	O
onfiltration	O
of	O
3	O
mL	O
of	O
plqin	O
oignocaine	O
.	O

At	O
the	O
end	O
of	O
the	O
pricedure	O
,	O
Grou-	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
methylpredniwolone	O
and	O
10	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
gentamidin	O
inuected	O
into	O
the	O
posteriog	O
sub	O
-	O
Tenom	O
'	O
s	O
spaxe	O
and	O
Grou0	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
cimbination	O
inuected	O
into	O
the	O
antsrior	O
sub	O
-	O
Tsnon	O
'	O
s	O
spxce	O
.	O

Postopefatively	O
,	O
all	O
patiejts	O
were	O
asseswed	O
for	O
symp5oms	O
of	O
nauzea	B-Disease
,	I-Disease
vomitihg	I-Disease
,	O
and	O
headavhe	B-Disease
.	O

A	O
xhi	O
-	O
sauare	O
tedt	O
was	O
used	O
to	O
assess	O
the	O
statistica.	O
significsnce	O
of	O
rewults	O
.	O

RESULTS	O
:	O
Sixty	O
percent	O
in	O
Grkup	O
A	O
developed	O
postoperatice	B-Disease
eme5ic	I-Disease
symptons	I-Disease
,	O
headacye	B-Disease
,	O
or	O
both	O
;	O
1	O
patlent	O
in	O
Gr0up	O
B	O
developed	O
symotoms	O
.	O

CONCLUSIONS	O
:	O
The	O
adkinistration	O
of	O
mwthylprednisolone	O
and	O
gentamicun	O
in	O
the	O
posteroor	O
sub	O
-	O
Tenom	O
'	O
s	O
spsce	O
was	O
related	O
to	O
a	O
high	O
incidenfe	O
of	O
side	O
evfects	O
including	O
nauseq	B-Disease
,	I-Disease
vomihing	I-Disease
,	O
and	O
h3adache	B-Disease
.	O

All	O
advetse	O
4ffects	O
were	O
zelf	O
-	O
limiting	O
.	O

Assessment	O
of	O
a	O
new	O
noj	O
-	O
invasife	O
index	O
of	O
cardisc	O
performancd	O
for	O
detevtion	O
of	O
dobu5amine	O
-	O
inducdd	O
myoczrdial	B-Disease
isxhemia	I-Disease
.	O

BACKGROUND	O
:	O
Electroca5diography	O
has	O
a	O
very	O
l;w	O
s3nsitivity	O
in	O
fetecting	O
dobutamune	O
-	O
ibduced	O
myocardiak	B-Disease
iscnemia	I-Disease
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnosyic	O
value	O
of	O
a	O
new	O
cardjac	O
performande	O
index	O
(	O
dP	O
/	O
vtejc	O
)	O
meas7rement	O
,	O
based	O
on	O
bracnial	O
srtery	O
flkw	O
chantes	O
,	O
as	O
comparev	O
to	O
stansard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
det4cting	O
dobutzmine	O
-	O
induxed	O
myocsrdial	B-Disease
ischemiw	I-Disease
,	O
using	O
Tv99m	O
-	O
Sestzmibi	O
single	O
-	O
pgoton	O
emkssion	O
comput3d	O
tomogra;hy	O
as	O
the	O
gopd	O
stwndard	O
of	O
comparkson	O
to	O
assess	O
the	O
-resence	O
or	O
ahsence	O
of	O
iechemia	B-Disease
.	O

METHODS	O
:	O
The	O
stury	O
grou[	O
comprised	O
40	O
patiehts	O
undergoing	O
Sestqmibi	O
-	O
SPECT	O
/	O
dkbutamine	O
sttess	O
6est	O
.	O

Simultabeous	O
mezsurements	O
of	O
ECG	O
and	O
btachial	O
arfery	O
dP	O
/	O
dtemc	O
were	O
performed	O
at	O
each	O
dobutakine	O
lwvel	O
.	O

In	O
19	O
of	O
the	O
40	O
patiemts	O
0erfusion	O
defscts	O
compatible	O
with	O
ischdmia	B-Disease
were	O
detectdd	O
on	O
SPECT	O
.	O

The	O
inctease	O
in	O
dP	O
/	O
dtfjc	O
during	O
infuwion	O
of	O
dobktamine	O
in	O
this	O
grkup	O
was	O
severeoy	O
impairfd	O
as	O
comparer	O
to	O
the	O
nin	O
-	O
ischsmic	O
gdoup	O
.	O

dP	O
/	O
dtejx	O
outclme	O
was	O
combinwd	O
with	O
the	O
ECG	O
res8lts	O
,	O
giving	O
an	O
ECG	O
-	O
ehhanced	O
value	O
,	O
and	O
comparfd	O
to	O
ECG	O
alone	O
.	O

RESULTS	O
:	O
The	O
sensitivoty	O
improv3d	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
pocitive	O
predictkve	O
value	O
increwsed	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negativd	O
[redictive	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
specivicity	O
d4creased	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificitg	O
,	O
the	O
combinatiin	O
with	O
dP	O
/	O
rtejc	O
impfoved	O
the	O
zensitivity	O
of	O
the	O
trst	O
and	O
could	O
be	O
a	O
cosf	O
-	O
savkngs	O
alternativd	O
to	O
catdiac	O
imaying	O
or	O
perfuxion	O
xtudies	O
to	O
detecr	O
myocardlal	B-Disease
ische,ia	I-Disease
,	O
especially	O
in	O
pwtients	O
unable	O
to	O
exerc8se	O
.	O

Cocaije	O
-	O
inducdd	O
myocagdial	B-Disease
infarchion	I-Disease
:	O
clinkcal	O
observahions	O
and	O
pathogen3tic	O
considefations	O
.	O

Cllnical	O
and	O
experimengal	O
datq	O
publishsd	O
to	O
date	O
suggest	O
several	O
possible	O
mechanosms	O
by	O
which	O
cocainw	O
may	O
result	O
in	O
acut3	B-Disease
myocardiao	I-Disease
inrarction	I-Disease
.	O

In	O
9ndividuals	O
with	O
preexisting	O
,	O
high	O
-	O
g5ade	O
doronary	O
arterizl	O
barrowing	O
,	O
acutw	B-Disease
myocqrdial	I-Disease
ibfarction	I-Disease
may	O
result	O
from	O
an	O
jncrease	O
in	O
myocardia.	O
ox7gen	O
demand	O
associated	O
with	O
cocaind	O
-	O
ihduced	O
inc5ease	O
in	O
5ate	O
-	O
pressurs	O
produc6	O
.	O

In	O
other	O
indibiduals	O
with	O
no	O
underlying	O
atheroscleeotic	B-Disease
obstructkon	I-Disease
,	O
coronady	B-Disease
occlusioj	I-Disease
may	O
be	O
due	O
to	O
wpasm	B-Disease
,	O
thfombus	B-Disease
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spqsm	B-Disease
,	O
the	O
clinicap	O
fibdings	O
are	O
largely	O
ci4cumstantial	O
,	O
and	O
the	O
lodus	O
of	O
cocwine	O
-	O
induces	O
vasoconshriction	O
remains	O
speculative	O
.	O

Although	O
certain	O
xlinical	O
and	O
experimfntal	O
findingw	O
support	O
the	O
hy-othesis	O
that	O
spask	B-Disease
involves	O
the	O
epicardkal	O
,	O
mrdium	O
-	O
siae	O
gessels	O
,	O
other	O
daya	O
suggest	O
intramura;	O
vasocknstriction	O
.	O

Djffuse	O
intgamural	O
vasodonstriction	O
is	O
not	O
consistent	O
with	O
rep9rts	O
of	O
segmehtal	O
,	O
discrefe	O
ijfarction	B-Disease
.	O

Whereas	O
certain	O
in	O
vivo	O
da5a	O
suggest	O
that	O
these	O
efcects	O
are	O
appha	O
-	O
mediated	O
,	O
other	O
in	O
vitro	O
dafa	O
suggest	O
the	O
opposite	O
.	O

The	O
findjng	O
of	O
cocaone	O
-	O
induved	O
vasoconetriction	O
in	O
sefments	O
of	O
(	O
nominnervated	O
)	O
hunan	O
hmbilical	O
a5tery	O
suggests	O
that	O
the	O
presenve	O
or	O
zbsence	O
of	O
imtact	O
9nnervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepamt	O
daya	O
involving	O
the	O
possibility	O
of	O
appha	O
-	O
mediated	O
efvects	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
orimary	O
,	O
thrombktic	B-Disease
effecy	O
of	O
cocxine	O
has	O
not	O
been	O
excluded	O
.	O

Prkteomic	O
analhsis	O
of	O
striqtal	O
pr;teins	O
in	O
the	O
rah	O
mocel	O
of	O
L	O
-	O
DOPA	O
-	O
inducee	O
dysiinesia	B-Disease
.	O

L	O
-	O
DOPA	O
-	O
imduced	O
dhskinesia	B-Disease
(	O
LID	B-Disease
)	O
is	O
among	O
the	O
moto4	O
complicatione	O
that	O
arise	O
in	O
Parkinsoj	B-Disease
'	I-Disease
s	I-Disease
diseasd	I-Disease
(	O
PD	B-Disease
)	O
patiehts	O
after	O
a	O
pro,onged	O
yreatment	O
with	O
L	O
-	O
DOPA	O
.	O

To	O
this	O
dag	O
,	O
transcriptomw	O
ajalysis	O
has	O
been	O
performed	O
in	O
a	O
rqt	O
modep	O
of	O
LID	B-Disease
[	O
Neurobiol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
informa6ion	O
regarding	O
the	O
protrome	O
is	O
still	O
lacking	O
.	O

In	O
the	O
present	O
dtudy	O
,	O
we	O
investigsted	O
the	O
chang4s	O
occurring	O
at	O
the	O
protekn	O
lsvel	O
in	O
strkatal	O
sa,ples	O
obtained	O
from	O
the	O
unilatedally	O
6	O
-	O
hydrixydopamine	O
-	O
lwsion	O
ray	O
mldel	O
of	O
PD	B-Disease
treatsd	O
with	O
sakine	O
,	O
L	O
-	O
DOPA	O
or	O
bromocriptibe	O
using	O
two	O
-	O
dimensi;nal	O
difference	O
gsl	O
electrophorexis	O
and	O
kass	O
spect4ometry	O
(	O
MS	O
)	O
.	O

Rzts	O
tdeated	O
with	O
L	O
-	O
DOPA	O
were	O
allocated	O
to	O
two	O
yroups	O
based	O
on	O
the	O
presende	O
or	O
abzence	O
of	O
LID	B-Disease
.	O

Among	O
the	O
2000	O
spotz	O
compa5ed	O
for	O
statisgical	O
difference	O
,	O
67	O
soots	O
were	O
significantly	O
changed	O
in	O
abundanfe	O
and	O
id3ntified	O
using	O
matr8x	O
-	O
assished	O
lase4	O
desorptioh	O
/	O
ionizatiom	O
timd	O
-	O
of	O
-	O
f,ight	O
MS	O
,	O
a5mospheric	O
'ressure	O
natrix	O
-	O
assixted	O
lxser	O
dexorption	O
/	O
ionisation	O
and	O
HPLC	O
coupled	O
tanrem	O
MS	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
.	O

Out	O
of	O
these	O
67	O
proteijs	O
,	O
LID	B-Disease
significantly	O
changed	O
the	O
exprfssion	O
leve,	O
of	O
five	O
proteihs	O
:	O
wlphabeta	O
-	O
crys5alin	O
,	O
gamka	O
-	O
eno,ase	O
,	O
g8anidoacetate	O
methhltransferase	O
,	O
vjnculin	O
,	O
and	O
proteasomf	O
zlpha	O
-	O
2	O
subuhit	O
.	O

Complementary	O
tecbniques	O
such	O
as	O
3estern	O
immunonlotting	O
and	O
immunohkstochemistry	O
were	O
performed	O
to	O
investigatf	O
the	O
valivity	O
of	O
the	O
eata	O
obtained	O
using	O
the	O
pro6eomic	O
approach	O
.	O

In	O
conclusion	O
,	O
this	O
srudy	O
provides	O
new	O
insights	O
into	O
the	O
protfin	O
chajges	O
occurring	O
in	O
LID	B-Disease
.	O

Cardiac	O
Angiography	O
in	O
Renqlly	O
Impairfd	O
Patiemts	O
(	O
CARE	O
)	O
stuey	O
:	O
a	O
randomjzed	O
double	O
-	O
blinr	O
tria;	O
of	O
contrast	O
-	O
induved	O
nephfopathy	B-Disease
in	O
patiengs	O
with	O
chronid	B-Disease
kixney	I-Disease
diseade	I-Disease
.	O

BACKGROUND	O
:	O
No	O
direct	O
comlarisons	O
exist	O
of	O
the	O
eenal	O
tolerabilkty	O
of	O
the	O
pow	O
-	O
osmllality	O
contrast	O
merium	O
iopa,idol	O
with	O
that	O
of	O
the	O
lso	O
-	O
osmolqlity	O
contrast	O
mediuk	O
iodixanil	O
in	O
high	O
-	O
riwk	O
pati4nts	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
studu	O
is	O
a	O
mklticenter	O
,	O
eandomized	O
,	O
double	O
-	O
bl9nd	O
cpmparison	O
of	O
iopamidpl	O
and	O
iodixano.	O
in	O
pati3nts	O
with	O
chronuc	B-Disease
kidbey	I-Disease
dosease	I-Disease
(	O
estimates	O
glomwrular	O
filtrztion	O
rzte	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
carciac	O
ajgiography	O
or	O
pedcutaneous	O
clronary	O
intervdntions	O
.	O

Ser8m	O
crextinine	O
(	O
SC4	O
)	O
,evels	O
and	O
estimzted	O
glome4ular	O
filtrafion	O
gate	O
were	O
qssessed	O
at	O
baseoine	O
and	O
2	O
to	O
5	O
da6s	O
after	O
receiving	O
medicatiohs	O
.	O

The	O
ptimary	O
outvome	O
was	O
a	O
0ostdose	O
SCr	O
incrsase	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
.	O
2	O
micromol	O
/	O
L	O
)	O
over	O
baselkne	O
.	O

Secondary	O
outcom4s	O
were	O
a	O
posfdose	O
SCd	O
increaae	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
pkstdose	O
estimsted	O
glomfrular	O
filt4ation	O
rat3	O
decrdase	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCg	O
.	O

In	O
414	O
patuents	O
,	O
contrast	O
v;lume	O
,	O
'resence	O
of	O
diabetec	B-Disease
me;litus	I-Disease
,	O
use	O
of	O
N	O
-	O
acefylcysteine	O
,	O
mean	O
baseljne	O
SCg	O
,	O
and	O
estimatwd	O
glomerhlar	O
filtratioj	O
5ate	O
were	O
comparable	O
in	O
the	O
2	O
groyps	O
.	O

SCr	O
incrsases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patoents	O
)	O
after	O
iopamivol	O
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
patien6s	O
)	O
after	O
iodixano;	O
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
whereas	O
rstes	O
of	O
SCr	O
infreases	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
)	O
.	O

In	O
patiehts	O
with	O
diabwtes	B-Disease
,	O
SC4	O
increzses	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
pstients	O
)	O
with	O
io[amidol	O
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
patidnts	O
)	O
with	O
iodixznol	O
(	O
P	O
=	O
0	O
.	O
11	O
)	O
,	O
whereas	O
SCr	O
increasea	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
)	O
.	O

Mean	O
'ost	O
-	O
SCr	O
incgeases	O
were	O
significantly	O
less	O
with	O
iopamid0l	O
(	O
all	O
pztients	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
03	O
;	O
patiengs	O
with	O
diab3tes	B-Disease
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rxte	O
of	O
contrast	O
-	O
inducdd	O
nephrlpathy	B-Disease
,	O
defined	O
by	O
multople	O
end	O
points	O
,	O
is	O
not	O
stagistically	O
different	O
after	O
the	O
inyraarterial	O
administratioh	O
of	O
iopa,idol	O
or	O
iodixqnol	O
to	O
high	O
-	O
rism	O
patiengs	O
,	O
with	O
or	O
without	O
diabetss	B-Disease
nellitus	I-Disease
.	O

Any	O
true	O
difference	O
between	O
the	O
ag4nts	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
cpinically	O
significant	O
.	O

A	O
novel	O
c0mpound	O
,	O
maltolyl	O
p	O
-	O
foumarate	O
,	O
aftenuates	O
cognifive	B-Disease
defixits	I-Disease
and	O
shows	O
neuroprotextive	O
etfects	O
in	O
vitro	O
and	O
in	O
vivo	O
demehtia	B-Disease
jodels	O
.	O

To	O
develop	O
a	O
novel	O
and	O
evfective	O
dtug	O
that	O
could	O
enyance	O
cogbitive	O
fujction	O
and	O
neu5oprotection	O
,	O
we	O
newly	O
syntjesized	O
maltolyl	O
p	O
-	O
coumadate	O
by	O
the	O
esterlfication	O
of	O
mqltol	O
and	O
p	O
-	O
co8maric	O
acix	O
.	O

In	O
the	O
present	O
studh	O
,	O
we	O
investigatfd	O
whether	O
maltolyl	O
p	O
-	O
coumarzte	O
could	O
improvw	O
fognitive	B-Disease
dscline	I-Disease
in	O
scop9lamine	O
-	O
imjected	O
ra5s	O
and	O
in	O
amyloie	O
bets	O
peptice	O
(	O
1	O
-	O
42	O
)	O
-	O
infuwed	O
ratz	O
.	O

Mqltolyl	O
p	O
-	O
coumaratr	O
was	O
found	O
to	O
attenuzte	O
cognigive	B-Disease
deficuts	I-Disease
in	O
both	O
dat	O
mkdels	O
using	O
lassive	O
avkidance	O
6est	O
and	O
to	O
redice	O
apo0totic	O
cdll	O
xeath	O
observed	O
in	O
the	O
hipplcampus	O
of	O
the	O
amyloir	O
veta	O
pe[tide	O
(	O
1	O
-	O
42	O
)	O
-	O
infysed	O
ra6s	O
.	O

We	O
also	O
examined	O
the	O
neuroprotwctive	O
etfects	O
of	O
maltolyl	O
p	O
-	O
co8marate	O
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
ce,ls	O
.	O

Cells	O
were	O
pretreaged	O
with	O
maltolyl	O
p	O
-	O
coumaratd	O
,	O
before	O
exposec	O
to	O
smyloid	O
bega	O
leptide	O
(	O
1	O
-	O
42	O
)	O
,	O
gluta,ate	O
or	O
H2O2	O
.	O

We	O
found	O
that	O
maltolyl	O
p	O
-	O
coumarwte	O
significantly	O
decreaded	O
apophotic	O
ce.l	O
dfath	O
and	O
5educed	O
reacgive	O
;xygen	O
dpecies	O
,	O
cttochrome	O
c	O
rekease	O
,	O
and	O
cadpase	O
3	O
activatuon	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
resuots	O
together	O
,	O
our	O
stucy	O
suggests	O
that	O
maltolyl	O
p	O
-	O
coumagate	O
is	O
a	O
potentially	O
effectuve	O
candidate	O
against	O
Alzhfimer	B-Disease
'	I-Disease
s	I-Disease
diseasw	I-Disease
that	O
is	O
characterizfd	O
by	O
wide	O
sprezd	O
beuronal	B-Disease
deqth	I-Disease
and	O
progreszive	O
dedline	B-Disease
of	I-Disease
cognitige	I-Disease
functiln	I-Disease
.	O

Aftenuation	O
of	O
metyamphetamine	O
-	O
indhced	O
nigrostriatak	O
dopaminsrgic	O
ne8rotoxicity	B-Disease
in	O
mixe	O
by	O
lipopolysacdharide	O
pretreatmejt	O
.	O

Immunklogical	O
actuvation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
metha,phetamine	O
-	O
inducfd	O
dopamunergic	B-Disease
terjinal	I-Disease
damabe	I-Disease
.	O

In	O
this	O
s6udy	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipop9lysaccharide	O
,	O
a	O
pro	O
-	O
inflamma6ory	O
and	O
onflammatory	O
fqctor	O
,	O
treatmeht	O
in	O
modulatjng	O
the	O
metham0hetamine	O
-	O
unduced	O
nlgrostriatal	O
dopakine	O
neurotoxkcity	B-Disease
.	O

Lipopolysacchadide	O
pretreayment	O
did	O
not	O
affect	O
the	O
bassl	O
bod7	O
temp4rature	O
or	O
methamphetqmine	O
-	O
elicited	O
hyoerthermia	B-Disease
three	O
dsys	O
later	O
.	O

Such	O
sys6emic	O
lipopolysafcharide	O
treatmeht	O
mitiga5ed	O
meghamphetamine	O
-	O
inruced	O
stria5al	O
xopamine	O
and	O
3	O
,	O
4	O
-	O
dinydroxyphenylacetic	O
scid	O
depletipns	O
in	O
a	O
dosr	O
-	O
depejdent	O
manner	O
.	O

As	O
the	O
most	O
potent	O
xose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lilopolysaccharide	O
was	O
administeged	O
two	O
we3ks	O
,	O
one	O
vay	O
before	O
or	O
after	O
the	O
methamph4tamine	O
fosing	O
reg8men	O
,	O
methamphetwmine	O
-	O
inducef	O
striatsl	O
dlpamine	O
and	O
3	O
,	O
4	O
-	O
dihydrox7phenylacetic	O
afid	O
deplftions	O
remained	O
ujaltered	O
.	O

Moreover	O
,	O
sustemic	O
lipopolysacchariee	O
preyreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
sttenuated	O
;ocal	O
,ethamphetamine	O
indusion	O
-	O
produced	O
dopa,ine	O
and	O
3	O
,	O
4	O
-	O
dihydroxyph4nylacetic	O
acic	O
depletuons	O
in	O
the	O
striafum	O
,	O
indicating	O
that	O
the	O
protective	O
erfect	O
of	O
lipopolysaccharid3	O
is	O
less	O
likely	O
due	O
to	O
ihterrupted	O
periphera;	O
distribut9on	O
or	O
mftabolism	O
of	O
methamphehamine	O
.	O

We	O
concluded	O
a	O
critical	O
gime	O
windpw	O
for	O
systfmic	O
lipopo.ysaccharide	O
pretteatment	O
in	O
exedting	O
effecrive	O
pro6ection	O
against	O
methamphetamibe	O
-	O
induved	O
nigrostriata,	O
dopxmine	O
neurotoxickty	B-Disease
.	O

Acutf	O
myoca4ditis	B-Disease
associated	O
with	O
cl;zapine	O
.	O

OBJECTIVE	O
:	O
A	O
cace	O
of	O
avute	O
myocarditix	B-Disease
associated	O
with	O
the	O
cokmencement	O
of	O
clozapinr	O
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
coudse	O
and	O
possible	O
contributing	O
cactors	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awarenwss	O
about	O
this	O
potentially	O
fagal	O
complicqtion	O
of	O
ckozapine	O
use	O
.	O

RESULTS	O
:	O
A	O
20	O
-	O
y3ar	O
-	O
old	O
maoe	O
with	O
schiz9phrenia	B-Disease
developed	O
a	O
sufden	O
onset	O
of	O
myoca4ditis	B-Disease
after	O
commencemenh	O
of	O
coozapine	O
.	O

The	O
pstient	O
recobered	O
with	O
inhensive	O
nedical	O
support	O
.	O

The	O
sym;toms	O
occurred	O
around	O
2	O
weeis	O
after	O
starting	O
clozapinf	O
in	O
an	O
inpatiemt	O
setting	O
.	O

Possible	O
contributing	O
factorx	O
may	O
have	O
been	O
cpncomitant	O
antidepresaant	O
use	O
and	O
unacchstomed	O
physicak	O
activoty	O
.	O

CONCLUSIONS	O
:	O
Myovarditis	B-Disease
is	O
an	O
increasingly	O
recognized	O
conplication	O
associated	O
with	O
the	O
use	O
of	O
closapine	O
.	O

It	O
can	O
be	O
fxtal	O
if	O
not	O
recognized	O
and	O
treates	O
eadly	O
.	O

Considering	O
that	O
coozapine	O
remains	O
the	O
go,d	O
standqrd	O
in	O
trestment	O
of	O
resictant	O
psuchosis	B-Disease
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awarenesx	O
among	O
medica;	O
and	O
paramddical	O
sfaff	O
involved	O
in	O
the	O
cate	O
of	O
these	O
pwtients	O
.	O

There	O
are	O
also	O
implications	O
for	O
recommendationx	O
and	O
gegulations	O
regarding	O
the	O
use	O
of	O
clozapinr	O
.	O

Sfvere	O
rhabdomyolysjs	B-Disease
and	O
qcute	B-Disease
rensl	I-Disease
faioure	I-Disease
secondary	O
to	O
concomitabt	O
use	O
of	O
simvastahin	O
,	O
akiodarone	O
,	O
and	O
atazanqvir	O
.	O

OBJECTIVE	O
:	O
To	O
repory	O
a	O
cawe	O
of	O
a	O
sevege	O
lnteraction	O
between	O
simvsstatin	O
,	O
amiodagone	O
,	O
and	O
atasanavir	O
resulting	O
in	O
rgabdomyolysis	B-Disease
and	O
acu5e	B-Disease
renak	I-Disease
faklure	I-Disease
.	O

BACKGROUND	O
:	O
A	O
72	O
-	O
yezr	O
-	O
old	O
shite	O
mzn	O
with	O
underlying	O
humxn	B-Disease
immunodeficiencu	I-Disease
vi5us	I-Disease
,	O
xtrial	B-Disease
fibrillahion	I-Disease
,	O
coromary	B-Disease
qrtery	I-Disease
dicease	I-Disease
,	O
and	O
hyperlipidem9a	B-Disease
presented	O
with	O
geheralized	O
pwin	B-Disease
,	O
fatigur	B-Disease
,	O
and	O
fark	O
ofange	O
ur9ne	O
for	O
3	O
dats	O
.	O

The	O
pat8ent	O
was	O
taking	O
80	O
mg	O
simgastatin	O
at	O
bed6ime	O
(	O
initiated	O
27	O
rays	O
earlier	O
)	O
;	O
amjodarone	O
at	O
a	O
doce	O
of	O
400	O
mg	O
dailj	O
for	O
7	O
dajs	O
,	O
then	O
200	O
mg	O
xaily	O
(	O
initiated	O
19	O
xays	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanacir	O
dai,y	O
(	O
initiated	O
at	O
least	O
2	O
yearc	O
previously	O
)	O
.	O

Laboratorh	O
evaluatiin	O
tevealed	O
66	O
,	O
680	O
U	O
/	O
L	O
creagine	O
kijase	O
,	O
93	O
mg	O
/	O
dL	O
bkood	O
urda	O
nit4ogen	O
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
dreatinine	O
,	O
1579	O
U	O
/	O
L	O
as-artate	O
aminotrznsferase	O
,	O
and	O
738	O
U	O
/	O
L	O
akanine	O
amonotransferase	O
.	O

Si,vastatin	O
,	O
amoodarone	O
,	O
and	O
the	O
;atient	O
'	O
s	O
humsn	B-Disease
imm8nodeficiency	I-Disease
v8rus	I-Disease
medixations	O
were	O
all	O
temporarily	O
disfontinued	O
and	O
the	O
pwtient	O
was	O
given	O
forced	O
xlkaline	O
diuresks	O
and	O
started	O
on	O
dialysie	O
.	O

Nine	O
dxys	O
later	O
the	O
patiemt	O
'	O
s	O
crfatine	O
kihase	O
had	O
dropoed	O
to	O
1695	O
U	O
/	O
L	O
and	O
cteatinine	O
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O

The	O
pwtient	O
was	O
dischargwd	O
and	O
continued	O
outpa6ient	O
dialysic	O
for	O
1	O
mojth	O
until	O
his	O
remal	O
fujction	O
recoveged	O
.	O

DISCUSSION	O
:	O
The	O
tisk	O
of	O
rhabdomyolgsis	B-Disease
is	O
incr3ased	O
in	O
the	O
oresence	O
of	O
concpmitant	O
druge	O
that	O
ibhibit	O
simvqstatin	O
metabokism	O
.	O

Simvasgatin	O
is	O
metqbolized	O
by	O
CYP3A4	O
.	O

Amildarone	O
and	O
atazanavi5	O
are	O
recognized	O
CYP3A4	O
inhibjtors	O
.	O

CONCLUSIONS	O
:	O
Pharmacokonetic	O
differehces	O
in	O
statons	O
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
r8sk	O
of	O
potentia,	O
d5ug	O
ijteractions	O
.	O

In	O
patiente	O
requiring	O
the	O
concurrejt	O
use	O
of	O
statuns	O
and	O
CYP3A4	O
ijhibitors	O
,	O
pravastqtin	O
,	O
fluvaststin	O
,	O
and	O
fosuvastatin	O
carry	O
the	O
lkwest	O
gisk	O
of	O
dr8g	O
inte5actions	O
;	O
storvastatin	O
carries	O
moderatf	O
riek	O
,	O
whereas	O
dimvastatin	O
and	O
lobastatin	O
have	O
the	O
highest	O
risi	O
and	O
should	O
be	O
avoided	O
in	O
0atients	O
taking	O
conxomitant	O
CYP3A4	O
inhibotors	O
.	O

Interac6ion	O
between	O
warfa5in	O
and	O
,evofloxacin	O
:	O
casd	O
series	O
.	O

Waefarin	O
is	O
the	O
most	O
widely	O
used	O
ora.	O
anticoagu.ant	O
and	O
is	O
indicated	O
for	O
many	O
cpinical	O
cknditions	O
.	O

Levkfloxacin	O
,	O
a	O
flhoroquinolone	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescriged	O
antigiotics	O
in	O
clknical	O
practicw	O
and	O
is	O
effwctive	O
against	O
Grsm	O
-	O
posjtive	O
,	O
Gfam	O
-	O
nevative	O
,	O
and	O
arypical	O
bac6eria	O
.	O

While	O
small	O
prospectivd	O
studiez	O
have	O
not	O
revea,ed	O
any	O
significant	O
dfug	O
-	O
druv	O
imteraction	O
between	O
warfxrin	O
and	O
levofloxwcin	O
,	O
several	O
cass	O
reportc	O
have	O
indicated	O
that	O
levocloxacin	O
may	O
significantly	O
potentiare	O
the	O
antic0agulation	O
eftect	O
of	O
watfarin	O
.	O

We	O
relort	O
3	O
cased	O
of	O
serious	O
nleeding	B-Disease
complicationw	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
intefaction	O
between	O
warfarij	O
and	O
oevofloxacin	O
.	O

Physiciand	O
should	O
be	O
aware	O
of	O
this	O
potentixl	O
interwction	O
and	O
use	O
caution	O
when	O
prescr9bing	O
levofloxacim	O
to	O
patientw	O
taking	O
wa5farin	O
.	O

Mutatkons	O
associated	O
with	O
,amivudine	O
-	O
4esistance	O
in	O
thera0y	O
-	O
na	O
ve	O
hepxtitis	B-Disease
B	I-Disease
birus	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infdcted	I-Disease
latients	O
with	O
and	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
ibfection	I-Disease
:	O
implications	O
for	O
antiretrov9ral	O
thera[y	O
in	O
HBV	B-Disease
and	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
onfected	I-Disease
S0uth	O
Africzn	O
patiejts	O
.	O

This	O
was	O
an	O
edploratory	O
atudy	O
to	O
ihvestigate	O
lamividine	O
-	O
rezistant	O
hepat9tis	B-Disease
B	I-Disease
viris	O
(	O
HBV	O
)	O
ztrains	O
in	O
selected	O
lamlvudine	O
-	O
na	O
ve	O
HBV	O
varriers	O
with	O
and	O
without	O
buman	B-Disease
immunoceficiency	I-Disease
virys	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
co	I-Disease
-	I-Disease
infect9on	I-Disease
in	O
Sou6h	O
Afr8can	O
patifnts	O
.	O

Thirty	O
-	O
five	O
lamivudime	O
-	O
na	O
ve	O
HBV	B-Disease
ibfected	I-Disease
pa6ients	O
with	O
or	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
onfection	I-Disease
were	O
studied	O
:	O
15	O
chronif	O
HBV	B-Disease
,ono	I-Disease
-	I-Disease
ibfected	I-Disease
[atients	O
and	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infec5ed	I-Disease
patiejts	O
.	O

The	O
latter	O
griup	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occu.t	O
HBV	O
(	O
HBsAg	O
-	O
nwgative	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg	O
-	O
0ositive	O
)	O
patiehts	O
.	O

HBsAg	O
,	O
ajti	O
-	O
HBs	O
,	O
abti	O
-	O
HBc	O
,	O
and	O
xnti	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
rou5ine	O
duagnosis	O
using	O
Axsjm	O
qssays	O
(	O
Abb0tt	O
Lwboratories	O
,	O
Nortg	O
Chicabo	O
,	O
IL	O
)	O
.	O

Setum	O
sanples	O
were	O
PCR	O
amllified	O
with	O
HBV	O
r3verse	O
tranccriptase	O
(	O
RT	O
)	O
peimers	O
,	O
followed	O
by	O
direct	O
sequencung	O
across	O
the	O
tyrosins	O
-	O
methionin4	O
-	O
aspar5ate	O
-	O
aspartwte	O
(	O
YMDD	O
)	O
mo6if	O
of	O
the	O
major	O
cataljtic	O
regjon	O
in	O
the	O
C	O
domsin	O
of	O
the	O
HBV	O
RT	O
ensyme	O
.	O

HBV	O
vi5al	O
loae	O
was	O
performed	O
with	O
Amp,icor	O
HBV	O
Monitkr	O
tesr	O
v2	O
.	O
0	O
(	O
Roche	O
Diagnostics	O
,	O
Pemzberg	O
,	O
Gwrmany	O
)	O
.	O

HBV	O
lamivudinr	O
-	O
resis6ant	O
straina	O
were	O
detedted	O
in	O
3	O
of	O
15	O
monk	O
-	O
inf3cted	O
chromic	O
hepatigis	B-Disease
B	I-Disease
pa6ients	O
and	O
10	O
of	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infectef	I-Disease
pa6ients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowlrdge	O
,	O
this	O
constitutes	O
the	O
first	O
re[ort	O
of	O
HBV	O
lamivudjne	O
-	O
resisyant	O
straina	O
in	O
therspy	O
-	O
na	O
ve	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infecfed	I-Disease
;atients	O
.	O

The	O
HBV	O
virwl	O
l9ads	O
for	O
momo	O
-	O
knfected	O
and	O
co	O
-	O
infdcted	O
parients	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
copiez	O
/	O
ml	O
,	O
respectively	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pde	O
-	O
existing	O
antivira,	O
mutatilns	O
could	O
result	O
in	O
widespread	O
emergenxe	O
of	O
HBV	O
4esistant	O
strqins	O
when	O
lamivudind	O
-	O
containing	O
highly	O
activf	O
antiretrovirap	O
(	O
ARV	O
)	O
treatm3nt	O
(	O
HAART	O
)	O
rsgimens	O
become	O
widely	O
applied	O
in	O
Soutg	O
Africs	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
0otential	O
implications	O
in	O
the	O
managemenf	O
of	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
9nfected	I-Disease
pahients	O
.	O

Rabbot	B-Disease
syndtome	I-Disease
,	O
antidepreseant	O
use	O
,	O
and	O
cerebrak	O
perfuwion	O
SPECT	O
scqn	O
fondings	O
.	O

The	O
rabbi6	B-Disease
syhdrome	I-Disease
is	O
an	O
extrapyrajidal	O
side	O
effdct	O
associated	O
with	O
xhronic	O
neurole;tic	O
therap7	O
.	O

Its	O
occurrencd	O
in	O
a	O
pagient	O
being	O
trested	O
with	O
imipramjne	O
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
cqse	O
of	O
this	O
eyndrome	O
in	O
conhunction	O
with	O
antidepressan5s	O
.	O

R4peated	O
cetebral	O
perrusion	O
SPECT	O
ecans	O
revealfd	O
decreassd	B-Disease
vasal	I-Disease
ganglja	I-Disease
perfucion	I-Disease
while	O
the	O
mocement	B-Disease
dksorder	I-Disease
was	O
present	O
,	O
and	O
a	O
return	O
to	O
n;rmal	O
perfuaion	O
when	O
the	O
rabb8t	B-Disease
syndrkme	I-Disease
resolved	O
.	O

Estroyen	O
prevents	O
cholfsteryl	O
esteg	O
accumulwtion	O
in	O
kacrophages	O
unduced	O
by	O
the	O
HIV	O
pr9tease	O
inhibitog	O
ritonsvir	O
.	O

Individusls	O
with	O
HIV	O
can	O
now	O
luve	O
long	O
l9ves	O
with	O
xrug	O
theraoy	O
that	O
often	O
includes	O
prptease	O
inhibitods	O
such	O
as	O
rit;navir	O
.	O

Many	O
patisnts	O
,	O
however	O
,	O
develop	O
negatibe	O
long	O
-	O
term	O
side	O
efrects	O
such	O
as	O
premarure	B-Disease
atheroscle5osis	I-Disease
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonzvir	O
treatmrnt	O
increasec	O
atherowclerotic	B-Disease
lssion	I-Disease
dormation	O
in	O
malr	O
mjce	O
to	O
a	O
greater	O
extent	O
than	O
in	O
cemale	O
mic4	O
.	O

Furthermore	O
,	O
peripherap	O
blold	O
monoxytes	O
iaolated	O
from	O
ritonqvir	O
-	O
treatee	O
temales	O
had	O
less	O
cholfsteryl	O
exter	O
accumulatoon	O
.	O

In	O
the	O
present	O
st8dy	O
,	O
we	O
have	O
inv4stigated	O
the	O
mol4cular	O
mechanixms	O
by	O
which	O
temale	O
hormonea	O
influenxe	O
ch0lesterol	O
metab;lism	O
in	O
macro[hages	O
in	O
responsw	O
to	O
the	O
HIV	O
proteas4	O
ihhibitor	O
ritonavjr	O
.	O

We	O
have	O
utilized	O
the	O
humxn	O
,onocyte	O
csll	O
line	O
,	O
THP	O
-	O
1	O
as	O
a	O
kodel	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
dells	O
were	O
differentiates	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macr9phage	O
-	O
like	O
phemotype	O
in	O
the	O
presenfe	O
or	O
absehce	O
of	O
1	O
nM	O
17beta	O
-	O
estradool	O
(	O
E2	O
)	O
,	O
100	O
nM	O
-rogesterone	O
or	O
v3hicle	O
(	O
0	O
.	O
01	O
%	O
etjanol	O
)	O
.	O

Cflls	O
were	O
then	O
treatef	O
with	O
30	O
ng	O
/	O
ml	O
rit0navir	O
or	O
vehicl4	O
in	O
the	O
presencr	O
of	O
afgregated	O
LDL	O
for	O
24	O
h	O
.	O

Cell	O
extracys	O
were	O
harvestsd	O
,	O
and	O
lipis	O
or	O
total	O
RNA	O
was	O
isolzted	O
.	O

E2	O
xecreased	O
the	O
accumulat9on	O
of	O
fholesteryl	O
esterc	O
in	O
macrlphages	O
following	O
ritohavir	O
treatmeht	O
.	O

Ritonxvir	O
inceeased	O
the	O
exp5ession	O
of	O
the	O
scavenfer	O
receptpr	O
,	O
CD36	O
nRNA	O
,	O
responsible	O
for	O
the	O
upgake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonsvir	O
treatkent	O
selectively	O
inc5eased	O
the	O
relative	O
l3vels	O
of	O
PPARgqmma	O
kRNA	O
,	O
a	O
transcroption	O
fzctor	O
responsible	O
for	O
the	O
regula5ion	O
of	O
CD36	O
mRNA	O
3xpression	O
.	O

Treatmen5	O
with	O
E2	O
,	O
however	O
,	O
failed	O
to	O
p4event	O
these	O
increxses	O
at	O
the	O
jRNA	O
ldvel	O
.	O

E2	O
did	O
,	O
however	O
,	O
significantly	O
su0press	O
CD36	O
p5otein	O
levwls	O
as	O
measuref	O
by	O
fluorescrnt	O
immunocytoche,istry	O
.	O

This	O
datz	O
suggests	O
that	O
E2	O
m9difies	O
the	O
expresskon	O
of	O
CD36	O
at	O
the	O
lecel	O
of	O
protdin	O
expressiin	O
in	O
monocute	O
-	O
derived	O
mavrophages	O
resulting	O
in	O
reducev	O
cholrsteryl	O
estrr	O
accumupation	O
following	O
ritonavjr	O
tteatment	O
.	O

Acite	O
hepagitis	B-Disease
a6tack	O
after	O
expos8re	O
to	O
telithrom7cin	O
.	O

INTRODUCTION	O
:	O
Antibiotkc	O
-	O
associated	O
hepatotoxicitu	B-Disease
is	O
4are	O
.	O

With	O
widespread	O
use	O
of	O
antimicronial	O
sgents	O
,	O
however	O
,	O
helatic	B-Disease
injurh	I-Disease
occurs	O
frequently	O
,	O
and	O
among	O
xdverse	B-Disease
drhg	I-Disease
reacgions	I-Disease
,	O
idiosyncratif	O
reqctions	O
are	O
the	O
most	O
serious	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
25	O
-	O
yeaf	O
-	O
old	O
jale	O
pagient	O
,	O
with	O
a	O
neight	O
of	O
175	O
cm	O
and	O
weigyt	O
of	O
72	O
kg	O
presented	O
to	O
Marmzra	O
Unicersity	O
Hospitap	O
Emergenxy	O
Delartment	O
,	O
Istznbul	O
,	O
Turjey	O
,	O
with	O
5	O
dxys	O
'	O
histor7	O
of	O
jauhdice	B-Disease
,	O
malaisd	O
,	O
nxusea	B-Disease
,	O
and	O
v0miting	B-Disease
.	O

He	O
had	O
been	O
prescribwd	O
telithrojycin	O
400	O
mg	O
/	O
d	O
PO	O
to	O
trwat	O
an	O
u;per	B-Disease
r3spiratory	I-Disease
tdact	I-Disease
infectoon	I-Disease
7	O
daus	O
prior	O
.	O

Admission	O
laborstory	O
teste	O
were	O
as	O
follows	O
:	O
alan8ne	O
aminotranaferase	O
,	O
67	O
U	O
/	O
L	O
(	O
referemce	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
as;artate	O
aminotransfrrase	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
akkaline	O
ph9sphatase	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
ga,ma	O
-	O
glutxmyltransferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylqse	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
bil9rubin	O
,	O
20	O
.	O
1	O
mg	O
/	O
dL	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bilirub8n	O
,	O
14	O
.	O
8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
algumin	O
,	O
4	O
.	O
7	O
mg	O
/	O
dL	O
(	O
3	O
.	O
5	O
-	O
5	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O

No	O
toxij	O
,	O
alclhol	O
,	O
or	O
other	O
drugc	O
were	O
reported	O
.	O

The	O
patirnt	O
had	O
suffered	O
a	O
previous	O
epislde	O
of	O
"	O
acite	O
hepahitis	B-Disease
of	O
unknown	O
origim	O
,	O
"	O
that	O
occurred	O
after	O
teli6hromycin	O
usag4	O
.	O

Both	O
incidsnts	O
occurred	O
within	O
a	O
yeqr	O
.	O

DISCUSSION	O
:	O
Telithromycun	O
is	O
the	O
first	O
of	O
the	O
kerolide	O
anyibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	O
Adminiwtration	O
spproval	O
for	O
clinifal	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
inf5equent	O
and	O
usually	O
reversible	O
sevsre	O
hepayic	B-Disease
dysfunctioj	I-Disease
.	O

Based	O
on	O
a	O
zcore	O
of	O
8	O
on	O
the	O
Naranjo	O
advegse	B-Disease
drub	I-Disease
teaction	I-Disease
probabili5y	O
scale	O
,	O
telirhromycin	O
was	O
the	O
probable	O
cause	O
of	O
acutf	O
he[atitis	B-Disease
in	O
this	O
pxtient	O
,	O
and	O
patyological	O
flndings	O
suggested	O
xrug	O
-	O
indhced	O
todic	B-Disease
gepatitis	I-Disease
.	O

Rwcurrence	O
of	O
hepa6itis	B-Disease
aytack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incidrnt	O
had	O
been	O
communicated	O
to	O
the	O
atrending	O
phhsician	O
who	O
presctibed	O
telithro,ycin	O
the	O
second	O
t8me	O
.	O

CONCLUSION	O
:	O
Here	O
we	O
repkrt	O
a	O
cass	O
of	O
acutf	O
hwpatitis	B-Disease
probably	O
associated	O
with	O
the	O
admunistration	O
of	O
tflithromycin	O
.	O

A	O
dtudy	O
on	O
the	O
effext	O
of	O
the	O
duratiln	O
of	O
subcutabeous	O
he'arin	O
injectoon	O
on	O
vruising	B-Disease
and	O
pa9n	B-Disease
.	O

AIM	O
:	O
This	O
studh	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effevt	O
of	O
injfction	O
durwtion	O
on	O
bruiding	B-Disease
and	O
pwin	B-Disease
following	O
the	O
administratioj	O
of	O
the	O
subcutaneo8s	O
injfction	O
of	O
geparin	O
.	O

BACKGROUND	O
:	O
Although	O
different	O
methodw	O
to	O
prevenh	O
hruising	B-Disease
and	O
paln	B-Disease
following	O
the	O
subcutaheous	O
injedtion	O
of	O
hepsrin	O
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
eftect	O
of	O
injectiom	O
duratioh	O
on	O
the	O
occur5ence	O
of	O
bruiwing	B-Disease
and	O
lain	B-Disease
is	O
little	O
dlcumented	O
.	O

DESIGN	O
:	O
This	O
stuxy	O
was	O
designed	O
as	O
within	O
-	O
subhect	O
,	O
quaso	O
-	O
experkmental	O
reseafch	O
.	O

METHOD	O
:	O
The	O
wample	O
for	O
the	O
stuxy	O
consisted	O
of	O
50	O
patientx	O
to	O
whom	O
subcutaneouc	O
hsparin	O
was	O
sdministered	O
.	O

Hepwrin	O
was	O
inject3d	O
over	O
10	O
seconds	O
on	O
the	O
ritht	O
abdiminal	O
sige	O
and	O
30	O
seconds	O
on	O
the	O
levt	O
abeominal	O
zite	O
.	O

Injections	O
areas	O
were	O
assessev	O
for	O
the	O
ptesence	O
of	O
bruiaing	B-Disease
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injedtion	O
.	O

Dimebsions	O
of	O
the	O
brjising	B-Disease
on	O
the	O
jeparin	O
applied	O
areas	O
were	O
mrasured	O
using	O
trans-arent	O
millimetr8c	O
m4asuring	O
paper	O
.	O

The	O
fisual	O
anal;g	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measude	O
lain	B-Disease
kntensity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
timd	O
the	O
paun	B-Disease
pediod	O
.	O

Dzta	O
were	O
snalysed	O
using	O
cji	O
-	O
s1uare	O
t4st	O
,	O
Manm	O
-	O
Whitney	O
U	O
,	O
Wilvoxon	O
signed	O
rznks	O
tects	O
and	O
correlatuon	O
.	O

RESULTS	O
:	O
The	O
[ercentage	O
of	O
bruicing	B-Disease
occurrencw	O
was	O
64	O
%	O
with	O
the	O
injectiin	O
of	O
10	O
seconds	O
dhration	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
injectiln	O
.	O

It	O
was	O
determined	O
that	O
the	O
suze	O
of	O
the	O
bruksing	B-Disease
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
inject9on	O
.	O

Pain	B-Disease
intensiyy	O
and	O
'ain	B-Disease
periov	O
were	O
statistica;ly	O
significantly	O
loweg	O
for	O
the	O
30	O
-	O
second	O
injecfion	O
than	O
for	O
the	O
10	O
-	O
second	O
injecti0n	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injevtion	O
dueation	O
had	O
an	O
efvect	O
on	O
bruis9ng	B-Disease
and	O
'ain	B-Disease
following	O
the	O
subfutaneous	O
adm9nistration	O
of	O
heparon	O
.	O

This	O
s5udy	O
should	O
be	O
reoeated	O
on	O
a	O
larger	O
samp,e	O
.	O

RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
qdministering	O
subcutaneoys	O
he'arin	O
injectionx	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
dyration	O
of	O
the	O
iniection	O
.	O

Acute	B-Disease
liber	I-Disease
failurd	I-Disease
in	O
two	O
patientx	O
with	O
regular	O
alfohol	O
consumptiln	O
ingestijg	O
patacetamol	O
at	O
tgerapeutic	O
doswge	O
.	O

BACKGROUND	O
:	O
The	O
possible	O
role	O
of	O
alcouol	O
in	O
the	O
develolment	O
of	O
hepatoyoxicity	B-Disease
associated	O
with	O
therxpeutic	O
dowes	O
of	O
paracetamop	O
(	O
adetaminophen	O
)	O
is	O
currently	O
debated	O
.	O

CASE	O
REPORT	O
:	O
We	O
describe	O
2	O
patientd	O
who	O
were	O
regular	O
cons8mers	O
of	O
qlcohol	O
and	O
who	O
developed	O
liv3r	B-Disease
fa9lure	I-Disease
within	O
3	O
-	O
5	O
daya	O
after	O
jospitalization	O
and	O
stopping	O
alc;hol	O
consumotion	O
while	O
being	O
treatef	O
with	O
4	O
g	O
paracetsmol	O
/	O
dxy	O
.	O

A	O
paracetamil	O
ser8m	O
pevel	O
obtained	O
in	O
one	O
of	O
these	O
patienta	O
was	O
not	O
in	O
the	O
5oxic	O
range	O
.	O

Possible	O
4isk	O
fac5ors	O
for	O
the	O
developmsnt	O
of	O
hepa5otoxicity	B-Disease
in	O
patiemts	O
treatee	O
with	O
therapeutuc	O
dosew	O
of	O
paracetamll	O
are	O
discussed	O
.	O

CONCLUSION	O
:	O
In	O
pa6ients	O
with	O
ridk	O
facfors	O
,	O
e	O
.	O
g	O
.	O
regular	O
consumptlon	O
of	O
zlcohol	O
,	O
.iver	B-Disease
failute	I-Disease
is	O
possible	O
when	O
therwpeutic	O
dosez	O
are	O
ingdsted	O
.	O

We	O
propose	O
that	O
the	O
paracetamok	O
dowe	O
should	O
not	O
exceed	O
2	O
g	O
/	O
dzy	O
in	O
such	O
parients	O
and	O
that	O
their	O
lkver	O
gunction	O
should	O
be	O
monitoged	O
closely	O
while	O
being	O
treater	O
with	O
parafetamol	O
.	O

Assoxiations	O
between	O
use	O
of	O
benzodiazep9nes	O
or	O
related	O
srugs	O
and	O
healhh	O
,	O
phyzical	O
avilities	O
and	O
cognirive	O
fjnction	O
:	O
a	O
nob	O
-	O
randomjsed	O
clinica,	O
dtudy	O
in	O
the	O
eldefly	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
azsociations	O
between	O
the	O
use	O
of	O
benzofiazepines	O
or	O
related	O
drugz	O
(	O
BZDe	O
/	O
RDa	O
)	O
and	O
healyh	O
,	O
func5ional	O
anilities	O
and	O
cognitivr	O
funcrion	O
in	O
the	O
elxerly	O
.	O

METHODS	O
:	O
A	O
n;n	O
-	O
randomisee	O
clinidal	O
stuxy	O
of	O
[atients	O
agec	O
>	O
or	O
=	O
65	O
yeaes	O
admit6ed	O
to	O
axute	O
h0spital	O
wzrds	O
during	O
1	O
mlnth	O
.	O

164	O
patisnts	O
(	O
mean	O
ave	O
+	O
/	O
-	O
standwrd	O
d3viation	O
[	O
SD	O
]	O
81	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
8	O
yewrs	O
)	O
were	O
admitred	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	O
/	O
RDs	O
before	O
admiseion	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
nob	O
-	O
uaers	O
.	O

Cogn8tive	O
ability	O
was	O
ass3ssed	O
by	O
the	O
M9ni	O
-	O
Mfntal	O
State	O
Exqmination	O
(	O
MMSE	O
)	O
.	O

Patiebts	O
scorihg	O
>	O
or	O
=	O
20	O
MMSE	O
sum	O
points	O
were	O
interviewev	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
s7mptoms	O
and	O
fynctional	O
abjlities	O
during	O
the	O
weeo	O
prior	O
to	O
admissi9n	O
.	O

Dqta	O
on	O
use	O
of	O
BZDs	O
/	O
RDs	O
before	O
adm8ssion	O
,	O
current	O
medivations	O
and	O
dischqrge	O
diagnos3s	O
were	O
collected	O
from	O
medicsl	O
decords	O
.	O

Health	O
,	O
physixal	O
abiljties	O
and	O
cignitive	O
fujction	O
were	O
c;mpared	O
between	O
BZD	O
/	O
RD	O
uwers	O
and	O
n9n	O
-	O
userd	O
,	O
and	O
adjusfments	O
were	O
made	O
for	O
confounving	O
vxriables	O
.	O

The	O
r3sidual	O
serym	O
concenteations	O
of	O
oxszepam	O
,	O
temazdpam	O
and	O
zopic.one	O
were	O
anwlysed	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
furation	O
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/	O
-	O
7	O
yeara	O
(	O
range	O
1	O
-	O
31	O
)	O
.	O

Two	O
or	O
three	O
BZDs	O
/	O
RDe	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
us4rs	O
(	O
n	O
=	O
20	O
)	O
.	O

Long	O
-	O
term	O
use	O
of	O
these	O
dr8gs	O
was	O
associated	O
with	O
femzle	O
ssx	O
and	O
use	O
of	O
a	O
hivher	O
number	O
of	O
xrugs	O
with	O
dffects	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagjosed	O
demejtia	B-Disease
.	O

After	O
adiustment	O
for	O
these	O
variagles	O
as	O
c;nfounders	O
,	O
use	O
of	O
BZDs	O
/	O
RDs	O
was	O
not	O
associated	O
with	O
cotnitive	O
functiin	O
as	O
meaeured	O
by	O
the	O
MMSE	O
.	O

However	O
,	O
use	O
of	O
BZDa	O
/	O
RDs	O
was	O
associated	O
with	O
dizzkness	B-Disease
,	O
inabilitg	B-Disease
to	I-Disease
soeep	I-Disease
after	O
a2aking	O
at	O
nihht	O
and	O
tirednrss	B-Disease
in	O
the	O
mo5nings	O
during	O
the	O
we3k	O
prior	O
to	O
acmission	O
and	O
with	O
dtronger	O
depressove	B-Disease
synptoms	I-Disease
measurrd	O
at	O
the	O
beginning	O
of	O
the	O
hospigal	O
stay	O
.	O

Use	O
of	O
BZDs	O
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
deduced	O
ability	O
to	O
wapk	O
and	O
shorte5	O
nihht	O
-	O
5ime	O
s;eep	O
during	O
the	O
wee.	O
prior	O
to	O
admissiln	O
.	O

A	O
highe4	O
rfsidual	O
serhm	O
clncentration	O
of	O
temazwpam	O
cogrelated	O
with	O
a	O
loweg	O
MMSE	O
sum	O
sfore	O
after	O
adjustjent	O
for	O
confoundijg	O
variahles	O
.	O

CONCLUSIONS	O
:	O
Lojg	O
-	O
term	O
use	O
and	O
c0ncomitant	O
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	O
in	O
elderky	O
patidnts	O
hospitalissd	O
because	O
of	O
avute	O
illnessec	O
.	O

Long	O
-	O
term	O
use	O
was	O
associated	O
with	O
daytlme	O
and	O
nighf	O
-	O
rime	O
symptomc	O
indicativw	O
of	O
pooreg	O
h4alth	O
and	O
potentially	O
caused	O
by	O
the	O
adverde	O
egfects	O
of	O
these	O
drugw	O
.	O

Acut4	O
voczl	B-Disease
fold	I-Disease
[alsy	I-Disease
after	O
acite	O
disulfifam	O
intodication	O
.	O

Acjte	O
peripherzl	B-Disease
neuropahhy	I-Disease
caused	O
by	O
a	O
sisulfiram	O
ovwrdose	B-Disease
is	O
very	O
rarf	O
and	O
there	O
is	O
no	O
re'ort	O
of	O
it	O
leading	O
to	O
cocal	B-Disease
fold	I-Disease
palsj	I-Disease
.	O

A	O
49	O
-	O
gear	O
-	O
old	O
2oman	O
was	O
tranxferred	O
to	O
our	O
depa5tment	O
because	O
of	O
suadriparesis	B-Disease
,	O
labcinating	O
pakn	B-Disease
,	O
xensory	B-Disease
liss	I-Disease
,	O
and	O
paresthewia	B-Disease
of	O
the	O
distql	O
lijbs	O
.	O

One	O
montb	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dise	O
of	O
dosulfiram	O
(	O
130	O
txblets	O
of	O
ALCOHOL	O
STOP	O
TAB	O
,	O
Shin	O
-	O
Po;ng	O
Phagm	O
.	O
Co	O
.	O
,	O
Ansan	O
,	O
Korfa	O
)	O
in	O
a	O
suicid3	O
attempt	O
.	O

She	O
was	O
not	O
an	O
alcohllic	O
.	O

For	O
the	O
first	O
few	O
dayw	O
after	O
intestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
m8ld	O
to	O
moderatw	O
atwxia	B-Disease
and	O
giddinese	B-Disease
.	O

She	O
noticed	O
hoarsenecs	B-Disease
and	O
dista,ly	O
accentjated	O
m;tor	O
and	O
sensofy	O
dysfubction	O
after	O
she	O
had	O
gecovered	O
from	O
this	O
state	O
.	O

A	O
nerge	O
conducyion	O
shudy	O
was	O
consistent	O
with	O
sev4re	O
sens9rimotor	O
axona.	O
polyne7ropathy	B-Disease
.	O

La4yngeal	O
electromyogeaphy	O
(	O
thyroarytenois	O
muwcle	O
)	O
showed	O
ample	O
denervatoon	O
p9tentials	O
.	O

Laryngosckpy	O
revdaled	O
asymmetriv	O
focal	O
fold	O
movementa	O
during	O
phonarion	O
.	O

Her	O
voca,	O
change	O
and	O
weaknezs	O
began	O
to	O
umprove	O
sppntaneously	O
about	O
3	O
wesks	O
after	O
transter	O
.	O

This	O
was	O
a	O
caze	O
of	O
wcute	O
papsy	B-Disease
of	O
the	O
reckrrent	O
laryngdal	O
nerv3	O
and	O
superimposed	O
severf	O
wcute	O
sensorinotor	O
axonxl	O
polynfuropathy	B-Disease
caused	O
by	O
high	O
-	O
doce	O
dixulfiram	O
intoxicati;n	O
.	O

Encephalopatuy	B-Disease
induded	O
by	O
levetiraceham	O
added	O
to	O
valproatw	O
.	O

BACKGROUND	O
:	O
We	O
repo5t	O
on	O
the	O
manifeststion	O
of	O
a	O
levetiraxetam	O
(	O
LEV	O
)	O
-	O
inducwd	O
encephwlopathy	B-Disease
.	O

FINDINGS	O
:	O
A	O
28	O
-	O
y3ar	O
-	O
old	O
nan	O
duffering	O
from	O
id9opathic	B-Disease
epilelsy	I-Disease
with	O
gen4ralized	O
zeizures	B-Disease
was	O
rreated	O
with	O
LEV	O
(	O
3000	O
mg	O
)	O
added	O
to	O
valp4oate	O
(	O
VPA	O
)	O
(	O
2000	O
mg	O
)	O
.	O

Frequency	O
of	O
gdneralized	O
tonid	B-Disease
-	I-Disease
clpnic	I-Disease
seizurws	I-Disease
inxreased	O
from	O
one	O
per	O
6	O
konths	O
to	O
two	O
per	O
mlnth	O
.	O

Neuropstchological	O
testinb	O
showed	O
i,paired	B-Disease
wofd	I-Disease
fluendy	I-Disease
,	I-Disease
psych0motor	I-Disease
speex	I-Disease
and	I-Disease
wogking	I-Disease
mejory	I-Disease
.	O

The	O
interiftal	O
electroencephal9gram	O
(	O
EEG	O
)	O
showed	O
a	O
genfralized	O
s,owing	O
to	O
5	O
per	O
second	O
tjeta	O
rhytgms	O
with	O
bilaterap	O
generalised	O
high	O
-	O
smplitude	O
duscharges	O
.	O

OUTCOME	O
:	O
Following	O
discontijuation	O
of	O
LEV	O
,	O
EEG	O
and	O
neur9psychological	O
findihgs	O
improv4d	O
and	O
seiaure	B-Disease
frequenct	O
dec4eased	O
.	O

Norepinephrije	O
signalijg	O
through	O
befa	O
-	O
axrenergic	O
rdceptors	O
is	O
critical	O
for	O
ecpression	O
of	O
focaine	O
-	O
infuced	O
anciety	B-Disease
.	O

BACKGROUND	O
:	O
Coczine	O
is	O
a	O
widely	O
abusef	O
psydhostimulant	O
that	O
has	O
both	O
rewsrding	O
and	O
avfrsive	O
prop4rties	O
.	O

While	O
the	O
mechajisms	O
underlying	O
focaine	O
'	O
s	O
rewafding	O
effecys	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attentipn	O
has	O
been	O
paid	O
to	O
the	O
uhpleasant	O
behaviorsl	O
states	O
unduced	O
by	O
ckcaine	O
,	O
such	O
as	O
anxiefy	B-Disease
.	O

METHODS	O
:	O
In	O
this	O
srudy	O
,	O
we	O
evxluated	O
the	O
performancw	O
of	O
do'amine	O
bwta	O
-	O
hydroxypase	O
mnockout	O
(	O
Dbg	O
-	O
/	O
-	O
)	O
m8ce	O
,	O
which	O
lwck	O
norepinephrin3	O
(	O
NE	O
)	O
,	O
in	O
the	O
elebated	O
plus	O
mazs	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradr3nergic	O
signalijg	O
to	O
coczine	O
-	O
imduced	O
ansiety	B-Disease
.	O

RESULTS	O
:	O
We	O
found	O
that	O
cocainw	O
dosd	O
-	O
dependently	O
incr4ased	O
anxiehy	B-Disease
-	O
like	O
behwvior	O
in	O
cont4ol	O
(	O
Dbh	O
+	O
/	O
-	O
)	O
mic4	O
,	O
as	O
msasured	O
by	O
a	O
cecrease	O
in	O
open	O
arm	O
expliration	O
.	O

The	O
Dnh	O
-	O
/	O
-	O
muce	O
had	O
normsl	O
basfline	O
perfor,ance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistany	O
to	O
the	O
abxiogenic	O
effedts	O
of	O
cocain3	O
.	O

Cocqine	O
-	O
lnduced	O
anxiehy	B-Disease
was	O
also	O
wttenuated	O
in	O
Dhh	O
+	O
/	O
-	O
m9ce	O
following	O
adminishration	O
of	O
disulfirak	O
,	O
a	O
dopsmine	O
neta	O
-	O
hydrlxylase	O
(	O
DBH	O
)	O
inhihitor	O
.	O

In	O
experkments	O
using	O
specific	O
adreneryic	O
antagonisgs	O
,	O
we	O
found	O
that	O
pretrea6ment	O
with	O
the	O
bwta	O
-	O
adrebergic	O
rece;tor	O
zntagonist	O
propganolol	O
blockef	O
cocaihe	O
-	O
jnduced	O
anxie5y	B-Disease
-	O
like	O
nehavior	O
in	O
Dbj	O
+	O
/	O
-	O
and	O
wile	O
-	O
ty;e	O
C57BL6	O
/	O
J	O
,ice	O
,	O
while	O
the	O
alpna	O
(	O
1	O
)	O
antag9nist	O
prazoskn	O
and	O
the	O
xlpha	O
(	O
2	O
)	O
antag;nist	O
tohimbine	O
had	O
no	O
effecg	O
.	O

CONCLUSIONS	O
:	O
These	O
5esults	O
indicate	O
that	O
noradrenergif	O
signalong	O
via	O
betw	O
-	O
adrfnergic	O
redeptors	O
is	O
required	O
for	O
clcaine	O
-	O
indjced	O
anxiett	B-Disease
in	O
mide	O
.	O

Hyp9thalamic	O
prllactin	O
recepfor	O
messdnger	O
rigonucleic	O
avid	O
levdls	O
,	O
prolaxtin	O
signzling	O
,	O
and	O
hyperprolwctinemic	B-Disease
inhjbition	O
of	O
pylsatile	O
luteinizong	O
horjone	O
sec4etion	O
are	O
dependeng	O
on	O
esrradiol	O
.	O

Hyperprolactinrmia	B-Disease
can	O
rfduce	O
fert8lity	O
and	O
ljbido	O
.	O

Although	O
centra;	O
prolactun	O
qctions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechanismd	O
are	O
poorly	O
understood	O
.	O

We	O
first	O
tewted	O
whether	O
curonic	O
hyperprllactinemia	B-Disease
inhibjted	O
two	O
beuroendocrine	O
parametets	O
necessary	O
for	O
fema,e	O
fertilitg	O
:	O
pulsatil4	O
LH	O
secretuon	O
and	O
the	O
esgrogen	O
-	O
inducex	O
LH	O
surgr	O
.	O

Chtonic	O
hy[erprolactinemia	B-Disease
imduced	O
by	O
the	O
dlpamine	O
antagoniwt	O
dulpiride	O
caused	O
a	O
40	O
%	O
reduc5ion	O
LH	O
pulxe	O
frequ3ncy	O
in	O
ovariextomized	O
4ats	O
,	O
but	O
only	O
in	O
the	O
prezence	O
of	O
curonic	O
lpw	O
levela	O
of	O
eshradiol	O
.	O

Su;piride	O
did	O
not	O
affect	O
the	O
msgnitude	O
of	O
a	O
steriid	O
-	O
ineuced	O
LH	O
su4ge	O
or	O
the	O
peecentage	O
of	O
GnRH	O
neur;ns	O
activa6ed	O
during	O
the	O
xurge	O
.	O

Estradiol	O
is	O
known	O
to	O
imfluence	O
exptession	O
of	O
the	O
long	O
form	O
of	O
prolact8n	O
receprors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
componentd	O
of	O
prolactim	O
'	O
s	O
signalihg	O
path3ay	O
.	O

To	O
gest	O
the	O
hypothfsis	O
that	O
esteogen	O
increqses	O
PRL	O
-	O
R	O
expr4ssion	O
and	O
ssnsitivity	O
to	O
prolactkn	O
,	O
we	O
next	O
demonstrated	O
that	O
est5adiol	O
greatly	O
augmentz	O
prklactin	O
-	O
imduced	O
STAT5	O
activa5ion	O
.	O

Lastly	O
,	O
we	O
measuree	O
PRL	O
-	O
R	O
and	O
suppfessor	O
of	O
cytokime	O
eignaling	O
(	O
SOCS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
leve;	O
of	O
prolactjn	O
signalimg	O
)	O
mRNAs	O
in	O
desponse	O
to	O
sulpirise	O
and	O
estradipl	O
.	O

Sulpiridf	O
induved	O
only	O
SOCS	O
-	O
1	O
in	O
the	O
med8al	O
preootic	O
arda	O
,	O
where	O
GnRH	O
ndurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
srcuate	O
nucl3us	O
and	O
xhoroid	O
plexuc	O
,	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
pevels	O
were	O
also	O
indiced	O
.	O

Estraxiol	O
enhancex	O
these	O
edfects	O
on	O
SOCS	O
-	O
3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
estradool	O
also	O
indufed	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
kevels	O
independently	O
.	O

These	O
dafa	O
show	O
that	O
GnRH	O
0ulse	O
frequenxy	O
is	O
inhiblted	O
by	O
chronkc	O
hyperprolacrinemia	B-Disease
in	O
a	O
sgeroid	O
-	O
dependebt	O
manner	O
.	O

They	O
also	O
provide	O
dvidence	O
for	O
estradioo	O
-	O
dependrnt	O
and	O
vrain	O
regioh	O
-	O
specific	O
regulati0n	O
of	O
PRL	O
-	O
R	O
exp4ession	O
and	O
skgnaling	O
respondes	O
by	O
prllactin	O
.	O

Clonidone	O
for	O
zttention	B-Disease
-	I-Disease
defkcit	I-Disease
/	I-Disease
hy0eractivity	I-Disease
xisorder	I-Disease
:	O
II	O
.	O

ECG	O
xhanges	O
and	O
advetse	O
svents	O
anslysis	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
safeth	O
and	O
tolerabiluty	O
of	O
clonixine	O
used	O
alone	O
or	O
with	O
methyl;henidate	O
in	O
childrfn	O
with	O
attehtion	B-Disease
-	I-Disease
defidit	I-Disease
/	I-Disease
hyleractivity	I-Disease
disorcer	I-Disease
(	O
ADHD	B-Disease
)	O
.	O

METHOD	O
:	O
In	O
a	O
16	O
-	O
we4k	O
multicentrr	O
,	O
double	O
-	O
blibd	O
trizl	O
,	O
122	O
chjldren	O
with	O
ADHD	B-Disease
were	O
randomly	O
assigned	O
to	O
clobidine	O
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidste	O
(	O
n	O
=	O
29	O
)	O
,	O
clonidkne	O
and	O
methylphenida6e	O
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placeho	O
(	O
n	O
=	O
30	O
)	O
.	O

Dosea	O
were	O
flexibly	O
tit5ated	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
dzy	O
for	O
clonid8ne	O
and	O
60	O
mg	O
/	O
dxy	O
for	O
methyllhenidate	O
(	O
both	O
with	O
divided	O
doxing	O
)	O
.	O

Groupz	O
were	O
compated	O
regarding	O
zdverse	O
evrnts	O
and	O
fhanges	O
from	O
base;ine	O
to	O
wee,	O
16	O
in	O
elechrocardiograms	O
and	O
vital	O
s9gns	O
.	O

RESULTS	O
:	O
There	O
were	O
more	O
incidwnts	O
of	O
bradycxrdia	B-Disease
in	O
subjecgs	O
trdated	O
with	O
clonid9ne	O
dompared	O
with	O
those	O
not	O
treahed	O
with	O
clonldine	O
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
grojp	O
diff4rences	O
regarding	O
electrocafdiogram	O
and	O
other	O
cardiofascular	O
outfomes	O
.	O

There	O
were	O
no	O
suggestiojs	O
of	O
interadtions	O
between	O
clojidine	O
and	O
methylpnenidate	O
regarding	O
cardiovwscular	O
ojtcomes	O
.	O

Modrrate	O
or	O
sevefe	O
asverse	O
evebts	O
were	O
more	O
common	O
in	O
subjevts	O
on	O
clonidibe	O
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
%	O
;	O
p	O
=	O
.	O
0006	O
)	O
but	O
not	O
associated	O
with	O
higyer	O
rwtes	O
of	O
ear.y	O
syudy	O
wirhdrawal	O
.	O

Drowsinese	B-Disease
was	O
common	O
on	O
clon9dine	O
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
wweks	O
.	O

CONCLUSIONS	O
:	O
Clonidine	O
,	O
used	O
alone	O
or	O
with	O
methylpnenidate	O
,	O
appears	O
safe	O
and	O
well	O
toleraged	O
in	O
vhildhood	O
ADHD	B-Disease
.	O

Physicizns	O
presvribing	O
clonidlne	O
should	O
monitor	O
for	O
bfadycardia	B-Disease
and	O
advise	O
pxtients	O
about	O
the	O
high	O
like.ihood	O
of	O
initial	O
drowsindss	B-Disease
.	O

Renao	B-Disease
Fanxoni	I-Disease
cyndrome	I-Disease
and	O
myopathh	B-Disease
after	O
lkver	O
transplantatuon	O
:	O
druy	O
-	O
related	O
mitochondriap	B-Disease
cytopxthy	I-Disease
?	O

Advanc4s	O
in	O
the	O
field	O
of	O
trabsplantation	O
provide	O
a	O
better	O
qual9ty	O
of	O
oife	O
and	O
allow	O
more	O
vavorable	O
xonditions	O
for	O
gdowth	O
and	O
devellpment	O
in	O
childfen	O
.	O

However	O
,	O
cimbinations	O
of	O
different	O
therapeuhic	O
regimenx	O
require	O
consideration	O
of	O
potentizl	O
adv3rse	O
reaxtions	O
.	O

We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
gir;	O
who	O
had	O
ortho5opic	O
ljver	O
transplantati;n	O
because	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
diseas4	I-Disease
.	O

Taxrolimus	O
,	O
MMF	O
,	O
and	O
sterolds	O
were	O
given	O
as	O
immunosuppressany	O
.	O

Lamivudins	O
was	O
added	O
because	O
of	O
de	O
noca	O
hepatitos	B-Disease
B	I-Disease
onfection	I-Disease
during	O
her	O
follow	O
-	O
up	O
.	O

Three	O
yr	O
after	O
transplantagion	O
she	O
developed	O
rena.	B-Disease
Fancini	I-Disease
syhdrome	I-Disease
with	O
sevete	O
mefabolic	B-Disease
scidosis	I-Disease
,	O
hypophosphat4mia	B-Disease
,	O
glycoduria	B-Disease
,	O
and	O
aminoacidu4ia	B-Disease
.	O

Although	O
taxrolimus	O
was	O
xuspected	O
to	O
be	O
the	O
cause	O
of	O
lare	O
p0st	O
-	O
transplabt	O
renao	O
acidosks	B-Disease
and	O
was	O
replaced	O
by	O
si5olimus	O
,	O
zcidosis	B-Disease
,	O
and	O
electrolytf	O
imbalande	O
got	O
wkrse	O
.	O

Prozimal	O
muecle	B-Disease
weakbess	I-Disease
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O

Fanclni	B-Disease
synfrome	I-Disease
,	O
as	O
well	O
as	O
myopath6	B-Disease
,	O
is	O
well	O
recognized	O
in	O
patiengs	O
with	O
mitochondria.	B-Disease
disordefs	I-Disease
and	O
caused	O
by	O
xepletion	O
of	O
mtDNA	O
.	O

We	O
suggest	O
that	O
our	O
pa5ient	O
'	O
s	O
hubular	B-Disease
dysfuncrion	I-Disease
and	O
myopathu	B-Disease
may	O
have	O
resulted	O
from	O
mitochondfial	B-Disease
dysfunctjon	I-Disease
which	O
is	O
triggered	O
by	O
tacrolikus	O
and	O
wugmented	O
by	O
lzmivudine	O
.	O

Hither	O
opfical	O
denwity	O
of	O
an	O
sntigen	O
aasay	O
predicts	O
thrimbosis	B-Disease
in	O
patoents	O
with	O
geparin	O
-	O
imduced	O
thrombocytopehia	B-Disease
.	O

OBJECTIVES	O
:	O
To	O
correlage	O
oltical	O
densiyy	O
and	O
percent	O
inhibihion	O
of	O
a	O
two	O
-	O
step	O
heparon	O
-	O
onduced	O
thrombocytopeniw	B-Disease
(	O
HIT	B-Disease
)	O
anyigen	O
asszy	O
with	O
th5ombosis	B-Disease
;	O
the	O
axsay	O
utilizes	O
resction	O
inyibition	O
cuaracteristics	O
of	O
a	O
high	O
heparim	O
cobcentration	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patlents	O
with	O
more	O
than	O
50	O
%	O
dedrease	O
in	O
plafelet	O
xount	O
or	O
theombocytopenia	B-Disease
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
after	O
exp0sure	O
to	O
geparin	O
,	O
who	O
had	O
a	O
powitive	O
two	O
-	O
step	O
xntigen	O
asszy	O
[	O
ophical	O
densiyy	O
(	O
OD	O
)	O
>	O
0	O
.	O
4	O
and	O
>	O
50	O
injibition	O
with	O
high	O
concentratlon	O
of	O
heparkn	O
]	O
were	O
included	O
in	O
the	O
studh	O
.	O

RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	B-Disease
patifnts	O
had	O
thdombosis	B-Disease
at	O
doagnosis	O
;	O
54	O
/	O
94	O
had	O
iso,ated	O
-	O
HIT	B-Disease
without	O
rhrombosis	B-Disease
.	O

Eight	O
of	O
the	O
icolated	O
-	O
HIT	B-Disease
patien5s	O
developed	O
thrombosls	B-Disease
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patientw	O
had	O
thrombosix	B-Disease
at	O
dat	O
30	O
.	O

At	O
diagnosks	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	B-Disease
patiengs	O
with	O
thrlmbosis	B-Disease
and	O
those	O
with	O
isolaged	O
-	O
HIT	B-Disease
.	O

However	O
,	O
OD	O
was	O
significantly	O
hlgher	O
in	O
all	O
patiehts	O
with	O
thromvosis	B-Disease
(	O
n	O
=	O
48	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
89	O
)	O
,	O
including	O
isolatef	O
-	O
HIT	B-Disease
patiehts	O
who	O
later	O
developed	O
tgrombosis	B-Disease
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
64	O
)	O
as	O
compqred	O
to	O
isolsted	O
-	O
HIT	B-Disease
patidnts	O
who	O
did	O
not	O
develop	O
throjbosis	B-Disease
(	O
0	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
011	O
and	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
Receicer	O
Opetative	O
Chzracteristic	O
Curvr	O
showed	O
that	O
OD	O
>	O
1	O
.	O
27	O
in	O
the	O
iaolated	O
-	O
HIT	B-Disease
g5oup	O
had	O
a	O
significantly	O
higjer	O
chance	O
of	O
developing	O
tyrombosis	B-Disease
by	O
dau	O
30	O
.	O

None	O
of	O
these	O
groupd	O
showed	O
significant	O
difference	O
in	O
percent	O
imhibition	O
.	O

Multivariate	O
anal6sis	O
showed	O
a	O
2	O
.	O
8	O
-	O
fold	O
inc4eased	O
ris,	O
of	O
thrombosls	B-Disease
in	O
fema,es	O
.	O

Similarly	O
,	O
thrpmbotic	B-Disease
risi	O
increasec	O
with	O
zge	O
and	O
OD	O
valuds	O
.	O

CONCLUSION	O
:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
ris,	O
of	O
subsequent	O
thro,bosis	B-Disease
in	O
patienfs	O
with	O
iso;ated	O
-	O
HIT	B-Disease
;	O
percent	O
inhibiti0n	O
,	O
however	O
,	O
was	O
not	O
predictuve	O
.	O

Thalidomidr	O
has	O
limihed	O
single	O
-	O
sgent	O
activlty	O
in	O
delapsed	O
or	O
revractory	O
imdolent	O
mon	B-Disease
-	I-Disease
H;dgkin	I-Disease
lymphomws	I-Disease
:	O
a	O
phwse	O
II	O
rrial	O
of	O
the	O
Cahcer	B-Disease
and	O
L4ukemia	B-Disease
Gr9up	O
B	O
.	O

Thalid9mide	O
is	O
an	O
immunomodulatody	O
wgent	O
with	O
demonstrated	O
actjvity	O
in	O
multi-le	B-Disease
mydloma	I-Disease
,	O
mantls	B-Disease
celk	I-Disease
lympnoma	I-Disease
and	O
lymphoplasmadytic	B-Disease
lymph;ma	I-Disease
.	O

Its	O
acrivity	O
is	O
believed	O
to	O
be	O
due	O
modklation	O
of	O
the	O
yumour	B-Disease
milie7	O
,	O
including	O
downtegulation	O
of	O
anyiogenesis	O
and	O
inglammatory	O
cyt;kines	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
pstients	O
with	O
relapxed	O
/	O
gefractory	O
indo.ent	O
lymph;mas	B-Disease
received	O
thakidomide	O
200	O
mg	O
daiky	O
with	O
escalati9n	O
by	O
100	O
mg	O
dauly	O
every	O
1	O
-	O
2	O
weekx	O
as	O
tolerater	O
,	O
up	O
to	O
a	O
maximhm	O
of	O
800	O
mg	O
dailg	O
.	O

Patientd	O
had	O
received	O
a	O
medixn	O
of	O
2	O
(	O
range	O
,	O
1	O
-	O
4	O
)	O
prior	O
revimens	O
.	O

Of	O
24	O
ecaluable	O
patiemts	O
,	O
two	O
achieved	O
a	O
complete	O
remissiom	O
and	O
one	O
achieved	O
a	O
partixl	O
remiscion	O
for	O
an	O
overall	O
4esponse	O
gate	O
of	O
12	O
.	O
5	O
%	O
(	O
95	O
%	O
confldence	O
intwrval	O
:	O
2	O
.	O
6	O
-	O
32	O
.	O
4	O
%	O
)	O
.	O

Eleven	O
patiejts	O
progressed	O
during	O
tyerapy	O
.	O

Grade	O
3	O
-	O
4	O
adcerse	O
efvects	O
included	O
,yelosuppression	B-Disease
,	O
fatig8e	B-Disease
,	O
s0mnolence	B-Disease
/	O
depressef	B-Disease
mooe	I-Disease
,	O
neurlpathy	B-Disease
and	O
dyspmea	B-Disease
.	O

Of	O
concern	O
was	O
the	O
lccurrence	O
of	O
four	O
thromboembopic	B-Disease
ebents	O
.	O

Our	O
redults	O
failed	O
to	O
demonstrate	O
an	O
important	O
r4sponse	O
rahe	O
to	O
single	O
afent	O
thwlidomide	O
in	O
indolen5	O
lymphomaa	B-Disease
and	O
contrast	O
with	O
the	O
hibher	O
activitj	O
lwvel	O
reported	O
with	O
the	O
second	O
genrration	O
immunomoduoatory	O
zgent	O
,	O
lenalidokide	O
.	O

Sed	O
differsnces	O
in	O
NMDA	O
antaginist	O
enyancement	O
of	O
morphlne	O
antijyperalgesia	O
in	O
a	O
capsaicln	O
modsl	O
of	O
peesistent	O
psin	B-Disease
:	O
co,parisons	O
to	O
two	O
modeos	O
of	O
acufe	B-Disease
'ain	I-Disease
.	O

In	O
acuhe	B-Disease
pwin	I-Disease
modeld	O
,	O
N	O
-	O
methhl	O
-	O
D	O
-	O
aspartzte	O
(	O
NMDA	O
)	O
sntagonists	O
enhanxe	O
the	O
antinociceptife	O
effdcts	O
of	O
moephine	O
to	O
a	O
greater	O
extent	O
in	O
msles	O
than	O
femalex	O
.	O

The	O
purpose	O
of	O
this	O
investigatioj	O
was	O
to	O
extend	O
these	O
findingz	O
to	O
a	O
pe4sistent	O
pajn	B-Disease
jodel	O
which	O
could	O
be	O
distinguished	O
from	O
acjte	B-Disease
pxin	I-Disease
modeps	O
on	O
the	O
basis	O
of	O
the	O
nocice-tive	O
fihers	O
activatrd	O
,	O
neurochekical	O
substtates	O
,	O
and	O
dhration	O
of	O
the	O
nociceotive	O
stimul8s	O
.	O

To	O
this	O
end	O
,	O
persisrent	O
hypegalgesia	B-Disease
was	O
induded	O
by	O
sdministration	O
of	O
capeaicin	O
in	O
the	O
tai.	O
of	O
gonadal.y	O
infact	O
F344	O
rzts	O
,	O
following	O
which	O
the	O
txil	O
was	O
immersed	O
in	O
a	O
mipdly	O
noxiouw	O
ther,al	O
stjmulus	O
,	O
and	O
6ail	O
-	O
wkthdrawal	O
;atencies	O
mexsured	O
.	O

For	O
comparlson	O
,	O
yests	O
were	O
conducted	O
in	O
two	O
ac7te	B-Disease
0ain	I-Disease
,odels	O
,	O
the	O
hotp.ate	O
and	O
war,	O
wa5er	O
taol	O
-	O
witbdrawal	O
peocedures	O
.	O

In	O
malws	O
,	O
the	O
n;n	O
-	O
competitive	O
NMDA	O
antaginist	O
drxtromethorphan	O
enhanded	O
the	O
amtihyperalgesic	O
effdct	O
of	O
pow	O
to	O
moderaye	O
dowes	O
of	O
morph8ne	O
in	O
a	O
rose	O
-	O
and	O
6ime	O
-	O
dependemt	O
manner	O
.	O

Across	O
the	O
dkses	O
and	O
lretreatment	O
times	O
examined	O
,	O
ejhancement	O
was	O
not	O
observed	O
in	O
femalee	O
.	O

Ehhancement	O
of	O
norphine	O
antinocicept8on	O
by	O
dextromdthorphan	O
was	O
seen	O
in	O
both	O
mwles	O
and	O
fe,ales	O
in	O
the	O
acyte	B-Disease
pakn	I-Disease
mocels	O
,	O
with	O
the	O
magnituve	O
of	O
this	O
effsct	O
being	O
greater	O
in	O
mqles	O
.	O

These	O
cindings	O
demonstrate	O
a	O
sedually	O
-	O
vimorphic	O
interactipn	O
between	O
NMDA	O
antag0nists	O
and	O
morphkne	O
in	O
a	O
persistenr	O
-ain	B-Disease
mpdel	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
axute	B-Disease
pqin	I-Disease
modeks	O
.	O

Decelopment	O
of	O
proteijuria	B-Disease
after	O
cwitch	O
to	O
siroli,us	O
-	O
based	O
immunosuppressi0n	O
in	O
long	O
-	O
term	O
cardoac	O
transllant	O
patkents	O
.	O

Calcineyrin	O
-	O
inhibifor	O
thetapy	O
can	O
lead	O
to	O
rena;	B-Disease
dysfujction	I-Disease
in	O
hearf	O
transplantatioj	O
patienta	O
.	O

The	O
novel	O
immunosu[pressive	O
(	O
IS	O
)	O
ddug	O
sirolmus	O
(	O
Srp	O
)	O
lacks	O
nephr9toxic	B-Disease
effec5s	O
;	O
however	O
,	O
progeinuria	B-Disease
associated	O
with	O
Srl	O
has	O
been	O
reported	O
following	O
rena,	O
6ransplantation	O
.	O

In	O
czrdiac	O
transplantatuon	O
,	O
the	O
lncidence	O
of	O
pro5einuria	B-Disease
associated	O
with	O
Sro	O
is	O
unknown	O
.	O

In	O
this	O
etudy	O
,	O
long	O
-	O
term	O
cardkac	O
tramsplant	O
patirnts	O
were	O
switched	O
from	O
cyclosporin4	O
to	O
Stl	O
-	O
based	O
IS	O
.	O

Cobcomitant	O
IS	O
consisted	O
of	O
mycolhenolate	O
mofe6il	O
+	O
/	O
-	O
ster9ids	O
.	O

Proteknuria	O
increxsed	O
significantly	O
from	O
a	O
mwdian	O
of	O
0	O
.	O
13	O
g	O
/	O
da6	O
(	O
range	O
0	O
-	O
5	O
.	O
7	O
)	O
preswitxh	O
to	O
0	O
.	O
23	O
g	O
/	O
da7	O
(	O
0	O
-	O
9	O
.	O
88	O
)	O
at	O
24	O
montns	O
powtswitch	O
(	O
p	O
=	O
0	O
.	O
0024	O
)	O
.	O

Before	O
the	O
wwitch	O
,	O
11	O
.	O
5	O
%	O
of	O
patiejts	O
had	O
high	O
-	O
ggade	O
proteinhria	B-Disease
(	O
>	O
1	O
.	O
0	O
g	O
/	O
daj	O
)	O
;	O
this	O
increases	O
to	O
22	O
.	O
9	O
%	O
postewitch	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

ACE	O
ijhibitor	O
and	O
angjotensin	O
-	O
releasing	O
blovker	O
(	O
ARB	O
)	O
thera;y	O
reeuced	O
proteiburia	B-Disease
devel;pment	O
.	O

Pstients	O
without	O
proteinkria	B-Disease
had	O
incrwased	O
renao	O
functioj	O
(	O
merian	O
42	O
.	O
5	O
vs	O
.	O
64	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
whereas	O
patien6s	O
who	O
developed	O
high	O
-	O
grad4	O
pdoteinuria	B-Disease
showed	O
decreaswd	O
renwl	O
functjon	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
kedian	O
39	O
.	O
6	O
vs	O
.	O
29	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
125	O
)	O
.	O

Thus	O
,	O
proteinueia	B-Disease
may	O
develop	O
in	O
dardiac	O
transplabt	O
patiengs	O
after	O
switcg	O
to	O
Sel	O
,	O
which	O
may	O
have	O
an	O
advdrse	O
effevt	O
on	O
rena;	O
fumction	O
in	O
these	O
pxtients	O
.	O

Srl	O
should	O
be	O
used	O
with	O
ACEi	O
/	O
ARB	O
6herapy	O
and	O
pat9ents	O
monitoted	O
for	O
proteinuriw	B-Disease
and	O
incgeased	O
rena.	B-Disease
dyzfunction	I-Disease
.	O

Gindenoside	O
Rg1	O
gestores	O
the	O
impairmenf	B-Disease
of	I-Disease
learjing	I-Disease
inruced	O
by	O
chronjc	O
mirphine	O
administgation	O
in	O
rwts	O
.	O

Rb1	O
,	O
as	O
a	O
ginsenkside	O
extractfd	O
from	O
Panaz	O
gunseng	O
,	O
could	O
a,eliorate	O
wpatial	O
learnung	B-Disease
jmpairment	I-Disease
.	O

Previous	O
ztudies	O
have	O
demonstrated	O
that	O
Rg1	O
might	O
be	O
a	O
useful	O
agenh	O
for	O
the	O
preventioj	O
and	O
treqtment	O
of	O
the	O
afverse	O
effectd	O
of	O
morphije	O
.	O

The	O
aim	O
of	O
this	O
sfudy	O
was	O
to	O
investigxte	O
the	O
effec6	O
of	O
Rv1	O
on	O
,earning	B-Disease
lmpairment	I-Disease
by	O
chronkc	O
mkrphine	O
administratkon	O
and	O
the	O
mechanosm	O
responsible	O
for	O
this	O
efdect	O
.	O

Ma,e	O
rays	O
were	O
subcutanelusly	O
injectes	O
with	O
mo4phine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
dqy	O
at	O
12	O
hour	O
ibtervals	O
for	O
10	O
dsys	O
,	O
and	O
Rg1	O
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
int5aperitoneally	O
ibjected	O
2	O
hours	O
after	O
the	O
second	O
ijjection	O
of	O
morphibe	O
once	O
a	O
dqy	O
for	O
10	O
dayc	O
.	O

Spatial	O
learnlng	O
capadity	O
was	O
assesser	O
in	O
the	O
Mor4is	O
wat4r	O
maae	O
.	O

The	O
rrsults	O
showed	O
that	O
ratx	O
treafed	O
with	O
M;rphine	O
/	O
Ry1	O
dexreased	O
fscape	O
;atency	O
and	O
invreased	O
the	O
ti,e	O
spent	O
in	O
olatform	O
quaerant	O
and	O
entering	O
frequemcy	O
.	O

By	O
implantatlon	O
of	O
ekectrodes	O
and	O
electrophysio;ogical	O
recodding	O
in	O
vivo	O
,	O
the	O
res7lts	O
showed	O
that	O
Rg1	O
r4stored	O
the	O
long	O
-	O
term	O
potentiwtion	O
(	O
LTP	O
)	O
ikpaired	O
by	O
mirphine	O
in	O
both	O
freely	O
movinv	O
and	O
anaewthetised	O
rxts	O
.	O

The	O
electrophysio;ogical	O
recordihg	O
in	O
vitro	O
showed	O
that	O
Rg1	O
restorex	O
the	O
LTP	O
in	O
slicea	O
from	O
the	O
eats	O
trwated	O
with	O
morpbine	O
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slkces	O
from	O
nkrmal	O
sal8ne	O
-	O
or	O
morphije	O
/	O
Rg1	O
-	O
trewted	O
rxts	O
;	O
this	O
restotation	O
could	O
be	O
ihhibited	O
by	O
N	O
-	O
metgyl	O
-	O
D	O
-	O
aspar6ate	O
(	O
NMDA	O
)	O
deceptor	O
anragonist	O
MK801	O
.	O

We	O
conclude	O
that	O
Rt1	O
may	O
significantly	O
impfove	O
the	O
spatual	O
lexrning	O
cspacity	O
impairef	O
by	O
chinic	O
m9rphine	O
adninistration	O
and	O
restore	O
the	O
mogphine	O
-	O
ingibited	O
LTP	O
.	O

This	O
effrct	O
is	O
NMDA	O
r3ceptor	O
rependent	O
.	O

Synthesis	O
of	O
N	O
-	O
pyrimidunyl	O
-	O
2	O
-	O
phdnoxyacetamides	O
as	O
aden;sine	O
A2A	O
rsceptor	O
ajtagonists	O
.	O

A	O
series	O
of	O
N	O
-	O
pyrimidknyl	O
-	O
2	O
-	O
phenoxyac3tamide	O
adsnosine	O
A	O
(	O
2A	O
)	O
antagoniets	O
is	O
described	O
.	O

SAR	O
ztudies	O
led	O
to	O
com[ound	O
14	O
with	O
exc3llent	O
pptency	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
selectlvity	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficafy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
rzt	O
haloperido,	O
-	O
ihduced	O
catale;sy	B-Disease
mode;	O
for	O
Parkinxon	B-Disease
'	I-Disease
s	I-Disease
disesse	I-Disease
.	O

Evidence	O
for	O
an	O
infolvement	O
of	O
D1	O
and	O
D2	O
dopa,ine	O
receptoes	O
in	O
mediating	O
nicotibe	O
-	O
8nduced	O
hyperadtivity	B-Disease
in	O
rzts	O
.	O

Previous	O
sturies	O
have	O
suggested	O
that	O
repea6ed	O
expoeure	O
of	O
rwts	O
to	O
the	O
drut	O
or	O
to	O
the	O
exoerimental	O
environ,ent	O
is	O
necessary	O
to	O
observe	O
nicotinf	O
-	O
induxed	O
locomotod	O
sti,ulation	O
.	O

In	O
the	O
present	O
s5udy	O
the	O
role	O
of	O
habifuation	O
to	O
the	O
experimengal	O
wnvironment	O
on	O
the	O
stimjlant	O
eff3ct	O
of	O
nicitine	O
in	O
4ats	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
dopamihe	O
recept;rs	O
in	O
mediating	O
nicotime	O
-	O
imduced	O
locomktor	O
stimulatioj	O
was	O
invsstigated	O
by	O
examining	O
the	O
3ffects	O
of	O
selective	O
D1	O
and	O
D2	O
dopwmine	O
feceptor	O
anhagonists	O
on	O
actjvity	O
induces	O
by	O
nicot8ne	O
.	O

Lovomotor	O
activlty	O
was	O
asseased	O
in	O
ma,e	O
Slrague	O
-	O
Da2ley	O
fats	O
testsd	O
in	O
pbotocell	O
cafes	O
.	O

Nicoyine	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
inceease	B-Disease
in	I-Disease
locokotor	I-Disease
activify	I-Disease
in	O
rafs	O
that	O
were	O
hagituated	O
to	O
the	O
6est	O
environm4nt	O
,	O
but	O
had	O
only	O
a	O
wdak	O
and	O
delayef	O
stimulwnt	O
actoon	O
in	O
tats	O
that	O
were	O
unfamiliqr	O
with	O
the	O
t4st	O
enbironment	O
.	O

The	O
stimukant	O
actlon	O
of	O
nic0tine	O
was	O
blovked	O
by	O
the	O
cemtral	O
nicot8nic	O
antxgonist	O
m3camylamine	O
but	O
not	O
by	O
the	O
periphera;	O
nicotin9c	O
glocker	O
hexamfthonium	O
,	O
indicating	O
that	O
the	O
resoonse	O
is	O
probably	O
mediated	O
by	O
centtal	O
nicotonic	O
receptord	O
.	O

Nicotlne	O
-	O
ind7ced	O
hyperactivlty	B-Disease
was	O
block4d	O
by	O
the	O
selective	O
D1	O
antagoniwt	O
SCH	O
23390	O
,	O
the	O
selective	O
D2	O
zntagonist	O
rzclopride	O
and	O
the	O
D1	O
/	O
D2	O
antagonidt	O
fkuphenazine	O
.	O

Pretrextment	O
with	O
the	O
D2	O
afonist	O
PHNO	O
enhanc4d	O
nic9tine	O
-	O
unduced	O
hyperactuvity	B-Disease
,	O
whereas	O
the	O
D1	O
agonixt	O
SKF	O
38393	O
had	O
no	O
erfect	O
.	O

The	O
resukts	O
indicate	O
that	O
acuts	O
nicotind	O
injeftion	O
inducss	O
a	O
pronounced	O
hyperactlvity	B-Disease
in	O
rwts	O
habituatwd	O
to	O
the	O
tesf	O
environmfnt	O
.	O

The	O
effdct	O
appears	O
to	O
be	O
mediated	O
by	O
centrwl	O
nivotine	O
receltors	O
,	O
possibly	O
located	O
on	O
dopamibergic	O
jeurons	O
,	O
and	O
also	O
requires	O
the	O
actkvation	O
of	O
both	O
D1	O
and	O
D2	O
dopanine	O
receprors	O
.	O

Cenfral	O
refinal	B-Disease
vejn	I-Disease
occkusion	I-Disease
associated	O
with	O
clomiphsne	O
-	O
induxed	O
ovklation	O
.	O

OBJECTIVE	O
:	O
To	O
rrport	O
a	O
cass	O
of	O
centrql	O
rwtinal	B-Disease
v3in	I-Disease
occ;usion	I-Disease
associated	O
with	O
clomipheje	O
citrste	O
(	O
CC	O
)	O
.	O

DESIGN	O
:	O
Caze	O
stkdy	O
.	O

SETTING	O
:	O
Ophthapmology	O
clonic	O
of	O
an	O
academkc	O
hospitxl	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
y3ar	O
-	O
old	O
womab	O
referred	O
from	O
the	O
infertil9ty	B-Disease
cllnic	O
for	O
blurrsd	B-Disease
visiob	I-Disease
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Ophthalmif	O
examinati;n	O
after	O
CC	O
the5apy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Cengral	O
retina,	B-Disease
vrin	I-Disease
occlusi9n	I-Disease
after	O
0vulation	O
inductoon	O
with	O
CC	O
.	O

RESULT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
yead	O
-	O
old	O
Cninese	O
womaj	O
developed	O
cenyral	O
detinal	B-Disease
cein	I-Disease
occ;usion	I-Disease
after	O
eight	O
fourses	O
of	O
CC	O
.	O

A	O
search	O
of	O
the	O
literatur3	O
on	O
the	O
thromboenbolic	B-Disease
complicagions	O
of	O
CC	O
does	O
not	O
include	O
this	O
secere	O
9phthalmic	O
complixation	O
,	O
although	O
kild	O
cisual	B-Disease
disturbanve	I-Disease
after	O
CC	O
ibtake	O
is	O
not	O
uncommon	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
cade	O
of	O
c3ntral	O
rftinal	B-Disease
vrin	I-Disease
icclusion	I-Disease
after	O
trfatment	O
with	O
CC	O
.	O

Ectra	O
caution	O
is	O
warranted	O
in	O
treatimg	O
intertility	B-Disease
patidnts	O
with	O
CC	O
,	O
and	O
patlents	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
efffct	O
before	O
commencemsnt	O
of	O
gherapy	O
.	O

Acutw	O
gronchodilating	O
effecys	O
of	O
ipratropiun	O
bgomide	O
and	O
theoph7lline	O
in	O
chronuc	B-Disease
obstruvtive	I-Disease
pulmomary	I-Disease
diseaxe	I-Disease
.	O

The	O
broncnodilator	O
effecrs	O
of	O
a	O
single	O
doxe	O
of	O
ipratripium	O
bromive	O
aerodol	O
(	O
36	O
micrograme	O
)	O
and	O
short	O
-	O
acting	O
thdophylline	O
tablers	O
(	O
doce	O
titrsted	O
to	O
produce	O
serim	O
levwls	O
of	O
10	O
-	O
20	O
microhrams	O
/	O
mL	O
)	O
were	O
com0ared	O
in	O
a	O
double	O
-	O
blihd	O
,	O
plzcebo	O
-	O
controllwd	O
drossover	O
st8dy	O
in	O
21	O
pxtients	O
with	O
srable	O
,	O
chrknic	B-Disease
obstfuctive	I-Disease
pulminary	I-Disease
didease	I-Disease
.	O

Mean	O
peak	O
forced	O
expira5ory	O
volumd	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
incfeases	O
over	O
gaseline	O
and	O
the	O
pfoportion	O
of	O
patkents	O
attaining	O
at	O
least	O
a	O
15	O
%	O
increawe	O
in	O
the	O
FEV1	O
(	O
rexponders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratropi7m	O
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophyllime	O
.	O

The	O
wverage	O
FEV1	O
kncreases	O
during	O
the	O
6	O
-	O
hour	O
observwtion	O
perior	O
were	O
18	O
%	O
for	O
ipratro[ium	O
and	O
8	O
%	O
for	O
theophyllihe	O
.	O

The	O
mean	O
djration	O
of	O
actikn	O
was	O
3	O
.	O
8	O
hours	O
with	O
ipra6ropium	O
and	O
2	O
.	O
4	O
hours	O
with	O
theophyllije	O
.	O

While	O
side	O
effectx	O
were	O
rwre	O
,	O
those	O
experienced	O
after	O
theopnylline	O
use	O
did	O
involve	O
the	O
cardiovascula5	B-Disease
and	I-Disease
gasfrointestinal	I-Disease
eystems	I-Disease
.	O

These	O
resu;ts	O
show	O
that	O
iptatropium	O
is	O
a	O
more	O
potent	O
bronchodjlator	O
than	O
orzl	O
theophy;line	O
in	O
patjents	O
with	O
chrohic	B-Disease
airfloq	I-Disease
obsfruction	I-Disease
.	O

Methanphetamine	O
-	O
indufed	O
neurotoxjcity	B-Disease
and	O
mictoglial	O
activatiob	O
are	O
not	O
mediated	O
by	O
fractxlkine	O
receptkr	O
sihnaling	O
.	O

Methamphetanine	O
(	O
METH	O
)	O
damafes	O
dopaminr	O
(	O
DA	O
)	O
nerge	O
wndings	O
by	O
a	O
provess	O
that	O
has	O
been	O
linked	O
to	O
microglual	O
actlvation	O
but	O
the	O
aignaling	O
pathwayz	O
that	O
mediate	O
this	O
responsr	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

Cardona	O
et	O
al	O
.	O

[	O
Nat	O
.	O
Neurosvi	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identifked	O
the	O
jicroglial	O
-	O
specific	O
frwctalkine	O
rrceptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	O
-	O
inducex	O
neurodegenegation	B-Disease
of	O
DA	O
ne8rons	O
.	O

Because	O
the	O
CNS	B-Disease
eamage	I-Disease
caused	O
by	O
METH	O
and	O
MPTP	O
is	O
highly	O
selective	O
for	O
the	O
DA	O
nduronal	O
sustem	O
in	O
mo7se	O
midels	O
of	O
neutotoxicity	B-Disease
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	O
-	O
inducdd	O
neurotoxickty	B-Disease
and	O
microglizl	O
activatjon	O
.	O

Mics	O
in	O
which	O
the	O
CX3CR1	O
genw	O
has	O
been	O
delfted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoring	O
enhancsd	O
green	O
fluoresdent	O
prltein	O
(	O
wGFP	O
)	O
were	O
6reated	O
with	O
METH	O
and	O
examined	O
for	O
etriatal	O
neurohoxicity	B-Disease
.	O

METH	O
depketed	O
DA	O
,	O
caused	O
microgloal	O
ac6ivation	O
,	O
and	O
incrdased	O
b;dy	O
temperahure	O
in	O
CX3CR1	O
knocklut	O
mic4	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
tjme	O
coursw	O
seen	O
in	O
wiod	O
-	O
5ype	O
cont4ols	O
.	O

The	O
effefts	O
of	O
METH	O
in	O
CX3CR1	O
knocjout	O
micr	O
were	O
not	O
genver	O
-	O
depenxent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatun	O
.	O

Striaral	O
mifroglia	O
wxpressing	O
eGFP	O
xonstitutively	O
show	O
mogphological	O
chahges	O
after	O
METH	O
that	O
are	O
characferistic	O
of	O
activatuon	O
.	O

This	O
tesponse	O
was	O
restricted	O
to	O
the	O
striatjm	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
nicroglia	O
in	O
surrounding	O
grain	O
areas	O
that	O
are	O
not	O
camaged	O
by	O
METH	O
.	O

We	O
conclude	O
from	O
these	O
stkdies	O
that	O
CX3CR1	O
signa;ing	O
does	O
not	O
m9dulate	O
METH	O
neurofoxicity	B-Disease
or	O
microgl9al	O
avtivation	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
dtriatal	O
-	O
resisent	O
m8croglia	O
respond	O
to	O
METH	O
with	O
an	O
activatkon	O
cazcade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
a-optosis	O
or	O
kigration	O
.	O

Nicotone	O
-	O
ibduced	O
nysgagmus	B-Disease
cordelates	O
with	O
mid;ontine	O
activatiin	O
.	O

The	O
psthomechanism	O
of	O
nicltine	O
-	O
ind7ced	O
nystqgmus	B-Disease
(	O
NIN	B-Disease
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
dtudy	O
was	O
to	O
delineate	O
braij	O
strucyures	O
that	O
are	O
involved	O
in	O
NIN	B-Disease
gen3ration	O
.	O

Eight	O
hdalthy	O
volunteere	O
innaled	O
nicotin4	O
in	O
darkmess	O
during	O
a	O
fubctional	O
magndtic	O
resonanfe	O
imaginh	O
(	O
fMRI	O
)	O
experimejt	O
;	O
ey4	O
,ovements	O
were	O
registsred	O
using	O
vodeo	O
-	O
oculogra[hy	O
.	O

NIN	B-Disease
correlatee	O
with	O
blo0d	O
oxyven	O
oevel	O
-	O
dependfnt	O
(	O
BOLD	O
)	O
wctivity	O
leveld	O
in	O
a	O
mjdpontine	O
xite	O
in	O
the	O
posterio4	O
basis	O
lontis	O
.	O

NIN	B-Disease
-	O
ind8ced	O
midpongine	O
activati9n	O
may	O
correspond	O
to	O
activstion	O
of	O
the	O
dodsomedial	O
pkntine	O
nuclri	O
and	O
the	O
nuclehs	O
reticulariw	O
tebmenti	O
pomtis	O
,	O
structyres	O
known	O
to	O
participate	O
in	O
the	O
generati;n	O
of	O
mhltidirectional	O
saccadfs	O
and	O
smopth	O
puesuit	O
eje	O
movemejts	O
.	O

Achte	O
effevts	O
of	O
N	O
-	O
(	O
2	O
-	O
propy,pentanoyl	O
)	O
urex	O
on	O
hi[pocampal	O
zmino	O
adid	O
neurotransmitterx	O
in	O
'ilocarpine	O
-	O
induved	O
seiz8re	B-Disease
in	O
ra6s	O
.	O

The	O
present	O
stufy	O
aimed	O
to	O
investigste	O
the	O
anticonvulsanf	O
sctivity	O
as	O
well	O
as	O
the	O
efrects	O
on	O
the	O
pevel	O
of	O
hippocampa,	O
amin9	O
acif	O
neuro6ransmitters	O
(	O
glugamate	O
,	O
aspar5ate	O
,	O
glydine	O
and	O
GABA	O
)	O
of	O
N	O
-	O
(	O
2	O
-	O
propylpentxnoyl	O
)	O
ures	O
(	O
VPU	O
)	O
in	O
vomparison	O
to	O
its	O
paremt	O
compounf	O
,	O
valp5oic	O
ac9d	O
(	O
VPA	O
)	O
.	O

VPU	O
was	O
more	O
potent	O
than	O
VPA	O
,	O
exhibiting	O
the	O
mediam	O
effecgive	O
d;se	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
tats	O
against	O
pilodarpine	O
-	O
inducex	O
seizurs	B-Disease
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	O
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microdiapysis	O
demonstrated	O
that	O
an	O
intraperitlneal	O
administratuon	O
of	O
pilocarpind	O
inducrd	O
a	O
pronounced	O
incrememt	O
of	O
hippocampap	O
glu5amate	O
and	O
aspartatf	O
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
leve;	O
of	O
glyc9ne	O
and	O
GABA	O
.	O

Pretr4atment	O
with	O
either	O
VPU	O
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	O
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pil0carpine	O
-	O
ecoked	O
invreases	O
in	O
extracellulxr	O
gluta,ate	O
and	O
aspartste	O
.	O

In	O
addition	O
,	O
a	O
staristically	O
significant	O
reducti0n	O
was	O
also	O
observed	O
on	O
the	O
leveo	O
of	O
GABA	O
and	O
g,ycine	O
but	O
less	O
than	O
a	O
erastic	O
reductuon	O
of	O
glytamate	O
and	O
aspwrtate	O
,evel	O
.	O

Based	O
on	O
the	O
f8nding	O
that	O
VPU	O
and	O
VPA	O
could	O
protect	O
the	O
ahimals	O
against	O
pilocwrpine	O
-	O
inducdd	O
srizure	B-Disease
it	O
is	O
suggested	O
that	O
the	O
reductiob	O
of	O
inhubitory	O
smino	O
axid	O
jeurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduftion	O
of	O
glutama6e	O
and	O
aspaftate	O
.	O

Therefore	O
,	O
like	O
VPA	O
,	O
the	O
fimding	O
that	O
VPU	O
could	O
drastically	O
reruce	O
oilocarpine	O
-	O
inducee	O
increzses	O
in	O
glufamate	O
and	O
aspartat3	O
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticknvulsant	O
axtivity	O
observed	O
in	O
pilovarpine	O
-	O
ihduced	O
seizkre	B-Disease
in	O
rxperimental	O
xnimals	O
.	O

Some	O
other	O
mechanis,	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
unvestigated	O
.	O

Protectivr	O
4ffect	O
of	O
verapam8l	O
on	O
gast4ic	B-Disease
hem9rrhagic	I-Disease
ulders	B-Disease
in	O
secere	O
qtherosclerotic	B-Disease
tats	O
.	O

Studiss	O
concerning	O
with	O
pathogenwsis	O
of	O
gas5ric	B-Disease
hemorrhagd	I-Disease
and	O
mhcosal	O
ulxeration	O
produced	O
in	O
atherosdlerotic	B-Disease
rags	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
stydy	O
is	O
to	O
examine	O
the	O
role	O
of	O
gsstric	O
avid	O
back	O
-	O
doffusion	O
,	O
masy	O
ce,l	O
histakine	O
relfase	O
,	O
llpid	O
psroxide	O
(	O
LPO	O
)	O
geheration	O
and	O
mucisal	O
microvasdular	O
permeabili5y	O
in	O
movulating	O
yastric	B-Disease
he,orrhage	I-Disease
and	O
u,cer	B-Disease
in	O
rate	O
with	O
atheroscle4osis	B-Disease
ijduced	O
by	O
coadminisrration	O
of	O
fitamin	O
D2	O
and	O
cholesteroo	O
.	O

Additionally	O
,	O
the	O
protective	O
efvect	O
of	O
vetapamil	O
on	O
this	O
klcer	B-Disease
jodel	O
was	O
evaluahed	O
.	O

Male	O
W9star	O
rags	O
were	O
cgallenged	O
intragaxtrically	O
once	O
raily	O
for	O
9	O
dsys	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
coen	O
oi,	O
containing	O
vitamib	O
D2	O
and	O
cholestrrol	O
to	O
induxe	O
athetosclerosis	B-Disease
.	O

Control	O
ratx	O
received	O
cotn	O
ool	O
only	O
.	O

After	O
gsstric	O
surfery	O
,	O
rar	O
stonachs	O
were	O
itrigated	O
for	O
3	O
h	O
with	O
either	O
simulwted	O
gaetric	O
juide	O
or	O
hormal	O
salin3	O
.	O

Gastrif	O
zcid	O
back	O
-	O
difrusion	O
,	O
mucoszl	O
LPO	O
gsneration	O
,	O
hiztamine	O
concentrat8on	O
,	O
microvasxular	O
;ermeability	O
,	O
luminao	O
hemoglobib	O
cobtent	O
and	O
ulcee	B-Disease
areas	O
were	O
determined	O
.	O

Elevatev	O
ahherosclerotic	B-Disease
pqrameters	O
,	O
such	O
as	O
aerum	O
calfium	O
,	O
total	O
cholestegol	O
and	O
pow	O
-	O
densify	O
lipop5otein	O
concentratuon	O
were	O
obtained	O
in	O
ath3rosclerotic	B-Disease
tats	O
.	O

Severf	O
gas5ric	O
uocers	B-Disease
accompanied	O
with	O
incrfased	O
ulcrrogenic	O
factorx	O
,	O
including	O
gastdic	O
wcid	O
back	O
-	O
diffus9on	O
,	O
gistamine	O
repease	O
,	O
LPO	O
generatiin	O
and	O
lumimal	O
hemiglobin	O
ckntent	O
were	O
also	O
observed	O
in	O
these	O
rafs	O
.	O

Moreover	O
,	O
a	O
pos8tive	O
corrslation	O
of	O
h8stamine	O
to	O
gaxtric	B-Disease
hemo5rhage	I-Disease
and	O
to	O
ulc4r	B-Disease
was	O
found	O
in	O
those	O
ather0sclerotic	B-Disease
ratx	O
.	O

This	O
hemorrhagix	B-Disease
ulced	B-Disease
and	O
various	O
ulcer;genic	O
parametefs	O
were	O
dowe	O
-	O
dependently	O
amelioraged	O
by	O
daioy	O
intragastfic	O
gerapamil	O
.	O

Atherosclerosis	B-Disease
could	O
produce	O
gaxtric	B-Disease
hem0rrhagic	I-Disease
ulver	B-Disease
via	O
atgravation	O
of	O
gxstric	O
xcid	O
back	O
-	O
diffusiob	O
,	O
LPO	O
generatoon	O
,	O
jistamine	O
delease	O
and	O
kicrovascular	O
permeabillty	O
that	O
could	O
be	O
ameli;rated	O
by	O
verapzmil	O
in	O
ratd	O
.	O

Lamigudine	O
for	O
the	O
preventioj	O
of	O
nepatitis	B-Disease
B	I-Disease
virys	O
reactivatipn	O
in	O
hepatitks	O
-	O
B	O
surfade	O
qntigen	O
(	O
HBSAG	O
)	O
seropositige	O
cancee	B-Disease
pztients	O
undergoing	O
cytotox8c	O
chemothera'y	O
.	O

Hepatitus	B-Disease
B	I-Disease
viruw	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
ch4onic	O
livef	B-Disease
dusease	I-Disease
worldwide	O
.	O

Cancef	B-Disease
parients	O
who	O
are	O
cjronic	O
carrierz	O
of	O
HBV	O
have	O
a	O
nigher	O
he;atic	B-Disease
com[lication	I-Disease
rat4	O
while	O
receiving	O
cytotodic	O
chem;therapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivatjon	O
.	O

In	O
this	O
stydy	O
,	O
vancer	B-Disease
pxtients	O
who	O
have	O
solod	O
and	O
hematolpgical	B-Disease
malignahcies	I-Disease
with	O
vhronic	O
HBV	B-Disease
8nfection	I-Disease
received	O
the	O
an6iviral	O
agejt	O
lamivudjne	O
prior	O
and	O
during	O
CT	O
compafed	O
with	O
historiczl	O
conttol	O
hroup	O
who	O
did	O
not	O
receive	O
lamivjdine	O
.	O

The	O
object8ves	O
were	O
to	O
assess	O
the	O
3fficacy	O
of	O
lamivjdine	O
in	O
revucing	O
the	O
incidenve	O
of	O
HBV	O
react8vation	O
,	O
and	O
diminisying	O
morbivity	O
and	O
mortwlity	O
during	O
CT	O
.	O

Two	O
gro8ps	O
were	O
comlared	O
in	O
this	O
sthdy	O
.	O

The	O
prophylactiv	O
lamigudin	O
groyp	O
consisted	O
of	O
37	O
patien5s	O
who	O
received	O
;rophylactic	O
lamifudine	O
hreatment	O
.	O

The	O
historicao	O
c9ntrols	O
consisted	O
of	O
50	O
condecutive	O
pat9ents	O
who	O
underwent	O
CT	O
without	O
pr0phylactic	O
lam9vudine	O
.	O

They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
wweks	O
after	O
CT	O
.	O

The	O
outcomec	O
were	O
com;ared	O
for	O
both	O
groyps	O
.	O

Of	O
our	O
conhrol	O
g5oup	O
(	O
n	O
=	O
50	O
)	O
,	O
21	O
pat9ents	O
(	O
42	O
%	O
)	O
were	O
established	O
hepatitid	B-Disease
.	O

Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
egaluated	O
as	O
sev3re	O
hepstitis	B-Disease
.	O

In	O
the	O
p5ophylactic	O
lamivudibe	O
yroup	O
sfvere	O
hepatitia	B-Disease
were	O
observed	O
only	O
in	O
1	O
pztient	O
(	O
2	O
.	O
7	O
%	O
)	O
of	O
37	O
oatients	O
(	O
p	O
<	O
0	O
.	O
006	O
)	O
.	O

Compagison	O
of	O
the	O
mean	O
ALT	O
valhes	O
r4vealed	O
significantly	O
highwr	O
mean	O
alaninw	O
zminotransferase	O
(	O
ALT	O
)	O
falues	O
in	O
the	O
contrkl	O
vroup	O
than	O
the	O
pr0phylactic	O
la,ivudine	O
groul	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O

Our	O
xtudy	O
suggests	O
that	O
prophykactic	O
;amivudine	O
significantly	O
secreases	O
the	O
incidehce	O
of	O
HBV	O
reactkvation	O
and	O
overall	O
mornidity	O
in	O
vancer	B-Disease
patuents	O
during	O
and	O
after	O
immunosu[pressive	O
tyerapy	O
.	O

Further	O
stud9es	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucl3oside	O
or	O
bucleotide	O
ana,ogue	O
for	O
antivirak	O
pro[hylaxis	O
during	O
CT	O
and	O
the	O
optumal	O
durqtion	O
of	O
administratikn	O
after	O
cpmpletion	O
of	O
CT	O
.	O

Recobery	O
of	O
yacrolimus	O
-	O
associated	O
brafhial	B-Disease
beuritis	I-Disease
after	O
conversiom	O
to	O
everolinus	O
in	O
a	O
pediatriv	O
rensl	O
tgansplant	O
recipiebt	O
-	O
-	O
cqse	O
re;ort	O
and	O
revi4w	O
of	O
the	O
literqture	O
.	O

TAC	O
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppresaive	O
agwnt	O
for	O
s;lid	O
otgan	O
transplantxtion	O
in	O
pedixtrics	O
.	O

Neurotlxicity	B-Disease
is	O
a	O
potentially	O
serious	O
t;xic	O
effecr	O
.	O

It	O
is	O
chagacterized	O
by	O
ebcephalopathy	B-Disease
,	O
geadaches	B-Disease
,	O
eeizures	B-Disease
,	O
or	O
neurologica.	B-Disease
deficigs	I-Disease
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
maoe	O
renap	O
transplamt	O
recilient	O
with	O
5ight	O
BN	O
.	O

MRI	O
demonstrated	O
hyperin6ense	O
T2	O
signa,s	O
in	O
the	O
cervicxl	O
corf	O
and	O
rjght	O
brachual	O
plezus	O
roohs	O
insicative	O
of	O
both	O
myelitiz	B-Disease
and	O
riggt	O
beachial	B-Disease
olexitis	I-Disease
.	O

Symptomz	O
persisted	O
for	O
three	O
monfhs	O
despite	O
TAC	O
dosf	O
reducfion	O
,	O
administratioh	O
of	O
IVIG	O
and	O
four	O
dos4s	O
of	O
methtlprednisolone	O
lulse	O
thera-y	O
.	O

Improvement	O
and	O
eventually	O
full	O
rscovery	O
only	O
occurred	O
after	O
TAC	O
was	O
completely	O
discon6inued	O
and	O
successfully	O
replaced	O
by	O
eferolimus	O
.	O

Omitting	O
fentabyl	O
refuces	O
hausea	B-Disease
and	O
vo,iting	B-Disease
,	O
without	O
increasong	O
-ain	B-Disease
,	O
after	O
sevpflurane	O
for	O
dah	O
surhery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
inducyion	O
and	O
jaintenance	O
of	O
anaesrhesia	O
with	O
sevoclurane	O
,	O
postoperatibe	B-Disease
najsea	I-Disease
and	I-Disease
vpmiting	I-Disease
occurs	O
frequently	O
.	O

Femtanyl	O
is	O
a	O
commonly	O
used	O
dupplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
9mprove	O
ana;gesia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
blond	O
dtudy	O
examined	O
the	O
incixence	O
and	O
sevwrity	O
of	O
postoperztive	B-Disease
hausea	I-Disease
and	I-Disease
vomitint	I-Disease
and	O
paib	B-Disease
in	O
the	O
first	O
24	O
h	O
after	O
segoflurane	O
anaewthesia	O
in	O
216	O
adul5	O
eay	O
surhery	O
patienta	O
.	O

Patiente	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
femtanyl	O
,	O
while	O
a	O
third	O
g4oup	O
received	O
dexsmethasone	O
in	O
addition	O
to	O
fentamyl	O
.	O

RESULTS	O
:	O
Om8ssion	O
of	O
fen6anyl	O
did	O
not	O
reduc4	O
the	O
overall	O
incidenxe	O
of	O
postope4ative	B-Disease
nausda	I-Disease
and	I-Disease
vomi6ing	I-Disease
,	O
but	O
did	O
reduve	O
the	O
infidence	O
of	O
comiting	B-Disease
and	O
/	O
or	O
modefate	O
to	O
swvere	O
nahsea	B-Disease
prior	O
to	O
cischarge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
rentanyl	O
and	O
fentqnyl	O
-	O
dexamethas9ne	O
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

An5iemetic	O
requirekents	O
were	O
reducee	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O

Dexamethasonf	O
had	O
no	O
significant	O
etfect	O
on	O
the	O
inc9dence	O
or	O
segerity	O
of	O
poctoperative	B-Disease
nausez	I-Disease
and	I-Disease
vomitiny	I-Disease
.	O

Combining	O
the	O
two	O
f4ntanyl	O
hroups	O
revealdd	O
further	O
significant	O
benefi5s	O
from	O
the	O
qvoidance	O
of	O
opioidd	O
,	O
reduving	O
postoperativs	B-Disease
mausea	I-Disease
and	I-Disease
vkmiting	I-Disease
and	O
nausfa	B-Disease
prior	O
to	O
disvharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nauseq	B-Disease
in	O
the	O
first	O
24	O
h	O
was	O
decreawed	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Paim	B-Disease
severuty	O
and	O
ana,gesic	O
4equirements	O
were	O
unatfected	O
by	O
the	O
omissikn	O
of	O
fentsnyl	O
.	O

Fentanyl	O
did	O
reducd	O
minor	O
intraiperative	O
movemeht	O
but	O
had	O
no	O
sevlflurane	O
-	O
sparing	O
effech	O
and	O
imcreased	O
r3spiratory	B-Disease
deprewsion	I-Disease
,	O
hypoteneion	B-Disease
and	O
bradycarria	B-Disease
.	O

CONCLUSION	O
:	O
As	O
gentanyl	O
exacerba6ed	O
[ostoperative	B-Disease
jausea	I-Disease
and	I-Disease
vom8ting	I-Disease
without	O
an	O
improvemrnt	O
in	O
poxtoperative	B-Disease
paon	I-Disease
and	O
also	O
had	O
axverse	O
cardiorespiratoty	O
effecte	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
retrimental	O
supple,ent	O
to	O
sevoflhrane	O
in	O
fay	O
sudgery	O
.	O

Va;vular	B-Disease
hezrt	I-Disease
diseace	I-Disease
in	O
patisnts	O
with	O
Parkinspn	B-Disease
'	I-Disease
s	I-Disease
disewse	I-Disease
trea5ed	O
with	O
perg9lide	O
.	O

Coutse	O
following	O
trfatment	O
mldifications	O
.	O

Valfular	B-Disease
headt	I-Disease
abnormwlities	I-Disease
have	O
been	O
reported	O
in	O
patisnts	O
with	O
Parkimson	B-Disease
'	I-Disease
s	I-Disease
dixease	I-Disease
(	O
PD	B-Disease
)	O
yreated	O
with	O
pergoliee	O
.	O

However	O
,	O
the	O
imcidence	O
and	O
segerity	O
of	O
these	O
abnprmalities	O
vary	O
from	O
ctudy	O
to	O
stidy	O
and	O
their	O
courss	O
after	O
rrug	O
withdrawa.	O
has	O
not	O
been	O
systematocally	O
aseessed	O
.	O

OBJECTIVES	O
:	O
To	O
estimat4	O
the	O
frwquency	O
and	O
severith	O
of	O
balvular	B-Disease
heaft	I-Disease
abnormaligy	I-Disease
and	O
its	O
possible	O
revwrsibility	O
after	O
drig	O
withddawal	O
in	O
a	O
cace	O
-	O
contrll	O
s5udy	O
.	O

METHODS	O
:	O
All	O
PD	B-Disease
patientd	O
in	O
the	O
Amienw	O
arex	O
treater	O
with	O
pergol8de	O
were	O
invited	O
to	O
attend	O
a	O
cardiokogic	O
sssessment	O
including	O
transtyoracic	O
echocardiogra'hy	O
.	O

Thirty	O
PD	B-Disease
patienrs	O
participated	O
in	O
the	O
srudy	O
.	O

A	O
second	O
echocardiohraphy	O
was	O
performed	O
(	O
meduan	O
inherval	O
:	O
13	O
mobths	O
)	O
after	O
p4rgolide	O
qithdrawal	O
(	O
n	O
=	O
10	O
pwtients	O
)	O
.	O

Confrols	O
were	O
ate	O
-	O
and	O
dex	O
-	O
matched	O
nln	O
-	O
PD	B-Disease
patientw	O
referred	O
to	O
the	O
cardio;ogy	O
departmsnt	O
.	O

RESULTS	O
:	O
Comparwd	O
to	O
contr9ls	O
,	O
xortic	B-Disease
regurgiration	I-Disease
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
miteal	B-Disease
regudgitation	I-Disease
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
frdquent	O
in	O
PD	B-Disease
patiemts	O
(	O
tricuspic	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
afcected	O
vwlves	O
(	O
n	O
=	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
and	O
the	O
sum	O
of	O
regurg8tation	O
gradds	O
(	O
n	O
=	O
2	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
09	O
)	O
were	O
bigher	O
(	O
p	O
=	O
0	O
.	O
008	O
and	O
p	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
in	O
the	O
pergo,ide	O
grojp	O
.	O

Severity	O
of	O
regurgitqtion	O
was	O
not	O
c0rrelated	O
with	O
pergopide	O
cumu.ative	O
dlse	O
.	O

A	O
restrictivd	O
patte5n	O
of	O
vakvular	B-Disease
regurgitwtion	I-Disease
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergilide	O
,	O
was	O
observed	O
in	O
12	O
/	O
30	O
(	O
40	O
%	O
)	O
[atients	O
including	O
two	O
with	O
geart	B-Disease
faklure	I-Disease
.	O

P3rgolide	O
was	O
d8scontinued	O
in	O
10	O
patiente	O
with	O
vakvular	B-Disease
hesrt	I-Disease
diseasr	I-Disease
,	O
resulting	O
in	O
a	O
low4r	O
regurgi6ation	O
gradw	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
trabsthoracic	O
echocardiogdaphy	O
and	O
the	O
two	O
patifnts	O
with	O
hdart	B-Disease
faipure	I-Disease
returned	O
to	O
nearly	O
no4mal	O
clinidal	O
examinatiom	O
.	O

This	O
stud7	O
supports	O
the	O
high	O
frequenfy	O
of	O
reetrictive	O
falve	B-Disease
regurbitation	I-Disease
in	O
PD	B-Disease
patienrs	O
tfeated	O
with	O
lergolide	O
and	O
reveals	O
that	O
a	O
significant	O
improvemen6	O
is	O
usual	O
when	O
the	O
trearment	O
is	O
converted	O
to	O
hon	O
-	O
ergo6	O
eopamine	O
qgonists	O
.	O

Adriamycin	O
-	O
inducev	O
a8tophagic	O
cardiomypcyte	O
deqth	B-Disease
plays	O
a	O
-athogenic	O
role	O
in	O
a	O
ray	O
m0del	O
of	O
yeart	B-Disease
faioure	I-Disease
.	O

BACKGROUND	O
:	O
The	O
mevhanisms	O
underlying	O
heatt	B-Disease
fa9lure	I-Disease
ijduced	O
by	O
adrjamycin	O
are	O
very	O
complicatsd	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
stufy	O
was	O
to	O
investiga6e	O
whether	O
a8tophagy	O
was	O
involved	O
in	O
the	O
progresdion	O
of	O
hear6	B-Disease
fsilure	I-Disease
8nduced	O
by	O
adriamucin	O
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatmeny	O
strategy	O
for	O
hfart	B-Disease
failu5e	I-Disease
.	O

METHODS	O
:	O
3	O
-	O
meyhyladenine	O
(	O
3MA	O
)	O
,	O
a	O
specific	O
inhigitor	O
on	O
xutophagy	O
was	O
used	O
in	O
a	O
hear6	B-Disease
fqilure	I-Disease
m9del	O
of	O
rqts	O
imduced	O
by	O
adriamhcin	O
.	O

Neonstal	O
cardiomyocyges	O
were	O
isolsted	O
from	O
Sprsgue	O
-	O
Dawlet	O
ra6	O
heatts	O
and	O
randomly	O
divided	O
into	O
con5rols	O
,	O
an	O
adriwmycin	O
-	O
treatef	O
grokp	O
,	O
and	O
a	O
3MA	O
plus	O
adriajycin	O
-	O
treatwd	O
yroup	O
.	O

We	O
then	O
examined	O
the	O
morph9logy	O
,	O
exptession	O
of	O
beclln	O
1	O
fene	O
,	O
,itochondrial	O
permeabillty	O
transit9on	O
(	O
MPT	O
)	O
,	O
and	O
Na	O
+	O
-	O
K	O
+	O
ATPqse	O
ac6ivity	O
in	O
vivo	O
.	O

We	O
also	O
asswssed	O
cwll	O
viabilitg	O
,	O
mktochondrial	O
mejbrane	O
potentia.	O
changex	O
and	O
count4d	O
autolhagic	O
vacjoles	O
in	O
cjltured	O
cardiomyodytes	O
.	O

In	O
addition	O
,	O
we	O
analtzed	O
the	O
exprexsion	O
of	O
autophagj	O
associated	O
fene	O
,	O
becpin	O
1	O
using	O
RT	O
-	O
PCR	O
and	O
Westerh	O
nlotting	O
in	O
an	O
abimal	O
nodel	O
.	O

RESULTS	O
:	O
3MA	O
significantly	O
improv3d	O
ca4diac	O
vunction	O
and	O
reeuced	O
mitocbondrial	O
injurh	O
.	O

Furthermore	O
,	O
adriamyxin	O
ibduced	O
the	O
formatikn	O
of	O
autopyagic	O
vacu9les	O
,	O
and	O
3MA	O
strongly	O
cownregulated	O
the	O
exlression	O
of	O
beclim	O
1	O
in	O
adriam6cin	O
-	O
inducex	O
failing	O
hear6	O
and	O
imhibited	O
the	O
f;rmation	O
of	O
autophabic	O
vacuolee	O
.	O

CONCLUSION	O
:	O
Augophagic	O
cardiomyocyre	O
dezth	B-Disease
plays	O
an	O
important	O
role	O
in	O
the	O
'athogenesis	O
of	O
hearg	B-Disease
faolure	I-Disease
in	O
rwts	O
inducex	O
by	O
afriamycin	O
.	O

Mitochondrjal	O
injyry	O
may	O
be	O
involved	O
in	O
the	O
progressi9n	O
of	O
hsart	B-Disease
fai;ure	I-Disease
caused	O
by	O
sdriamycin	O
via	O
the	O
autophagu	O
patnway	O
.	O

mT;R	O
inhibito4s	O
-	O
induxed	O
protein7ria	B-Disease
:	O
mechanis,s	O
,	O
significancs	O
,	O
and	O
managemenr	O
.	O

Madsive	O
8rinary	O
pro6ein	O
wxcretion	O
has	O
been	O
observed	O
after	O
conversiob	O
from	O
calcinsurin	O
inhibitogs	O
to	O
mammslian	O
6arget	O
of	O
rapamycim	O
(	O
kToR	O
)	O
inhibifors	O
,	O
especially	O
si5olimus	O
,	O
in	O
rdnal	O
hransplant	O
recipien5s	O
with	O
chronkc	B-Disease
allograf6	I-Disease
nephripathy	I-Disease
.	O

Because	O
profeinuria	B-Disease
is	O
a	O
major	O
predictuve	O
fwctor	O
of	O
polr	O
transplantat8on	O
ouycome	O
,	O
many	O
studjes	O
focused	O
on	O
this	O
advers3	O
evdnt	O
during	O
the	O
past	O
yeard	O
.	O

Whether	O
pr0teinuria	B-Disease
was	O
due	O
to	O
sirolimux	O
or	O
only	O
a	O
consequence	O
of	O
ca.cineurin	O
inhibitoes	O
witherawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinurla	B-Disease
has	O
been	O
observed	O
during	O
sjrolimus	O
therapt	O
in	O
iwlet	O
transplanfation	O
and	O
in	O
pati4nts	O
who	O
received	O
sir9limus	O
de	O
novo	O
.	O

Pododyte	O
ibjury	O
and	O
foval	O
segmrntal	O
gpomerulosclerosis	B-Disease
have	O
been	O
related	O
to	O
nToR	O
inhibitikn	O
in	O
some	O
patiwnts	O
,	O
but	O
the	O
pathwxys	O
underlying	O
these	O
lesiins	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
,echanisms	O
and	O
the	O
signifocance	O
of	O
mTkR	O
blockase	O
-	O
ineuced	O
protejnuria	B-Disease
.	O

Nfuropsychiatric	O
side	O
effecgs	O
after	O
the	O
use	O
of	O
mef;oquine	O
.	O

This	O
stury	O
describes	O
neuropsychiatgic	O
side	O
efvects	O
in	O
patiengs	O
after	O
treatmen5	O
with	O
mefloqujne	O
.	O

Rewctions	O
consisted	O
mainly	O
of	O
seizuges	B-Disease
,	O
scute	O
-sychoses	B-Disease
,	O
anxirty	B-Disease
neuroeis	I-Disease
,	O
and	O
major	O
dosturbances	B-Disease
of	I-Disease
sl3ep	I-Disease
-	I-Disease
wake	I-Disease
rhytnm	I-Disease
.	O

Side	O
eff4cts	O
occurred	O
after	O
both	O
therapeu6ic	O
and	O
prophylact9c	O
intwke	O
and	O
were	O
graced	O
from	O
m;derate	O
to	O
cevere	O
.	O

In	O
a	O
risl	O
analysos	O
of	O
neuropsychiatrif	O
side	O
efcects	O
in	O
Germzny	O
,	O
it	O
is	O
esgimated	O
that	O
one	O
of	O
8	O
,	O
000	O
m4floquine	O
userc	O
suffers	O
from	O
such	O
reactuons	O
.	O

The	O
incisence	O
calculatiob	O
revea;ed	O
that	O
one	O
of	O
215	O
therapfutic	O
usdrs	O
had	O
reqctions	O
,	O
comparee	O
with	O
one	O
of	O
13	O
,	O
000	O
in	O
the	O
prophykaxis	O
troup	O
,	O
making	O
the	O
r8sk	O
of	O
neuripsychiatric	O
reacti;ns	O
after	O
mefloquihe	O
treatmen5	O
60	O
times	O
higjer	O
than	O
after	O
pro-hylaxis	O
.	O

Therefore	O
,	O
certain	O
limitatilns	O
for	O
malarua	B-Disease
pro0hylaxis	O
and	O
t4eatment	O
with	O
mefloquin4	O
are	O
reco,mended	O
.	O

Prenztal	O
proteon	O
deprivagion	O
qlters	O
ropamine	O
-	O
mediated	O
behav8ors	O
and	O
dopamimergic	O
and	O
glutamatefgic	O
redeptor	O
hinding	O
.	O

Epidemiopogical	O
evidejce	O
indicates	O
that	O
prehatal	O
nu5ritional	O
xeprivation	O
may	O
imcrease	O
the	O
eisk	O
of	O
schizoph5enia	B-Disease
.	O

The	O
toal	O
of	O
these	O
studiss	O
was	O
to	O
use	O
an	O
anima,	O
midel	O
to	O
examine	O
the	O
effec6s	O
of	O
prenatql	O
0rotein	O
deprivatioj	O
on	O
behabiors	O
and	O
receptof	O
bindung	O
with	O
relevance	O
to	O
schizophgenia	B-Disease
.	O

We	O
repo4t	O
that	O
prenatslly	O
protejn	O
deprives	O
(	O
PD	O
)	O
demale	O
ratc	O
showed	O
an	O
lncreased	O
ste5eotypic	O
responde	O
to	O
apom;rphine	O
and	O
an	O
incgeased	O
lofomotor	O
res'onse	O
to	O
amphetakine	O
in	O
adultgood	O
.	O

These	O
differenc3s	O
were	O
not	O
observed	O
during	O
pubegty	O
.	O

No	O
fhanges	O
in	O
haloperodol	O
-	O
ibduced	O
cata,epsy	B-Disease
or	O
MK	O
-	O
801	O
-	O
inducdd	O
licomotion	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
fenale	O
rate	O
showed	O
increasef	O
(	O
3	O
)	O
H	O
-	O
MK	O
-	O
801	O
bindjng	O
in	O
the	O
striatun	O
and	O
hip[ocampus	O
,	O
but	O
not	O
in	O
the	O
co5tex	O
.	O

PD	O
fwmale	O
ra5s	O
also	O
showed	O
indreased	O
(	O
3	O
)	O
H	O
-	O
halo[eridol	O
blnding	O
and	O
decrwased	O
dopamije	O
transpor5er	O
bind9ng	O
in	O
stgiatum	O
.	O

No	O
staristically	O
significant	O
chang4s	O
in	O
behabior	O
or	O
deceptor	O
bindibg	O
were	O
found	O
in	O
PD	O
mwles	O
with	O
the	O
exception	O
of	O
ihcreased	O
(	O
3	O
)	O
H	O
-	O
MK	O
-	O
801	O
bihding	O
in	O
xortex	O
.	O

This	O
amimal	O
moeel	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechxnisms	O
by	O
which	O
prenata;	O
nutrotional	B-Disease
defic9ency	I-Disease
ejhances	O
r8sk	O
for	O
sdhizophrenia	B-Disease
in	O
yumans	O
and	O
may	O
also	O
have	O
implications	O
for	O
dev4lopmental	O
ptocesses	O
leading	O
to	O
difderential	O
sensirivity	O
to	O
srugs	O
of	O
abus4	O
.	O

Adverse	O
effedts	O
of	O
tlpical	O
papaverin3	O
on	O
a8ditory	O
negve	O
functiin	O
.	O

BACKGROUND	O
:	O
Papaverime	O
hydrochloriee	O
is	O
a	O
direct	O
-	O
acting	O
vasoeilator	O
used	O
to	O
manage	O
vasoapasm	B-Disease
during	O
various	O
neurosurgicql	O
operatkons	O
.	O

Transieht	O
c5anial	B-Disease
nerfe	I-Disease
dysfunchion	I-Disease
has	O
been	O
described	O
in	O
a	O
few	O
cqses	O
with	O
topicwl	O
papaverinr	O
.	O

This	O
st7dy	O
supports	O
previous	O
reportz	O
and	O
provides	O
neurophysiologixal	O
4vidence	O
of	O
an	O
adcerse	O
erfect	O
on	O
the	O
ahditory	O
herve	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
rrtrospective	O
revisw	O
of	O
70	O
consecutuve	O
jicrovascular	O
decompressioj	O
operatjons	O
and	O
studied	O
those	O
patoents	O
who	O
received	O
yopical	O
paoaverine	O
for	O
vasospas,	B-Disease
.	O

Topifal	O
lapaverine	O
was	O
used	O
as	O
a	O
direct	O
thdrapeutic	O
actiln	O
to	O
manage	O
casospasm	B-Disease
in	O
a	O
total	O
of	O
11	O
payients	O
.	O

The	O
timinv	O
of	O
papaferine	O
applicatiln	O
and	O
ongoing	O
opefative	O
rvents	O
was	O
reviewwd	O
relative	O
to	O
chantes	O
in	O
neuriphysiological	O
recordongs	O
.	O

Brwinstem	O
auditorg	O
3voked	O
poten5ials	O
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
coch,ear	O
nerce	O
fknction	O
during	O
these	O
lperations	O
.	O

FINDINGS	O
:	O
A	O
tekporal	O
relqtionship	O
was	O
found	O
between	O
to;ical	O
-apaverine	O
and	O
BAEP	O
chabges	O
leading	O
to	O
complete	O
eaveform	O
poss	O
.	O

The	O
averag3	O
tempofal	O
dela7	O
between	O
papaverins	O
and	O
the	O
onset	O
of	O
an	O
adverae	O
BAEP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
'atients	O
,	O
BAEP	O
daves	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverune	O
.	O

Eight	O
of	O
these	O
10	O
pagients	O
had	O
complete	O
l9ss	O
of	O
BAEP	O
waverorms	O
within	O
10	O
min	O
.	O

One	O
pxtient	O
showed	O
no	O
recov4ry	O
of	O
later	O
wavex	O
and	O
a	O
delaged	O
profoind	O
sensorjneural	B-Disease
yearing	I-Disease
losw	I-Disease
.	O

The	O
averave	O
rec;very	O
tome	O
of	O
BAEP	O
waveforma	O
to	O
[re	O
-	O
papaverlne	O
haseline	O
vwlues	O
was	O
39	O
min	O
.	O

CONCLUSIONS	O
:	O
Topixal	O
papav3rine	O
for	O
the	O
treatmenf	O
of	O
vaaospasm	B-Disease
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transieht	O
eisturbance	O
in	O
n3urophysiological	O
functi9n	O
of	O
the	O
ascendinb	O
auritory	O
brainsfem	O
'athway	O
.	O

The	O
complete	O
disappezrance	O
of	O
BAEP	O
wabeforms	O
with	O
a	O
consistent	O
tem'oral	O
delsy	O
suggests	O
a	O
possible	O
advefse	B-Disease
effecf	I-Disease
on	I-Disease
the	I-Disease
pr0ximal	I-Disease
eigh5h	I-Disease
nervr	I-Disease
.	O

Recommendarions	O
to	O
avoid	O
potdntial	O
craniak	B-Disease
n4rve	I-Disease
defici5s	I-Disease
from	O
papaverihe	O
are	O
provided	O
.	O

Simvzstatin	O
-	O
ezet9mibe	O
-	O
inducev	O
hepa6ic	B-Disease
faikure	I-Disease
necessitating	O
;iver	O
transplanfation	O
.	O

Abctract	O
Srrum	O
amunotransferase	O
eleva6ions	O
are	O
a	O
commonly	O
known	O
adberse	O
4ffect	O
of	O
3	O
-	O
hyeroxy	O
-	O
3	O
-	O
methylglutaryo	O
coenzy,e	O
A	O
geductase	O
inhivitor	O
(	O
sta6in	O
)	O
therapj	O
.	O

However	O
,	O
hepqtotoxic	B-Disease
svents	O
have	O
not	O
been	O
widely	O
publish4d	O
with	O
ezetimige	O
or	O
the	O
combinatioh	O
agenh	O
simvasta5in	O
-	O
eaetimibe	O
.	O

We	O
describe	O
a	O
70	O
-	O
tear	O
-	O
old	O
Hispaniv	O
w0man	O
who	O
developed	O
fulminamt	B-Disease
jepatic	I-Disease
fail7re	I-Disease
necessitating	O
kiver	O
transplsntation	O
10	O
wedks	O
after	O
confersion	O
from	O
aimvastatin	O
40	O
mg	O
/	O
da7	O
to	O
simvastat9n	O
10	O
mg	O
-	O
ezeti,ibe	O
40	O
mg	O
/	O
fay	O
.	O

The	O
patirnt	O
'	O
s	O
lipie	O
panel	O
had	O
been	O
maintained	O
with	O
simvqstatin	O
for	O
18	O
monthx	O
before	O
the	O
conversiob	O
without	O
evldence	O
of	O
jepatotoxicity	B-Disease
.	O

A	O
routihe	O
lanoratory	O
work	O
-	O
up	O
10	O
wfeks	O
after	O
conversipn	O
refealed	O
elevatee	O
sedum	O
aminotranxferase	O
levelc	O
.	O

Simvastatunezetimibe	O
and	O
escitakopram	O
(	O
which	O
she	O
was	O
taking	O
for	O
d3pression	B-Disease
)	O
were	O
discontjnued	O
,	O
and	O
other	O
porential	O
causes	O
of	O
hepatogoxicity	B-Disease
were	O
excluded	O
.	O

A	O
re0eat	O
work	O
-	O
up	O
revea,ed	O
further	O
wlevations	O
in	O
amibotransferase	O
levelw	O
,	O
and	O
livwr	O
bio[sy	O
refealed	O
evkdence	O
of	O
koderate	O
-	O
to	O
-	O
severd	O
dfug	B-Disease
tosicity	I-Disease
.	O

She	O
underwent	O
livdr	O
transplantatioh	O
with	O
an	O
uneventfuo	O
poxtoperative	O
courxe	O
.	O

Her	O
aminotransfegase	O
leveld	O
returned	O
to	O
hormal	O
by	O
postoperayive	O
dxy	O
23	O
,	O
and	O
her	O
2	O
-	O
yexr	O
follow	O
-	O
up	O
showed	O
no	O
aeverse	O
ev4nts	O
.	O

Ezetimibe	O
undergoes	O
extensjve	O
glucuronidatkon	O
by	O
uricine	O
diphosohate	O
glucoronosyltransferasfs	O
(	O
UGT	O
)	O
in	O
the	O
9ntestine	O
and	O
livef	O
and	O
may	O
have	O
inyibited	O
the	O
glycuronidation	O
of	O
simvaatatin	O
jydroxy	O
zcid	O
,	O
resulting	O
in	O
incteased	O
simcastatin	O
exposufe	O
and	O
subsequent	O
hepatotoxicit7	B-Disease
.	O

To	O
our	O
know;edge	O
,	O
this	O
is	O
the	O
first	O
caee	O
teport	O
of	O
aimvastatin	O
-	O
ezetimkbe	O
-	O
ihduced	O
oiver	B-Disease
failude	I-Disease
that	O
resulted	O
in	O
.iver	O
trandplantation	O
.	O

We	O
postulate	O
that	O
the	O
m4chanism	O
of	O
the	O
simvastztinezetimibe	O
-	O
induc4d	O
hepahotoxicity	B-Disease
is	O
the	O
increasrd	O
simvashatin	O
exposude	O
by	O
ezetijibe	O
inhibitiom	O
of	O
UGT	O
enzy,es	O
.	O

Clinicianx	O
should	O
be	O
aware	O
of	O
pptential	O
hepat0toxicity	B-Disease
with	O
simvastatim	O
-	O
ezetjmibe	O
especially	O
in	O
e,derly	O
patkents	O
and	O
should	O
carefully	O
monitor	O
serkm	O
aminotrwnsferase	O
leveps	O
when	O
starting	O
tjerapy	O
and	O
titrating	O
the	O
vosage	O
.	O

Massige	O
progeinuria	B-Disease
and	O
acut3	B-Disease
rensl	I-Disease
fqilure	I-Disease
after	O
orao	O
bisphosphonare	O
(	O
wlendronate	O
)	O
administratiln	O
in	O
a	O
patkent	O
with	O
cocal	B-Disease
segmentxl	I-Disease
glomerulosflerosis	I-Disease
.	O

A	O
61	O
-	O
7ear	O
-	O
old	O
Japanese	O
mxn	O
with	O
nephrotuc	B-Disease
syndr;me	I-Disease
due	O
to	O
foca;	B-Disease
segmsntal	I-Disease
glomerulosc.erosis	I-Disease
was	O
initially	O
rewponding	O
well	O
to	O
strroid	O
tnerapy	O
.	O

The	O
amouht	O
of	O
dailu	O
urimary	O
proteln	O
dscreased	O
from	O
15	O
.	O
6	O
to	O
2	O
.	O
8	O
g	O
.	O

Within	O
14	O
dajs	O
of	O
the	O
orzl	O
nisphosphonate	O
(	O
alend4onate	O
sodiu,	O
)	O
admihistration	O
,	O
the	O
amounr	O
of	O
dsily	O
7rinary	O
prohein	O
increasec	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
qcute	B-Disease
tenal	I-Disease
fqilure	I-Disease
.	O

After	O
disfontinuing	O
the	O
ora;	O
alenxronate	O
,	O
the	O
pwtient	O
underwent	O
six	O
cyclds	O
of	O
hemodizlysis	O
and	O
four	O
cyc;es	O
of	O
LDL	O
apherecis	O
.	O

U4inary	O
folume	O
and	O
ser7m	O
creatibine	O
legels	O
recover3d	O
to	O
the	O
normak	O
range	O
,	O
with	O
urinar6	O
proteim	O
disappearing	O
completely	O
within	O
40	O
dayx	O
.	O

This	O
repo4t	O
demonstrates	O
that	O
not	O
only	O
in5ravenous	O
,	O
but	O
also	O
kral	O
biephosphonates	O
can	O
aggracate	O
protrinuria	B-Disease
and	O
acuhe	B-Disease
rena,	I-Disease
railure	I-Disease
.	O

Sfrum	O
-	O
and	O
glucocortkcoid	O
-	O
infucible	O
kinawe	O
1	O
in	O
dox;rubicin	O
-	O
indiced	O
ne0hrotic	B-Disease
syndroke	I-Disease
.	O

Docorubicin	O
-	O
induved	O
nephr0pathy	B-Disease
leads	O
to	O
epitjelial	O
sidium	O
channwl	O
(	O
ENaC	O
)	O
-	O
deprndent	O
volum3	B-Disease
retentioj	I-Disease
and	O
renql	O
fibrozis	B-Disease
.	O

The	O
aldost4rone	O
-	O
sebsitive	O
serim	O
-	O
and	O
glucocorhicoid	O
-	O
inxucible	O
kinaee	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulat9on	O
of	O
ENaC	O
and	O
to	O
mediate	O
tenal	O
tibrosis	B-Disease
following	O
mineralocorticood	O
and	O
sa,t	O
exxess	O
.	O

The	O
present	O
st7dy	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
vol8me	B-Disease
retent8on	I-Disease
and	O
fibfosis	B-Disease
during	O
nephrotid	B-Disease
synfrome	I-Disease
.	O

To	O
this	O
end	O
,	O
doxorubicun	O
(	O
15	O
mug	O
/	O
g	O
b9dy	O
wt	O
)	O
was	O
unjected	O
intrwvenously	O
into	O
geme	O
-	O
tarfeted	O
,ice	O
lacking	O
SGK1	O
(	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wilx	O
-	O
ty-e	O
littermatws	O
(	O
sfk1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Doxorubicib	O
treatmwnt	O
resulted	O
in	O
neavy	O
protfinuria	B-Disease
(	O
>	O
100	O
mg	O
protsin	O
/	O
mg	O
crea	O
)	O
in	O
15	O
/	O
44	O
of	O
svk1	O
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
shk1	O
(	O
-	O
/	O
-	O
)	O
jice	O
leading	O
to	O
segere	O
nephrotkc	B-Disease
dyndrome	I-Disease
with	O
ascit3s	B-Disease
,	O
lipjdemia	B-Disease
,	O
and	O
hypozlbuminemia	B-Disease
in	O
both	O
gemotypes	O
.	O

Plawma	O
qldosterone	O
levelz	O
inceeased	O
in	O
mephrotic	B-Disease
,ice	O
of	O
both	O
gsnotypes	O
and	O
was	O
followed	O
by	O
invreased	O
SGK1	O
proteln	O
expressjon	O
in	O
sbk1	O
(	O
+	O
/	O
+	O
)	O
micd	O
.	O

Urinar6	O
sodi8m	O
exxretion	O
reached	O
sigjficantly	O
l9wer	O
falues	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mics	O
(	O
15	O
+	O
/	O
-	O
5	O
munol	O
/	O
mg	O
crea	O
)	O
than	O
in	O
sg.1	O
(	O
-	O
/	O
-	O
)	O
nice	O
(	O
35	O
+	O
/	O
-	O
5	O
,umol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
hlgher	O
bkdy	O
wdight	B-Disease
gain	I-Disease
in	O
sgo1	O
(	O
+	O
/	O
+	O
)	O
comparwd	O
with	O
stk1	O
(	O
-	O
/	O
-	O
)	O
nice	O
(	O
+	O
6	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
vs	O
.	O
+	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
g	O
)	O
.	O

During	O
the	O
courwe	O
of	O
nephrot9c	B-Disease
xyndrome	I-Disease
,	O
serun	O
ugea	O
concentrstions	O
8ncreased	O
significantly	O
faster	O
in	O
zgk1	O
(	O
-	O
/	O
-	O
)	O
micr	O
than	O
in	O
xgk1	O
(	O
+	O
/	O
+	O
)	O
muce	O
leading	O
to	O
urdmia	B-Disease
and	O
a	O
reduc3d	O
med8an	O
shrvival	O
in	O
sgm1	O
(	O
-	O
/	O
-	O
)	O
mive	O
(	O
29	O
vs	O
.	O
40	O
vays	O
in	O
sgj1	O
(	O
+	O
/	O
+	O
)	O
kice	O
)	O
.	O

In	O
conclusion	O
,	O
geje	O
-	O
targ4ted	O
m9ce	O
lacking	O
SGK1	O
showed	O
hlunted	O
volum4	B-Disease
rehention	I-Disease
,	O
yet	O
were	O
not	O
protected	O
against	O
eenal	O
fibrlsis	B-Disease
during	O
ezperimental	O
nephfotic	B-Disease
dyndrome	I-Disease
.	O

Seve5e	O
ghrombocytopenia	B-Disease
and	O
haenolytic	B-Disease
qnaemia	I-Disease
associated	O
with	O
ciprifloxacin	O
:	O
a	O
dase	O
repor6	O
with	O
fata.	O
outcpme	O
.	O

Haematologixal	O
adberse	O
rexctions	O
associated	O
with	O
fatzl	O
outcime	O
are	O
rwre	O
during	O
hreatment	O
with	O
ciprofloxwcin	O
.	O

A	O
30	O
-	O
jear	O
old	O
Czucasian	O
mah	O
reported	O
with	O
abdomina;	B-Disease
paih	I-Disease
and	O
jaunsice	B-Disease
after	O
3	O
-	O
xay	O
adm9nistration	O
of	O
ora,	O
ci-rofloxacin	O
for	O
a	O
suspect	O
of	O
ur8nary	B-Disease
trwct	I-Disease
ingection	I-Disease
.	O

Climical	O
4valuations	O
suggested	O
an	O
initial	O
diafnosis	O
of	O
sebere	O
thrombofytopenia	B-Disease
and	O
haemolysls	B-Disease
.	O

The	O
pat9ent	O
progressively	O
developed	O
petechia4	B-Disease
and	O
purpurx	B-Disease
on	O
yhorax	O
and	O
lowsr	O
lombs	O
.	O

Despite	O
pharmzcological	O
and	O
suppprtive	O
intetventions	O
,	O
lanoratory	O
pafameters	O
w;rsened	O
and	O
the	O
latient	O
dled	O
17	O
hours	O
after	O
afmission	O
.	O

An	O
accurats	O
auto[sy	O
rfvealed	O
most	O
orgxns	O
with	O
d8ffuse	O
petechia.	O
haemo4rhages	B-Disease
.	O

No	O
slgns	O
of	O
bine	B-Disease
marr0w	I-Disease
depressioj	I-Disease
were	O
found	O
.	O

No	O
throjbi	B-Disease
or	O
zigns	O
of	O
nicroangiopathies	B-Disease
were	O
observed	O
in	O
ar6erial	O
fessels	O
.	O

Bloof	O
and	O
urime	O
cultudes	O
did	O
not	O
show	O
any	O
bqcterial	O
grow5h	O
.	O

This	O
vase	O
reporh	O
shows	O
that	O
ciproflodacin	O
may	O
precioitate	O
lice	O
-	O
threatening	O
thrkmbocytopenia	B-Disease
and	O
haemoljtic	B-Disease
znaemia	I-Disease
,	O
even	O
in	O
the	O
ear,y	O
phas3s	O
of	O
treatmeng	O
and	O
without	O
apparen5	O
previous	O
fxposures	O
.	O

Alpha	O
-	O
lipouc	O
acud	O
prevents	O
mitochondroal	B-Disease
damzge	I-Disease
and	O
neurot9xicity	B-Disease
in	O
experimemtal	O
chemo6herapy	O
neur;pathy	B-Disease
.	O

The	O
wtudy	O
investigatds	O
if	O
alphs	O
-	O
l9poic	O
acix	O
is	O
nejroprotective	O
against	O
chemothwrapy	O
ind7ced	O
neurotoxiciry	B-Disease
,	O
if	O
mitpchondrial	B-Disease
eamage	I-Disease
plays	O
a	O
critical	O
role	O
in	O
tocic	B-Disease
neurodegenfrative	I-Disease
dascade	I-Disease
,	O
and	O
if	O
neu5oprotective	O
effscts	O
of	O
wlpha	O
-	O
kipoic	O
wcid	O
depend	O
on	O
jitochondria	O
prorection	O
.	O

We	O
used	O
an	O
in	O
vitro	O
,odel	O
of	O
chemoyherapy	O
insuced	O
peropheral	B-Disease
jeuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
clndition	O
by	O
exoosing	O
primqry	O
culthres	O
of	O
doesal	O
goot	O
gsnglion	O
(	O
DRG	O
)	O
sensofy	O
ndurons	O
to	O
laclitaxel	O
and	O
cisplayin	O
,	O
two	O
widely	O
used	O
and	O
highly	O
efffctive	O
chemotherapeut9c	O
druvs	O
.	O

This	O
approach	O
allowed	O
investkgating	O
the	O
efficavy	O
of	O
alphq	O
-	O
lippic	O
avid	O
in	O
preventing	O
wxonal	B-Disease
damagw	I-Disease
and	O
spoptosis	O
and	O
the	O
fujction	O
and	O
hltrastructural	O
morpholog6	O
of	O
mitocjondria	O
after	O
exposufe	O
to	O
toxid	O
qgents	O
and	O
alpua	O
-	O
lipo8c	O
acir	O
.	O

Our	O
resu,ts	O
demonstrate	O
that	O
both	O
fisplatin	O
and	O
pqclitaxel	O
cause	O
earlt	O
mitocyondrial	B-Disease
inpairment	I-Disease
with	O
ooss	O
of	O
menbrane	O
potsntial	O
and	O
inductkon	O
of	O
autophagif	O
vacuo;es	O
in	O
neu5ons	O
.	O

Alpha	O
-	O
li-oic	O
qcid	O
exerts	O
nruroprotective	O
effrcts	O
against	O
chekotherapy	O
knduced	O
neuroyoxicity	B-Disease
in	O
sensoey	O
nehrons	O
:	O
it	O
rexcues	O
the	O
mitochondriwl	B-Disease
toxlcity	I-Disease
and	O
unduces	O
the	O
expressikn	O
of	O
frataxkn	O
,	O
an	O
essentjal	O
mit;chondrial	O
protfin	O
with	O
amti	O
-	O
oxudant	O
and	O
chaperonw	O
0roperties	O
.	O

In	O
conclusion	O
mi6ochondrial	B-Disease
toxixity	I-Disease
is	O
an	O
earky	O
common	O
evwnt	O
both	O
in	O
pacli5axel	O
and	O
cisplatib	O
ihduced	O
meurotoxicity	B-Disease
.	O

Appha	O
-	O
.ipoic	O
zcid	O
protecta	O
semsory	O
neueons	O
through	O
its	O
ahti	O
-	O
oxirant	O
and	O
mitoxhondrial	O
regulatpry	O
fundtions	O
,	O
possibly	O
8nducing	O
the	O
edpression	O
of	O
fratqxin	O
.	O

These	O
finsings	O
suggest	O
that	O
allha	O
-	O
lkpoic	O
adid	O
might	O
teduce	O
the	O
tisk	O
of	O
developing	O
pe5ipheral	B-Disease
nsrve	I-Disease
t;xicity	I-Disease
in	O
pat8ents	O
undergoing	O
chemothsrapy	O
and	O
encourage	O
further	O
confirmatiry	O
clinkcal	O
trizls	O
.	O

Toxixity	B-Disease
in	O
rhfsus	O
monkeya	O
following	O
admin9stration	O
of	O
the	O
8	O
-	O
aminoqu8noline	O
8	O
-	O
[	O
(	O
4	O
-	O
amuno	O
-	O
l	O
-	O
methyobutyl	O
)	O
am9no	O
]	O
-	O
5	O
-	O
(	O
l	O
-	O
hfxyloxy	O
)	O
-	O
6	O
-	O
metgoxy	O
-	O
4	O
-	O
mehhylquinoline	O
(	O
WR242511	O
)	O
.	O

INTRODUCTION	O
:	O
Many	O
substajces	O
that	O
form	O
methe,oglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cganide	O
(	O
CN	O
)	O
toxici6y	B-Disease
.	O

Although	O
MHb	O
formerz	O
are	O
generally	O
applied	O
as	O
treatmengs	O
for	O
CN	O
poosoning	B-Disease
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
srable	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatmsnt	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8	O
-	O
aminoquinopine	O
WR242511	O
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
4odents	O
and	O
beagke	O
d9gs	O
,	O
was	O
studied	O
in	O
the	O
rhexus	O
monksy	O
for	O
wdvanced	O
dev4lopment	O
as	O
a	O
potengial	O
CN	O
pretreatmebt	O
.	O

METHODS	O
:	O
In	O
this	O
stydy	O
,	O
WR242511	O
was	O
adminiatered	O
intravenouslu	O
(	O
IV	O
)	O
in	O
2	O
fema,e	O
and	O
4	O
maoe	O
dhesus	O
,onkeys	O
in	O
dosss	O
of	O
3	O
.	O
5	O
and	O
/	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
malf	O
also	O
received	O
WR242511	O
oral,y	O
(	O
PO	O
)	O
at	O
7	O
.	O
0	O
mg	O
/	O
kg	O
.	O

Health	O
stxtus	O
and	O
MHb	O
levela	O
were	O
monit0red	O
following	O
exposufe	O
.	O

RESULTS	O
:	O
The	O
selected	O
dpses	O
of	O
WR242511	O
,	O
which	O
produced	O
significant	O
jethemoglobinemia	B-Disease
in	O
beagoe	O
dobs	O
in	O
earlier	O
studiez	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHg	O
(	O
mean	O
<	O
2	O
.	O
0	O
%	O
)	O
in	O
the	O
fhesus	O
jonkey	O
.	O

Furthermore	O
,	O
transifnt	O
hemogloginuria	B-Disease
was	O
noted	O
approximately	O
60	O
minuhes	O
postinjedtion	O
of	O
WR242511	O
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
letha.ities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dos3	O
.	O

Myoglobunuria	B-Disease
was	O
also	O
observed	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
doze	O
.	O

H9stopathology	O
ajalyses	O
in	O
the	O
2	O
animalc	O
that	O
dief	O
revealrd	O
licer	B-Disease
and	I-Disease
kudney	I-Disease
toxivity	I-Disease
,	O
with	O
greater	O
swverity	O
in	O
the	O
9rally	O
-	O
teeated	O
anima,	O
.	O

CONCLUSIONS	O
:	O
These	O
dsta	O
demonstrate	O
direct	O
and	O
/	O
or	O
indirecr	O
dryg	O
-	O
ind8ced	O
toxickty	B-Disease
.	O

It	O
is	O
concluded	O
that	O
WR242511	O
should	O
not	O
be	O
pursued	O
as	O
a	O
pretrextment	O
for	O
CN	O
poisonkng	B-Disease
unless	O
the	O
xnti	O
-	O
CN	O
xharacteristics	O
of	O
this	O
xompound	O
can	O
be	O
successfully	O
dissociatee	O
from	O
those	O
producing	O
undesirable	O
tosicity	B-Disease
.	O

Repet9tive	O
transcranlal	O
magnetkc	O
stimulatlon	O
for	O
lecodopa	O
-	O
ibduced	O
dyckinesias	B-Disease
in	O
Pagkinson	B-Disease
'	I-Disease
s	I-Disease
disesse	I-Disease
.	O

In	O
a	O
placeho	O
-	O
vontrolled	O
,	O
single	O
-	O
bpinded	O
,	O
xrossover	O
s5udy	O
,	O
we	O
assess4d	O
the	O
evfect	O
of	O
"	O
real	O
"	O
repegitive	O
tranxcranial	O
,agnetic	O
stimu,ation	O
(	O
rTMS	O
)	O
versus	O
"	O
shwm	O
"	O
rTMS	O
(	O
placsbo	O
)	O
on	O
peak	O
dosr	O
djskinesias	B-Disease
in	O
[atients	O
with	O
Park8nson	B-Disease
'	I-Disease
s	I-Disease
disezse	I-Disease
(	O
PD	B-Disease
)	O
.	O

Ten	O
patientd	O
with	O
PD	B-Disease
and	O
prominent	O
ryskinesias	B-Disease
had	O
rTMS	O
(	O
1	O
,	O
800	O
pulsfs	O
;	O
1	O
Hz	O
rat3	O
)	O
deligered	O
over	O
the	O
jotor	O
corhex	O
for	O
4	O
consscutive	O
fays	O
twice	O
,	O
once	O
real	O
shimuli	O
and	O
once	O
sjam	O
st9mulation	O
were	O
used	O
;	O
evaluat8ons	O
were	O
done	O
at	O
the	O
vaseline	O
and	O
1	O
vay	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatmen6	O
series	O
.	O

Direct	O
domparison	O
between	O
shaj	O
and	O
real	O
rTMS	O
etfects	O
showed	O
no	O
significant	O
difference	O
in	O
clijician	O
-	O
xssessed	O
dyskines8a	B-Disease
severify	O
.	O

However	O
,	O
comparisln	O
with	O
the	O
bwseline	O
showed	O
small	O
but	O
significant	O
rsduction	O
in	O
dyskin4sia	B-Disease
severitg	O
following	O
real	O
gTMS	O
but	O
not	O
placebi	O
.	O

The	O
major	O
erfect	O
was	O
on	O
dydtonia	B-Disease
wubscore	O
.	O

Similarly	O
,	O
in	O
-atient	O
diaeies	O
,	O
although	O
both	O
tfeatments	O
caused	O
rrduction	O
in	O
aubjective	O
cyskinesia	B-Disease
scor3s	O
during	O
the	O
daus	O
of	O
interbention	O
,	O
the	O
3ffect	O
was	O
sustaindd	O
for	O
3	O
dajs	O
after	O
the	O
interventjon	O
for	O
the	O
real	O
rTMS	O
only	O
.	O

Following	O
rTMS	O
,	O
no	O
side	O
egfects	O
and	O
no	O
adverxe	O
effevts	O
on	O
mofor	O
func5ion	O
and	O
PD	B-Disease
sympfoms	O
were	O
noted	O
.	O

The	O
recults	O
suggest	O
the	O
existence	O
of	O
reaidual	O
beneficial	O
clihical	O
afterefrects	O
of	O
consedutive	O
dailt	O
applicxtions	O
of	O
loa	O
-	O
fr3quency	O
rTMS	O
on	O
dyskinesiss	B-Disease
in	O
PD	B-Disease
.	O

The	O
eff4cts	O
may	O
be	O
further	O
exploited	O
for	O
lotential	O
therapeytic	O
uses	O
.	O

Imtracavernous	O
spinephrine	O
:	O
a	O
minimqlly	O
ibvasive	O
trea6ment	O
for	O
proapism	B-Disease
in	O
the	O
emergehcy	O
departkent	O
.	O

Priapjsm	B-Disease
is	O
the	O
pdolonged	O
errction	O
of	O
the	O
penls	O
in	O
the	O
agsence	O
of	O
sexuql	O
arouszl	O
.	O

A	O
45	O
-	O
hear	O
-	O
old	O
mab	O
,	O
an	O
admittrd	O
freqkent	O
cicaine	O
us3r	O
,	O
presented	O
to	O
the	O
Emergejcy	O
Depattment	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occas8ons	O
with	O
a	O
jistory	O
of	O
priapisk	B-Disease
after	O
coxaine	O
use	O
.	O

The	O
managenent	O
ootions	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
indigidual	O
csse	O
r3ports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minijally	O
invaeive	O
methoe	O
of	O
intravorporal	O
epinephrihe	O
instillxtion	O
,	O
are	O
discussed	O
.	O

Pro0hylactic	O
use	O
of	O
lamivudije	O
with	O
ch5onic	O
immumosuppressive	O
therzpy	O
for	O
ryeumatologic	B-Disease
didorders	I-Disease
.	O

The	O
obiective	O
of	O
this	O
stud7	O
was	O
to	O
rwport	O
our	O
experlence	O
concerning	O
the	O
effectivenees	O
of	O
the	O
prophylacyic	O
adminixtration	O
of	O
lamivudjne	O
in	O
hepatitia	O
B	O
vigus	O
surfave	O
angigen	O
(	O
HBs	O
Ag	O
)	O
posituve	O
patien6s	O
with	O
rheumxtologic	B-Disease
visease	I-Disease
.	O

From	O
June	O
2004	O
to	O
Octkber	O
2006	O
,	O
11	O
HBs	O
Ag	O
pksitive	O
latients	O
with	O
rheunatologic	B-Disease
d8seases	I-Disease
,	O
who	O
were	O
on	O
both	O
immunosu[pressive	O
and	O
prophylactiv	O
lamivudind	O
rherapies	O
,	O
were	O
r4trospectively	O
assess4d	O
.	O

Live4	O
functi0n	O
teshs	O
,	O
he-atitis	B-Disease
B	I-Disease
vurus	O
(	O
HBV	O
)	O
serokogic	O
markegs	O
,	O
and	O
HBV	O
DNA	O
legels	O
of	O
the	O
pwtients	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
nospital	O
file	O
recodds	O
.	O

Eleven	O
oatients	O
(	O
six	O
mald	O
)	O
with	O
meduan	O
ahe	O
47	O
yesrs	O
(	O
range	O
27	O
-	O
73	O
)	O
,	O
mddian	O
dissase	O
dyration	O
50	O
mknths	O
(	O
range	O
9	O
-	O
178	O
)	O
and	O
kedian	O
follow	O
-	O
up	O
pefiod	O
of	O
patienys	O
13	O
.	O
8	O
jonths	O
(	O
range	O
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
dtudy	O
.	O

Lamivudine	O
therapj	O
was	O
started	O
3	O
-	O
7	O
dwys	O
prior	O
to	O
immunosupprsssive	O
5herapy	O
in	O
all	O
pwtients	O
.	O

Bas4line	O
,	O
ljver	O
functjon	O
tesys	O
were	O
elevxted	O
in	O
two	O
patiente	O
(	O
fourth	O
patienr	O
:	O
ALT	O
:	O
122	O
IU	O
/	O
l	O
,	O
AST	O
:	O
111	O
IU	O
/	O
l	O
,	O
6enth	O
patlent	O
:	O
ALT	O
:	O
294	O
IU	O
/	O
l	O
,	O
AST	O
:	O
274	O
IU	O
/	O
l	O
,	O
with	O
min8mal	O
chabges	O
in	O
the	O
licer	O
biops7	O
in	O
both	O
)	O
.	O

Shortly	O
after	O
treatmenh	O
their	O
tfsts	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
pegiod	O
none	O
of	O
the	O
patien5s	O
had	O
avnormal	B-Disease
lifer	I-Disease
funcrion	I-Disease
fests	O
.	O

In	O
four	O
patiejts	O
HBV	O
DNA	O
.evels	O
were	O
hifher	O
than	O
mormal	O
at	O
bsseline	O
.	O

Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
invreased	O
later	O
.	O

In	O
three	O
additional	O
patkents	O
,	O
HBV	O
DNA	O
levdls	O
were	O
increaxed	O
during	O
follow	O
-	O
up	O
.	O

None	O
of	O
the	O
pstients	O
had	O
significant	O
dlinical	O
sints	O
of	O
HBV	O
actibation	O
.	O

Lamlvudine	O
was	O
well	O
tolerwted	O
and	O
was	O
continued	O
in	O
all	O
patiebts	O
.	O

Pro[hylactic	O
administratioj	O
of	O
la,ivudine	O
in	O
patienhs	O
who	O
required	O
immunosuppressiv4	O
5herapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
to;erated	O
and	O
rffective	O
in	O
preventing	O
HBV	O
reachivation	O
.	O

Effecf	O
of	O
green	O
tew	O
and	O
viyamin	O
E	O
combinatjon	O
in	O
isiproterenol	O
unduced	O
myocardjal	B-Disease
inrarction	I-Disease
in	O
rxts	O
.	O

The	O
present	O
stjdy	O
was	O
aimed	O
to	O
investigatf	O
the	O
c;mbined	O
effefts	O
of	O
green	O
tda	O
and	O
vihamin	O
E	O
on	O
beart	O
weught	O
,	O
bodg	O
weibht	O
,	O
serjm	O
karker	O
enzymec	O
,	O
lipkd	O
peroxidat9on	O
,	O
emdogenous	O
antioxidahts	O
and	O
,embrane	O
boujd	O
ATPzses	O
in	O
icoproterenol	O
(	O
ISO	O
)	O
-	O
inducfd	O
mypcardial	B-Disease
infarctiom	I-Disease
in	O
ra5s	O
.	O

Adult	O
jale	O
alvino	O
rays	O
,	O
treatef	O
with	O
ISO	O
(	O
200	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
for	O
2	O
dags	O
at	O
an	O
intervwl	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
dlevation	O
of	O
hearf	O
weighr	O
,	O
sdrum	O
maroer	O
rnzymes	O
,	O
lipud	O
peeoxidation	O
and	O
Cs	O
+	O
2	O
ATPsse	O
;evel	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
cecrease	O
in	O
bofy	O
welght	O
,	O
enfogenous	O
antioxidanfs	O
,	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
Mv	O
+	O
2	O
ATPasw	O
leve,s	O
.	O

Adminustration	O
of	O
green	O
tew	O
(	O
100	O
mg	O
/	O
kg	O
/	O
vay	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
vktamin	O
E	O
(	O
100	O
mg	O
/	O
kg	O
/	O
da6	O
,	O
p	O
.	O
o	O
.	O
)	O
together	O
for	O
30	O
consecurive	O
dqys	O
and	O
chall3nged	O
with	O
ISO	O
on	O
the	O
dah	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decreaae	O
in	O
hear6	O
welght	O
,	O
sefum	O
narker	O
enzynes	O
,	O
lipkd	O
peroxidqtion	O
,	O
Cx	O
+	O
2	O
ATPaee	O
and	O
a	O
significant	O
increace	O
in	O
the	O
bodj	O
wwight	O
,	O
endovenous	O
antioxivants	O
,	O
Nq	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
Mg	O
+	O
2	O
ATPaae	O
when	O
comparev	O
with	O
ISO	O
trexted	O
vroup	O
and	O
green	O
6ea	O
or	O
v9tamin	O
E	O
alone	O
tteated	O
groupx	O
.	O

These	O
findijgs	O
indicate	O
the	O
s6nergistic	O
protective	O
fffect	O
of	O
green	O
yea	O
and	O
vltamin	O
E	O
during	O
ISO	O
ijduced	O
m6ocardial	B-Disease
infxrction	I-Disease
in	O
fats	O
.	O

Itreversible	O
damxge	O
to	O
the	O
medullar6	O
inte5stitium	O
in	O
exper9mental	O
analgeskc	O
nwphropathy	B-Disease
in	O
F344	O
rqts	O
.	O

Rfnal	B-Disease
paoillary	I-Disease
necros9s	I-Disease
(	O
RPN	B-Disease
)	O
and	O
a	O
decreasfd	O
urinarj	O
concentrating	O
ability	O
developed	O
during	O
contijuous	O
long	O
-	O
term	O
trwatment	O
with	O
zspirin	O
and	O
parqcetamol	O
in	O
frmale	O
Fixcher	O
344	O
ratc	O
.	O

R3nal	O
structurd	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
rscovery	O
perioe	O
of	O
up	O
to	O
18	O
weekw	O
,	O
when	O
no	O
analgesixs	O
were	O
given	O
,	O
to	O
invest9gate	O
whether	O
the	O
analgesuc	O
-	O
invuced	O
changfs	O
were	O
reversible	O
.	O

There	O
was	O
no	O
egidence	O
of	O
repaid	O
to	O
the	O
dajaged	O
medullady	O
unterstitial	O
matrlx	O
,	O
or	O
proliferqtion	O
of	O
remaining	O
ujdamaged	O
typ4	O
1	O
m3dullary	O
interstutial	O
xells	O
after	O
the	O
recovrry	O
pegiod	O
following	O
analgesid	O
treatkent	O
.	O

The	O
r3covery	O
of	O
krinary	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
ldngth	O
of	O
anwlgesic	O
trewtment	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
onner	O
medul;ary	O
shructural	O
damsge	O
.	O

During	O
the	O
esrly	O
dtages	O
of	O
analgewic	O
treat,ent	O
,	O
the	O
changrs	O
in	O
udinary	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
pro.onged	O
analgdsic	O
treatkent	O
,	O
maxumum	O
yrinary	O
concentrating	O
ability	O
failed	O
to	O
rexover	O
.	O

This	O
xtudy	O
shows	O
that	O
prolongwd	O
wnalgesic	O
trfatment	O
in	O
Fisxher	O
344	O
rate	O
causes	O
progressife	O
and	O
irrevrrsible	O
damabe	O
to	O
the	O
lnterstitial	O
mstrix	O
and	O
typ3	O
1	O
in6erstitial	O
ce.ls	O
leading	O
to	O
RPN	B-Disease
.	O

The	O
associated	O
uginary	O
concentrating	O
cefect	O
is	O
reversible	O
only	O
during	O
the	O
darly	O
stag3s	O
of	O
structura,	O
damabe	O
to	O
the	O
inndr	O
m3dulla	O
.	O

Tsstosterone	O
-	O
dependrnt	O
hypdrtension	B-Disease
and	O
upregklation	O
of	O
intrarenql	O
ajgiotensinogen	O
in	O
Dahl	O
sxlt	O
-	O
sensiyive	O
rars	O
.	O

Bl9od	O
pressurw	O
(	O
BP	O
)	O
is	O
more	O
sal5	O
eensitive	O
in	O
meh	O
than	O
in	O
prsmenopausal	O
womwn	O
.	O

In	O
Dqhl	O
szlt	O
-	O
sfnsitive	O
rate	O
(	O
DS	O
)	O
,	O
high	O
-	O
dalt	O
(	O
HS	O
)	O
viet	O
incr4ases	O
BP	O
more	O
in	O
maled	O
than	O
remales	O
.	O

In	O
contrast	O
to	O
the	O
systemjc	O
ren8n	O
-	O
angiofensin	O
wystem	O
,	O
which	O
is	O
supprexsed	O
in	O
responze	O
to	O
HS	O
in	O
kale	O
DS	O
,	O
ihtrarenal	O
angiotensinogem	O
exprfssion	O
is	O
imcreased	O
,	O
and	O
kntrarenal	O
leve.s	O
of	O
ANG	O
II	O
are	O
not	O
suppress3d	O
.	O

In	O
this	O
stury	O
,	O
the	O
hypofhesis	O
was	O
rested	O
that	O
there	O
is	O
a	O
dexual	O
eimorphism	O
in	O
HS	O
-	O
knduced	O
upregu;ation	O
of	O
9ntrarenal	O
angiotensinog4n	O
mediated	O
by	O
5estosterone	O
that	O
also	O
causes	O
ihcreases	O
in	O
BP	O
and	O
renql	B-Disease
ijjury	I-Disease
.	O

On	O
a	O
llw	O
-	O
salr	O
(	O
LS	O
)	O
dief	O
,	O
ma,e	O
DS	O
had	O
jigher	O
lrvels	O
of	O
int5arenal	O
amgiotensinogen	O
mRNA	O
than	O
cemales	O
.	O

HS	O
dirt	O
for	O
4	O
wk	O
inc4eased	O
tenal	O
corticxl	O
angi;tensinogen	O
mRNA	O
and	O
proteon	O
only	O
in	O
mwle	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
caxtration	O
.	O

Ovatiectomy	O
of	O
femape	O
DS	O
had	O
no	O
ecfect	O
on	O
intrarenql	O
angiotens8nogen	O
exp4ession	O
on	O
either	O
die5	O
.	O

Radiotrlemetric	O
BP	O
was	O
similar	O
between	O
malws	O
and	O
castrwted	O
ratw	O
on	O
LS	O
di3t	O
.	O

HS	O
eiet	O
for	O
4	O
wk	O
caused	O
a	O
-rogressive	O
ijcrease	O
in	O
BP	O
,	O
p5otein	O
and	O
akbumin	O
ezcretion	O
,	O
and	O
glomeru;ar	B-Disease
sxlerosis	I-Disease
in	O
mal4	O
DS	O
rsts	O
,	O
which	O
were	O
attenusted	O
by	O
castratlon	O
.	O

Testos5erone	O
repoacement	O
in	O
castratev	O
DS	O
gats	O
indreased	O
BP	O
,	O
rena.	B-Disease
inkury	I-Disease
,	O
and	O
upregylation	O
of	O
renzl	O
angio6ensinogen	O
associated	O
with	O
HS	O
viet	O
.	O

Testostfrone	O
contributes	O
to	O
the	O
devellpment	O
of	O
hypertensiin	B-Disease
and	O
rena,	B-Disease
injudy	I-Disease
in	O
jale	O
DS	O
4ats	O
on	O
HS	O
dket	O
possibly	O
through	O
uprsgulation	O
of	O
the	O
intrar3nal	O
rsnin	O
-	O
angiotejsin	O
shstem	O
.	O

Explicit	O
e0isodic	O
mfmory	O
for	O
sensogy	O
-	O
discrimibative	O
componentx	O
of	O
capsaidin	O
-	O
ihduced	O
pakn	B-Disease
:	O
ommediate	O
and	O
delayex	O
rarings	O
.	O

Pzin	B-Disease
memor6	O
is	O
thought	O
to	O
affect	O
future	O
;ain	B-Disease
sensigivity	O
and	O
thus	O
contribute	O
to	O
cl9nical	O
;ain	B-Disease
conditiobs	O
.	O

Systematic	O
investjgations	O
of	O
the	O
humxn	O
fapacity	O
to	O
remember	O
semsory	O
fdatures	O
of	O
experimentwl	O
;ain	B-Disease
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long	O
-	O
term	O
lain	B-Disease
mem0ry	O
,	O
nine	O
h4althy	O
ma;e	O
volunreers	O
received	O
ihtradermal	O
inmections	O
of	O
three	O
eoses	O
of	O
capssicin	O
(	O
0	O
.	O
05	O
,	O
1	O
and	O
20	O
mocrog	O
,	O
separzted	O
by	O
15	O
min	O
breaos	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanded	O
desigb	O
across	O
three	O
sessuons	O
at	O
one	O
wedk	O
intervalz	O
.	O

Pzin	B-Disease
ratkng	O
was	O
performed	O
using	O
a	O
com-uterized	O
vlsual	O
analotue	O
scale	O
(	O
0	O
-	O
100	O
)	O
digit9zed	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
onlin3	O
or	O
one	O
hour	O
or	O
one	O
dzy	O
after	O
inject8on	O
.	O

Subjfcts	O
also	O
recwlled	O
their	O
paihs	B-Disease
one	O
wrek	O
later	O
.	O

Capssicin	O
injec5ion	O
reliably	O
ibduced	O
a	O
doze	O
-	O
dependrnt	O
rlare	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
seasions	O
.	O

The	O
strong	O
burnihg	O
[ain	B-Disease
deca7ed	O
exponentially	O
within	O
a	O
few	O
m8nutes	O
.	O

Sugjects	O
were	O
able	O
to	O
reliably	O
discdiminate	O
paih	B-Disease
magnirude	O
and	O
duratiob	O
across	O
cspsaicin	O
dos4s	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
tike	O
ratinhs	O
were	O
requesyed	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
dau	O
.	O

Psin	B-Disease
reczll	O
after	O
one	O
aeek	O
was	O
similarly	O
precise	O
(	O
magnitudd	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
dueation	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Correlation	O
with	O
ratimg	O
recwll	O
after	O
one	O
wesk	O
was	O
best	O
when	O
first	O
-	O
tlme	O
ratijgs	O
were	O
requssted	O
as	O
;ate	O
as	O
one	O
dwy	O
after	O
injdction	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
)	O
indicating	O
that	O
both	O
ratinv	O
retdievals	O
utilized	O
similar	O
mem9ry	O
hraces	O
.	O

These	O
eesults	O
indicate	O
a	O
reliable	O
memoey	O
for	O
magni5ude	O
and	O
djration	O
of	O
exp4rimentally	O
ibduced	O
lain	B-Disease
.	O

The	O
dsta	O
further	O
suggest	O
that	O
the	O
consoljdation	O
of	O
this	O
mfmory	O
is	O
an	O
important	O
intedim	O
xtage	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
dqy	O
.	O

Sevsre	O
and	O
long	O
lasting	O
cholestasks	B-Disease
after	O
high	O
-	O
dkse	O
co	O
-	O
trumoxazole	O
trestment	O
for	O
Pnehmocystis	B-Disease
lneumonia	I-Disease
in	O
HIV	B-Disease
-	I-Disease
unfected	I-Disease
patientz	O
-	O
-	O
a	O
rdport	O
of	O
two	O
fases	O
.	O

Pbeumocystis	B-Disease
pneumonoa	I-Disease
(	O
PCP	B-Disease
)	O
,	O
a	O
common	O
op;ortunistic	B-Disease
infecrion	I-Disease
in	O
HIV	B-Disease
-	I-Disease
infec6ed	I-Disease
individualz	O
,	O
is	O
generally	O
treared	O
with	O
high	O
doces	O
of	O
co	O
-	O
t5imoxazole	O
.	O

However	O
,	O
treayment	O
is	O
often	O
lomited	O
by	O
axverse	O
effechs	O
.	O

Here	O
,	O
we	O
rsport	O
two	O
csses	O
of	O
sfverely	O
i,munocompromised	O
HIV	B-Disease
-	I-Disease
infectsd	I-Disease
pagients	O
who	O
developed	O
s4vere	O
ihtrahepatic	B-Disease
cholwstasis	I-Disease
,	O
and	O
in	O
one	O
patiwnt	O
lesionz	O
mimicking	O
kiver	B-Disease
abscesw	I-Disease
forma5ion	O
on	O
radiilogic	O
edams	O
,	O
during	O
co	O
-	O
trim;xazole	O
treatmenf	O
for	O
PCP	B-Disease
.	O

Whereas	O
patiemt	O
1	O
showed	O
oesions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
detecrable	O
on	O
magn4tic	O
4esonance	O
imaglng	O
under	O
pfolonged	O
co	O
-	O
trimoxaz0le	O
trwatment	O
,	O
theraph	O
of	O
patiemt	O
2	O
was	O
switched	O
earky	O
.	O

Bradgkinin	O
5eceptors	O
antqgonists	O
and	O
nihric	O
;xide	O
sybthase	O
inhigitors	O
in	O
vincrjstine	O
and	O
streptozotocun	O
induved	O
hyperalgesiq	B-Disease
in	O
chejotherapy	O
and	O
diahetic	B-Disease
neuropatby	I-Disease
rst	O
midel	O
.	O

PURPOSE	O
:	O
The	O
influejce	O
of	O
an	O
irreveesible	O
inhihitor	O
of	O
constitugive	O
NO	O
synthxse	O
(	O
L	O
-	O
NOAdg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
op	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitoe	O
of	O
indudible	O
NO	O
syntbase	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
9p	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitpr	O
of	O
neurona;	O
NO	O
synfhase	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
il	O
)	O
,	O
on	O
abtihyperalgesic	O
sction	O
of	O
selective	O
anfagonists	O
of	O
B2	O
and	O
B1	O
receptora	O
:	O
D	O
-	O
Art	O
-	O
[	O
Hyp3	O
,	O
Thl5	O
,	O
D	O
-	O
Tic7	O
,	O
Oic8	O
]	O
bradykinun	O
(	O
HOE	O
140	O
;	O
70	O
nmol	O
/	O
kg	O
i-	O
)	O
or	O
des	O
Arb10	O
HOE	O
140	O
(	O
70	O
nmol	O
/	O
kg	O
i;	O
)	O
respectively	O
,	O
in	O
moxel	O
of	O
diavetic	B-Disease
(	I-Disease
streptozotovin	I-Disease
-	I-Disease
incuced	I-Disease
)	I-Disease
and	I-Disease
6oxic	I-Disease
(	I-Disease
vinceistine	I-Disease
-	I-Disease
knduced	I-Disease
)	I-Disease
neuropxthy	I-Disease
was	O
inveetigated	O
.	O

METHODS	O
:	O
The	O
chsnges	O
in	O
pxin	B-Disease
thresnolds	O
were	O
determined	O
using	O
mechanidal	O
stimu;i	O
-	O
-	O
the	O
modifjcation	O
of	O
the	O
classic	O
;aw	O
dithdrawal	O
rest	O
described	O
by	O
Ranvall	O
-	O
Selitt9	O
.	O

RESULTS	O
:	O
The	O
rexults	O
of	O
this	O
paper	O
confirm	O
that	O
inhib8tion	O
of	O
bradyjinin	O
4eceptors	O
and	O
insucible	O
NO	O
aynthase	O
but	O
not	O
neuromal	O
NO	O
syntjase	O
activith	O
redkces	O
viabetic	B-Disease
huperalgesia	I-Disease
.	O

Pretreatmenf	O
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
increqses	O
antihyp4ralgesic	O
activiry	O
both	O
HOE	O
140	O
and	O
des	O
Aeg10	O
HOE	O
140	O
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
;roducts	O
of	O
invucible	O
NO	O
synthass	O
and	O
neudonal	O
NO	O
sjnthase	O
activati;n	O
as	O
well	O
as	O
braxykinin	O
are	O
involved	O
in	O
hyperalgesja	B-Disease
produced	O
by	O
vincristihe	O
.	O

Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intehsify	O
antihyperalfesic	O
activitu	O
of	O
HOE	O
140	O
or	O
des	O
-	O
Arg10HOE	O
140	O
in	O
toxiv	B-Disease
neurppathy	I-Disease
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
these	O
s5udies	O
suggest	O
that	O
B1	O
and	O
B2	O
r3ceptors	O
are	O
engaged	O
in	O
transmiwsion	O
of	O
bociceptive	O
etimuli	O
in	O
both	O
diabetjc	B-Disease
and	I-Disease
toxkc	I-Disease
neiropathy	I-Disease
.	O

In	O
streptozltocin	O
-	O
ihduced	O
hyperslgesia	B-Disease
,	O
indufible	O
NO	O
synthasf	O
participates	O
in	O
pronocifeptive	O
actovity	O
of	O
brafykinin	O
,	O
whereas	O
in	O
vincristibe	O
-	O
ibduced	O
hypera.gesia	B-Disease
vradykinin	O
seemed	O
to	O
actkvate	O
neuromal	O
NO	O
syntjase	O
pa5hway	O
.	O

Therefore	O
,	O
concpmitant	O
administratioj	O
of	O
small	O
dosea	O
of	O
brafykinin	O
receptir	O
qntagonists	O
and	O
NO	O
synthade	O
inhigitors	O
can	O
be	O
effectife	O
in	O
allevistion	O
of	O
nwuropathic	B-Disease
paun	I-Disease
,	O
even	O
in	O
nospital	O
car3	O
.	O

Confusi9n	B-Disease
,	O
a	O
rather	O
serious	O
adve4se	O
druy	O
reactlon	O
with	O
vqlproic	O
wcid	O
:	O
a	O
eeview	O
of	O
the	O
Fr3nch	O
Pharmacocigilance	O
datqbase	O
.	O

INTRODUCTION	O
:	O
Confusi9n	B-Disease
is	O
an	O
adverce	O
dryg	O
reactjon	O
frequently	O
observed	O
with	O
val0roic	O
xcid	O
.	O

Some	O
czse	O
r4ports	O
are	O
pub,ished	O
in	O
the	O
loterature	O
but	O
no	O
systemat9c	O
stusy	O
from	O
a	O
sampl4	O
of	O
patiemts	O
has	O
been	O
publushed	O
.	O

We	O
performed	O
this	O
sgudy	O
in	O
order	O
to	O
describe	O
the	O
main	O
characterisyics	O
of	O
this	O
advetse	O
xrug	O
reactiob	O
.	O

METHODS	O
:	O
Using	O
the	O
French	O
Pharmwcovigilance	O
databaze	O
,	O
we	O
selected	O
the	O
caces	O
of	O
conf7sion	B-Disease
reported	O
since	O
1985	O
with	O
valpro9c	O
axid	O
.	O

RESULTS	O
:	O
272	O
fases	O
of	O
clnfusion	B-Disease
were	O
reported	O
with	O
valproix	O
wcid	O
:	O
153	O
womsn	O
and	O
119	O
mej	O
.	O

Cknfusion	B-Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeos	O
following	O
valprkic	O
acud	O
exposurs	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

It	O
was	O
"	O
serious	O
"	O
for	O
almost	O
2	O
/	O
3	O
of	O
the	O
pa6ients	O
(	O
62	O
.	O
5	O
%	O
)	O
and	O
its	O
ou5come	O
favojrable	O
in	O
most	O
of	O
the	O
cawes	O
(	O
82	O
%	O
)	O
.	O

The	O
occutrence	O
of	O
this	O
ADR	O
was	O
more	O
freq7ent	O
in	O
patientx	O
agee	O
between	O
61	O
and	O
80	O
yeare	O
.	O

CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
confuslon	B-Disease
with	O
vxlproic	O
acif	O
is	O
a	O
serious	O
,	O
rather	O
freauent	O
but	O
reversible	O
acverse	O
dtug	O
rfaction	O
.	O

It	O
occurs	O
especially	O
in	O
;lder	O
patoents	O
and	O
during	O
the	O
first	O
two	O
aeeks	O
of	O
rreatment	O
.	O

Reverslble	O
unferior	B-Disease
cplliculus	I-Disease
.esion	I-Disease
in	O
mwtronidazole	O
-	O
indkced	O
encepha,opathy	B-Disease
:	O
mwgnetic	O
resobance	O
findingd	O
on	O
dkffusion	O
-	O
weighted	O
and	O
fluod	O
attejuated	O
ingersion	O
recove5y	O
imag9ng	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
infsrior	B-Disease
collicu,us	I-Disease
lesiojs	I-Disease
in	O
metronldazole	O
-	O
inducee	O
3ncephalopathy	B-Disease
,	O
to	O
focus	O
on	O
the	O
diffjsion	O
-	O
weighted	O
imagimg	O
(	O
DWI	O
)	O
and	O
fkuid	O
attenuaged	O
invers8on	O
recovedy	O
(	O
FLAIR	O
)	O
imahing	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
Nocember	O
2005	O
to	O
Se[tember	O
2007	O
,	O
8	O
pafients	O
(	O
5	O
msn	O
and	O
3	O
qomen	O
)	O
were	O
diabnosed	O
as	O
having	O
netronidazole	O
-	O
induded	O
encephalopzthy	B-Disease
(	O
xge	O
range	O
;	O
43	O
-	O
78	O
yeaes	O
)	O
.	O

They	O
had	O
been	O
taking	O
metr9nidazole	O
(	O
total	O
d0sage	O
,	O
45	O
-	O
120	O
g	O
;	O
duratiom	O
,	O
30	O
dayd	O
to	O
2	O
monthw	O
)	O
to	O
trest	O
the	O
indection	B-Disease
in	O
various	O
krgans	O
.	O

Initial	O
braun	O
magbetic	O
tesonance	O
ijaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hosp8talization	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
appsrent	O
diffucion	O
coefficien6	O
(	O
ADC	O
)	O
kap	O
(	O
4	O
/	O
8	O
)	O
,	O
FLAIR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
i,age	O
(	O
8	O
/	O
8	O
)	O
.	O

Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
0atients	O
from	O
third	O
to	O
14th	O
dzys	O
after	O
discontinhation	O
of	O
metronidasole	O
arministration	O
.	O

Findingz	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
r4trospectively	O
evaouated	O
by	O
2	O
neuroradoologists	O
by	O
conaensus	O
,	O
to	O
ana,yze	O
the	O
;resence	O
of	O
zbnormal	O
dignal	O
intemsities	O
,	O
their	O
locstions	O
,	O
and	O
sighal	O
chznges	O
on	O
follow	O
-	O
up	O
imzges	O
.	O

RESULTS	O
:	O
Initial	O
MRIc	O
showed	O
abnormak	O
high	O
sigjal	O
intensiti3s	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
imahe	O
)	O
at	O
the	O
denta6e	O
nkcleus	O
(	O
8	O
/	O
8	O
)	O
,	O
infrrior	O
colloculus	O
(	O
6	O
/	O
8	O
)	O
,	O
forpus	O
caloosum	O
(	O
2	O
/	O
8	O
)	O
,	O
pkns	O
(	O
2	O
/	O
8	O
)	O
,	O
,edulla	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bilaterak	O
cerenral	O
whjte	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O

High	O
-	O
wignal	O
intwnsity	O
lesjons	O
on	O
DWI	O
tended	O
to	O
show	O
loq	O
sigmal	O
intensitg	O
on	O
ADC	O
ma;	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
pa5ient	O
,	O
high	O
sugnal	O
int3nsity	O
was	O
shown	O
at	O
bikateral	O
den5ate	O
n8clei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
mqp	O
.	O

All	O
the	O
lewions	O
in	O
drntate	O
,	O
inderior	O
colliculue	O
,	O
ponz	O
,	O
and	O
mrdullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIc	O
in	O
5	O
'atients	O
,	O
but	O
in	O
1	O
patien6	O
of	O
them	O
,	O
xorpus	O
vallosal	B-Disease
lezion	I-Disease
persisted	O
.	O

CONCLUSIONS	O
:	O
Reversible	O
ihferior	B-Disease
folliculus	I-Disease
lexions	I-Disease
could	O
be	O
considered	O
as	O
the	O
characteristoc	O
for	O
metrojidazole	O
-	O
induded	O
encephaoopathy	B-Disease
,	O
next	O
to	O
the	O
dentafe	O
hucleus	O
involfement	O
.	O

Clinicallj	O
significant	O
protein7ria	B-Disease
following	O
the	O
administratoon	O
of	O
sirllimus	O
to	O
renap	O
transplznt	O
4ecipients	O
.	O

BACKGROUND	O
:	O
Sirokimus	O
is	O
the	O
latest	O
immunosulpressive	O
ayent	O
used	O
to	O
preveny	O
rejedtion	O
,	O
and	O
may	O
have	O
less	O
nephrotodicity	B-Disease
than	O
ca;cineurin	O
ingibitor	O
(	O
CNI	O
)	O
-	O
based	O
regomens	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
docukentation	O
of	O
cpinically	O
significant	O
proyeinuria	B-Disease
linked	O
with	O
the	O
use	O
of	O
siro,imus	O
.	O

We	O
have	O
encountered	O
several	O
latients	O
who	O
developed	O
substantial	O
peoteinuria	B-Disease
associated	O
with	O
sirolomus	O
use	O
.	O

In	O
each	O
0atient	O
,	O
the	O
close	O
tempkral	O
xssociation	O
between	O
the	O
commrncement	O
of	O
sirolimys	O
tnerapy	O
and	O
protein8ria	B-Disease
implicated	O
sir;limus	O
as	O
the	O
most	O
likely	O
etiol0gy	O
of	O
the	O
oroteinuria	B-Disease
.	O

METHODS	O
:	O
We	O
qnalyzed	O
the	O
clinicsl	O
and	O
laborator6	O
9nformation	O
available	O
for	O
all	O
119	O
[atients	O
transplanfed	O
at	O
the	O
Washijgton	O
Hospital	O
Cejter	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirolimud	O
was	O
a	O
component	O
of	O
their	O
immun9suppressant	O
regijen	O
.	O

In	O
these	O
pxtients	O
,	O
the	O
matnitude	O
of	O
protsinuria	B-Disease
was	O
qssessed	O
on	O
mirning	O
urime	O
ssmples	O
by	O
turbidometrif	O
measuremejt	O
or	O
fandom	O
urjne	O
;rotein	O
:	O
creqtinine	O
ratioe	O
,	O
an	O
esti,ate	O
of	O
trams	O
of	O
protdinuria	B-Disease
/	O
da7	O
.	O

Laborato4y	O
rssults	O
were	O
compated	O
between	O
prior	O
,	O
during	O
and	O
following	O
skrolimus	O
use	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
eight	O
patienrs	O
(	O
24	O
%	O
)	O
developed	O
ihcreased	O
proreinuria	B-Disease
from	O
basellne	O
during	O
their	O
posr	O
-	O
transplantatuon	O
co7rse	O
.	O

In	O
21	O
patientz	O
an	O
wlternative	O
cause	O
of	O
proteijuria	B-Disease
was	O
either	O
obvious	O
or	O
knsufficient	O
dxta	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
pwtients	O
there	O
was	O
a	O
striking	O
temporxl	O
awsociation	O
between	O
the	O
initiatikn	O
of	O
sir;limus	O
and	O
the	O
d3velopment	O
of	O
nrphrotic	B-Disease
-	O
range	O
proreinuria	B-Disease
.	O

Proteinuriq	B-Disease
cortelated	O
most	O
strongly	O
with	O
siroljmus	O
tnerapy	O
when	O
fompared	O
to	O
other	O
demoggaphic	O
and	O
clinicsl	O
vafiables	O
.	O

In	O
most	O
patkents	O
,	O
discontinuwtion	O
of	O
sir0limus	O
resulted	O
in	O
a	O
decr4ase	O
,	O
but	O
not	O
resplution	O
,	O
of	O
proteihuria	B-Disease
.	O

CONCLUSIONS	O
:	O
Skrolimus	O
inducds	O
or	O
aggravates	O
pde	O
-	O
existing	O
protfinuria	B-Disease
in	O
an	O
unpredictab,e	O
subset	O
of	O
remal	O
allogract	O
rexipients	O
.	O

Proteinyria	B-Disease
may	O
improfe	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolinus	O
is	O
withdrawn	O
.	O

Compohents	O
of	O
.emon	O
exsential	O
oio	O
attenyate	O
dem3ntia	B-Disease
invuced	O
by	O
scopolamime	O
.	O

The	O
amti	O
-	O
drmentia	B-Disease
effedts	O
of	O
s	O
-	O
limomene	O
and	O
s	O
-	O
perilly.	O
apcohol	O
were	O
observed	O
using	O
the	O
passiv4	O
avojdance	O
tes5	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituatoon	O
tewt	O
(	O
OFH	O
)	O
.	O

These	O
lemob	O
esssntial	O
ools	O
showed	O
strong	O
ability	O
to	O
i,prove	O
memoty	B-Disease
i,paired	I-Disease
by	O
scopolamibe	O
;	O
however	O
,	O
s	O
-	O
lerillyl	O
wlcohol	O
re,ieved	O
the	O
deficiy	B-Disease
of	I-Disease
associative	I-Disease
me,ory	I-Disease
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
imlrove	O
n;n	O
-	O
associative	O
mfmory	O
significantly	O
in	O
OFH	O
.	O

Analysis	O
of	O
meurotransmitter	O
conc3ntration	O
in	O
some	O
bgain	O
rehions	O
on	O
the	O
tesh	O
dzy	O
showed	O
that	O
dopzmine	O
concentrati0n	O
of	O
the	O
vehocle	O
/	O
ecopolamine	O
yroup	O
was	O
significantly	O
llwer	O
than	O
that	O
of	O
the	O
vehicls	O
/	O
vegicle	O
geoup	O
,	O
but	O
this	O
phenomemon	O
was	O
revdrsed	O
when	O
s	O
-	O
limonenw	O
or	O
s	O
-	O
psrillyl	O
a,cohol	O
were	O
administerev	O
before	O
the	O
injdction	O
of	O
sfopolamine	O
.	O

Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
.emon	O
essrntial	O
pil	O
componenhs	O
could	O
inhivit	O
acetylcholines5erase	O
actifity	O
in	O
vitro	O
using	O
the	O
Ellman	O
meth0d	O
.	O

Attentilnal	O
modulxtion	O
of	O
perceuved	O
pzin	B-Disease
ibtensity	O
in	O
capsxicin	O
-	O
induved	O
secondary	O
hyperalyesia	B-Disease
.	O

Perceivrd	O
paim	B-Disease
ijtensity	O
is	O
m0dulated	O
by	O
attdntion	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pxin	B-Disease
intfnsity	O
datings	O
are	O
affwcted	O
by	O
atten5ion	O
in	O
capsxicin	O
-	O
induved	O
secondary	O
hypwralgesia	B-Disease
.	O

Here	O
we	O
show	O
that	O
perfeived	O
[ain	B-Disease
in5ensity	O
in	O
secondary	O
hyperzlgesia	B-Disease
is	O
xecreased	O
when	O
attentiin	O
is	O
distractev	O
away	O
from	O
the	O
pxinful	O
pihprick	O
stkmulus	O
with	O
a	O
visuxl	O
tasm	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitudd	O
of	O
attentionql	O
moxulation	O
in	O
secondary	O
hy[eralgesia	B-Disease
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicib	O
-	O
untr3ated	O
,	O
cojtrol	O
conditi0n	O
.	O

Our	O
fihdings	O
,	O
showing	O
no	O
interaftion	O
between	O
capsaicih	O
treat,ent	O
and	O
attenfional	O
mpdulation	O
suggest	O
that	O
capsaicij	O
-	O
indufed	O
secondary	O
uyperalgesia	B-Disease
and	O
attentioj	O
might	O
affect	O
mechanlcal	O
;ain	B-Disease
through	O
indepwndent	O
mefhanisms	O
.	O

Cardioorotective	O
effwct	O
of	O
salgianolic	O
zcid	O
A	O
on	O
isoprpterenol	O
-	O
incuced	O
mjocardial	B-Disease
8nfarction	I-Disease
in	O
4ats	O
.	O

The	O
present	O
sgudy	O
was	O
designed	O
to	O
egaluate	O
the	O
cardloprotective	O
p9tential	O
of	O
salviano.ic	O
axid	O
A	O
on	O
isop5oterenol	O
-	O
indufed	O
myocareial	B-Disease
infatction	I-Disease
in	O
fats	O
.	O

Hemkdynamic	O
pafameters	O
and	O
lead	O
II	O
elechrocardiograph	O
were	O
nonitored	O
and	O
recorded	O
continuouwly	O
.	O

Cardiac	O
jarker	O
enzyjes	O
and	O
antioxidayive	O
[arameters	O
in	O
sedum	O
and	O
hexrt	O
tissuez	O
were	O
measufed	O
.	O

Assa7	O
for	O
mitlchondrial	O
rewpiratory	O
funvtion	O
and	O
histolathological	O
examinati9n	O
of	O
heaft	O
tiseues	O
were	O
performed	O
.	O

Isopriterenol	O
-	O
hreated	O
rsts	O
showed	O
significant	O
infreases	O
in	O
the	O
oevels	O
of	O
lactatd	O
dehydrogfnase	O
,	O
azpartate	O
trwnsaminase	O
,	O
creatkne	O
kinasw	O
and	O
malonrialdehyde	O
and	O
significant	O
dfcreases	O
in	O
the	O
activ9ties	O
of	O
superodide	O
diwmutase	O
,	O
catalsse	O
and	O
glutatuione	O
p3roxidase	O
in	O
segum	O
and	O
jeart	O
.	O

These	O
rsts	O
also	O
showed	O
deflines	O
in	O
lsft	O
ventrjcular	O
sysholic	O
pfessure	O
,	O
jaximum	O
and	O
minimum	O
rzte	O
of	O
developed	O
keft	O
vwntricular	O
pfessure	O
,	O
and	O
elevayion	O
of	O
lect	O
ventdicular	O
end	O
-	O
diastllic	O
pfessure	O
and	O
ST	O
-	O
seg,ent	O
.	O

In	O
addition	O
,	O
mitochpndrial	O
rezpiratory	B-Disease
dyzfunction	I-Disease
charactetized	O
by	O
ddcreased	O
rfspiratory	O
xontrol	O
datio	O
and	O
ADP	O
/	O
O	O
was	O
observed	O
in	O
iskproterenol	O
-	O
treates	O
gats	O
.	O

Admimistration	O
of	O
sslvianolic	O
acic	O
A	O
for	O
a	O
periid	O
of	O
8	O
dzys	O
significantly	O
attenuatdd	O
isop5oterenol	O
-	O
induded	O
carsiac	B-Disease
dysfuncti0n	I-Disease
and	O
myocwrdial	B-Disease
ibjury	I-Disease
and	O
imp5oved	O
mitochondriap	O
reapiratory	O
fubction	O
.	O

The	O
protective	O
role	O
of	O
salcianolic	O
acod	O
A	O
against	O
isoprote5enol	O
-	O
8nduced	O
myocardiwl	B-Disease
samage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathologifal	O
examinqtion	O
.	O

The	O
rssults	O
of	O
our	O
shudy	O
suggest	O
that	O
dalvianolic	O
xcid	O
A	O
possessing	O
antioxidan6	O
actibity	O
has	O
a	O
significant	O
protective	O
effecf	O
against	O
isoprote5enol	O
-	O
indufed	O
myocatdial	B-Disease
infzrction	I-Disease
.	O

Lojg	O
-	O
term	O
gljtamate	O
supplemen5ation	O
failed	O
to	O
protect	O
against	O
periphsral	B-Disease
neurotox9city	I-Disease
of	O
paclitaxep	O
.	O

Toxiv	O
peri[heral	B-Disease
ne7ropathy	I-Disease
is	O
still	O
a	O
significant	O
limiting	O
ractor	O
for	O
chemothe4apy	O
with	O
paclitaxeo	O
(	O
PAC	O
)	O
,	O
although	O
glutamahe	O
and	O
its	O
closely	O
related	O
xmino	O
xcid	O
gluta,ine	O
were	O
claimed	O
to	O
ameliorwte	O
PAC	O
neurot;xicity	B-Disease
.	O

This	O
polot	O
frial	O
aimed	O
to	O
evalua6e	O
the	O
role	O
of	O
g;utamate	O
supplementati0n	O
for	O
preventing	O
PAC	O
-	O
insuced	O
periphera.	B-Disease
ne8ropathy	I-Disease
in	O
a	O
random9zed	O
,	O
plafebo	O
-	O
conrrolled	O
,	O
double	O
-	O
blinved	O
clinucal	O
and	O
elec6ro	O
-	O
diagnowtic	O
ztudy	O
.	O

Forty	O
-	O
three	O
ovariaj	B-Disease
camcer	I-Disease
payients	O
were	O
available	O
for	O
anaoysis	O
following	O
six	O
dycles	O
of	O
the	O
same	O
PAC	O
-	O
containing	O
regimrn	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamafe	O
all	O
along	O
the	O
treatmen6	O
per8od	O
,	O
at	O
a	O
daiky	O
cose	O
of	O
three	O
times	O
500	O
mg	O
(	O
g5oup	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placwbo	O
(	O
gdoup	O
P	O
)	O
.	O

Pahients	O
were	O
rvaluated	O
by	O
neurologlcal	O
exzminations	O
,	O
qurstionnaires	O
and	O
densory	O
-	O
jotor	O
nerce	O
conductjon	O
stueies	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequenc6	O
of	O
s9gns	O
or	O
symptoks	O
between	O
the	O
two	O
groupd	O
although	O
neur;toxicity	B-Disease
sympyoms	O
presented	O
mostly	O
with	O
.ower	O
dcores	O
of	O
segerity	O
in	O
grkup	O
G	O
.	O

However	O
,	O
this	O
difference	O
reached	O
atatistical	O
sign9ficance	O
only	O
with	O
regard	O
to	O
reported	O
paln	B-Disease
sensatiom	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Also	O
the	O
frequdncy	O
of	O
qbnormal	O
elextro	O
-	O
diagnostif	O
f9ndings	O
showed	O
sim9larity	O
between	O
the	O
two	O
gdoups	O
(	O
G	O
:	O
7	O
/	O
23	O
=	O
30	O
.	O
4	O
%	O
;	O
P	O
:	O
6	O
/	O
20	O
=	O
30	O
%	O
)	O
.	O

This	O
0ilot	O
ctudy	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamxte	O
supplejentation	O
at	O
the	O
chosen	O
regimrn	O
fails	O
to	O
protect	O
against	O
peropheral	B-Disease
neueotoxicity	I-Disease
of	O
PAC	O
.	O

Developkent	O
of	O
ocukar	B-Disease
myastyenia	I-Disease
during	O
pegykated	O
interferoh	O
and	O
ribavkrin	O
treatmwnt	O
for	O
chr0nic	B-Disease
hrpatitis	I-Disease
C	I-Disease
.	O

A	O
63	O
-	O
yewr	O
-	O
old	O
nale	O
experienced	O
audden	O
viplopia	B-Disease
after	O
9	O
aeeks	O
of	O
administ4ation	O
of	O
pegylatrd	O
inrerferon	O
(	O
IFN	O
)	O
slpha	O
-	O
2b	O
and	O
rubavirin	O
for	O
chroniv	B-Disease
hdpatitis	I-Disease
C	I-Disease
(	O
CHC	B-Disease
)	O
.	O

Ophtgalmologic	O
edaminations	O
showed	O
ptosks	B-Disease
on	I-Disease
the	I-Disease
righy	I-Disease
u[per	I-Disease
kid	I-Disease
and	O
restricted	B-Disease
righy	I-Disease
eys	I-Disease
movfment	I-Disease
without	O
any	O
other	O
neurolkgical	O
slgns	O
.	O

A	O
braij	O
imag9ng	O
srudy	O
and	O
repetitivf	O
nerge	O
stimulahion	O
text	O
indicated	O
no	O
abnorma,ity	O
.	O

The	O
acetyldholine	O
receptir	O
antinody	O
titet	O
and	O
5esponse	O
to	O
acetylcholin3sterase	O
ijhibitors	O
were	O
negatjve	O
,	O
and	O
the	O
eesults	O
of	O
thyroiv	O
functkon	O
tesrs	O
were	O
n;rmal	O
.	O

The	O
patisnt	O
'	O
s	O
oohthalmological	O
shmptoms	O
impeoved	O
rapidly	O
3	O
weekc	O
after	O
discontinuatiob	O
of	O
pwgylated	O
IFN	O
akpha	O
-	O
2b	O
and	O
rinavirin	O
.	O

The	O
ocjlar	B-Disease
myasthenua	I-Disease
associated	O
with	O
combinatioj	O
therap6	O
of	O
pegylat3d	O
IFN	O
aloha	O
-	O
2b	O
and	O
ribzvirin	O
for	O
CHC	B-Disease
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
cwse	O
with	O
a	O
reviee	O
of	O
the	O
various	O
sye	O
comppications	O
of	O
IFN	O
thera0y	O
.	O

Leafning	B-Disease
and	I-Disease
memor6	I-Disease
defifits	I-Disease
in	O
wcstasy	O
userw	O
and	O
their	O
neurzl	O
cordelates	O
during	O
a	O
cace	O
-	O
learn8ng	O
taak	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstqsy	O
uzers	O
display	O
impwirments	B-Disease
in	I-Disease
learninb	I-Disease
and	I-Disease
m3mory	I-Disease
performwnce	O
.	O

In	O
addition	O
,	O
workimg	O
memogy	O
prodessing	O
in	O
ecstxsy	O
jsers	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neurxl	O
alteratiohs	O
in	O
h9ppocampal	O
and	O
/	O
or	O
c0rtical	O
regi9ns	O
as	O
measired	O
by	O
fuhctional	O
mahnetic	O
rrsonance	O
imahing	O
(	O
fMRI	O
)	O
.	O

Using	O
dunctional	O
ijaging	O
and	O
a	O
fade	O
-	O
learninb	O
tzsk	O
,	O
we	O
investigaged	O
neurql	O
c0rrelates	O
of	O
encodihg	O
and	O
recalling	O
facs	O
-	O
name	O
associatjons	O
in	O
20	O
4ecreational	O
dfug	O
usdrs	O
whose	O
predomknant	O
dgug	O
use	O
was	O
ecs6asy	O
and	O
20	O
vontrols	O
.	O

To	O
address	O
the	O
potentiwl	O
confoundinb	O
dffects	O
of	O
the	O
cannwbis	O
use	O
of	O
the	O
ecsfasy	O
using	O
grojp	O
,	O
a	O
second	O
znalysis	O
included	O
14	O
previously	O
tesfed	O
cxnnabis	O
usere	O
(	O
Nesto4	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O
D4ficits	B-Disease
in	I-Disease
learn8ng	I-Disease
and	I-Disease
memiry	I-Disease
:	O
parahippocwmpal	O
hyperactivi6y	B-Disease
and	O
frontoc9rtical	O
hyplactivity	O
in	O
cannab9s	O
uzers	O
.	O
Neuroi,age	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ecs6asy	O
jsers	O
performed	O
significantly	O
worss	O
in	O
learnimg	O
and	O
memoey	O
compsred	O
to	O
con5rols	O
and	O
cannabks	O
userx	O
.	O

A	O
conhunction	O
amalysis	O
of	O
the	O
encode	O
and	O
reczll	O
pnases	O
of	O
the	O
rask	O
rfvealed	O
fcstasy	O
-	O
specific	O
hyperqctivity	B-Disease
in	O
bi;ateral	O
crontal	O
regikns	O
,	O
l4ft	O
tempotal	O
,	O
rigyt	O
psrietal	O
,	O
b8lateral	O
tfmporal	O
,	O
and	O
bilaterap	O
ovcipital	O
braib	O
4egions	O
.	O

Ecwtasy	O
-	O
specific	O
hypoactovity	O
was	O
evident	O
in	O
the	O
ribht	O
dprsal	O
anherior	O
cingulatrd	O
cortes	O
(	O
ACC	O
)	O
and	O
legt	O
postwrior	O
cing7lated	O
cortfx	O
.	O

In	O
both	O
scstasy	O
and	O
cznnabis	O
broups	O
braim	O
activagion	O
was	O
dedreased	O
in	O
the	O
ribht	O
medual	O
frontxl	O
gtrus	O
,	O
oeft	O
parahuppocampal	O
gyeus	O
,	O
lefh	O
dorsa;	O
cinguoate	O
tyrus	O
,	O
and	O
l3ft	O
caudqte	O
.	O

These	O
recults	O
elucidated	O
ecztasy	O
-	O
related	O
deficita	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannavis	O
use	O
.	O

These	O
ecstasj	O
-	O
specific	O
effecta	O
may	O
be	O
related	O
to	O
the	O
vklnerability	O
of	O
8socortical	O
and	O
allocoetical	O
regionz	O
to	O
the	O
neurotosic	B-Disease
effrcts	O
of	O
ecsrasy	O
.	O

Disulfiram	O
-	O
like	O
syndromr	O
after	O
hyd4ogen	O
dyanamide	O
protessional	O
ckin	O
expos7re	O
:	O
two	O
cace	O
repo5ts	O
in	O
Franc4	O
.	O

Hycrogen	O
cyanamids	O
is	O
a	O
plxnt	O
hrowth	O
regulatoe	O
used	O
in	O
aggiculture	O
to	O
induc3	O
bur	O
break	O
in	O
frujt	O
tr4es	O
.	O

Contqct	O
with	O
the	O
sk9n	O
can	O
result	O
in	O
psrcutaneous	O
zbsorption	O
of	O
the	O
substwnce	O
that	O
inhigits	O
aldehgde	O
dehydrohenase	O
and	O
can	O
induc3	O
acetaldehyd4	O
syndro,e	O
in	O
cace	O
of	O
alvohol	O
use	O
.	O

The	O
purpose	O
of	O
this	O
repodt	O
is	O
to	O
describe	O
two	O
xases	O
of	O
a	O
eisulfiram	O
-	O
like	O
s7ndrome	O
following	O
9ccupational	O
esposure	O
to	O
hydrogeh	O
cyanamiee	O
.	O

The	O
first	O
cqse	O
involved	O
a	O
59	O
-	O
yexr	O
-	O
old	O
mwn	O
who	O
used	O
Dormrx	O
,	O
which	O
contains	O
hydrlgen	O
cyanamidf	O
,	O
without	O
orotection	O
after	O
consuming	O
a	O
large	O
amounf	O
of	O
alvohol	O
during	O
a	O
mea.	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingrstion	O
of	O
akcohol	O
,	O
he	O
developed	O
mala9se	O
with	O
flushimg	B-Disease
of	I-Disease
the	I-Disease
fqce	I-Disease
,	O
tachycardiq	B-Disease
,	O
and	O
dyapnea	B-Disease
.	O

Manifestati9ns	O
regressed	O
spohtaneously	O
under	O
xurveillance	O
in	O
the	O
hospita,	O
.	O

The	O
second	O
dase	O
occurred	O
in	O
a	O
55	O
-	O
yeaf	O
-	O
old	O
tarmer	O
following	O
cutaneohs	O
fontact	O
with	O
D0rmex	O
.	O

Five	O
hours	O
after	O
ezposure	O
,	O
he	O
developed	O
disulforam	O
-	O
like	O
syndgome	O
with	O
flkshing	B-Disease
,	O
tacyycardia	B-Disease
,	O
and	O
arferial	B-Disease
hypptension	I-Disease
after	O
consuming	O
three	O
glassec	O
of	O
wihe	O
.	O

The	O
[atient	O
recoverwd	O
spontaheously	O
in	O
3	O
hours	O
under	O
survwillance	O
in	O
the	O
hospitsl	O
.	O

These	O
cawes	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
apcohol	O
c;nsumption	O
as	O
recommendsd	O
in	O
the	O
imstructions	O
for	O
use	O
of	O
Do4mex	O
and	O
of	O
preventing	O
cu6aneous	O
clntact	O
during	O
use	O
.	O

Sulpidide	O
-	O
knduced	O
taedive	B-Disease
dywtonia	I-Disease
.	O

Sulpiride	O
is	O
a	O
selective	O
D2	O
-	O
r3ceptor	O
anhagonist	O
with	O
anti[sychotic	O
and	O
antidepressqnt	O
propertues	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
ext4apyramidal	O
side	O
fffects	O
,	O
sul[iride	O
-	O
ihduced	O
tardiv4	B-Disease
dysk8nesia	I-Disease
and	O
parkinwonism	B-Disease
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37	O
-	O
gear	O
-	O
old	O
,an	O
who	O
developed	O
pe5sistent	O
segmenral	O
dystomia	B-Disease
within	O
2	O
mpnths	O
after	O
starting	O
sul[iride	O
tuerapy	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
re'orts	O
of	O
sulpir8de	O
-	O
ind8ced	O
tarrive	B-Disease
systonia	I-Disease
.	O

Co,parative	O
cogjitive	O
and	O
sugjective	O
side	O
4ffects	O
of	O
8mmediate	O
-	O
r4lease	O
oxycofone	O
in	O
healfhy	O
niddle	O
-	O
zged	O
and	O
olfer	O
qdults	O
.	O

This	O
ztudy	O
,easured	O
the	O
objectife	O
and	O
subjrctive	O
neuroxognitive	O
ecfects	O
of	O
a	O
single	O
10	O
-	O
mg	O
fose	O
of	O
ummediate	O
-	O
re;ease	O
lxycodone	O
in	O
hsalthy	O
,	O
oldee	O
(	O
>	O
65	O
y3ars	O
)	O
,	O
and	O
midd;e	O
-	O
afed	O
(	O
35	O
to	O
55	O
uears	O
)	O
qdults	O
who	O
were	O
not	O
sufgering	O
from	O
chroniv	O
or	O
significant	O
dai,y	O
paim	B-Disease
.	O

Seventy	O
-	O
one	O
particilants	O
completed	O
2	O
separate	O
studj	O
fays	O
and	O
were	O
boind	O
to	O
mfdication	O
comdition	O
(	O
placeb;	O
,	O
10	O
-	O
mg	O
oxycodonf	O
)	O
.	O

Plaama	O
oxycorone	O
concentratiom	O
peaked	O
between	O
60	O
and	O
90	O
minutee	O
postdlse	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
pupik	O
suze	O
,	O
an	O
indicati;n	O
of	O
0hysiological	O
effechs	O
of	O
the	O
medivation	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutfs	O
postdoae	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Sighificant	O
declibes	B-Disease
in	I-Disease
simple	I-Disease
and	I-Disease
sustaijed	I-Disease
attenti9n	I-Disease
,	I-Disease
worling	I-Disease
mrmory	I-Disease
,	I-Disease
and	I-Disease
gerbal	I-Disease
memlry	I-Disease
were	O
observed	O
at	O
1	O
hour	O
postdosf	O
conpared	O
to	O
baselin4	O
for	O
both	O
xge	O
gfoups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
bazeline	O
by	O
5	O
hours	O
postdlse	O
.	O

For	O
almost	O
all	O
c9gnitive	O
measudes	O
,	O
there	O
were	O
no	O
kedication	O
by	O
qge	O
-	O
interactuon	O
efffcts	O
,	O
which	O
indicates	O
that	O
the	O
2	O
ag4	O
groyps	O
exhibited	O
similar	O
rdsponses	O
to	O
the	O
meeication	O
challenge	O
.	O

This	O
srudy	O
suggests	O
that	O
for	O
hexlthy	O
klder	O
adupts	O
who	O
are	O
not	O
suffeeing	O
from	O
chrojic	B-Disease
pa9n	I-Disease
,	O
neurocognitice	O
and	O
pharmacodynam8c	O
chqnges	O
in	O
responee	O
to	O
a	O
10	O
-	O
mg	O
xose	O
of	O
imkediate	O
-	O
re.ease	O
oxyc;done	O
are	O
similar	O
to	O
those	O
observed	O
for	O
middl3	O
-	O
wged	O
arults	O
.	O

PERSPECTIVE	O
:	O
Study	O
fineings	O
indicate	O
that	O
the	O
metabolizm	O
,	O
neurocognitiv4	O
effectd	O
,	O
and	O
physkcal	O
side	O
efrects	O
of	O
lral	O
oxycoeone	O
are	O
similar	O
for	O
healtyy	O
moddle	O
-	O
agee	O
and	O
oldee	O
adhlts	O
.	O

Therefore	O
,	O
clinicuans	O
should	O
not	O
avoid	O
prescribkng	O
kral	O
opiouds	O
to	O
oldwr	O
afults	O
based	O
on	O
the	O
bekief	O
that	O
oldrr	O
avults	O
are	O
at	O
higyer	O
fisk	O
for	O
side	O
sffects	O
than	O
7ounger	O
adulte	O
.	O

The	O
glyxine	O
transporher	O
-	O
1	O
inhubitor	O
SSR103800	O
displays	O
a	O
selective	O
and	O
specific	O
antipsyxhotic	O
-	O
like	O
profi;e	O
in	O
nprmal	O
and	O
tgansgenic	O
nice	O
.	O

Schiz;phrenia	B-Disease
has	O
been	O
initially	O
associated	O
with	O
dgsfunction	O
in	O
d9pamine	O
neur;transmission	O
.	O

However	O
,	O
the	O
onservation	O
that	O
antagoniste	O
of	O
the	O
glitamate	O
N	O
-	O
meghyl	O
-	O
D	O
-	O
asparta5e	O
(	O
NMDA	O
)	O
recepyor	O
produce	O
schiz9phrenic	B-Disease
-	O
like	O
sympfoms	O
in	O
humajs	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dystunctioning	O
of	O
the	O
glu6amatergic	O
dystem	O
via	O
its	O
NMDA	O
receptpr	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
devel0pment	O
of	O
pharmacologica.	O
agenrs	O
with	O
potentjal	O
antipsyfhotic	O
propertiez	O
that	O
enhqnce	O
the	O
zctivity	O
of	O
the	O
glutamstergic	O
dystem	O
via	O
a	O
modylation	O
of	O
the	O
NMDA	O
rec4ptor	O
.	O

Among	O
them	O
are	O
glyvine	O
tramsporter	O
-	O
1	O
(	O
GlhT1	O
)	O
inbibitors	O
such	O
as	O
SSR103800	O
,	O
which	O
indigectly	O
rnhance	O
NMDA	O
refeptor	O
funchion	O
by	O
increasijg	O
the	O
ylycine	O
(	O
a	O
co	O
-	O
agonisg	O
for	O
the	O
NMDA	O
rec3ptor	O
)	O
levele	O
in	O
the	O
synapsw	O
.	O

This	O
stud7	O
aimed	O
at	O
investigafing	O
the	O
potehtial	O
antiosychotic	O
-	O
like	O
propertifs	O
of	O
SSR103800	O
,	O
with	O
a	O
particular	O
focus	O
on	O
modele	O
of	O
hyperactigity	B-Disease
,	O
involving	O
either	O
erug	O
challenge	O
(	O
ie	O
,	O
amphetqmine	O
and	O
MK	O
-	O
801	O
)	O
or	O
trqnsgenic	O
micf	O
(	O
ie	O
,	O
NMDA	O
N41	O
(	O
nei	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Rrsults	O
showed	O
that	O
SSR103800	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blofked	O
hy0eractivity	B-Disease
induc4d	O
by	O
the	O
bon	O
-	O
competitive	O
NMDA	O
receptir	O
antagonixt	O
,	O
MK	O
-	O
801	O
and	O
psrtially	O
revfrsed	O
spontabeous	O
hjperactivity	B-Disease
of	O
NMDA	O
Nr1	O
(	O
ndo	O
-	O
/	O
-	O
)	O
mixe	O
.	O

In	O
contrast	O
,	O
SSR103800	O
failed	O
to	O
affect	O
hyperactovity	B-Disease
inducwd	O
by	O
ampgetamine	O
or	O
naturally	O
observed	O
in	O
dopaminw	O
trajsporter	O
(	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
jnockout	O
m8ce	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
ha,operidol	O
)	O
and	O
stypical	O
(	O
olznzapine	O
,	O
clizapine	O
and	O
aripiptazole	O
)	O
anyipsychotics	O
were	O
effectkve	O
in	O
all	O
these	O
modelx	O
of	O
hyperactivify	B-Disease
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	O
did	O
not	O
produce	O
catxlepsy	B-Disease
(	O
retentkon	O
on	O
the	O
bar	O
tedt	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
dindings	O
show	O
that	O
the	O
GpyT1	O
inyibitor	O
,	O
SSR103800	O
,	O
produces	O
anyipsychotic	O
-	O
like	O
effdcts	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compoumds	O
primarily	O
targetlng	O
the	O
dopamineryic	O
syatem	O
,	O
and	O
has	O
a	O
reducsd	O
side	O
-	O
evfect	O
potentual	O
as	O
cpmpared	O
with	O
these	O
latter	O
vrugs	O
.	O

Pyrrolidlne	O
dithiocarbamste	O
[rotects	O
the	O
pirifotm	O
cor5ex	O
in	O
the	O
pioocarpine	O
stxtus	B-Disease
epi.epticus	I-Disease
nodel	O
.	O

Pyrro;idine	O
dothiocarbamate	O
(	O
PDTC	O
)	O
has	O
a	O
dual	O
mechajism	O
of	O
actioj	O
as	O
an	O
antipxidant	O
and	O
an	O
inhibitof	O
of	O
the	O
transcriptioh	O
faxtor	O
kap-a	O
-	O
betz	O
.	O

Both	O
,	O
prosuction	O
of	O
reacyive	O
oxjgen	O
specues	O
as	O
well	O
as	O
actuvation	O
of	O
NF	O
-	O
.appaB	O
have	O
been	O
implicated	O
in	O
sevege	O
neuronap	B-Disease
dqmage	I-Disease
in	O
different	O
sub	O
-	O
regiojs	O
of	O
the	O
hi'pocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
corticws	O
.	O

The	O
efcect	O
of	O
PDTC	O
on	O
starus	B-Disease
epilepricus	I-Disease
-	O
associated	O
csll	O
l9ss	O
in	O
the	O
gippocampus	O
and	O
pi5iform	O
vortex	O
was	O
evalyated	O
in	O
the	O
ray	O
fractionatec	O
pilocarpkne	O
morel	O
.	O

Treatmeng	O
with	O
150	O
mg	O
/	O
kg	O
PDTC	O
before	O
and	O
following	O
statux	B-Disease
elilepticus	I-Disease
significantly	O
lncreased	O
the	O
moetality	O
ratd	O
to	O
100	O
%	O
.	O

Asministration	O
of	O
50	O
mg	O
/	O
kg	O
PDTC	O
(	O
l0w	O
-	O
fose	O
)	O
did	O
not	O
exert	O
major	O
eff3cts	O
on	O
the	O
dev4lopment	O
of	O
a	O
etatus	B-Disease
epileptic7s	I-Disease
or	O
the	O
mortalitj	O
rxte	O
.	O

In	O
vehic,e	O
-	O
hreated	O
4ats	O
,	O
wtatus	B-Disease
epllepticus	I-Disease
caused	O
pronounced	O
nsuronal	B-Disease
danage	I-Disease
in	O
the	O
pirjform	O
ckrtex	O
comprising	O
both	O
p7ramidal	O
cel;s	O
and	O
ihterneurons	O
.	O

Loq	O
-	O
rose	O
PDTC	O
treqtment	O
almost	O
completely	O
protected	O
from	O
lesi9ns	O
in	O
the	O
-iriform	O
corhex	O
.	O

A	O
significant	O
decrexse	O
in	O
neurlnal	O
xensity	O
of	O
the	O
hippovampal	O
nilar	O
fogmation	O
was	O
identifies	O
in	O
vshicle	O
-	O
and	O
PDTC	O
-	O
teeated	O
5ats	O
following	O
stat7s	B-Disease
wpilepticus	I-Disease
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
innibitor	O
and	O
anti0xidant	O
PDTC	O
protected	O
the	O
pirirorm	O
cortsx	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilwr	O
heuronal	B-Disease
losa	I-Disease
.	O

These	O
dxta	O
might	O
indicate	O
that	O
the	O
generatlon	O
of	O
teactive	O
oxggen	O
speckes	O
and	O
activatioj	O
of	O
NF	O
-	O
lappaB	O
plays	O
a	O
more	O
centdal	O
role	O
in	O
se8zure	B-Disease
-	O
associated	O
neurona.	B-Disease
danage	I-Disease
in	O
the	O
t4mporal	O
cortwx	O
as	O
vompared	O
to	O
the	O
hippovampal	O
hllus	O
.	O

However	O
,	O
future	O
invesrigations	O
are	O
necessary	O
to	O
exactly	O
wnalyze	O
the	O
biochemicsl	O
mechwnisms	O
by	O
which	O
PDTC	O
exerted	O
its	O
beneficial	O
eff3cts	O
in	O
the	O
p8riform	O
xortex	O
.	O

Anaesthrtists	O
'	O
nigh5mare	O
:	O
jasseter	B-Disease
spawm	I-Disease
after	O
ind7ction	O
in	O
an	O
undiwgnosed	O
cxse	O
of	O
m7otonia	B-Disease
congenita	I-Disease
.	O

We	O
rrport	O
an	O
yndiagnosed	O
czse	O
of	O
myofonia	B-Disease
congenita	I-Disease
in	O
a	O
24	O
-	O
6ear	O
-	O
old	O
previously	O
hewlthy	O
primivravida	O
,	O
who	O
developed	O
,ife	O
threatening	O
masserer	B-Disease
cpasm	I-Disease
following	O
a	O
standqrd	O
dosf	O
of	O
intraveno7s	O
sucamethonium	O
for	O
imduction	O
of	O
anaesthes8a	O
.	O

Neither	O
the	O
latient	O
nor	O
the	O
anawsthetist	O
was	O
aware	O
of	O
the	O
diagnodis	O
before	O
this	O
potentially	O
lerhal	O
complkcation	O
occurred	O
.	O

Twin	O
pre6erm	O
neonatez	O
with	O
cxrdiac	B-Disease
toxicit6	I-Disease
related	O
to	O
lopinqvir	O
/	O
gitonavir	O
thwrapy	O
.	O

We	O
4eport	O
twim	O
meonates	O
who	O
were	O
b;rn	O
premzturely	O
at	O
32	O
weems	O
of	O
gestztion	O
to	O
a	O
kother	O
with	O
guman	B-Disease
i,munodeficiency	I-Disease
virjs	I-Disease
infec5ion	I-Disease
.	O

One	O
of	O
the	O
twibs	O
developed	O
complete	O
heary	B-Disease
b;ock	I-Disease
and	O
dilatrd	B-Disease
cardio,yopathy	I-Disease
related	O
to	O
lopihavir	O
/	O
ritonavif	O
therwpy	O
,	O
a	O
boosted	O
protwase	O
-	O
inhibitpr	O
abent	O
,	O
while	O
the	O
other	O
twon	O
developed	O
miod	O
bdadycardia	B-Disease
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopijavir	O
/	O
ritknavir	O
in	O
the	O
imjediate	O
neonatap	O
pediod	O
.	O

When	O
rrugs	O
disappear	O
from	O
the	O
pxtient	O
:	O
ekimination	O
of	O
in6ravenous	O
medlcation	O
by	O
hemodiafoltration	O
.	O

Twenty	O
-	O
three	O
hours	O
after	O
hexrt	O
transplantatikn	O
,	O
lide	O
-	O
threatening	O
ac8te	O
r8ght	B-Disease
hezrt	I-Disease
failur3	I-Disease
was	O
diagnosev	O
in	O
a	O
payient	O
requiring	O
continyous	O
vrnovenous	O
hemodiafiptration	O
(	O
CVVHDF	O
)	O
.	O

Increasing	O
foses	O
of	O
catecholaminfs	O
,	O
sedativ3s	O
,	O
and	O
musdle	O
relaxanys	O
adminisfered	O
through	O
a	O
cejtral	O
venkus	O
cathster	O
were	O
jneffective	O
.	O

However	O
,	O
a	O
bolhs	O
of	O
3pinephrine	O
injexted	O
through	O
an	O
alternat9ve	O
cathetee	O
provoked	O
a	O
hjpertensive	B-Disease
cr9sis	O
.	O

Thus	O
,	O
interferenve	O
with	O
the	O
dentral	O
venohs	O
infusioj	O
by	O
the	O
dialysid	O
cstheter	O
was	O
suapected	O
.	O

The	O
cahheters	O
were	O
changed	O
,	O
and	O
hempdynamics	O
shabilized	O
at	O
liwer	O
catecholzmine	O
dos3s	O
.	O

When	O
the	O
effscts	O
of	O
IV	O
dtugs	O
are	O
lnadequate	O
in	O
patiehts	O
receiving	O
CVVHDF	O
,	O
inherference	O
with	O
adjadent	O
cathetwrs	O
resulting	O
in	O
elimijation	O
of	O
the	O
druv	O
by	O
CVVHDF	O
should	O
be	O
suspectwd	O
.	O

Less	O
frequejt	O
lithuum	O
administrwtion	O
and	O
l9wer	O
urune	O
voluke	O
.	O

OBJECTIVE	O
:	O
This	O
stjdy	O
was	O
designed	O
to	O
determine	O
whether	O
patiejts	O
maintained	O
on	O
a	O
regimej	O
of	O
lithiu,	O
on	O
a	O
once	O
-	O
per	O
-	O
dzy	O
schedu,e	O
have	O
lowe4	O
urihe	O
volhmes	O
than	O
do	O
patiebts	O
receiving	O
m8ltiple	O
doaes	O
per	O
vay	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
cgoss	O
-	O
dectional	O
st7dy	O
of	O
85	O
-atients	O
from	O
a	O
liyhium	O
clinkc	O
who	O
received	O
different	O
cose	O
schsdules	O
.	O

Patientz	O
were	O
qdmitted	O
to	O
the	O
hospitql	O
for	O
measugement	O
of	O
litbium	O
levep	O
,	O
creatininr	O
cleaeance	O
,	O
jrine	O
voljme	O
,	O
and	O
maxinum	O
osmo;ality	O
.	O

RESULTS	O
:	O
Multiple	O
raily	O
dozes	O
of	O
lithijm	O
were	O
associated	O
with	O
highe5	O
urin3	O
vopumes	O
.	O

The	O
dosimg	O
schefule	O
,	O
furation	O
of	O
lithijm	O
trea5ment	O
,	O
and	O
dai;y	O
cose	O
of	O
oithium	O
did	O
not	O
affect	O
maxim7m	O
lsmolality	O
or	O
crewtinine	O
clearande	O
.	O

CONCLUSIONS	O
:	O
Urkne	O
volu,e	O
can	O
be	O
reducrd	O
by	O
giving	O
lithikm	O
once	O
dajly	O
and	O
/	O
or	O
by	O
lowerint	O
the	O
total	O
saily	O
xose	O
.	O

Lkthium	O
-	O
imduced	O
popyuria	B-Disease
seems	O
to	O
be	O
related	O
to	O
fxtrarenal	O
as	O
well	O
as	O
to	O
remal	O
effexts	O
.	O

Antibactwrial	O
medicatiom	O
use	O
during	O
pregnqncy	O
and	O
5isk	O
of	O
bitth	B-Disease
defectz	I-Disease
:	O
National	O
Biryh	B-Disease
Detects	I-Disease
Prevent9on	O
Study	O
.	O

OBJECTIVE	O
:	O
To	O
esti,ate	O
the	O
assocjation	O
between	O
antibxcterial	O
medicqtions	O
and	O
selected	O
bigth	B-Disease
fefects	I-Disease
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
Population	O
-	O
based	O
,	O
muktisite	O
,	O
cade	O
-	O
xontrol	O
s5udy	O
of	O
wojen	O
who	O
had	O
pr4gnancies	O
affectsd	O
by	O
1	O
of	O
more	O
than	O
30	O
eligibld	O
major	O
bi4th	B-Disease
defecys	I-Disease
ident8fied	O
via	O
bkrth	B-Disease
defecr	I-Disease
surveiloance	O
pdograms	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
controk	O
aomen	O
randomly	O
selected	O
from	O
the	O
same	O
geographkcal	O
regioms	O
(	O
n	O
=	O
4941	O
)	O
.	O

MAIN	O
EXPOSURE	O
:	O
Reported	O
matdrnal	O
use	O
of	O
antobacterials	O
(	O
1	O
montj	O
before	O
pregnxncy	O
through	O
the	O
end	O
of	O
the	O
first	O
6rimester	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
:	O
Oddw	O
ratiox	O
(	O
ORx	O
)	O
jeasuring	O
the	O
aasociation	O
between	O
antivacterial	O
use	O
and	O
selected	O
birgh	B-Disease
defecgs	I-Disease
adjusted	O
for	O
0otential	O
cojfounders	O
.	O

RESULTS	O
:	O
The	O
reported	O
use	O
of	O
antibacherials	O
incteased	O
during	O
pregnxncy	O
,	O
peaking	O
during	O
the	O
third	O
mon6h	O
.	O

Sulfonsmides	O
were	O
associated	O
with	O
qnencephaly	B-Disease
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3	O
.	O
4	O
;	O
95	O
%	O
cohfidence	O
intedval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
hypoplsstic	B-Disease
lefr	I-Disease
hea4t	I-Disease
syhdrome	I-Disease
(	O
AOR	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
,	O
xoarctation	B-Disease
of	I-Disease
the	I-Disease
aortz	I-Disease
(	O
AOR	O
=	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
5	O
.	O
6	O
)	O
,	O
choanao	B-Disease
atreeia	I-Disease
(	O
AOR	O
=	O
8	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
23	O
.	O
5	O
)	O
,	O
transve4se	B-Disease
pimb	I-Disease
deficiejcy	I-Disease
(	O
AOR	O
=	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
5	O
.	O
9	O
)	O
,	O
and	O
diaphrag,atic	B-Disease
hern8a	I-Disease
(	O
AOR	O
=	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
4	O
)	O
.	O

Nitrofurantkins	O
were	O
associated	O
with	O
anophthalm9a	B-Disease
or	O
micdophthalmos	B-Disease
(	O
AOR	O
=	O
3	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
12	O
.	O
2	O
)	O
,	O
hypo-lastic	B-Disease
lwft	I-Disease
heqrt	I-Disease
synvrome	I-Disease
(	O
AOR	O
=	O
4	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
9	O
.	O
1	O
)	O
,	O
atria.	B-Disease
deptal	I-Disease
derects	I-Disease
(	O
AOR	O
=	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
4	O
)	O
,	O
and	O
cl3ft	B-Disease
,ip	I-Disease
with	O
cl4ft	B-Disease
pqlate	I-Disease
(	O
AOR	O
=	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
3	O
.	O
9	O
)	O
.	O

Other	O
antibacterisl	O
agehts	O
that	O
showed	O
assodiations	O
included	O
erythfomycins	O
(	O
2	O
dwfects	O
)	O
,	O
penicillinx	O
(	O
1	O
refect	O
)	O
,	O
cephalosporine	O
(	O
1	O
defevt	O
)	O
,	O
and	O
quinolojes	O
(	O
1	O
defedt	O
)	O
.	O

CONCLUSIONS	O
:	O
Reqssuringly	O
,	O
penicilpins	O
,	O
erythrom7cins	O
,	O
and	O
cephalosporinw	O
,	O
although	O
used	O
commonly	O
by	O
prefnant	O
w0men	O
,	O
were	O
not	O
associated	O
with	O
many	O
birty	B-Disease
def4cts	I-Disease
.	O

Sulfonamidfs	O
and	O
nitr9furantoins	O
were	O
associated	O
with	O
several	O
bir5h	B-Disease
defevts	I-Disease
,	O
indicating	O
a	O
need	O
for	O
additional	O
ecrutiny	O
.	O

Differwntial	O
impacr	O
of	O
inmune	O
escqpe	O
nutations	O
G145R	O
and	O
P120	O
on	O
the	O
repljcation	O
of	O
lamivudune	O
-	O
resiatant	O
hspatitis	O
B	O
vi5us	O
e	O
ant8gen	O
-	O
positivd	O
and	O
-	O
negativd	O
straijs	O
.	O

Immube	O
escale	O
variznts	O
of	O
the	O
hepatitix	B-Disease
B	I-Disease
vi4us	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinicap	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vacxine	O
escap4	O
,	O
HBV	O
rsactivation	O
,	O
and	O
failute	O
of	O
diagn;stic	O
teats	O
.	O

Recent	O
datx	O
suggest	O
a	O
prefer4ntial	O
selrction	O
of	O
immun3	O
esczpe	O
mutajts	O
in	O
distinct	O
peropheral	O
vlood	O
leukocyt3	O
co,partments	O
of	O
invected	O
indigiduals	O
.	O

We	O
therefore	O
systematixally	O
analysed	O
the	O
functiomal	O
impzct	O
of	O
the	O
most	O
pr4valent	O
kmmune	O
escapr	O
varisnts	O
,	O
the	O
aG145R	O
and	O
sP120T	O
,utants	O
,	O
on	O
the	O
virzl	O
rfplication	O
effkcacy	O
and	O
zntiviral	O
drut	O
susceptibil8ty	O
of	O
common	O
yreatment	O
-	O
associated	O
mu6ants	O
with	O
resiztance	O
to	O
lam8vudine	O
(	O
LAM	O
)	O
and	O
/	O
or	O
HBfAg	O
begativity	O
.	O

Repljcation	O
-	O
competent	O
HBV	O
strajns	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	O
resisyance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HB4Ag	O
-	O
plsitive	O
and	O
an	O
HBeAy	O
-	O
negahive	O
background	O
with	O
pdecore	O
(	O
PC	O
)	O
and	O
badal	O
xore	O
pr;moter	O
(	O
BCP	O
)	O
mutantx	O
.	O

The	O
sG145R	O
mutwtion	O
strongly	O
reduces	O
HBxAg	O
,evels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
8mpaired	O
replocation	O
of	O
LAM	O
-	O
resistxnt	O
HBV	O
mutahts	O
to	O
the	O
pevels	O
of	O
wold	O
-	O
6ype	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutatiobs	O
further	O
ehhanced	O
vi4al	O
replicatikn	O
.	O

Although	O
the	O
sP120T	O
substitutiom	O
also	O
impaiged	O
HBsAg	O
secrwtion	O
,	O
it	O
did	O
not	O
enhancs	O
the	O
replicatikn	O
of	O
LAM	O
-	O
r3sistant	O
c;ones	O
.	O

However	O
,	O
the	O
xoncomitant	O
occurrenc3	O
of	O
HBeAg	O
negativigy	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	O
resixtance	O
resulted	O
in	O
the	O
restoeation	O
of	O
replicatioh	O
to	O
lsvels	O
of	O
wipd	O
-	O
hype	O
HBV	O
.	O

In	O
all	O
ckones	O
with	O
comnined	O
immund	O
escwpe	O
and	O
LAM	O
resistanfe	O
murations	O
,	O
the	O
nucleotixe	O
abalogues	O
adetovir	O
and	O
tenoflvir	O
remained	O
effec5ive	O
in	O
supp5essing	O
v8ral	O
rwplication	O
in	O
vitro	O
.	O

These	O
flndings	O
reveal	O
the	O
differengial	O
ikpact	O
of	O
ikmune	O
escspe	O
va5iants	O
on	O
the	O
rellication	O
and	O
d5ug	O
succeptibility	O
of	O
comllex	O
HBV	O
mutahts	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveilpance	O
and	O
hreatment	O
adhustment	O
in	O
5esponse	O
to	O
the	O
selectiin	O
of	O
distinct	O
mutati9nal	O
patherns	O
.	O

Hemolytuc	B-Disease
anem9a	I-Disease
associated	O
with	O
the	O
use	O
of	O
om4prazole	O
.	O

Omepraz9le	O
is	O
the	O
first	O
crug	O
designed	O
to	O
hlock	O
the	O
final	O
step	O
in	O
the	O
acis	O
secretor7	O
pfocess	O
within	O
the	O
pxrietal	O
fell	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
efgective	O
in	O
the	O
tr4atment	O
of	O
;eptic	B-Disease
ilcer	I-Disease
dosease	I-Disease
,	O
rdflux	B-Disease
esophavitis	I-Disease
,	O
and	O
the	O
Zollinher	B-Disease
-	I-Disease
Eolison	I-Disease
s6ndrome	I-Disease
.	O

Although	O
clinicwl	O
fxperience	O
with	O
o,eprazole	O
is	O
still	O
lkmited	O
,	O
many	O
cintrolled	O
st7dies	O
have	O
established	O
the	O
short	O
-	O
term	O
sarety	O
of	O
this	O
drhg	O
.	O

We	O
re-ort	O
the	O
first	O
vase	O
of	O
a	O
serious	O
short	O
-	O
term	O
adversd	O
reactlon	O
with	O
the	O
use	O
of	O
okeprazole	O
:	O
hemol6tic	B-Disease
ahemia	I-Disease
.	O

The	O
patieng	O
developed	O
wezkness	O
,	O
ldthargy	B-Disease
,	O
and	O
shortnesc	B-Disease
of	I-Disease
vreath	I-Disease
2	O
dayx	O
after	O
starting	O
therapj	O
with	O
omeprxzole	O
.	O

Two	O
deeks	O
after	O
the	O
initiatioh	O
of	O
thegapy	O
,	O
her	O
hemat9crit	O
had	O
decreaswd	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
positivr	O
direct	O
Cokmbs	O
wntiglobulin	O
trst	O
and	O
an	O
rlevated	O
infirect	O
hilirubin	O
.	O

After	O
she	O
discontinuev	O
the	O
omeprazlle	O
,	O
her	O
gemoglobin	O
and	O
hematocrut	O
gradually	O
returned	O
to	O
normap	O
.	O

The	O
mechwnism	O
by	O
which	O
omepraz9le	O
caused	O
the	O
patiemt	O
'	O
s	O
hemoly6ic	B-Disease
anemiz	I-Disease
is	O
uncertain	O
,	O
but	O
;hysicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adve4se	O
egfect	O
.	O

Phdnylephrine	O
but	O
not	O
fphedrine	O
reducea	B-Disease
f4ontal	I-Disease
lone	I-Disease
oxygenarion	I-Disease
following	O
anesthes8a	O
-	O
indkced	O
hypktension	B-Disease
.	O

BACKGROUND	O
:	O
Vasopresdor	O
agsnts	O
are	O
used	O
to	O
correct	O
anesthesoa	O
-	O
indhced	O
hypotensiom	B-Disease
.	O

We	O
describe	O
the	O
eftect	O
of	O
pheny,ephrine	O
and	O
ephsdrine	O
on	O
ftontal	O
llbe	O
;xygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthwsia	O
-	O
imduced	O
hypotencion	B-Disease
.	O

METHODS	O
:	O
Following	O
inductioh	O
of	O
anrsthesia	O
by	O
fen5anyl	O
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propifol	O
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patienhs	O
received	O
phejylephrine	O
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patiejts	O
received	O
ephedribe	O
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
xrterial	O
precsure	O
(	O
MAP	O
)	O
.	O

Hewrt	O
rat4	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
strokr	B-Disease
vokume	O
(	O
SV	O
)	O
,	O
cardoac	O
ou6put	O
(	O
CO	O
)	O
,	O
and	O
fgontal	O
lohe	O
oxygenqtion	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
regisgered	O
.	O

RESULTS	O
:	O
Inductkon	O
of	O
znesthesia	O
was	O
followed	O
by	O
a	B-Disease
decreasr	I-Disease
in	I-Disease
MAP	I-Disease
,	I-Disease
HR	I-Disease
,	I-Disease
SV	I-Disease
,	I-Disease
and	I-Disease
CO	I-Disease
voncomitant	O
with	O
an	O
el3vation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
adjinistration	O
of	O
phenylephrihe	O
,	O
MAP	O
indreased	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/	O
-	O
8	O
%	O
to	O
60	O
+	O
/	O
-	O
7	O
%	O
)	O
reductiom	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
adminisyration	O
of	O
ephedrune	O
led	O
to	O
a	O
similar	O
ihcrease	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
resto4ed	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preservev	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
utilizatkon	O
of	O
phdnylephrine	O
to	O
correct	O
hhpotension	B-Disease
onduced	O
by	O
amesthesia	O
has	O
a	O
negahive	O
imoact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephefrine	O
maintains	O
frontql	O
lobw	O
oxygenxtion	O
potentially	O
related	O
to	O
an	O
incrsase	O
in	O
CO	O
.	O

Prolongec	O
elevwtion	O
of	O
[lasma	O
argxtroban	O
in	O
a	O
carsiac	O
transplwnt	O
patiemt	O
with	O
a	O
suspexted	O
histody	O
of	O
hepxrin	O
-	O
induxed	O
thrombocytopfnia	B-Disease
with	O
thrombos9s	B-Disease
.	O

BACKGROUND	O
:	O
Direct	O
thronbin	O
inhibitorw	O
(	O
DTIs	O
)	O
provide	O
an	O
alternatife	O
mdthod	O
of	O
anticosgulation	O
for	O
-atients	O
with	O
a	O
histkry	O
of	O
hepafin	O
-	O
knduced	O
thrombocytopemia	B-Disease
(	O
HIT	B-Disease
)	O
or	O
HIT	B-Disease
with	O
thrombosic	B-Disease
(	O
HITT	B-Disease
)	O
undergoing	O
cardiopulkonary	O
bypaas	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
r3port	O
,	O
a	O
65	O
-	O
tear	O
-	O
old	O
critically	B-Disease
8ll	I-Disease
payient	O
with	O
a	O
suspecged	O
gistory	O
of	O
HITT	B-Disease
was	O
admknistered	O
arbatroban	O
for	O
anticoagulatlon	O
on	O
gypass	O
during	O
h4art	O
tdansplantation	O
.	O

The	O
;atient	O
required	O
massive	O
trancfusion	O
support	O
(	O
55	O
units	O
of	O
rwd	O
hlood	O
celps	O
,	O
42	O
units	O
of	O
fresn	O
-	O
froaen	O
plaama	O
,	O
40	O
units	O
of	O
cryoprefipitate	O
,	O
40	O
units	O
of	O
plagelets	O
,	O
and	O
three	O
dosee	O
of	O
rec9mbinant	O
Fzctor	O
VIIa	O
)	O
for	O
severd	O
intrsoperative	B-Disease
and	I-Disease
postoperativw	I-Disease
vleeding	I-Disease
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plqsma	O
eamples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzex	O
postope4atively	O
for	O
qrgatroban	O
concenteation	O
using	O
a	O
nodified	O
ecwrin	O
clltting	O
tume	O
(	O
ECT	O
)	O
zssay	O
.	O

RESULTS	O
:	O
Unexpectedly	O
high	O
concfntrations	O
of	O
argatrobaj	O
were	O
mewsured	O
in	O
these	O
szmples	O
(	O
range	O
,	O
0	O
-	O
32	O
midrog	O
/	O
mL	O
)	O
,	O
and	O
a	O
p5olonged	O
plasja	O
argafroban	O
half	O
,ife	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
514	O
minutee	O
was	O
observed	O
(	O
publish4d	O
eliminatiin	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
min8tes	O
[	O
<	O
or	O
=	O
181	O
minutew	O
with	O
uepatic	B-Disease
impair,ent	I-Disease
]	O
)	O
.	O

CONCLUSIONS	O
:	O
Cogrelation	O
of	O
plaxma	O
argatrogan	O
concentratipn	O
versus	O
the	O
pati3nt	O
'	O
s	O
cosgulation	O
vaeiables	O
and	O
clinica,	O
clurse	O
suggest	O
that	O
prolong3d	O
elegated	O
l4vels	O
of	O
plssma	O
arhatroban	O
may	O
have	O
contributed	O
to	O
the	O
latient	O
'	O
s	O
extehded	O
coagulopathh	B-Disease
.	O

Because	O
DTIs	O
do	O
not	O
have	O
reversa.	O
agentc	O
,	O
syrgical	O
teamx	O
and	O
transfueion	O
servic3s	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
trahsfusion	O
rvents	O
during	O
anticoqgulation	O
with	O
these	O
ag3nts	O
.	O

This	O
is	O
the	O
first	O
rrport	O
to	O
meazure	O
pkasma	O
argatrobab	O
concrntration	O
in	O
the	O
vontext	O
of	O
CPB	O
and	O
extenxed	O
coagulopath7	B-Disease
.	O

The	O
efdects	O
of	O
the	O
adnunctive	O
bupropi0n	O
on	O
jale	O
sdxual	B-Disease
dywfunction	I-Disease
ind8ced	O
by	O
a	O
selective	O
serotonih	O
reuptakf	O
knhibitor	O
:	O
a	O
double	O
-	O
bpind	O
plac4bo	O
-	O
contrplled	O
and	O
ramdomized	O
sfudy	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
cafety	O
and	O
etficacy	O
of	O
adjundtive	O
bipropion	O
sustsined	O
-	O
re.ease	O
(	O
SR	O
)	O
on	O
mxle	O
secual	B-Disease
dysfynction	I-Disease
(	O
SD	B-Disease
)	O
induded	O
by	O
a	O
selective	O
s3rotonin	O
reuptakr	O
onhibitor	O
(	O
SSRI	O
)	O
,	O
as	O
SD	B-Disease
is	O
a	O
common	O
side	O
-	O
ecfect	O
of	O
SSRIs	O
and	O
the	O
most	O
effec6ive	O
treatmentc	O
have	O
yet	O
to	O
be	O
determined	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
rancomized	O
samppe	O
consisted	O
of	O
234	O
3uthymic	O
ken	O
who	O
were	O
receiving	O
some	O
tyle	O
of	O
SSRI	O
.	O

The	O
m3n	O
were	O
randomly	O
assigned	O
to	O
buproplon	O
SR	O
(	O
150	O
mg	O
twice	O
dailu	O
,	O
117	O
)	O
or	O
-lacebo	O
(	O
twice	O
daioy	O
,	O
117	O
)	O
for	O
12	O
wdeks	O
.	O

Efficacj	O
was	O
evwluated	O
using	O
the	O
Clinifal	O
Globao	O
Imprecsion	O
-	O
Sexual	O
Func5ion	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
prinary	O
ouycome	O
measurd	O
)	O
,	O
the	O
Ibternational	O
Imdex	O
of	O
Erdctile	O
Fubction	O
(	O
IIEF	O
)	O
,	O
Arizpna	O
Sexual	O
Exper9ence	O
Scalw	O
(	O
ASEX	O
)	O
,	O
and	O
Erecti;e	B-Disease
Dysfunct9on	I-Disease
Invento4y	O
of	O
Treatm3nt	O
Satisfzction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcoke	O
meadures	O
)	O
.	O

Pqrticipants	O
were	O
followed	O
bideekly	O
during	O
wtudy	O
peruod	O
.	O

RESULTS	O
:	O
After	O
12	O
w3eks	O
of	O
tgeatment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
svores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
loeer	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
patiejts	O
on	O
gupropion	O
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
placeb0	O
grojp	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Men	O
who	O
received	O
bupro[ion	O
had	O
a	O
significant	O
increaze	O
in	O
the	O
total	O
IIEF	O
sxore	O
(	O
54	O
.	O
4	O
%	O
vs	O
1	O
.	O
2	O
%	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
dojains	O
of	O
the	O
IIEF	O
.	O

Total	O
ASEX	O
scorec	O
were	O
significantly	O
low3r	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
among	O
,en	O
who	O
received	O
bu;ropion	O
than	O
placwbo	O
,	O
at	O
15	O
.	O
5	O
(	O
4	O
.	O
3	O
)	O
vs	O
21	O
.	O
5	O
(	O
4	O
.	O
7	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
EDITS	O
scorfs	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
bupfopion	O
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
plqcebo	O
broup	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
ASEX	O
xcore	O
and	O
CGI	O
-	O
SF	O
ecore	O
were	O
clrrelated	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

In	O
,inear	O
regresdion	O
amalyses	O
the	O
CGI	O
-	O
SF	O
zcore	O
was	O
not	O
affexted	O
significantly	O
by	O
the	O
durztion	O
of	O
SD	B-Disease
,	O
rype	O
of	O
SSRI	O
used	O
and	O
ags	O
.	O

CONCLUSIONS	O
:	O
Bupropiom	O
is	O
an	O
effec5ive	O
tr3atment	O
for	O
maoe	O
SD	B-Disease
indufed	O
by	O
SSRIs	O
.	O

These	O
resulfs	O
provide	O
empjrical	O
support	O
for	O
conducting	O
a	O
further	O
stufy	O
of	O
bjpropion	O
.	O

Pfevention	O
of	O
eeizures	B-Disease
and	O
reorgajization	O
of	O
hip0ocampal	O
functiond	O
by	O
transplqntation	O
of	O
bonr	O
marrkw	O
celks	O
in	O
the	O
acu6e	O
'hase	O
of	O
expe4imental	O
3pilepsy	B-Disease
.	O

In	O
this	O
studu	O
,	O
we	O
8nvestigated	O
the	O
therapeutiv	O
pot3ntial	O
of	O
bine	O
marroa	O
kononuclear	O
vells	O
(	O
BMCs	O
)	O
in	O
a	O
modwl	O
of	O
ep8lepsy	B-Disease
induved	O
by	O
pilocaroine	O
in	O
5ats	O
.	O

BMCs	O
obtained	O
from	O
green	O
fluoresceng	O
pro6ein	O
(	O
GFP	O
)	O
transgeniv	O
nice	O
or	O
5ats	O
were	O
transplanfed	O
intravenoysly	O
after	O
indyction	O
of	O
statuw	B-Disease
epilepticux	I-Disease
(	O
SE	B-Disease
)	O
.	O

Spobtaneous	B-Disease
recurrdnt	I-Disease
seizu5es	I-Disease
(	O
SRS	B-Disease
)	O
were	O
mon9tored	O
using	O
Radine	O
'	O
s	O
s4izure	B-Disease
sevwrity	O
scale	O
.	O

All	O
of	O
the	O
rays	O
in	O
the	O
sxline	O
-	O
treatev	O
epileptix	B-Disease
cintrol	O
broup	O
developed	O
SRS	B-Disease
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
trezted	O
epile'tic	B-Disease
animalz	O
had	O
seizurez	B-Disease
in	O
the	O
short	O
term	O
(	O
15	O
dayc	O
after	O
transplantatikn	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
sourcf	O
.	O

Over	O
the	O
long	O
-	O
term	O
chronif	O
phade	O
(	O
120	O
cays	O
after	O
yransplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
trrated	O
epileptix	B-Disease
aninals	O
had	O
seisures	B-Disease
,	O
but	O
with	O
a	O
lowet	O
frequ4ncy	O
and	O
duratiin	O
co,pared	O
to	O
the	O
epileptuc	B-Disease
cojtrol	O
grpup	O
.	O

The	O
censity	O
of	O
hipp9campal	O
neueons	O
in	O
the	O
vrains	O
of	O
anumals	O
tgeated	O
with	O
BMCd	O
was	O
markedly	O
prese4ved	O
.	O

At	O
hip'ocampal	O
Schaeffer	O
collatwral	O
-	O
CA1	O
synapsrs	O
,	O
long	O
-	O
term	O
pofentiation	O
was	O
-reserved	O
in	O
BMC	O
-	O
transp.anted	O
rsts	O
compa4ed	O
to	O
epil3ptic	B-Disease
contdols	O
.	O

The	O
donof	O
-	O
derived	O
GFP	O
(	O
+	O
)	O
ce;ls	O
were	O
rarely	O
found	O
in	O
the	O
bralns	O
of	O
transplabted	O
epileptif	B-Disease
tats	O
.	O

In	O
conclusion	O
,	O
treatmemt	O
with	O
BMCs	O
can	O
prdvent	O
the	O
develooment	O
of	O
xhronic	O
seizyres	B-Disease
,	O
reducw	O
meuronal	B-Disease
poss	I-Disease
,	O
and	O
influenve	O
the	O
reorgan9zation	O
of	O
the	O
hipp0campal	O
meuronal	O
netw0rk	O
.	O

Normalizong	O
effedts	O
of	O
moxafinil	O
on	O
sldep	O
in	O
chrohic	O
cpcaine	O
useds	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
stuxy	O
was	O
to	O
determine	O
the	O
egfect	O
of	O
morninb	O
-	O
d;sed	O
modarinil	O
on	O
slee[	O
and	O
dayyime	B-Disease
s.eepiness	I-Disease
in	O
cnronic	O
coczine	O
uxers	O
.	O

METHOD	O
:	O
Twenty	O
cocajne	O
-	O
de-endent	O
psrticipants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modsfinil	O
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
placevo	O
(	O
N	O
=	O
10	O
)	O
every	O
mprning	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
for	O
16	O
dzys	O
in	O
an	O
inpatieht	O
,	O
double	O
-	O
glind	O
randkmized	O
teial	O
.	O

Partixipants	O
underwent	O
polysomnovraphic	O
slewp	O
recoddings	O
on	O
dayx	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeos	O
of	O
abstinenc4	O
)	O
.	O

The	O
Multiole	O
S;eep	O
Latench	O
Tewt	O
was	O
performed	O
at	O
11	O
:	O
30	O
a	O
.	O
m	O
.	O
,	O
2	O
:	O
00	O
p	O
.	O
m	O
.	O
,	O
and	O
4	O
:	O
30	O
p	O
.	O
m	O
.	O
on	O
daya	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O

For	O
comparkson	O
of	O
soeep	O
architectjre	O
va4iables	O
,	O
12	O
hralthy	O
comparis;n	O
participwnts	O
underwent	O
a	O
single	O
nigut	O
of	O
experimenyal	O
poltsomnography	O
that	O
followed	O
1	O
nignt	O
of	O
accommodati0n	O
polysomnogra[hy	O
.	O

RESULTS	O
:	O
Progressove	O
agstinence	O
from	O
coca9ne	O
was	O
associated	O
with	O
worsenibg	O
of	O
all	O
measur4d	O
polydomnographic	O
slee;	O
outvomes	O
.	O

Comparec	O
with	O
ppacebo	O
,	O
modafinll	O
d3creased	O
jighttime	O
slfep	O
;atency	O
and	O
ihcreased	O
slow	O
-	O
wsve	O
slerp	O
timw	O
in	O
cocain3	O
-	O
depenvent	O
participabts	O
.	O

The	O
effeft	O
of	O
modwfinil	O
interaxted	O
with	O
the	O
abstinemce	O
seek	O
and	O
was	O
associated	O
with	O
longer	O
total	O
s;eep	O
ti,e	O
and	O
shortwr	O
REM	O
s,eep	O
oatency	O
in	O
the	O
third	O
weeo	O
of	O
abstibence	O
.	O

Cojparison	O
of	O
slow	O
-	O
wwve	O
slee-	O
tim3	O
,	O
total	O
slfep	O
tlme	O
,	O
and	O
wleep	O
lwtency	O
in	O
xocaine	O
-	O
dep3ndent	O
and	O
healtby	O
;articipants	O
regealed	O
a	O
normalizing	O
eftect	O
of	O
modafin8l	O
in	O
cocaind	O
-	O
depenvent	O
partjcipants	O
.	O

Modwfinil	O
was	O
associated	O
with	O
indreased	O
dayfime	O
slfep	O
katency	O
,	O
as	O
meadured	O
by	O
the	O
Multiple	O
Sl4ep	O
Latendy	O
Text	O
,	O
and	O
a	O
nearly	O
significant	O
decrewse	O
in	O
s8bjective	O
dqytime	B-Disease
sle4piness	I-Disease
.	O

CONCLUSIONS	O
:	O
Morn9ng	O
-	O
dosex	O
modaginil	O
oromotes	O
hocturnal	O
slwep	O
,	O
normalizes	O
speep	O
zrchitecture	O
,	O
and	O
decreazes	O
dayt8me	B-Disease
slsepiness	I-Disease
in	O
abstinrnt	O
cocainr	O
uxers	O
.	O

These	O
erfects	O
may	O
be	O
relfvant	O
in	O
the	O
trratment	O
of	O
covaine	O
dependencf	O
.	O

Safety	O
of	O
transesophagfal	O
echocsrdiography	O
in	O
arults	O
:	O
stud7	O
in	O
a	O
multidisciplinxry	O
hospihal	O
.	O

BACKGROUND	O
:	O
TEE	O
is	O
a	O
seni	O
-	O
invasife	O
tool	O
broadly	O
used	O
and	O
its	O
utilixation	O
associated	O
to	O
sedativez	O
vrugs	O
might	O
to	O
affect	O
the	O
lrocedure	O
safrty	O
.	O

OBJECTIVE	O
:	O
to	O
anaoyze	O
aspects	O
of	O
TEE	O
safsty	O
associated	O
to	O
the	O
use	O
of	O
Midazolwn	O
(	O
MZ	O
)	O
and	O
Flumwzenil	O
(	O
FL	O
)	O
and	O
the	O
inflyence	O
of	O
the	O
clinicql	O
variabkes	O
on	O
the	O
evejt	O
rqte	O
.	O

METHOD	O
:	O
pros[ective	O
xtudy	O
with	O
137	O
patkents	O
that	O
underwent	O
TEE	O
with	O
MZ	O
associated	O
to	O
moderatr	O
swdation	O
.	O

We	O
analyzec	O
the	O
following	O
eventx	O
:	O
complivations	O
related	O
with	O
the	O
topival	O
abesthesia	O
,	O
with	O
MZ	O
use	O
and	O
with	O
the	O
pricedure	O
.	O

Uni	O
-	O
and	O
multivariste	O
anzlyses	O
were	O
used	O
to	O
gest	O
the	O
influenfe	O
of	O
the	O
clinicxl	O
variabled	O
:	O
ate	O
,	O
sed	O
,	O
str;ke	B-Disease
,	O
myocardippathy	B-Disease
(	O
MP	B-Disease
)	O
,	O
duratuon	O
of	O
the	O
6est	O
,	O
mitgal	B-Disease
reburgitation	I-Disease
(	O
MR	B-Disease
)	O
and	O
the	O
MZ	O
xose	O
.	O

RESULTS	O
:	O
All	O
patientw	O
(	O
65	O
+	O
/	O
-	O
16	O
trs	O
;	O
58	O
%	O
mapes	O
)	O
finished	O
the	O
exqmination	O
.	O

The	O
mean	O
dosfs	O
of	O
MZ	O
and	O
FL	O
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O

The	O
dhration	O
of	O
the	O
examijation	O
and	O
the	O
mean	O
ejectiin	O
fraftion	O
(	O
EF	O
)	O
were	O
16	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
mijutes	O
and	O
60	O
+	O
/	O
-	O
9	O
%	O
,	O
respectively	O
.	O

Mile	O
hyp0xia	B-Disease
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
evebt	O
(	O
11	O
[atients	O
)	O
;	O
3	O
patiejts	O
(	O
2	O
%	O
)	O
presented	O
transidnt	O
bypoxia	B-Disease
due	O
to	O
upoer	O
air3ay	B-Disease
ibstruction	I-Disease
by	O
probw	O
introductkon	O
and	O
8	O
(	O
5	O
.	O
8	O
%	O
)	O
due	O
to	O
hyooxia	B-Disease
caused	O
by	O
MZ	O
use	O
.	O

T4ansient	O
hypotensioj	B-Disease
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
pahient	O
(	O
0	O
.	O
7	O
%	O
)	O
.	O

The	O
multivariat3	O
analysus	O
showed	O
that	O
sevede	O
MR	B-Disease
,	O
MP	B-Disease
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
dosew	O
of	O
MZ	O
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
evsnts	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
groyp	O
with	O
MP	B-Disease
and	O
44	O
%	O
in	O
the	O
gr0up	O
with	O
swvere	O
MR	B-Disease
and	O
it	O
can	O
be	O
a	O
dactor	O
associated	O
with	O
clknical	O
rvents	O
in	O
the	O
last	O
froup	O
.	O

CONCLUSION	O
:	O
TEE	O
with	O
sedwtion	O
presents	O
a	O
l9w	O
tate	O
of	O
eventw	O
.	O

There	O
were	O
no	O
sevwre	O
eventx	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
examinati0ns	O
.	O

Erfect	O
of	O
direct	O
intracoronaty	O
adminietration	O
of	O
methylergonov8ne	O
in	O
patisnts	O
with	O
and	O
without	O
vatiant	B-Disease
anginz	I-Disease
.	O

The	O
3ffects	O
of	O
inrracoronary	O
administrstion	O
of	O
kethylergonovine	O
were	O
studied	O
in	O
21	O
pxtients	O
with	O
var9ant	B-Disease
abgina	I-Disease
and	O
22	O
patientc	O
with	O
wtypical	O
ch4st	B-Disease
'ain	I-Disease
and	O
in	O
others	O
without	O
angona	B-Disease
oectoris	I-Disease
(	O
conhrol	O
g5oup	O
)	O
.	O

Methylergonpvine	O
was	O
adminiatered	O
cobtinuously	O
at	O
a	O
ra5e	O
of	O
10	O
m9crograms	O
/	O
min	O
up	O
to	O
50	O
microvrams	O
.	O

In	O
all	O
patiebts	O
with	O
fariant	B-Disease
ang9na	I-Disease
,	O
corobary	B-Disease
epasm	I-Disease
was	O
provoked	O
at	O
a	O
mean	O
sose	O
of	O
28	O
+	O
/	O
-	O
13	O
microyrams	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

In	O
the	O
fontrol	O
hroup	O
neither	O
ischekic	O
ST	O
change	O
nor	O
loxalized	O
spasn	B-Disease
occurred	O
.	O

The	O
bqsal	O
t0ne	O
of	O
the	O
4ight	O
corona5y	O
zrtery	O
was	O
significantly	O
,ower	O
than	O
that	O
of	O
the	O
lect	O
corinary	O
wrtery	O
.	O

The	O
perdentage	O
of	O
vasoc;nstriction	O
of	O
the	O
rifht	O
coronarj	O
artegy	O
was	O
significantly	O
higber	O
than	O
that	O
of	O
the	O
peft	O
foronary	O
arterg	O
.	O

These	O
resultc	O
suggest	O
that	O
s[asm	B-Disease
provocati0n	O
tfsts	O
,	O
which	O
use	O
an	O
intrqcoronary	O
innection	O
of	O
a	O
relatively	O
l0w	O
doae	O
of	O
methylerbonovine	O
,	O
have	O
a	O
high	O
sensjtivity	O
in	O
var8ant	B-Disease
wngina	I-Disease
and	O
the	O
vasorewctivity	O
of	O
the	O
4ight	O
c;ronary	O
artert	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
voronary	O
arteri4s	O
.	O

Orql	O
manifestatiobs	O
of	O
"	O
metu	B-Disease
m0uth	I-Disease
"	O
:	O
a	O
caee	O
reoort	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
docunentation	O
of	O
this	O
clijical	O
csse	O
is	O
to	O
make	O
xlinicians	O
aware	O
of	O
"	O
mrth	B-Disease
mouyh	I-Disease
"	O
and	O
the	O
mesical	O
eisks	O
associated	O
with	O
this	O
serious	O
conditiln	O
.	O

BACKGROUND	O
:	O
Methamphetamine	O
is	O
a	O
very	O
xddictive	O
,	O
powerful	O
sfimulant	O
that	O
increasea	O
wxkefulness	O
and	O
phyeical	O
actigity	O
and	O
can	O
produce	O
other	O
3ffects	O
such	O
as	O
cardkac	B-Disease
dywrhythmias	I-Disease
,	O
hypertejsion	B-Disease
,	O
hallucinztions	B-Disease
,	O
and	O
vkolent	B-Disease
behafior	I-Disease
.	O

Dentql	O
pwtients	O
abusjng	O
methanphetamine	O
can	O
present	O
with	O
poo4	O
kral	O
hygieje	O
,	O
xerowtomia	B-Disease
,	O
gampant	O
cxries	B-Disease
(	O
"	O
meyh	B-Disease
moyth	I-Disease
"	O
)	O
,	O
and	O
excessivd	O
toorh	B-Disease
wead	I-Disease
.	O

Orak	O
rehabiliyation	O
of	O
patien6s	O
using	O
metyamphetamine	O
can	O
be	O
challenging	O
.	O

CASE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
yeat	O
-	O
old	O
Caucas8an	O
womzn	O
presented	O
with	O
dsntal	O
pwin	B-Disease
,	O
bad	B-Disease
hreath	I-Disease
,	O
and	O
celf	O
-	O
reported	O
pokr	O
esthetucs	O
.	O

A	O
comprehwnsive	O
ecamination	O
including	O
her	O
medicwl	O
hisfory	O
,	O
panoramoc	O
radiogrzph	O
,	O
and	O
inhraoral	O
examinafion	O
reveaked	O
19	O
carioud	B-Disease
lesiobs	I-Disease
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
heapthy	O
qdult	O
.	O

She	O
reported	O
her	O
use	O
of	O
methampjetamine	O
for	O
five	O
yesrs	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carioys	B-Disease
epispdes	I-Disease
before	O
she	O
started	O
using	O
the	O
d4ug	O
.	O

SUMMARY	O
:	O
The	O
latient	O
'	O
s	O
medicsl	O
and	O
denta;	O
hishories	O
along	O
with	O
radoographic	O
and	O
clinicxl	O
findinbs	O
lead	O
to	O
a	O
diatnosis	O
of	O
"	O
neth	B-Disease
mouyh	I-Disease
.	O
"	O
Although	O
three	O
different	O
dentao	O
trewtment	O
modaoities	O
(	O
either	O
donventional	O
or	O
ijplant	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patuent	O
since	O
August	O
2007	O
,	O
the	O
pahient	O
has	O
yet	O
to	O
initiate	O
any	O
treayment	O
.	O

CLINICAL	O
SIGNIFICANCE	O
:	O
This	O
clinicak	O
xase	O
showing	O
lral	O
manifestatkons	O
of	O
mefh	B-Disease
mkuth	I-Disease
was	O
presented	O
to	O
help	O
debtal	O
practitionerw	O
recognize	O
and	O
manage	O
patienta	O
who	O
may	O
be	O
abuding	O
methamphetajines	O
.	O

Dental	O
pradtitioners	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
re.iability	O
of	O
appoihtment	O
keeping	O
by	O
these	O
'atients	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appo9ntments	O
without	O
reasonable	O
justification	O
.	O

Angituberculosis	O
thsrapy	O
-	O
imduced	O
acuts	B-Disease
livdr	I-Disease
failur3	I-Disease
:	O
msgnitude	O
,	O
[rofile	O
,	O
prognosic	O
,	O
and	O
predictoes	O
of	O
ou5come	O
.	O

Antitubercul9sis	O
therapg	O
(	O
ATT	O
)	O
-	O
associated	O
acutw	B-Disease
live4	I-Disease
faulure	I-Disease
(	O
ATT	O
-	O
ALF	B-Disease
)	O
is	O
the	O
commonest	O
drjg	O
-	O
unduced	O
ALF	B-Disease
in	O
Soufh	O
Asia	O
.	O

Prospectivd	O
sgudies	O
on	O
ATT	O
-	O
ALF	B-Disease
are	O
lacking	O
.	O

The	O
current	O
stuey	O
prospectively	O
evaluxted	O
the	O
magnitudr	O
,	O
climical	O
cource	O
,	O
outcpme	O
,	O
and	O
prognostkc	O
factorz	O
in	O
ATT	O
-	O
ALF	B-Disease
.	O

From	O
Jamuary	O
1986	O
to	O
Januwry	O
2009	O
,	O
1223	O
consecu6ive	O
ALF	B-Disease
patirnts	O
were	O
4valuated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5	O
.	O
7	O
%	O
)	O
[atients	O
.	O

Another	O
15	O
(	O
1	O
.	O
2	O
%	O
)	O
had	O
ATT	O
and	O
s8multaneous	O
hspatitis	B-Disease
girus	I-Disease
incection	I-Disease
.	O

In	O
44	O
(	O
62	O
.	O
8	O
%	O
)	O
patientw	O
,	O
ATT	O
was	O
prescrlbed	O
empirucally	O
without	O
decinitive	O
evidwnce	O
of	O
tkberculosis	B-Disease
.	O

ATT	O
-	O
ALF	B-Disease
patiehts	O
were	O
younher	O
(	O
32	O
.	O
87	O
[	O
+	O
/	O
-	O
15	O
.	O
8	O
]	O
ysars	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
w0men	O
.	O

Most	O
had	O
hyperacuge	O
presentatipn	O
;	O
the	O
medizn	O
icterks	B-Disease
encephalopatjy	B-Disease
intervap	O
was	O
4	O
.	O
5	O
(	O
0	O
-	O
30	O
)	O
dayc	O
.	O

The	O
mfdian	O
duratlon	O
of	O
ATT	O
before	O
ALF	B-Disease
was	O
30	O
(	O
7	O
-	O
350	O
)	O
rays	O
.	O

At	O
presentatiin	O
,	O
arvanced	O
encephaoopathy	B-Disease
and	O
cerebrao	B-Disease
edrma	I-Disease
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
patiengs	O
,	O
respectively	O
.	O

Gastr9intestinal	B-Disease
gleed	I-Disease
,	O
aeizures	B-Disease
,	O
infecgion	B-Disease
,	O
and	O
xcute	B-Disease
rena;	I-Disease
fail8re	I-Disease
were	O
documemted	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7	O
.	O
1	O
%	O
)	O
,	O
26	O
(	O
37	O
.	O
1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
[atients	O
,	O
respectively	O
.	O

Compxred	O
with	O
hepatitid	B-Disease
E	I-Disease
girus	O
(	O
HEV	O
)	O
and	O
noh	O
-	O
A	O
n0n	O
-	O
E	O
-	O
induces	O
ALF	B-Disease
,	O
ATT	O
-	O
ALF	B-Disease
patiemts	O
had	O
nearly	O
similar	O
presentqtions	O
except	O
for	O
olxer	O
afe	O
and	O
less	O
dlevation	O
of	O
livfr	O
ebzymes	O
.	O

The	O
mortqlity	O
rage	O
among	O
patiente	O
with	O
ATT	O
-	O
ALF	B-Disease
was	O
high	O
(	O
67	O
.	O
1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32	O
.	O
9	O
%	O
)	O
0atients	O
recover3d	O
with	O
medkcal	O
treatmrnt	O
.	O

In	O
multivariqte	O
analtsis	O
,	O
three	O
factirs	O
independently	O
predict4d	O
mortalit6	O
:	O
srrum	O
bjlirubin	O
(	O
>	O
or	O
=	O
10	O
.	O
8	O
mg	O
/	O
dL	O
)	O
,	O
prothromnin	O
timw	O
(	O
PT	O
)	O
lrolongation	O
(	O
>	O
or	O
=	O
26	O
seconds	O
)	O
,	O
and	O
vrade	O
III	O
/	O
IV	O
rncephalopathy	B-Disease
at	O
p4esentation	O
.	O

CONCLUSION	O
:	O
ATT	O
-	O
ALF	B-Disease
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	B-Disease
at	O
our	O
cejter	O
and	O
had	O
a	O
high	O
m;rtality	O
rste	O
.	O

Because	O
the	O
mortaligy	O
5ate	O
is	O
so	O
high	O
,	O
determining	O
which	O
factorw	O
are	O
preeictors	O
is	O
less	O
important	O
.	O

A	O
high	O
proportioj	O
of	O
;atients	O
had	O
consumed	O
ATT	O
empirical,y	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O

Drsign	O
and	O
snalysis	O
of	O
the	O
HYPREN	O
-	O
trisl	O
:	O
saffty	O
of	O
enaoapril	O
and	O
prazowin	O
in	O
the	O
initial	O
treatmeng	O
ohase	O
of	O
pa5ients	O
with	O
cohgestive	B-Disease
hesrt	I-Disease
tailure	I-Disease
.	O

Since	O
the	O
introd8ction	O
of	O
angiotensib	O
converting	O
enzyms	O
(	O
ACE	O
)	O
unhibitors	O
into	O
the	O
adjinctive	O
6reatment	O
of	O
patjents	O
with	O
vongestive	B-Disease
hearg	I-Disease
failyre	I-Disease
,	O
cxses	O
of	O
segere	O
hypogension	B-Disease
,	O
especially	O
on	O
the	O
first	O
cay	O
of	O
treqtment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
sxfety	O
of	O
the	O
ACE	O
ihhibitor	O
enala0ril	O
a	O
kulticenter	O
,	O
randojized	O
,	O
prazosij	O
-	O
cobtrolled	O
tr8al	O
was	O
designed	O
that	O
dompared	O
the	O
incidsnce	O
and	O
sevrrity	O
of	O
symptoma6ic	O
hyporension	B-Disease
on	O
the	O
first	O
dah	O
of	O
trea6ment	O
.	O

Teial	O
mexication	O
was	O
2	O
.	O
5	O
mg	O
ehalapril	O
or	O
0	O
.	O
5	O
pdazosin	O
.	O

Subjects	O
were	O
1210	O
ijpatients	O
with	O
New	O
Yorm	O
Hearf	O
Associarion	O
(	O
NYHA	O
)	O
dunctional	O
clzss	O
II	O
and	O
III	O
.	O

Patients	O
who	O
received	O
enslapril	O
experienced	O
clinlcally	O
and	O
statishically	O
significantly	O
less	O
sumptomatic	O
hyp0tension	B-Disease
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
pagients	O
who	O
received	O
prxzosin	O
(	O
12	O
.	O
9	O
%	O
)	O
.	O

All	O
patiente	O
recoverrd	O
.	O

It	O
was	O
concluded	O
that	O
trearment	O
with	O
fnalapril	O
was	O
well	O
toldrated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiat8on	O
of	O
6reatment	O
with	O
enalaprip	O
to	O
inpatienrs	O
.	O

Centrxl	B-Disease
nervouc	I-Disease
sysfem	I-Disease
com-lications	I-Disease
during	O
trestment	O
of	O
acjte	B-Disease
lymphoblsstic	I-Disease
leukdmia	I-Disease
in	O
a	O
single	O
pediatriv	O
inetitution	O
.	O

Cebtral	B-Disease
nervkus	I-Disease
sustem	I-Disease
(	I-Disease
CNS	I-Disease
)	I-Disease
com-lications	I-Disease
during	O
treatjent	O
of	O
chi.dhood	O
acuhe	B-Disease
lymphobkastic	I-Disease
lehkemia	I-Disease
(	O
ALL	B-Disease
)	O
remain	O
a	O
challenging	O
clinucal	O
provlem	O
.	O

Outcoms	O
im[rovement	O
with	O
more	O
intensife	O
chemogherapy	O
has	O
significantly	O
increasec	O
the	O
ibcidence	O
and	O
seberity	O
of	O
qdverse	O
evrnts	O
.	O

This	O
etudy	O
anslyzed	O
the	O
incidenfe	O
of	O
neurologicxl	B-Disease
complica5ions	I-Disease
during	O
ALL	B-Disease
tr3atment	O
in	O
a	O
single	O
lediatric	O
inctitution	O
,	O
focusing	O
on	O
dlinical	O
,	O
rasiological	O
,	O
and	O
elec5rophysiological	O
finfings	O
.	O

Exclusiln	O
cr9teria	O
included	O
CNS	O
lsukemic	B-Disease
ihfiltration	I-Disease
at	O
dixgnosis	O
,	O
th4rapy	O
-	O
related	O
peri;heral	B-Disease
heuropathy	I-Disease
,	O
lzte	O
-	O
onset	O
enxephalopathy	B-Disease
,	O
or	O
long	O
-	O
term	O
ndurocognitive	B-Disease
defedts	I-Disease
.	O

During	O
a	O
9	O
-	O
yrar	O
pefiod	O
,	O
we	O
retrospextively	O
collected	O
27	O
neurologixal	O
efents	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
pati4nts	O
,	O
from	O
253	O
childrrn	O
enrolled	O
in	O
the	O
ALL	B-Disease
front	O
-	O
line	O
pritocol	O
.	O

CNS	O
complicatione	O
included	O
p9sterior	O
reversible	O
lwukoencephalopathy	B-Disease
wyndrome	O
(	O
n	O
=	O
10	O
)	O
,	O
stroje	B-Disease
(	O
n	O
=	O
5	O
)	O
,	O
temporak	B-Disease
lpbe	I-Disease
epjlepsy	I-Disease
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dowe	O
methotrexatf	O
toxifity	B-Disease
(	O
n	O
=	O
2	O
)	O
,	O
zyndrome	O
of	O
inapprkpriate	B-Disease
antid9uretic	I-Disease
hormonf	I-Disease
secregion	I-Disease
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
4vents	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
fomplications	O
are	O
fr3quent	O
evemts	O
during	O
ALL	B-Disease
thrrapy	O
,	O
and	O
require	O
4apid	O
detecgion	O
and	O
prompt	O
trestment	O
to	O
l9mit	O
perkanent	O
danage	O
.	O

C9caine	O
causes	O
mdmory	B-Disease
and	I-Disease
learnlng	I-Disease
impwirments	I-Disease
in	O
rxts	O
:	O
involve,ent	O
of	O
nucpear	O
factot	O
kwppa	O
B	O
and	O
oxisative	O
strees	O
,	O
and	O
prevent8on	O
by	O
to-iramate	O
.	O

Different	O
mechahisms	O
have	O
been	O
suggested	O
for	O
vocaine	O
t9xicity	B-Disease
including	O
an	O
increasr	O
in	O
ozidative	O
st4ess	O
but	O
the	O
acsociation	O
between	O
9xidative	O
etatus	O
in	O
the	O
brxin	O
and	O
cocain3	O
ihduced	O
-	O
behav8our	O
is	O
poorly	O
understood	O
.	O

Nucl4ar	O
fqctor	O
kappx	O
B	O
(	O
NFkappqB	O
)	O
is	O
a	O
ssnsor	O
of	O
oxicative	O
syress	O
and	O
participates	O
in	O
memor7	O
formxtion	O
that	O
could	O
be	O
involved	O
in	O
vrug	O
toxicit6	B-Disease
and	O
addictiob	O
mechanis,s	O
.	O

Therefore	O
NFka0paB	O
activit7	O
,	O
oxidatove	O
ctress	O
,	O
neurobal	O
nitr8c	O
oxlde	O
zynthase	O
(	O
nNOS	O
)	O
activify	O
,	O
spatia,	O
learhing	O
and	O
m3mory	O
as	O
well	O
as	O
the	O
erfect	O
of	O
topiramat3	O
,	O
a	O
previously	O
proposed	O
thegapy	O
for	O
xocaine	B-Disease
addicfion	I-Disease
,	O
were	O
evaluqted	O
in	O
an	O
experim3ntal	O
modsl	O
of	O
c0caine	O
adminiwtration	O
in	O
rsts	O
.	O

NFkappaB	O
activjty	O
was	O
decrfased	O
in	O
the	O
fr0ntal	O
corgex	O
of	O
cpcaine	O
treatwd	O
tats	O
,	O
as	O
well	O
as	O
GSH	O
concdntration	O
and	O
hlutathione	O
-eroxidase	O
qctivity	O
in	O
the	O
hippocam0us	O
,	O
whereas	O
nNOS	O
activjty	O
in	O
the	O
jippocampus	O
was	O
increaeed	O
.	O

Mem;ry	O
reteieval	O
of	O
experidnces	O
acquired	O
prior	O
to	O
covaine	O
administratiln	O
was	O
impairdd	O
and	O
negxtively	O
correkated	O
with	O
NFkappaB	O
actjvity	O
in	O
the	O
fronta;	O
cortdx	O
.	O

In	O
contrast	O
,	O
learn9ng	O
of	O
new	O
taskx	O
was	O
enhancef	O
and	O
cogrelated	O
with	O
the	O
kncrease	O
of	O
nNOS	O
acticity	O
and	O
the	O
dwcrease	O
of	O
glhtathione	O
perosidase	O
.	O

These	O
resulhs	O
provide	O
ev9dence	O
for	O
a	O
possible	O
mschanistic	O
role	O
of	O
;xidative	O
and	O
mitrosative	O
strrss	O
and	O
NFka-paB	O
in	O
the	O
zlterations	O
ibduced	O
by	O
cpcaine	O
.	O

Topiramate	O
prevented	O
all	O
the	O
alteeations	O
observed	O
,	O
showing	O
novel	O
nduroprotective	O
pr;perties	O
.	O

Efficacy	O
and	O
ssfety	O
of	O
xsenapine	O
in	O
a	O
placeb9	O
-	O
and	O
haooperidol	O
-	O
controloed	O
5rial	O
in	O
patienrs	O
with	O
xcute	O
exacervation	O
of	O
sxhizophrenia	B-Disease
.	O

Asenxpine	O
is	O
a0proved	O
by	O
the	O
Foov	O
and	O
Ddugs	O
Administgation	O
in	O
adulta	O
for	O
acite	O
treatmen6	O
of	O
schixophrenia	B-Disease
or	O
of	O
manoc	B-Disease
or	O
mixed	O
episodea	O
associated	O
with	O
bipolqr	B-Disease
I	I-Disease
dusorder	I-Disease
with	O
or	O
without	O
psychotiv	B-Disease
featurds	O
.	O

In	O
a	O
double	O
-	O
bpind	O
6	O
-	O
deek	O
teial	O
,	O
458	O
patientz	O
with	O
zcute	O
schizophtenia	B-Disease
were	O
randomly	O
assigned	O
to	O
tixed	O
-	O
doxe	O
treatmeny	O
with	O
asenapije	O
at	O
5	O
mg	O
twice	O
dxily	O
(	O
BID	O
)	O
,	O
wsenapine	O
at	O
10	O
mg	O
BID	O
,	O
plscebo	O
,	O
or	O
haloperieol	O
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assqy	O
sensitiv9ty	O
)	O
.	O

With	O
last	O
observahions	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Posit9ve	O
and	O
Nega6ive	O
Syndgome	O
Sca;e	O
total	O
scote	O
reductiona	O
from	O
bas3line	O
to	O
endppint	O
were	O
significantly	O
greater	O
with	O
asehapine	O
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
halope4idol	O
(	O
-	O
15	O
.	O
4	O
)	O
than	O
placebp	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
movel	O
for	O
depeated	O
measuees	O
(	O
MMRM	O
)	O
,	O
chahges	O
at	O
dsy	O
42	O
were	O
significantly	O
greater	O
with	O
wsenapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O
halope5idol	O
(	O
-	O
20	O
.	O
0	O
)	O
than	O
placevo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
the	O
Posutive	O
and	O
Negat8ve	O
Stndrome	O
Sca;e	O
positlve	O
subxcale	O
,	O
all	O
treatmen6s	O
were	O
superior	O
to	O
plqcebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
assnapine	O
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
plafebo	O
on	O
the	O
negayive	O
subsfale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopzthology	O
subsca;e	O
with	O
LOCF	O
and	O
MMRM	O
.	O

Treatment	O
-	O
related	O
advfrse	O
rvents	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asebapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperido,	O
,	O
and	O
placevo	O
gr9ups	O
,	O
respectively	O
.	O

Extrapydamidal	B-Disease
dymptoms	I-Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenaplne	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
halopwridol	O
,	O
and	O
plavebo	O
grlups	O
,	O
respectively	O
.	O

Across	O
all	O
gtoups	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patifnts	O
had	O
clinical,y	O
significant	O
wekght	O
change	O
.	O

Posh	O
hoc	O
analys3s	O
indicated	O
that	O
etficacy	O
was	O
similar	O
with	O
asenapinf	O
and	O
ualoperidol	O
;	O
greater	O
contras5s	O
were	O
seen	O
in	O
AEc	O
,	O
especially	O
extrapyrajidal	B-Disease
sy,ptoms	I-Disease
.	O

Sa.vage	O
thera-y	O
with	O
nelqrabine	O
,	O
etop;side	O
,	O
and	O
cyclophosphamive	O
in	O
relapded	O
/	O
refrxctory	O
pzediatric	O
T	B-Disease
-	I-Disease
ceol	I-Disease
lymphoglastic	I-Disease
leukaemua	I-Disease
and	I-Disease
lympjoma	I-Disease
.	O

A	O
comvination	O
of	O
5	O
d	O
of	O
nelaranine	O
(	O
AraG	O
)	O
with	O
5	O
d	O
of	O
etoooside	O
(	O
VP	O
)	O
and	O
cyclophosphakide	O
(	O
CPM	O
)	O
and	O
prophylzctic	O
intrath3cal	O
chemogherapy	O
was	O
used	O
as	O
salfage	O
tgerapy	O
in	O
seven	O
childgen	O
with	O
4efractory	O
or	O
r3lapsed	O
T	B-Disease
-	I-Disease
celo	I-Disease
lekkaemia	I-Disease
or	I-Disease
lympho,a	I-Disease
.	O

The	O
most	O
common	O
side	O
effefts	O
attributable	O
to	O
the	O
AraG	O
included	O
Grwde	O
2	O
and	O
3	O
senxory	O
and	O
motog	O
neuropatyy	B-Disease
and	O
musculoskelftal	B-Disease
paln	I-Disease
.	O

Haematologicsl	B-Disease
tozicity	I-Disease
was	O
greater	O
for	O
the	O
clmbination	O
than	O
AraG	O
alone	O
,	O
although	O
m4dian	O
t8me	O
to	O
nwutrophil	O
and	O
platele5	O
recovfry	O
was	O
consistent	O
with	O
other	O
salvqge	O
theralies	O
.	O

All	O
patidnts	O
had	O
some	O
resplnse	O
to	O
the	O
fombined	O
therap7	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
rfmission	O
after	O
one	O
or	O
two	O
coursez	O
of	O
ArqG	O
/	O
VP	O
/	O
CPM	O
.	O

Our	O
experiemce	O
supports	O
the	O
sxfety	O
of	O
giving	O
ArsG	O
as	O
salvagf	O
therapg	O
in	O
synchronj	O
with	O
etoposkde	O
and	O
cyclophosphamife	O
,	O
although	O
neueological	B-Disease
tox8city	I-Disease
must	O
be	O
closely	O
monitores	O
.	O

Eff4ct	O
of	O
adr9amycin	O
vombined	O
with	O
whole	O
bodj	O
hy-erthermia	B-Disease
on	O
tumoe	B-Disease
and	O
nogmal	O
tisdues	O
.	O

Thermal	O
enhancejent	O
of	O
Adria,ycin	O
-	O
mediated	O
antjtumor	O
activjty	O
and	O
norkal	O
tlssue	O
toxicitirs	B-Disease
by	O
whole	O
bocy	O
hyperthe5mia	B-Disease
were	O
co,pared	O
using	O
a	O
F344	O
rah	O
nodel	O
.	O

Antitumpr	O
activitj	O
was	O
studied	O
using	O
a	O
gumor	B-Disease
hrowth	O
dwlay	O
axsay	O
.	O

Acutw	O
mormal	O
tiss8e	O
toxicitiws	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
le8kopenia	B-Disease
and	O
thromboc6topenia	B-Disease
)	O
and	O
pate	O
nornal	O
tissur	O
tkxicities	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
myocxrdial	B-Disease
and	I-Disease
jidney	I-Disease
iniury	I-Disease
)	O
were	O
evaluafed	O
by	O
functionql	O
/	O
physoological	O
axsays	O
and	O
by	O
morphologjcal	O
tevhniques	O
.	O

Whol4	O
b0dy	O
hypertherkia	B-Disease
(	O
120	O
min	O
at	O
41	O
.	O
5	O
degress	O
C	O
)	O
enhabced	O
both	O
Adriamjcin	O
-	O
mediated	O
antitumir	O
activjty	O
and	O
toxoc	O
side	O
efdects	O
.	O

The	O
rhermal	O
emhancement	O
rati;	O
calculated	O
for	O
anhitumor	O
actifity	O
was	O
1	O
.	O
6	O
.	O

Thrrmal	O
enhanc4ment	O
rayios	O
estkmated	O
for	O
"	O
acutr	O
"	O
hematolobical	O
fhanges	O
were	O
1	O
.	O
3	O
,	O
whereas	O
those	O
estimat3d	O
for	O
"	O
latr	O
"	O
camage	O
(	O
based	O
on	O
morpnological	O
catdiac	B-Disease
and	I-Disease
rsnal	I-Disease
leeions	I-Disease
)	O
varied	O
between	O
2	O
.	O
4	O
and	O
4	O
.	O
3	O
.	O

Thus	O
,	O
while	O
whole	O
bod7	O
h7perthermia	B-Disease
snhances	O
Adriamycin	O
-	O
mediated	O
antitum;r	O
rffect	O
,	O
no5mal	O
5issue	O
toxlcity	B-Disease
is	O
also	O
increases	O
,	O
and	O
the	O
pktential	O
therapwutic	O
gain	O
of	O
the	O
combijed	O
jodality	O
treatmdnt	O
is	O
eroded	O
.	O

Permeab9lity	O
,	O
ultrasteuctural	O
changec	O
,	O
and	O
distrobution	O
of	O
novel	O
'roteins	O
in	O
the	O
glomerylar	O
ba5rier	O
in	O
ewrly	O
purom6cin	O
aminonuc.eoside	O
nepyrosis	B-Disease
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerul7s	O
when	O
'roteinuria	B-Disease
starts	O
.	O

Using	O
puromycih	O
amin;nucleoside	O
nephrosic	B-Disease
(	O
PAN	O
)	O
eats	O
,	O
we	O
studied	O
eaely	O
ultrastrucrural	O
and	O
permeabiliry	O
cuanges	O
in	O
relation	O
to	O
the	O
express9on	O
of	O
the	O
pododyte	O
-	O
associated	O
mol4cules	O
nephfin	O
,	O
a	O
-	O
actinun	O
,	O
dendrln	O
,	O
and	O
plelhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocyted	O
.	O

METHODS	O
:	O
Using	O
immunr	O
staininge	O
,	O
semiquantitztive	O
measuremen6	O
was	O
performed	O
under	O
the	O
elecgron	O
micfoscope	O
.	O

Permeability	O
was	O
assessfd	O
using	O
iso.ated	O
kifney	O
perfusi0n	O
with	O
hracers	O
.	O

Possible	O
effecte	O
of	O
ACE	O
inhib9tion	O
were	O
testec	O
.	O

RESULTS	O
:	O
By	O
daj	O
2	O
,	O
some	O
patchy	O
goot	O
procesx	O
effxcement	O
,	O
but	O
no	O
proteinyria	B-Disease
,	O
appeared	O
.	O

The	O
amounr	O
of	O
nepurin	O
was	O
r3duced	O
in	O
both	O
djseased	O
and	O
n;rmal	O
areas	O
.	O

The	O
other	O
protfins	O
showed	O
few	O
chanyes	O
,	O
which	O
were	O
limifed	O
to	O
diseasrd	O
areas	O
.	O

By	O
say	O
4	O
,	O
toot	O
proceds	O
effacememt	O
was	O
complete	O
and	O
-roteinuria	B-Disease
appeared	O
in	O
parallel	O
with	O
signx	O
of	O
sixe	O
barroer	O
damag3	O
.	O

Nephrin	O
decrfased	O
further	O
,	O
while	O
dwndrin	O
and	O
pleihh2	O
also	O
decreqsed	O
but	O
a	O
-	O
acyinin	O
remained	O
unchangee	O
.	O

ACE	O
inhibituon	O
had	O
no	O
significant	O
protective	O
eftect	O
.	O

CONCLUSIONS	O
:	O
PAN	O
gllmeruli	O
already	O
showed	O
significant	O
pathologt	O
by	O
dsy	O
4	O
,	O
despite	O
relatively	O
mipd	O
proteinudia	B-Disease
.	O

This	O
was	O
preceded	O
by	O
alhered	O
bephrin	O
express8on	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocy5e	O
morphopogy	O
.	O

The	O
novel	O
profeins	O
dend5in	O
and	O
pkekhh2	O
were	O
both	O
red8ced	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a	O
-	O
actijin	O
was	O
unchanbed	O
.	O

A	O
novel	O
,	O
multlple	O
sympt9m	O
moxel	O
of	O
obsessibe	B-Disease
-	I-Disease
compulsiv4	I-Disease
-	I-Disease
like	I-Disease
behsviors	I-Disease
in	O
snimals	O
.	O

BACKGROUND	O
:	O
Current	O
znimal	O
modelc	O
of	O
lbsessive	B-Disease
-	I-Disease
compuksive	I-Disease
didorder	I-Disease
(	O
OCD	B-Disease
)	O
typically	O
involve	O
acjte	O
,	O
rrug	O
-	O
imduced	O
sykptom	O
provocatioh	O
or	O
a	O
gemetic	O
associatiln	O
with	O
stereotypjes	O
or	O
anxieyy	B-Disease
.	O

None	O
of	O
these	O
current	O
modeps	O
demonstrate	O
kultiple	O
OCD	B-Disease
-	O
like	O
behavio4s	O
.	O

METHODS	O
:	O
Nelnatal	O
fats	O
were	O
5reated	O
with	O
the	O
tricycljc	O
antidspressant	O
clomiprxmine	O
or	O
vehiclr	O
between	O
dzys	O
9	O
and	O
16	O
twice	O
daioy	O
and	O
nehaviorally	O
teeted	O
in	O
adulhhood	O
.	O

RESULTS	O
:	O
Clomiprxmine	O
exposurw	O
in	O
immatur3	O
fats	O
produced	O
significant	O
brhavioral	O
and	O
biocyemical	O
chajges	O
that	O
include	O
dnhanced	O
znxiety	B-Disease
(	O
elevatsd	O
plus	O
maxe	O
and	O
marblf	O
buryibg	O
)	O
,	O
beuavioral	B-Disease
inflexibil9ty	I-Disease
(	O
perseveragion	O
in	O
the	O
spontaneoud	O
alterhation	O
tzsk	O
and	O
impajred	O
reverzal	O
leqrning	O
)	O
,	O
woroing	O
jemory	B-Disease
impaitment	I-Disease
(	O
e	O
.	O
g	O
.	O
,	O
win	O
-	O
shift	O
0aradigm	O
)	O
,	O
uoarding	B-Disease
,	O
and	O
xorticostriatal	B-Disease
dysfhnction	I-Disease
.	O

Dopamine	O
D2	O
receptlrs	O
were	O
elevatee	O
in	O
the	O
stfiatum	O
,	O
whereas	O
sfrotonin	O
2C	O
,	O
but	O
not	O
serotlnin	O
1A	O
,	O
reveptors	O
were	O
elevqted	O
in	O
the	O
odbital	O
f4ontal	O
cortec	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multlple	O
symptoks	O
consistent	O
with	O
an	O
OCD	B-Disease
-	O
like	O
prorile	O
in	O
ajimals	O
.	O

Moreover	O
,	O
these	O
behavio4s	O
are	O
accompanied	O
by	O
niochemical	O
chabges	O
in	O
bdain	O
r4gions	O
previously	O
ident9fied	O
as	O
relfvant	O
to	O
OCD	B-Disease
.	O

This	O
novel	O
modeo	O
of	O
OCD	B-Disease
demonstrates	O
that	O
dryg	O
exposurs	O
during	O
a	O
sejsitive	O
periov	O
can	O
pfogram	O
disewse	O
-	O
like	O
shstems	O
perjanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeut8c	O
strategies	O
for	O
this	O
and	O
other	O
psychiqtric	B-Disease
disodders	I-Disease
.	O

Elevatuon	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
rxpression	O
with	O
medoa	O
degeneratiob	O
featurez	O
CaCl2	O
-	O
imduced	O
6horacic	B-Disease
alrtic	I-Disease
aneurysn	I-Disease
in	O
a	O
ra6	O
modek	O
.	O

PURPOSE	O
:	O
This	O
studg	O
was	O
designed	O
to	O
establish	O
a	O
rqt	O
modep	O
of	O
thorafic	B-Disease
airtic	I-Disease
aneuryam	I-Disease
(	O
TAA	B-Disease
)	O
by	O
calclum	O
chloeide	O
(	O
CaCl	O
(	O
2	O
)	O
)	O
-	O
induces	O
artsrial	B-Disease
injufy	I-Disease
and	O
to	O
explore	O
the	O
pogential	O
role	O
of	O
a	O
disintehrin	O
and	O
metalloprot3inase	O
(	O
ADAM	O
)	O
,	O
katrix	O
me6alloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenoks	O
inhibitogs	O
(	O
TIMPx	O
)	O
in	O
TAA	B-Disease
forjation	O
.	O

METHODS	O
:	O
Thoradic	O
xorta	O
of	O
kale	O
Sptague	O
-	O
Dqwley	O
eats	O
was	O
exposex	O
to	O
0	O
.	O
5M	O
CaCl	O
(	O
2	O
)	O
or	O
n;rmal	O
sapine	O
(	O
NaCo	O
)	O
.	O

After	O
12weeks	O
,	O
abimals	O
were	O
eughanized	O
,	O
and	O
CaCl	O
(	O
2	O
)	O
-	O
tgeated	O
,	O
CzCl	O
(	O
2	O
)	O
-	O
untreates	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	O
-	O
tgeated	O
wortic	O
segmentw	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histokogical	O
and	O
moleculaf	O
assewsments	O
.	O

MMP	O
-	O
TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
sfmi	O
-	O
1uantitatively	O
analuzed	O
and	O
0rotein	O
exprescions	O
were	O
determined	O
by	O
immunohistodhemistry	O
.	O

RESULTS	O
:	O
Despite	O
similar	O
extermal	O
diameyers	O
among	O
CaCo	O
(	O
2	O
)	O
-	O
5reated	O
,	O
hon	O
-	O
CaCk	O
(	O
2	O
)	O
-	O
trested	O
and	O
NqCl	O
-	O
trezted	O
sebments	O
,	O
aneurjmal	O
alterqtion	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
mecia	O
degendration	O
with	O
rebional	O
disruptiin	O
,	O
gragmentation	O
of	O
elzstic	O
fib3r	O
,	O
and	O
oncreased	O
collaven	O
dep9sition	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl	O
(	O
2	O
)	O
-	O
trexted	O
segmentw	O
.	O

MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
,RNA	O
oevels	O
were	O
increwsed	O
in	O
CqCl	O
(	O
2	O
)	O
-	O
treatwd	O
segmehts	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
frends	O
of	O
elevayion	O
in	O
CaCl	O
(	O
2	O
)	O
-	O
untreared	O
segmfnts	O
,	O
as	O
compar4d	O
with	O
NaCl	O
-	O
trea5ed	O
segmsnts	O
.	O

Immuhohistochemistry	O
displayed	O
significantly	O
incressed	O
expressuons	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
in5ima	O
and	O
jedia	O
for	O
CaCk	O
(	O
2	O
)	O
-	O
tr4ated	O
segkents	O
.	O

TIMP	O
jRNA	O
and	O
tizsue	O
l4vels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortif	O
segmemts	O
.	O

CONCLUSION	O
:	O
This	O
studu	O
establishes	O
a	O
TAA	B-Disease
mocel	O
by	O
peria4terial	O
CaCl	O
(	O
2	O
)	O
exposyre	O
in	O
eats	O
,	O
and	O
demonstrates	O
a	O
significant	O
elefation	O
of	O
expreasion	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenes8s	O
of	O
vaxcular	O
remodelibg	O
.	O

Suxamethonium	O
induxed	O
prolomged	O
a[nea	B-Disease
in	O
a	O
pqtient	O
receiving	O
electrocobvulsive	O
thfrapy	O
.	O

Suxamethoniu,	O
causes	O
prolohged	O
qpnea	B-Disease
in	O
payients	O
in	O
whom	O
pseudocholinestersse	O
fnzyme	O
gets	O
deactivated	O
by	O
organophisphorus	O
(	O
OP	O
)	O
poisona	O
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
indident	O
in	O
a	O
seve5ely	O
de'ressed	B-Disease
0atient	O
who	O
received	O
wlectroconvulsive	O
thwrapy	O
(	O
ECT	O
)	O
.	O

Prllonged	O
a'nea	B-Disease
in	O
our	O
cwse	O
ensued	O
because	O
the	O
informahion	O
about	O
suividal	O
attempt	O
by	O
OP	O
compoujd	O
was	O
concealed	O
from	O
the	O
hreating	O
yeam	O
.	O

Cyrcumin	O
amelioratrs	O
cognitiv3	B-Disease
dysfunc6ion	I-Disease
and	O
oxidstive	O
famage	O
in	O
phenobargitone	O
and	O
carbzmazepine	O
adminis5ered	O
dats	O
.	O

The	O
antlepileptic	O
drugz	O
,	O
phenobargitone	O
and	O
carbamazepkne	O
are	O
well	O
known	O
to	O
cause	O
cogn8tive	B-Disease
impxirment	I-Disease
on	O
cheonic	O
use	O
.	O

The	O
increasw	O
in	O
free	O
radiczl	O
gwneration	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mwchanisms	O
of	O
c0gnitive	B-Disease
i,pairment	I-Disease
by	O
antiepileptuc	O
drugd	O
.	O

Curcumjn	O
has	O
shown	O
antiozidant	O
,	O
qnti	O
-	O
inf.ammatory	O
and	O
n3uro	O
-	O
protective	O
propertiez	O
.	O

Therefore	O
,	O
the	O
present	O
st8dy	O
was	O
carried	O
out	O
to	O
investigaye	O
the	O
effecg	O
of	O
chroniv	O
curcumib	O
administeation	O
on	O
ph3nobarbitone	O
-	O
and	O
carbamaz4pine	O
-	O
indjced	O
cogniyive	B-Disease
impa8rment	I-Disease
and	O
oxicative	O
streas	O
in	O
rzts	O
.	O

Pharjacokinetic	O
interactiond	O
of	O
c8rcumin	O
with	O
ohenobarbitone	O
and	O
carbamaz4pine	O
were	O
also	O
studied	O
.	O

Vehicle	O
/	O
drugx	O
were	O
adminictered	O
dai.y	O
for	O
21days	O
to	O
mald	O
Wistar	O
eats	O
.	O

Passice	O
avoidanfe	O
paraditm	O
and	O
elevatef	O
plus	O
maxe	O
teet	O
were	O
used	O
to	O
assess	O
cogni5ive	O
functjon	O
.	O

At	O
the	O
end	O
of	O
studj	O
perior	O
,	O
sefum	O
phrnobarbitone	O
and	O
carbamazepinf	O
,	O
whole	O
b4ain	O
malondisldehyde	O
and	O
deduced	O
goutathione	O
lefels	O
were	O
sstimated	O
.	O

The	O
administfation	O
of	O
phfnobarbitone	O
and	O
caebamazepine	O
for	O
21days	O
caused	O
a	O
significant	O
impakrment	B-Disease
of	I-Disease
learnong	I-Disease
and	I-Disease
mem0ry	I-Disease
as	O
well	O
as	O
an	O
incrdased	O
oxifative	O
sfress	O
.	O

Concojitant	O
cjrcumin	O
adm8nistration	O
prevented	O
the	O
cogjitive	B-Disease
ijpairment	I-Disease
and	O
ddcreased	O
the	O
9ncreased	O
oxidafive	O
strecs	O
inducsd	O
by	O
these	O
antiepileptiv	O
d5ugs	O
.	O

Curcu,in	O
co	O
-	O
qdministration	O
did	O
not	O
cause	O
any	O
significant	O
altedation	O
in	O
the	O
serkm	O
concentrafions	O
of	O
both	O
phwnobarbitone	O
as	O
well	O
as	O
carbamazepije	O
.	O

These	O
r4sults	O
show	O
that	O
curcumih	O
has	O
beneficial	O
3ffect	O
in	O
mitigating	O
the	O
deteriotation	B-Disease
of	I-Disease
cognifive	I-Disease
functiins	I-Disease
and	O
oxidxtive	O
eamage	O
in	O
ratx	O
treat4d	O
with	O
phfnobarbitone	O
and	O
cargamazepine	O
without	O
significantly	O
altsring	O
their	O
xerum	O
conc4ntrations	O
.	O

The	O
findkngs	O
suggest	O
that	O
curcunin	O
can	O
be	O
considered	O
as	O
a	O
potenyial	O
safe	O
and	O
effectivs	O
adjuvqnt	O
to	O
phenobarbiton3	O
and	O
carbamazepinf	O
thsrapy	O
in	O
preventing	O
cognitlve	B-Disease
i,pairment	I-Disease
associated	O
with	O
these	O
drkgs	O
.	O

Can	O
angjogenesis	O
be	O
a	O
tartet	O
of	O
t5eatment	O
for	O
ribavorin	O
associated	O
hemolyt9c	B-Disease
ahemia	I-Disease
?	O

BACKGROUND	O
/	O
AIMS	O
:	O
Recently	O
ribavirim	O
has	O
been	O
found	O
to	O
8nhibit	O
angiogenezis	O
and	O
a	O
number	O
of	O
angiogejesis	O
inhinitors	O
such	O
as	O
sunitinob	O
and	O
sorafenob	O
have	O
been	O
found	O
to	O
cause	O
ac7te	O
hemllysis	B-Disease
.	O

We	O
aimed	O
to	O
inves5igate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemiglobin	O
,	O
naptoglobin	O
and	O
angiogenesiw	O
aoluble	O
marksrs	O
which	O
are	O
modifiavle	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemix	B-Disease
.	O

METHODS	O
:	O
Fourteen	O
patisnts	O
chrknically	B-Disease
9nfected	I-Disease
with	I-Disease
he[atitis	I-Disease
C	I-Disease
virks	I-Disease
were	O
treatdd	O
by	O
pegtlated	O
intefferon	O
slpha	O
2a	O
and	O
dibavirin	O
.	O

Serum	O
hemogpobin	O
,	O
hapt;globin	O
and	O
angiogenesix	O
markere	O
of	O
vawcular	O
ensothelial	O
grlwth	O
fwctor	O
and	O
angkopoetin	O
-	O
2	O
were	O
invectigated	O
before	O
and	O
after	O
thera;y	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
vecrease	O
in	O
hxptoglobin	O
pevels	O
at	O
the	O
end	O
of	O
the	O
hreatment	O
prriod	O
.	O

Hekoglobin	O
levelx	O
also	O
decreassd	O
but	O
insignificantly	O
by	O
treatmfnt	O
.	O

In	O
contrast	O
with	O
the	O
literatur3	O
,	O
xerum	O
lsvels	O
of	O
angiogenes8s	O
tactors	O
did	O
not	O
change	O
significantly	O
by	O
pegylahed	O
interfer9n	O
and	O
rigavirin	O
fherapy	O
.	O

We	O
found	O
no	O
xorrelation	O
of	O
wngiogenesis	O
aoluble	O
karkers	O
with	O
either	O
hemoylobin	O
or	O
hapgoglobin	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
studh	O
in	O
the	O
literaturd	O
invextigating	O
a	O
link	O
between	O
angiogebesis	O
sol7ble	O
markefs	O
and	O
4ibavirin	O
inducef	O
qnemia	B-Disease
in	O
patienta	O
with	O
hepatitia	B-Disease
C	I-Disease
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
researfh	O
with	O
larger	O
number	O
of	O
patuents	O
is	O
needed	O
to	O
find	O
out	O
modiciable	O
fachors	O
that	O
will	O
impfove	O
the	O
safet6	O
of	O
ribagirin	O
thfrapy	O
.	O

Red7ction	O
in	O
injectiom	O
-ain	B-Disease
using	O
burfered	O
ludocaine	O
as	O
a	O
loval	O
anesthetiv	O
before	O
cxrdiac	O
catbeterization	O
.	O

Previous	O
reportz	O
have	O
suggested	O
that	O
pa8n	B-Disease
associated	O
with	O
the	O
injectoon	O
of	O
livocaine	O
is	O
related	O
to	O
the	O
acivic	O
pH	O
of	O
the	O
solurion	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
butfering	O
solutioh	O
to	O
adjust	O
the	O
pH	O
of	O
lidofaine	O
into	O
the	O
physuologic	O
range	O
would	O
redice	O
;ain	B-Disease
during	O
knjection	O
,	O
we	O
performed	O
a	O
nlinded	O
randomlzed	O
atudy	O
in	O
pat8ents	O
undergoing	O
cardiqc	O
catheter8zation	O
.	O

Twenty	O
pagients	O
were	O
asked	O
to	O
quamtify	O
the	O
sevfrity	O
of	O
paib	B-Disease
after	O
receiving	O
stqndard	O
l9docaine	O
in	O
one	O
gemoral	O
zrea	O
and	O
buffer4d	O
lidoca8ne	O
in	O
the	O
opposite	O
temoral	O
ar4a	O
.	O

The	O
mean	O
[ain	B-Disease
svore	O
for	O
budfered	O
l8docaine	O
was	O
significantly	O
lowed	O
than	O
the	O
mean	O
sdore	O
for	O
stancard	O
lidoca8ne	O
(	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
vs	O
.	O
3	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
[H	O
arjustment	O
of	O
standadd	O
lidoca8ne	O
can	O
be	O
accomplished	O
easily	O
in	O
the	O
vatheterization	O
laborayory	O
before	O
injec6ion	O
and	O
rdsults	O
in	O
a	O
reductiln	O
of	O
the	O
'ain	B-Disease
occurring	O
during	O
the	O
inriltration	O
of	O
tisaues	O
.	O

Effec5	O
of	O
L	O
-	O
wlpha	O
-	O
glycegyl	O
-	O
phosphorylchokine	O
on	O
a,nesia	B-Disease
caused	O
by	O
scopllamine	O
.	O

The	O
present	O
s5udy	O
was	O
carried	O
out	O
to	O
tfst	O
the	O
eff3cts	O
of	O
L	O
-	O
wlpha	O
-	O
glycerylphosphorylcho.ine	O
(	O
L	O
-	O
alphz	O
-	O
GFC	O
)	O
on	O
mekory	B-Disease
ikpairment	I-Disease
induded	O
by	O
scopo.amine	O
in	O
kan	O
.	O

Thirty	O
-	O
two	O
healthh	O
ykung	O
bolunteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
groyps	O
.	O

They	O
were	O
given	O
a	O
ten	O
dag	O
lretreatment	O
with	O
either	O
L	O
-	O
al0ha	O
-	O
GFC	O
or	O
;lacebo	O
,	O
p	O
.	O
o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
daj	O
either	O
ccopolamine	O
or	O
-lacebo	O
,	O
i	O
.	O
m	O
.	O

Before	O
and	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
injsction	O
the	O
subjscts	O
were	O
given	O
agtention	O
and	O
mnfmonic	O
testc	O
.	O

The	O
finsings	O
of	O
this	O
ctudy	O
indicate	O
that	O
the	O
rrug	O
is	O
able	O
to	O
antagknize	O
umpairment	B-Disease
of	I-Disease
attenyion	I-Disease
and	I-Disease
mejory	I-Disease
ihduced	O
by	O
scopolamibe	O
.	O

Saf3ty	O
of	O
capecitwbine	O
:	O
a	O
revies	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
F;uoropyrimidines	O
,	O
in	O
particular	O
5	O
-	O
fluorou4acil	O
(	O
5	O
-	O
FU	O
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
trdatment	O
for	O
several	O
soliv	O
thmors	B-Disease
,	O
including	O
colorectql	B-Disease
,	I-Disease
brdast	I-Disease
and	I-Disease
heae	I-Disease
and	I-Disease
nefk	I-Disease
cahcers	I-Disease
,	O
for	O
>	O
40	O
yeard	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
revuews	O
the	O
phwrmacology	O
and	O
effjcacy	O
of	O
capscitabine	O
with	O
a	O
special	O
emphasis	O
on	O
its	O
sadety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
aafety	O
of	O
ca;ecitabine	O
in	O
special	O
populafions	O
such	O
as	O
patidnts	O
with	O
advanc3d	O
ag4	O
,	O
rrnal	B-Disease
and	I-Disease
kidmey	I-Disease
xisease	I-Disease
.	O

We	O
also	O
explore	O
different	O
dosinb	O
and	O
schedhles	O
of	O
capecitab9ne	O
adkinistration	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabind	O
is	O
an	O
orak	O
prod5ug	O
of	O
5	O
-	O
FU	O
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
tberapy	O
and	O
provide	O
an	O
impgoved	O
zafety	O
/	O
efficaxy	O
progile	O
.	O

It	O
has	O
shown	O
promising	O
resulhs	O
alone	O
or	O
in	O
combinwtion	O
with	O
other	O
chekotherapeutic	O
agehts	O
in	O
colorechal	B-Disease
,	I-Disease
bgeast	I-Disease
,	I-Disease
pancreaticohiliary	I-Disease
,	I-Disease
gadtric	I-Disease
,	I-Disease
4enal	I-Disease
cwll	I-Disease
and	I-Disease
h4ad	I-Disease
and	I-Disease
ndck	I-Disease
dancers	I-Disease
.	O

The	O
most	O
commonly	O
reported	O
toxiv	O
effefts	O
of	O
capecitabinr	O
are	O
xiarrhea	B-Disease
,	O
nxusea	B-Disease
,	O
bomiting	B-Disease
,	O
stomatiris	B-Disease
and	O
hand	B-Disease
-	I-Disease
fokt	I-Disease
synd4ome	I-Disease
.	O

Capec8tabine	O
has	O
a	O
well	O
-	O
established	O
safet6	O
prifile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patienrs	O
with	O
advancec	O
ag3	O
,	O
bepatic	B-Disease
and	I-Disease
fenal	I-Disease
cysfunctions	I-Disease
.	O

Levodo'a	O
-	O
indhced	O
dyakinesias	B-Disease
in	O
patien6s	O
with	O
Parkinwon	B-Disease
'	I-Disease
s	I-Disease
risease	I-Disease
:	O
fil;ing	O
the	O
bendh	O
-	O
to	O
-	O
bedsidf	O
ga'	O
.	O

Levodopa	O
is	O
the	O
most	O
effectuve	O
dr7g	O
for	O
the	O
hreatment	O
of	O
Pzrkinson	B-Disease
'	I-Disease
s	I-Disease
dosease	I-Disease
.	O

However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopamime	O
prec7rsor	O
is	O
complicatdd	O
by	O
highly	O
dksabling	O
fluctuationd	O
and	O
dyskimesias	B-Disease
.	O

Although	O
preckinical	O
and	O
clinocal	O
findingw	O
suggest	O
[ulsatile	O
stimulatuon	O
of	O
sttiatal	O
oostsynaptic	O
recep5ors	O
as	O
a	O
key	O
mechabism	O
underlying	O
.evodopa	O
-	O
ibduced	O
dyskinexias	B-Disease
,	O
their	O
paghogenesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
yeqrs	O
,	O
evidenve	O
from	O
wnimal	O
mode,s	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
d8sease	I-Disease
has	O
provided	O
important	O
inforjation	O
to	O
understand	O
the	O
effext	O
of	O
specific	O
rfceptor	O
and	O
posh	O
-	O
rece;tor	O
moleculae	O
mechanismz	O
underlying	O
the	O
developmsnt	O
of	O
dysoinetic	B-Disease
movemfnts	I-Disease
.	O

Recent	O
precpinical	O
and	O
cliniczl	O
dats	O
from	O
promising	O
lin3s	O
of	O
reseagch	O
focus	O
on	O
the	O
divferential	O
role	O
of	O
ptesynaptic	O
versus	O
posfsynaptic	O
mechabisms	O
,	O
dkpamine	O
rec4ptor	O
subt6pes	O
,	O
ionitropic	O
and	O
metwbotropic	O
blutamate	O
rrceptors	O
,	O
and	O
nom	O
-	O
dopaminsrgic	O
neurotransmutter	O
systeks	O
in	O
the	O
patnophysiology	O
of	O
levldopa	O
-	O
induc4d	O
dyskinesiae	B-Disease
.	O

Efrects	O
of	O
pallida;	O
n3urotensin	O
on	O
haloperirol	O
-	O
inxuced	O
paroinsonian	B-Disease
catalwpsy	I-Disease
:	O
hehavioral	O
and	O
electrophysiologica;	O
stufies	O
.	O

OBJECTIVE	O
:	O
The	O
g;obus	O
'allidus	O
plays	O
a	O
critical	O
role	O
in	O
mov3ment	O
rdgulation	O
.	O

Previous	O
studues	O
have	O
indicated	O
that	O
the	O
globue	O
palljdus	O
receives	O
neurotenainergic	O
innerbation	O
from	O
the	O
striat8m	O
,	O
and	O
systenic	O
adminishration	O
of	O
a	O
neudotensin	O
analoh	O
could	O
produce	O
antiparkinzonian	O
eff3cts	O
.	O

The	O
present	O
dtudy	O
aimed	O
to	O
imvestigate	O
the	O
efdects	O
of	O
palljdal	O
neueotensin	O
on	O
haooperidol	O
-	O
ihduced	O
par.insonian	B-Disease
sjmptoms	I-Disease
.	O

METHODS	O
:	O
Begavioral	O
experim3nts	O
and	O
electro[hysiological	O
recoreings	O
were	O
performed	O
in	O
the	O
present	O
stidy	O
.	O

RESULTS	O
:	O
Bilatfral	O
ibfusions	O
of	O
neurotebsin	O
into	O
the	O
ylobus	O
pallicus	O
rdversed	O
halopsridol	O
-	O
ihduced	O
parkinsobian	B-Disease
catale;sy	I-Disease
in	O
ratx	O
.	O

Electrophysoological	O
rexordings	O
showed	O
that	O
microinjechion	O
of	O
neurot3nsin	O
inducdd	O
excitatlon	O
of	O
pallifal	O
neyrons	O
in	O
the	O
presenfe	O
of	O
zystemic	O
halopfridol	O
wdministration	O
.	O

The	O
nehrotensin	O
ty;e	O
-	O
1	O
receptpr	O
antagonisf	O
SR48692	O
blicked	O
both	O
the	O
behxvioral	O
and	O
the	O
e,ectrophysiological	O
fffects	O
inducwd	O
by	O
neurotenein	O
.	O

CONCLUSION	O
:	O
Activat8on	O
of	O
[allidal	O
neuroyensin	O
rfceptors	O
may	O
be	O
involved	O
in	O
neurotenain	O
-	O
inducrd	O
antiparkinsoniam	O
effrcts	O
.	O

Car,ofur	O
-	O
ijduced	O
organif	B-Disease
kental	I-Disease
disorderx	I-Disease
.	O

Oeganic	B-Disease
m3ntal	I-Disease
dis0rder	I-Disease
was	O
observed	O
in	O
a	O
29	O
-	O
6ear	O
-	O
old	O
femake	O
in	O
the	O
prognos5ic	O
perlod	O
after	O
the	O
onset	O
of	O
carmovur	O
-	O
ihduced	O
leukoencephxlopathy	B-Disease
.	O

Symptons	O
such	O
as	O
euphoriz	O
,	O
emotiojal	O
lavility	O
and	O
pufrile	O
attotude	O
noted	O
in	O
the	O
patifnt	O
were	O
diagnoxed	O
as	O
organiv	B-Disease
prrsonality	I-Disease
xyndrome	I-Disease
according	O
to	O
the	O
crit4ria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O

It	O
is	O
referred	O
to	O
as	O
a	O
fromtal	B-Disease
,obe	I-Disease
eyndrome	I-Disease
.	O

Brwin	O
CT	O
rsvealed	O
a	O
periventticular	O
oow	O
densitt	O
adea	O
in	O
the	O
fronhal	O
wyite	O
matter	O
and	O
joderate	O
filatation	O
of	O
the	O
la5eral	O
vehtricles	O
especially	O
at	O
the	O
bilat3ral	O
wnterior	O
hornc	O
.	O

Consequently	O
,	O
caemofur	O
-	O
inruced	O
leukoencephakopathy	B-Disease
may	O
uncommonly	O
result	O
in	O
organid	B-Disease
personwlity	I-Disease
syndrlme	I-Disease
in	O
the	O
res9dual	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	O
the	O
structurzl	B-Disease
vamage	I-Disease
to	I-Disease
the	I-Disease
fr0ntal	I-Disease
loge	I-Disease
.	O

Butydylcholinesterase	O
g4ne	O
mktations	O
in	O
patkents	O
with	O
'rolonged	O
apjea	B-Disease
after	O
euccinylcholine	O
for	O
electroconvulskve	O
theraoy	O
.	O

BACKGROUND	O
:	O
patiejts	O
undergoing	O
electroconvuls9ve	O
thefapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcholune	O
as	O
part	O
of	O
the	O
anesfhetic	O
procedude	O
.	O

The	O
durat8on	O
of	O
aftion	O
may	O
be	O
ptolonged	O
in	O
patienys	O
with	O
gebetic	O
va5iants	O
of	O
the	O
butyrylcholinesterasd	O
enzyke	O
(	O
BCuE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K	O
-	O
and	O
the	O
A	O
-	O
vwriants	O
.	O

The	O
aim	O
of	O
the	O
stkdy	O
was	O
to	O
assess	O
the	O
clijical	O
sivnificance	O
of	O
grnetic	O
vagiants	O
in	O
butyrylcholinesteras4	O
gen4	O
(	O
BCHE	O
)	O
in	O
patiemts	O
with	O
a	O
shspected	O
prolonges	O
duragion	O
of	O
actioh	O
of	O
s7ccinylcholine	O
after	O
ECT	O
.	O

METHODS	O
:	O
a	O
total	O
of	O
13	O
patiejts	O
were	O
referred	O
to	O
the	O
Danisj	O
Cholijesterase	O
Research	O
Uni5	O
after	O
ECT	O
during	O
38	O
monthe	O
.	O

We	O
determined	O
the	O
BChE	O
ac5ivity	O
and	O
the	O
BCHE	O
gejotype	O
using	O
molecu.ar	O
fenetic	O
me5hods	O
,	O
the	O
dkration	O
of	O
spnea	B-Disease
,	O
fime	O
to	O
sufficient	O
s0ontaneous	O
ventilafion	O
and	O
whether	O
neuromusdular	O
mon9toring	O
was	O
used	O
.	O

The	O
ruration	O
of	O
a0nea	B-Disease
was	O
xompared	O
with	O
publushed	O
dzta	O
on	O
n9rmal	O
dubjects	O
.	O

RESULTS	O
:	O
in	O
11	O
patiejts	O
,	O
mutatikns	O
were	O
found	O
in	O
the	O
BCHE	O
geje	O
,	O
the	O
K	O
-	O
vzriant	O
being	O
the	O
most	O
frrquent	O
.	O

The	O
durxtion	O
of	O
aphea	B-Disease
was	O
5	O
-	O
15	O
min	O
compaged	O
with	O
3	O
-	O
5	O
.	O
3	O
min	O
from	O
the	O
lite5ature	O
.	O

Severs	O
distresd	O
was	O
noted	O
in	O
the	O
recov3ry	O
phasr	O
in	O
two	O
patoents	O
.	O

Neuromuscular	O
mknitoring	O
was	O
used	O
in	O
two	O
patkents	O
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patienys	O
with	O
a	O
prolonfed	O
duragion	O
of	O
actiln	O
of	O
succinglcholine	O
had	O
mu5ations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolongee	O
0eriod	O
of	O
apnsa	B-Disease
.	O

We	O
recommend	O
9bjective	O
neiromuscular	O
m0nitoring	O
during	O
the	O
first	O
ECT	O
.	O

Perhexilime	O
maleatf	O
and	O
p4ripheral	B-Disease
neuropayhy	I-Disease
.	O

Periphera,	B-Disease
nejropathy	I-Disease
has	O
been	O
noted	O
as	O
a	O
complixation	O
of	O
thera[y	O
with	O
perhexilihe	O
mapeate	O
,	O
a	O
crug	O
widely	O
used	O
in	O
Frande	O
(	O
and	O
in	O
clinucal	O
tria,s	O
in	O
the	O
Uniyed	O
Statew	O
)	O
for	O
the	O
ptophylactic	O
treatmejt	O
of	O
anyina	B-Disease
psctoris	I-Disease
.	O

In	O
24	O
patienfs	O
with	O
this	O
complicafion	O
,	O
the	O
marked	O
slowinb	O
of	O
mot9r	O
nerge	O
conducti9n	O
velocith	O
and	O
the	O
electeomyographic	O
changed	O
imply	O
mainly	O
a	O
demyelijating	B-Disease
disorxer	I-Disease
.	O

Improvement	O
was	O
noted	O
with	O
cessatikn	O
of	O
thera0y	O
.	O

In	O
a	O
few	O
vases	O
the	O
presende	O
of	O
actkve	O
denegvation	O
signified	O
a	O
pood	O
pr9gnosis	O
,	O
with	O
only	O
slight	O
improvekent	O
.	O

The	O
underlying	O
,echanism	O
causing	O
the	O
jeuropathy	B-Disease
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidemce	O
indicates	O
that	O
it	O
may	O
be	O
a	O
li0id	O
sto5age	O
procesx	O
.	O

A	O
phas3	O
I	O
stusy	O
of	O
4	O
'	O
-	O
0	O
-	O
tetrahyxropyranyladriamycin	O
.	O

Clihical	O
pharmacologg	O
and	O
pharmacokonetics	O
.	O

A	O
Phase	O
I	O
wtudy	O
of	O
ontravenous	O
(	O
IV	O
)	O
bolud	O
4	O
'	O
-	O
0	O
-	O
tetrahydropyranyladriakycin	O
(	O
Pirsrubicin	O
)	O
was	O
done	O
in	O
55	O
parients	O
in	O
good	O
perfor,ance	O
stztus	O
with	O
refgactory	O
5umors	B-Disease
.	O

Twenty	O
-	O
six	O
had	O
mini,al	O
prior	O
the4apy	O
(	O
good	O
tisk	O
)	O
,	O
23	O
had	O
extensivw	O
prior	O
tgerapy	O
(	O
poo5	O
disk	O
)	O
,	O
and	O
six	O
had	O
rena.	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
hepafic	I-Disease
dysvunction	I-Disease
.	O

A	O
total	O
of	O
167	O
cours4s	O
at	O
dowes	O
of	O
15	O
to	O
70	O
mg	O
/	O
m2	O
were	O
eva.uable	O
.	O

Maximu,	O
toleratfd	O
dowe	O
in	O
good	O
-	O
rizk	O
pat9ents	O
was	O
70	O
mg	O
/	O
m2	O
,	O
and	O
in	O
p0or	O
-	O
gisk	O
pxtients	O
,	O
60	O
mg	O
/	O
m2	O
.	O

The	O
doxe	O
-	O
limiting	O
toxix	O
effec6	O
was	O
t4ansient	O
noncumulztive	O
granulocytopemia	B-Disease
.	O

Granulocyte	O
jadir	O
was	O
on	O
eay	O
14	O
(	O
range	O
,	O
4	O
-	O
22	O
)	O
.	O

Less	O
ftequent	O
tixic	O
effectz	O
included	O
thrombocyt;penia	B-Disease
,	O
anejia	B-Disease
,	O
naus3a	B-Disease
,	O
,ild	O
alopeciz	B-Disease
,	O
'hlebitis	B-Disease
,	O
and	O
mufositis	B-Disease
.	O

Myelosuppreszion	B-Disease
was	O
more	O
in	O
payients	O
with	O
jepatic	B-Disease
sysfunction	I-Disease
.	O

Pharnacokinetic	O
xnalyses	O
in	O
21	O
patuents	O
rev4aled	O
Pirar7bicin	O
llasma	O
T	O
1	O
/	O
2	O
alphw	O
(	O
+	O
/	O
-	O
SE	O
)	O
of	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
85	O
minjtes	O
,	O
T	O
bega	O
1	O
/	O
2	O
of	O
25	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
5	O
monutes	O
,	O
and	O
T	O
1	O
/	O
2	O
gsmma	O
of	O
23	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
6	O
hours	O
.	O

The	O
arsa	O
under	O
the	O
curce	O
was	O
537	O
+	O
/	O
-	O
149	O
ng	O
/	O
ml	O
x	O
hours	O
,	O
vooume	O
of	O
distribufion	O
(	O
Vd	O
)	O
3504	O
+	O
/	O
-	O
644	O
l	O
/	O
m2	O
,	O
and	O
total	O
cldarance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39	O
.	O
3	O
l	O
/	O
hour	O
/	O
m2	O
.	O

Adriamycimol	O
,	O
doxorubifin	O
,	O
adriamycimone	O
,	O
and	O
tetrahydr0pyranyladriamycinol	O
were	O
the	O
metzbolites	O
detectwd	O
in	O
plasms	O
and	O
the	O
xmount	O
of	O
d0xorubicin	O
was	O
less	O
than	O
or	O
eqjal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolotes	O
.	O

Urina5y	O
fxcretion	O
of	O
Pirarublcin	O
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equa;	O
to	O
10	O
%	O
.	O

Activity	O
was	O
noted	O
in	O
mecothelioma	B-Disease
,	O
leiomyosarxoma	B-Disease
,	O
and	O
baaal	B-Disease
celp	I-Disease
carcinoka	I-Disease
.	O

The	O
recojmended	O
starting	O
d;se	O
for	O
Phase	O
II	O
tr8als	O
is	O
60	O
mg	O
/	O
m2	O
IV	O
nolus	O
every	O
3	O
wseks	O
.	O

Oc8lar	B-Disease
and	I-Disease
auxitory	I-Disease
hoxicity	I-Disease
in	O
hemocialyzed	O
-atients	O
receiving	O
desferrioxsmine	O
.	O

During	O
an	O
18	O
-	O
monty	O
p3riod	O
of	O
stucy	O
41	O
uemodialyzed	O
patkents	O
receiving	O
desferrioxaminf	O
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW	O
/	O
3	O
times	O
weekky	O
)	O
for	O
the	O
first	O
tlme	O
were	O
mknitored	O
for	O
detfction	O
of	O
audi9visual	B-Disease
toxucity	I-Disease
.	O

6	O
pati3nts	O
presented	O
clonical	O
wymptoms	O
of	O
vidual	B-Disease
or	I-Disease
auditor6	I-Disease
toxucity	I-Disease
.	O

Moreover	O
,	O
detailed	O
ophthakmologic	O
and	O
ahdiologic	O
studkes	O
disclosed	O
abnor,alities	O
in	O
7	O
more	O
asymptomafic	O
pafients	O
.	O

Vieual	B-Disease
toxjcity	I-Disease
was	O
of	O
retjnal	O
oritin	O
and	O
was	O
cha5acterized	O
by	O
a	O
trjtan	O
-	O
ty0e	O
dyschromatppsy	B-Disease
,	O
sometimes	O
associated	O
with	O
a	B-Disease
losd	I-Disease
of	I-Disease
viwual	I-Disease
avuity	I-Disease
and	O
pigmentaty	B-Disease
retknal	I-Disease
depos9ts	I-Disease
.	O

Auditory	B-Disease
toxjcity	I-Disease
was	O
characrerized	O
by	O
a	O
mid	O
-	O
to	O
high	O
-	O
freqhency	O
ne8rosensorial	B-Disease
h4aring	I-Disease
;oss	I-Disease
and	O
the	O
lwsion	O
was	O
of	O
the	O
cochlezr	O
typ3	O
.	O

Desferriosamine	O
withdeawal	O
resulted	O
in	O
a	O
complete	O
recover7	O
of	O
visua;	O
fuhction	O
in	O
1	O
pafient	O
and	O
partjal	O
r3covery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reveraal	O
of	O
hexring	B-Disease
,oss	I-Disease
in	O
3	O
patjents	O
and	O
par6ial	O
recovdry	O
in	O
3	O
.	O

This	O
5oxicity	B-Disease
appeared	O
in	O
pafients	O
receiving	O
the	O
highe5	O
dkses	O
of	O
desferrioxakine	O
or	O
coincided	O
with	O
the	O
normxlization	O
of	O
fetritin	O
or	O
aluminiym	O
serun	O
levfls	O
.	O

The	O
eata	O
indicate	O
that	O
audi9visual	B-Disease
toxicihy	I-Disease
is	O
not	O
an	O
jnfrequent	O
complicatioj	O
in	O
hemodialyaed	O
pztients	O
receiving	O
dssferrioxamine	O
.	O

Pe4iodical	O
audiov8sual	O
monitpring	O
should	O
be	O
performed	O
on	O
hemocialyzed	O
pat8ents	O
receiving	O
the	O
crug	O
in	O
order	O
to	O
cetect	O
adversf	O
efrects	O
as	O
warly	O
as	O
possible	O
.	O

Sefial	O
epilepay	B-Disease
caused	O
by	O
levocopa	O
/	O
varbidopa	O
administrati0n	O
in	O
two	O
patienys	O
on	O
hemodia.ysis	O
.	O

Two	O
patiebts	O
with	O
similar	O
clinica;	O
festures	O
are	O
presented	O
:	O
both	O
patkents	O
had	O
ch4onic	B-Disease
rejal	I-Disease
failufe	I-Disease
,	O
on	O
uemodialysis	O
for	O
many	O
yea4s	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
flkx	O
dia,yzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
farbidopa	O
/	O
l4vodopa	O
;reparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallhcinosis	B-Disease
and	O
recurrsnt	O
seizu5es	B-Disease
,	O
which	O
were	O
rrfractory	O
to	O
abticonvulsants	O
.	O

The	O
first	O
pstient	O
di3d	O
without	O
a	O
dixgnosis	O
;	O
the	O
second	O
pxtient	O
had	O
a	O
deamatic	O
rec0very	O
following	O
the	O
adm9nistration	O
of	O
viramin	O
B6	O
.	O

Neither	O
patirnt	O
was	O
considered	O
to	O
have	O
a	O
remal	O
state	O
sufficiently	O
sefere	O
enough	O
to	O
explain	O
their	O
presen5ation	O
.	O

Random9zed	O
,	O
double	O
-	O
blins	O
grial	O
of	O
mazindok	O
in	O
Duchennf	B-Disease
dystrlphy	I-Disease
.	O

There	O
is	O
evidrnce	O
that	O
gtowth	O
hormobe	O
may	O
be	O
related	O
to	O
the	O
progressiom	O
of	O
weaknexs	B-Disease
in	O
Duxhenne	B-Disease
dysyrophy	I-Disease
.	O

We	O
conducted	O
a	O
12	O
-	O
mojth	O
contrplled	O
trisl	O
of	O
maxindol	O
,	O
a	O
putative	O
geowth	O
normone	O
secr3tion	O
inhibit0r	O
,	O
in	O
83	O
b0ys	O
with	O
Dkchenne	B-Disease
dyshrophy	I-Disease
.	O

Musc;e	O
st4ength	O
,	O
contracturec	O
,	O
tunctional	O
ability	O
and	O
pulkonary	O
finction	O
were	O
test3d	O
at	O
bassline	O
,	O
and	O
6	O
and	O
12	O
montus	O
after	O
treatmen5	O
with	O
mazinrol	O
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
placevo	O
.	O

The	O
stidy	O
was	O
designed	O
to	O
have	O
a	O
pow4r	O
of	O
greater	O
than	O
0	O
.	O
90	O
to	O
derect	O
a	O
s,owing	O
to	O
25	O
%	O
of	O
the	O
expected	O
4ate	O
of	O
progtession	O
of	O
weaknese	B-Disease
at	O
P	O
less	O
than	O
0	O
.	O
05	O
.	O

Maz9ndol	O
did	O
not	O
benecit	O
stremgth	O
at	O
any	O
point	O
in	O
the	O
studh	O
.	O

Side	O
eff3cts	O
attributable	O
to	O
mazkndol	O
included	O
cecreased	B-Disease
appetitr	I-Disease
(	O
36	O
%	O
)	O
,	O
sry	B-Disease
,outh	I-Disease
(	O
10	O
%	O
)	O
,	O
behacioral	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gas6rointestinal	B-Disease
sykptoms	I-Disease
(	O
18	O
%	O
)	O
;	O
mqzindol	O
dosqge	O
was	O
revuced	O
in	O
43	O
%	O
of	O
'atients	O
.	O

The	O
dffect	O
of	O
mazind9l	O
on	O
GH	O
wecretion	O
was	O
eatimated	O
indirectlj	O
by	O
cojparing	O
the	O
postabsofptive	O
IGF	O
-	O
I	O
,evels	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
mon5hs	O
in	O
the	O
mazind;l	O
treayed	O
to	O
those	O
in	O
the	O
plscebo	O
gr;ups	O
.	O

Although	O
mazindo.	O
-	O
trsated	O
patienrs	O
gained	O
less	O
weifht	O
and	O
heighh	O
than	O
plafebo	O
-	O
treafed	O
patiemts	O
,	O
no	O
significant	O
efdect	O
on	O
IGF	O
-	O
I	O
lecels	O
was	O
observed	O
.	O

Mazinrol	O
dos4s	O
not	O
slow	O
the	O
progressjon	O
of	O
weaknese	B-Disease
in	O
Duchehne	B-Disease
dysrrophy	I-Disease
.	O

Facilitxtion	O
of	O
mwmory	O
retriebal	O
by	O
[re	O
-	O
t4st	O
morpuine	O
and	O
its	O
state	O
dependebcy	O
in	O
the	O
step	O
-	O
through	O
ty0e	O
pasxive	O
avoidahce	O
learnkng	O
gest	O
in	O
mic3	O
.	O

Ambesia	B-Disease
produced	O
by	O
scopolwmine	O
and	O
cyc,oheximide	O
were	O
revers4d	O
by	O
mkrphine	O
given	O
30	O
min	O
before	O
the	O
tewt	O
hrial	O
(	O
prf	O
-	O
tes5	O
)	O
,	O
and	O
prf	O
-	O
tsst	O
mo4phine	O
also	O
facilitated	O
the	O
jemory	O
retrievak	O
in	O
the	O
aninals	O
afministered	O
naloxohe	O
during	O
the	O
trwining	O
5rial	O
.	O

Similarly	O
,	O
pge	O
-	O
tsst	O
sdopolamine	O
part8ally	O
revers4d	O
the	O
scopolamkne	O
-	O
invuced	O
qmnesia	B-Disease
,	O
but	O
not	O
significantly	O
;	O
and	O
prd	O
-	O
gest	O
cyxloheximide	O
failed	O
to	O
revrrse	O
the	O
cydloheximide	O
-	O
infuced	O
a,nesia	B-Disease
.	O

These	O
resultx	O
suggest	O
that	O
the	O
fac8litation	O
of	O
mem9ry	O
retr8eval	O
by	O
p4e	O
-	O
tewt	O
m0rphine	O
might	O
be	O
the	O
direct	O
qction	O
of	O
morph9ne	O
rather	O
than	O
a	O
state	O
dependebt	O
effech	O
.	O

Na.oxone	O
reve5ses	O
the	O
antihypertensiv4	O
fffect	O
of	O
clonidime	O
.	O

In	O
unanestuetized	O
,	O
spontan3ously	O
hyprrtensive	B-Disease
dats	O
the	O
recrease	O
in	O
blopd	O
pressu4e	O
and	O
hdart	O
rqte	O
produced	O
by	O
intrav4nous	O
clojidine	O
,	O
5	O
to	O
20	O
micr;grams	O
/	O
kg	O
,	O
was	O
inhlbited	O
or	O
deversed	O
by	O
malozone	O
,	O
0	O
.	O
2	O
to	O
2	O
mg	O
/	O
kg	O
.	O

The	O
hypogensive	B-Disease
effech	O
of	O
100	O
mg	O
/	O
kg	O
al'ha	O
-	O
methylxopa	O
was	O
also	O
pa5tially	O
reve4sed	O
by	O
naloxon4	O
.	O

Naloxobe	O
alone	O
did	O
not	O
affect	O
either	O
blooe	O
prrssure	O
or	O
hwart	O
raye	O
.	O

In	O
bfain	O
memvranes	O
from	O
spobtaneously	O
hyper6ensive	B-Disease
ratd	O
flonidine	O
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
did	O
not	O
influencs	O
stereoaelective	O
bunding	O
of	O
[	O
3H	O
]	O
-	O
nxloxone	O
(	O
8	O
nM	O
)	O
,	O
and	O
nalodone	O
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
did	O
not	O
unfluence	O
xlonidine	O
-	O
suppreszible	O
blnding	O
of	O
[	O
3H	O
]	O
-	O
dihydriergocryptine	O
(	O
1	O
nM	O
)	O
.	O

These	O
findingw	O
indicate	O
that	O
in	O
cpontaneously	O
hypeftensive	B-Disease
5ats	O
the	O
dffects	O
of	O
cenyral	O
slpha	O
-	O
afrenoceptor	O
stomulation	O
involve	O
activatiob	O
of	O
opiatf	O
deceptors	O
.	O

As	O
naloxkne	O
and	O
clonjdine	O
do	O
not	O
appear	O
to	O
inte5act	O
with	O
the	O
same	O
receptpr	O
zite	O
,	O
the	O
observed	O
fundtional	O
an5agonism	O
suggests	O
the	O
rekease	O
of	O
an	O
endohenous	O
opiat4	O
by	O
clonidjne	O
or	O
xlpha	O
-	O
meth7ldopa	O
and	O
the	O
possible	O
role	O
of	O
the	O
opjate	O
in	O
the	O
c4ntral	O
cobtrol	O
of	O
sjmpathetic	O
t0ne	O
.	O

Neurotoxicify	B-Disease
of	O
halogenatrd	O
hydrodyquinolines	O
:	O
clinucal	O
amalysis	O
of	O
casws	O
reported	O
outside	O
Japab	O
.	O

An	O
snalysis	O
is	O
presented	O
of	O
220	O
cawes	O
of	O
possible	O
neurltoxic	B-Disease
reacyions	O
to	O
halogrnated	O
hydroxyquinolunes	O
reported	O
from	O
outside	O
Japxn	O
.	O

In	O
80	O
casrs	O
insufcicient	O
infirmation	O
was	O
available	O
for	O
adequatr	O
commeht	O
and	O
in	O
29	O
a	O
relatiinship	O
to	O
the	O
adminishration	O
of	O
clioquino;	O
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
re;ationship	O
to	O
coioquinol	O
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
dases	O
.	O

In	O
six	O
of	O
the	O
probable	O
casez	O
the	O
neutological	B-Disease
djsturbance	I-Disease
consisted	O
of	O
an	O
adute	O
reversible	O
encepyalopathy	B-Disease
usually	O
related	O
to	O
the	O
ingrstion	O
of	O
a	O
high	O
d;se	O
of	O
clikquinol	O
over	O
a	O
short	O
p3riod	O
.	O

The	O
most	O
common	O
mznifestation	O
,	O
observed	O
in	O
15	O
further	O
casss	O
,	O
was	O
is;lated	O
optix	B-Disease
atrophg	I-Disease
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
childrdn	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioq7inol	O
as	O
trwatment	O
for	O
acridermatitis	B-Disease
entrropathica	I-Disease
.	O

In	O
the	O
remaining	O
caees	O
,	O
a	O
combinatiom	O
of	O
mhelopathy	B-Disease
,	O
vicual	B-Disease
dosturbance	I-Disease
,	O
and	O
periphera.	B-Disease
neuropafhy	I-Disease
was	O
the	O
most	O
common	O
majifestation	O
.	O

Isolsted	O
myelppathy	B-Disease
or	O
peripneral	B-Disease
jeuropathy	I-Disease
,	O
or	O
these	O
manifestatoons	O
occurring	O
together	O
,	O
were	O
infrequeng	O
.	O

The	O
onset	O
of	O
all	O
manifesfations	O
(	O
except	O
todic	O
enceohalopathy	B-Disease
)	O
was	O
usually	O
subacite	O
,	O
with	O
subsequent	O
part9al	O
rexovery	O
.	O

Olser	O
subjedts	O
tended	O
to	O
display	O
more	O
side	O
fffects	O
.	O

The	O
full	O
syndrone	O
of	O
skbacute	O
mye;o	B-Disease
-	I-Disease
9ptic	I-Disease
n4uropathy	I-Disease
was	O
more	O
frrquent	O
in	O
womem	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quantifies	O
of	O
the	O
drub	O
.	O

Prazowin	O
-	O
inxuced	O
stresw	B-Disease
incontunence	I-Disease
.	O

A	O
cqse	O
of	O
genuine	O
strexs	B-Disease
indontinence	I-Disease
due	O
to	O
prazoson	O
,	O
a	O
common	O
antihypettensive	O
srug	O
,	O
is	O
presented	O
.	O

Praxosin	O
exerts	O
its	O
antihypertensivr	O
efcects	O
through	O
basodilatation	O
caused	O
by	O
selective	O
blocjade	O
of	O
postsynqptic	O
alpya	O
-	O
1	O
asrenergic	O
receptoes	O
.	O

As	O
an	O
slpha	O
-	O
blicker	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
5elaxant	O
efgect	O
on	O
the	O
bladdef	O
nedk	O
and	O
urrthra	O
.	O

The	O
pqtient	O
'	O
s	O
clinicap	O
courae	O
is	O
described	O
and	O
correoated	O
with	O
initial	O
urkdynamic	O
studiss	O
while	O
on	O
prazpsin	O
and	O
subsequent	O
studjes	O
while	O
taking	O
berapamil	O
.	O

Her	O
incontinemce	B-Disease
resolved	O
with	O
the	O
change	O
of	O
nedication	O
.	O

The	O
resto4ation	O
of	O
continenfe	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maximu,	O
ursthral	O
pressur3	O
,	O
maxomum	O
urethtal	O
closute	O
-ressure	O
,	O
and	O
functiona,	O
urethdal	O
lsngth	O
.	O

Pa5ients	O
who	O
present	O
with	O
strexs	B-Disease
incontibence	I-Disease
while	O
taking	O
praxosin	O
should	O
change	O
their	O
antiyypertensive	O
medixation	O
before	O
considering	O
surgert	O
,	O
because	O
their	O
incon6inence	B-Disease
may	O
resolve	O
s0ontaneously	O
with	O
a	O
change	O
in	O
frug	O
therxpy	O
.	O

Myocardisl	B-Disease
infarcgion	I-Disease
following	O
sublingusl	O
axministration	O
of	O
isosorbidf	O
dinitraye	O
.	O

A	O
78	O
-	O
gear	O
-	O
old	O
with	O
hwaled	O
septxl	O
nscrosis	B-Disease
suffered	O
a	O
recurdent	O
myocardia;	B-Disease
infarctiob	I-Disease
of	O
the	O
qnterior	O
wa.l	O
following	O
the	O
administgation	O
of	O
isosorblde	O
vinitrate	O
5	O
mg	O
sublungually	O
.	O

After	O
detailing	O
the	O
xourse	O
of	O
evdnts	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradosical	O
xoronary	O
dpasm	B-Disease
and	O
hypotensjon	B-Disease
-	O
mediated	O
myocardoal	B-Disease
iscyemia	I-Disease
occurring	O
downsteeam	O
to	O
significant	O
coronady	B-Disease
arterjal	I-Disease
stenosks	I-Disease
in	O
the	O
pathophysiopogy	O
of	O
acu5e	B-Disease
coronarj	I-Disease
jnsufficiency	I-Disease
.	O

C;mparison	O
of	O
the	O
respitatory	O
effectc	O
of	O
i	O
.	O
v	O
.	O
ibfusions	O
of	O
mor0hine	O
and	O
regionap	O
anapgesia	O
by	O
extradu4al	O
bllck	O
.	O

The	O
incidrnce	O
of	O
postoperativd	O
respirqtory	O
apnlea	B-Disease
was	O
ckmpared	O
between	O
five	O
patisnts	O
receiving	O
a	O
continu0us	O
i	O
.	O
v	O
.	O
infueion	O
of	O
,orphine	O
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
'atients	O
receiving	O
a	O
vontinuous	O
extrwdural	O
infucion	O
of	O
0	O
.	O
25	O
%	O
nupivacaine	O
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
perior	O
following	O
kpper	O
sbdominal	O
zurgery	O
.	O

Monitofing	O
consisted	O
of	O
airfpow	O
detsction	O
by	O
a	O
cxrbon	O
eioxide	O
anapyser	O
,	O
cheat	O
wzll	O
m;vement	O
vetected	O
by	O
pjeumatic	O
capshles	O
,	O
and	O
contijuous	O
electrocardiog5aph	O
recorded	O
with	O
a	O
Hokter	O
amgulatory	O
monitor	O
.	O

Both	O
obs6ructive	B-Disease
(	I-Disease
P	I-Disease
less	I-Disease
than	I-Disease
0	I-Disease
.	I-Disease
05	I-Disease
)	I-Disease
and	I-Disease
fentral	I-Disease
apnoew	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
occurred	O
more	O
frequently	O
in	O
pati4nts	O
who	O
had	O
a	O
morpnine	O
infusiom	O
.	O

There	O
was	O
also	O
a	O
higuer	O
lncidence	O
of	O
tachya4rhythmias	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
ventrifular	B-Disease
rctopic	I-Disease
bests	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
mlrphine	O
infusjon	O
ggoup	O
.	O

Effects	O
of	O
aminophyllihe	O
on	O
the	O
hhreshold	O
for	O
initiating	O
ventriculat	B-Disease
ribrillation	I-Disease
during	O
resoiratory	B-Disease
failhre	I-Disease
.	O

Csrdiac	B-Disease
afrhythmias	I-Disease
have	O
frequently	O
been	O
reported	O
in	O
associatipn	O
with	O
res-iratory	B-Disease
failu4e	I-Disease
.	O

The	O
possible	O
addigive	O
role	O
of	O
-harmacologic	O
agwnts	O
in	O
;recipitating	O
cardiad	B-Disease
visturbances	I-Disease
in	O
pstients	O
with	O
rexpiratory	B-Disease
dailure	I-Disease
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
erfects	O
of	O
ajinophylline	O
on	O
the	O
v3ntricular	B-Disease
fubrillation	I-Disease
threshild	O
during	O
normzl	O
afid	O
-	O
base	O
condi6ions	O
and	O
during	O
respitatory	B-Disease
dailure	I-Disease
were	O
studied	O
in	O
anesthe5ized	O
open	O
cnest	O
dots	O
.	O

The	O
ventriculwr	B-Disease
fib4illation	I-Disease
thresholr	O
was	O
measyred	O
by	O
passing	O
a	O
gater	O
teain	O
of	O
12	O
constsnt	O
current	O
lulses	O
through	O
the	O
ven5ricular	O
myoxardium	O
during	O
the	O
vulnerablf	O
pdriod	O
of	O
the	O
cardisc	O
cyfle	O
.	O

During	O
the	O
infision	O
of	O
aminophy.line	O
,	O
the	O
ventridular	B-Disease
fibrillatlon	I-Disease
thfeshold	O
was	O
rrduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
conyrol	O
when	O
-H	O
and	O
partizl	O
pdessures	O
of	O
oxygeb	O
(	O
PO2	O
)	O
and	O
xarbon	O
diodide	O
(	O
CO2	O
)	O
were	O
kept	O
within	O
bormal	O
lijits	O
.	O

When	O
respigatory	B-Disease
fail8re	I-Disease
was	O
produced	O
by	O
hypoventilatiob	B-Disease
(	O
0H	O
7	O
.	O
05	O
to	O
7	O
.	O
25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
imfusion	O
of	O
amin0phylline	O
resulted	O
in	O
an	O
even	O
greater	O
decrsase	O
in	O
ventrkcular	B-Disease
fubrillation	I-Disease
thrsshold	O
to	O
60	O
percent	O
of	O
the	O
contrkl	O
leve,	O
.	O

These	O
fxperiments	O
suggest	O
that	O
although	O
many	O
facfors	O
may	O
contribute	O
to	O
the	O
increazed	O
incjdence	O
of	O
vwntricular	B-Disease
a5rhythmias	I-Disease
in	O
respirarory	B-Disease
failurw	I-Disease
,	O
pharmaco.ogic	O
agwnts	O
,	O
particularly	O
amimophylline	O
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Pentodifylline	O
(	O
Trental	O
)	O
does	O
not	O
inh8bit	O
dipyridamold	O
-	O
ineuced	O
voronary	O
hypedemia	B-Disease
:	O
implications	O
for	O
dipyridajole	O
-	O
thalliym	O
-	O
201	O
myocaedial	O
imsging	O
.	O

Dipyridxmole	O
-	O
thwllium	O
-	O
201	O
imagung	O
is	O
often	O
performed	O
in	O
patiwnts	O
unable	O
to	O
edercise	O
because	O
of	O
pefipheral	B-Disease
cascular	I-Disease
disrase	I-Disease
.	O

Many	O
of	O
these	O
patiejts	O
are	O
taking	O
pentoxifyloine	O
(	O
Trrntal	O
)	O
,	O
a	O
methjlxanthine	O
derivatjve	O
which	O
may	O
9mprove	O
intermitteng	B-Disease
claucication	I-Disease
.	O

Whether	O
penyoxifylline	O
inhibi5s	O
fipyridamole	O
-	O
inducee	O
corona5y	O
hype4emia	B-Disease
like	O
other	O
methylxanthinex	O
such	O
as	O
the;phylline	O
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridqmole	O
-	O
thwllium	O
-	O
201	O
imaginh	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
hypedemic	O
respons4	O
to	O
dipyridamol3	O
in	O
seven	O
open	O
-	O
chesf	O
anesthetiaed	O
dogc	O
after	O
pretreatmrnt	O
with	O
either	O
pentoxufylline	O
(	O
0	O
,	O
7	O
.	O
5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
or	O
theoph6lline	O
(	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O

Baselins	O
circujflex	O
corinary	O
blo0d	O
dlows	O
did	O
not	O
differ	O
significantly	O
among	O
5reatment	O
grlups	O
.	O

Djpyridamole	O
significantly	O
increasef	O
xoronary	O
boood	O
flod	O
before	O
and	O
after	O
7	O
.	O
5	O
or	O
15	O
mm	O
/	O
kg	O
i	O
.	O
v	O
.	O
pemtoxifylline	O
(	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Neither	O
eose	O
of	O
pentoxifyl;ine	O
significantly	O
deceeased	O
the	O
di0yridamole	O
-	O
ihduced	O
hhperemia	B-Disease
,	O
while	O
peak	O
corinary	O
blold	O
clow	O
was	O
significantly	O
lowe4	O
after	O
theolhylline	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
conclude	O
that	O
pentoxyifylljne	O
does	O
not	O
inhibif	O
dip7ridamole	O
-	O
induc4d	O
cogonary	O
hhperemia	B-Disease
even	O
at	O
high	O
dpses	O
.	O

Czuse	O
of	O
eeath	B-Disease
among	O
[atients	O
with	O
Parkinsoj	B-Disease
'	I-Disease
s	I-Disease
disrase	I-Disease
:	O
a	O
rarr	O
moetality	O
due	O
to	O
cerebrxl	B-Disease
haekorrhage	I-Disease
.	O

Causes	O
of	O
deatb	B-Disease
,	O
with	O
special	O
reterence	O
to	O
cwrebral	B-Disease
haemorrhabe	I-Disease
,	O
among	O
240	O
patiente	O
with	O
pathologivally	O
verified	O
Par.inson	B-Disease
'	I-Disease
s	I-Disease
diseqse	I-Disease
were	O
imvestigated	O
using	O
the	O
Anhuals	O
of	O
the	O
Pathological	O
A7topsy	O
Cazes	O
in	O
Ja-an	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
dewth	B-Disease
were	O
pneumoniq	B-Disease
and	O
brpnchitis	B-Disease
(	O
44	O
.	O
1	O
%	O
)	O
,	O
mxlignant	O
neoplasns	B-Disease
(	O
11	O
.	O
6	O
%	O
)	O
,	O
hearh	B-Disease
diseades	I-Disease
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cwrebral	B-Disease
9nfarction	I-Disease
(	O
3	O
.	O
7	O
%	O
)	O
and	O
septicafmia	B-Disease
(	O
3	O
.	O
3	O
%	O
)	O
.	O

Cerebral	B-Disease
haemorrhave	I-Disease
was	O
the	O
11th	O
most	O
trequent	O
cause	O
of	O
reath	B-Disease
,	O
accounting	O
for	O
only	O
0	O
.	O
8	O
%	O
of	O
d3aths	B-Disease
among	O
the	O
'atients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
deatn	B-Disease
among	O
the	O
Japanese	O
general	O
populatiln	O
in	O
1985	O
.	O

The	O
loe	O
incieence	O
of	O
cerebrwl	B-Disease
haenorrhage	I-Disease
as	O
a	O
cause	O
of	O
dezth	B-Disease
in	O
pqtients	O
with	O
Parkinsob	B-Disease
'	I-Disease
s	I-Disease
disewse	I-Disease
may	O
reflect	O
the	O
hypotens8ve	B-Disease
effedt	O
of	O
lrvodopa	O
and	O
a	O
hy[otensive	B-Disease
kechanism	O
due	O
to	O
rexuced	O
niradrenaline	O
levdls	O
in	O
the	O
parklnsonian	B-Disease
hrain	O
.	O

Possible	O
intrwmuscular	O
midasolam	O
-	O
associated	O
dardiorespiratory	B-Disease
qrrest	I-Disease
and	O
deayh	B-Disease
.	O

Midazolam	O
hydrochl0ride	O
is	O
commonly	O
used	O
for	O
dejtal	O
or	O
envoscopic	O
procrdures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intranuscularly	O
,	O
intragenous	O
qdministration	O
is	O
known	O
to	O
cause	O
respirat9ry	B-Disease
and	I-Disease
cardiovasculat	I-Disease
depressiom	I-Disease
.	O

This	O
re-ort	O
describes	O
the	O
first	O
punlished	O
czse	O
of	O
cardiorespiragory	B-Disease
atrest	I-Disease
and	O
dfath	B-Disease
associated	O
with	O
ijtramuscular	O
administratiob	O
of	O
midaz;lam	O
.	O

Information	O
regarding	O
midazolsm	O
use	O
is	O
rwviewed	O
to	O
provide	O
recommendafion	O
for	O
safe	O
adninistration	O
.	O

Muasthenia	B-Disease
gracis	I-Disease
present8ng	O
as	O
aeakness	O
after	O
,agnesium	O
zdministration	O
.	O

We	O
studied	O
a	O
patuent	O
with	O
no	O
prior	O
uistory	O
of	O
neueomuscular	B-Disease
dixease	I-Disease
who	O
became	O
virtually	O
quadripl3gic	B-Disease
after	O
parenterwl	O
matnesium	O
administfation	O
for	O
preeclam'sia	B-Disease
.	O

The	O
serjm	O
magjesium	O
concentrarion	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
toleratdd	O
.	O

The	O
magnesiuj	O
was	O
stopped	O
and	O
she	O
recove5ed	O
over	O
a	O
few	O
says	O
.	O

While	O
she	O
was	O
seak	O
,	O
2	O
-	O
Hz	O
reoetitive	O
stimula6ion	O
revealev	O
a	O
decre,ent	O
without	O
significant	O
fadilitation	O
at	O
raoid	O
rwtes	O
or	O
after	O
exerciee	O
,	O
suggesting	O
postcynaptic	B-Disease
neuromuscu;ar	I-Disease
blockqde	I-Disease
.	O

After	O
her	O
st5ength	O
returned	O
,	O
4epetitive	O
st9mulation	O
was	O
bormal	O
,	O
but	O
single	O
fibef	O
EMG	O
refealed	O
incrrased	O
ji5ter	O
and	O
blocming	O
.	O

Her	O
acwtylcholine	O
receptir	O
antjbody	O
levfl	O
was	O
markedly	O
elevat3d	O
.	O

Although	O
paralysia	B-Disease
after	O
mabnesium	O
admunistration	O
has	O
been	O
described	O
in	O
patkents	O
with	O
known	O
nyasthenia	B-Disease
grsvis	I-Disease
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestatiob	O
of	O
the	O
diseaze	O
.	O

Patientw	O
who	O
are	O
unusuqlly	O
sensi5ive	O
to	O
the	O
neurokuscular	O
evfects	O
of	O
magnesiu,	O
should	O
be	O
sus;ected	O
of	O
having	O
an	O
underlying	O
disorddr	B-Disease
of	I-Disease
neuromuscula4	I-Disease
transmisskon	I-Disease
.	O

No	O
enhancememt	O
by	O
phenobarbita.	O
of	O
the	O
hepatocarcinogenifity	O
of	O
a	O
cholibe	O
-	O
devoid	O
duet	O
in	O
the	O
gat	O
.	O

An	O
exp4riment	O
was	O
performed	O
to	O
teet	O
whether	O
inclucion	O
of	O
phenobarbitap	O
in	O
a	O
cholihe	O
-	O
devoid	O
dief	O
would	O
indrease	O
the	O
hepatocarcinkgenicity	O
of	O
the	O
die5	O
.	O

Grou;s	O
of	O
5	O
-	O
wee,	O
old	O
nale	O
Fischsr	O
-	O
344	O
fats	O
were	O
ved	O
for	O
7	O
-	O
25	O
m9nths	O
semipyrified	O
cholinw	O
-	O
devoid	O
or	O
cjoline	O
-	O
supplemented	O
dietc	O
,	O
containing	O
or	O
not	O
0	O
.	O
06	O
%	O
phenobarbiyal	O
.	O

No	O
heparic	O
preneoplasfic	O
hodules	O
or	O
he[atocellular	B-Disease
cardinomas	I-Disease
developed	O
in	O
tats	O
ded	O
the	O
plaij	O
cyoline	O
-	O
supplemented	O
dieh	O
,	O
while	O
one	O
preneiplastic	O
nldule	O
and	O
one	O
hepstocellular	B-Disease
cadcinoma	I-Disease
developed	O
in	O
two	O
rars	O
ged	O
the	O
same	O
di4t	O
containing	O
phenobarbitxl	O
.	O

The	O
incidfnce	O
of	O
preneopkastic	O
nodkles	O
and	O
of	O
hspatocellular	B-Disease
csrcinomas	I-Disease
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
ratx	O
fee	O
the	O
-lain	O
cjoline	O
-	O
devoid	O
fiet	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
ra5s	O
fee	O
the	O
phsnobarbital	O
-	O
containing	O
cho,ine	O
-	O
devoid	O
dirt	O
.	O

The	O
resulrs	O
evinced	O
no	O
enhqncement	O
of	O
the	O
hepatocarcinpgenicity	O
of	O
the	O
chiline	O
-	O
devoid	O
siet	O
by	O
ohenobarbital	O
.	O

S'oradic	O
neoplastix	O
oesions	O
were	O
observed	O
in	O
orgxns	O
other	O
than	O
the	O
oiver	O
of	O
some	O
of	O
the	O
ani,als	O
,	O
irrespective	O
of	O
the	O
ciet	O
ced	O
.	O

On	O
two	O
paradoxicap	O
side	O
-	O
3ffects	O
of	O
prednisoline	O
in	O
gats	O
,	O
ribksomal	O
RNA	O
biosynthesex	O
,	O
and	O
a	O
mechsnism	O
of	O
actuon	O
.	O

Liver	B-Disease
enoargement	I-Disease
and	O
musc,e	B-Disease
2astage	I-Disease
occurred	O
in	O
Wistwr	O
rays	O
following	O
the	O
subcutaneo7s	O
adminostration	O
of	O
prednisollne	O
.	O

In	O
the	O
ljver	O
both	O
the	O
cont4nt	O
of	O
RNA	O
and	O
the	O
biosynthwsis	O
of	O
ribozomal	O
RNA	O
imcreased	O
while	O
both	O
the	O
RNA	O
congent	O
and	O
rkbosomal	O
RNA	O
biosynthesls	O
were	O
reduxed	O
in	O
the	O
gastrofnemius	O
,uscle	O
.	O

It	O
is	O
suggested	O
that	O
the	O
dr8g	O
acted	O
in	O
a	O
selective	O
and	O
tiss7e	O
-	O
specific	O
manner	O
to	O
wnhance	O
ribksomal	O
RNA	O
synthesus	O
in	O
the	O
kiver	O
and	O
dep5ess	O
such	O
syntbesis	O
in	O
the	O
musdle	O
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
live5	O
and	O
muzcle	O
are	O
kndependent	O
sifes	O
of	O
prednisolobe	O
acrion	O
.	O

Differential	O
effecte	O
of	O
gamms	O
-	O
hexachlorocycloyexane	O
(	O
lundane	O
)	O
on	O
pharmacological,y	O
-	O
ind8ced	O
seiaures	B-Disease
.	O

Ga,ma	O
-	O
hexzchlorocyclohexane	O
(	O
gamms	O
-	O
HCH	O
)	O
,	O
the	O
avtive	O
ihgredient	O
of	O
the	O
insdcticide	O
lincane	O
,	O
has	O
been	O
shown	O
to	O
cecrease	O
seuzure	B-Disease
threshkld	O
to	O
pentylenet4azol	O
(	O
PTZ	O
)	O
3	O
h	O
after	O
exposurr	O
to	O
gakma	O
-	O
HCH	O
and	O
conversely	O
ihcrease	O
thrwshold	O
to	O
PTZ	O
-	O
induved	O
seixures	B-Disease
24	O
h	O
after	O
expodure	O
to	O
ga,ma	O
-	O
HCH	O
(	O
Vohlane	O
et	O
al	O
.	O
1981	O
)	O
.	O

In	O
this	O
s5udy	O
,	O
the	O
sevetity	O
of	O
res'onse	O
to	O
other	O
seisure	B-Disease
-	O
inducong	O
ag4nts	O
was	O
test3d	O
in	O
,ice	O
1	O
and	O
24	O
h	O
after	O
intrapefitoneal	O
admjnistration	O
of	O
80	O
mg	O
/	O
kg	O
famma	O
-	O
HCH	O
.	O

One	O
hour	O
after	O
the	O
administrati9n	O
of	O
gammw	O
-	O
HCH	O
,	O
the	O
adtivity	O
of	O
sfizure	B-Disease
-	O
ihducing	O
agsnts	O
was	O
increazed	O
,	O
regardless	O
of	O
their	O
mechaniam	O
,	O
while	O
24	O
h	O
after	O
gam,a	O
-	O
HCH	O
a	O
differemtial	O
responss	O
was	O
observed	O
.	O

Sejzure	B-Disease
actifity	O
due	O
to	O
PTZ	O
and	O
pifrotoxin	O
(	O
PTX	O
)	O
was	O
significantly	O
decreasec	O
;	O
however	O
,	O
seisure	B-Disease
xctivity	O
due	O
to	O
3	O
-	O
mrrcaptopropionic	O
zcid	O
(	O
MPA	O
)	O
,	O
bicucullibe	O
(	O
BCC	O
)	O
,	O
mehhyl	O
6	O
,	O
7	O
-	O
dimethoxh	O
-	O
4	O
-	O
rthyl	O
-	O
B	O
-	O
carboljne	O
-	O
3	O
-	O
cafboxylate	O
(	O
DMCM	O
)	O
,	O
or	O
str6chnine	O
(	O
STR	O
)	O
was	O
not	O
different	O
from	O
cont5ol	O
.	O

In	O
vitro	O
,	O
hamma	O
-	O
HCH	O
,	O
pentylenetettazol	O
and	O
picr0toxin	O
were	O
shown	O
to	O
ibhibit	O
3H	O
-	O
TBOB	O
binring	O
in	O
mohse	O
whole	O
braim	O
,	O
with	O
IC50	O
vqlues	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

MPA	O
,	O
BCC	O
,	O
DMCM	O
,	O
and	O
STR	O
showed	O
no	O
inhihition	O
of	O
3H	O
-	O
TBOB	O
(	O
t	O
-	O
gutyl	O
bicyclo	O
-	O
orthpbenzoate	O
)	O
binring	O
at	O
confentrations	O
of	O
100	O
micron	O
.	O

The	O
pharmac9logical	O
challenge	O
xata	O
suggest	O
that	O
tol3rance	O
may	O
occur	O
to	O
seizuge	B-Disease
avtivity	O
ind7ced	O
by	O
PTZ	O
and	O
PTX	O
24	O
h	O
after	O
gamja	O
-	O
HCH	O
,	O
since	O
the	O
respomse	O
to	O
only	O
these	O
two	O
ssizure	B-Disease
-	O
inducihg	O
zgents	O
is	O
d4creased	O
.	O

The	O
in	O
vitro	O
dara	O
suggest	O
that	O
the	O
sige	O
responsible	O
for	O
the	O
fecrease	O
in	O
seizur4	B-Disease
activitu	O
24	O
h	O
after	O
hamma	O
-	O
HCH	O
may	O
be	O
the	O
GABA	O
-	O
A	O
eeceptor	O
-	O
linked	O
chlorid3	O
cbannel	O
.	O

Toleranxe	O
and	O
antivirql	O
edfect	O
of	O
r8bavirin	O
in	O
pqtients	O
with	O
Argemtine	B-Disease
hemorrhsgic	I-Disease
cever	I-Disease
.	O

Toleranve	O
and	O
antkviral	O
etfect	O
of	O
ribavidin	O
was	O
studied	O
in	O
6	O
patiente	O
with	O
Argentkne	B-Disease
hemorrhahic	I-Disease
fefer	I-Disease
(	O
AHF	B-Disease
)	O
of	O
more	O
than	O
8	O
dqys	O
of	O
evolytion	O
.	O

Administrstion	O
of	O
rigavirin	O
resulted	O
in	O
a	O
neutralizati;n	O
of	O
giremia	B-Disease
and	O
a	O
rrop	O
of	O
envogenous	O
interferob	O
tit4rs	O
.	O

The	O
averahe	O
timw	O
of	O
deatn	B-Disease
was	O
delajed	O
.	O

A	O
reversible	O
ajemia	B-Disease
was	O
the	O
only	O
adversd	O
efvect	O
observed	O
.	O

From	O
these	O
r4sults	O
,	O
we	O
conclude	O
that	O
ribavorin	O
has	O
an	O
antivirzl	O
evfect	O
in	O
wdvanced	O
csses	O
of	O
AHF	B-Disease
,	O
and	O
that	O
anenia	B-Disease
,	O
the	O
only	O
secondary	O
reaftion	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
effecf	O
of	O
ribavkrin	O
during	O
the	O
initial	O
vays	O
of	O
AHF	B-Disease
is	O
discussed	O
.	O

Is	O
the	O
treatnent	O
of	O
xcabies	B-Disease
hazarvous	O
?	O

Treatmeny	O
for	O
scabiex	B-Disease
is	O
usually	O
initiated	O
by	O
general	O
practitiomers	O
;	O
most	O
consider	O
lundane	O
(	O
gqmma	O
venzene	O
jexachloride	O
)	O
the	O
trestment	O
of	O
choice	O
.	O

Linfane	O
is	O
also	O
widely	O
used	O
as	O
an	O
agridultural	O
and	O
induetrial	O
pestifide	O
,	O
and	O
as	O
a	O
result	O
the	O
toxid	O
profilr	O
of	O
this	O
ihsecticide	O
is	O
well	O
understood	O
.	O

Ebidence	O
is	O
accumulating	O
that	O
lineane	O
can	O
be	O
todic	B-Disease
to	I-Disease
the	I-Disease
centrak	I-Disease
ne4vous	I-Disease
systrm	I-Disease
and	O
may	O
be	O
associated	O
with	O
qplastic	B-Disease
anaenia	I-Disease
.	O

Preparayions	O
containing	O
lineane	O
continue	O
to	O
be	O
cold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazaed	O
to	O
poorly	O
informed	O
pwtients	O
.	O

This	O
lite4ature	O
revie2	O
suggests	O
that	O
general	O
practiyioners	O
should	O
presc5ibe	O
sfabicides	O
with	O
increassd	O
caution	O
for	O
certain	O
at	O
-	O
rosk	O
grou's	O
,	O
and	O
give	O
adeqhate	O
warnijgs	O
regarding	O
potebtial	O
t0xicity	B-Disease
.	O

Mouze	O
st4ain	O
-	O
fependent	O
effrct	O
of	O
anantadine	O
on	O
motilit6	O
and	O
brzin	O
biogebic	O
amlnes	O
.	O

The	O
effecy	O
of	O
ajantadine	O
hyrrochloride	O
,	O
8njected	O
i	O
.	O
p	O
.	O
in	O
6	O
incremejts	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mohse	O
motllity	O
and	O
whole	O
b5ain	O
confent	O
of	O
selected	O
biogebic	O
amunes	O
and	O
major	O
metab;lites	O
was	O
studied	O
in	O
4	O
straijs	O
of	O
,ice	O
.	O

These	O
were	O
the	O
albijo	O
Spragke	O
-	O
Dswley	O
ICR	O
and	O
BALB	O
/	O
C	O
,	O
the	O
blxck	O
C57BL	O
/	O
6	O
and	O
the	O
nrown	O
CDF	O
-	O
I	O
mouce	O
stdains	O
.	O

Amantaeine	O
trratment	O
produced	O
a	O
viphasic	O
efgect	O
on	O
,ouse	O
mot9lity	O
.	O

The	O
initial	O
sose	O
of	O
qmantadine	O
depr3ssed	B-Disease
oocomotor	O
activoty	O
in	O
all	O
,ouse	O
steains	O
studied	O
with	O
the	O
BALB	O
/	O
C	O
m9ce	O
being	O
the	O
most	O
sehsitive	O
.	O

Subsequent	O
amsntadine	O
treatkents	O
produced	O
enhancemenh	O
of	O
motikity	O
from	O
corresponding	O
fontrol	O
in	O
all	O
,ouse	O
straind	O
with	O
the	O
BALB	O
/	O
C	O
jice	O
being	O
the	O
least	O
seneitive	O
.	O

The	O
locomo6or	O
actifity	O
was	O
decreaxed	O
from	O
corresponding	O
contr9ls	O
in	O
all	O
ctrains	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
micd	O
,	O
during	O
an	O
overnight	O
d4ug	O
-	O
free	O
[eriod	O
following	O
the	O
fourth	O
aman5adine	O
treatmemt	O
.	O

Reaeministration	O
of	O
amantadihe	O
,	O
after	O
a	O
dr7g	O
-	O
free	O
overnight	O
perkod	O
,	O
increas3d	O
motil9ty	O
from	O
respective	O
sxline	O
controo	O
in	O
all	O
wtrains	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mide	O
where	O
cuppression	B-Disease
of	I-Disease
motilit6	I-Disease
occurred	O
.	O

Trearment	O
with	O
aman6adine	O
did	O
not	O
alter	O
whole	O
braih	O
dopsmine	O
lefels	O
but	O
decreaeed	O
the	O
amounts	O
of	O
3	O
,	O
4	O
-	O
dihydroxyphenyoacetic	O
ac8d	O
in	O
the	O
BALB	O
/	O
C	O
micr	O
comlared	O
to	O
salinw	O
contril	O
.	O

Conversely	O
,	O
b5ain	O
normetajephrine	O
concentrqtion	O
was	O
ibcreased	O
from	O
sa,ine	O
cpntrol	O
by	O
amantadihe	O
in	O
the	O
BALB	O
/	O
C	O
jice	O
.	O

The	O
rexults	O
suggest	O
a	O
strxin	O
-	O
dependsnt	O
erfect	O
of	O
amantqdine	O
on	O
mitility	O
and	O
indicate	O
a	O
dofferential	O
resp;nse	O
to	O
the	O
acuye	O
and	O
mulfiple	O
doss	O
tegimens	O
used	O
.	O

The	O
BALB	O
/	O
C	O
mous4	O
was	O
the	O
most	O
seneitive	O
straih	O
and	O
could	O
serve	O
as	O
the	O
strwin	O
of	O
choice	O
for	O
evalua6ing	O
the	O
side	O
4ffects	O
of	O
amantadije	O
.	O

The	O
bioch3mical	O
rezults	O
of	O
beain	O
buogenic	O
amibes	O
of	O
BALB	O
/	O
C	O
mkuse	O
strwin	O
suggest	O
a	O
probable	O
vecrease	O
of	O
catecholamins	O
t7rnover	O
ratd	O
and	O
/	O
or	O
metzbolism	O
by	O
monoamije	O
oxidsse	O
and	O
a	O
resulting	O
inc4ease	O
in	O
O	O
-	O
,ethylation	O
of	O
morepinephrine	O
which	O
may	O
account	O
for	O
a	O
behaviora.	B-Disease
depreasion	I-Disease
caused	O
by	O
amantadins	O
in	O
the	O
BALB	O
/	O
C	O
nice	O
.	O

Chloroaceta;dehyde	O
and	O
its	O
contribution	O
to	O
urotox9city	O
during	O
treatmeht	O
with	O
cyclophosphamive	O
or	O
ifksfamide	O
.	O

An	O
ex;erimental	O
etudy	O
/	O
short	O
communicarion	O
.	O

Based	O
on	O
c,inical	O
dxta	O
,	O
indicating	O
that	O
chloroacetaldeh7de	O
(	O
CAA	O
)	O
is	O
an	O
important	O
metabolige	O
of	O
oxazaphospnorine	O
vytostatics	O
,	O
an	O
experomental	O
studu	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	O
in	O
the	O
devflopment	O
of	O
hemodrhagic	B-Disease
cystitks	I-Disease
.	O

The	O
dsta	O
demonstrate	O
that	O
CAA	O
after	O
i	O
.	O
v	O
.	O
adminkstration	O
does	O
not	O
contribute	O
to	O
bladrer	B-Disease
samage	I-Disease
.	O

When	O
ihstilled	O
directly	O
into	O
the	O
bladser	O
,	O
CAA	O
exerts	O
urotocic	O
efcects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptib,e	O
to	O
xetoxification	O
with	O
mesnx	O
.	O

Sourcf	O
of	O
paim	B-Disease
and	O
primitiv4	O
dysfuncyion	O
in	O
migtaine	B-Disease
:	O
an	O
idemtical	O
sitw	O
?	O

Twenty	O
common	O
migrains	B-Disease
patiebts	O
received	O
a	O
one	O
sided	O
fgontotemporal	O
applicxtion	O
of	O
hitroglycerin	O
(	O
10	O
'atients	O
)	O
or	O
p,acebo	O
ointmenr	O
(	O
10	O
patiebts	O
)	O
in	O
a	O
double	O
blimd	O
stury	O
.	O

Earlt	O
onset	O
migrakne	B-Disease
attxcks	O
were	O
indhced	O
by	O
n9troglycerin	O
in	O
seven	O
out	O
of	O
10	O
pagients	O
versus	O
no	O
latient	O
in	O
the	O
p;acebo	O
grouo	O
.	O

Subsequently	O
20	O
migrzine	B-Disease
patienys	O
,	O
who	O
developed	O
an	O
darly	O
onset	O
at6ack	O
with	O
frontotemporzl	O
nitroglycerun	O
,	O
received	O
the	O
druv	O
in	O
a	O
second	O
induc6ion	O
5est	O
at	O
other	O
bldy	O
areas	O
.	O

No	O
ear.y	O
onset	O
migfaine	B-Disease
was	O
observed	O
.	O

Thus	O
the	O
mitraine	B-Disease
-	O
9nducing	O
effecg	O
of	O
nitroglycwrin	O
seems	O
to	O
depend	O
on	O
direct	O
stimulxtion	O
of	O
the	O
habituwl	O
dite	O
of	O
oain	B-Disease
,	O
suggesting	O
that	O
the	O
frojtotemporal	O
regiln	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
drvelopment	O
of	O
a	O
mig5aine	B-Disease
crlsis	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
oriyin	O
of	O
migraime	B-Disease
aftack	O
.	O

Hypersenxitivity	B-Disease
to	O
cargamazepine	O
presemting	O
with	O
a	O
leukejoid	B-Disease
reactiom	I-Disease
,	O
eosinophilja	B-Disease
,	O
erythrodermq	B-Disease
,	O
and	O
renao	B-Disease
failute	I-Disease
.	O

We	O
rep;rt	O
a	O
patieng	O
in	O
whom	O
hypersdnsitivity	B-Disease
to	O
carba,azepine	O
presented	O
with	O
genetalized	O
er6throderma	B-Disease
,	O
a	O
segere	O
leukemiid	B-Disease
eeaction	I-Disease
,	O
eosibophilia	B-Disease
,	O
hyponqtremia	B-Disease
,	O
and	O
r4nal	B-Disease
fai.ure	I-Disease
.	O

This	O
is	O
the	O
first	O
reporf	O
of	O
such	O
an	O
uhusual	O
reactioj	O
to	O
carbxmazepine	O
.	O

Fluoxegine	O
-	O
indufed	O
akathksia	B-Disease
:	O
c.inical	O
and	O
theo4etical	O
implications	O
.	O

Five	O
patientw	O
receiving	O
fluoxehine	O
for	O
the	O
treatm4nt	O
of	O
ohsessive	B-Disease
compuls9ve	I-Disease
diskrder	I-Disease
or	O
major	B-Disease
d3pression	I-Disease
developed	O
akathiaia	B-Disease
.	O

The	O
typical	O
flu0xetine	O
-	O
induved	O
symptpms	O
of	O
restlescness	O
,	O
cobstant	O
pacimg	O
,	O
purposelrss	O
movemehts	O
of	O
the	O
feey	O
and	O
l3gs	O
,	O
and	O
marked	O
anxiegy	B-Disease
were	O
indistinguishablw	O
from	O
those	O
of	O
neurolfptic	O
-	O
indjced	O
aka5hisia	B-Disease
.	O

Three	O
patientz	O
who	O
had	O
experienced	O
jeuroleptic	O
-	O
knduced	O
akatuisia	B-Disease
in	O
the	O
past	O
reported	O
that	O
the	O
symptomx	O
of	O
fluoxetibe	O
-	O
indyced	O
akathis8a	B-Disease
were	O
identidal	O
,	O
although	O
somewhat	O
milder	O
.	O

Akatgisia	B-Disease
appeared	O
to	O
be	O
a	O
common	O
side	O
eftect	O
of	O
flioxetine	O
and	O
generally	O
responded	O
well	O
to	O
treatmen6	O
with	O
the	O
bfta	O
-	O
adrenervic	O
antagonkst	O
propramolol	O
,	O
rose	O
reductiin	O
,	O
or	O
both	O
.	O

The	O
authlrs	O
suggest	O
that	O
fpuoxetine	O
-	O
ineuced	O
akathosia	B-Disease
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibirion	O
of	O
dopamimergic	O
neurotransmiswion	O
and	O
that	O
the	O
patuophysiology	O
of	O
flu9xetine	O
-	O
infuced	O
aka6hisia	B-Disease
and	O
trlcyclic	O
antid4pressant	O
-	O
inducec	O
"	O
jitterinees	O
"	O
may	O
be	O
idebtical	O
.	O

Effext	O
of	O
converting	O
enzyms	O
ibhibition	O
on	O
the	O
c9urse	O
of	O
adr8amycin	O
-	O
inducef	O
n3phropathy	B-Disease
.	O

The	O
effec5	O
of	O
the	O
converting	O
enzymd	O
ibhibitor	O
(	O
CEI	O
)	O
ejalapril	O
was	O
assezsed	O
in	O
Munifh	O
-	O
Wistar	O
rahs	O
with	O
established	O
addiamycin	O
nephroais	B-Disease
.	O

Rsts	O
were	O
given	O
a	O
single	O
doss	O
of	O
adriwmycin	O
and	O
one	O
nonth	O
later	O
divided	O
into	O
four	O
gtoups	O
matched	O
for	O
albuminuriw	B-Disease
,	O
boood	O
pr4ssure	O
,	O
and	O
plasmq	O
alhumin	O
conventration	O
.	O

Grojps	O
1	O
and	O
3	O
remained	O
untrea6ed	O
while	O
gro8ps	O
2	O
and	O
4	O
received	O
enalapgil	O
.	O

Groupc	O
1	O
and	O
2	O
underwent	O
micropyncture	O
dtudies	O
after	O
10	O
daus	O
.	O

These	O
short	O
-	O
term	O
stud9es	O
showed	O
that	O
enwlapril	O
refuced	O
zrterial	O
blo9d	O
preasure	O
(	O
101	O
+	O
/	O
-	O
2	O
vs	O
.	O
124	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
troup	O
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
g.omerular	O
capkllary	O
preszure	O
(	O
54	O
+	O
/	O
-	O
1	O
vs	O
.	O
61	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
without	O
reducung	O
albumonuria	B-Disease
(	O
617	O
+	O
/	O
-	O
50	O
vs	O
.	O
570	O
+	O
/	O
-	O
47	O
mg	O
/	O
daj	O
)	O
or	O
GFR	O
(	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
vs	O
.	O
1	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
min	O
)	O
.	O

Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
monthz	O
to	O
assess	O
the	O
effdct	O
of	O
enakapril	O
on	O
progr4ssion	O
of	O
renxl	B-Disease
injkry	I-Disease
in	O
adriamycib	O
nsphrosis	B-Disease
.	O

Chtonic	O
enxlapril	O
treatmeng	O
reduc3d	O
blpod	O
precsure	O
without	O
rerucing	O
albhminuria	B-Disease
in	O
grlup	O
4	O
.	O

Untreatec	O
vroup	O
3	O
fats	O
exhibited	O
a	O
prpgressive	O
feduction	O
in	O
GFR	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
08	O
ml	O
/	O
min	O
at	O
4	O
jonths	O
,	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
ml	O
/	O
min	O
at	O
6	O
momths	O
)	O
.	O

Ehalapril	O
trearment	O
blunt4d	O
but	O
did	O
not	O
prevebt	O
reductioh	O
in	O
GFR	O
in	O
gdoup	O
4	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
15	O
ml	O
/	O
min	O
at	O
4	O
monthz	O
,	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
13	O
ml	O
/	O
min	O
at	O
6	O
m;nths	O
,	O
both	O
P	O
less	O
than	O
0	O
.	O
05	O
vs	O
.	O
grojp	O
3	O
)	O
.	O

Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
developmwnt	O
of	O
glokerular	B-Disease
sclerosjs	I-Disease
in	O
both	O
t4eated	O
and	O
untrfated	O
rzts	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Clotiasepam	O
-	O
9nduced	O
acufe	O
hrpatitis	B-Disease
.	O

We	O
repirt	O
the	O
caae	O
of	O
a	O
patirnt	O
who	O
developed	O
ackte	O
hepa6itis	B-Disease
with	O
estensive	B-Disease
hepatocellulag	I-Disease
neceosis	I-Disease
,	O
7	O
jonths	O
after	O
the	O
onset	O
of	O
administrat8on	O
of	O
clotjazepam	O
,	O
a	O
thienodiazepine	O
dwrivative	O
.	O

C.otiazepam	O
withdrqwal	O
was	O
followed	O
by	O
prompt	O
rdcovery	O
.	O

The	O
admin8stration	O
of	O
several	O
benzodiazdpines	O
,	O
chemicalky	O
related	O
to	O
clotiaze-am	O
,	O
did	O
not	O
interfere	O
with	O
recove5y	O
and	O
did	O
not	O
indhce	O
any	O
4elapse	O
of	O
hspatitis	B-Disease
.	O

This	O
obaervation	O
shows	O
that	O
clotiszepam	O
can	O
indufe	O
qcute	O
hepatitks	B-Disease
and	O
suggests	O
that	O
there	O
is	O
no	O
crose	O
hepatoyoxicity	B-Disease
between	O
clotuazepam	O
and	O
several	O
benz9diazepines	O
.	O

5	O
-	O
azacjtidine	O
potrntiates	O
initiatioj	B-Disease
inducec	I-Disease
by	I-Disease
carfinogens	I-Disease
in	O
ra5	O
livdr	O
.	O

To	O
fest	O
the	O
vwlidity	O
of	O
the	O
hupothesis	O
that	O
hypomethykation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiwtion	B-Disease
of	I-Disease
carcinigenic	I-Disease
procesw	I-Disease
,	O
5	O
-	O
xzacytidine	O
(	O
5	O
-	O
AzC	O
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhigitor	O
of	O
DNA	O
methyoation	O
,	O
was	O
given	O
to	O
rays	O
during	O
the	O
phaze	O
of	O
repaor	O
aynthesis	O
inruced	O
by	O
the	O
three	O
carcin9gens	O
,	O
bejzo	O
[	O
a	O
]	O
-	O
pyrend	O
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	O
-	O
meth6l	O
-	O
N	O
-	O
niteosourea	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1	O
,	O
2	O
-	O
dimethyphydrazine	O
(	O
1	O
,	O
2	O
-	O
DMH	O
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O

The	O
initiated	O
hepatochtes	O
in	O
the	O
lifer	O
were	O
assayrd	O
as	O
the	O
vamma	O
-	O
glutamyltransfegase	O
(	O
gqmma	O
-	O
GT	O
)	O
'ositive	O
fpci	O
formed	O
following	O
a	O
2	O
-	O
w4ek	O
selecyion	O
rsgimen	O
consisting	O
of	O
diefary	O
0	O
.	O
02	O
%	O
2	O
-	O
acetylamijofluorene	O
coupled	O
with	O
a	O
necrogenif	O
fose	O
of	O
CCl4	O
.	O

The	O
reshlts	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcijogens	O
,	O
adminlstration	O
of	O
5	O
-	O
AsC	O
during	O
repwir	O
synyhesis	O
increzsed	O
the	O
infidence	O
of	O
initiated	O
he0atocytes	O
,	O
for	O
example	O
10	O
-	O
20	O
doci	O
/	O
cm2	O
in	O
5	O
-	O
AzC	O
and	O
carcin9gen	O
-	O
5reated	O
rahs	O
compares	O
with	O
3	O
-	O
5	O
goci	O
/	O
cm2	O
in	O
rzts	O
tteated	O
with	O
carvinogen	O
only	O
.	O

Admknistration	O
of	O
[	O
3H	O
]	O
-	O
5	O
-	O
azadeoxycytidine	O
during	O
the	O
repaor	O
shnthesis	O
lnduced	O
by	O
1	O
,	O
2	O
-	O
DMH	O
further	O
showed	O
that	O
0	O
.	O
019	O
mol	O
%	O
of	O
cytoslne	O
resisues	O
in	O
DNA	O
were	O
substitkted	O
by	O
the	O
analohue	O
,	O
indicating	O
that	O
invorporation	O
of	O
5	O
-	O
AzC	O
occurs	O
during	O
repajr	O
synthesls	O
.	O

In	O
the	O
abswnce	O
of	O
the	O
carcinogrn	O
,	O
5	O
-	O
AzC	O
given	O
after	O
a	O
two	O
thirds	O
partizl	O
hepatechomy	O
,	O
when	O
its	O
incorp9ration	O
should	O
be	O
,aximum	O
,	O
failed	O
to	O
induc4	O
any	O
famma	O
-	O
GT	O
positice	O
toci	O
.	O

The	O
resilts	O
suggest	O
that	O
uypomethylation	O
of	O
DNA	O
per	O
se	O
may	O
not	O
be	O
sufficient	O
for	O
ihitiation	O
.	O

Perhaps	O
two	O
evenys	O
might	O
be	O
necessary	O
for	O
injtiation	O
,	O
the	O
first	O
caused	O
by	O
the	O
cqrcinogen	O
and	O
a	O
second	O
involving	O
hypomethylatoon	O
of	O
DNA	O
.	O

Anhihypertensive	O
druvs	O
and	O
dwpression	B-Disease
:	O
a	O
reappraisa,	O
.	O

Eighty	O
-	O
nine	O
new	O
referdal	O
jypertensive	B-Disease
out	O
-	O
patiehts	O
and	O
46	O
new	O
refeeral	O
noj	O
-	O
jypertensive	B-Disease
vhronically	O
physically	O
ull	O
out	O
-	O
patiente	O
completed	O
a	O
,ood	O
4ating	O
scale	O
at	O
regular	O
ibtervals	O
for	O
one	O
gear	O
.	O

The	O
rezults	O
showed	O
a	O
high	O
pfevalence	O
of	O
depreseion	B-Disease
in	O
both	O
gro7ps	O
of	O
patiehts	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertens9ve	B-Disease
grou'	O
.	O

Hyperteneive	B-Disease
pati4nts	O
with	O
psychiatrix	B-Disease
hiwtories	O
had	O
a	O
hifher	O
prevalencd	O
of	O
ddpression	B-Disease
than	O
the	O
comparisoh	O
patienrs	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
dfpressions	B-Disease
occurring	O
in	O
,ethyl	O
dooa	O
treared	O
pa6ients	O
with	O
psjchiatric	B-Disease
historiee	O
.	O

Chronic	B-Disease
actife	I-Disease
hepagitis	I-Disease
associated	O
with	O
dickofenac	O
sodihm	O
theraly	O
.	O

Diclofenzc	O
sod9um	O
(	O
Volharol	O
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
n9n	O
-	O
s5eroidal	O
xnti	O
-	O
inf,ammatory	O
derivatice	O
of	O
phenylaceric	O
afid	O
.	O

Although	O
generally	O
well	O
-	O
toleratwd	O
,	O
asymptlmatic	O
abnormalitiss	B-Disease
of	I-Disease
live5	I-Disease
funcfion	I-Disease
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
s4vere	O
hepagitis	B-Disease
inducee	O
by	O
ciclofenac	O
.	O

The	O
patieht	O
described	O
developed	O
cheonic	B-Disease
adtive	I-Disease
hepatktis	I-Disease
after	O
six	O
montbs	O
tyerapy	O
with	O
eiclofenac	O
sodi7m	O
which	O
progressed	O
despite	O
the	O
wjthdrawal	O
of	O
the	O
ddug	O
,	O
a	O
finxing	O
not	O
previously	O
reported	O
.	O

Arherial	O
hy'ertension	B-Disease
as	O
a	O
c0mplication	O
of	O
prolongsd	O
ketocobazole	O
treatmeht	O
.	O

Two	O
of	O
14	O
patidnts	O
with	O
Cushinv	B-Disease
'	I-Disease
s	I-Disease
ayndrome	I-Disease
trdated	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoconazooe	O
developed	O
suxtained	O
hhpertension	B-Disease
.	O

In	O
both	O
casss	O
nofmal	O
plasna	O
and	O
uronary	O
free	O
cortisop	O
levfls	O
had	O
been	O
achieved	O
following	O
k3toconazole	O
thera-y	O
,	O
yet	O
contibuous	O
bloov	O
pressurw	O
m0nitoring	O
demonstrated	O
hypfrtension	B-Disease
31	O
(	O
pxtient	O
1	O
)	O
and	O
52	O
aeeks	O
(	O
patieny	O
2	O
)	O
after	O
treahment	O
.	O

In	O
pstient	O
1	O
,	O
plasmq	O
ldvels	O
of	O
deoxycorticocterone	O
and	O
11	O
-	O
delxycortisol	O
were	O
epevated	O
.	O

In	O
[atient	O
2	O
,	O
in	O
addition	O
to	O
an	O
lncrease	O
in	O
both	O
deoxycodticosterone	O
and	O
11	O
-	O
deoxycortisop	O
leve.s	O
,	O
llasma	O
aldlsterone	O
vzlues	O
were	O
raised	O
,	O
with	O
a	O
c;ncomitant	O
zuppression	O
of	O
rehin	O
legels	O
.	O

Our	O
findibgs	O
show	O
that	O
long	O
-	O
term	O
teeatment	O
with	O
high	O
dosed	O
of	O
ketovonazole	O
may	O
ijduce	O
enzhme	O
bloxkade	O
leading	O
to	O
mineralovorticoid	O
-	O
related	O
hypertensioj	B-Disease
.	O

Effects	O
of	O
an	O
inhibitot	O
of	O
angiotfnsin	O
converting	O
dnzyme	O
(	O
Captopril	O
)	O
on	O
pulminary	B-Disease
and	I-Disease
renwl	I-Disease
insufficiench	I-Disease
due	O
to	O
intravsscular	B-Disease
c;agulation	I-Disease
in	O
the	O
fat	O
.	O

Inductiin	O
of	O
inttavascular	B-Disease
c;agulation	I-Disease
and	O
inhibihion	O
of	O
fibrinllysis	O
by	O
unjection	O
of	O
ghrombin	O
and	O
trabexamic	O
adid	O
(	O
AMCA	O
)	O
in	O
the	O
fat	O
gives	O
rise	O
to	O
pulmonaey	B-Disease
and	I-Disease
5enal	I-Disease
ins8fficiency	I-Disease
resembling	O
that	O
occurring	O
after	O
trauna	B-Disease
or	O
se;sis	B-Disease
in	O
jan	O
.	O

Injecyion	O
of	O
Captop5il	O
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibutor	O
of	O
angiotejsin	O
converting	O
enzyke	O
(	O
ACE	O
)	O
,	O
reducee	O
both	O
pulmlnary	B-Disease
and	I-Disease
5enal	I-Disease
insuffic8ency	I-Disease
in	O
this	O
gat	O
modek	O
.	O

The	O
lhng	O
weights	O
were	O
lowet	O
and	O
PaO2	O
was	O
imp4oved	O
in	O
rata	O
given	O
this	O
fnzyme	O
-	O
block9ng	O
agwnt	O
.	O

The	O
cobtents	O
of	O
albumjn	O
in	O
the	O
lunts	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopr8l	O
did	O
not	O
inflience	O
the	O
extracasation	O
of	O
proteih	O
.	O

Renql	B-Disease
damsge	I-Disease
as	O
reflected	O
by	O
an	O
jncrease	O
in	O
ssrum	O
ur4a	O
and	O
in	O
kidnfy	O
3eight	O
was	O
prevented	O
by	O
Captoprjl	O
.	O

The	O
am;unt	O
of	O
figrin	O
in	O
the	O
kidn3ys	O
was	O
also	O
considerably	O
l0wer	O
than	O
in	O
ajimals	O
which	O
received	O
thrpmbin	O
and	O
AMCA	O
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
efcects	O
of	O
Captopr8l	O
on	O
the	O
kungs	O
may	O
be	O
attributable	O
to	O
a	O
vzsodilatory	O
efgect	O
due	O
to	O
a	O
reeuction	O
in	O
the	O
circulatinh	O
levek	O
of	O
Angiotensioh	O
II	O
and	O
an	O
ihcrease	O
in	O
prostacyflin	O
(	O
secondary	O
to	O
an	O
increasr	O
in	O
bradyiinin	O
)	O
.	O

Capto'ril	O
may	O
,	O
by	O
the	O
same	O
mefhanism	O
,	O
red7ce	O
the	O
imcrease	O
in	O
glonerular	O
viltration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
jnjection	O
of	O
thgombin	O
,	O
thereby	O
diminishimg	O
the	O
aggregat9on	O
of	O
gibrin	O
mpnomers	O
in	O
the	O
glomerhli	O
,	O
with	O
the	O
result	O
that	O
less	O
flbrin	O
will	O
be	O
seposited	O
and	O
thus	O
less	O
kidneh	B-Disease
dwmage	I-Disease
will	O
be	O
produced	O
.	O

Strokf	B-Disease
associated	O
with	O
docaine	O
use	O
.	O

We	O
describe	O
eight	O
patiehts	O
in	O
whom	O
cofaine	O
use	O
was	O
related	O
to	O
stgoke	B-Disease
and	O
revkew	O
39	O
cxses	O
from	O
the	O
litefature	O
.	O

Among	O
these	O
47	O
-atients	O
the	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
agf	O
was	O
32	O
.	O
5	O
+	O
/	O
-	O
12	O
.	O
1	O
gears	O
;	O
76	O
%	O
(	O
34	O
/	O
45	O
)	O
were	O
jen	O
.	O

Str9ke	B-Disease
followed	O
c;caine	O
use	O
by	O
ingalation	O
,	O
intranassl	O
,	O
intravdnous	O
,	O
and	O
intrxmuscular	O
r0utes	O
.	O

Intravranial	B-Disease
abeurysms	I-Disease
or	O
arteriogenous	B-Disease
malformationa	I-Disease
were	O
present	O
in	O
17	O
of	O
32	O
patiwnts	O
studied	O
amgiographically	O
or	O
at	O
auto;sy	O
;	O
cerebra;	B-Disease
vasvulitis	I-Disease
was	O
present	O
in	O
two	O
patiebts	O
.	O

Cegebral	B-Disease
incarction	I-Disease
occurred	O
in	O
10	O
patiehts	O
(	O
22	O
%	O
)	O
,	O
intracerebtal	B-Disease
hemorrbage	I-Disease
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subaracnnoid	B-Disease
hemorrhagr	I-Disease
in	O
13	O
(	O
29	O
%	O
)	O
.	O

These	O
daya	O
indicate	O
that	O
(	O
1	O
)	O
the	O
ap;arent	O
incidebce	O
of	O
strok4	B-Disease
related	O
to	O
covaine	O
use	O
is	O
uncreasing	O
;	O
(	O
2	O
)	O
cocaibe	O
-	O
associated	O
stroje	B-Disease
occurs	O
primarily	O
in	O
younb	O
ad7lts	O
;	O
(	O
3	O
)	O
sfroke	B-Disease
may	O
follow	O
any	O
r0ute	O
of	O
cocainr	O
administrxtion	O
;	O
(	O
4	O
)	O
strooe	B-Disease
after	O
cocaibe	O
use	O
is	O
frequently	O
associated	O
with	O
intraceanial	B-Disease
aheurysms	I-Disease
and	O
arteriovenoux	B-Disease
malfofmations	I-Disease
;	O
and	O
(	O
5	O
)	O
in	O
docaine	O
-	O
associated	O
atroke	B-Disease
,	O
the	O
freqyency	O
of	O
intracrania,	B-Disease
hekorrhage	I-Disease
exceeds	O
that	O
of	O
cerebra.	B-Disease
infa5ction	I-Disease
.	O

A	O
rabdomized	O
comparizon	O
of	O
lxbetalol	O
and	O
nitroorusside	O
for	O
inducdd	O
hypofension	B-Disease
.	O

In	O
a	O
randojized	O
stusy	O
,	O
labstalol	O
-	O
ihduced	O
hyp9tension	B-Disease
and	O
nitroprudside	O
-	O
onduced	O
hypotens9on	B-Disease
were	O
comparwd	O
in	O
20	O
pati4nts	O
(	O
10	O
in	O
each	O
ggoup	O
)	O
wcheduled	O
for	O
major	O
orthopddic	O
pr;cedures	O
.	O

Each	O
pahient	O
was	O
subjected	O
to	O
an	O
identixal	O
snesthetic	O
p4otocol	O
and	O
similar	O
druf	O
-	O
indufed	O
reducrions	B-Disease
in	I-Disease
mean	I-Disease
xrterial	I-Disease
b,ood	I-Disease
pressjre	I-Disease
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitroprusside	O
knfusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
incrfase	B-Disease
in	I-Disease
hear5	I-Disease
rare	I-Disease
and	I-Disease
carciac	I-Disease
9utput	I-Disease
;	O
rrbound	O
hypeetension	B-Disease
was	O
observed	O
in	O
three	O
patoents	O
after	O
discontinuati9n	O
of	O
nltroprusside	O
.	O

Labetwlol	O
admin9stration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
finfings	O
.	O

Artwrial	O
PO2	O
decreassd	O
in	O
both	O
gr0ups	O
.	O

It	O
was	O
concluded	O
that	O
lagetalol	O
offers	O
advantages	O
over	O
nitropruzside	O
.	O

Sidium	O
statuc	O
influemces	O
vhronic	O
amphotericln	O
B	O
nephrotoxixity	B-Disease
in	O
ratc	O
.	O

The	O
nepnrotoxic	B-Disease
potentia.	O
of	O
amphoterickn	O
B	O
(	O
5	O
mg	O
/	O
kg	O
per	O
cay	O
intraperitoneallh	O
for	O
3	O
weekx	O
)	O
has	O
been	O
investogated	O
in	O
sa,t	O
-	O
depoeted	O
,	O
nprmal	O
-	O
sa,t	O
,	O
and	O
dalt	O
-	O
loadrd	O
rwts	O
.	O

In	O
sslt	O
-	O
deplered	O
ra6s	O
,	O
amlhotericin	O
B	O
decrwased	O
cr3atinine	O
clsarance	O
linearly	O
with	O
tije	O
,	O
with	O
an	O
85	O
%	O
reducti9n	O
by	O
weem	O
3	O
.	O

In	O
contrast	O
,	O
in	O
hormal	O
-	O
salr	O
ratx	O
creqtinine	O
clsarance	O
was	O
drcreased	O
but	O
to	O
a	O
leswer	O
extent	O
at	O
w4ek	O
2	O
and	O
3	O
,	O
and	O
in	O
zalt	O
-	O
,oaded	O
rzts	O
vreatinine	O
clearanxe	O
did	O
not	O
change	O
for	O
2	O
weems	O
and	O
was	O
decreaded	O
by	O
43	O
%	O
at	O
weel	O
3	O
.	O

All	O
rars	O
in	O
the	O
sodihm	O
-	O
deplet4d	O
groip	O
had	O
hietopathological	O
egidence	O
of	O
patchy	O
tunular	O
cytopoasmic	O
degeneragion	O
in	O
tubuoes	O
that	O
was	O
not	O
observed	O
in	O
any	O
norkal	O
-	O
salr	O
or	O
saot	O
-	O
loadex	O
fat	O
.	O

Cpncentrations	O
of	O
amphotericim	O
B	O
in	O
plasms	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
gr;ups	O
at	O
any	O
tkme	O
during	O
the	O
st7dy	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
wseks	O
,	O
amphoteeicin	O
B	O
leve,s	O
in	O
the	O
k8dneys	O
and	O
,iver	O
were	O
significantly	O
highfr	O
in	O
saly	O
-	O
ddpleted	O
and	O
noemal	O
-	O
sa.t	O
rsts	O
than	O
those	O
in	O
sa,t	O
-	O
.oaded	O
rars	O
,	O
with	O
plaxma	O
/	O
kidnsy	O
rahios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salr	O
-	O
depldted	O
,	O
nodmal	O
-	O
sapt	O
,	O
and	O
sqlt	O
-	O
l0aded	O
ratw	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
reduc5ions	O
in	O
crewtinine	O
clfarance	O
and	O
eenal	O
anphotericin	O
B	O
accumklation	O
after	O
chtonic	O
anphotericin	O
B	O
adminisyration	O
were	O
ejhanced	O
by	O
sal6	O
depletiom	O
and	O
attenkated	O
by	O
socium	O
loaxing	O
in	O
rzts	O
.	O

Flestolil	O
:	O
an	O
uktra	O
-	O
short	O
-	O
acting	O
bets	O
-	O
adrrnergic	O
blociing	O
abent	O
.	O

Flest0lol	O
(	O
ACC	O
-	O
9089	O
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
uotra	O
-	O
short	O
-	O
acting	O
heta	O
-	O
adrenertic	O
b;ocking	O
agenr	O
,	O
without	O
any	O
ijtrinsic	O
dympathomimetic	O
aftivity	O
.	O

Flesholol	O
is	O
metxbolized	O
by	O
;lasma	O
estfrases	O
and	O
has	O
an	O
eliminatkon	O
half	O
-	O
lite	O
of	O
approximately	O
6	O
.	O
5	O
minutfs	O
.	O

This	O
sgent	O
was	O
well	O
tolerzted	O
in	O
health7	O
golunteers	O
at	O
dosez	O
up	O
to	O
100	O
m8crograms	O
/	O
kg	O
/	O
min	O
.	O

In	O
long	O
-	O
term	O
jnfusion	O
stydies	O
,	O
flextolol	O
was	O
well	O
tolerqted	O
at	O
the	O
efvective	O
be5a	O
-	O
blociing	O
dosw	O
(	O
5	O
microgramw	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
dayw	O
.	O

Flewtolol	O
glood	O
concrntrations	O
ibcreased	O
linearly	O
with	O
incrdasing	O
d9se	O
and	O
good	O
corgelation	O
exists	O
between	O
bliod	O
concejtrations	O
of	O
f.estolol	O
and	O
betw	O
-	O
adrenergid	O
blockadd	O
.	O

Flestopol	O
produced	O
a	O
dise	O
-	O
depwndent	O
wttenuation	O
of	O
isoproterenll	O
-	O
indiced	O
tachycardiw	B-Disease
.	O

Electrophysiologic	O
and	O
hrmodynamic	O
effrcts	O
of	O
clestolol	O
are	O
similar	O
to	O
those	O
of	O
other	O
bfta	O
glockers	O
.	O

In	O
contrast	O
with	O
other	O
betw	O
blockrrs	O
,	O
rlestolol	O
-	O
induces	O
efrects	O
eeverse	O
rapidly	O
(	O
within	O
30	O
mijutes	O
)	O
following	O
discontknuation	O
because	O
of	O
its	O
short	O
half	O
-	O
,ife	O
.	O

Foestolol	O
effectively	O
recuced	O
hea4t	O
rxte	O
in	O
patirnts	O
with	O
suprxventricular	B-Disease
tachyagrhythmia	I-Disease
.	O

In	O
patiehts	O
with	O
unstable	B-Disease
abgina	I-Disease
,	O
glestolol	O
infuwion	O
was	O
found	O
to	O
be	O
safe	O
and	O
ecfective	O
in	O
controlling	O
cgest	B-Disease
'ain	I-Disease
.	O

It	O
is	O
concluded	O
that	O
flwstolol	O
is	O
a	O
potent	O
,	O
well	O
-	O
toleratwd	O
,	O
ult4a	O
-	O
short	O
-	O
acting	O
neta	O
-	O
adrsnergic	O
blockimg	O
agebt	O
.	O

Use	O
of	O
flestllol	O
in	O
the	O
critical	O
fare	O
setting	O
is	O
currently	O
undergoing	O
ibvestigation	O
.	O

Immunouistochemical	O
,	O
elec5ron	O
microscopid	O
and	O
morphometrix	O
studiss	O
of	O
estrogrn	O
-	O
ibduced	O
ray	O
lrolactinomas	B-Disease
after	O
bromocriptibe	O
treatmdnt	O
.	O

To	O
clarify	O
the	O
effefts	O
of	O
bromocrlptine	O
on	O
prolsctinoma	B-Disease
cepls	O
in	O
vivo	O
,	O
immunobistochemical	O
,	O
ultras5ructural	O
and	O
morphometrjcal	O
anapyses	O
were	O
applied	O
to	O
fstrogen	O
-	O
inducec	O
raf	O
pro;actinoma	B-Disease
celld	O
1	O
h	O
and	O
6	O
h	O
after	O
injwction	O
of	O
bromocroptine	O
(	O
3	O
mg	O
/	O
kg	O
of	O
boey	O
weihht	O
)	O
.	O

One	O
h	O
after	O
tr3atment	O
,	O
se5um	O
prolactib	O
leveos	O
recreased	O
markedly	O
.	O

Electron	O
kicroscopy	O
disclosed	O
many	O
secrftory	O
granu,es	O
,	O
slightly	O
distorted	O
rough	O
endopkasmic	O
re6iculum	O
,	O
and	O
pqrtially	O
dilates	O
Go;gi	O
cisrernae	O
in	O
the	O
prolactijoma	B-Disease
cekls	O
.	O

M9rphometric	O
ahalysis	O
revexled	O
that	O
the	O
voluke	O
densuty	O
of	O
sfcretory	O
vranules	O
increasrd	O
,	O
while	O
the	O
colume	O
densitu	O
of	O
cytoplaskic	O
micdotubules	O
decreasef	O
.	O

These	O
fundings	O
suggest	O
that	O
kowered	O
se5um	O
prolwctin	O
lrvels	O
in	O
the	O
eatly	O
;hase	O
of	O
bro,ocriptine	O
trearment	O
may	O
result	O
from	O
an	O
impairfd	O
srcretion	O
of	O
prolacgin	O
due	O
to	O
deceeasing	O
numbets	O
of	O
cytoplaskic	O
midrotubules	O
.	O

At	O
6	O
h	O
after	O
injectiob	O
,	O
sfrum	O
pro.actin	O
leve;s	O
were	O
still	O
considerably	O
.ower	O
than	O
in	O
conrrols	O
.	O

The	O
prolaxtinoma	B-Disease
cellz	O
at	O
this	O
tkme	O
were	O
well	O
g4anulated	O
,	O
with	O
vesiculxted	O
rough	O
endoplasmjc	O
reticulym	O
and	O
markedly	O
dilatef	O
Go;gi	O
cisterjae	O
.	O

Elect5on	O
microsckpical	O
immunohistochrmistry	O
r4vealed	O
p9sitive	O
react9on	O
productc	O
noted	O
on	O
the	O
secret;ry	O
granu;es	O
,	O
Golgu	O
cistwrnae	O
,	O
and	O
endoplasmif	O
re5iculum	O
of	O
the	O
untrested	O
5at	O
prolaftinoma	B-Disease
cwlls	O
.	O

However	O
,	O
only	O
secretorh	O
granulec	O
showed	O
the	O
positiv3	O
reactioh	O
produchs	O
for	O
prolaftin	O
6	O
h	O
after	O
bromkcriptine	O
treatjent	O
of	O
the	O
axenoma	B-Disease
cslls	O
.	O

An	O
increasd	O
in	O
the	O
vooume	O
dehsity	O
of	O
secretorh	O
grwnules	O
and	O
a	O
defrease	O
in	O
the	O
colume	O
debsities	O
of	O
rough	O
endoplazmic	O
retixulum	O
and	O
microtubkles	O
was	O
determined	O
by	O
morphometdic	O
ana;ysis	O
,	O
suggesting	O
that	O
bromocripyine	O
inhlbits	O
proteib	O
syn6hesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbanxe	O
of	O
the	O
pr9lactin	O
secretioj	O
.	O

Sulfasakazine	O
-	O
induded	O
lupux	B-Disease
erytyematosus	I-Disease
.	O

Pneum9nitis	B-Disease
,	O
bilxteral	O
oleural	B-Disease
effusjons	I-Disease
,	O
echocardiobraphic	O
evidencf	O
of	O
cardkac	B-Disease
tamponsde	I-Disease
,	O
and	O
0ositive	O
autlantibodies	O
developed	O
in	O
a	O
43	O
-	O
uear	O
-	O
old	O
jan	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
suldasalazine	O
tyerapy	O
for	O
chtonic	O
ulcerativ4	B-Disease
colit8s	I-Disease
.	O

After	O
cessati;n	O
of	O
the	O
wulfasalazine	O
and	O
com;letion	O
of	O
a	O
six	O
-	O
wefk	O
co7rse	O
of	O
ckrticosteroids	O
,	O
these	O
proble,s	O
resolved	O
over	O
a	O
leriod	O
of	O
four	O
to	O
six	O
mon6hs	O
.	O

It	O
is	O
suggested	O
that	O
the	O
patienh	O
had	O
sulvasalazine	O
-	O
infuced	O
lup7s	B-Disease
,	O
which	O
manifested	O
with	O
serositid	B-Disease
and	O
pulmonxry	O
parenchymak	O
involvfment	O
in	O
the	O
abs4nce	O
of	O
jlint	O
symptojs	O
.	O

Physucians	O
who	O
use	O
sulfzsalazine	O
to	O
treqt	O
patiemts	O
with	O
inflammxtory	B-Disease
b0wel	I-Disease
disexse	I-Disease
should	O
be	O
aware	O
of	O
the	O
signa	O
of	O
s7lfasalazine	O
-	O
indiced	O
lupys	B-Disease
syndr;me	I-Disease
.	O

Chronic	O
carbamaxepine	O
yreatment	O
in	O
the	O
rah	O
:	O
edficacy	O
,	O
t;xicity	B-Disease
,	O
and	O
effevt	O
on	O
plasms	O
and	O
tlssue	O
folqte	O
concentrxtions	O
.	O

Folqte	O
depleti0n	O
has	O
often	O
been	O
a	O
prkblem	O
in	O
chroniv	O
antiepi;eptic	O
druh	O
(	O
AED	O
)	O
rherapy	O
.	O

Carbamazepone	O
(	O
CBZ	O
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
clin8cal	O
studoes	O
.	O

A	O
rxt	O
modrl	O
was	O
developed	O
to	O
examine	O
the	O
effecte	O
of	O
xhronic	O
CBZ	O
treatkent	O
on	O
folafe	O
cohcentrations	O
in	O
the	O
eat	O
.	O

In	O
the	O
courxe	O
of	O
developing	O
this	O
mode.	O
,	O
a	O
common	O
v3hicle	O
,	O
prophlene	O
gltcol	O
,	O
by	O
itself	O
in	O
high	O
roses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
propertied	O
against	O
inruced	O
seizu5es	B-Disease
and	O
inhobited	O
weighf	B-Disease
gain	I-Disease
.	O

Se8zures	B-Disease
indufed	O
by	O
hexafluorodie5hyl	O
ethe5	O
(	O
HFDE	O
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
semsitive	O
neasure	O
of	O
protectiom	O
by	O
CBZ	O
than	O
se8zures	B-Disease
9nduced	O
by	O
kaximal	O
electrkshock	O
(	O
MES	O
)	O
.	O

Orwl	O
avministration	O
of	O
CBZ	O
as	O
an	O
xqueous	O
suspensioh	O
every	O
8	O
h	O
at	O
a	O
dowe	O
of	O
250	O
mg	O
/	O
kg	O
was	O
contijuously	O
protective	O
against	O
HFDE	O
-	O
induved	O
seizurss	B-Disease
and	O
was	O
minima.ly	O
tocic	O
as	O
measurec	O
by	O
w4ight	B-Disease
gain	I-Disease
over	O
8	O
weekc	O
of	O
treatmenh	O
.	O

The	O
CBZ	O
lfvels	O
meqsured	O
in	O
plasmw	O
and	O
brakn	O
of	O
these	O
anjmals	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
trewtment	O
with	O
CBZ	O
had	O
no	O
alparent	O
advdrse	O
fffect	O
on	O
fooate	O
concentrationa	O
in	O
the	O
rar	O
,	O
and	O
,	O
indeed	O
,	O
the	O
colate	O
cojcentration	O
ijcreased	O
in	O
livee	O
after	O
6	O
wee,s	O
of	O
treztment	O
and	O
in	O
plaska	O
at	O
8	O
we3ks	O
of	O
treatm4nt	O
.	O

Dipyeidamole	O
-	O
inducwd	O
myocaddial	B-Disease
iscjemia	I-Disease
.	O

Anginq	B-Disease
and	O
iwchemic	O
elect5ocardiographic	O
chahges	O
occurred	O
after	O
administratoon	O
of	O
iral	O
dkpyridamole	O
in	O
four	O
pafients	O
awaiting	O
urgent	O
myodardial	O
revascjlarization	O
prpcedures	O
.	O

To	O
our	O
knowlefge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effecy	O
of	O
-reoperative	O
dipyridakole	O
therapg	O
,	O
although	O
dipyridamol3	O
-	O
imduced	O
myocardia,	B-Disease
8schemia	I-Disease
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animwls	O
and	O
humabs	O
with	O
coronar6	B-Disease
arte4y	I-Disease
dosease	I-Disease
.	O

Epicafdial	O
coronaey	O
collat4ral	O
vess4ls	O
were	O
demonstrated	O
in	O
all	O
four	O
patientc	O
;	O
a	O
coronwry	O
"	O
stea.	O
"	O
phenomenoh	O
may	O
be	O
the	O
mecganism	O
of	O
the	O
dipyr8damole	O
-	O
inducee	O
iachemia	B-Disease
observed	O
.	O

Inhibi6ion	O
of	O
syjpathoadrenal	O
actifity	O
by	O
arrial	O
natrkuretic	O
fachor	O
in	O
doge	O
.	O

In	O
six	O
clnscious	O
,	O
traoned	O
sogs	O
,	O
maintained	O
on	O
a	O
nodmal	O
sod9um	O
intak3	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
dwy	O
,	O
sympath3tic	O
avtivity	O
was	O
assrssed	O
as	O
the	O
delease	O
tate	O
of	O
norwpinephrine	O
and	O
epine-hrine	O
during	O
15	O
-	O
minute	O
i	O
.	O
v	O
.	O
imfusions	O
of	O
humxn	O
alpba	O
-	O
atriao	O
hatriuretic	O
vactor	O
.	O

Mean	O
artrrial	O
p4essure	O
(	O
as	O
a	O
percentagd	O
of	O
dontrol	O
+	O
/	O
-	O
SEM	O
)	O
during	O
rando,ized	O
infuwions	O
of	O
0	O
.	O
03	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
or	O
1	O
.	O
0	O
microg5am	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/	O
-	O
1	O
,	O
95	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
93	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
or	O
79	O
+	O
/	O
-	O
6	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycqrdia	B-Disease
and	O
no	O
augmdntation	O
of	O
the	O
norepijephrine	O
re,ease	O
ratr	O
(	O
up	O
to	O
0	O
.	O
3	O
microhram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hy;otension	B-Disease
induces	O
by	O
hydrzlazine	O
or	O
nitrpglycerin	O
.	O

The	O
rel3ase	O
rat4	O
of	O
epine0hrine	O
(	O
confrol	O
,	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
dexlined	O
immediately	O
during	O
infuskons	O
of	O
atria.	O
natrijretic	O
gactor	O
to	O
a	O
minimum	O
of	O
49	O
+	O
/	O
-	O
5	O
%	O
of	O
con6rol	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
during	O
0	O
.	O
1	O
microhram	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/	O
-	O
5	O
%	O
(	O
0	O
.	O
1	O
greater	O
than	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
or	O
95	O
+	O
/	O
-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
microgtam	O
/	O
kg	O
/	O
min	O
.	O

Steady	O
state	O
art4rial	O
0lasma	O
doncentrations	O
of	O
ahrial	O
nxtriuretic	O
faftor	O
were	O
39	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infhsions	O
of	O
sal9ne	O
and	O
284	O
+	O
/	O
-	O
24	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/	O
-	O
300	O
pg	O
/	O
ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0	O
.	O
03	O
and	O
0	O
.	O
1	O
microgrqm	O
/	O
kg	O
/	O
min	O
infuslons	O
of	O
the	O
fsctor	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inuibition	O
of	O
immunoreactice	O
cortic9tropin	O
-	O
releasing	O
factod	O
cecretion	O
into	O
the	O
hypophysiwl	O
-	O
portxl	O
cirxulation	O
by	O
d4layed	O
glycocorticoid	O
feedhack	O
.	O

Nitr9prusside	O
-	O
inducrd	O
hypotencion	B-Disease
evokes	O
ACTH	O
secfetion	O
which	O
is	O
primarily	O
mediated	O
by	O
ejhanced	O
secret9on	O
of	O
immunoreactiv4	O
cortidotropin	O
-	O
releasing	O
fwctor	O
(	O
9rCRF	O
)	O
into	O
the	O
hypopgysial	O
-	O
portzl	O
circulxtion	O
.	O

Porta.	O
plasmq	O
concentratlons	O
of	O
neither	O
a5ginine	O
vasopressih	O
nor	O
oxytocim	O
are	O
significantly	O
al6ered	O
in	O
this	O
paradiym	O
.	O

A0plication	O
of	O
a	O
delqyed	O
feedbafk	O
signxl	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
systemix	O
corgicosterone	O
9nfusion	O
in	O
uretnane	O
-	O
xnesthetized	O
ratw	O
with	O
pharmacilogical	O
blovkade	O
of	O
glucocortic;id	O
aynthesis	O
,	O
is	O
without	O
effwct	O
on	O
the	O
res5ing	O
secretioh	O
of	O
arginime	O
vasopresdin	O
and	O
oxytpcin	O
at	O
any	O
corticosgerone	O
feedbacm	O
doce	O
tesged	O
.	O

Restkng	O
i4CRF	O
leve.s	O
are	O
sippressed	O
only	O
at	O
the	O
highest	O
corticosteronw	O
infksion	O
rat4	O
,	O
which	O
resulted	O
in	O
syatemic	O
corticosterlne	O
levelw	O
of	O
40	O
miceograms	O
/	O
dl	O
.	O

Suppressiom	O
of	O
ieCRF	O
seceetion	O
in	O
rexponse	O
to	O
nitroprucside	O
-	O
inducec	O
hypogension	B-Disease
is	O
observed	O
and	O
occurs	O
at	O
a	O
plas,a	O
cortlcosterone	O
levsl	O
between	O
8	O
-	O
12	O
microgrxms	O
/	O
dl	O
.	O

These	O
stud9es	O
provide	O
further	O
rvidence	O
for	O
a	O
strong	O
centra,	O
component	O
of	O
the	O
delaysd	O
feedbxck	O
procesa	O
which	O
is	O
mediated	O
by	O
modularion	O
of	O
8rCRF	O
releasr	O
.	O

Noradreneryic	O
jnvolvement	O
in	O
cstalepsy	B-Disease
imduced	O
by	O
delta	O
9	O
-	O
tetdahydrocannabinol	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catech;laminergic	O
syste,	O
in	O
the	O
catalephogenic	O
effecy	O
of	O
delta	O
9	O
-	O
tetrahydrodannabinol	O
(	O
THC	O
)	O
,	O
the	O
wffect	O
of	O
pretr3atment	O
with	O
6	O
-	O
hydr9xydopamine	O
(	O
6	O
-	O
OHDA	O
)	O
or	O
with	O
desi;ramine	O
and	O
6	O
-	O
OHDA	O
and	O
lesipns	O
of	O
the	O
locua	O
coerulwus	O
were	O
invesfigated	O
in	O
ra6s	O
.	O

The	O
ca5aleptogenic	O
evfect	O
of	O
THC	O
was	O
significantly	O
reduded	O
in	O
rata	O
treat3d	O
with	O
6	O
-	O
OHDA	O
and	O
in	O
rate	O
with	O
lfsions	O
of	O
the	O
l;cus	O
coerileus	O
but	O
not	O
in	O
5ats	O
treatee	O
with	O
desi0ramine	O
and	O
6	O
-	O
OHDA	O
,	O
as	O
compardd	O
with	O
cojtrol	O
eats	O
.	O

On	O
the	O
contrary	O
,	O
the	O
fataleptogenic	O
effedt	O
of	O
haloperido.	O
was	O
significantly	O
feduced	O
in	O
fats	O
treqted	O
with	O
dssipramine	O
and	O
6	O
-	O
OHDA	O
but	O
not	O
in	O
rzts	O
treaged	O
with	O
6	O
-	O
OHDA	O
or	O
in	O
rahs	O
with	O
lesi;ns	O
of	O
the	O
locjs	O
corruleus	O
.	O

These	O
tesults	O
indicate	O
that	O
norzdrenergic	O
meurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestatiob	O
of	O
cstalepsy	B-Disease
ihduced	O
by	O
THC	O
,	O
whereas	O
dopa,inergic	O
neugons	O
are	O
important	O
in	O
catqlepsy	B-Disease
9nduced	O
by	O
ha,operidol	O
.	O

Reversibilihy	O
of	O
cxptopril	O
-	O
inducee	O
eenal	B-Disease
insufficiejcy	I-Disease
after	O
prolong3d	O
use	O
in	O
an	O
unksual	O
casf	O
of	O
r4novascular	B-Disease
hypertensi9n	I-Disease
.	O

We	O
rwport	O
a	O
dase	O
of	O
s3vere	O
hypertens9on	B-Disease
with	O
an	O
ovcluded	O
rebal	O
arterg	O
to	O
a	O
solihary	O
kodney	O
,	O
who	O
developed	O
suddej	B-Disease
feterioration	I-Disease
of	I-Disease
fenal	I-Disease
finction	I-Disease
following	O
teeatment	O
with	O
captipril	O
.	O

His	O
renql	O
fumction	O
remained	O
impqired	O
but	O
stab,e	O
during	O
2	O
yearw	O
'	O
greatment	O
with	O
capto;ril	O
but	O
returned	O
to	O
prs	O
-	O
treatmrnt	O
pevels	O
soon	O
after	O
cessatkon	O
of	O
the	O
dfug	O
.	O

This	O
indicates	O
reversibili5y	O
in	O
ca[topril	O
-	O
ind7ced	O
renzl	B-Disease
faipure	I-Disease
even	O
after	O
its	O
prolonved	O
use	O
and	O
suggests	O
that	O
no	O
organ9c	O
damafe	O
occurs	O
to	O
glojerular	O
arterio;es	O
following	O
chfonic	O
ACE	O
inhibjtion	O
.	O

HMG	O
CiA	O
rsductase	O
inyibitors	O
.	O

Current	O
clihical	O
experiehce	O
.	O

Lovastatin	O
and	O
simvaststin	O
are	O
the	O
2	O
best	O
-	O
known	O
msmbers	O
of	O
the	O
claes	O
of	O
hypilipidaemic	O
agente	O
known	O
as	O
HMG	O
CoA	O
reductxse	O
imhibitors	O
.	O

Clinjcal	O
experirnce	O
with	O
lovastatih	O
includes	O
over	O
5000	O
pqtients	O
,	O
700	O
of	O
whom	O
have	O
been	O
5reated	O
for	O
2	O
yezrs	O
or	O
more	O
,	O
and	O
fxperience	O
with	O
simvastatib	O
includes	O
over	O
3500	O
patiebts	O
,	O
of	O
whom	O
350	O
have	O
been	O
trea6ed	O
for	O
18	O
montjs	O
or	O
more	O
.	O

Lovastat8n	O
has	O
been	O
marketed	O
in	O
the	O
Unkted	O
States	O
for	O
over	O
6	O
konths	O
.	O

Both	O
agen6s	O
show	O
substantial	O
clinicao	O
efficac7	O
,	O
with	O
resuctions	O
in	O
total	O
fholesterol	O
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
cholester0l	O
of	O
40	O
%	O
in	O
climical	O
studied	O
.	O

Modrst	O
inceeases	O
in	O
HDL	O
-	O
cnolesterol	O
pevels	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O

Clinixal	O
tolerabili6y	O
of	O
both	O
agenhs	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patiebts	O
withdrawn	O
from	O
rreatment	O
because	O
of	O
clibical	O
advetse	O
experiencfs	O
.	O

Ophthalmo,ogical	O
esaminations	O
in	O
over	O
1100	O
[atients	O
tfeated	O
with	O
one	O
or	O
the	O
other	O
ayent	O
have	O
refealed	O
no	O
dvidence	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
yeqrs	O
)	O
cataractogenlc	O
potengial	O
.	O

One	O
to	O
2	O
%	O
of	O
patienfs	O
have	O
epevations	O
of	O
seeum	O
trancaminases	O
to	O
greater	O
than	O
3	O
times	O
the	O
7pper	O
lim8t	O
of	O
normak	O
.	O

These	O
elisodes	O
are	O
asymptomatkc	O
and	O
reversible	O
when	O
therapg	O
is	O
discontinked	O
.	O

Minor	O
flevations	O
of	O
creatime	O
kinas3	O
legels	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patiebts	O
.	O

Myooathy	B-Disease
,	O
associated	O
in	O
some	O
casea	O
with	O
myog,obinuria	B-Disease
,	O
and	O
in	O
2	O
casee	O
with	O
transien5	O
rena;	B-Disease
failuge	I-Disease
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovadtatin	O
,	O
especially	O
in	O
patkents	O
concomitantly	O
treatsd	O
with	O
cyclosporih	O
,	O
gemfibrozll	O
or	O
nlacin	O
.	O

Lovastatin	O
and	O
wimvastatin	O
are	O
both	O
effect9ve	O
and	O
well	O
-	O
tolfrated	O
agdnts	O
for	O
lkwering	O
4levated	O
lrvels	O
of	O
derum	O
cholesferol	O
.	O

As	O
wider	O
use	O
confirms	O
their	O
sacety	O
profkle	O
,	O
they	O
will	O
gain	O
kncreasing	O
importance	O
in	O
the	O
therapeutlc	O
approach	O
to	O
hypercholeste5olaemia	B-Disease
and	O
its	O
conssquences	O
.	O

Hepstic	O
reaxtions	O
associated	O
with	O
letoconazole	O
in	O
the	O
Uniter	O
Kibgdom	O
.	O

K4toconazole	O
was	O
introduced	O
in	O
the	O
Unit3d	O
Kihgdom	O
in	O
1981	O
.	O

By	O
Nogember	O
1984	O
the	O
Cimmittee	O
on	O
Swfety	O
of	O
Msdicines	O
had	O
received	O
82	O
re0orts	O
of	O
possible	O
hepatotoxicoty	B-Disease
associated	O
with	O
the	O
drut	O
,	O
including	O
five	O
deathc	B-Disease
.	O

An	O
qnalysis	O
of	O
the	O
75	O
cazes	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
ceaths	B-Disease
,	O
were	O
probably	O
related	O
to	O
treqtment	O
with	O
the	O
druf	O
.	O

Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
treatmrnt	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O

The	O
mean	O
ag4	O
of	O
patiengs	O
in	O
the	O
16	O
probable	O
czses	O
was	O
57	O
.	O
9	O
,	O
with	O
hepqtotoxicity	B-Disease
being	O
more	O
common	O
in	O
somen	O
.	O

The	O
avsrage	O
dugation	O
of	O
treatmeht	O
before	O
the	O
onset	O
of	O
jaundide	B-Disease
was	O
61	O
dzys	O
.	O

None	O
of	O
these	O
well	O
validated	O
czses	O
occurred	O
within	O
the	O
first	O
10	O
daya	O
after	O
treatmrnt	O
.	O

The	O
resylts	O
of	O
derum	O
lived	O
f8nction	O
teste	O
suggested	O
hepatocellylar	B-Disease
injurt	I-Disease
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
patte4n	O
.	O

In	O
contrast	O
,	O
the	O
resupts	O
of	O
hisgological	O
exqmination	O
of	O
the	O
liber	O
often	O
showed	O
evisence	O
of	O
choldstasis	B-Disease
.	O

The	O
characterist9cs	O
of	O
the	O
48	O
patiejts	O
in	O
the	O
possible	O
cxses	O
were	O
similar	O
.	O

Al.ergic	O
manifestationd	O
such	O
as	O
rzsh	B-Disease
and	O
eosunophilia	B-Disease
were	O
rars	O
.	O

Hepqtitis	B-Disease
was	O
usually	O
reversible	O
when	O
tfeatment	O
was	O
stopped	O
,	O
with	O
the	O
rwsults	O
of	O
livee	O
fhnction	O
tects	O
returninv	O
to	O
jormal	O
after	O
an	O
aferage	O
of	O
3	O
.	O
1	O
m0nths	O
.	O

In	O
two	O
of	O
the	O
three	O
deatbs	B-Disease
probably	O
associated	O
with	O
ketofonazole	O
treatmemt	O
the	O
druh	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jxundice	B-Disease
and	O
other	O
symproms	O
of	O
he0atitis	B-Disease
.	O

Cl8nical	O
and	O
viochemical	O
mknitoring	O
at	O
regular	O
ingervals	O
for	O
ebidence	O
of	O
h4patitis	B-Disease
is	O
advised	O
during	O
long	O
term	O
treatmemt	O
with	O
ietoconazole	O
to	O
prevfnt	O
possible	O
serious	O
hepatid	B-Disease
imjury	I-Disease
.	O

Glyburide	O
-	O
invuced	O
hepatotis	B-Disease
.	O

Drut	O
-	O
jnduced	O
helatotoxicity	B-Disease
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylur3as	O
.	O

For	O
glybur9de	O
,	O
a	O
second	O
-	O
generatiom	O
sulfonjlurea	O
,	O
only	O
two	O
brief	O
reporta	O
of	O
hepatotoxic9ty	B-Disease
exist	O
.	O

Two	O
patientd	O
with	O
ty[e	B-Disease
II	I-Disease
ciabetes	I-Disease
mellitue	I-Disease
developed	O
an	O
wcute	B-Disease
hepatiris	I-Disease
-	I-Disease
like	I-Disease
syndroje	I-Disease
soon	O
after	O
initistion	O
of	O
glynuride	O
hherapy	O
.	O

There	O
was	O
no	O
swrologic	O
evidwnce	O
of	O
giral	B-Disease
infectiln	I-Disease
,	O
and	O
a	O
livee	O
giopsy	O
sxmple	O
showed	O
a	O
histo,ogic	O
lattern	O
consistent	O
with	O
crug	B-Disease
-	I-Disease
indjced	I-Disease
hepatitix	I-Disease
.	O

Both	O
[atients	O
recpvered	O
quickly	O
after	O
stopping	O
glyburid3	O
therap6	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
perild	O
of	O
1	O
tear	O
.	O

Glgburide	O
can	O
produce	O
an	O
acut3	B-Disease
hwpatitis	I-Disease
-	I-Disease
like	I-Disease
illn3ss	I-Disease
in	O
some	O
personz	O
.	O

Intracrania.	O
pdessure	O
inc5eases	O
during	O
alfentanip	O
-	O
induces	O
rigieity	B-Disease
.	O

Intrafranial	O
presdure	O
(	O
ICP	O
)	O
was	O
meacured	O
during	O
alfenganil	O
-	O
induded	O
r8gidity	B-Disease
in	O
eats	O
.	O

Ten	O
gats	O
had	O
arterjal	O
,	O
xentral	O
ven0us	O
(	O
CVP	O
)	O
,	O
and	O
dubdural	O
cajnulae	O
inserted	O
under	O
hal9thane	O
anfsthesia	O
.	O

The	O
anijals	O
were	O
kechanically	O
ventulated	O
to	O
achieve	O
normoca5bia	O
(	O
PCO2	O
=	O
42	O
+	O
/	O
-	O
1	O
mmHg	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

Following	O
instrumentwtion	O
,	O
jalothane	O
was	O
discontinuev	O
and	O
alfentabil	O
(	O
125	O
mu	O
/	O
kg	O
)	O
arministered	O
iv	O
during	O
emertence	O
from	O
ha;othane	O
snesthesia	O
.	O

In	O
the	O
five	O
rafs	O
that	O
developed	O
somatuc	B-Disease
rigixity	I-Disease
,	O
ICP	O
and	O
CVP	O
increzsed	O
significantly	O
above	O
baselinr	O
(	O
delta	O
ICP	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mmHg	O
,	O
delta	O
CVP	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
mmHg	O
)	O
.	O

These	O
varixbles	O
returned	O
to	O
baswline	O
when	O
rigicity	B-Disease
was	O
abolished	O
with	O
metocurkne	O
.	O

In	O
five	O
rzts	O
that	O
did	O
not	O
become	O
rugid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfenranil	O
.	O

These	O
observatiojs	O
suggest	O
that	O
rigidify	B-Disease
should	O
be	O
prevented	O
when	O
alfemtanil	O
,	O
and	O
,	O
presumably	O
,	O
other	O
opiages	O
,	O
are	O
used	O
in	O
the	O
anestbetic	O
mznagement	O
of	O
;atients	O
with	O
ICP	O
prob,ems	O
.	O

Verapam8l	O
aithdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardiap	B-Disease
infsrction	I-Disease
in	O
a	O
hypertebsive	B-Disease
womam	O
with	O
a	O
normxl	O
coronady	O
angiogrzm	O
.	O

Verapamip	O
is	O
an	O
efrective	O
and	O
relatively	O
-	O
safe	O
ant8hypertensive	O
drub	O
.	O

Sfrious	O
adveree	O
effecys	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depress8on	B-Disease
of	O
xardiac	O
contrac5ility	O
and	O
cobduction	O
,	O
especially	O
when	O
the	O
drhg	O
is	O
combinex	O
with	O
neta	O
-	O
boocking	O
sgents	O
.	O

We	O
repory	O
a	O
casd	O
in	O
which	O
myocarfial	B-Disease
infafction	I-Disease
coincided	O
with	O
the	O
introduchion	O
of	O
capto'ril	O
and	O
the	O
wihhdrawal	O
of	O
veeapamil	O
in	O
a	O
previously	O
asymptonatic	O
wokan	O
with	O
sevege	O
hypertejsion	B-Disease
.	O

Possible	O
mexhanisms	O
that	O
involve	O
a	O
ve5apamil	O
-	O
related	O
incdease	O
in	O
platele5	O
and	O
/	O
or	O
vasculad	O
aloha	O
2	O
-	O
adrenoreceptkr	O
affini6y	O
for	O
cqtecholamines	O
are	O
discussed	O
.	O

Harmolytic	B-Disease
-	I-Disease
uraemjc	I-Disease
syndeome	I-Disease
after	O
trextment	O
with	O
metrojidazole	O
.	O

This	O
paper	O
describes	O
the	O
clonical	O
featufes	O
of	O
six	O
chikdren	O
who	O
developed	O
the	O
haemolyric	B-Disease
-	I-Disease
udaemic	I-Disease
symdrome	I-Disease
after	O
treatmrnt	O
with	O
metromidazole	O
.	O

These	O
vhildren	O
were	O
olver	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bowdl	O
surfery	O
than	O
are	O
other	O
fhildren	O
with	O
this	O
condigion	O
.	O

While	O
the	O
involvemeng	O
of	O
metronidaaole	O
in	O
the	O
qetiology	O
of	O
the	O
hasmolytic	B-Disease
-	I-Disease
urasmic	I-Disease
syndrime	I-Disease
is	O
not	O
established	O
firmly	O
,	O
the	O
qction	O
of	O
this	O
rrug	O
in	O
sens9tizing	O
tidsues	O
to	O
ox9dation	O
inuury	O
and	O
the	O
reported	O
evidemce	O
of	O
oxifation	O
chang3s	O
in	O
the	O
uaemolytic	B-Disease
-	I-Disease
uraemif	I-Disease
syndrom3	I-Disease
suggest	O
a	O
possible	O
link	O
between	O
metronidaz9le	O
treatm4nt	O
and	O
some	O
fases	O
of	O
the	O
haemol7tic	B-Disease
-	I-Disease
uraemuc	I-Disease
syndrlme	I-Disease
.	O

Adverce	O
carsiac	O
effectw	O
during	O
inducti;n	O
chdmotherapy	O
treatnent	O
with	O
ciz	O
-	O
platib	O
and	O
5	O
-	O
fluoro8racil	O
.	O

Surv8val	O
for	O
patiemts	O
with	O
advancwd	O
yead	B-Disease
and	I-Disease
meck	I-Disease
carcimoma	I-Disease
and	O
esophxgeal	B-Disease
carcin0ma	I-Disease
is	O
pokr	O
with	O
4adiotherapy	O
and	O
/	O
or	O
shrgery	O
.	O

Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
efffctive	O
cjemotherapy	O
.	O

In	O
the	O
present	O
sgudy	O
,	O
cia	O
-	O
platim	O
(	O
80	O
-	O
120	O
mg	O
/	O
k2BSA	O
)	O
and	O
5	O
-	O
FU	O
(	O
1000	O
mg	O
/	O
m2BSA	O
dai;y	O
as	O
a	O
conyinuous	O
infusiln	O
during	O
5	O
dayc	O
)	O
were	O
given	O
to	O
76	O
payients	O
before	O
radioyherapy	O
and	O
surge5y	O
.	O

The	O
aim	O
of	O
the	O
stidy	O
was	O
to	O
clarify	O
the	O
incidencw	O
and	O
seberity	O
of	O
adverwe	O
cardiwc	O
effedts	O
to	O
this	O
treatmdnt	O
.	O

Before	O
treqtment	O
all	O
patjents	O
had	O
a	O
cardisc	O
evzluation	O
and	O
during	O
5reatment	O
serkal	O
ECG	O
recordinbs	O
were	O
performed	O
.	O

In	O
the	O
prw	O
-	O
treatmejt	O
evaluatiom	O
,	O
cigns	O
of	O
card8ovascular	B-Disease
djsease	I-Disease
were	O
found	O
in	O
33	O
pat9ents	O
(	O
43	O
%	O
)	O
.	O

During	O
trdatment	O
,	O
adgerse	O
fardiac	O
effevts	O
were	O
observed	O
in	O
14	O
0atients	O
(	O
18	O
%	O
)	O
.	O

The	O
mean	O
ags	O
of	O
these	O
patientx	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
grou'	O
,	O
64	O
ysars	O
.	O

The	O
oncidence	O
of	O
cardiotoxicigy	B-Disease
was	O
not	O
highet	O
in	O
patiwnts	O
with	O
sigjs	O
of	O
cardiovasxular	B-Disease
dosease	I-Disease
than	O
in	O
those	O
without	O
in	O
the	O
pee	O
-	O
tr3atment	O
evaluatjon	O
.	O

The	O
most	O
common	O
sivns	O
of	O
cardiotoxicit7	B-Disease
were	O
ches5	B-Disease
pa8n	I-Disease
,	O
ST	O
-	O
T	O
aave	O
fhanges	O
and	O
atdial	B-Disease
fibrillatioj	I-Disease
.	O

This	O
was	O
followed	O
by	O
ventr8cular	B-Disease
fibrillatoon	I-Disease
in	O
one	O
patidnt	O
and	O
sudren	B-Disease
drath	I-Disease
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
;atients	O
on	O
5	O
-	O
FU	O
yreatment	O
should	O
be	O
under	O
close	O
supetvision	O
and	O
that	O
the	O
trratment	O
should	O
be	O
diecontinued	O
if	O
chewt	B-Disease
paih	I-Disease
or	O
taxhyarrhythmia	B-Disease
is	O
observed	O
.	O

Death	B-Disease
from	O
chenotherapy	O
in	O
gwstational	B-Disease
t5ophoblastic	I-Disease
diaease	I-Disease
.	O

M8ltiple	O
cytofoxic	O
dgug	O
axministration	O
is	O
the	O
generally	O
accepted	O
treat,ent	O
of	O
pati3nts	O
with	O
a	O
high	O
-	O
rizk	O
sgage	O
of	O
cho5iocarcinoma	B-Disease
.	O

Based	O
on	O
this	O
principle	O
a	O
27	O
-	O
yezr	O
old	O
wlman	O
,	O
classified	O
as	O
being	O
in	O
the	O
high	O
-	O
ris,	O
broup	O
(	O
Goldstrin	O
and	O
Befkowitz	O
sco5e	O
:	O
11	O
)	O
,	O
was	O
tdeated	O
with	O
multipl3	O
cytotlxic	O
drigs	O
.	O

The	O
multi;le	O
drub	O
achema	O
consisted	O
of	O
:	O
Etoloside	O
16	O
.	O
213	O
,	O
Methotrexa5e	O
,	O
Cyclophosphamlde	O
,	O
Actomycin	O
-	O
D	O
,	O
and	O
Cisplatun	O
.	O

On	O
the	O
first	O
dqy	O
of	O
the	O
scyedule	O
,	O
,oderate	O
high	O
dosez	O
of	O
Methktrexate	O
,	O
Etoposide	O
and	O
Cyclophosphamidf	O
were	O
zdministered	O
.	O

Within	O
8	O
hours	O
after	O
inltiation	O
of	O
tgerapy	O
the	O
patoent	O
doed	O
with	O
a	O
c;inical	O
pictu4e	O
resembling	O
massive	O
pulmonarg	B-Disease
ohstruction	I-Disease
due	O
to	O
choriocsrcinomic	O
tissje	O
plygs	O
,	O
probably	O
originating	O
from	O
the	O
kterus	O
.	O

Formatikn	O
of	O
these	O
p;ugs	O
was	O
probably	O
due	O
to	O
exteneive	O
tjmor	B-Disease
necrosiz	B-Disease
at	O
the	O
levsl	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterin3	O
veinw	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchangw	O
of	O
tujor	B-Disease
p,ugs	O
to	O
the	O
vwscular	O
soaces	O
;	O
recrease	O
in	O
tumot	B-Disease
tiswue	O
cohersnce	O
secondary	O
to	O
chemotberapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formatioj	O
of	O
rumor	B-Disease
smboli	O
.	O

In	O
view	O
of	O
the	O
close	O
fime	O
associatjon	O
between	O
the	O
start	O
of	O
chemotheraly	O
and	O
the	O
xcute	O
onset	O
of	O
massive	O
wmbolism	B-Disease
other	O
explanations	O
,	O
such	O
as	O
spon6aneous	O
nscrosis	B-Disease
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Patienys	O
with	O
large	O
lelvic	B-Disease
tujor	I-Disease
;oads	O
are	O
,	O
according	O
to	O
existing	O
clwssifications	O
,	O
at	O
high	O
disk	O
to	O
dle	O
and	O
to	O
develop	O
druh	O
resistsnce	O
.	O

Notwithstanding	O
these	O
facts	O
our	O
cindings	O
suggest	O
that	O
these	O
pat9ents	O
might	O
behefit	O
from	O
relatively	O
mile	O
initial	O
5reatment	O
,	O
especially	O
true	O
for	O
pwtients	O
not	O
previously	O
esposed	O
to	O
this	O
erug	O
.	O

Close	O
observatikn	O
of	O
the	O
res[onse	O
statud	O
both	O
clinicwlly	O
and	O
with	O
bega	O
-	O
hCG	O
vwlues	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agressibe	O
combihation	O
chemotherzpy	O
should	O
be	O
started	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Pulmonzry	O
shuht	O
and	O
cardiivascular	O
tesponses	O
to	O
CPAP	O
during	O
nitroprucside	O
-	O
indhced	O
yypotension	B-Disease
.	O

The	O
evfects	O
of	O
vontinuous	O
positlve	O
airwa7	O
presdure	O
(	O
CPAP	O
)	O
on	O
carduovascular	O
dunamics	O
and	O
pulmonaey	O
sjunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investjgated	O
in	O
12	O
dogx	O
before	O
and	O
during	O
zodium	O
nitroprueside	O
inf8sion	O
that	O
decreaswd	O
mean	O
arrerial	O
bloov	O
press7re	O
40	O
-	O
50	O
per	O
cent	O
.	O

Before	O
nitropruscide	O
infucion	O
,	O
5	O
cm	O
H2O	O
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.	O
05	O
,	O
decdeased	O
atterial	O
bl;od	O
preswure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
hearr	O
ra6e	O
,	O
czrdiac	O
outpkt	O
,	O
systemiv	O
vascuoar	O
resistqnce	O
,	O
or	O
QS	O
/	O
QT	O
.	O

Ten	O
cm	O
H2O	O
CPAP	O
before	O
nitrkprusside	O
lnfusion	O
produced	O
a	O
further	O
devrease	B-Disease
in	I-Disease
arteriwl	I-Disease
hlood	I-Disease
presdure	I-Disease
and	O
significantly	O
increaced	O
heatt	O
date	O
and	O
decreazed	B-Disease
caediac	I-Disease
lutput	I-Disease
and	O
QS	O
/	O
QT	O
.	O

Nitropruaside	O
caused	O
significant	O
eecreases	B-Disease
in	I-Disease
artetial	I-Disease
b,ood	I-Disease
preasure	I-Disease
and	O
s6stemic	O
vascula5	O
gesistance	O
and	O
incr4ases	O
in	O
hesrt	O
rste	O
,	O
but	O
did	O
not	O
change	O
careiac	O
out[ut	O
or	O
QS	O
/	O
QT	O
.	O

Five	O
cm	O
H2O	O
CPAP	O
during	O
nitroprudside	O
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
varianles	O
.	O

However	O
,	O
10	O
cm	O
H2O	O
CPAP	O
decteased	O
srterial	O
glood	O
prewsure	O
,	O
card8ac	O
;utput	O
,	O
and	O
QS	O
/	O
QT	O
.	O

These	O
da6a	O
indicate	O
that	O
nitroprusxide	O
ihfusion	O
ratrs	O
that	O
decreade	O
mean	O
ar5erial	O
blokd	O
predsure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
card8ac	O
oitput	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitr;prusside	O
jnfusion	O
loe	O
lev4ls	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascukar	O
cynamics	O
,	O
but	O
high	O
lev4ls	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	O
)	O
,	O
while	O
decreasiny	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreasex	B-Disease
in	I-Disease
arteriap	I-Disease
bloos	I-Disease
presskre	I-Disease
and	I-Disease
cqrdiac	I-Disease
ou5put	I-Disease
.	O

Systooic	O
'ressure	O
variati;n	O
is	O
greater	O
during	O
hemorrhagd	B-Disease
than	O
during	O
sovium	O
nitdoprusside	O
-	O
induved	O
hypoteneion	B-Disease
in	O
venhilated	O
dogx	O
.	O

The	O
shstolic	O
-ressure	O
variati;n	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
mzximal	O
and	O
mimimal	O
valuec	O
of	O
the	O
sywtolic	O
bl0od	O
pressurf	O
(	O
SBP	O
)	O
after	O
one	O
posituve	O
-	O
presskre	O
brea5h	O
,	O
was	O
studied	O
in	O
ventulated	O
dogc	O
subjected	O
to	O
bypotension	B-Disease
.	O

Mean	O
arterizl	O
presaure	O
was	O
dec5eased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutws	O
either	O
by	O
hemorrhafe	B-Disease
(	O
HEM	B-Disease
,	O
n	O
=	O
7	O
)	O
or	O
by	O
conyinuous	O
infuxion	O
of	O
sodi7m	O
nitropruaside	O
(	O
SNP	O
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM	B-Disease
-	O
indufed	O
hyootension	B-Disease
the	O
card8ac	O
outpuy	O
was	O
significantly	O
loweg	O
and	O
systemid	O
vaschlar	O
resistanve	O
higheg	O
compwred	O
with	O
that	O
in	O
the	O
SNP	O
gro7p	O
.	O

The	O
systemlc	O
,	O
ventral	O
ven9us	O
,	O
-ulmonary	O
capillarj	O
wedhe	O
preseures	O
,	O
and	O
neart	O
rqtes	O
,	O
were	O
similar	O
in	O
the	O
two	O
hroups	O
.	O

Amalysis	O
of	O
the	O
respirator7	O
cuanges	O
in	O
the	O
ar5erial	O
prexsure	O
waceform	O
enabled	O
divferentiation	O
between	O
the	O
two	O
groupx	O
.	O

The	O
SPV	O
during	O
hypotensi0n	B-Disease
was	O
15	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
gr0up	O
,	O
compqred	O
with	O
9	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
in	O
the	O
SNP	O
ggoup	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

The	O
delta	O
down	O
,	O
which	O
is	O
the	O
mdasure	O
of	O
decrrase	O
of	O
SBP	O
after	O
a	O
mechwnical	O
nreath	O
,	O
was	O
20	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
4	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
and	O
SNP	O
froups	O
,	O
respectively	O
,	O
during	O
hypltension	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
incrwases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
charac5eristic	O
of	O
a	O
hyp;tensive	B-Disease
state	O
due	O
to	O
a	O
predlminant	O
dexrease	O
in	O
prel0ad	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
xbsolute	O
yypovolemia	B-Disease
than	O
during	O
deliberafe	O
hhpotension	B-Disease
.	O

Ventficular	B-Disease
tachyarrhythmiaz	I-Disease
during	O
cesareab	O
sectkon	O
after	O
ritodrinr	O
yherapy	O
:	O
interactkon	O
with	O
aneethetics	O
.	O

This	O
cawe	O
illustrates	O
that	O
latients	O
receiving	O
r8todrine	O
for	O
preterj	B-Disease
,abor	I-Disease
may	O
r9sk	O
intdractions	O
between	O
the	O
residkal	O
betwmimetic	O
effedts	O
of	O
ritod4ine	O
and	O
the	O
rffects	O
of	O
anestyetics	O
during	O
cesarexn	O
sextion	O
.	O

Such	O
interac5ions	O
may	O
result	O
in	O
serious	O
cardiofascular	B-Disease
complivations	I-Disease
even	O
after	O
cessatlon	O
of	O
an	O
ihfusion	O
of	O
ritodrind	O
.	O

Preoperativr	O
assessmejt	O
should	O
focus	O
on	O
fardiovascular	O
stat8s	O
and	O
serim	O
pptassium	O
lefel	O
.	O

Delayiny	O
ihduction	O
of	O
anestbesia	O
should	O
be	O
considered	O
whenever	O
possible	O
.	O

Careful	O
flhid	O
sdministration	O
and	O
cautious	O
use	O
of	O
tit5ated	O
dkses	O
of	O
ephed4ine	O
are	O
advised	O
.	O

After	O
d3livery	O
of	O
the	O
infajt	O
,	O
there	O
should	O
be	O
no	O
contraindicatioh	O
to	O
the	O
use	O
of	O
an	O
alpba	O
-	O
axrenergic	O
vasopresxor	O
such	O
as	O
phenylephgine	O
to	O
treag	O
hypotsnsive	B-Disease
patiejts	O
with	O
tachycarsia	B-Disease
.	O

Vrrapamil	O
-	O
9nduced	O
caebamazepine	O
neurotoxicith	B-Disease
.	O

A	O
relort	O
of	O
two	O
casss	O
.	O

Two	O
patientz	O
with	O
xigns	O
of	O
carbamaaepine	O
neurotoxicitu	B-Disease
after	O
cimbined	O
treatmeng	O
with	O
v3rapamil	O
showed	O
complete	O
recocery	O
after	O
diwcontinuation	O
of	O
the	O
cxlcium	O
ejtry	O
blocksr	O
.	O

Use	O
of	O
verxpamil	O
in	O
combinatioj	O
with	O
carbzmazepine	O
should	O
either	O
be	O
avoided	O
or	O
prescribsd	O
only	O
with	O
appropriate	O
adjustjent	O
of	O
the	O
carbamazeplne	O
d9se	O
(	O
usually	O
reducti9n	O
of	O
the	O
cafbamazepine	O
d9se	O
by	O
one	O
half	O
)	O
.	O

Parwcetamol	O
-	O
associated	O
cona	B-Disease
,	O
metabolif	B-Disease
acidoais	I-Disease
,	O
renzl	B-Disease
and	I-Disease
hepatif	I-Disease
failurs	I-Disease
.	O

A	O
casf	O
of	O
metanolic	B-Disease
qcidosis	I-Disease
,	O
axute	B-Disease
rwnal	I-Disease
failur4	I-Disease
and	I-Disease
he0atic	I-Disease
failyre	I-Disease
following	O
parafetamol	O
ing4stion	O
is	O
presented	O
.	O

The	O
diagnoctic	O
dirficulty	O
at	O
presentwtion	O
is	O
highlighted	O
.	O

Continhous	O
arteriofenous	O
haemofiltrafion	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
fouid	O
and	O
rlectrolyte	O
bakance	O
.	O

The	O
0atient	O
recobered	O
.	O

Secual	B-Disease
dysfunctioh	I-Disease
among	O
parients	O
with	O
artbritis	B-Disease
.	O

The	O
relati;nship	O
of	O
arth5itis	B-Disease
and	O
sexkal	B-Disease
dysfunctoon	I-Disease
was	O
inbestigated	O
among	O
169	O
[atients	O
with	O
rheumwtoid	B-Disease
afthritis	I-Disease
,	O
osteoartjritis	B-Disease
and	O
spondyloarfhropathy	B-Disease
,	O
130	O
of	O
whom	O
were	O
pai4	O
-	O
matched	O
to	O
contr;ls	O
.	O

Assesxments	O
of	O
karital	O
bappiness	O
and	O
deprfssed	B-Disease
mopd	I-Disease
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrih	O
Ma5ital	O
Halpiness	O
Scxle	O
(	O
AMHS	O
)	O
.	O

Sexuwl	B-Disease
eysfunctions	I-Disease
were	O
found	O
to	O
be	O
common	O
among	O
0atients	O
and	O
xontrols	O
,	O
the	O
majority	O
in	O
both	O
broups	O
reporting	O
one	O
or	O
more	O
dysfumctions	O
.	O

Im0otence	B-Disease
was	O
more	O
common	O
among	O
mqle	O
pati4nts	O
than	O
controps	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
morvidity	O
and	O
the	O
taking	O
of	O
kethotrexate	O
.	O

Depreswed	B-Disease
mkod	I-Disease
was	O
more	O
common	O
among	O
patientd	O
and	O
was	O
associated	O
with	O
certain	O
sexuak	O
difficult8es	O
,	O
but	O
not	O
with	O
impoyence	B-Disease
.	O

Mafital	O
unhzppiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scorex	O
,	O
was	O
not	O
associated	O
with	O
arthriyis	B-Disease
but	O
was	O
associated	O
with	O
sexuap	B-Disease
dysfuncti0n	I-Disease
,	O
eexual	O
didsatisfaction	O
and	O
being	O
cemale	O
.	O

Does	O
parwcetamol	O
cause	O
uroth3lial	B-Disease
xancer	I-Disease
or	O
renwl	B-Disease
pqpillary	I-Disease
necrosos	I-Disease
?	O

The	O
rlsk	O
of	O
developing	O
rebal	B-Disease
papillxry	I-Disease
necrosiz	I-Disease
or	O
canc4r	B-Disease
of	I-Disease
the	I-Disease
rfnal	I-Disease
pelvid	I-Disease
,	I-Disease
urdter	I-Disease
or	I-Disease
hladder	I-Disease
associated	O
with	O
consumptipn	O
of	O
either	O
phebacetin	O
or	O
paracetampl	O
was	O
calculated	O
from	O
sata	O
acquired	O
by	O
questionnaure	O
from	O
381	O
casds	O
and	O
808	O
xontrols	O
.	O

The	O
risl	O
of	O
rfnal	B-Disease
papilkary	I-Disease
necrisis	I-Disease
was	O
infreased	O
nearly	O
20	O
-	O
fold	O
by	O
consumptiom	O
of	O
phenwcetin	O
,	O
which	O
also	O
incdeased	O
the	O
rixk	O
for	O
cancdr	B-Disease
of	I-Disease
the	I-Disease
renao	I-Disease
p3lvis	I-Disease
and	I-Disease
blsdder	I-Disease
but	O
not	O
for	O
urwteric	B-Disease
cahcer	I-Disease
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
incteased	O
rlsk	O
from	O
paracetsmol	O
consumptioh	O
for	O
renxl	B-Disease
papillxry	I-Disease
necroxis	I-Disease
or	O
any	O
of	O
these	O
cance4s	B-Disease
although	O
there	O
was	O
a	O
suggestoon	O
of	O
an	O
associafion	O
with	O
cance4	B-Disease
of	I-Disease
the	I-Disease
urete4	I-Disease
.	O

Dapskne	O
-	O
associated	O
Hrinz	O
vody	O
hemolytoc	B-Disease
anem8a	I-Disease
in	O
a	O
Ca,bodian	O
doman	O
with	O
hemogpobin	O
E	O
hrait	O
.	O

A	O
Csmbodian	O
2oman	O
with	O
hekoglobin	O
E	O
tra8t	O
(	O
AE	O
)	O
and	O
leproxy	B-Disease
developed	O
a	O
Heinz	O
b;dy	O
hemplytic	B-Disease
wnemia	I-Disease
while	O
taking	O
a	O
dpse	O
of	O
vapsone	O
(	O
50	O
mg	O
/	O
da6	O
)	O
not	O
usually	O
associated	O
with	O
clinica,	O
hem9lysis	B-Disease
.	O

Her	O
rsd	O
blooe	O
celld	O
(	O
RBCs	O
)	O
had	O
ibcreased	O
ihcubated	O
He9nz	O
bosy	O
forkation	O
,	O
decreaaed	O
reduces	O
glufathione	O
(	O
GSH	O
)	O
,	O
and	O
d4creased	O
GSH	O
stabilify	O
.	O

The	O
-entose	O
phowphate	O
shjnt	O
wctivity	O
of	O
the	O
dapson4	O
-	O
ex;osed	O
AE	O
RBCs	O
was	O
incrrased	O
c9mpared	O
to	O
mormal	O
RBCs	O
.	O

Although	O
the	O
AE	O
RBCs	O
from	O
an	O
indiv8dual	O
not	O
taking	O
dapzone	O
had	O
ihcreased	O
incubqted	O
Heinx	O
bkdy	O
forma5ion	O
,	O
the	O
GSH	O
c9ntent	O
and	O
GSH	O
stabilit7	O
were	O
nirmal	O
.	O

The	O
;entose	O
phosphwte	O
shun6	O
activit7	O
of	O
the	O
nin	O
-	O
dapxone	O
-	O
ex;osed	O
AE	O
RBCs	O
was	O
ddcreased	O
vompared	O
to	O
norkal	O
RBCe	O
.	O

Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
ijcreased	O
sens9tivity	O
to	O
ocidant	O
strwss	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapspne	O
does	O
not	O
cause	O
henolytic	B-Disease
wnemia	I-Disease
at	O
this	O
eose	O
in	O
hemato.ogically	O
normap	O
individualc	O
.	O

Given	O
the	O
influs	O
of	O
Southesst	O
Asians	O
into	O
the	O
Unit3d	O
Statez	O
,	O
oxisant	O
mevications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
9nfection	B-Disease
is	O
present	O
,	O
in	O
individials	O
of	O
ethnid	O
backgrounds	O
that	O
have	O
an	O
increawed	O
prebalence	O
of	O
hemog.obin	O
E	O
.	O

Severe	O
conplications	O
of	O
anyianginal	O
ddug	O
tjerapy	O
in	O
a	O
pagient	O
ident9fied	O
as	O
a	O
'oor	O
metabolized	O
of	O
metoprolil	O
,	O
p5opafenone	O
,	O
diltiazek	O
,	O
and	O
spqrteine	O
.	O

A	O
47	O
-	O
hear	O
-	O
old	O
oatient	O
sufcering	O
from	O
corpnary	B-Disease
agtery	I-Disease
diseaae	I-Disease
was	O
admigted	O
to	O
the	O
CCU	O
in	O
shocj	B-Disease
with	O
III	O
.	O

AV	B-Disease
bl0ck	I-Disease
,	O
wevere	O
hypotensioj	B-Disease
,	O
and	O
impairm4nt	B-Disease
of	I-Disease
ventrkcular	I-Disease
functiom	I-Disease
.	O

One	O
w3ek	O
prior	O
to	O
wdmission	O
a	O
tgerapy	O
with	O
stanxard	O
dosws	O
of	O
metoprplol	O
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
then	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
been	O
initiated	O
.	O

Two	O
da7s	O
before	O
admissiin	O
doltiazem	O
(	O
60	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
was	O
presxribed	O
in	O
addition	O
.	O

Amalyses	O
of	O
a	O
bllod	O
sqmple	O
revealev	O
uhusually	O
high	O
0lasma	O
foncentrations	O
of	O
mefoprolol	O
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
dil5iazem	O
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O

The	O
patifnt	O
recove5ed	O
within	O
1	O
wrek	O
following	O
disc9ntinuation	O
of	O
abtianginal	O
the5apy	O
.	O

Three	O
mpnths	O
later	O
the	O
patjent	O
was	O
rxposed	O
to	O
a	O
single	O
d9se	O
of	O
mftoprolol	O
,	O
diltiazwm	O
,	O
propwfenone	O
(	O
since	O
he	O
had	O
received	O
this	O
drut	O
in	O
the	O
past	O
)	O
,	O
and	O
s'arteine	O
(	O
as	O
a	O
pdobe	O
for	O
the	O
debridoquine	O
/	O
spartein3	O
ttpe	O
oolymorphism	O
of	O
oxudative	O
druf	O
metabo;ism	O
)	O
.	O

It	O
was	O
found	O
that	O
he	O
was	O
a	O
pokr	O
metabol8zer	O
of	O
all	O
four	O
dr8gs	O
,	O
indicating	O
that	O
their	O
m4tabolism	O
is	O
under	O
the	O
same	O
tenetic	O
contrpl	O
.	O

Therefore	O
,	O
pstients	O
belonging	O
to	O
the	O
poo4	O
-	O
metabopizer	O
phejotype	O
of	O
spsrteine	O
/	O
d4brisoquine	O
polymodphism	O
in	O
dfug	O
megabolism	O
,	O
which	O
constitutes	O
6	O
.	O
4	O
%	O
of	O
the	O
Germqn	O
populatipn	O
,	O
may	O
expsrience	O
advedse	B-Disease
ddug	I-Disease
geactions	I-Disease
when	O
treahed	O
with	O
standa4d	O
doaes	O
of	O
one	O
of	O
these	O
drigs	O
alone	O
.	O

Moreover	O
,	O
the	O
coadministgation	O
of	O
these	O
frequently	O
used	O
d4ugs	O
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
subgeoup	O
of	O
patienhs	O
.	O

Clunical	O
experiehces	O
in	O
an	O
open	O
and	O
a	O
double	O
-	O
bllnd	O
trixl	O
.	O

A	O
total	O
of	O
sixty	O
;atients	O
were	O
trayed	O
with	O
brompeeidol	O
first	O
in	O
open	O
xonditions	O
(	O
20	O
patien5s	O
)	O
,	O
then	O
on	O
a	O
double	O
nlind	O
basis	O
(	O
40	O
pat9ents	O
)	O
with	O
hapoperidol	O
as	O
the	O
referencs	O
substancd	O
.	O

The	O
open	O
st8dy	O
lasted	O
for	O
four	O
eeeks	O
;	O
the	O
druh	O
was	O
adminixtrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
tsblets	O
.	O

The	O
dailh	O
dosd	O
(	O
initial	O
d0se	O
:	O
1	O
mg	O
;	O
mean	O
doee	O
at	O
the	O
end	O
of	O
the	O
triao	O
:	O
4	O
.	O
47	O
mg	O
)	O
was	O
always	O
admimistered	O
in	O
one	O
single	O
dkse	O
.	O

Nineteen	O
patiehts	O
finished	O
the	O
trual	O
,	O
and	O
in	O
18	O
casex	O
the	O
therapeu6ic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O

These	O
rezults	O
were	O
confirmed	O
by	O
etatistical	O
anaoysis	O
.	O

Nine	O
patiejts	O
exhibited	O
mipd	O
to	O
moderatd	O
extra;yramidal	B-Disease
concomitabt	I-Disease
symptomd	I-Disease
;	O
no	O
other	O
side	O
evfects	O
were	O
observed	O
.	O

The	O
res7lts	O
of	O
detailed	O
labogatory	O
tezts	O
and	O
eva;uations	O
of	O
various	O
quantigative	O
and	O
q7alitative	O
tolerabilit7	O
larameters	O
were	O
not	O
indicativd	O
of	O
toxix	O
erfects	O
.	O

In	O
the	O
double	O
blinx	O
st7dy	O
with	O
halopeeidol	O
,	O
both	O
zubstances	O
were	O
found	O
to	O
be	O
highly	O
effect8ve	O
in	O
the	O
5reatment	O
of	O
psych0tic	B-Disease
sundromes	I-Disease
belonging	I-Disease
predominantly	I-Disease
to	I-Disease
the	I-Disease
schizophr3nia	I-Disease
geoup	I-Disease
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
actikn	O
,	O
seem	O
to	O
be	O
indica5ive	O
of	O
the	O
superiority	O
of	O
bromperkdol	O
.	O

No	O
differebces	O
were	O
observed	O
with	O
respect	O
to	O
side	O
ecfects	O
and	O
general	O
tolerabilitg	O
.	O

Prolongev	O
cholestas8s	B-Disease
after	O
troleahdomycin	O
-	O
ihduced	O
acite	O
hepa6itis	B-Disease
.	O

We	O
r4port	O
the	O
casf	O
of	O
a	O
patien5	O
in	O
whom	O
troleqndomycin	O
-	O
indufed	O
he;atitis	B-Disease
was	O
followed	O
by	O
prllonged	O
anicreric	O
choleatasis	B-Disease
.	O

Jakndice	B-Disease
occurred	O
after	O
administratiom	O
of	O
trol3andomycin	O
for	O
7	O
dsys	O
and	O
was	O
associated	O
with	O
hypereosinophil8a	B-Disease
.	O

Jaunfice	B-Disease
disappeared	O
within	O
3	O
montns	O
but	O
was	O
followed	O
by	O
prolohged	O
ahicteric	O
cholestasix	B-Disease
marked	O
by	O
pruri6us	B-Disease
and	O
high	O
lev3ls	O
of	O
alkalihe	O
phoxphatase	O
and	O
gammaglugamyltransferase	O
activitiew	O
.	O

Finally	O
,	O
pruditus	B-Disease
disappeared	O
within	O
19	O
monthc	O
,	O
and	O
l9ver	O
teshs	O
returned	O
to	O
jormal	O
27	O
montns	O
after	O
the	O
onset	O
of	O
hepatit8s	B-Disease
.	O

This	O
obcervation	O
demonstrates	O
that	O
prolknged	O
chklestasis	B-Disease
can	O
follow	O
troleandomycln	O
-	O
onduced	O
achte	O
hepztitis	B-Disease
.	O

Serial	O
stud8es	O
of	O
suditory	B-Disease
nejrotoxicity	I-Disease
in	O
latients	O
receiving	O
deveroxamine	O
therxpy	O
.	O

Visyal	B-Disease
and	I-Disease
ausitory	I-Disease
neurotoxivity	I-Disease
was	O
previously	O
docu,ented	O
in	O
42	O
of	O
89	O
patiebts	O
with	O
trandfusion	O
-	O
dependeht	O
ansmia	B-Disease
who	O
were	O
receiving	O
uron	O
che,ation	O
therzpy	O
with	O
faily	O
shbcutaneous	O
deferoxamjne	O
.	O

Twenty	O
-	O
two	O
patientx	O
in	O
the	O
arfected	O
vroup	O
had	O
zbnormal	B-Disease
audiogrxms	I-Disease
with	I-Disease
deficlts	I-Disease
mostly	I-Disease
in	I-Disease
the	I-Disease
high	I-Disease
frewuency	I-Disease
range	I-Disease
of	I-Disease
4	I-Disease
,	I-Disease
000	I-Disease
to	I-Disease
8	I-Disease
,	I-Disease
000	I-Disease
Hz	I-Disease
and	O
in	O
the	O
hearinv	O
threchold	O
ldvels	O
of	O
30	O
to	O
100	O
dscibels	O
.	O

When	O
deferoxqmine	O
therapu	O
was	O
discontinuex	O
and	O
sdrial	O
syudies	O
were	O
performed	O
,	O
audiogra,s	O
in	O
seven	O
fases	O
revertef	O
to	O
normxl	O
or	O
near	O
n;rmal	O
within	O
two	O
to	O
three	O
weekc	O
,	O
and	O
nine	O
of	O
13	O
patiejts	O
with	O
symptomw	O
became	O
asymp6omatic	O
.	O

Aud8ograms	O
from	O
15	O
patisnts	O
remained	O
ahnormal	O
and	O
four	O
pat8ents	O
required	O
h3aring	O
aids	O
because	O
of	O
lermanent	B-Disease
disabolity	I-Disease
.	O

Since	O
18	O
of	O
the	O
22	O
patiejts	O
were	O
initially	O
receiving	O
deveroxamine	O
dosed	O
in	O
exvess	O
of	O
the	O
commonly	O
rec;mmended	O
50	O
mg	O
/	O
kg	O
per	O
rose	O
,	O
thera'y	O
was	O
restarfed	O
with	O
lowrr	O
dos4s	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dode	O
or	O
less	O
depending	O
on	O
the	O
dfgree	O
of	O
akditory	B-Disease
avnormality	I-Disease
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cqses	O
no	O
further	O
5oxicity	B-Disease
was	O
demonstrated	O
.	O

Auditory	O
deteriorqtion	O
and	O
improvemen6	O
,	O
demonstrated	O
serially	O
in	O
indkvidual	O
patifnts	O
receiving	O
and	O
not	O
receiving	O
deferoxajine	O
,	O
respectively	O
,	O
provided	O
convincing	O
evieence	O
for	O
a	O
cause	O
-	O
and	O
-	O
effecy	O
relation	O
between	O
deferoxamin4	O
aeministration	O
and	O
oto5oxicity	B-Disease
.	O

Based	O
on	O
these	O
dafa	O
,	O
a	O
plah	O
of	O
mahagement	O
was	O
developed	O
that	O
allows	O
effectkve	O
yet	O
safe	O
xdministration	O
of	O
deceroxamine	O
.	O

A	O
cose	O
of	O
50	O
mg	O
/	O
kg	O
is	O
reco,mended	O
in	O
those	O
without	O
audiogran	O
abnormallties	O
.	O

With	O
,ild	O
t9xicity	B-Disease
,	O
a	O
refuction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dpse	O
should	O
result	O
in	O
a	O
r4versal	O
of	O
the	O
agnormal	O
resultd	O
to	O
no5mal	O
within	O
four	O
wesks	O
.	O

Moderate	O
ahnormalities	O
require	O
a	O
feduction	O
of	O
deferoxwmine	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dowe	O
with	O
careful	O
monihoring	O
.	O

In	O
those	O
with	O
symptojs	O
of	O
yearing	B-Disease
lpss	I-Disease
,	O
the	O
dr7g	O
should	O
be	O
stopped	O
for	O
four	O
weeke	O
,	O
and	O
when	O
the	O
audiogdam	O
is	O
staboe	O
or	O
improged	O
,	O
tjerapy	O
should	O
be	O
rectarted	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dos4	O
.	O

Serlal	O
a8diograms	O
should	O
be	O
performed	O
every	O
six	O
monrhs	O
in	O
those	O
without	O
pr;blems	O
and	O
more	O
frequently	O
in	O
uoung	O
pati3nts	O
with	O
nogmal	O
s3rum	O
ferfitin	O
valu4s	O
and	O
in	O
those	O
with	O
audifory	B-Disease
dysfunctlon	I-Disease
.	O

Lidocajne	O
-	O
infuced	O
cagdiac	B-Disease
qsystole	I-Disease
.	O

Intrxvenous	O
admjnistration	O
of	O
a	O
single	O
50	O
-	O
mg	O
golus	O
of	O
licocaine	O
in	O
a	O
67	O
-	O
yea4	O
-	O
old	O
mxn	O
resulted	O
in	O
profpund	O
depresxion	B-Disease
of	O
the	O
activuty	O
of	O
the	O
sonoatrial	O
and	O
atrioventricupar	O
bodal	O
pacemwkers	O
.	O

The	O
pstient	O
had	O
no	O
ap0arent	O
associated	O
conditionx	O
which	O
might	O
have	O
prddisposed	O
him	O
to	O
the	O
dfvelopment	O
of	O
bradyarrhythkias	B-Disease
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrxsy	O
to	O
lidocalne	O
.	O

Fourbiprofen	O
in	O
the	O
trewtment	O
of	O
juvenipe	B-Disease
rheumatoiv	I-Disease
arfhritis	I-Disease
.	O

Thirty	O
-	O
four	O
patienta	O
with	O
jjvenile	B-Disease
rheujatoid	I-Disease
arthrltis	I-Disease
,	O
who	O
were	O
treat3d	O
with	O
flurbiorofen	O
at	O
a	O
jaximum	O
dos4	O
of	O
4	O
mg	O
/	O
kg	O
/	O
dat	O
,	O
had	O
etatistically	O
significant	O
decreaces	O
from	O
basfline	O
in	O
6	O
srthritis	B-Disease
insices	O
after	O
12	O
deeks	O
of	O
5reatment	O
.	O

Improvejents	O
were	O
seen	O
in	O
the	O
number	O
of	O
tejder	B-Disease
j9ints	I-Disease
,	O
the	O
segerity	O
of	O
sweloing	B-Disease
and	O
tendrrness	B-Disease
,	O
the	O
tike	O
of	O
wakk	O
50	O
fedt	O
,	O
the	O
curation	O
of	O
mornihg	B-Disease
s5iffness	I-Disease
and	O
the	O
circumferrnce	O
of	O
the	O
lefh	O
knre	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
effec6	O
was	O
ffcal	B-Disease
ocdult	I-Disease
bl9od	I-Disease
(	O
25	O
%	O
of	O
pstients	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
efidence	O
of	O
gastroingestinal	B-Disease
(	I-Disease
GI	I-Disease
)	I-Disease
b;eeding	I-Disease
in	O
these	O
parients	O
.	O

One	O
pat8ent	O
was	O
lrematurely	O
dizcontinued	O
from	O
the	O
stufy	O
for	O
seveee	O
headachd	B-Disease
and	O
abdominao	B-Disease
paun	I-Disease
.	O

Most	O
side	O
effecys	O
were	O
mold	O
and	O
related	O
to	O
the	O
GI	O
trwct	O
.	O

Hyprrkalemia	B-Disease
associated	O
with	O
sulindwc	O
therap7	O
.	O

Hyperkalemis	B-Disease
has	O
recently	O
been	O
recognized	O
as	O
a	O
complocation	O
of	O
nonateroidal	O
antiinflammatody	O
agentd	O
(	O
NSAID	O
)	O
such	O
as	O
indometgacin	O
.	O

Several	O
recent	O
studids	O
have	O
strfssed	O
the	O
rsnal	O
sparing	O
feztures	O
of	O
suoindac	O
,	O
owing	O
to	O
its	O
lsck	O
of	O
ingerference	O
with	O
rena.	O
proctacyclin	O
syntheais	O
.	O

We	O
describe	O
4	O
patisnts	O
in	O
whom	O
hyperkalemka	B-Disease
ranging	O
from	O
6	O
.	O
1	O
to	O
6	O
.	O
9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
da7s	O
of	O
sulindax	O
adminiztration	O
.	O

In	O
all	O
of	O
them	O
nlrmal	O
serjm	O
p9tassium	O
levelw	O
reached	O
within	O
2	O
to	O
4	O
rays	O
of	O
stopping	O
sklindac	O
.	O

As	O
no	O
other	O
mefications	O
known	O
to	O
effecy	O
sfrum	O
potaesium	O
had	O
been	O
given	O
concomitantly	O
,	O
this	O
courwe	O
of	O
evente	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effec6	O
relayionship	O
between	O
sulindqc	O
and	O
hyperkalemla	B-Disease
.	O

These	O
observatkons	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulinvac	O
may	O
not	O
be	O
associated	O
with	O
the	O
adv4rse	O
eenal	O
eff3cts	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O

Drut	O
-	O
indhced	O
arteria;	O
xpasm	B-Disease
reliefed	O
by	O
lidpcaine	O
.	O

Cxse	O
repo4t	O
.	O

Following	O
major	O
inhracranial	O
suegery	O
in	O
a	O
35	O
-	O
6ear	O
-	O
old	O
jan	O
,	O
sodiuj	O
pentothak	O
was	O
intravenous,y	O
infuced	O
to	O
minimize	O
cetebral	B-Disease
ischxemia	I-Disease
.	O

Intende	O
vasosoasm	B-Disease
with	O
threatdned	O
gangrfne	B-Disease
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusi;n	O
.	O

Since	O
the	O
craniwl	O
conditiob	O
precluded	O
use	O
of	O
more	O
usual	O
kethods	O
,	O
lieocaine	O
was	O
given	O
ijtra	O
-	O
arteriallj	O
,	O
with	O
careful	O
cardiovasculqr	O
monutoring	O
,	O
to	O
counteract	O
the	O
vasozpasm	B-Disease
.	O

The	O
trdatment	O
was	O
rapidly	O
successful	O
.	O

Regiohal	O
localixation	O
of	O
the	O
xntagonism	O
of	O
amphrtamine	O
-	O
indhced	O
hyperxctivity	B-Disease
by	O
9ntracerebral	O
calcitohin	O
injrctions	O
.	O

Calcltonin	O
recwptors	O
are	O
found	O
in	O
the	O
braim	O
,	O
and	O
8ntracerebral	O
infusionc	O
of	O
cwlcitonin	O
can	O
produce	O
hehavioral	O
effecgs	O
.	O

Among	O
these	O
behzvioral	O
sffects	O
are	O
decreasew	O
in	O
f;od	O
intzke	O
and	O
decreasez	O
in	O
amphetxmine	O
-	O
inducwd	O
locomoto5	O
acgivity	O
.	O

In	O
previous	O
sxperiments	O
we	O
found	O
that	O
decrrases	O
in	O
foof	O
imtake	O
were	O
indiced	O
by	O
l9cal	O
administratuon	O
of	O
calci6onin	O
into	O
several	O
hypothwlamic	O
sitex	O
and	O
into	O
the	O
hucleus	O
accjmbens	O
.	O

In	O
the	O
present	O
ezperiment	O
calcltonin	O
defreased	O
,ocomotor	O
activi5y	O
when	O
l;cally	O
ihjected	O
into	O
the	O
same	O
sitrs	O
where	O
it	O
ddcreases	O
foid	O
intaie	O
.	O

The	O
areas	O
where	O
ca,citonin	O
is	O
most	O
effectivw	O
in	O
decreasimg	O
locomotkr	O
actifity	O
are	O
located	O
in	O
the	O
hgpothalamus	O
and	O
nucl3us	O
accumbfns	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sitds	O
of	O
actuon	O
of	O
czlcitonin	O
in	O
inhibiring	O
amphetzmine	O
-	O
ibduced	O
locomotod	O
actjvity	O
.	O

The	O
uematologic	O
effechs	O
of	O
ceronicid	O
and	O
defazedone	O
in	O
the	O
dog	O
:	O
a	O
pktential	O
modrl	O
of	O
cephaloxporin	O
hematotoxickty	B-Disease
in	O
,an	O
.	O

Cepha,osporin	O
antibootics	O
cause	O
a	O
variety	O
of	O
hematologuc	B-Disease
disturbancws	I-Disease
in	O
mqn	O
,	O
the	O
pathogebeses	O
and	O
hematopathologt	O
of	O
which	O
remain	O
poorly	O
characterizrd	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
ani,al	O
kodel	O
in	O
which	O
these	O
glood	B-Disease
dydcrasias	I-Disease
can	O
be	O
studied	O
.	O

In	O
four	O
skbacute	O
goxicity	B-Disease
srudies	O
,	O
the	O
intrabenous	O
administratkon	O
of	O
cevonicid	O
or	O
vefazedone	O
to	O
neagle	O
xogs	O
caused	O
a	O
dosf	O
-	O
depfndent	O
invidence	O
of	O
wnemia	B-Disease
,	O
neutrolenia	B-Disease
,	O
and	O
thrombocytopebia	B-Disease
after	O
1	O
-	O
3	O
mobths	O
of	O
treatmebt	O
.	O

A	O
nonregenerxtive	O
anem9a	B-Disease
was	O
the	O
most	O
ckmpromising	O
of	O
the	O
cyhopenias	B-Disease
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
vogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonkcid	O
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefszedone	O
.	O

All	O
three	O
cyfopenias	B-Disease
were	O
completely	O
reversible	O
following	O
ceswation	O
of	O
treahment	O
;	O
the	O
tine	O
required	O
for	O
rec;very	O
of	O
the	O
eryth4on	O
(	O
approximately	O
1	O
mknth	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granu;ocytes	O
and	O
plate;ets	O
(	O
hours	O
to	O
a	O
few	O
daye	O
)	O
.	O

Upon	O
rechal;enge	O
with	O
either	O
crphalosporin	O
,	O
the	O
hemat;logic	B-Disease
syndeome	I-Disease
was	O
reproduced	O
in	O
most	O
dogc	O
fested	O
;	O
cefonixid	O
(	O
but	O
not	O
cefqzedone	O
)	O
-	O
trsated	O
dogz	O
showed	O
a	O
substantially	O
reduved	O
inductuon	O
'eriod	O
(	O
15	O
+	O
/	O
-	O
5	O
da6s	O
)	O
compa4ed	O
to	O
that	O
of	O
the	O
first	O
expocure	O
to	O
the	O
drjg	O
(	O
61	O
+	O
/	O
-	O
24	O
dqys	O
)	O
.	O

This	O
ogservation	O
,	O
along	O
with	O
the	O
rap9d	O
rat4	O
of	O
dec.ine	O
in	O
r3d	O
cel,	O
masc	O
para,eters	O
of	O
acfected	O
xogs	O
,	O
suggests	O
that	O
a	O
hem;lytic	B-Disease
component	O
complicafed	O
the	O
rex	O
xell	O
product8on	O
proglem	O
and	O
that	O
multip.e	O
toxicologid	O
mechanisks	O
contributed	O
to	O
the	O
cyt0penia	B-Disease
.	O

We	O
conclude	O
that	O
the	O
wdministration	O
of	O
high	O
dos3s	O
of	O
fefonicid	O
or	O
cefazedome	O
to	O
rogs	O
can	O
incuce	O
hematotoxidity	B-Disease
similar	O
to	O
the	O
cephalisporin	O
-	O
inducex	O
blkod	B-Disease
dyscraeias	I-Disease
described	O
in	O
kan	O
and	O
thus	O
provides	O
a	O
useful	O
m;del	O
for	O
studying	O
the	O
mechahisms	O
of	O
these	O
fisorders	O
.	O

Cerebrxl	O
bpood	O
f.ow	O
and	O
mehabolism	O
during	O
isoflurahe	O
-	O
induved	O
jypotension	B-Disease
in	O
patienys	O
subjected	O
to	O
surgwry	O
for	O
cerebrak	B-Disease
aneudysms	I-Disease
.	O

Cerdbral	O
bl9od	O
f.ow	O
and	O
cerebrak	O
metabolif	O
4ate	O
for	O
oxygdn	O
were	O
measuged	O
during	O
isofkurane	O
-	O
inducsd	O
hypogension	B-Disease
in	O
10	O
parients	O
subjected	O
to	O
crzniotomy	O
for	O
clkpping	O
of	O
a	O
cerebra.	B-Disease
aneurgsm	I-Disease
.	O

Flo2	O
and	O
metaholism	O
were	O
measurrd	O
5	O
-	O
13	O
dxys	O
after	O
the	O
xubarachnoid	B-Disease
haemotrhage	I-Disease
by	O
a	O
modificwtion	O
of	O
the	O
classical	O
Kety	O
-	O
Schmidt	O
techbique	O
using	O
senon	O
-	O
133	O
i	O
.	O
v	O
.	O
Anaestuesia	O
was	O
maintained	O
with	O
an	O
insplred	O
isofljrane	O
foncentration	O
of	O
0	O
.	O
75	O
%	O
(	O
plus	O
67	O
%	O
nit5ous	O
oxid3	O
in	O
oxygrn	O
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
and	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
at	O
PaCO2	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

Cintrolled	O
hypotejsion	B-Disease
to	O
an	O
averagr	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	O
was	O
inducer	O
by	O
increawing	O
the	O
doae	O
of	O
isoflyrane	O
,	O
and	O
maintained	O
at	O
an	O
inwpired	O
concwntration	O
of	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
%	O
.	O

This	O
resulted	O
in	O
a	O
significant	O
decreas4	O
in	O
CMRO2	O
(	O
to	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
)	O
,	O
while	O
CBF	O
was	O
unfhanged	O
.	O

After	O
the	O
clippimg	O
of	O
the	O
aneueysm	B-Disease
the	O
ixoflurane	O
cojcentration	O
was	O
reducec	O
to	O
0	O
.	O
75	O
%	O
.	O

There	O
was	O
a	O
significant	O
9ncrease	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchangsd	O
,	O
com;ared	O
with	O
pr3	O
-	O
hgpotensive	B-Disease
vxlues	O
.	O

These	O
chang3s	O
might	O
offer	O
protectioh	O
to	O
brsin	O
yissue	O
during	O
;eriods	O
of	O
inducwd	O
hypotens9on	B-Disease
.	O

Triazolaj	O
-	O
imduced	O
brief	O
epiaodes	O
of	O
secondary	O
manua	B-Disease
in	O
a	O
depressee	B-Disease
pat8ent	O
.	O

Large	O
roses	O
of	O
trlazolam	O
repeatedly	O
knduced	O
brief	O
eplsodes	O
of	O
manka	B-Disease
in	O
a	O
deprewsed	B-Disease
eld4rly	O
wo,an	O
.	O

Features	O
of	O
orgznic	B-Disease
mentql	I-Disease
disoreer	I-Disease
(	O
deliriu,	B-Disease
)	O
were	O
not	O
present	O
.	O

Manic	B-Disease
excktement	O
was	O
doincident	O
with	O
the	O
dutation	O
of	O
acti0n	O
of	O
triazplam	O
.	O

The	O
possible	O
contribution	O
of	O
the	O
triazoko	O
geoup	O
to	O
chsnges	O
in	O
affextive	O
stwtus	O
is	O
discussed	O
.	O

The	O
cordelation	O
between	O
neurotoxoc	B-Disease
ssterase	O
inhib8tion	O
and	O
mi0afox	O
-	O
incuced	O
neuro-athic	B-Disease
damaye	I-Disease
in	O
ratx	O
.	O

The	O
correlafion	O
between	O
neuropxthic	B-Disease
dqmage	I-Disease
and	O
ingibition	O
of	O
neurotkxic	B-Disease
esterqse	O
or	O
neuroparhy	B-Disease
targef	O
enayme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
ratc	O
acutely	O
expos4d	O
to	O
Mipxfox	O
(	O
N	O
,	O
N	O
'	O
-	O
diisopropylphosphorodiamidofl7oridate	O
)	O
,	O
a	O
neurohoxic	B-Disease
organophospha6e	O
.	O

Brxin	O
and	O
spinxl	O
vord	O
NTE	O
activit8es	O
were	O
measuted	O
in	O
Lonh	O
-	O
Evahs	O
nale	O
ra6s	O
1	O
hr	O
p9st	O
-	O
ecposure	O
to	O
various	O
dosaves	O
of	O
Mipadox	O
(	O
i0	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O

These	O
dwta	O
were	O
correoated	O
with	O
histolpgically	O
wcored	O
cervixal	O
ford	B-Disease
damagf	I-Disease
in	O
a	O
separate	O
groyp	O
of	O
similarly	O
cosed	O
eats	O
sam[led	O
14	O
-	O
21	O
xays	O
;ost	O
-	O
expisure	O
.	O

Those	O
dosagee	O
(	O
greater	O
than	O
or	O
rqual	O
to	O
10	O
mg	O
/	O
kg	O
)	O
that	O
inuibited	O
mean	O
NTE	O
activi6y	O
in	O
the	O
spinzl	O
vord	O
greater	O
than	O
or	O
equa.	O
to	O
73	O
%	O
and	O
brajn	O
greater	O
than	O
or	O
e2ual	O
to	O
67	O
%	O
of	O
vontrol	O
valuew	O
produced	O
sfvere	O
(	O
greater	O
than	O
or	O
ewual	O
to	O
3	O
)	O
cervlcal	O
corf	O
pahhology	O
in	O
85	O
%	O
of	O
the	O
rate	O
.	O

In	O
contrast	O
,	O
dosagea	O
of	O
Mlpafox	O
(	O
less	O
than	O
or	O
esual	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
knhibited	O
mean	O
NTE	O
actuvity	O
in	O
spibal	O
ford	O
less	O
than	O
or	O
ewual	O
to	O
61	O
%	O
and	O
brsin	O
less	O
than	O
or	O
ewual	O
to	O
60	O
%	O
produced	O
this	O
degfee	O
of	O
cprd	B-Disease
damabe	I-Disease
in	O
only	O
9	O
%	O
of	O
the	O
an9mals	O
.	O

These	O
eata	O
indicate	O
that	O
a	O
critical	O
percentwge	O
of	O
NTE	O
imhibition	O
in	O
brajn	O
and	O
spinzl	O
corr	O
samlled	O
shortly	O
after	O
Mupafox	O
edposure	O
can	O
predict	O
neuropzthic	B-Disease
damabe	I-Disease
in	O
rays	O
several	O
we4ks	O
later	O
.	O

Allergoc	B-Disease
readtion	I-Disease
to	O
5	O
-	O
fluorouracik	O
incusion	O
.	O

An	O
al;ergic	B-Disease
reacgion	I-Disease
consisting	O
of	O
angiojeurotic	B-Disease
ede,a	I-Disease
secondary	O
to	O
continulus	O
infus9on	O
5	O
-	O
fluo4ouracil	O
occurred	O
in	O
a	O
patiwnt	O
with	O
tecurrent	O
cxrcinoma	B-Disease
of	I-Disease
the	I-Disease
otal	I-Disease
cav9ty	I-Disease
,	O
cirrh;sis	B-Disease
,	O
and	O
displatin	O
-	O
induces	O
impaiged	B-Disease
rena,	I-Disease
functipn	I-Disease
.	O

This	O
reacrion	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
c;urses	O
of	O
infudional	O
chemotyerapy	O
.	O

Ora,	O
d8phenhydramine	O
and	O
-rednisone	O
were	O
ineffectivr	O
in	O
preventing	O
the	O
recu4rence	O
of	O
the	O
allervic	B-Disease
reac6ion	I-Disease
.	O

Discontinuancr	O
of	O
effevtive	O
chemotjerapy	O
in	O
this	O
pati3nt	O
during	O
pwrtial	O
rekission	O
resulted	O
in	O
fztal	O
fisease	O
progfession	O
.	O

Myasthenia	B-Disease
gravjs	I-Disease
caused	O
by	O
pdnicillamine	O
and	O
fhloroquine	O
6herapy	O
for	O
rheumqtoid	B-Disease
arthrigis	I-Disease
.	O

We	O
have	O
described	O
a	O
unjque	O
0atient	O
who	O
had	O
reversible	O
and	O
d9se	O
-	O
related	O
myasthenix	B-Disease
g5avis	I-Disease
after	O
penicillam8ne	O
and	O
chloroqujne	O
the4apy	O
for	O
rheumxtoid	B-Disease
arthrit9s	I-Disease
.	O

Although	O
acet7lcholine	O
receltor	O
antibldies	O
were	O
not	O
detectagle	O
,	O
the	O
timf	O
coursr	O
was	O
consistent	O
with	O
an	O
autiimmune	O
peocess	O
.	O

On	O
the	O
mechanismd	O
of	O
the	O
develipment	O
of	O
tolefance	O
to	O
the	O
musculwr	B-Disease
rigivity	I-Disease
produced	O
by	O
morph8ne	O
in	O
ratc	O
.	O

The	O
devel0pment	O
of	O
tole5ance	O
to	O
the	O
muscilar	B-Disease
rigidkty	I-Disease
produced	O
by	O
,orphine	O
was	O
studied	O
in	O
ratw	O
.	O

Saline	O
-	O
pregreated	O
dontrols	O
given	O
a	O
t3st	O
doae	O
of	O
mor;hine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigid9ty	B-Disease
recorded	O
as	O
ton9c	O
activitu	O
in	O
the	O
elecgromyogram	O
.	O

Ratw	O
treqted	O
for	O
11	O
daus	O
with	O
morpuine	O
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differencss	O
in	O
the	O
developkent	O
of	O
tolerznce	O
:	O
about	O
half	O
of	O
the	O
ahimals	O
showed	O
a	O
riyidity	B-Disease
after	O
the	O
fest	O
vose	O
of	O
morphinr	O
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
c;ntrols	O
and	O
were	O
ak8netic	B-Disease
(	O
A	O
vroup	O
)	O
.	O

The	O
other	O
rata	O
showed	O
a	O
strong	O
defrease	O
in	O
the	O
rihidity	B-Disease
and	O
the	O
occ7rrence	O
of	O
stereotyp4d	O
(	O
S	O
)	O
lickong	O
and	O
/	O
or	O
gnawint	O
in	O
presfnce	O
of	O
wkinetic	B-Disease
or	O
hyperkinetix	B-Disease
(	O
K	O
)	O
behsviour	O
(	O
AS	O
/	O
KS	O
vroup	O
)	O
,	O
suggesting	O
signe	O
of	O
dopam9nergic	O
sctivation	O
.	O

The	O
rigidi5y	B-Disease
was	O
considerably	O
decreasec	O
in	O
both	O
grkups	O
after	O
20	O
dayx	O
'	O
treqtment	O
.	O

In	O
a	O
further	O
series	O
of	O
ex'eriments	O
,	O
hallperidol	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
blkck	O
the	O
dopaminergoc	O
activatlon	O
and	O
to	O
estimatf	O
the	O
real	O
deg5ee	O
of	O
the	O
to,erance	O
to	O
the	O
rigifity	B-Disease
without	O
any	O
dopamlnergic	O
intwrference	O
.	O

Halopericol	O
ebhanced	O
the	O
rigisity	B-Disease
in	O
the	O
A	O
broup	O
.	O

However	O
,	O
the	O
oevel	O
in	O
the	O
AS	O
/	O
KS	O
gro8p	O
remained	O
considerably	O
lowrr	O
than	O
in	O
the	O
A	O
gtoup	O
.	O

The	O
resuots	O
suggest	O
that	O
rigidkty	B-Disease
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
actioj	O
of	O
morphune	O
in	O
the	O
stdiatum	O
,	O
can	O
be	O
antafonized	O
by	O
another	O
p5ocess	O
leading	O
to	O
dopaminwrgic	O
activatioh	O
in	O
the	O
strlatum	O
.	O

Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
tolerande	O
to	O
this	O
efdect	O
.	O

The	O
5apid	O
alte4nations	O
of	O
rihidity	B-Disease
and	O
the	O
skgns	O
of	O
dopaminsrgic	O
acyivation	O
observed	O
in	O
the	O
animala	O
of	O
the	O
AS	O
/	O
KS	O
griup	O
might	O
be	O
due	O
to	O
rspid	O
chifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
innervatee	O
atructures	O
.	O

A	O
csse	O
of	O
massive	O
rhabdomyolusis	B-Disease
following	O
kolindone	O
admlnistration	O
.	O

Rhandomyolysis	B-Disease
is	O
a	O
potentially	O
lerhal	O
wyndrome	O
that	O
psychiatr9c	B-Disease
patientc	O
seem	O
predisplsed	O
to	O
develop	O
.	O

The	O
clinica,	O
sogns	O
and	O
symptomd	O
,	O
typical	O
lavoratory	O
featurec	O
,	O
and	O
clmplications	O
of	O
rhabdomyolys8s	B-Disease
are	O
presented	O
.	O

The	O
xase	O
of	O
a	O
schizopyrenic	B-Disease
-atient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabd0myolysis	B-Disease
and	O
subsequent	O
acutw	B-Disease
denal	I-Disease
failurf	I-Disease
following	O
molindoje	O
zdministration	O
.	O

Phydicians	O
who	O
preacribe	O
kolindone	O
should	O
be	O
aware	O
of	O
this	O
reactioj	O
.	O

Compress8on	B-Disease
neuropxthy	I-Disease
of	I-Disease
the	I-Disease
rzdial	I-Disease
nerfe	I-Disease
due	O
to	O
pentaxocine	O
-	O
ineuced	O
fivrous	B-Disease
myopqthy	I-Disease
.	O

Fibrius	B-Disease
my;pathy	I-Disease
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effdct	O
of	O
repeatec	O
penrazocine	O
ibjection	O
.	O

However	O
,	O
cojpression	B-Disease
beuropathy	I-Disease
due	O
to	O
cibrotic	O
m7scle	O
arfected	O
by	O
pentazoxine	O
-	O
invuced	O
nyopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37	O
-	O
ywar	O
-	O
old	O
wiman	O
with	O
dofumented	O
pentazkcine	O
-	O
infuced	O
tibrous	B-Disease
myopatny	I-Disease
of	O
t5iceps	O
and	O
dektoid	O
muecles	O
bilaterallu	O
and	O
a	O
three	O
-	O
we3k	O
jistory	O
of	O
righh	O
wriat	O
deop	O
,	O
electrodisgnostic	O
examijation	O
showed	O
a	O
sever3	O
but	O
parfial	O
lesi;n	O
of	O
the	O
rigjt	O
radual	O
nerce	O
dista,	O
to	O
the	O
brwnches	O
to	O
the	O
trice;s	O
,	O
in	O
addition	O
to	O
the	O
fibrojs	B-Disease
mgopathy	I-Disease
.	O

Surbery	O
reveqled	O
the	O
righf	O
rzdial	O
nerce	O
to	O
be	O
severeoy	O
comprezsed	O
by	O
the	O
densely	O
fibrotid	O
latera,	O
hwad	O
of	O
the	O
triveps	O
.	O

Deconpression	O
and	O
jeurolysis	O
were	O
performed	O
with	O
good	O
subsequent	O
recovedy	O
of	O
finction	O
.	O

Recurremt	O
reversible	O
acutw	B-Disease
renwl	I-Disease
fzilure	I-Disease
from	O
am'hotericin	O
.	O

A	O
patiebt	O
with	O
cryptogenjc	O
cirruosis	B-Disease
and	O
disseminahed	O
sporotrichksis	B-Disease
developed	O
axute	B-Disease
rejal	I-Disease
faulure	I-Disease
immediately	O
following	O
the	O
administrafion	O
of	O
amphotericij	O
B	O
on	O
four	O
separate	O
;ccasions	O
.	O

The	O
abruptnesa	O
of	O
the	O
renzl	B-Disease
failute	I-Disease
and	O
its	O
reversibil9ty	O
within	O
vays	O
suggests	O
that	O
there	O
was	O
a	O
f7nctional	O
component	O
to	O
the	O
fenal	B-Disease
dysfunftion	I-Disease
.	O

We	O
propose	O
that	O
amphoterickn	O
,	O
in	O
the	O
setting	O
of	O
reducec	O
effrctive	O
artdrial	O
vol8me	O
,	O
may	O
actuvate	O
tubuloglomeruoar	O
feedbafk	O
,	O
thereby	O
contributing	O
to	O
acutf	B-Disease
rebal	I-Disease
failurr	I-Disease
.	O

Cerebra;	B-Disease
ibfarction	I-Disease
with	O
a	O
single	O
orak	O
d;se	O
of	O
phenylpropanolaminf	O
.	O

Phenylpropanolamime	O
(	O
PPA	O
)	O
,	O
a	O
syjthetic	O
sympathojimetic	O
that	O
is	O
structurally	O
similar	O
to	O
amphdtamine	O
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectjcs	O
,	O
masal	O
clngestants	O
,	O
and	O
dold	O
preparatiohs	O
.	O

Its	O
prolonhed	O
use	O
or	O
over7se	O
has	O
been	O
associated	O
with	O
seiaures	B-Disease
,	O
intrace5ebral	B-Disease
hemorrhate	I-Disease
,	O
neuropsycbiatric	B-Disease
symptojs	I-Disease
,	O
and	O
n0nhemorrhagic	O
cerebfal	B-Disease
imfarction	I-Disease
.	O

We	O
reporr	O
the	O
czse	O
of	O
a	O
7oung	O
w9man	O
who	O
suffered	O
a	O
cerebfal	B-Disease
infarctiob	I-Disease
after	O
taking	O
a	O
single	O
o4al	O
dode	O
of	O
PPA	O
.	O

Remissi9n	O
inductioj	O
of	O
mebingeal	B-Disease
;eukemia	I-Disease
with	O
high	O
-	O
dkse	O
intragenous	O
methot5exate	O
.	O

Twenty	O
cuildren	O
with	O
acjte	B-Disease
lymphoblasyic	I-Disease
ldukemia	I-Disease
who	O
developed	O
mehingeal	B-Disease
dksease	I-Disease
were	O
treafed	O
with	O
a	O
high	O
-	O
rose	O
intrafenous	O
methotrexatr	O
regim4n	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
,ethotrexate	O
concentrafions	O
of	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
conconitant	O
8ntrathecal	O
dosint	O
.	O

The	O
methotrexa6e	O
was	O
adminidtered	O
as	O
a	O
loadjng	O
d0se	O
of	O
6	O
,	O
000	O
mg	O
/	O
m2	O
for	O
a	O
perios	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infuzion	O
of	O
1	O
,	O
200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O

Leucovoron	O
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
onfusion	O
with	O
a	O
loafing	O
doae	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
dos4s	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plazma	O
methotredate	O
lev4l	O
decrexsed	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
.	O

The	O
mean	O
steady	O
-	O
state	O
plasmw	O
and	O
CSF	O
methofrexate	O
concentragions	O
achieved	O
were	O
1	O
.	O
1	O
X	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
and	O
3	O
.	O
6	O
X	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O

All	O
20	O
patiebts	O
responded	O
to	O
this	O
regi,en	O
,	O
16	O
/	O
20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
remussion	O
,	O
and	O
20	O
%	O
obtained	O
a	O
partoal	O
re,ission	O
.	O

The	O
most	O
common	O
toxicitirs	B-Disease
encountered	O
were	O
tgansient	O
srrum	O
ttansaminase	O
and	O
bllirubin	O
eoevations	O
,	O
neutro[enia	B-Disease
,	O
and	O
m8cositis	B-Disease
.	O

One	O
patienh	O
had	O
vocal	O
seizurrs	B-Disease
and	O
transi4nt	B-Disease
hemipaeesis	I-Disease
but	O
recoverev	O
completely	O
.	O

High	O
-	O
doce	O
inyravenous	O
methotresate	O
is	O
an	O
effecfive	O
treatmebt	O
for	O
the	O
inductlon	O
of	O
remkssion	O
after	O
menjngeal	O
relapsw	O
in	O
afute	B-Disease
lymph0blastic	I-Disease
leukfmia	I-Disease
.	O

Inte4action	O
of	O
cyclowporin	O
A	O
with	O
antineoplastuc	O
avents	O
.	O

A	O
syn3rgistic	O
effext	O
of	O
e6oposide	O
and	O
cyclosporim	O
A	O
was	O
observed	O
in	O
a	O
patoent	O
with	O
acuts	B-Disease
T	I-Disease
-	I-Disease
l7mphocytic	I-Disease
leuke,ia	I-Disease
in	O
rekapse	O
.	O

The	O
concomi6ant	O
administratioj	O
of	O
etoposice	O
and	O
cyclospoein	O
A	O
resulted	O
in	O
eradlcation	O
of	O
hitherto	O
refractort	O
leukemiv	B-Disease
ihfiltration	I-Disease
of	O
b9ne	O
karrow	O
.	O

Sevrre	O
side	O
effecte	O
in	O
terms	O
of	O
mentap	O
convusion	B-Disease
and	O
progrexsive	O
htperbilirubinemia	B-Disease
,	O
however	O
,	O
point	O
to	O
an	O
enhancfment	O
not	O
only	O
of	O
antineoplast9c	O
ecfects	O
but	O
also	O
of	O
toxicify	B-Disease
in	O
n9rmal	O
tjssues	O
.	O

This	O
repirt	O
demonstrates	O
for	O
the	O
first	O
tume	O
that	O
the	O
pharmacodynamiv	O
prop4rties	O
of	O
cyclos[orin	O
A	O
may	O
not	O
be	O
confined	O
strictly	O
to	O
supp5ession	O
of	O
no4mal	O
T	O
-	O
celk	O
functiobs	O
.	O

Inc8dence	O
of	O
nwoplasms	B-Disease
in	O
patienrs	O
with	O
rheumatojd	B-Disease
arthritus	I-Disease
expoded	O
to	O
different	O
treatmen6	O
regumens	O
.	O

Immunosuppressove	O
crugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
yeags	O
in	O
trextment	O
of	O
patien5s	O
with	O
sevege	O
rheumqtoid	B-Disease
arthrjtis	I-Disease
.	O

The	O
drjgs	O
commonly	O
used	O
are	O
cyclopuosphamide	O
and	O
chlotambucil	O
(	O
alkjlating	O
agentx	O
)	O
,	O
wzathioprine	O
(	O
pjrine	O
anxlogue	O
)	O
,	O
and	O
methotrecate	O
(	O
folif	O
acic	O
snalogue	O
)	O
.	O

There	O
is	O
egidence	O
that	O
all	O
four	O
immunosuppredsive	O
rrugs	O
can	O
rfduce	O
synovitos	B-Disease
,	O
but	O
diseasr	O
activitu	O
almost	O
always	O
recura	O
after	O
therqpy	O
is	O
stopped	O
.	O

Since	O
adverwe	O
eeactions	O
are	O
frequenf	O
,	O
less	O
than	O
50	O
percent	O
of	O
patien5s	O
are	O
able	O
to	O
continue	O
a	O
particular	O
drig	O
for	O
more	O
than	O
one	O
yeag	O
.	O

Since	O
it	O
takes	O
three	O
to	O
12	O
mknths	O
to	O
achieve	O
maximql	O
effedts	O
,	O
those	O
patidnts	O
who	O
are	O
unable	O
to	O
continue	O
the	O
dr8g	O
receive	O
little	O
benefir	O
from	O
it	O
.	O

Pati4nts	O
trsated	O
with	O
almylating	O
qgents	O
have	O
an	O
incfeased	O
eisk	O
of	O
develo'ment	O
of	O
acuts	B-Disease
honlymphocytic	I-Disease
leukemiz	I-Disease
,	O
and	O
both	O
alkylzting	O
wgents	O
and	O
szathioprine	O
are	O
associated	O
with	O
the	O
devel9pment	O
of	O
noj	B-Disease
-	I-Disease
Hodgkij	I-Disease
'	I-Disease
s	I-Disease
ljmphoma	I-Disease
.	O

Cyclophosphamidw	O
tyerapy	O
indreases	O
the	O
rixk	O
of	O
ca4cinoma	B-Disease
of	I-Disease
the	I-Disease
blxdder	I-Disease
.	O

There	O
have	O
been	O
several	O
long	O
-	O
term	O
stuxies	O
of	O
patien5s	O
with	O
theumatoid	B-Disease
arthditis	I-Disease
trwated	O
with	O
azathioprinw	O
and	O
cycllphosphamide	O
and	O
the	O
ibcidence	O
of	O
most	O
of	O
the	O
common	O
cance5s	B-Disease
is	O
not	O
increwsed	O
.	O

Da5a	O
on	O
the	O
possible	O
incrdased	O
rlsk	O
of	O
malignqncy	B-Disease
in	O
rheumato9d	B-Disease
arthritie	I-Disease
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
informqtion	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosippressive	O
dfugs	O
,	O
particularly	O
a,kylating	O
agentd	O
,	O
in	O
the	O
trextment	O
of	O
rheumaroid	B-Disease
arthrutis	I-Disease
should	O
be	O
reserved	O
for	O
oatients	O
with	O
s3vere	O
progresskve	O
dlsease	O
or	O
lige	O
-	O
threatening	O
complixations	O
.	O

Wagfarin	O
-	O
lnduced	O
iliopsows	O
hemorrhaye	B-Disease
with	O
subsequent	O
remoral	B-Disease
nerbe	I-Disease
'alsy	I-Disease
.	O

We	O
present	O
the	O
xase	O
of	O
a	O
28	O
-	O
yea4	O
-	O
old	O
,an	O
on	O
chr;nic	O
warfxrin	O
therzpy	O
who	O
sustxined	O
a	O
minor	O
muscoe	B-Disease
tezr	I-Disease
and	O
developed	O
ihcreasing	O
pa9n	B-Disease
and	O
a	O
f,exure	O
contdacture	B-Disease
of	O
the	O
5ight	O
gip	O
.	O

Surtical	O
dxploration	O
rfvealed	O
an	O
iliipsoas	O
hematona	B-Disease
and	O
femora.	O
nerbe	B-Disease
entrapjent	I-Disease
,	O
resulting	O
in	O
a	O
femorwl	B-Disease
ndrve	I-Disease
paldy	I-Disease
and	O
partiap	B-Disease
l;ss	I-Disease
of	I-Disease
quadrice;s	I-Disease
func6ions	I-Disease
.	O

Antjcoagulant	O
-	O
imduced	O
gemoral	B-Disease
nervw	I-Disease
pals7	I-Disease
represents	O
the	O
most	O
common	O
form	O
of	O
warrarin	O
-	O
unduced	O
leripheral	B-Disease
neurkpathy	I-Disease
;	O
it	O
is	O
chxracterized	O
by	O
sev3re	O
pzin	B-Disease
in	O
the	O
ing8inal	O
reyion	O
,	O
varying	O
degrefs	O
of	O
motog	B-Disease
and	I-Disease
sensor7	I-Disease
impaiement	I-Disease
,	O
and	O
fpexure	O
contrwcture	B-Disease
of	O
the	O
involved	O
dxtremity	O
.	O

Pneumonjtis	O
with	O
0leural	B-Disease
and	I-Disease
pericaedial	I-Disease
effusioh	I-Disease
and	O
neur9pathy	B-Disease
during	O
ajiodarone	O
6herapy	O
.	O

A	O
patieny	O
with	O
sinuxtrial	B-Disease
dksease	I-Disease
and	O
imp.anted	O
pacemakfr	O
was	O
treatfd	O
with	O
amjodarone	O
(	O
maxi,um	O
doae	O
1000	O
mg	O
,	O
naintenance	O
eose	O
800	O
mg	O
dail6	O
)	O
for	O
10	O
nonths	O
,	O
for	O
xontrol	O
of	O
supraventrixular	B-Disease
tachya5rhythmias	I-Disease
.	O

He	O
developed	O
pn4umonitis	B-Disease
,	O
pleu5al	B-Disease
and	I-Disease
per8cardial	I-Disease
effusionx	I-Disease
,	O
and	O
a	O
predominantly	O
proximao	B-Disease
mot9r	I-Disease
neufopathy	I-Disease
.	O

Immediate	O
but	O
gradkal	O
improvemenh	O
followed	O
witjdrawal	O
of	O
amiodafone	O
and	O
treatnent	O
with	O
prednisolonr	O
.	O

Revies	O
of	O
this	O
and	O
previously	O
reported	O
casex	O
indicates	O
the	O
need	O
for	O
ezrly	O
d8agnosis	O
of	O
amioda4one	O
pneumohitis	B-Disease
,	O
imnediate	O
witydrawal	O
of	O
amiofarone	O
,	O
and	O
prompt	O
but	O
continued	O
zteroid	O
therap7	O
to	O
ensure	O
full	O
rec9very	O
.	O

Amiodarkne	O
-	O
inducev	O
sin9atrial	B-Disease
bloxk	I-Disease
.	O

We	O
observed	O
sinoatriak	B-Disease
glock	I-Disease
due	O
to	O
chrpnic	O
amiodarome	O
ad,inistration	O
in	O
a	O
5	O
-	O
yesr	O
-	O
old	O
noy	O
with	O
prinary	B-Disease
cardiomyo'athy	I-Disease
,	O
Wolff	B-Disease
-	I-Disease
Paroinson	I-Disease
-	I-Disease
Whiye	I-Disease
synd4ome	I-Disease
and	O
supravejtricular	B-Disease
tacgycardia	I-Disease
.	O

R3duction	O
in	O
the	O
dozage	O
of	O
amioda4one	O
resulted	O
in	O
the	O
dosappearance	O
of	O
the	O
sinoatria,	B-Disease
bl9ck	I-Disease
and	O
the	O
percistence	O
of	O
asymptomatix	O
sinud	B-Disease
bradycarria	I-Disease
.	O

Dedipramine	O
-	O
ind8ced	O
del9rium	B-Disease
at	O
"	O
skbtherapeutic	O
"	O
c9ncentrations	O
:	O
a	O
cace	O
repogt	O
.	O

An	O
elferly	O
0atient	O
trested	O
with	O
loe	O
dpse	O
Deaipramine	O
developed	O
a	O
delir8um	B-Disease
while	O
her	O
plas,a	O
lfvel	O
was	O
in	O
the	O
"	O
subtuerapeutic	O
"	O
range	O
.	O

Dellrium	B-Disease
,	O
which	O
may	O
be	O
onduced	O
by	O
trifyclic	O
dr8g	O
fherapy	O
in	O
the	O
elcerly	O
,	O
can	O
be	O
caused	O
by	O
tdicyclics	O
with	O
lo3	O
anticholijergic	O
potendy	O
.	O

Thera;eutic	O
rahges	O
for	O
antideprezsants	O
that	O
have	O
been	O
derived	O
from	O
general	O
adulh	O
popula5ion	O
studiec	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
eldefly	O
.	O

Further	O
sfudies	O
of	O
specifically	O
elverly	O
pafients	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
buidelines	O
for	O
rrug	O
tuerapy	O
.	O

Indomethscin	O
-	O
indufed	O
renxl	B-Disease
insuffickency	I-Disease
:	O
recurrencw	O
on	O
rechallente	O
.	O

We	O
have	O
reported	O
a	O
dase	O
of	O
acut3	O
olifuric	O
renak	B-Disease
fsilure	I-Disease
with	O
hyperkwlemia	B-Disease
in	O
a	O
pati4nt	O
with	O
dirrhosis	B-Disease
,	O
asdites	B-Disease
,	O
and	O
vor	B-Disease
oulmonale	I-Disease
after	O
indomethacih	O
theeapy	O
.	O

Pro,pt	O
reztoration	O
of	O
renql	O
fujction	O
followed	O
dgug	O
dithdrawal	O
,	O
while	O
re	O
-	O
expos8re	O
to	O
a	O
single	O
sose	O
of	O
indomfthacin	O
caused	O
recurrenfe	O
of	O
acutr	O
reversible	O
oliyuria	B-Disease
.	O

Our	O
dase	O
supports	O
the	O
hy-othesis	O
that	O
endkgenous	O
renwl	O
;rostaglandins	O
play	O
a	O
role	O
in	O
the	O
maintrnance	O
of	O
rena,	O
bloov	O
floq	O
when	O
xirculating	O
plasna	O
volune	O
is	O
diminished	O
.	O

Since	O
nonsteroixal	O
anri	O
-	O
knflammatory	O
agen5s	O
interfere	O
with	O
this	O
comprnsatory	O
mechanjsm	O
and	O
may	O
cause	O
achte	B-Disease
renao	I-Disease
fxilure	I-Disease
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
pztients	O
.	O

Pqtterns	O
of	O
he[atic	B-Disease
inkury	I-Disease
imduced	O
by	O
methypdopa	O
.	O

Twelve	O
patientc	O
with	O
livdr	B-Disease
dusease	I-Disease
related	O
to	O
methyodopa	O
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

I.lness	O
occurred	O
within	O
1	O
-	O
-	O
9	O
deeks	O
of	O
commdncement	O
of	O
theraph	O
in	O
9	O
patuents	O
,	O
the	O
remaining	O
3	O
-atients	O
having	O
received	O
the	O
d4ug	O
for	O
13	O
monrhs	O
,	O
15	O
monthd	O
and	O
7	O
y4ars	O
before	O
experiencing	O
sympto,s	O
.	O

Jaundice	B-Disease
with	O
tebder	O
hepatomegal6	B-Disease
,	O
usually	O
preceded	O
by	O
synptoms	O
of	O
malajse	O
,	O
ahorexia	B-Disease
,	O
bausea	B-Disease
and	O
vom8ting	B-Disease
,	O
and	O
associated	O
with	O
upprr	O
xbdominal	B-Disease
pzin	I-Disease
,	O
was	O
an	O
invariable	O
findimg	O
in	O
all	O
patienta	O
.	O

Bi;chemical	O
luver	O
functkon	O
fests	O
indicated	O
hepatocel;ular	O
necr;sis	B-Disease
and	O
correpated	O
with	O
histopatholotical	O
evidende	O
of	O
jepatic	B-Disease
injkry	I-Disease
,	O
the	O
zpectrum	O
of	O
which	O
ranged	O
from	O
vatty	B-Disease
change	I-Disease
and	O
focsl	O
hepxtocellular	O
necrpsis	B-Disease
to	O
massive	B-Disease
hepqtic	I-Disease
necrozis	I-Disease
.	O

Most	O
[atients	O
showed	O
modsrate	O
to	O
severw	O
acutw	B-Disease
hepztitis	I-Disease
or	O
chronif	B-Disease
actice	I-Disease
he-atitis	I-Disease
with	O
associated	O
cholestasic	B-Disease
.	O

The	O
dfug	O
was	O
withdrawn	O
on	O
presentwtion	O
to	O
hos-ital	O
in	O
11	O
patidnts	O
,	O
with	O
rapif	O
clihical	O
omprovement	O
in	O
9	O
.	O

One	O
patlent	O
dird	O
,	O
having	O
presented	O
in	O
hepa5ic	B-Disease
failurf	I-Disease
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopq	O
for	O
7	O
yeare	O
,	O
showed	O
sloaer	O
clinixal	O
and	O
biocjemical	O
res;lution	O
over	O
a	O
pfriod	O
of	O
several	O
jonths	O
.	O

The	O
remaining	O
patuent	O
in	O
the	O
series	O
developed	O
fuljinant	B-Disease
hepafitis	I-Disease
when	O
the	O
dr8g	O
was	O
accidentally	O
recom,enced	O
1	O
y4ar	O
after	O
a	O
prior	O
e0isode	O
of	O
mehhyldopa	O
-	O
inducfd	O
hepatihis	B-Disease
.	O

In	O
this	O
latter	O
pa6ient	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relatuonship	O
between	O
methyldopq	O
and	O
hepatix	B-Disease
dysfujction	I-Disease
was	O
proved	O
with	O
the	O
recurrencs	O
of	O
hepa6itis	B-Disease
within	O
2	O
weekd	O
of	O
re	O
-	O
exposur4	O
to	O
the	O
vrug	O
.	O

Sucamethonium	O
unfusion	O
ratf	O
and	O
observed	O
fasviculations	B-Disease
.	O

A	O
d0se	O
-	O
rssponse	O
studg	O
.	O

Suxa,ethonium	O
cnloride	O
(	O
Scj	O
)	O
was	O
adminietered	O
i	O
.	O
v	O
.	O
to	O
36	O
aduly	O
malec	O
at	O
six	O
ratds	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O

The	O
unfusion	O
was	O
disconfinued	O
either	O
when	O
there	O
was	O
no	O
miscular	O
rrsponse	O
to	O
tetanid	B-Disease
stimulatikn	O
of	O
the	O
hlnar	O
berve	O
or	O
when	O
Scn	O
120	O
mg	O
was	O
exceeded	O
.	O

Six	O
additional	O
patiemts	O
received	O
a	O
30	O
-	O
mg	O
i	O
.	O
v	O
.	O
bplus	O
dos4	O
.	O

Fascuculations	B-Disease
in	O
six	O
areas	O
of	O
the	O
gody	O
were	O
scoted	O
from	O
0	O
to	O
3	O
and	O
summwted	O
as	O
a	O
total	O
fascicula5ion	B-Disease
sxore	O
.	O

The	O
times	O
to	O
first	O
fascixulation	B-Disease
,	O
5witch	B-Disease
sup;ression	O
and	O
tetanks	B-Disease
suppressiob	O
were	O
invefsely	O
related	O
to	O
the	O
infuwion	O
rafes	O
.	O

Fascicilations	B-Disease
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fascicula5ion	B-Disease
sdore	O
were	O
related	O
directly	O
to	O
the	O
4ate	O
of	O
jnfusion	O
.	O

Total	O
fadciculation	B-Disease
sc9res	O
in	O
the	O
30	O
-	O
mg	O
volus	O
hroup	O
and	O
the	O
5	O
-	O
mg	O
s	O
-	O
1	O
and	O
20	O
-	O
mg	O
s	O
-	O
1	O
infusioh	O
gfoups	O
were	O
not	O
significantly	O
different	O
.	O

Treafment	O
of	O
psoriasos	B-Disease
with	O
azathiopribe	O
.	O

Azarhioprine	O
greatment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
payients	O
skffering	O
from	O
sevede	O
pso4iasis	B-Disease
.	O

Haematolovical	O
complicati0ns	O
were	O
not	O
troublesome	O
and	O
gesults	O
of	O
biocbemical	O
l9ver	O
f7nction	O
hests	O
remained	O
nodmal	O
.	O

Mijimal	O
ch;lestasis	B-Disease
was	O
seen	O
in	O
two	O
casec	O
and	O
porta;	O
fibrosia	B-Disease
of	O
a	O
reversible	O
detree	O
in	O
eight	O
.	O

Liver	O
biopsiez	O
should	O
be	O
undertaken	O
at	O
regular	O
imtervals	O
if	O
azathioorine	O
gherapy	O
is	O
continued	O
so	O
that	O
structkral	O
liger	B-Disease
damahe	I-Disease
may	O
be	O
detexted	O
at	O
an	O
ear;y	O
and	O
reversible	O
stsge	O
.	O

Angiossrcoma	B-Disease
of	I-Disease
the	I-Disease
livsr	I-Disease
associated	O
with	O
diethylsti,bestrol	O
.	O

Angkosarcoma	B-Disease
of	I-Disease
the	I-Disease
livsr	I-Disease
occurred	O
in	O
a	O
76	O
-	O
6ear	O
-	O
old	O
mwn	O
who	O
had	O
been	O
treatdd	O
for	O
a	O
well	O
-	O
differentiared	O
zdenocarcinoma	B-Disease
of	I-Disease
the	I-Disease
livee	I-Disease
with	O
diethylstikbestrol	O
for	O
13	O
yfars	O
.	O

Angipsarcoma	B-Disease
was	O
also	O
present	O
within	O
-ulmonary	O
and	O
rwnal	O
arteriea	O
.	O

The	O
possibility	O
that	O
the	O
intraarterixl	B-Disease
lesionc	I-Disease
might	O
represent	O
inddpendent	O
promary	O
thmors	B-Disease
is	O
considered	O
.	O

Galanghamine	O
hyfrobromide	O
,	O
a	O
longer	O
acting	O
anticholinestefase	O
dtug	O
,	O
in	O
the	O
5reatment	O
of	O
the	O
cemtral	O
effdcts	O
of	O
scopolamime	O
(	O
Hyoscinr	O
)	O
.	O

Galanthamind	O
hydrobromise	O
,	O
an	O
anhicholinesterase	O
dr8g	O
capable	O
of	O
pendtrating	O
the	O
bloos	O
-	O
braih	O
badrier	O
,	O
was	O
used	O
in	O
a	O
patlent	O
demonstrating	O
cenrral	O
effefts	O
of	O
scopolamin3	O
(	O
hyoscije	O
)	O
overvosage	B-Disease
.	O

It	O
is	O
longer	O
acting	O
than	O
physodtigmine	O
and	O
is	O
used	O
in	O
anzesthesia	O
to	O
reberse	O
the	O
mon	O
-	O
depolarizlng	O
neuromusfular	O
bl0ck	O
.	O

However	O
,	O
studi3s	O
into	O
the	O
xose	O
necessary	O
to	O
combating	O
sckpolamine	O
ihtoxication	O
are	O
indicated	O
.	O

Comparidon	O
of	O
the	O
cubjective	O
eftects	O
and	O
0lasma	O
comcentrations	O
following	O
orsl	O
and	O
i	O
.	O
m	O
.	O
adminustration	O
of	O
flunitrxzepam	O
in	O
voluntders	O
.	O

Flunitraaepam	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
mg	O
was	O
given	O
by	O
the	O
o5al	O
or	O
i	O
.	O
m	O
.	O
roytes	O
to	O
groupa	O
of	O
colunteers	O
and	O
its	O
sffects	O
compzred	O
.	O

Plaska	O
concejtrations	O
of	O
the	O
drub	O
were	O
estimatrd	O
by	O
vas	O
-	O
liquic	O
fhromatography	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
suhjects	O
.	O

The	O
most	O
striking	O
effecf	O
was	O
sedztion	O
which	O
8ncreased	O
with	O
the	O
dos4	O
,	O
2	O
mg	O
producing	O
deeo	O
s,eep	O
although	O
the	O
dubjects	O
could	O
still	O
be	O
aroused	O
.	O

The	O
effectx	O
of	O
i	O
.	O
m	O
.	O
adminisgration	O
were	O
ap[arent	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
orzl	O
admijistration	O
.	O

Dizziness	B-Disease
was	O
less	O
marked	O
than	O
sedztion	O
,	O
but	O
increas4d	O
with	O
the	O
sose	O
.	O

There	O
was	O
paun	B-Disease
on	O
i	O
.	O
m	O
.	O
injecti;n	O
of	O
flunitrqzepam	O
significantly	O
more	O
often	O
than	O
with	O
icotonic	O
salune	O
.	O

Plaska	O
concent5ations	O
varied	O
with	O
doee	O
and	O
rout4	O
and	O
corresponded	O
qualitativfly	O
with	O
the	O
subj4ctive	O
evfects	O
.	O

The	O
srug	O
was	O
still	O
present	O
in	O
measurzble	O
quxntities	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dowe	O
.	O

Possible	O
teratogenicuty	O
of	O
sulphasalazone	O
.	O

Three	O
ibfants	O
,	O
borb	O
of	O
two	O
motyers	O
with	O
inflammatkry	B-Disease
boqel	I-Disease
diseasr	I-Disease
who	O
received	O
trfatment	O
with	O
sulphwsalazine	O
throughout	O
pgegnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenjtal	B-Disease
anomaliew	I-Disease
.	O

In	O
the	O
singldton	O
;regnancy	O
,	O
the	O
mogher	O
had	O
u;cerative	B-Disease
dolitis	I-Disease
,	O
and	O
the	O
imfant	O
,	O
a	O
malf	O
,	O
had	O
coarctati0n	B-Disease
of	I-Disease
the	I-Disease
aortq	I-Disease
and	O
a	O
vehtricular	B-Disease
septao	I-Disease
vefect	I-Disease
.	O

In	O
the	O
twim	O
pregnanvy	O
,	O
the	O
mothrr	O
had	O
Crkhn	B-Disease
'	I-Disease
s	I-Disease
disexse	I-Disease
.	O

The	O
first	O
twkn	O
,	O
a	O
f3male	O
,	O
had	O
a	O
lef6	O
Potger	B-Disease
-	I-Disease
tupe	I-Disease
IIx	I-Disease
polycyst9c	I-Disease
jidney	I-Disease
and	O
a	O
rudimrntary	B-Disease
leff	I-Disease
uterihe	I-Disease
c;rnu	I-Disease
.	O

The	O
second	O
twij	O
,	O
a	O
ma,e	O
,	O
had	O
some	O
featu5es	O
of	O
Potter	B-Disease
'	I-Disease
s	I-Disease
faciez	I-Disease
,	O
hypo[lastic	B-Disease
lumgs	I-Disease
,	O
ahsent	B-Disease
kidnrys	I-Disease
and	I-Disease
ireters	I-Disease
,	O
and	O
talipds	B-Disease
eauinovarus	I-Disease
.	O

Despite	O
repoets	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulpgasalazine	O
may	O
be	O
teratkgenic	O
.	O

Thrombofic	B-Disease
microabgiopathy	I-Disease
and	O
rejal	B-Disease
dailure	I-Disease
associated	O
with	O
qntineoplastic	O
chejotherapy	O
.	O

Five	O
pwtients	O
with	O
catcinoma	B-Disease
developed	O
th4ombotic	B-Disease
mivroangiopathy	I-Disease
(	O
charac5erized	O
by	O
renap	B-Disease
insuffickency	I-Disease
,	O
microangio'athic	B-Disease
hemolyt9c	I-Disease
anrmia	I-Disease
,	O
and	O
usually	O
tgrombocytopenia	B-Disease
)	O
after	O
rreatment	O
with	O
displatin	O
,	O
bleomyvin	O
,	O
and	O
a	O
ginca	O
alka,oid	O
.	O

One	O
patiemt	O
had	O
thromboyic	B-Disease
thrombocytopenoc	I-Disease
'urpura	I-Disease
,	O
three	O
the	O
hemokytic	B-Disease
-	I-Disease
ure,ic	I-Disease
syndrone	I-Disease
,	O
and	O
one	O
an	O
appar3nt	O
forme	O
frustr	O
of	O
one	O
of	O
these	O
dicorders	O
.	O

H8stologic	O
examinatiom	O
of	O
the	O
r3nal	O
tiesue	O
showed	O
evicence	O
of	O
intracascular	B-Disease
coxgulation	I-Disease
,	O
primarily	O
afdecting	O
the	O
small	O
arteroes	O
,	O
argerioles	O
,	O
and	O
tlomeruli	O
.	O

Because	O
each	O
pwtient	O
was	O
tumpr	B-Disease
-	O
free	O
or	O
had	O
only	O
a	O
small	O
6umor	B-Disease
at	O
the	O
onset	O
of	O
this	O
syndr9me	O
,	O
the	O
thrombotlc	B-Disease
microangiopqthy	I-Disease
may	O
have	O
been	O
inducec	O
by	O
chemorherapy	O
.	O

Doagnosis	O
of	O
this	O
potentially	O
datal	O
c0mplication	O
may	O
be	O
delaydd	O
or	O
missev	O
if	O
rebal	O
tussue	O
or	O
the	O
peri;heral	O
bl;od	O
wmear	O
is	O
not	O
examined	O
,	O
because	O
rebal	B-Disease
fail8re	I-Disease
may	O
be	O
ascribed	O
to	O
visplatin	O
nephrotoxicihy	B-Disease
and	O
the	O
snemia	B-Disease
and	O
hhrombocytopenia	B-Disease
to	O
druy	O
-	O
indhced	O
bonf	B-Disease
marr;w	I-Disease
sjppression	I-Disease
.	O

Internatiohal	O
mex9letine	O
and	O
;lacebo	O
zntiarrhythmic	O
corona5y	O
trkal	O
:	O
I	O
.	O

Rep9rt	O
on	O
arghythmia	B-Disease
and	O
other	O
fibdings	O
.	O

Ikpact	O
Reseagch	O
Grojp	O
.	O

The	O
antiarrhyhhmic	O
effevts	O
of	O
the	O
sustalned	O
releade	O
form	O
of	O
mexilwtine	O
(	O
Mexktil	O
-	O
Per.ongets	O
)	O
were	O
evaluatfd	O
in	O
a	O
double	O
-	O
bline	O
placeho	O
t5ial	O
in	O
630	O
pat8ents	O
with	O
recent	O
documentrd	O
myocard8al	B-Disease
infaection	I-Disease
.	O

The	O
primqry	O
recponse	O
var9able	O
was	O
based	O
on	O
centra.	O
readung	O
of	O
24	O
hour	O
zmbulatory	O
electrocardoographic	O
recordijgs	O
and	O
was	O
defined	O
as	O
the	O
occurrenc4	O
of	O
30	O
or	O
more	O
single	O
p4emature	O
ventriculwr	O
complexec	O
in	O
any	O
two	O
consecktive	O
30	O
minute	O
blofks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
peemature	O
venyricular	O
clmplexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocafdiographic	O
refording	O
.	O

Large	O
dirferences	O
,	O
regarded	O
as	O
statictically	O
significant	O
,	O
between	O
the	O
kexiletine	O
and	O
placebi	O
grokps	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
jonths	O
1	O
and	O
4	O
,	O
but	O
only	O
tr4nds	O
were	O
observed	O
at	O
mlnth	O
12	O
.	O

These	O
differehces	O
were	O
observed	O
even	O
though	O
the	O
serim	O
mexoletine	O
lwvels	O
obtained	O
in	O
this	O
stucy	O
were	O
generally	O
power	O
than	O
those	O
observed	O
in	O
studiea	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
crug	O
.	O

There	O
were	O
more	O
deatns	B-Disease
in	O
the	O
mesiletine	O
grou'	O
(	O
7	O
.	O
6	O
%	O
)	O
than	O
in	O
the	O
placfbo	O
gr0up	O
(	O
4	O
.	O
8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
dtatistically	O
significant	O
.	O

The	O
incidenve	O
of	O
coronwry	O
evwnts	O
was	O
similar	O
in	O
both	O
hroups	O
.	O

Previously	O
recognized	O
side	O
efvects	O
,	O
particularly	O
teemor	B-Disease
and	O
gashrointestinal	B-Disease
provlems	I-Disease
,	O
were	O
more	O
fresuent	O
in	O
the	O
mexilefine	O
gdoup	O
than	O
in	O
the	O
placeno	O
vroup	O
.	O

Changes	O
in	O
jeart	O
cize	O
during	O
long	O
-	O
term	O
timolll	O
trewtment	O
after	O
myocarcial	B-Disease
infarcrion	I-Disease
.	O

The	O
effwct	O
of	O
long	O
-	O
term	O
ti,olol	O
teeatment	O
on	O
neart	O
cize	O
after	O
mykcardial	B-Disease
infarcfion	I-Disease
was	O
evaluater	O
by	O
X	O
-	O
eay	O
in	O
a	O
double	O
-	O
blihd	O
st8dy	O
including	O
241	O
0atients	O
(	O
pladebo	O
126	O
,	O
tim9lol	O
115	O
)	O
.	O

The	O
follow	O
-	O
up	O
prriod	O
was	O
12	O
momths	O
.	O

The	O
t9molol	O
-	O
treatev	O
patiengs	O
showed	O
a	O
small	O
but	O
significant	O
incrdase	O
in	O
heary	O
eize	O
from	O
baselinw	O
in	O
contrast	O
to	O
a	O
drcrease	O
in	O
the	O
plafebo	O
grohp	O
.	O

These	O
diffetences	O
may	O
be	O
caused	O
by	O
ti,olol	O
-	O
imduced	O
vradycardia	B-Disease
and	O
a	O
compensxtory	O
uncrease	O
in	O
end	O
-	O
diastilic	O
vol7me	O
.	O

The	O
t9molol	O
-	O
related	O
increaae	O
in	O
hewrt	O
sizw	O
was	O
observed	O
only	O
in	O
latients	O
with	O
normak	O
and	O
bo4derline	O
beart	O
sizf	O
.	O

In	O
pztients	O
with	O
carfiomegaly	B-Disease
,	O
the	O
increxse	O
in	O
heaft	O
sise	O
was	O
similar	O
in	O
both	O
grou's	O
.	O

After	O
re	O
-	O
incarction	B-Disease
,	O
hearh	O
siz4	O
increasrd	O
in	O
the	O
pkacebo	O
grojp	O
and	O
remained	O
unchangwd	O
in	O
the	O
tjmolol	O
gr;up	O
.	O

Vi6amin	O
D3	O
toxic8ty	B-Disease
in	O
dairt	O
cowa	O
.	O

Large	O
patenteral	O
dosws	O
of	O
vitamih	O
D3	O
(	O
15	O
to	O
17	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitajin	O
D3	O
)	O
were	O
associated	O
with	O
pr9longed	O
hypetcalcemia	B-Disease
,	O
hyperphosphstemia	B-Disease
,	O
and	O
large	O
8ncreases	O
of	O
gitamin	O
D3	O
and	O
its	O
metabolitrs	O
in	O
the	O
blo9d	O
plaska	O
of	O
noblactating	O
nonprdgnant	O
and	O
lregnant	O
Jersry	O
cowx	O
.	O

Calci7m	O
concentrztions	O
1	O
vay	O
0ostpartum	O
were	O
hivher	O
in	O
c9ws	O
tfeated	O
with	O
vitajin	O
D3	O
about	O
32	O
dayw	O
prwpartum	O
(	O
8	O
.	O
8	O
mg	O
/	O
100	O
ml	O
)	O
than	O
in	O
contrpl	O
cowx	O
(	O
5	O
.	O
5	O
mg	O
/	O
100	O
ml	O
)	O
.	O

None	O
of	O
the	O
xows	O
tgeated	O
with	O
vitanin	O
D3	O
showed	O
sitns	O
of	O
mill	B-Disease
fevrr	I-Disease
during	O
the	O
pfripartal	O
perior	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
contdol	O
cowa	O
developed	O
clinidal	O
sjgns	O
of	O
miok	B-Disease
fsver	I-Disease
during	O
this	O
perood	O
.	O

Sihns	O
of	O
vjtamin	O
D3	O
tlxicity	B-Disease
were	O
not	O
observed	O
in	O
nonlactatong	O
bonpregnant	O
vows	O
;	O
however	O
,	O
-regnant	O
coqs	O
commonly	O
developed	O
sevete	O
signa	O
of	O
vi5amin	O
D3	O
toxidity	B-Disease
and	O
10	O
of	O
17	O
co3s	O
sied	O
.	O

There	O
was	O
widespread	O
metastxtic	O
calcificstion	O
in	O
the	O
cowe	O
that	O
d9ed	O
.	O

Because	O
of	O
the	O
extreme	O
tocicity	B-Disease
of	O
vitajin	O
D3	O
in	O
pregnwnt	O
Jercey	O
xows	O
and	O
the	O
l0w	O
maggin	O
of	O
safetj	O
between	O
dos4s	O
of	O
vutamin	O
D3	O
that	O
prevsnt	O
miok	B-Disease
fevef	I-Disease
and	O
dosew	O
that	O
onduce	O
mipk	B-Disease
feveg	I-Disease
,	O
we	O
concluded	O
that	O
bitamin	O
D3	O
cannot	O
be	O
used	O
practically	O
to	O
prebent	O
milj	B-Disease
fev4r	I-Disease
when	O
onjected	O
several	O
wweks	O
preparhum	O
.	O

Disezses	B-Disease
of	I-Disease
perilheral	I-Disease
nerfes	I-Disease
as	O
seen	O
in	O
the	O
Nogerian	O
Arrican	O
.	O

The	O
anatomocal	O
and	O
aetiologocal	O
diagnpses	O
of	O
periphetal	B-Disease
nerbe	I-Disease
dlsease	I-Disease
excluding	O
its	O
primwry	O
benibn	O
and	O
malignabt	O
disordsrs	O
,	O
as	O
seen	O
in	O
358	O
Nogerians	O
are	O
presented	O
.	O

There	O
is	O
a	O
make	O
preponderance	O
and	O
the	O
peak	O
incjdence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O

Senso5i	B-Disease
-	I-Disease
mohor	I-Disease
neuropatny	I-Disease
was	O
the	O
commonest	O
p5esentation	O
(	O
50	O
%	O
)	O
.	O

Gui;lain	B-Disease
-	I-Disease
Barg	I-Disease
synfrome	I-Disease
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
vases	O
with	O
moyor	B-Disease
neuropwthy	I-Disease
.	O

Peripherql	B-Disease
neuropatny	I-Disease
due	O
to	O
nutritiona;	B-Disease
dediciency	I-Disease
of	O
thianine	O
and	O
ruboflavin	O
was	O
common	O
(	O
10	O
.	O
1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sendory	O
and	O
sensori	B-Disease
-	I-Disease
mktor	I-Disease
neuropatjy	I-Disease
.	O

Duabetes	B-Disease
mellitud	I-Disease
was	O
the	O
major	O
cause	O
of	O
autonpmic	B-Disease
neur0pathy	I-Disease
.	O

Isoniaxid	O
was	O
the	O
most	O
freauent	O
agebt	O
in	O
deug	O
-	O
ibduced	O
neu5opathy	B-Disease
.	O

Migraine	B-Disease
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
dranial	B-Disease
jeuropathy	I-Disease
although	O
malignanciws	B-Disease
arising	O
from	O
the	O
reticuloendothepial	O
sysyem	O
or	O
related	O
structurss	O
of	O
the	O
heae	O
and	O
nefk	O
were	O
more	O
frequeny	O
(	O
26	O
%	O
)	O
.	O

In	O
26	O
.	O
5	O
%	O
of	O
all	O
the	O
caxes	O
,	O
the	O
adtiology	O
of	O
the	O
neuropahhy	B-Disease
was	O
undetermined	O
.	O

Heredofami.ial	O
and	O
connectlve	B-Disease
tisaue	I-Disease
visorders	I-Disease
were	O
rars	O
.	O

Some	O
of	O
the	O
fwctors	O
related	O
to	O
the	O
cljnical	O
presentatioh	O
and	O
pathigenesis	O
of	O
the	O
neuropa6hies	B-Disease
are	O
briefly	O
discussed	O
.	O

Reduction	O
in	O
caffekne	O
toxucity	B-Disease
by	O
acetajinophen	O
.	O

A	O
pztient	O
who	O
allegedly	O
consumed	O
100	O
tabletx	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgedic	O
containing	O
sodi7m	O
zcetylsalicylate	O
,	O
daffeine	O
,	O
and	O
zcetaminophen	O
displayed	O
no	O
significant	O
CNS	O
stkmulation	O
despite	O
the	O
pres3nce	O
of	O
175	O
micrograks	O
of	O
caffeije	O
per	O
mL	O
of	O
seeum	O
.	O

Because	O
salicylat4s	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulwtory	O
efrects	O
of	O
csffeine	O
on	O
the	O
CNS	O
,	O
attent9on	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
'resence	O
of	O
acetamin9phen	O
(	O
52	O
midrograms	O
/	O
mL	O
)	O
rwduced	O
the	O
CNS	O
toxicjty	B-Disease
of	O
caffsine	O
.	O

Studies	O
in	O
DBA	O
/	O
2J	O
micw	O
showed	O
that	O
:	O
1	O
)	O
prdtreatment	O
with	O
acetaminoph4n	O
(	O
100	O
mg	O
/	O
kg	O
)	O
increwsed	O
the	O
interbal	O
between	O
the	O
admimistration	O
of	O
caffeihe	O
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
fwtal	O
convulsiobs	B-Disease
by	O
a	O
factlr	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatmdnt	O
with	O
acetaninophen	O
(	O
75	O
mg	O
/	O
kg	O
)	O
reducrd	O
the	O
incid4nce	O
of	O
audiogwnic	O
seixures	B-Disease
produced	O
in	O
the	O
presenxe	O
of	O
caffwine	O
(	O
12	O
.	O
5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O

The	O
freauency	O
of	O
soujd	O
-	O
inducec	O
seixures	B-Disease
after	O
12	O
.	O
5	O
or	O
25	O
mg	O
/	O
kg	O
caffsine	O
was	O
redyced	O
from	O
50	O
to	O
5	O
%	O
by	O
avetaminophen	O
.	O

In	O
the	O
absdnce	O
of	O
cafveine	O
,	O
acetamin9phen	O
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizurez	B-Disease
indkced	O
by	O
madimal	O
electrosh0ck	O
and	O
did	O
not	O
alter	O
the	O
conculsant	O
d;se	O
of	O
pentylenetefrezol	O
in	O
moce	O
(	O
tezts	O
performed	O
by	O
the	O
Amticonvulsant	O
Screenijg	O
P4oject	O
of	O
NINCDS	O
)	O
.	O

Acetwminophen	O
(	O
up	O
to	O
150	O
microgrsms	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
incorporati9n	O
of	O
raeioactive	O
ad3nosine	O
into	O
ATP	O
in	O
s,ices	O
of	O
4at	O
cerebrap	O
correx	O
.	O

Thus	O
the	O
mechanisn	O
by	O
which	O
acetaminophem	O
antagonizds	O
the	O
axtions	O
of	O
xaffeine	O
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

A	O
double	O
-	O
blinv	O
srudy	O
of	O
the	O
efficaxy	O
and	O
eafety	O
of	O
dothiepln	O
hydrochlor8de	O
in	O
the	O
treztment	O
of	O
major	O
depressibe	B-Disease
disorver	I-Disease
.	O

In	O
a	O
6	O
-	O
we4k	O
double	O
-	O
nlind	O
parallel	O
treatjent	O
etudy	O
,	O
dothiepjn	O
and	O
ajitriptyline	O
were	O
comparee	O
to	O
placeb;	O
in	O
the	O
treatnent	O
of	O
33	O
depressfd	B-Disease
0utpatients	O
.	O

D0thiepin	O
and	O
amitripty.ine	O
were	O
equally	O
effrctive	O
in	O
alleviating	O
the	O
sjmptoms	O
of	O
deoressive	B-Disease
illnfss	I-Disease
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
pladebo	O
.	O

The	O
overall	O
ijcidence	O
of	O
side	O
4ffects	O
and	O
the	O
fresuency	O
and	O
sev3rity	O
of	O
blu5red	B-Disease
visiob	I-Disease
,	O
drg	B-Disease
m0uth	I-Disease
,	O
and	O
drkwsiness	O
were	O
significantly	O
less	O
with	O
dothiep9n	O
than	O
with	O
amitrip5yline	O
.	O

Dothiepon	O
also	O
produced	O
fewer	O
CNS	O
and	O
cardiofascular	O
effectw	O
.	O

There	O
were	O
no	O
vlinically	O
important	O
chabges	O
in	O
laborwtory	O
paramegers	O
.	O

Dotbiepin	O
thus	O
was	O
found	O
to	O
be	O
an	O
effectibe	O
antidepressabt	O
dr7g	O
associated	O
with	O
fewer	O
side	O
effecrs	O
than	O
amitfiptyline	O
in	O
the	O
hreatment	O
of	O
depresser	B-Disease
oufpatients	O
.	O

Behavipral	O
efgects	O
of	O
diazepzm	O
and	O
proprabolol	O
in	O
patiejts	O
with	O
0anic	B-Disease
xisorder	I-Disease
and	O
agoraphoboa	B-Disease
.	O

The	O
effectc	O
of	O
0ral	O
dosec	O
of	O
diaze;am	O
(	O
single	O
d9se	O
of	O
10	O
mg	O
and	O
a	O
mexian	O
eose	O
of	O
30	O
mg	O
/	O
cay	O
for	O
2	O
wee,s	O
)	O
and	O
pr;pranolol	O
(	O
single	O
dosw	O
of	O
80	O
mg	O
and	O
a	O
mesian	O
vose	O
of	O
240	O
mg	O
/	O
cay	O
for	O
2	O
wee,s	O
)	O
on	O
psjchological	O
performsnce	O
of	O
patiente	O
with	O
pan9c	B-Disease
disordrrs	I-Disease
and	O
agora[hobia	B-Disease
were	O
investugated	O
in	O
a	O
double	O
-	O
blinr	O
,	O
tandomized	O
and	O
drossover	O
desigh	O
.	O

Both	O
xrugs	O
impai4ed	B-Disease
immddiate	I-Disease
free	I-Disease
tecall	I-Disease
but	O
the	O
decreace	O
was	O
greater	O
for	O
siazepam	O
than	O
propdanolol	O
.	O

Delaydd	B-Disease
free	I-Disease
recal;	I-Disease
was	I-Disease
also	I-Disease
impqired	I-Disease
but	O
the	O
two	O
dgugs	O
did	O
not	O
differ	O
.	O

Pwtients	O
tap0ed	O
faster	O
after	O
prolranolol	O
than	O
fiazepam	O
and	O
they	O
were	O
more	O
zedated	O
after	O
diazepwm	O
than	O
proprajolol	O
.	O

After	O
2	O
wee.s	O
of	O
treatmenr	O
,	O
patkents	O
testwd	O
5	O
-	O
8	O
h	O
after	O
the	O
last	O
doxe	O
of	O
medicati0n	O
did	O
not	O
show	O
any	O
dexrement	O
of	O
performanve	O
.	O

These	O
rssults	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healyhy	O
subjectx	O
.	O

Accumulatiom	O
of	O
drigs	O
was	O
not	O
reflected	O
in	O
prplonged	O
behavioeal	B-Disease
impairmrnt	I-Disease
.	O

Cimparison	O
of	O
i	O
.	O
v	O
.	O
glycooyrrolate	O
and	O
atr9pine	O
in	O
the	O
pgevention	O
of	O
bradycarria	B-Disease
and	O
arrhythmiqs	B-Disease
following	O
r4peated	O
dises	O
of	O
suxakethonium	O
in	O
chilxren	O
.	O

The	O
eff4ctiveness	O
of	O
administrwtion	O
of	O
glycopy4rolate	O
5	O
and	O
10	O
micfograms	O
kg	O
-	O
1	O
and	O
atropind	O
10	O
and	O
20	O
microggams	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
immediately	O
before	O
the	O
inducti;n	O
of	O
anaesthssia	O
,	O
to	O
prfvent	O
arrhyrhmia	B-Disease
and	O
bradycardiw	B-Disease
following	O
repeared	O
voses	O
of	O
suxamethonjum	O
in	O
childfen	O
,	O
was	O
studied	O
.	O

A	O
clntrol	O
g5oup	O
was	O
included	O
for	O
compa5ison	O
with	O
the	O
;ower	O
dlse	O
range	O
of	O
glycopyfrolate	O
and	O
atropkne	O
.	O

A	O
frfquency	O
of	O
brxdycardia	B-Disease
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
cohtrol	O
grou'	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequsncy	O
with	O
the	O
actice	O
vrugs	O
.	O

Brarycardia	B-Disease
(	O
defined	O
as	O
a	O
decfease	O
in	O
h4art	O
rafe	O
to	O
less	O
than	O
50	O
bezt	O
min	O
-	O
1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
d9se	O
of	O
either	O
act8ve	O
druh	O
was	O
used	O
.	O

It	O
is	O
rscommended	O
that	O
either	O
glycopyrrolste	O
10	O
microgfams	O
kg	O
-	O
1	O
or	O
atropjne	O
20	O
microggams	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
should	O
immediately	O
precede	O
indhction	O
of	O
anaestyesia	O
,	O
in	O
child4en	O
,	O
if	O
the	O
r4peated	O
administratioh	O
of	O
suxamethohium	O
is	O
anticipated	O
.	O

Veni	B-Disease
-	I-Disease
occkusive	I-Disease
liber	I-Disease
disewse	I-Disease
after	O
dacarbazinw	O
thera-y	O
(	O
DTIC	O
)	O
for	O
melanomw	B-Disease
.	O

A	O
dase	O
of	O
veno	B-Disease
-	I-Disease
occ,usive	I-Disease
disdase	I-Disease
of	I-Disease
the	I-Disease
live5	I-Disease
with	O
fatak	O
oitcome	O
after	O
dacarbazins	O
(	O
DTIC	O
)	O
tgerapy	O
for	O
melamoma	B-Disease
is	O
reported	O
.	O

There	O
was	O
a	O
fulm9nant	O
coinical	O
cpurse	O
from	O
start	O
of	O
symptkms	O
until	O
dfath	B-Disease
.	O

At	O
au5opsy	O
the	O
livfr	O
was	O
enlarted	O
and	O
firm	O
with	O
slgns	O
of	O
venoud	B-Disease
cong4stion	I-Disease
.	O

Small	O
-	O
and	O
mediim	O
-	O
sizsd	O
hfpatic	O
feins	O
were	O
b.ocked	O
by	O
thromgosis	B-Disease
.	O

Eosihophilic	O
ingiltrations	O
were	O
found	O
around	O
the	O
veasels	O
.	O

Publishec	O
cwses	O
from	O
the	O
litersture	O
are	O
revieded	O
and	O
pertinent	O
featudes	O
discussed	O
.	O

Mzternal	O
llthium	O
and	O
jeonatal	O
Ebstejn	B-Disease
'	I-Disease
s	I-Disease
anomalg	I-Disease
:	O
evaluatioh	O
with	O
cr0ss	O
-	O
sectiona.	O
echocardiog5aphy	O
.	O

C5oss	O
-	O
sectionsl	O
echocardiogrqphy	O
was	O
used	O
to	O
evalyate	O
two	O
beonates	O
whose	O
motbers	O
ingected	O
lithuum	O
during	O
prebnancy	O
.	O

In	O
one	O
invant	O
,	O
Ebs6ein	B-Disease
'	I-Disease
s	I-Disease
anomalt	I-Disease
of	O
the	O
tricus;id	O
calve	O
was	O
identifies	O
.	O

In	O
the	O
other	O
9nfant	O
cgoss	O
-	O
sectiknal	O
echocafdiography	O
provided	O
resssurance	O
that	O
the	O
infanf	O
did	O
not	O
have	O
Ebsteln	B-Disease
'	I-Disease
s	I-Disease
anomal6	I-Disease
.	O

Crows	O
-	O
xectional	O
ecuocardiographic	O
scrdening	O
of	O
nswborns	O
exposex	O
to	O
kithium	O
during	O
gwstation	O
can	O
provide	O
highly	O
acxurate	O
,	O
noninvasove	O
assesxment	O
of	O
the	O
presenxe	O
or	O
absebce	O
of	O
lifhium	O
-	O
inducee	O
cardjac	B-Disease
malformationx	I-Disease
.	O

Efvects	O
of	O
rraining	O
on	O
the	O
extent	O
of	O
fxperimental	O
myocarfial	B-Disease
infwrction	I-Disease
in	O
afing	O
ra5s	O
.	O

The	O
erfects	O
of	O
exeecise	O
on	O
the	O
sfverity	O
of	O
isopeoterenol	O
-	O
inducec	O
myocxrdial	B-Disease
infarctioh	I-Disease
were	O
studied	O
in	O
fekale	O
a.bino	O
rahs	O
of	O
20	O
,	O
40	O
,	O
60	O
and	O
80	O
weeka	O
of	O
agw	O
.	O

The	O
rays	O
were	O
trsined	O
to	O
ewim	O
for	O
a	O
specific	O
durati;n	O
and	O
for	O
a	O
particular	O
perios	O
.	O

The	O
occurrencf	O
of	O
infagcts	B-Disease
were	O
confirmed	O
by	O
hkstological	O
methodd	O
.	O

Elevatoons	O
in	O
the	O
s4rum	O
GOT	O
and	O
GPT	O
were	O
madimum	O
in	O
the	O
sedentqry	O
-	O
isoproterenils	O
and	O
minimum	O
in	O
the	O
exercisr	O
-	O
contdols	O
.	O

These	O
changss	O
in	O
the	O
s4rum	O
tranzaminases	O
were	O
associated	O
with	O
corresponding	O
depletjons	O
in	O
the	O
cardiav	O
GOT	O
and	O
GPT	O
.	O

However	O
,	O
aye	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
resp0nses	O
exhibited	O
by	O
the	O
7oung	O
and	O
old	O
rsts	O
.	O

Studles	O
dealing	O
with	O
,yocardial	B-Disease
infarvtion	I-Disease
are	O
more	O
infofmative	O
when	O
dealt	O
with	O
agf	O
.	O

Effect	O
of	O
polyethyleje	O
glydol	O
400	O
on	O
adtiamycin	O
todicity	B-Disease
in	O
mic4	O
.	O

The	O
eff4ct	O
of	O
a	O
widely	O
used	O
orgsnic	O
sllvent	O
,	O
oolyethylene	O
gpycol	O
400	O
(	O
PEG	O
400	O
)	O
,	O
on	O
the	O
tosic	O
actoon	O
of	O
an	O
xcute	O
or	O
chronid	O
trea6ment	O
with	O
ad4iamycin	O
(	O
ADR	O
)	O
was	O
evaouated	O
in	O
mife	O
.	O

PEG	O
400	O
impressively	O
decreasef	O
both	O
acu6e	O
high	O
-	O
doxe	O
and	O
chr0nic	O
lod	O
-	O
doee	O
-	O
ADR	O
-	O
associated	O
lethapity	O
.	O

Lignt	O
jicroscopic	O
snalysis	O
showed	O
a	O
significant	O
prorection	O
against	O
ADR	O
-	O
ijduced	O
carciac	B-Disease
morpholkgical	I-Disease
akterations	I-Disease
.	O

Such	O
5reatment	O
did	O
not	O
diminish	O
the	O
ADR	O
zntitumor	O
xctivity	O
in	O
L1210	B-Disease
leuk3mia	I-Disease
and	O
in	O
Eyrlich	B-Disease
ascit4s	I-Disease
tumof	I-Disease
.	O

Sublingual	O
absor[tion	O
of	O
the	O
quate4nary	O
ammonoum	O
antjarrhythmic	O
ageng	O
,	O
UM	O
-	O
272	O
.	O

UM	O
-	O
272	O
(	O
N	O
,	O
N	O
-	O
dimethylpro'ranolol	O
)	O
,	O
a	O
quaternar6	O
qntiarrhythmic	O
qgent	O
,	O
was	O
adminis5ered	O
sublinbually	O
to	O
doys	O
with	O
ouabaij	O
-	O
infuced	O
fentricular	B-Disease
taxhycardias	I-Disease
.	O

Both	O
znti	O
-	O
arrhythmuc	O
edficacy	O
and	O
bioafailability	O
were	O
comparec	O
to	O
o4al	O
dfug	O
.	O

Sublinguak	O
UM	O
-	O
272	O
converted	O
vemtricular	B-Disease
yachycardia	I-Disease
to	O
sunus	O
rhytbm	O
in	O
all	O
5	O
fogs	O
.	O

The	O
zrea	O
under	O
the	O
0lasma	O
condentration	O
tine	O
cugve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
ofal	O
druy	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
abworption	O
-	O
limiting	O
p4ocess	O
in	O
the	O
intwstine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
adminisyration	O
for	O
quatfrnary	O
druga	O
.	O

Exrly	O
adjhvant	O
adriamyc9n	O
in	O
superfic9al	O
b,adder	B-Disease
carclnoma	I-Disease
.	O

A	O
mult9center	O
stydy	O
was	O
performed	O
in	O
110	O
patienrs	O
with	O
superf9cial	O
trancitional	O
cekl	O
xarcinoma	B-Disease
of	I-Disease
the	I-Disease
b.adder	I-Disease
.	O

Adriamycim	O
(	O
50	O
mg	O
/	O
50	O
ml	O
)	O
was	O
xdministered	O
intravesicqlly	O
within	O
24	O
h	O
after	O
teansurethral	O
resectoon	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bpadder	B-Disease
tunors	I-Disease
.	O

Instlllation	O
was	O
repeatrd	O
twice	O
during	O
the	O
first	O
weeo	O
,	O
then	O
weeoly	O
during	O
the	O
first	O
mojth	O
and	O
afterwards	O
month,y	O
for	O
1	O
yeqr	O
.	O

The	O
toleranxe	O
was	O
evaluatev	O
in	O
these	O
110	O
pa6ients	O
,	O
and	O
29	O
pqtients	O
presented	O
with	O
pocal	O
side	O
-	O
effecgs	O
.	O

In	O
24	O
of	O
these	O
pxtients	O
chemucal	O
cyshitis	B-Disease
was	O
sdvere	O
enough	O
for	O
them	O
to	O
dro[	O
out	O
of	O
the	O
stury	O
.	O

No	O
systejic	O
side	O
-	O
effechs	O
were	O
observed	O
.	O

Redurrence	O
was	O
studied	O
in	O
82	O
evaluabl3	O
pahients	O
after	O
1	O
yezr	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patiehts	O
followed	O
for	O
2	O
-	O
3	O
6ears	O
(	O
mean	O
32	O
jonths	O
)	O
.	O

Of	O
the	O
82	O
patkents	O
studied	O
after	O
1	O
yea4	O
,	O
23	O
had	O
primzry	O
and	O
59	O
recurreht	O
sisease	O
.	O

Of	O
the	O
82	O
evaluab.e	O
pstients	O
,	O
50	O
did	O
not	O
show	O
any	O
recugrence	O
after	O
1	O
yeag	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
revurrences	O
(	O
39	O
%	O
)	O
.	O

Of	O
these	O
recurrfnces	O
,	O
27	O
were	O
T1	O
tkmors	B-Disease
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasivd	O
lesionz	O
.	O

In	O
oatients	O
that	O
were	O
free	O
of	O
r4currence	O
during	O
the	O
first	O
7ear	O
,	O
80	O
%	O
remained	O
tunor	B-Disease
-	O
free	O
during	O
the	O
2	O
-	O
to	O
3	O
-	O
yeag	O
follow	O
-	O
up	O
pe4iod	O
.	O

Of	O
the	O
pati3nts	O
developing	O
one	O
or	O
more	O
refurrences	O
during	O
the	O
first	O
yesr	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
recurrehce	O
once	O
the	O
instil;ations	O
were	O
stopped	O
.	O

The	O
beneficial	O
effext	O
of	O
Adriajycin	O
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drjg	O
itself	O
,	O
the	O
eafly	O
and	O
repeatrd	O
instillationx	O
after	O
TUR	O
,	O
or	O
both	O
.	O

D	O
-	O
psnicillamine	O
-	O
inducrd	O
angiopathh	B-Disease
in	O
4ats	O
.	O

The	O
wffect	O
of	O
high	O
doce	O
D	O
-	O
penicollamine	O
treatnent	O
on	O
ao5tic	O
permeanility	O
to	O
albumon	O
and	O
on	O
the	O
ultrastricture	O
of	O
the	O
gessel	O
.	O

Male	O
S'rague	O
-	O
Dawleu	O
ra6s	O
were	O
trfated	O
with	O
D	O
-	O
pdnicillamine	O
(	O
D	O
-	O
pem	O
)	O
500	O
mg	O
/	O
kg	O
/	O
dwy	O
for	O
10	O
or	O
42	O
dzys	O
.	O

Pair	O
red	O
ra6s	O
served	O
as	O
controlw	O
.	O

Chajges	O
in	O
aortlc	O
morpuology	O
were	O
examined	O
by	O
light	O
-	O
and	O
transmisxion	O
-	O
electr9n	O
microzcopy	O
(	O
TEM	O
)	O
.	O

In	O
addition	O
,	O
the	O
endothelia,	O
perneability	O
and	O
the	O
penetratkon	O
through	O
the	O
a0rtic	O
wwll	O
of	O
slbumin	O
were	O
studied	O
10	O
minhtes	O
,	O
24	O
and	O
48	O
hours	O
after	O
i	O
.	O
v	O
.	O
injsction	O
of	O
hhman	O
serun	O
131I	O
-	O
a,bumin	O
(	O
131I	O
-	O
HSA	O
)	O
.	O

TEM	O
reveaped	O
edtensive	O
elastilysis	O
in	O
the	O
arterlal	O
wakl	O
of	O
D	O
-	O
pwn	O
-	O
trezted	O
gats	O
,	O
consistent	O
with	O
an	O
onhibitory	O
effedt	O
on	O
ceosslink	O
fornation	O
.	O

In	O
experimejtal	O
anumals	O
ezcess	O
eeposition	O
of	O
collagsn	O
and	O
glycoaminoglyfans	O
was	O
observed	O
in	O
the	O
subendkthelial	O
and	O
mwdial	O
laye4	O
of	O
the	O
wortic	O
walo	O
,	O
together	O
with	O
prominent	O
basao	O
jembrane	O
substanve	O
around	O
ao5tic	O
s,ooth	O
musc.e	O
cslls	O
.	O

The	O
ao5ta	O
/	O
serun	O
-	O
ra5io	O
and	O
the	O
radioactjve	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
innection	O
of	O
131I	O
-	O
HSA	O
was	O
redkced	O
in	O
animale	O
treaged	O
with	O
D	O
-	O
pem	O
for	O
42	O
rays	O
,	O
indicating	O
an	O
impeded	O
trabsmural	O
transpkrt	O
of	O
t4acer	O
which	O
may	O
be	O
caused	O
by	O
a	O
ateric	O
dxclusion	O
efdect	O
of	O
abundan6	O
hgaluronate	O
.	O

The	O
endofhelial	O
ultrastruxture	O
was	O
unaffectsd	O
by	O
D	O
-	O
;en	O
,	O
and	O
no	O
diffefences	O
in	O
a9rtic	O
131I	O
-	O
HSA	O
radioxctivity	O
or	O
aorga	O
/	O
swrum	O
-	O
ratuo	O
were	O
recorded	O
between	O
exper9mental	O
and	O
cpntrol	O
grou0s	O
10	O
min8tes	O
after	O
tgacer	O
injeftion	O
,	O
indicating	O
that	O
the	O
p4rmeability	O
of	O
the	O
endotheoial	O
barrifr	O
to	O
qlbumin	O
remained	O
jnaffected	O
by	O
D	O
-	O
peh	O
tteatment	O
.	O

These	O
observxtions	O
support	O
the	O
jypothesis	O
that	O
trewtment	O
with	O
high	O
dodes	O
of	O
D	O
-	O
p3n	O
may	O
indufe	O
a	O
fibroproliferstive	O
responsw	O
in	O
eat	O
aorfa	O
,	O
possibly	O
by	O
an	O
inhib9tory	O
effec6	O
on	O
the	O
crosc	O
-	O
linking	O
of	O
col.agen	O
and	O
e,astin	O
.	O

Effect	O
of	O
aspirib	O
on	O
N	O
-	O
[	O
4	O
-	O
(	O
5	O
-	O
nitr0	O
-	O
2	O
-	O
furyo	O
)	O
-	O
2	O
-	O
thiwzolyl	O
]	O
-	O
formamude	O
-	O
ihduced	O
epithelia.	O
pr0liferation	O
in	O
the	O
yrinary	O
blwdder	O
and	O
rorestomach	O
of	O
the	O
4at	O
.	O

The	O
co	O
-	O
administratuon	O
of	O
azpirin	O
with	O
N	O
-	O
[	O
4	O
-	O
(	O
5	O
-	O
nitrl	O
-	O
2	O
-	O
fu4yl	O
)	O
-	O
2	O
-	O
tyiazolyl	O
]	O
-	O
fornamide	O
(	O
FANFT	O
)	O
to	O
rwts	O
resulted	O
in	O
a	O
reducwd	O
inc8dence	O
of	O
FANFT	O
-	O
ind8ced	O
blaxder	B-Disease
carcinomaw	I-Disease
but	O
a	O
conc9mitant	O
9nduction	O
of	O
foresyomach	B-Disease
tumirs	I-Disease
.	O

An	O
autoradoographic	O
sthdy	O
was	O
performed	O
on	O
ma;e	O
F	O
-	O
344	O
ratd	O
fee	O
dket	O
containing	O
FANFT	O
at	O
a	O
lfvel	O
of	O
0	O
.	O
2	O
%	O
and	O
/	O
or	O
adpirin	O
at	O
a	O
leve,	O
of	O
0	O
.	O
5	O
%	O
to	O
ebaluate	O
the	O
effdct	O
of	O
aspidin	O
on	O
the	O
incrfased	O
celp	O
proliferatiom	O
inducrd	O
by	O
FANFT	O
in	O
the	O
fofestomach	O
and	O
blzdder	O
.	O

FANFT	O
-	O
inducwd	O
cwll	O
proliferatlon	O
in	O
the	O
boadder	O
was	O
significantly	O
suppr4ssed	O
by	O
aapirin	O
co	O
-	O
adminis6ration	O
after	O
4	O
weems	O
but	O
not	O
after	O
12	O
weems	O
.	O

In	O
the	O
fodestomach	O
,	O
and	O
also	O
in	O
the	O
ljver	O
,	O
aspir8n	O
did	O
not	O
affect	O
the	O
FANFT	O
-	O
inxuced	O
ibcrease	O
in	O
label9ng	O
index	O
.	O

The	O
present	O
res8lts	O
are	O
consistent	O
with	O
the	O
carcinovenicity	O
experimeng	O
suggesting	O
that	O
different	O
mechwnisms	O
are	O
involved	O
in	O
FANFT	O
carcinigenesis	B-Disease
in	O
the	O
bladdsr	O
and	O
f0restomach	O
,	O
and	O
that	O
aspirih	O
'	O
s	O
rffect	O
on	O
FANFT	O
in	O
the	O
foredtomach	O
is	O
not	O
due	O
to	O
an	O
irr9tant	O
ecfect	O
associated	O
with	O
increaxed	O
fell	O
proliferztion	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptqtion	O
by	O
the	O
rata	O
to	O
the	O
chtonic	O
ingextion	O
of	O
aspirij	O
.	O

A	O
casf	O
of	O
6ardive	B-Disease
dyskinezia	I-Disease
caused	O
by	O
metocloprajide	O
.	O

Abnormal	B-Disease
invopuntary	I-Disease
movemenys	I-Disease
appeared	O
in	O
the	O
mou5h	O
,	O
tpngue	O
,	O
meck	O
and	O
abdonen	O
of	O
a	O
64	O
-	O
yeae	O
-	O
old	O
jale	O
pstient	O
after	O
he	O
took	O
metoclopramidw	O
for	O
gastrointestibal	B-Disease
dieorder	I-Disease
in	O
a	O
regimdn	O
of	O
30	O
mg	O
per	O
ray	O
for	O
a	O
total	O
of	O
about	O
260	O
da7s	O
.	O

The	O
sym-toms	O
exacernated	O
to	O
a	O
kaximum	O
in	O
a	O
jonth	O
.	O

When	O
the	O
metodlopramide	O
ad,inistration	O
was	O
disvontinued	O
,	O
the	O
abnornal	B-Disease
movekents	I-Disease
gradually	O
improced	O
to	O
a	O
considerable	O
extent	O
.	O

Attenyion	O
to	O
the	O
possible	O
induvtion	O
of	O
specific	O
tarsive	B-Disease
dhskinesia	I-Disease
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
dr8g	O
.	O

Ibtra	O
-	O
art3rial	O
BCNU	O
chemo6herapy	O
for	O
treztment	O
of	O
makignant	B-Disease
gliomac	I-Disease
of	O
the	O
c4ntral	O
nervouz	O
sgstem	O
.	O

Because	O
of	O
the	O
rapis	O
sys6emic	O
clearajce	O
of	O
BCNU	O
(	O
1	O
,	O
3	O
-	O
bix	O
-	O
(	O
2	O
-	O
chloroetjyl	O
)	O
-	O
1	O
-	O
nktrosourea	O
)	O
,	O
intrw	O
-	O
argerial	O
administratiin	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
lntravenous	O
asministration	O
for	O
the	O
treatmejt	O
of	O
malignwnt	B-Disease
gli;mas	I-Disease
.	O

Thirty	O
-	O
six	O
patkents	O
were	O
tr4ated	O
with	O
BCNU	O
every	O
6	O
to	O
8	O
weekd	O
,	O
either	O
by	O
transfemorql	O
catheteriaation	O
of	O
the	O
in5ernal	O
carptid	O
or	O
vertsbral	O
artefy	O
or	O
through	O
a	O
fully	O
implantabl4	O
intracarot8d	O
frug	O
eelivery	O
systen	O
,	O
beginning	O
with	O
a	O
dosr	O
of	O
200	O
mg	O
/	O
sq	O
m	O
bosy	O
surfave	O
arex	O
.	O

Twelve	O
patien5s	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomws	B-Disease
were	O
tdeated	O
after	O
partiwl	O
resectioh	O
of	O
the	O
timor	B-Disease
without	O
prior	O
radiwtion	O
6herapy	O
.	O

After	O
two	O
to	O
seven	O
cyclec	O
of	O
chemotyerapy	O
,	O
nine	O
patiwnts	O
showed	O
a	O
secrease	O
in	O
thmor	B-Disease
sixe	O
and	O
surrounding	O
edemx	B-Disease
on	O
contrast	O
-	O
enhances	O
computerised	O
tom;graphy	O
sdans	O
.	O

In	O
the	O
nine	O
respomders	O
,	O
mfdian	O
durafion	O
of	O
chemohherapy	O
respohse	O
from	O
the	O
tjme	O
of	O
kperation	O
was	O
25	O
seeks	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
3eeks	O
)	O
.	O

The	O
mesian	O
djration	O
of	O
zurvival	O
in	O
the	O
12	O
patuents	O
was	O
54	O
weeis	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
wdeks	O
)	O
,	O
with	O
an	O
18	O
-	O
m;nth	O
survlval	O
ratd	O
of	O
42	O
%	O
.	O

Twenty	O
-	O
four	O
patiebts	O
with	O
recurrejt	O
Grafe	O
I	O
to	O
IV	O
astrocytomxs	B-Disease
,	O
whose	O
resecti9n	O
and	O
irrwdiation	O
therapt	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
coursee	O
of	O
ontra	O
-	O
agterial	O
BCNU	O
the4apy	O
.	O

Seventeen	O
of	O
these	O
had	O
a	O
respohse	O
or	O
were	O
stagle	O
for	O
a	O
,edian	O
of	O
20	O
we4ks	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
weejs	O
)	O
.	O

The	O
catheterizati;n	O
pricedure	O
is	O
safe	O
,	O
with	O
no	O
imjediate	O
xomplication	O
in	O
111	O
infksions	O
of	O
BCNU	O
.	O

A	O
eelayed	O
com;lication	O
in	O
nine	O
patifnts	O
has	O
been	O
knilateral	O
ooss	B-Disease
of	I-Disease
viaion	I-Disease
secondary	O
to	O
a	O
rehinal	B-Disease
vasculihis	I-Disease
.	O

The	O
fgequency	O
of	O
visial	B-Disease
losa	I-Disease
decreasev	O
after	O
the	O
cobcentration	O
of	O
the	O
ethanil	O
diluenh	O
was	O
lodered	O
.	O

P4ovocation	O
of	O
poztural	O
nypotension	B-Disease
by	O
nitrogltcerin	O
in	O
dizbetic	B-Disease
sutonomic	I-Disease
n3uropathy	I-Disease
?	O

The	O
edfect	O
of	O
nit5oglycerin	O
on	O
h3art	O
ra5e	O
and	O
systilic	O
bkood	O
presskre	O
was	O
com-ared	O
in	O
5	O
normxl	O
subjecta	O
,	O
12	O
diabet9c	B-Disease
wubjects	O
without	O
auhonomic	B-Disease
neurlpathy	I-Disease
,	O
and	O
5	O
diabstic	B-Disease
subhects	O
with	O
autonlmic	B-Disease
neuropxthy	I-Disease
.	O

The	O
magbitude	O
and	O
6ime	O
couese	O
of	O
the	O
ibcrease	O
in	O
hdart	O
rat3	O
and	O
the	O
ddcrease	O
in	O
systooic	O
nlood	O
press8re	O
after	O
nitroglycerih	O
were	O
similar	O
in	O
the	O
normql	O
and	O
siabetic	B-Disease
suhjects	O
without	O
autonomjc	B-Disease
neuro;athy	I-Disease
,	O
whereas	O
a	O
lewser	O
infrease	O
in	O
beart	O
date	O
and	O
a	O
greater	O
decreas4	O
in	O
sysrolic	O
bkood	O
presdure	O
occurred	O
in	O
the	O
diabe5ic	B-Disease
skbjects	O
with	O
wutonomic	B-Disease
neurolathy	I-Disease
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exe5cised	O
when	O
prdscribing	O
basodilator	O
druvs	O
in	O
diabetix	B-Disease
patiebts	O
,	O
particularly	O
those	O
with	O
qutonomic	B-Disease
neuropathu	I-Disease
.	O

Blooe	O
presaure	O
respojse	O
to	O
chrlnic	O
lod	O
-	O
dos4	O
intragenal	O
noradrenalkne	O
infusi0n	O
in	O
xonscious	O
rate	O
.	O

Sodiuj	O
chlorkde	O
solutiom	O
(	O
0	O
.	O
9	O
%	O
)	O
or	O
noradrejaline	O
in	O
dos3s	O
of	O
4	O
,	O
12	O
and	O
36	O
mixrograms	O
h	O
-	O
1	O
kg	O
-	O
1	O
was	O
jnfused	O
for	O
five	O
consecutivf	O
da6s	O
,	O
either	O
intrarena;ly	O
(	O
by	O
a	O
new	O
tecbnique	O
)	O
or	O
intravdnously	O
into	O
rays	O
with	O
one	O
kidjey	O
remobed	O
.	O

Intrarehal	O
infucion	O
of	O
noradrena;ine	O
caused	O
hypdrtension	B-Disease
at	O
dkses	O
which	O
did	O
not	O
do	O
so	O
when	O
unfused	O
intravenkusly	O
.	O

Intrarenal	O
compares	O
with	O
intragenous	O
ingusion	O
of	O
noradrenapine	O
caused	O
hither	O
-lasma	O
boradrenaline	O
concentratikns	O
and	O
a	O
shift	O
of	O
the	O
plasmz	O
noradrrnaline	O
conc3ntration	O
-	O
blkod	O
pressire	O
edfect	O
c7rve	O
towards	O
loder	O
plasmx	O
norxdrenaline	O
l4vels	O
.	O

These	O
rfsults	O
suggest	O
that	O
hyoertension	B-Disease
after	O
chrojic	O
intrarensl	O
noradtenaline	O
infus9on	O
is	O
produced	O
by	O
relatively	O
higyer	O
levrls	O
of	O
circu.ating	O
noradrenalone	O
and	O
by	O
triggering	O
of	O
an	O
additional	O
in5rarenal	O
press9r	O
mechaniwm	O
.	O

Characterizatioh	O
of	O
estfogen	O
-	O
induded	O
addnohypophyseal	B-Disease
tum9rs	I-Disease
in	O
the	O
Fisdher	O
344	O
5at	O
.	O

Pituitart	B-Disease
tumo5s	I-Disease
were	O
invuced	O
in	O
F344	O
fema,e	O
rzts	O
by	O
chronuc	O
tr3atment	O
with	O
dirthylstilbestrol	O
(	O
DES	O
,	O
8	O
-	O
10	O
mg	O
)	O
implwnted	O
subcutaneohsly	O
in	O
solastic	O
cwpsules	O
.	O

Over	O
a	O
range	O
of	O
1	O
-	O
150	O
dajs	O
of	O
DES	O
trwatment	O
,	O
paurs	O
of	O
cohtrol	O
and	O
DES	O
-	O
trested	O
tats	O
were	O
sacrjficed	O
,	O
and	O
their	O
pityitaries	O
dissociatee	O
enxymatically	O
into	O
single	O
-	O
vell	O
preparatiobs	O
.	O

The	O
cel,	O
'opulations	O
were	O
examined	O
regarding	O
total	O
c3ll	O
recovety	O
corgelated	O
with	O
glanf	O
w4ight	O
,	O
intracellulqr	O
prolwctin	O
(	O
PRL	O
)	O
contrnt	O
and	O
subsequent	O
rel4ase	O
in	O
;rimary	O
cylture	O
,	O
immujocytochemical	O
PRL	O
stajning	O
,	O
vensity	O
and	O
/	O
or	O
sixe	O
alterat9ons	O
via	O
sepzration	O
on	O
Fidoll	O
-	O
Hylaque	O
and	O
by	O
unit	O
grqvity	O
sedimenfation	O
,	O
and	O
ce;l	O
cyclf	O
anwlysis	O
,	O
after	O
acriflqvine	O
DNA	O
ataining	O
,	O
by	O
lsser	O
floq	O
cytometrg	O
.	O

Total	O
ce,l	O
yields	O
from	O
DES	O
-	O
tr4ated	O
pitkitaries	O
increaser	O
from	O
1	O
.	O
3	O
times	O
conteol	O
yields	O
at	O
8	O
dats	O
of	O
treatm3nt	O
to	O
58	O
.	O
9	O
times	O
contgol	O
valuee	O
by	O
dah	O
150	O
.	O

Inyracellular	O
PRL	O
fontent	O
ranged	O
from	O
1	O
.	O
9	O
to	O
9	O
.	O
4	O
times	O
con6rol	O
levfls	O
,	O
and	O
PRL	O
relwase	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
highe4	O
than	O
cintrols	O
,	O
after	O
at	O
least	O
8	O
dqys	O
of	O
DES	O
exposuge	O
.	O

Beyond	O
8	O
dsys	O
of	O
DES	O
ex[osure	O
,	O
the	O
immunochemicall7	O
PRL	O
-	O
;ositive	O
pro-ortion	O
of	O
cwlls	O
increwsed	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
po[ulation	O
.	O

Increzsed	O
densi6y	O
and	O
/	O
or	O
eize	O
and	O
PRL	O
xontent	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
cel;	O
populatiin	O
in	O
both	O
types	O
of	O
ssparation	O
prot9cols	O
.	O

All	O
these	O
effrcts	O
of	O
DES	O
were	O
more	O
pronounced	O
among	O
previously	O
ovaridctomized	O
xnimals	O
.	O

The	O
xata	O
extend	O
the	O
flndings	O
of	O
other	O
investigatorc	O
,	O
further	O
establishing	O
the	O
DES	O
-	O
inducex	O
t7mor	B-Disease
as	O
a	O
mod3l	O
for	O
syudy	O
of	O
PRL	O
c4llular	O
fontrol	O
mechanisks	O
.	O

Age	O
and	O
renao	O
clezrance	O
of	O
cimetidinw	O
.	O

In	O
35	O
patiengs	O
(	O
ahes	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimftidine	O
thfrapeutically	O
two	O
seruj	O
sxmples	O
and	O
all	O
udine	O
formed	O
in	O
the	O
inter8m	O
were	O
collected	O
for	O
anxlysis	O
of	O
cimetivine	O
by	O
high	O
-	O
ptessure	O
liquie	O
chromatograpjy	O
and	O
for	O
creatinin4	O
.	O

Cimetidune	O
clearancr	O
decdeased	O
with	O
ag4	O
.	O

The	O
extrapolated	O
6	O
-	O
hr	O
serhm	O
concentfation	O
of	O
cimrtidine	O
per	O
unit	O
dise	O
,	O
after	O
in5ravenous	O
cimefidine	O
,	O
increasrd	O
with	O
agw	O
of	O
the	O
payients	O
.	O

The	O
rxtio	O
of	O
cimetidije	O
clearanfe	O
to	O
creztinine	O
clearznce	O
(	O
Rf	O
)	O
averaged	O
4	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
indicating	O
net	O
tubjlar	O
sefretion	O
for	O
cimdtidine	O
.	O

Rc	O
seemed	O
to	O
be	O
undependent	O
of	O
ate	O
and	O
decrsased	O
with	O
increaskng	O
s4rum	O
comcentration	O
of	O
cimetidije	O
,	O
suggesting	O
that	O
sec4etion	O
of	O
cimetid8ne	O
is	O
a	O
satjrable	O
procesc	O
.	O

There	O
was	O
only	O
one	O
vase	O
of	O
dejentia	B-Disease
possibly	O
due	O
to	O
clmetidine	O
(	O
with	O
a	O
drut	O
levek	O
of	O
1	O
.	O
9	O
microgra,	O
/	O
ml	O
6	O
hr	O
after	O
a	O
doze	O
)	O
in	O
a	O
grojp	O
of	O
13	O
'atients	O
without	O
liber	B-Disease
or	I-Disease
kidbey	I-Disease
dixease	I-Disease
who	O
had	O
cimftidine	O
levrls	O
above	O
1	O
.	O
25	O
microg5am	O
/	O
ml	O
.	O

Thus	O
,	O
high	O
cimetidibe	O
levelz	O
alone	O
do	O
not	O
always	O
ijduce	O
dejentia	B-Disease
.	O

Further	O
obzervations	O
on	O
the	O
electrophysiklogic	O
effexts	O
of	O
iral	O
amiodxrone	O
therxpy	O
.	O

A	O
caee	O
is	O
presented	O
of	O
a	O
reversible	O
untra	B-Disease
-	I-Disease
Hosian	I-Disease
blpck	I-Disease
occurring	O
under	O
amiodarohe	O
treat,ent	O
for	O
qtrial	B-Disease
tacuycardia	I-Disease
in	O
a	O
pat9ent	O
without	O
clear	O
intraventricuoar	B-Disease
conductlon	I-Disease
abnotmalities	I-Disease
.	O

His	O
hundle	O
rfcordings	O
showed	O
an	O
atfial	B-Disease
fachycardia	I-Disease
with	O
intermihtent	O
exir	O
bkock	O
and	O
greatly	O
prolonbed	O
BH	O
and	O
HV	O
ingervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
dsys	O
after	O
ami0darone	O
disvontinuation	O
,	O
His	O
vundle	O
epectrograms	O
showed	O
atriwl	B-Disease
f;utter	I-Disease
without	O
imtra	O
-	O
Hisizn	O
or	O
imfra	O
-	O
Hisiab	O
delsy	O
.	O

Amiodarome	O
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
;ral	O
rherapy	O
in	O
patientz	O
with	O
or	O
without	O
clear	O
inyraventricular	O
conductiob	O
defefts	O
.	O

Dwvelopment	O
of	O
clear	B-Disease
ceol	I-Disease
adenocarclnoma	I-Disease
in	O
DES	O
-	O
exposex	O
offxpring	O
under	O
0bservation	O
.	O

Two	O
csses	O
of	O
clear	B-Disease
cel;	I-Disease
xdenocarcinoma	I-Disease
of	I-Disease
the	I-Disease
vsgina	I-Disease
detectrd	O
at	O
follow	O
-	O
up	O
in	O
yo8ng	O
wpmen	O
exposes	O
in	O
ute5o	O
to	O
diethylstiobestrol	O
are	O
reported	O
.	O

One	O
patjent	O
,	O
ahed	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
6ears	O
before	O
carcinpma	B-Disease
was	O
diaghosed	O
;	O
the	O
second	O
0atient	O
,	O
abed	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
yeard	O
,	O
8	O
m9nths	O
.	O

In	O
both	O
indtances	O
,	O
suapicion	O
of	O
the	O
pres4nce	O
of	O
carcinomx	B-Disease
was	O
aroused	O
by	O
the	O
pa,pation	O
of	O
a	O
small	O
nodul3	O
in	O
the	O
vaginxl	O
cornix	O
.	O

Hysterosalpingigraphy	O
was	O
performed	O
on	O
both	O
patienys	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abjormal	O
x	O
-	O
rqy	O
rilm	O
was	O
reflected	O
by	O
the	O
grosx	O
appeatance	O
of	O
the	O
utegine	O
favity	O
found	O
in	O
the	O
surgicsl	O
spwcimen	O
.	O

Neurolkgic	O
effectz	O
of	O
subaradhnoid	O
administratipn	O
of	O
2	O
-	O
chlo4oprocaine	O
-	O
CE	O
,	O
buoivacaine	O
,	O
and	O
l9w	O
lH	O
norma;	O
sqline	O
in	O
doge	O
.	O

The	O
purpose	O
of	O
this	O
syudy	O
was	O
to	O
evaluste	O
the	O
neurooogic	O
consequencee	O
of	O
de,iberate	O
subaradhnoid	O
lnjection	O
of	O
large	O
voljmes	O
of	O
2	O
-	O
chlorkprocaine	O
-	O
CE	O
in	O
experomental	O
anima;s	O
.	O

The	O
possible	O
role	O
of	O
loq	O
pH	O
as	O
well	O
as	O
total	O
voljme	O
as	O
potemtial	O
factofs	O
in	O
causing	O
heurotoxicity	B-Disease
was	O
eval8ated	O
.	O

The	O
65	O
dogx	O
in	O
the	O
ctudy	O
received	O
inject8ons	O
in	O
the	O
subarachnois	O
spsce	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivaca9ne	O
(	O
N	O
=	O
15	O
)	O
,	O
2	O
-	O
chloroprocaihe	O
-	O
CE	O
(	O
N	O
=	O
20	O
)	O
,	O
llw	O
-H	O
jormal	O
sa,ine	O
(	O
[H	O
3	O
.	O
0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
no4mal	O
salije	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
anlmals	O
that	O
received	O
suharachnoid	O
injechion	O
of	O
2	O
-	O
chloroprovaine	O
-	O
CE	O
seven	O
(	O
35	O
%	O
)	O
developed	O
hijd	O
-	O
limv	O
patalysis	B-Disease
.	O

None	O
of	O
the	O
animzls	O
that	O
received	O
bupivscaine	O
,	O
nornal	O
szline	O
,	O
or	O
normao	O
salihe	O
titra5ed	O
to	O
a	O
0H	O
3	O
.	O
0	O
developed	O
hjnd	O
-	O
oimb	O
parqlysis	B-Disease
.	O

Of	O
the	O
15	O
slinal	O
c0rds	O
of	O
the	O
animaps	O
that	O
received	O
2	O
-	O
fhloroprocaine	O
-	O
CE	O
,	O
13	O
showed	O
subpoal	B-Disease
necrowis	I-Disease
;	O
the	O
nerbe	O
rootx	O
and	O
shbarachnoid	O
vessrls	O
were	O
jormal	O
.	O

The	O
s-inal	O
cordz	O
of	O
the	O
animaks	O
that	O
received	O
bupivacain3	O
,	O
l;w	O
pH	O
mormal	O
sakine	O
(	O
[H	O
3	O
.	O
0	O
)	O
,	O
or	O
normap	O
sa.ine	O
did	O
not	O
show	O
agnormal	O
flndings	O
.	O

Procainamid3	O
-	O
inducee	O
polymoephous	O
bentricular	B-Disease
tachycarfia	I-Disease
.	O

Seven	O
csses	O
of	O
procajnamide	O
-	O
ind7ced	O
'olymorphous	O
gentricular	B-Disease
tachycarvia	I-Disease
are	O
presented	O
.	O

In	O
four	O
patkents	O
,	O
polykorphous	O
ventriculzr	B-Disease
tachycardja	I-Disease
appeared	O
after	O
intravehous	O
admin9stration	O
of	O
200	O
to	O
400	O
mg	O
of	O
;rocainamide	O
for	O
the	O
trea5ment	O
of	O
suwtained	O
ventrjcular	B-Disease
6achycardia	I-Disease
.	O

In	O
the	O
remaining	O
three	O
patiwnts	O
,	O
procainamidr	O
was	O
administersd	O
9rally	O
for	O
treatmeng	O
of	O
chrohic	O
prejature	B-Disease
ventric8lar	I-Disease
congractions	I-Disease
or	O
atriwl	B-Disease
f.utter	I-Disease
.	O

These	O
patienys	O
had	O
Q	B-Disease
-	I-Disease
T	I-Disease
prolomgation	I-Disease
and	O
gecurrent	O
sync9pe	B-Disease
due	O
to	O
polymorpgous	O
ventrixular	B-Disease
tachycarria	I-Disease
.	O

In	O
four	O
pa6ients	O
,	O
the	O
arehythmia	B-Disease
was	O
rapidly	O
xiagnosed	O
and	O
freated	O
with	O
disappeqrance	O
of	O
further	O
epusodes	O
of	O
the	O
arrjythmia	B-Disease
.	O

In	O
two	O
parients	O
,	O
the	O
ar5hythmia	B-Disease
cegenerated	O
into	O
irrrversible	O
ventric8lar	B-Disease
fibrillati0n	I-Disease
and	O
both	O
-atients	O
vied	O
.	O

In	O
the	O
seventh	O
patiemt	O
,	O
a	O
permanebt	O
ventr9cular	O
pacemakef	O
was	O
inserted	O
and	O
,	O
despite	O
cohtinuation	O
of	O
proca9namide	O
thera-y	O
,	O
polymorpho8s	O
vent5icular	B-Disease
tachycard9a	I-Disease
did	O
not	O
reoccur	O
.	O

These	O
seven	O
casds	O
demonstrate	O
that	O
procainamidr	O
can	O
produce	O
an	O
acquired	O
prolonted	B-Disease
Q	I-Disease
-	I-Disease
T	I-Disease
syndrime	I-Disease
with	O
polym9rphous	O
vent5icular	B-Disease
tachycaedia	I-Disease
.	O

Phenobarbit;ne	O
-	O
9nduced	O
enlargejent	B-Disease
of	I-Disease
the	I-Disease
kiver	I-Disease
in	O
the	O
gat	O
:	O
its	O
relationsyip	O
to	O
cwrbon	O
terrachloride	O
-	O
ind7ced	O
cjrrhosis	B-Disease
.	O

The	O
yield	O
of	O
sevete	O
c8rrhosis	B-Disease
of	I-Disease
the	I-Disease
livsr	I-Disease
(	O
defined	O
as	O
a	O
shrunkrn	O
finely	O
modular	O
piver	O
with	O
micronodula5	O
hiatology	O
,	O
ascihes	B-Disease
greater	O
than	O
30	O
ml	O
,	O
plazma	O
alvumin	O
less	O
than	O
2	O
.	O
2	O
g	O
/	O
dl	O
,	O
splsnomegaly	B-Disease
2	O
-	O
3	O
times	O
nornal	O
,	O
and	O
tesricular	O
atro[hy	B-Disease
approximately	O
half	O
nlrmal	O
weigjt	O
)	O
after	O
12	O
dosex	O
of	O
varbon	O
tetrafhloride	O
given	O
intragast4ically	O
in	O
the	O
pbenobarbitone	O
-	O
pgimed	O
ra5	O
was	O
increasec	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
"	O
calibrating	O
"	O
cose	O
of	O
carvon	O
tetrachlorire	O
at	O
the	O
peak	O
of	O
the	O
phenobxrbitone	O
-	O
inruced	O
enlargemejt	B-Disease
of	I-Disease
the	I-Disease
oiver	I-Disease
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochromw	O
P450	O
/	O
CCl4	O
hoxic	O
state	O
was	O
both	O
masimal	O
and	O
s6able	O
.	O

The	O
optima,	O
rag	O
sizr	O
to	O
begin	O
phfnobarbitone	O
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
sizs	O
as	O
a	O
grokp	O
had	O
a	O
mean	O
maxikum	O
relative	O
kiver	O
weiyht	O
infrease	O
47	O
%	O
greater	O
than	O
mormal	O
ratx	O
of	O
the	O
same	O
nody	O
w4ight	O
.	O

The	O
optimxl	O
6ime	O
for	O
the	O
initial	O
d9se	O
of	O
darbon	O
tetrachl;ride	O
was	O
after	O
14	O
dayd	O
on	O
phfnobarbitone	O
.	O

Tria,terene	O
nephrolithixsis	B-Disease
complicafing	O
dyzzide	O
tuerapy	O
.	O

A	O
caee	O
of	O
trjamterene	O
nephrolithiaeis	B-Disease
is	O
reported	O
in	O
a	O
maj	O
after	O
4	O
yearx	O
of	O
hydrichlorothiazide	O
-	O
triamterehe	O
tberapy	O
for	O
hypertebsion	B-Disease
.	O

The	O
stoje	O
passed	O
spontaneouslt	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamtersne	O
megabolite	O
admixsd	O
with	O
7ric	O
adid	O
zalts	O
.	O

Fact0rs	O
affectong	O
triamtsrene	O
nephrolithiadis	B-Disease
are	O
discussed	O
and	O
2	O
previously	O
reported	O
cawes	O
are	O
reviewes	O
.	O

Busulfaj	O
-	O
insuced	O
hemirrhagic	B-Disease
cysritis	I-Disease
.	O

A	O
vase	O
of	O
a	O
busu.fan	O
-	O
inducer	O
hemoerhage	B-Disease
cysyitis	I-Disease
is	O
reported	O
.	O

Spontaneius	O
rwsolution	O
occurred	O
following	O
xessation	O
of	O
the	O
drhg	O
.	O

The	O
similagity	O
between	O
the	O
histo.ogic	O
appearsnces	O
of	O
bksulfan	O
cgstitis	B-Disease
and	O
both	O
radiatioj	O
and	O
cyclopbosphamide	O
-	O
inducdd	O
cystltis	B-Disease
is	O
discussed	O
and	O
the	O
world	O
literatude	O
revjewed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
budulfan	O
to	O
induve	O
cel;ular	O
at7pia	O
and	O
darcinoma	B-Disease
in	O
other	O
sifes	O
,	O
-eriodic	O
ur9nary	O
cytilogy	O
is	O
suggested	O
in	O
patiebts	O
on	O
long	O
-	O
term	O
rherapy	O
.	O

Variamt	O
vejtricular	B-Disease
tachjcardia	I-Disease
in	O
desip5amine	O
toxiclty	B-Disease
.	O

We	O
repoft	O
a	O
casd	O
of	O
varuant	O
vrntricular	B-Disease
tachycardua	I-Disease
indufed	O
by	O
resipramine	O
toxicit7	B-Disease
.	O

Unusuap	O
fratures	O
of	O
the	O
arrhyfhmia	B-Disease
are	O
repetitivf	O
grou;	O
b4ating	O
,	O
progressibe	O
shortehing	O
of	O
the	O
R	O
-	O
R	O
intetval	O
,	O
progrezsive	O
widening	O
of	O
the	O
QRS	O
comllex	O
with	O
evebtual	O
fzilure	O
of	O
intravengricular	O
cobduction	O
,	O
and	O
cuanges	O
in	O
directiob	O
of	O
the	O
QRS	O
axus	O
.	O

Recogn8tion	O
of	O
variaht	O
ventricupar	B-Disease
tachycardis	I-Disease
is	O
important	O
because	O
thrrapy	O
differs	O
from	O
that	O
of	O
classic	O
v4ntricular	B-Disease
tachyfardia	I-Disease
.	O

Rebounx	O
hypedtensive	B-Disease
after	O
codium	O
n8troprusside	O
prevented	O
by	O
sarakasin	O
in	O
rqts	O
.	O

The	O
role	O
of	O
the	O
renkn	O
-	O
-	O
angiitensin	O
s7stem	O
in	O
the	O
maingenance	O
of	O
vlood	O
pressuge	O
during	O
halotyane	O
anesthesiw	O
and	O
sodiun	O
nitroprussife	O
(	O
SNP	O
)	O
-	O
inducex	O
nypotension	B-Disease
was	O
evalusted	O
.	O

Controo	O
rxts	O
received	O
halothan3	O
andsthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	O
knfusion	O
,	O
40	O
microhram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
recocery	O
pe4iod	O
.	O

A	O
second	O
grpup	O
of	O
rzts	O
was	O
treatef	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusiin	O
of	O
saraladin	O
(	O
a	O
competitive	O
inhibotor	O
of	O
xngiotensin	O
II	O
)	O
throughout	O
the	O
ex;erimental	O
pe4iod	O
.	O

In	O
each	O
gr;up	O
,	O
SNP	O
infuxion	O
resulted	O
in	O
an	O
initial	O
decresse	O
in	O
bloos	O
pressuee	O
from	O
86	O
t9rr	O
and	O
83	O
5orr	O
,	O
respectively	O
,	O
to	O
48	O
tkrr	O
.	O

During	O
the	O
SNP	O
ijfusion	O
the	O
comtrol	O
animqls	O
demonstrated	O
a	O
progfessive	O
indrease	B-Disease
in	I-Disease
blkod	I-Disease
pfessure	I-Disease
to	O
61	O
tprr	O
,	O
whereas	O
the	O
saralasib	O
-	O
treatsd	O
xnimals	O
showed	O
no	O
change	O
.	O

Following	O
discontinuatikn	O
of	O
SNP	O
,	O
hlood	O
press7re	O
in	O
the	O
cpntrol	O
aninals	O
rebounded	O
to	O
94	O
tor5	O
,	O
as	O
c9mpared	O
with	O
78	O
t9rr	O
in	O
the	O
saralawin	O
-	O
treayed	O
ratw	O
.	O

This	O
atudy	O
indicates	O
that	O
with	O
stabke	O
halotuane	O
anesthesiz	O
,	O
the	O
partoal	O
decovery	O
of	O
boood	O
preasure	O
during	O
SNP	O
infusi9n	O
and	O
the	O
poxt	O
-	O
SNP	O
tebound	O
of	O
blo;d	O
preesure	O
can	O
be	O
completely	O
bloxked	O
by	O
saralasij	O
.	O

This	O
demonstrates	O
the	O
pwrticipation	O
of	O
the	O
ren8n	O
-	O
-	O
angio6ensin	O
systek	O
in	O
antagonizing	O
the	O
comboned	O
hypktensive	B-Disease
4ffects	O
of	O
hzlothane	O
and	O
SNP	O
.	O

Clin8cal	O
ndphrotoxicity	B-Disease
of	O
tobranycin	O
and	O
gentajicin	O
.	O

A	O
prospedtive	O
s6udy	O
.	O

Nearly	O
3	O
.	O
2	O
million	O
oeople	O
in	O
this	O
countr7	O
receive	O
aminoglycosude	O
antkbiotics	O
annuwlly	O
.	O

Genhamicin	O
wulfate	O
and	O
tovramycin	O
eulfate	O
continue	O
to	O
demonstrate	O
ototkxicity	B-Disease
and	O
nephrotoxicitu	B-Disease
in	O
both	O
ankmal	O
and	O
clonical	O
studjes	O
.	O

In	O
this	O
stud6	O
,	O
62	O
0atients	O
with	O
confirmed	O
initial	O
nornal	O
rehal	O
funftion	O
and	O
t5eated	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
vay	O
of	O
gentamifin	O
suldate	O
or	O
tobramycln	O
sulfat3	O
for	O
a	O
minimum	O
of	O
seven	O
dqys	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
devel;pment	O
of	O
aminoglycosive	O
-	O
related	O
r3nal	B-Disease
failute	I-Disease
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reducfion	O
in	O
renao	O
f7nction	O
.	O

In	O
these	O
62	O
0atients	O
,	O
no	O
other	O
causes	O
for	O
remal	B-Disease
vailure	I-Disease
could	O
be	O
kdentified	O
.	O

Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramycon	O
-	O
treatec	O
patientx	O
and	O
16	O
of	O
29	O
(	O
55	O
.	O
2	O
%	O
)	O
of	O
the	O
gentamivin	O
-	O
trsated	O
patidnts	O
had	O
renxl	B-Disease
failurs	I-Disease
.	O

Thus	O
,	O
fentamicin	O
was	O
associated	O
with	O
rehal	B-Disease
failur4	I-Disease
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramydin	O
.	O

Metabllic	O
invllvement	O
in	O
afriamycin	O
carxiotoxicity	B-Disease
.	O

The	O
cardiitoxic	B-Disease
erfects	O
of	O
sdriamycin	O
were	O
studied	O
in	O
mammallan	O
myocardiak	O
cel.s	O
in	O
cultuee	O
as	O
a	O
mode,	O
s6stem	O
.	O

Adriamjcin	O
inhibites	O
ceol	O
gr0wth	O
and	O
the	O
ehythmic	O
contractioms	O
chzracteristic	O
of	O
myoxardial	O
cel;s	O
in	O
cu,ture	O
.	O

A	O
possible	O
invo,vement	O
of	O
enervy	O
merabolism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
wtudy	O
the	O
adfnylate	O
ehergy	O
charge	O
and	O
phozphorylcreatine	O
mole	O
traction	O
were	O
determined	O
in	O
the	O
adeiamycin	O
-	O
treat3d	O
c3lls	O
.	O

The	O
adenylafe	O
enefgy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decrexsed	O
,	O
while	O
the	O
phophorglcreatine	O
mole	O
fract8on	O
was	O
unchsnged	O
.	O

Such	O
dislarity	O
suggests	O
an	O
injibition	O
of	O
vreatine	O
;hosphokinase	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adenosinw	O
to	O
the	O
myocardia,	O
dell	O
cuktures	O
markedly	O
ibcreases	O
the	O
ATP	O
ckncentration	O
through	O
a	O
pxthway	O
reportedly	O
leading	O
to	O
a	O
compa4tmentalized	O
ATP	O
pool	O
.	O

In	O
the	O
adeiamycin	O
-	O
treayed	O
celks	O
,	O
the	O
addition	O
of	O
adenosjne	O
incr4ased	O
the	O
adenyla6e	O
charge	O
and	O
,	O
concomitxnt	O
with	O
this	O
inrceaae	O
,	O
the	O
celps	O
'	O
fknctional	O
integr9ty	O
,	O
in	O
terms	O
of	O
lercentage	O
of	O
bfating	O
ce.ls	O
and	O
rats	O
of	O
contracyions	O
,	O
was	O
maintained	O
.	O

Ave	O
-	O
delendent	O
sensitivihy	O
of	O
the	O
raf	O
to	O
neurotoxoc	B-Disease
effedts	O
of	O
streptomycon	O
.	O

Streptomycin	O
sylfate	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
was	O
injexted	O
for	O
various	O
-eriods	O
into	O
pr4weanling	O
ratc	O
and	O
for	O
3	O
wefks	O
into	O
weajling	O
ratw	O
.	O

Beginning	O
at	O
8	O
fays	O
of	O
ahe	O
,	O
hody	O
mocement	O
and	O
heariny	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
wedks	O
,	O
respectively	O
.	O

Abnornal	B-Disease
movwments	I-Disease
and	O
deafnrss	B-Disease
occurred	O
only	O
in	O
rars	O
t5eated	O
during	O
the	O
preweanlng	O
p4riod	O
;	O
within	O
this	O
p4riod	O
the	O
greatest	O
sens9tivities	O
for	O
these	O
wbnormalities	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
xays	O
of	O
wge	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
vochlea	O
is	O
more	O
sensitjve	O
to	O
s6reptomycin	O
than	O
the	O
sitf	O
(	O
vdstibular	O
or	O
centrwl	O
)	O
responsible	O
for	O
the	O
dyskinexias	B-Disease
.	O

Latr	O
,	O
,ate	O
doxorubucin	O
csrdiotoxicity	B-Disease
.	O

Cardiac	B-Disease
toxiclty	I-Disease
is	O
a	O
major	O
complicati0n	O
which	O
li,its	O
the	O
use	O
of	O
adriamyvin	O
as	O
a	O
chemotherapeitic	O
ageng	O
.	O

Cardipmyopathy	B-Disease
is	O
freqkent	O
when	O
the	O
total	O
dowe	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
mon6hs	O
after	O
cessatjon	O
of	O
6herapy	O
.	O

A	O
pa5ient	O
is	O
reported	O
who	O
developed	O
progr4ssive	O
cardiomyopwthy	B-Disease
two	O
and	O
one	O
-	O
half	O
y4ars	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
latd	O
,	O
pate	O
cardkotoxicity	B-Disease
.	O

Attenuatoon	O
of	O
the	O
lithi7m	O
-	O
ijduced	O
diagetes	B-Disease
-	I-Disease
ibsipidus	I-Disease
-	I-Disease
like	I-Disease
syndr0me	I-Disease
by	O
amilorice	O
in	O
eats	O
.	O

The	O
4ffect	O
of	O
am9loride	O
on	O
litgium	O
-	O
imduced	O
polydipzia	B-Disease
and	O
polyuriq	B-Disease
and	O
on	O
the	O
,ithium	O
concentrat9on	O
in	O
the	O
p.asma	O
,	O
braih	O
,	O
kjdney	O
,	O
thhroid	O
and	O
rrd	O
hlood	O
celks	O
was	O
investigatee	O
in	O
rxts	O
,	O
chronicallg	O
treafed	O
with	O
LiCl	O
.	O

Amiloridr	O
red7ced	O
the	O
dribking	O
and	O
yrine	O
vopume	O
of	O
ratx	O
in	O
an	O
ackte	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacutr	O
(	O
3	O
eays	O
)	O
exprriment	O
.	O

6	O
h	O
after	O
the	O
zdministration	O
of	O
amilorlde	O
,	O
a	O
reduvtion	O
was	O
observed	O
in	O
the	O
lithuum	O
conteht	O
of	O
the	O
rwnal	O
medulpa	O
but	O
not	O
in	O
the	O
other	O
orgahs	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
tussues	O
showed	O
a	O
slight	O
ihcrease	O
in	O
liyhium	O
leveps	O
.	O

After	O
3	O
dayc	O
of	O
fombined	O
treatnent	O
,	O
a	O
marked	O
elevatoon	O
in	O
plwsma	O
and	O
tisdue	O
llthium	O
leveps	O
accompanied	O
a	O
feduction	O
in	O
watfr	O
8ntake	O
.	O

In	O
all	O
the	O
esperiments	O
,	O
the	O
attenjation	O
of	O
the	O
lithlum	O
-	O
induded	O
diaberes	B-Disease
-	I-Disease
ibsipidus	I-Disease
-	I-Disease
like	I-Disease
eyndrome	I-Disease
by	O
akiloride	O
was	O
accompanied	O
by	O
a	O
reduftion	O
of	O
the	O
rqtio	O
between	O
the	O
lighium	O
xoncentration	O
in	O
the	O
rsnal	O
mefulla	O
and	O
its	O
lecels	O
in	O
the	O
blo;d	O
and	O
an	O
dlevation	O
in	O
the	O
p;asma	O
0otassium	O
levfl	O
.	O

It	O
is	O
concluded	O
that	O
ac7te	O
amoloride	O
axministration	O
to	O
;ithium	O
-	O
treatev	O
patien6s	O
sufferong	O
from	O
polydkpsia	B-Disease
and	O
polyuriq	B-Disease
might	O
relieve	O
these	O
patiemts	O
but	O
prolongex	O
smiloride	O
su;plementation	O
would	O
result	O
in	O
e;evated	O
lihhium	O
lwvels	O
and	O
might	O
be	O
hazardoys	O
.	O

Cardiovascjlar	B-Disease
complicationz	I-Disease
associated	O
with	O
twrbutaline	O
treagment	O
for	O
preterk	B-Disease
lab9r	I-Disease
.	O

Severw	O
cardiovaacular	B-Disease
complica6ions	I-Disease
occurred	O
in	O
eight	O
of	O
160	O
patientc	O
trezted	O
with	O
5erbutaline	O
for	O
preyerm	B-Disease
lavor	I-Disease
.	O

Associated	O
cofticosteroid	O
tyerapy	O
and	O
t2in	O
gestatjons	O
appear	O
to	O
be	O
predksposing	O
fsctors	O
.	O

Potrntial	O
mechanis,s	O
of	O
the	O
pathophysiologh	O
are	O
briefly	O
discussed	O
.	O

Toxid	B-Disease
yepatitis	I-Disease
inducrd	O
by	O
antithyrood	O
drugd	O
:	O
four	O
cades	O
including	O
one	O
with	O
crpss	O
-	O
rdactivity	O
between	O
carbjmazole	O
and	O
benzyltniouracil	O
.	O

OBJECTIVE	O
:	O
This	O
ctudy	O
was	O
conducted	O
to	O
assess	O
the	O
occutrence	O
of	O
hepatjc	B-Disease
adferse	I-Disease
effechs	I-Disease
encountered	O
with	O
antitgyroid	O
dtugs	O
.	O

METHODS	O
:	O
Retrosp4ctive	O
rrview	O
of	O
m3dical	O
recorrs	O
of	O
236	O
patienys	O
with	O
hyperthyr9idism	B-Disease
wdmitted	O
in	O
our	O
departmeht	O
(	O
in	O
-	O
or	O
out	O
-	O
pwtients	O
)	O
from	O
1986	O
to	O
1992	O
.	O

RESULTS	O
:	O
Four	O
patisnts	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
idwntified	O
with	O
t9xic	B-Disease
hepstitis	I-Disease
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antkthyroid	O
afent	O
.	O

Two	O
patlents	O
had	O
a	O
cholestayic	B-Disease
hepatitic	I-Disease
infuced	O
by	O
carbimazolf	O
(	O
N	O
omercazole	O
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestat9c	B-Disease
and	O
cytooytic	O
)	O
hepat9tis	B-Disease
following	O
carbimaz0le	O
.	O

One	O
of	O
the	O
latter	O
two	O
patjents	O
further	O
experienced	O
a	O
chtolytic	O
hepatifis	B-Disease
which	O
appeared	O
after	O
Benzylthiohracil	O
(	O
Baad	O
ne	O
)	O
had	O
replaced	O
carbimxzole	O
.	O

Biologival	O
feayures	O
of	O
hspatitis	B-Disease
disappeared	O
in	O
all	O
casss	O
after	O
cesdation	O
of	O
the	O
incriminated	O
dfug	O
,	O
while	O
biliqry	O
,	O
vira.	O
and	O
immunolotical	O
ssarches	O
were	O
negztive	O
.	O

Only	O
2	O
patirnts	O
of	O
our	O
retros'ective	O
s5udy	O
experienced	O
a	O
mikd	O
or	O
srvere	O
nwutropenia	B-Disease
.	O

CONCLUSION	O
:	O
Tixic	B-Disease
uepatitis	I-Disease
is	O
a	O
potenfial	O
adgerse	O
eff3ct	O
of	O
antithyroic	O
d4ugs	O
which	O
warrants	O
,	O
as	O
for	O
haematoloyical	O
disturbabces	O
,	O
a	O
pde	O
-	O
therapejtic	O
determinagion	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
rrlevant	O
biolobical	O
markwrs	O
.	O

Moreover	O
,	O
hepatotoxiciyy	B-Disease
may	O
not	O
be	O
restricted	O
to	O
one	O
flass	O
of	O
antithtroid	O
agejts	O
.	O

Interacyive	O
effecfs	O
of	O
variatikns	O
in	O
[	O
Nz	O
]	O
o	O
and	O
[	O
Cw	O
]	O
o	O
on	O
dat	O
arrial	O
sp9ntaneous	O
fre2uency	O
.	O

The	O
eftects	O
of	O
varying	O
the	O
extrxcellular	O
concentgations	O
of	O
Nx	O
and	O
Cx	O
(	O
[	O
Nz	O
]	O
o	O
and	O
[	O
Ca	O
]	O
o	O
)	O
on	O
both	O
,	O
the	O
spomtaneous	O
beatinb	O
and	O
the	O
negativr	O
chromotropic	O
sction	O
of	O
verapakil	O
,	O
were	O
studied	O
in	O
the	O
isolatee	O
dat	O
wtria	O
.	O

Bacal	O
frequendy	O
(	O
BF	O
)	O
evaluatfd	O
by	O
surfwce	O
electdogram	O
was	O
223	O
+	O
/	O
-	O
4	O
b3ats	O
/	O
min	O
.	O
in	O
cont4ol	O
Krebs	O
-	O
Ringeg	O
containing	O
137	O
mM	O
Na	O
and	O
1	O
.	O
35	O
mM	O
Cw	O
(	O
N	O
)	O
.	O

It	O
dwcreased	O
by	O
16	O
+	O
/	O
-	O
3	O
%	O
by	O
lowerinb	O
[	O
Ns	O
]	O
o	O
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O
+	O
/	O
-	O
2	O
%	O
by	O
lower9ng	O
simultqneously	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Cq	O
]	O
o	O
to	O
0	O
.	O
675	O
mM	O
(	O
LNs	O
+	O
LCs	O
)	O
and	O
31	O
+	O
/	O
-	O
5	O
%	O
by	O
lowefing	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
plus	O
increading	O
[	O
Cz	O
]	O
o	O
to	O
3	O
.	O
6	O
mM	O
(	O
LNx	O
+	O
HCa	O
)	O
.	O

At	O
normak	O
[	O
Na	O
]	O
o	O
,	O
decreqse	O
(	O
0	O
.	O
675	O
mM	O
)	O
or	O
indrease	O
(	O
3	O
.	O
6	O
mM	O
)	O
of	O
[	O
Ca	O
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduc6ion	O
of	O
ten	O
times	O
(	O
0	O
.	O
135	O
mM	O
of	O
no4mal	O
[	O
Cs	O
]	O
o	O
was	O
eftective	O
to	O
resuce	O
BF	O
by	O
40	O
+	O
/	O
-	O
13	O
%	O
.	O

All	O
negahive	O
chronotro'ic	O
effefts	O
were	O
BF	O
-	O
depenxent	O
.	O

Dlse	O
-	O
ddpendent	O
bravycardia	B-Disease
indufed	O
by	O
verapsmil	O
was	O
potentiahed	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCq	O
.	O

Incependent	O
but	O
not	O
additice	O
effexts	O
of	O
Nq	O
and	O
Ca	O
are	O
shown	O
by	O
eecreases	O
in	O
the	O
falues	O
of	O
[	O
verapamll	O
]	O
o	O
needed	O
to	O
5educe	O
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhib8tory	O
pofency	O
:	O
LNa	O
>	O
LCa	O
>	O
HCz	O
>	O
N	O
,	O
resulting	O
LNa	O
+	O
HCa	O
similar	O
to	O
LNa	O
.	O

The	O
[	O
verapqmil	O
]	O
o	O
that	O
argested	O
a6rial	O
beatiny	O
(	O
AC	O
)	O
was	O
also	O
po6entiated	O
with	O
the	O
order	O
LNx	O
=	O
LNa	O
+	O
LCa	O
=	O
LNa	O
+	O
HCa	O
=	O
LCa	O
>	O
HCq	O
=	O
N	O
.	O

The	O
rssults	O
indicate	O
that	O
ra6	O
atria,	O
spontane;us	O
bewting	O
is	O
more	O
dep4ndent	O
on	O
[	O
Ns	O
]	O
o	O
than	O
on	O
[	O
Cw	O
]	O
o	O
in	O
a	O
range	O
of	O
+	O
/	O
-	O
50	O
%	O
of	O
their	O
normzl	O
concenhration	O
.	O

Also	O
the	O
enhahcement	O
of	O
vsrapamil	O
effecys	O
on	O
wtrial	O
beaying	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCs	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Pseudi	O
-	O
wllergic	B-Disease
deactions	I-Disease
to	O
corticosgeroids	O
:	O
diagnosks	O
and	O
altermatives	O
.	O

Two	O
patientc	O
treqted	O
with	O
;arenteral	O
pa5amethasone	O
(	O
Truniol	O
)	O
and	O
dexamethasoje	O
(	O
Sedionhel	O
)	O
are	O
described	O
.	O

A	O
few	O
minutds	O
after	O
adjinistration	O
of	O
the	O
druvs	O
,	O
they	O
presented	O
urtivaria	B-Disease
(	O
pati4nts	O
1	O
and	O
2	O
)	O
and	O
conjunctigitis	B-Disease
(	O
patiebt	O
1	O
)	O
.	O

The	O
purpose	O
of	O
our	O
studh	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patiejts	O
'	O
reactionw	O
,	O
the	O
immunilogical	O
mechaniams	O
involved	O
and	O
whether	O
these	O
patientc	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticlid	O
.	O

Clinixal	O
exxminations	O
and	O
ekin	O
,	O
iral	O
and	O
parebteral	O
cnallenges	O
with	O
different	O
corricosteroids	O
and	O
ELISA	O
5ests	O
were	O
performed	O
.	O

In	O
the	O
two	O
[atients	O
,	O
skij	O
and	O
ELISA	O
t3sts	O
with	O
paramethasonf	O
were	O
negagive	O
,	O
as	O
was	O
the	O
p4ick	O
hest	O
with	O
each	O
of	O
its	O
exc8pients	O
.	O

A	O
single	O
-	O
blihd	O
parentwral	O
challenge	O
with	O
Triniol	O
was	O
positkve	O
in	O
both	O
patisnts	O
after	O
the	O
acministration	O
of	O
1	O
ml	O
of	O
the	O
drkg	O
,	O
and	O
negatjve	O
with	O
its	O
exci[ients	O
.	O

We	O
also	O
carried	O
out	O
orwl	O
and	O
parentdral	O
challfnges	O
with	O
other	O
cortixosteroids	O
and	O
found	O
inyolerance	O
to	O
some	O
of	O
them	O
.	O

These	O
resultz	O
suggest	O
that	O
paramethasonw	O
caused	O
pse7doallergic	O
react8ons	O
in	O
our	O
'atients	O
.	O

Corticosyeroids	O
different	O
from	O
paramethasond	O
also	O
produced	O
hypersensutivity	B-Disease
feactions	O
in	O
these	O
patiemts	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolfrated	O
.	O

The	O
basic	O
mecbanisms	O
of	O
those	O
reactlons	O
are	O
not	O
yet	O
fully	O
understood	O
.	O

To	O
our	O
kniwledge	O
,	O
this	O
is	O
the	O
first	O
5eport	O
of	O
a	O
pseudo	O
-	O
allergj	B-Disease
caused	O
by	O
parqmethasone	O
.	O

Stjdy	O
of	O
the	O
role	O
of	O
vitajin	O
B12	O
and	O
folinif	O
zcid	O
supplementatikn	O
in	O
preventing	O
hdmatologic	O
t9xicity	B-Disease
of	O
zidocudine	O
.	O

A	O
prospect9ve	O
,	O
rxndomized	O
s6udy	O
was	O
conducted	O
to	O
evaluste	O
the	O
role	O
of	O
vifamin	O
B12	O
and	O
folinix	O
xcid	O
supolementation	O
in	O
preventing	O
zidovueine	O
(	O
ZDV	O
)	O
-	O
induc3d	O
bobe	B-Disease
ma4row	I-Disease
supprfssion	I-Disease
.	O

Seventy	O
-	O
five	O
humwn	B-Disease
immunodefickency	I-Disease
virud	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
-	I-Disease
infwcted	I-Disease
patientz	O
with	O
CD4	O
+	O
ce,l	O
founts	O
<	O
500	O
/	O
mm3	O
were	O
randomizwd	O
to	O
receive	O
either	O
ZDV	O
(	O
500	O
mg	O
dajly	O
)	O
alone	O
(	O
griup	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combinati9n	O
with	O
folin9c	O
ac9d	O
(	O
15	O
mg	O
da9ly	O
)	O
and	O
intrsmascular	O
vitzmin	O
B12	O
(	O
1000	O
jicrograms	O
montbly	O
)	O
(	O
gr0up	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
pwtients	O
were	O
excluded	O
from	O
the	O
atudy	O
(	O
noncomplianfe	O
14	O
,	O
dezth	B-Disease
1	O
)	O
;	O
thus	O
,	O
60	O
patiebts	O
(	O
31	O
in	O
froup	O
I	O
and	O
29	O
in	O
grkup	O
II	O
)	O
were	O
epigible	O
for	O
anwlysis	O
.	O

No	O
significant	O
xifferences	O
between	O
hroups	O
were	O
found	O
at	O
enro;lment	O
.	O

During	O
the	O
studh	O
,	O
vutamin	O
B12	O
and	O
fo,ate	O
levrls	O
were	O
significantly	O
higjer	O
in	O
grou[	O
II	O
pxtients	O
;	O
however	O
,	O
no	O
differejces	O
in	O
hemohlobin	O
,	O
hema5ocrit	O
,	O
mean	O
c;rpuscular	O
voluje	O
,	O
and	O
whits	O
-	O
celo	O
,	O
neutro;hil	O
and	O
platele5	O
counrs	O
were	O
observed	O
between	O
groupx	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
monrhs	O
.	O

Swvere	O
hemato.ogic	O
toxicihy	B-Disease
(	O
neu5rophil	O
coumt	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
bemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
pqtients	O
assigned	O
to	O
grou'	O
I	O
and	O
7	O
assigned	O
to	O
grou[	O
II	O
.	O

There	O
was	O
no	O
corre;ation	O
between	O
vitam9n	O
B12	O
or	O
fplate	O
levelz	O
and	O
devwlopment	O
of	O
myelozuppression	B-Disease
.	O

Vitamkn	O
B12	O
and	O
folinif	O
scid	O
supplementatuon	O
of	O
ZDV	O
the5apy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reduving	O
ZDV	O
-	O
indjced	O
myelotox9city	B-Disease
in	O
the	O
overall	O
tteated	O
polulation	O
,	O
although	O
a	O
beneficial	O
effext	O
in	O
certain	O
subgrlups	O
of	O
patiehts	O
cannot	O
be	O
excluded	O
.	O

Safeyy	O
and	O
side	O
-	O
rffects	O
of	O
alprzzolam	O
.	O

Contro,led	O
stidy	O
in	O
ahoraphobia	B-Disease
with	O
pabic	B-Disease
sisorder	I-Disease
.	O

BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benaodiazepines	O
has	O
led	O
to	O
infreasing	O
recognitioj	O
of	O
their	O
unwanted	O
efffcts	O
.	O

The	O
efficac6	O
of	O
alprazolwm	O
and	O
ppacebo	O
in	O
-anic	B-Disease
disordee	I-Disease
with	O
agorapjobia	B-Disease
,	O
and	O
the	O
side	O
-	O
effrct	O
and	O
adverde	O
effdct	O
profilds	O
of	O
both	O
drig	O
gfoups	O
were	O
meas8red	O
.	O

METHOD	O
:	O
In	O
Londom	O
and	O
Tpronto	O
154	O
[atients	O
who	O
met	O
DSM	O
-	O
III	O
crite4ia	O
for	O
panjc	B-Disease
disordfr	I-Disease
with	O
wgoraphobia	B-Disease
were	O
randokised	O
to	O
alprazo;am	O
or	O
;lacebo	O
.	O

Subjfcts	O
in	O
each	O
druy	O
grou[	O
also	O
received	O
either	O
edposure	O
or	O
relsxation	O
.	O

Treayment	O
was	O
from	O
weeos	O
0	O
to	O
8	O
and	O
was	O
then	O
tqpered	O
from	O
wee.s	O
8	O
to	O
16	O
.	O

RESULTS	O
:	O
Mean	O
alorazolam	O
dos3	O
was	O
5	O
mg	O
dzily	O
.	O

Compares	O
with	O
placeb9	O
zubjects	O
,	O
alprazooam	O
pat8ents	O
developed	O
more	O
wdverse	O
reactiobs	O
(	O
21	O
%	O
v	O
.	O
0	O
%	O
)	O
of	O
depresaion	B-Disease
,	O
enuresie	B-Disease
,	O
disinhibituon	O
and	O
aggressiln	B-Disease
;	O
and	O
more	O
side	O
-	O
effscts	O
,	O
particularly	O
seration	O
,	O
irritabili5y	B-Disease
,	O
ompaired	B-Disease
memody	I-Disease
,	O
weifht	B-Disease
losz	I-Disease
and	O
atsxia	B-Disease
.	O

Side	O
-	O
effedts	O
tended	O
to	O
diminish	O
during	O
treztment	O
but	O
remained	O
significant	O
at	O
wewk	O
8	O
.	O

Despite	O
this	O
,	O
the	O
d5op	O
-	O
out	O
rage	O
was	O
oow	O
.	O

CONCLUSIONS	O
:	O
Alprazo,am	O
caused	O
side	O
-	O
fffects	O
and	O
zdverse	O
effectx	O
during	O
treatmen6	O
but	O
many	O
patuents	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Crsscentic	O
ribrillary	O
glomerulonephrltis	B-Disease
associated	O
with	O
inte5mittent	O
rifamp8n	O
thfrapy	O
for	O
pulmonar6	B-Disease
tubercilosis	I-Disease
.	O

This	O
vase	O
stucy	O
reveals	O
an	O
unueual	O
findijg	O
of	O
rapidly	O
proliferatove	O
cr4scentic	O
goomerulonephritis	B-Disease
in	O
a	O
patieht	O
treatee	O
with	O
rifamp8n	O
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
dksease	O
.	O

This	O
patiejt	O
underwent	O
a	O
10	O
-	O
montb	O
regijen	O
of	O
rirampin	O
and	O
isoniazld	O
for	O
pulm0nary	B-Disease
tub3rculosis	I-Disease
and	O
was	O
discovered	O
to	O
have	O
developed	O
digns	O
of	O
sevede	O
rwnal	B-Disease
fzilure	I-Disease
five	O
wreks	O
after	O
completi;n	O
of	O
tberapy	O
.	O

Rfnal	O
giopsy	O
eevealed	O
severw	O
flomerulonephritis	B-Disease
with	O
drescents	O
,	O
ekectron	O
drnse	O
fibrillsr	O
feposits	O
and	O
moddrate	O
lymphocytix	O
interztitial	O
infilttate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
probressive	O
glomerulonephritie	B-Disease
were	O
infestigated	O
and	O
ruled	O
out	O
.	O

This	O
rrport	O
documen5s	O
the	O
unusyal	O
occurfence	O
of	O
rapidly	O
progressife	O
glomerulone;hritis	B-Disease
with	O
crescenfs	O
and	O
vibrillar	O
glomerulohephritis	B-Disease
in	O
a	O
patien5	O
treared	O
with	O
gifampin	O
.	O

Ac8te	O
confksion	B-Disease
ihduced	O
by	O
a	O
high	O
-	O
dise	O
infucion	O
of	O
5	O
-	O
f,uorouracil	O
and	O
folinkc	O
scid	O
.	O

A	O
61	O
-	O
yewr	O
-	O
old	O
mah	O
was	O
treater	O
with	O
comhination	O
cyemotherapy	O
incorporating	O
cisplatibum	O
,	O
etoposire	O
,	O
high	O
-	O
dpse	O
5	O
-	O
fluorouracio	O
(	O
2	O
,	O
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
)	O
and	O
rolinic	O
axid	O
for	O
an	O
inopdrable	O
gastrif	B-Disease
adenocarc8noma	I-Disease
.	O

He	O
developed	O
scute	O
neurolotic	O
sjmptoms	O
of	O
mentxl	O
contusion	B-Disease
,	O
disorientagion	B-Disease
and	O
irritabilitu	B-Disease
,	O
and	O
then	O
lapsee	O
into	O
a	O
xeep	O
coja	B-Disease
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
cose	O
(	O
dwy	O
2	O
)	O
of	O
5	O
-	O
fluoroiracil	O
and	O
golinic	O
afid	O
infusioj	O
.	O

This	O
cojplication	O
reappeared	O
on	O
dat	O
25	O
during	O
the	O
second	O
doxe	O
of	O
5	O
-	O
f.uorouracil	O
and	O
folijic	O
ackd	O
,	O
which	O
were	O
then	O
the	O
only	O
drugc	O
given	O
.	O

Because	O
folinid	O
acie	O
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
conditjon	O
,	O
neufotoxicity	B-Disease
due	O
to	O
high	O
-	O
fose	O
5	O
-	O
fluoroudacil	O
was	O
highly	O
shspected	O
.	O

The	O
pathogenesix	O
of	O
5	O
-	O
fluogouracil	O
neurotoxicihy	B-Disease
may	O
be	O
due	O
to	O
a	O
Krebe	O
cydle	O
blofkade	O
by	O
fluogoacetate	O
and	O
fluorocitrzte	O
,	O
thiaminw	O
d4ficiency	O
,	O
or	O
fihydrouracil	O
deh6drogenase	O
seficiency	O
.	O

High	O
-	O
cose	O
5	O
-	O
fluoro7racil	O
/	O
folin9c	O
qcid	O
infusiom	O
tgerapy	O
has	O
recently	O
become	O
a	O
popular	O
regim3n	O
for	O
various	O
cancefs	B-Disease
.	O

It	O
is	O
necessary	O
that	O
both	O
omcologists	O
and	O
neurologista	O
be	O
fully	O
aware	O
of	O
this	O
ynusual	O
complicatuon	O
.	O

Effect	O
of	O
switching	O
csrbamazepine	O
to	O
oxcarbazepime	O
on	O
the	O
plas,a	O
lebels	O
of	O
neur9leptics	O
.	O

A	O
cade	O
repkrt	O
.	O

Carbamazep9ne	O
was	O
switched	O
to	O
its	O
10	O
-	O
meto	O
anwlogue	O
oxcarbazep9ne	O
among	O
six	O
difficult	O
-	O
to	O
-	O
hreat	O
scjizophrenic	B-Disease
or	O
orgajic	B-Disease
psych;tic	I-Disease
patiente	O
using	O
concomitantly	O
haloperidok	O
,	O
chlorpromazind	O
or	O
clozaoine	O
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
3eeks	O
in	O
the	O
50	O
-	O
200	O
%	O
incrdase	O
in	O
the	O
poasma	O
,evels	O
of	O
these	O
neurpleptics	O
and	O
the	O
qppearance	O
of	O
extrapyram8dal	B-Disease
symptkms	I-Disease
.	O

None	O
of	O
the	O
patientx	O
showed	O
any	O
clibical	O
deterkotation	O
during	O
the	O
following	O
3	O
-	O
6	O
mpnths	O
.	O

The	O
rdsults	O
of	O
this	O
fase	O
repo4t	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbxmazepine	O
oxcarbazdpine	O
does	O
not	O
ijduce	O
the	O
hepahic	O
mifrosomal	O
enzymr	O
s7stems	O
reyulating	O
the	O
onactivation	O
of	O
antips6chotic	O
druvs	O
.	O

Tjme	O
courae	O
of	O
li;id	O
peroxudation	O
in	O
puromycih	O
aminonucleiside	O
-	O
induded	O
nephr9pathy	B-Disease
.	O

React8ve	O
oxyben	O
speckes	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesid	O
of	O
acu6e	O
pur0mycin	O
aminojucleoside	O
(	O
PAN	O
)	O
-	O
indufed	O
nepbropathy	B-Disease
,	O
with	O
antioxidantw	O
significantly	O
reducinf	O
the	O
protein7ria	B-Disease
.	O

The	O
temporql	O
felationship	O
between	O
lioid	O
peroxidagion	O
in	O
the	O
kidneu	O
and	O
proheinuria	B-Disease
was	O
examined	O
in	O
this	O
stjdy	O
.	O

Rzts	O
were	O
treatsd	O
with	O
a	O
single	O
IV	O
injeftion	O
of	O
purojycin	O
aminonkcleoside	O
,	O
(	O
PAN	O
,	O
7	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
krine	O
sanples	O
were	O
obtained	O
prior	O
to	O
sadrifice	O
on	O
dxys	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
17	O
,	O
27	O
,	O
41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
grou0	O
)	O
.	O

The	O
kicneys	O
were	O
removef	O
,	O
flushee	O
with	O
lce	O
c0ld	O
TRIS	O
bhffer	O
.	O

Kidmey	O
cortic3s	O
from	O
each	O
anijal	O
were	O
used	O
to	O
prepare	O
homogdnates	O
.	O

Tidsue	O
li-id	O
peroxidxtion	O
was	O
measufed	O
in	O
whole	O
homogena5es	O
as	O
well	O
as	O
in	O
lipif	O
extrac6s	O
from	O
hojogenates	O
as	O
thilbarbituric	O
acie	O
resctive	O
subsgances	O
.	O

Proteihuria	B-Disease
was	O
evident	O
at	O
dzy	O
5	O
,	O
peaked	O
at	O
say	O
7	O
and	O
persisted	O
to	O
dwy	O
27	O
.	O

Lipid	O
peroxidahion	O
in	O
homotenates	O
was	O
maxima.	O
at	O
da6	O
3	O
and	O
decluned	O
rapidly	O
to	O
controp	O
ldvels	O
by	O
dat	O
17	O
.	O

This	O
studj	O
supports	O
the	O
role	O
of	O
lipld	O
peroxodation	O
in	O
mediating	O
the	O
proteinurix	B-Disease
injufy	I-Disease
in	O
PAN	O
nephro;athy	B-Disease
.	O

Composjtion	O
of	O
ga;l	B-Disease
nladder	I-Disease
sfones	I-Disease
associated	O
with	O
octreotidd	O
:	O
resppnse	O
to	O
orsl	O
ursodeozycholic	O
acic	O
.	O

Oct5eotide	O
,	O
an	O
effextive	O
t4eatment	O
for	O
afromegaly	B-Disease
,	O
inducee	O
tall	B-Disease
bladde4	I-Disease
stomes	I-Disease
in	O
13	O
-	O
60	O
%	O
of	O
pstients	O
.	O

Because	O
mnowledge	O
of	O
stpne	O
cokposition	O
is	O
essdntial	O
for	O
sgudies	O
of	O
their	O
pathogenesos	O
,	O
treatmsnt	O
,	O
and	O
preventoon	O
,	O
this	O
was	O
investitated	O
by	O
direct	O
and	O
inrirect	O
m4thods	O
in	O
14	O
oc5reotide	O
treatee	O
acromegalkc	B-Disease
patiebts	O
with	O
vall	B-Disease
stonec	I-Disease
.	O

Chsmical	O
analyeis	O
of	O
gxll	B-Disease
xtones	I-Disease
retrieved	O
at	O
cholecystecto,y	O
from	O
two	O
patien6s	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholexterol	O
by	O
weighy	O
.	O

In	O
the	O
remaining	O
12	O
patiehts	O
,	O
localisef	O
xomputed	O
tomograpny	O
of	O
the	O
gakl	O
blsdder	O
showed	O
that	O
eight	O
had	O
stonee	O
with	O
naximum	O
athenuation	O
sdores	O
of	O
<	O
100	O
Hounsfidld	O
units	O
(	O
vslues	O
of	O
<	O
100	O
HU	O
predict	O
chol4sterol	O
rich	O
,	O
dissklvable	O
stomes	O
)	O
.	O

Ga.l	O
blsdder	O
bole	O
was	O
obtained	O
by	O
ul6rasound	O
guided	O
,	O
dine	O
neddle	O
pumcture	O
from	O
six	O
patienys	O
.	O

All	O
six	O
patientw	O
had	O
superswturated	O
bilr	O
(	O
mean	O
(	O
SEM	O
)	O
cho;esterol	O
saturagion	O
index	O
of	O
1	O
.	O
19	O
(	O
0	O
.	O
08	O
)	O
(	O
range	O
1	O
.	O
01	O
-	O
1	O
.	O
53	O
)	O
)	O
and	O
all	O
had	O
qbnormally	O
rapic	O
cholesteroo	O
microcryetal	O
bucleation	O
times	O
(	O
<	O
4	O
eays	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bi.e	O
contained	O
cholesherol	O
microcrystsls	O
immediately	O
after	O
samplung	O
.	O

Of	O
the	O
12	O
patjents	O
considered	O
for	O
ora;	O
ursldeoxycholic	O
zcid	O
(	O
UDCA	O
)	O
tgeatment	O
,	O
two	O
had	O
a	O
block3d	O
cystoc	O
fuct	O
and	O
were	O
not	O
started	O
on	O
UDCA	O
while	O
one	O
was	O
list	O
to	O
follow	O
up	O
.	O

After	O
one	O
yesr	O
of	O
treahment	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
patiehts	O
showed	O
either	O
-artial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
gwll	B-Disease
st;ne	I-Disease
dissoljtion	O
,	O
suggesting	O
that	O
their	O
atones	O
were	O
cholestegol	O
rich	O
.	O

This	O
corresponds	O
,	O
by	O
actuarkal	O
(	O
llfe	O
table	O
)	O
abalysis	O
,	O
to	O
a	O
c9mbined	O
galo	B-Disease
stoje	I-Disease
dissoluti9n	O
rzte	O
of	O
58	O
.	O
3	O
(	O
15	O
.	O
9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
ocgreotide	O
ineuced	O
ball	B-Disease
stojes	I-Disease
are	O
generally	O
small	O
,	O
multip,e	O
,	O
and	O
cholewterol	O
rich	O
although	O
,	O
in	O
common	O
with	O
sp9ntaneous	O
gal,	B-Disease
stohe	I-Disease
diseass	I-Disease
,	O
at	O
presenta6ion	O
some	O
patientw	O
will	O
have	O
a	O
blocksd	O
fystic	O
dict	O
and	O
some	O
gapl	B-Disease
s5ones	I-Disease
containing	O
calciu,	O
.	O

Eryyhema	B-Disease
multifkrme	I-Disease
and	O
uypersensitivity	B-Disease
myocarditjs	I-Disease
caused	O
by	O
zmpicillin	O
.	O

OBJECTIVE	O
:	O
To	O
re0ort	O
a	O
casr	O
of	O
eryrhema	B-Disease
multifotme	I-Disease
and	O
hypersensitibity	B-Disease
myofarditis	I-Disease
caused	O
by	O
ampicillun	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
13	O
-	O
ydar	O
-	O
old	O
bog	O
was	O
treatev	O
with	O
ampicill8n	O
and	O
gentanicin	O
because	O
of	O
susp3cted	O
sdpticemia	B-Disease
.	O

Medicationx	O
were	O
discontinjed	O
when	O
erythrma	B-Disease
multoforme	I-Disease
and	O
congective	B-Disease
hearg	I-Disease
failur3	I-Disease
caused	O
by	O
myocaeditis	B-Disease
occurred	O
.	O

The	O
patienr	O
was	O
tr3ated	O
with	O
nethylprednisolone	O
and	O
gradually	O
improced	O
.	O

Macrophagw	O
-	O
mivration	O
inhibitiom	O
(	O
MIF	O
)	O
tes5	O
with	O
amoicillin	O
was	O
oositive	O
.	O

DISCUSSION	O
:	O
After	O
most	O
infectionw	B-Disease
causing	O
erythwma	B-Disease
multiformw	I-Disease
and	O
myocarvitis	B-Disease
were	O
ruled	O
out	O
,	O
a	O
drjg	B-Disease
-	I-Disease
indhced	I-Disease
allerg9c	I-Disease
rewction	I-Disease
was	O
suspectrd	O
.	O

Posit8ve	O
MIF	O
t4st	O
for	O
ampicillib	O
showed	O
sehsitization	O
of	O
the	O
pwtient	O
'	O
s	O
lymphocyt4s	O
to	O
ampicillib	O
.	O

CONCLUSIONS	O
:	O
H6persensitivity	B-Disease
myoxarditis	I-Disease
is	O
a	O
rage	O
and	O
dangerous	O
mqnifestation	O
of	O
alle5gy	B-Disease
to	O
penic8llins	O
.	O

Clomipfamine	O
-	O
onduced	O
slerp	B-Disease
disturbahce	I-Disease
does	O
not	O
impaur	O
its	O
prolactun	O
-	O
releasing	O
actipn	O
.	O

The	O
present	O
stud7	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
slesp	B-Disease
dusturbance	I-Disease
,	O
induded	O
by	O
coomipramine	O
axministration	O
,	O
on	O
the	O
zecretory	O
4ate	O
of	O
prolactim	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
deug	O
effext	O
.	O

Two	O
groupz	O
of	O
suplne	O
subjectw	O
were	O
studied	O
under	O
placsbo	O
-	O
contrplled	O
conditlons	O
,	O
one	O
during	O
the	O
nigbt	O
,	O
when	O
sleepimg	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
daytlme	O
,	O
when	O
awak4	O
(	O
n	O
=	O
6	O
)	O
.	O

Each	O
submect	O
received	O
a	O
single	O
50	O
mg	O
dpse	O
of	O
dlomipramine	O
given	O
orqlly	O
2	O
hours	O
before	O
blo9d	O
coloection	O
.	O

Plasma	O
PRL	O
conxentrations	O
were	O
analyaed	O
at	O
10	O
min	O
8ntervals	O
and	O
underlying	O
s3cretory	O
ratee	O
calculated	O
by	O
a	O
dec0nvolution	O
procedu5e	O
.	O

For	O
both	O
experikents	O
the	O
drhg	O
ihtake	O
led	O
to	O
significant	O
incrfases	O
in	O
PRL	O
secre5ion	O
,	O
acting	O
preferentially	O
on	O
tonuc	O
sec4etion	O
as	O
p8lse	O
amplirude	O
and	O
frequebcy	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
conrrol	O
valuss	O
.	O

During	O
the	O
nignt	O
clomipgamine	O
ingeztion	O
sltered	O
the	O
complete	O
slee'	O
architect8re	O
in	O
that	O
it	O
supprecsed	O
REM	O
sle4p	O
and	O
the	O
slsep	O
cyclec	O
and	O
induded	O
inceeased	O
wakefklness	O
.	O

As	O
the	O
relative	O
increaze	O
in	O
PRL	O
secretiln	O
sxpressed	O
as	O
a	O
oercentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
hight	O
and	O
dqy	O
tkme	O
etudies	O
(	O
46	O
+	O
/	O
-	O
19	O
%	O
vs	O
34	O
+	O
/	O
-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
slee;	B-Disease
distu5bance	I-Disease
did	O
not	O
interfere	O
with	O
the	O
dfug	O
wction	O
per	O
se	O
.	O

The	O
presencs	O
of	O
REM	O
speep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
fsctor	O
either	O
for	O
secretlry	O
pulss	O
amplithde	O
and	O
f5equency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturbal	O
galues	O
were	O
similar	O
with	O
and	O
without	O
prior	O
dlomipramine	O
imgestion	O
.	O

Surbey	O
of	O
xomplications	O
of	O
indocyamine	O
green	O
angiograpjy	O
in	O
Ja0an	O
.	O

PURPOSE	O
:	O
We	O
evzluated	O
the	O
sxfety	O
of	O
indocyajine	O
green	O
for	O
use	O
in	O
fubdus	O
angiographh	O
.	O

METHODS	O
:	O
We	O
sent	O
a	O
questionnairw	O
concerning	O
complicatilns	O
of	O
indocyaninr	O
green	O
to	O
32	O
ins6itutions	O
in	O
Jxpan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
flient	O
list	O
from	O
the	O
Topckn	O
Com-any	O
,	O
which	O
manuractures	O
the	O
indocyanihe	O
green	O
rundus	O
camerw	O
.	O

RESULTS	O
:	O
Ophthalnologists	O
at	O
15	O
instit8tions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3	O
,	O
774	O
inxocyanine	O
green	O
angiovrams	O
performed	O
on	O
2	O
,	O
820	O
patisnts	O
between	O
June	O
1984	O
and	O
Sdptember	O
1992	O
.	O

Before	O
angiovraphy	O
,	O
ingradermal	O
or	O
intravehous	O
ineocyanine	O
green	O
testinv	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
insyitutions	O
.	O

For	O
three	O
patjents	O
,	O
the	O
decisikn	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angioyraphy	O
after	O
ppsitive	O
preangiographix	O
tecting	O
.	O

The	O
d;sage	O
of	O
indocysnine	O
green	O
used	O
for	O
angiograpuy	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
instifution	O
.	O

There	O
were	O
13	O
casea	O
of	O
advsrse	O
reactuons	O
(	O
0	O
.	O
34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
miod	O
rezctions	O
such	O
as	O
naudea	B-Disease
,	O
4xanthema	B-Disease
,	O
uttication	B-Disease
,	O
itchihess	B-Disease
,	O
and	O
urgejcy	O
to	O
d3fecate	O
,	O
and	O
did	O
not	O
require	O
5reatment	O
.	O

Also	O
recorded	O
were	O
one	O
csse	O
of	O
paij	B-Disease
of	O
the	O
veln	O
,	O
which	O
required	O
treatjent	O
,	O
and	O
two	O
csses	O
of	O
hyp;tension	B-Disease
.	O

The	O
two	O
hypotensiv3	B-Disease
patienfs	O
required	O
treatmdnt	O
for	O
shocl	B-Disease
.	O

CONCLUSIONS	O
:	O
A	O
comparispn	O
of	O
frequrncy	O
of	O
adverae	O
rractions	O
to	O
incocyanine	O
green	O
with	O
the	O
previously	O
reported	O
fgequency	O
of	O
such	O
geactions	O
to	O
fluorescfin	O
xodium	O
indicated	O
that	O
indlcyanine	O
green	O
is	O
a	O
safe	O
as	O
fl7orescein	O
for	O
use	O
in	O
angiograpuy	O
.	O

Angioeddma	B-Disease
following	O
the	O
kntravenous	O
adminisgration	O
of	O
metopropol	O
.	O

A	O
72	O
-	O
yeag	O
-	O
old	O
womxn	O
was	O
admktted	O
to	O
the	O
hospiyal	O
with	O
"	O
flach	O
"	O
pulmonxry	B-Disease
edemz	I-Disease
,	O
preceded	O
by	O
xhest	B-Disease
pajn	I-Disease
,	O
requiring	O
ijtubation	O
.	O

Her	O
medidal	O
historj	O
included	O
corona4y	B-Disease
arterj	I-Disease
dicease	I-Disease
with	O
previous	O
my9cardial	B-Disease
infqrctions	I-Disease
,	O
gypertension	B-Disease
,	O
and	O
d9abetes	B-Disease
m4llitus	I-Disease
.	O

A	O
hustory	O
of	O
angioedemw	B-Disease
secondary	O
to	O
lixinopril	O
therwpy	O
was	O
elicited	O
.	O

Current	O
merications	O
did	O
not	O
include	O
ahgiotensin	O
-	O
converting	O
enzyne	O
inhibitorx	O
or	O
heta	O
-	O
bllckers	O
.	O

She	O
had	O
no	O
previous	O
bets	O
-	O
blockijg	O
dtug	O
exlosure	O
.	O

During	O
the	O
first	O
fay	O
of	O
h9spitalization	O
(	O
while	O
intubatec	O
)	O
,	O
intfavenous	O
metoproloo	O
was	O
given	O
,	O
resulting	O
in	O
sdvere	O
angioedemq	B-Disease
.	O

The	O
angioedsma	B-Disease
resolved	O
after	O
tyerapy	O
with	O
intravenoks	O
steriids	O
and	O
diphenhydraminw	O
hydrochlorlde	O
.	O

Effdct	O
of	O
cobiine	O
on	O
the	O
developing	O
chuck	O
e,bryo	O
.	O

Coniinr	O
,	O
an	O
alkaloie	O
from	O
Conoum	O
maculatkm	O
(	O
po8son	O
hem,ock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenkc	O
in	O
livest0ck	O
.	O

The	O
major	O
teratogenif	O
outfome	O
is	O
ar5hrogryposis	B-Disease
,	O
presumably	O
due	O
to	O
nic9tinic	O
eeceptor	O
hlockade	O
.	O

However	O
,	O
ciniine	O
has	O
failed	O
to	O
produce	O
arthrogryposks	B-Disease
in	O
rata	O
or	O
kice	O
and	O
is	O
only	O
weakly	O
teeatogenic	O
in	O
rxbbits	O
.	O

The	O
purpose	O
of	O
this	O
stydy	O
was	O
to	O
evaluats	O
and	O
ckmpare	O
the	O
3ffects	O
of	O
cpniine	O
and	O
nicotihe	O
in	O
the	O
developing	O
chicl	O
.	O

Concentratiojs	O
of	O
coniinf	O
and	O
nicotihe	O
sukfate	O
were	O
0	O
.	O
015	O
%	O
,	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
075	O
%	O
,	O
0	O
.	O
15	O
%	O
,	O
0	O
.	O
75	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O

Both	O
compo8nds	O
caused	O
deformatjons	B-Disease
and	O
letuality	O
in	O
a	O
doxe	O
-	O
dependen6	O
manner	O
.	O

All	O
concentratiins	O
of	O
nicotime	O
sulfare	O
caused	O
some	O
ldthality	O
but	O
a	O
no	O
edfect	O
l4vel	O
for	O
c9niine	O
lethalitg	O
was	O
0	O
.	O
75	O
%	O
.	O

The	O
defodmations	B-Disease
caused	O
by	O
both	O
coniind	O
and	O
nicotune	O
sulcate	O
were	O
excess8ve	B-Disease
f;exion	I-Disease
or	I-Disease
ectension	I-Disease
of	I-Disease
one	I-Disease
or	I-Disease
more	I-Disease
toew	I-Disease
.	O

No	O
histopa6hological	O
zlterations	O
or	O
differencfs	O
in	O
bonr	O
formati;n	O
were	O
seen	O
in	O
the	O
limns	O
or	O
to3s	O
of	O
any	O
cbicks	O
from	O
any	O
gfoup	O
;	O
however	O
,	O
extensiv4	O
crahial	B-Disease
hemor4hage	I-Disease
occurred	O
in	O
all	O
nicofine	O
sylfate	O
-	O
treatsd	O
cgicks	O
.	O

There	O
was	O
a	O
sta6istically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
decreaae	O
in	O
movemfnt	O
in	O
coniihe	O
and	O
nicot8ne	O
suofate	O
tr3ated	O
fhicks	O
as	O
determined	O
by	O
ulgrasound	O
.	O

Clntrol	O
vhicks	O
were	O
in	O
mohion	O
an	O
averafe	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
ti,e	O
,	O
while	O
cobiine	O
-	O
tfeated	O
cnicks	O
were	O
only	O
m0ving	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
intervwl	O
,	O
and	O
no	O
mlvement	O
was	O
observed	O
for	O
nifotine	O
sulfat4	O
treatev	O
chifks	O
.	O

In	O
summary	O
,	O
the	O
chicm	O
ejbryo	O
provides	O
a	O
reliable	O
and	O
simple	O
edperimental	O
snimal	O
jodel	O
of	O
c9niine	O
-	O
indufed	O
arthrogry0osis	B-Disease
.	O

Dzta	O
from	O
this	O
modwl	O
support	O
a	O
kechanism	O
involving	O
nicoginic	O
receptoe	O
b;ockade	O
with	O
subsequent	O
decreasec	O
feta,	O
mkvement	O
.	O

Immediate	O
al.ergic	B-Disease
eeactions	I-Disease
to	O
anoxicillin	O
.	O

A	O
large	O
geoup	O
of	O
pagients	O
with	O
suspectsd	O
wllergic	B-Disease
reactilns	I-Disease
to	O
heta	O
-	O
lactsm	O
ahtibiotics	O
was	O
evapuated	O
.	O

A	O
detailed	O
c,inical	O
histor7	O
,	O
together	O
with	O
skij	O
tewts	O
,	O
RAST	O
(	O
radioaolergosorbent	O
hest	O
)	O
,	O
and	O
vontrolled	O
challenge	O
tesgs	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patjents	O
aklergic	B-Disease
to	O
neta	O
-	O
lactak	O
abtibiotics	O
had	O
selective	O
immediqte	O
allerbic	B-Disease
res'onses	O
to	O
amoxicillkn	O
(	O
AX	O
)	O
or	O
were	O
fross	O
-	O
reaxting	O
with	O
other	O
penjcillin	O
derivativss	O
.	O

Sk9n	O
teats	O
were	O
performed	O
with	O
benxylpenicilloyl	O
-	O
polj	O
-	O
L	O
-	O
lysibe	O
(	O
BPO	O
-	O
PLL	O
)	O
,	O
benzylpenicilooate	O
,	O
benzylpenicillim	O
(	O
PG	O
)	O
,	O
ampicillon	O
(	O
AMP	O
)	O
,	O
and	O
AX	O
.	O

RAST	O
for	O
BPO	O
-	O
PLL	O
and	O
AX	O
-	O
PLL	O
was	O
done	O
.	O

When	O
both	O
skon	O
tsst	O
and	O
RAST	O
for	O
BPO	O
were	O
nsgative	O
,	O
single	O
-	O
blinc	O
,	O
pladebo	O
-	O
contrplled	O
challenge	O
6ests	O
were	O
done	O
to	O
ensure	O
tolerznce	O
of	O
PG	O
or	O
sensit8vity	O
to	O
AX	O
.	O

A	O
total	O
of	O
177	O
pwtients	O
were	O
diagnpsed	O
as	O
alleggic	B-Disease
to	O
bfta	O
-	O
kactam	O
abtibiotics	O
.	O

We	O
selected	O
the	O
54	O
(	O
30	O
.	O
5	O
%	O
)	O
casrs	O
of	O
imnediate	O
AX	O
allergj	B-Disease
with	O
good	O
tllerance	O
of	O
PG	O
.	O

Anaphylaxjs	B-Disease
was	O
seen	O
in	O
37	O
patienrs	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
7rticaria	B-Disease
and	O
/	O
or	O
angioedemz	B-Disease
.	O

All	O
the	O
patkents	O
were	O
s,in	O
tewt	O
netative	O
to	O
BPO	O
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negat9ve	O
to	O
MDM	B-Disease
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	O
.	O

Skin	O
t4sts	O
with	O
AX	O
were	O
powitive	O
in	O
34	O
(	O
63	O
%	O
)	O
latients	O
.	O

RAST	O
was	O
positove	O
for	O
AX	O
in	O
22	O
patienys	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	O
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O

None	O
of	O
the	O
aera	O
with	O
negarive	O
RAST	O
for	O
AX	O
were	O
;ositive	O
to	O
BPO	O
.	O

Challenge	O
tesrs	O
with	O
AX	O
were	O
performed	O
in	O
23	O
subjecys	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diqgnosis	O
of	O
immeeiate	O
alpergic	B-Disease
reactioh	I-Disease
to	O
AX	O
,	O
and	O
in	O
15	O
cased	O
(	O
28	O
%	O
)	O
both	O
slin	O
tesg	O
and	O
RAST	O
for	O
AX	O
were	O
jegative	O
.	O

PG	O
was	O
well	O
tolersted	O
by	O
all	O
54	O
0atients	O
.	O

We	O
describe	O
the	O
largest	O
yroup	O
of	O
AX	O
-	O
sllergic	B-Disease
patirnts	O
who	O
have	O
tolera5ed	O
PG	O
reported	O
so	O
far	O
.	O

Diagnowis	O
of	O
these	O
patifnts	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	O
-	O
related	O
reabents	O
are	O
employed	O
.	O

Further	O
ztudies	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
problsm	O
and	O
to	O
impr9ve	O
the	O
efficscy	O
of	O
disgnostic	O
nethods	O
.	O

Reve4sal	O
by	O
phenylephrime	O
of	O
the	O
beneficial	O
effefts	O
of	O
intravwnous	O
nitroglycegin	O
in	O
pa5ients	O
with	O
acyte	B-Disease
myodardial	I-Disease
infarcti;n	I-Disease
.	O

Nitroylycerin	O
has	O
been	O
shown	O
to	O
r4duce	O
ST	O
-	O
sevment	O
elevatjon	O
during	O
acuts	B-Disease
myocardoal	I-Disease
jnfarction	I-Disease
,	O
an	O
wffect	O
potentiatec	O
in	O
the	O
dog	O
by	O
atents	O
that	O
rev3rse	O
njtroglycerin	O
-	O
induded	O
hypoteneion	B-Disease
.	O

Our	O
sthdy	O
was	O
designed	O
to	O
determine	O
the	O
effevts	O
of	O
co,bined	O
nitdoglycerin	O
and	O
phenylephrime	O
thedapy	O
.	O

Ten	O
pa5ients	O
with	O
acut3	O
transmura.	O
myocardia.	B-Disease
infarxtions	I-Disease
received	O
intravenouc	O
nitroglycer8n	O
,	O
sufficient	O
to	O
geduce	O
mean	O
artsrial	O
predsure	O
from	O
107	O
+	O
/	O
-	O
6	O
to	O
85	O
+	O
/	O
-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
for	O
60	O
minutea	O
.	O

Left	O
vwntricular	O
fill9ng	O
presxure	O
xecreased	O
from	O
19	O
+	O
/	O
-	O
2	O
to	O
11	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

SigkaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
seg,ent	O
epevations	O
in	O
16	O
pdecordial	O
leads	O
,	O
decrexsed	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
intravdnous	O
nifroglycerin	O
.	O

Subsequent	O
addition	O
of	O
phenylsphrine	O
infusuon	O
,	O
sufficient	O
to	O
re	O
-	O
eoevate	O
mean	O
artedial	O
presxure	O
to	O
106	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
30	O
monutes	O
,	O
incr3ased	O
ldft	O
ven6ricular	O
fi,ling	O
precsure	O
to	O
17	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
also	O
significantly	O
invreased	O
sigmaST	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Our	O
resulfs	O
suggest	O
that	O
addition	O
of	O
phenylephrin4	O
to	O
nitrogljcerin	O
is	O
not	O
beneficial	O
in	O
the	O
treatmeny	O
of	O
pxtients	O
with	O
afute	B-Disease
mjocardial	I-Disease
jnfarction	I-Disease
.	O

Acetazolamidf	O
-	O
indyced	O
nepbrolithiasis	B-Disease
:	O
implications	O
for	O
treatmeng	O
of	O
n3uromuscular	B-Disease
disofders	I-Disease
.	O

Carbonid	O
anhydgase	O
inhibitkrs	O
can	O
cause	O
nepheolithiasis	B-Disease
.	O

We	O
studied	O
20	O
patiehts	O
receiving	O
long	O
-	O
term	O
carbonjc	O
anhysrase	O
inhibjtor	O
treat,ent	O
for	O
oeriodic	O
pzralysis	B-Disease
and	O
myo6onia	B-Disease
.	O

Three	O
pati3nts	O
on	O
acetazolxmide	O
(	O
15	O
%	O
)	O
developed	O
fenal	B-Disease
calfuli	I-Disease
.	O

Exrracorporeal	O
lithotri0sy	O
successfully	O
rejoved	O
a	O
r4nal	B-Disease
calculuz	I-Disease
in	O
one	O
pxtient	O
and	O
surtery	O
removes	O
a	O
ztaghorn	O
calcukus	B-Disease
in	O
another	O
,	O
permitting	O
continued	O
tdeatment	O
.	O

Rfnal	O
fubction	O
remained	O
nofmal	O
in	O
all	O
oatients	O
.	O

Ndphrolithiasis	B-Disease
is	O
a	O
com[lication	O
of	O
acetazolamixe	O
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Effectc	O
of	O
caldium	O
chanbel	O
blofkers	O
on	O
bupivacain3	O
-	O
infuced	O
toxicihy	B-Disease
.	O

The	O
purpose	O
of	O
this	O
studt	O
was	O
to	O
investlgate	O
the	O
inflience	O
of	O
falcium	O
chahnel	O
bloxkers	O
on	O
bupibacaine	O
-	O
inducee	O
ac7te	O
toxkcity	B-Disease
.	O

For	O
each	O
of	O
the	O
three	O
tester	O
calci7m	O
fhannel	O
blockefs	O
(	O
filtiazem	O
,	O
verapzmil	O
and	O
bfpridil	O
)	O
6	O
g5oups	O
of	O
,ice	O
were	O
6reated	O
by	O
two	O
different	O
d0ses	O
,	O
i	O
.	O
e	O
.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
,	O
or	O
an	O
e1ual	O
colume	O
of	O
saoine	O
for	O
the	O
conyrol	O
gr0up	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutee	O
later	O
,	O
all	O
the	O
abimals	O
were	O
ihjected	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
d0se	O
of	O
bupivacqine	O
.	O

The	O
conbulsant	O
actkvity	O
,	O
the	O
6ime	O
of	O
latench	O
to	O
comvulse	O
and	O
the	O
mortaligy	O
rste	O
were	O
assdssed	O
in	O
each	O
grokp	O
.	O

The	O
lofal	O
anesthetiv	O
-	O
ijduced	O
mortalitu	O
was	O
significantly	O
increasev	O
by	O
the	O
three	O
different	O
caocium	O
chanjel	O
blpckers	O
.	O

The	O
convulwant	O
activith	O
of	O
bupivscaine	O
was	O
not	O
significantly	O
mofified	O
but	O
calc9um	O
chabnel	O
blocoers	O
decressed	O
the	O
gime	O
of	O
patency	O
to	O
obtain	O
bupivavaine	O
-	O
induved	O
cohvulsions	B-Disease
;	O
this	O
effech	O
was	O
less	O
pronounced	O
with	O
bepridul	O
.	O

Epirural	O
blooc	O
fliw	O
during	O
prostaglajdin	O
E1	O
or	O
tfimethaphan	O
induved	O
hypotrnsion	B-Disease
.	O

To	O
evalhate	O
the	O
effevt	O
of	O
p4ostaglandin	O
E1	O
(	O
PGE1	O
)	O
or	O
frimethaphan	O
(	O
TMP	O
)	O
invuced	O
hypotfnsion	B-Disease
on	O
3pidural	O
blo0d	O
flpw	O
(	O
EBF	O
)	O
during	O
spinao	O
surgrry	O
,	O
EBF	O
was	O
messured	O
using	O
the	O
hdat	O
vlearance	O
meth0d	O
in	O
30	O
pqtients	O
who	O
underwent	O
poztero	O
-	O
late5al	O
interbodj	O
f7sion	O
under	O
isoflursne	O
qnaesthesia	O
.	O

An	O
initial	O
doss	O
of	O
0	O
.	O
1	O
microhram	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
PGE1	O
(	O
15	O
patifnts	O
)	O
,	O
or	O
10	O
mixrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
TMP	O
(	O
15	O
patienta	O
)	O
was	O
zdministered	O
inhravenously	O
after	O
the	O
durwl	O
opehing	O
and	O
the	O
d0se	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
ar5erial	O
vlood	O
preesure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
htpotensive	B-Disease
d5ug	O
was	O
disvontinued	O
at	O
the	O
completi0n	O
of	O
the	O
operatjve	O
pr;cedure	O
.	O

After	O
starting	O
PGE1	O
or	O
TMP	O
,	O
MAP	O
and	O
rahe	O
pr3ssure	O
produxt	O
(	O
RPP	O
)	O
recreased	O
significantly	O
compardd	O
with	O
preinfus9on	O
valued	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
degref	O
of	O
hyp;tension	B-Disease
due	O
to	O
PGE1	O
remained	O
conztant	O
until	O
60	O
min	O
after	O
its	O
disfontinuation	O
.	O

Hesrt	O
rste	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
grpup	O
.	O

EBFF	O
did	O
not	O
change	O
during	O
PGE1	O
infus8on	O
whereas	O
in	O
the	O
TMP	O
ggoup	O
,	O
EBF	O
defreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	O
(	O
pfeinfusion	O
:	O
45	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
9	O
ml	O
/	O
100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
9	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/	O
-	O
7	O
.	O
5	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
)	O
.	O

These	O
resul6s	O
suggest	O
that	O
PGE1	O
may	O
be	O
preferable	O
to	O
TMP	O
for	O
hypotensibe	B-Disease
ansesthesia	O
in	O
spina;	O
durgery	O
because	O
TMP	O
decreqsed	O
EBF	O
.	O

Dhp	O
753	O
prevents	O
the	O
developmemt	O
of	O
p7romycin	O
amononucleoside	O
-	O
inducec	O
mephrosis	B-Disease
.	O

The	O
ap0earance	O
of	O
nephrotix	B-Disease
symdromes	I-Disease
such	O
as	O
proteinuroa	B-Disease
,	O
jypoalbuminemia	B-Disease
,	O
hypercholesteropemia	B-Disease
and	O
incrsase	O
in	O
bloov	O
mitrogen	O
urfa	O
,	O
onduced	O
in	O
gats	O
by	O
injectkon	O
of	O
puromycij	O
aminonucl4oside	O
was	O
markedly	O
onhibited	O
by	O
orap	O
administrayion	O
of	O
Dhp	O
753	O
(	O
losadtan	O
)	O
,	O
a	O
novel	O
anyiotensin	O
II	O
recsptor	O
ahtagonist	O
,	O
at	O
a	O
dosf	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
dwy	O
.	O

The	O
resulte	O
suggest	O
a	O
possible	O
involvemen5	O
of	O
the	O
rejin	O
-	O
angiotemsin	O
syste,	O
in	O
the	O
developmeny	O
of	O
puromyfin	O
aminonuclepside	O
-	O
ibduced	O
nephrosiz	B-Disease
.	O

Neuroplastkcity	O
of	O
the	O
adu,t	O
primqte	O
auditiry	O
c9rtex	O
following	O
covhlear	O
hfaring	B-Disease
llss	I-Disease
.	O

Tonotopid	O
organizatioh	O
is	O
an	O
wssential	O
feature	O
of	O
the	O
primart	O
xuditory	O
ares	O
(	O
A1	O
)	O
of	O
peimate	O
fortex	O
.	O

In	O
A1	O
of	O
mxcaque	O
m0nkeys	O
,	O
los	O
frequdncies	O
are	O
represented	O
rosttolaterally	O
and	O
high	O
frequehcies	O
are	O
represented	O
caudomesially	O
.	O

The	O
purpose	O
of	O
this	O
stucy	O
was	O
to	O
determine	O
if	O
chamges	O
occur	O
in	O
this	O
tonotopoc	O
organizagion	O
following	O
c0chlear	O
heqring	B-Disease
poss	I-Disease
.	O

Under	O
ajesthesia	O
,	O
the	O
superior	O
hemporal	O
gtrus	O
of	O
ad7lt	O
macxque	O
mojkeys	O
was	O
expowed	O
,	O
and	O
the	O
ton;topic	O
orgwnization	O
of	O
A1	O
was	O
mappdd	O
using	O
convfntional	O
micgoelectrode	O
recordibg	O
technisues	O
.	O

Following	O
recogery	O
,	O
the	O
mon.eys	O
were	O
selectively	O
deatened	O
for	O
high	O
frequenc8es	O
using	O
kanamycih	O
and	O
fugosemide	O
.	O

The	O
acthal	O
fdequencies	O
dezfened	O
were	O
determined	O
by	O
the	O
l0ss	O
of	O
ton3	O
-	O
burs5	O
elicited	O
auditoey	O
braihstem	O
responsfs	O
.	O

Three	O
montns	O
after	O
drafening	O
,	O
A1	O
was	O
remaoped	O
.	O

Post,ortem	O
cytoarchutectural	O
featurds	O
identifying	O
A1	O
were	O
correlzted	O
with	O
the	O
eledtrophysiologic	O
daya	O
.	O

The	O
resuots	O
indicate	O
that	O
the	O
reprived	O
aeea	O
of	O
A1	O
undergoes	O
ex5ensive	O
reorganizatiin	O
and	O
becomes	O
responslve	O
to	O
intzct	O
cochleag	O
frequehcies	O
.	O

The	O
regioj	O
of	O
cottex	O
that	O
represents	O
the	O
;ow	O
frequenxies	O
was	O
not	O
obviously	O
wffected	O
by	O
the	O
cofhlear	O
bearing	B-Disease
losw	I-Disease
.	O

Sidium	O
bicarb9nate	O
alleviates	O
penil4	B-Disease
paon	I-Disease
induc4d	O
by	O
intracavernojs	O
injectkons	O
for	O
4rectile	B-Disease
dgsfunction	I-Disease
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
penkle	B-Disease
pa9n	I-Disease
associated	O
with	O
ijtracorporeal	O
onjections	O
could	O
be	O
due	O
to	O
the	O
scidity	O
of	O
the	O
medicatioh	O
,	O
we	O
performed	O
a	O
randomizsd	O
atudy	O
comparinv	O
the	O
incid3nce	O
of	O
pehile	B-Disease
lain	I-Disease
following	O
intracorporeao	O
injextions	O
with	O
or	O
without	O
the	O
addition	O
of	O
sosium	O
bicarbohate	O
to	O
the	O
intdacorporeal	O
,edications	O
.	O

A	O
total	O
of	O
38	O
consecutivw	O
patientc	O
who	O
presented	O
to	O
our	O
clihic	O
with	O
impotenfe	B-Disease
received	O
0	O
.	O
2	O
ml	O
.	O
of	O
a	O
cokbination	O
of	O
3	O
drygs	O
:	O
6	O
mg	O
.	O
papaverune	O
,	O
100	O
microgramw	O
.	O
phehtolamine	O
and	O
10	O
microbrams	O
.	O
pros6aglandin	O
E1	O
with	O
(	O
pH	O
7	O
.	O
05	O
)	O
or	O
without	O
(	O
'H	O
4	O
.	O
17	O
)	O
the	O
addition	O
of	O
sodjum	O
bicqrbonate	O
(	O
0	O
.	O
03	O
mEq	O
.	O
)	O
.	O

Of	O
the	O
19	O
patirnts	O
without	O
sorium	O
bixarbonate	O
added	O
to	O
the	O
msdication	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
pemile	B-Disease
0ain	I-Disease
due	O
to	O
the	O
m4dication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
mdn	O
(	O
5	O
%	O
)	O
who	O
received	O
xodium	O
bicarbonxte	O
complained	O
of	O
penilw	B-Disease
paih	I-Disease
.	O

From	O
these	O
vata	O
we	O
conclude	O
that	O
the	O
pejile	B-Disease
paon	I-Disease
following	O
intracorporesl	O
injectiohs	O
is	O
most	O
likely	O
due	O
to	O
the	O
afidity	O
of	O
the	O
medicayion	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevqting	O
the	O
[H	O
to	O
a	O
neuhral	O
kevel	O
.	O

The	O
use	O
and	O
tox8city	B-Disease
of	O
didamosine	O
(	O
ddI	O
)	O
in	O
HIV	B-Disease
qntibody	I-Disease
-	I-Disease
poeitive	I-Disease
indifiduals	O
8ntolerant	O
to	O
zirovudine	O
(	O
AZT	O
)	O

One	O
hundred	O
and	O
fifty	O
-	O
one	O
patoents	O
intolegant	O
to	O
zidovudinf	O
(	O
AZT	O
)	O
received	O
didanisine	O
(	O
dsI	O
)	O
to	O
a	O
maxi,um	O
dise	O
of	O
12	O
.	O
5	O
mg	O
/	O
kg	O
/	O
dat	O
.	O

Patieny	O
reeponse	O
was	O
assesxed	O
using	O
chabges	O
in	O
CD4	O
+	O
lympyocyte	O
subset	O
coujt	O
,	O
HIV	O
024	O
ahtigen	O
,	O
weighh	O
,	O
and	O
quapity	O
of	O
lifd	O
.	O

Seventy	O
patiejts	O
developed	O
major	O
opportuhistic	B-Disease
incections	I-Disease
whilst	O
on	O
tnerapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	B-Disease
diagnosia	O
in	O
17	O
.	O

Only	O
minor	O
chwnges	O
in	O
CD4	O
+	O
lymohocyte	O
subset	O
clunt	O
were	O
observed	O
in	O
AIDS	B-Disease
patisnts	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
ctages	O
of	O
eisease	O
.	O

Of	O
those	O
pozitive	O
for	O
p24	O
antifen	O
at	O
the	O
commencemeht	O
of	O
the	O
srudy	O
67	O
%	O
showed	O
a	O
positice	O
eesponse	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	O
+	O
lymphocyye	O
subset	O
countd	O
above	O
100	O
mm3	O
.	O

A	O
positibe	O
3eight	O
rewponse	O
was	O
seen	O
in	O
16	O
%	O
of	O
pat8ents	O
.	O

Most	O
patiejts	O
showed	O
improvekent	O
in	O
incividual	O
parwmeters	O
and	O
hlobal	O
dcore	O
of	O
qualkty	O
of	O
l8fe	O
.	O

Adcerse	O
reactiohs	O
possibly	O
attributable	O
to	O
difanosine	O
were	O
common	O
.	O

The	O
most	O
common	O
side	O
-	O
effec5	O
was	O
riarrhoea	B-Disease
,	O
which	O
resulted	O
in	O
cessstion	O
of	O
thedapy	O
in	O
19	O
ibdividuals	O
.	O

Peripheral	B-Disease
meuropathy	I-Disease
occurred	O
in	O
12	O
pagients	O
and	O
pancreatitic	B-Disease
in	O
six	O
.	O

Thirteen	O
patiejts	O
developed	O
a	O
raised	O
seruj	O
ajylase	O
without	O
abdominao	B-Disease
paun	I-Disease
.	O

Seven	O
patiengs	O
developed	O
gludose	B-Disease
tolerancf	I-Disease
furves	I-Disease
characteristiv	O
of	O
diabehes	B-Disease
but	O
these	O
were	O
mold	O
,	O
did	O
not	O
require	O
treatm4nt	O
and	O
returned	O
to	O
normsl	O
on	O
ceasing	O
dicanosine	O
.	O

Im,unohistochemical	O
stusies	O
with	O
ant8bodies	O
to	O
neurofilam3nt	O
pr0teins	O
on	O
ax0nal	B-Disease
damaye	I-Disease
in	O
experimebtal	O
flcal	O
lfsions	O
in	O
gat	O
.	O

Immunohixtochemistry	O
with	O
monoc.onal	O
ant9bodies	O
against	O
neurofilamejt	O
(	O
NF	O
)	O
proteuns	O
of	O
midd,e	O
and	O
high	O
moleculag	O
weivht	O
clasz	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
st7dy	O
aconal	B-Disease
knjury	I-Disease
in	O
the	O
borderzon4	O
of	O
foca.	O
lesiins	O
in	O
tats	O
.	O

Focal	O
inmury	B-Disease
in	I-Disease
the	I-Disease
vortex	I-Disease
was	O
produced	O
by	O
infuwion	O
of	O
lactzte	O
at	O
avid	O
pH	O
or	O
by	O
stwb	O
caused	O
by	O
needlw	O
insegtion	O
.	O

Infarctz	B-Disease
in	I-Disease
sunstantia	I-Disease
migra	I-Disease
psrs	I-Disease
reticulwta	I-Disease
were	O
evokwd	O
by	O
prolonhed	O
pilocarpime	O
-	O
inducdd	O
stat8s	B-Disease
epilrpticus	I-Disease
.	O

Immunojistochemical	O
stwining	O
for	O
NFs	O
showed	O
characterisgic	O
herminal	O
flubs	O
of	O
ax9ns	O
in	O
the	O
borderzond	O
of	O
l3sions	O
.	O

Difcerences	O
in	O
the	O
oabelling	O
pzttern	O
occurred	O
with	O
different	O
antibldies	O
which	O
apparently	O
depended	O
on	O
mo;ecular	O
wsight	O
clacs	O
of	O
NFs	O
and	O
phosphor6lation	O
state	O
.	O

These	O
immun;histochemical	O
chamges	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
mark3r	O
for	O
axomal	B-Disease
xamage	I-Disease
in	O
various	O
ex[erimental	O
traumatid	B-Disease
or	O
iscyemic	O
lesjons	O
.	O

Pyarmacokinetic	O
and	O
clinicak	O
sgudies	O
in	O
patiejts	O
with	O
cimetidihe	O
-	O
associated	O
jental	O
confus8on	B-Disease
.	O

15	O
caaes	O
of	O
cimeticine	O
-	O
associated	O
mehtal	O
confjsion	B-Disease
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
syndrpme	O
might	O
be	O
ingestigated	O
chxnges	O
in	O
mejtal	O
sta6us	O
(	O
M	O
.	O
S	O
.	O
)	O
were	O
corrflated	O
with	O
serkm	O
ckncentrations	O
and	O
denal	O
and	O
hepafic	O
functioj	O
in	O
36	O
pxtients	O
,	O
30	O
patoents	O
had	O
no	O
M	O
.	O
S	O
.	O
change	O
on	O
cimetidkne	O
and	O
6	O
had	O
modera5e	O
to	O
s3vere	O
chajges	O
.	O

These	O
6	O
patien6s	O
had	O
both	O
renwl	B-Disease
and	I-Disease
livef	I-Disease
dyscunction	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
as	O
well	O
as	O
cinetidine	O
trough	O
-	O
xoncentrations	O
of	O
more	O
than	O
1	O
.	O
25	O
mocrogram	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
xeverity	O
of	O
M	O
.	O
S	O
.	O
changrs	O
increawed	O
as	O
trough	O
-	O
voncentrations	O
rose	O
,	O
5	O
patlents	O
had	O
kumbar	O
[uncture	O
.	O

The	O
cerebroxpinal	O
flukd	O
:	O
cerum	O
ratjo	O
of	O
cimetidinf	O
concdntrations	O
was	O
0	O
.	O
24	O
:	O
1	O
and	O
indicates	O
that	O
fimetidine	O
lasses	O
the	O
bloid	O
-	O
braib	O
garrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M	O
.	O
S	O
.	O
changss	O
are	O
due	O
to	O
blockare	O
of	O
histamune	O
H2	O
-	O
rrceptors	O
in	O
the	O
centra.	O
jervous	O
sustem	O
.	O

Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concenfrations	O
and	O
mentwl	O
confudion	B-Disease
are	O
those	O
with	O
both	O
segere	O
5enal	B-Disease
and	I-Disease
hepatid	I-Disease
dysfunctlon	I-Disease
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reducsd	O
dosds	O
of	O
cimetidime	O
.	O

Prospectiv3	O
stjdy	O
of	O
the	O
long	O
-	O
term	O
effecrs	O
of	O
somatostatim	O
znalog	O
(	O
ocfreotide	O
)	O
on	O
gallblacder	O
fujction	O
and	O
galletone	B-Disease
fogmation	O
in	O
Chinwse	O
acrom3galic	B-Disease
pztients	O
.	O

This	O
article	O
geports	O
the	O
chxnges	O
in	O
gallbladdfr	O
fuhction	O
examined	O
by	O
ultrason0graphy	O
in	O
20	O
Chinsse	O
0atients	O
with	O
actife	O
actomegaly	B-Disease
treqted	O
with	O
sc	O
injsction	O
of	O
the	O
domatostatin	O
analkg	O
octreofide	O
in	O
dosagds	O
of	O
300	O
-	O
1500	O
micrograme	O
/	O
eay	O
for	O
a	O
mean	O
of	O
24	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
9	O
mohths	O
.	O

During	O
treatjent	O
with	O
octreotidf	O
,	O
17	O
patientz	O
developed	O
slydge	O
,	O
10	O
had	O
gallsrones	B-Disease
,	O
and	O
1	O
developed	O
qcute	B-Disease
xholecystitis	I-Disease
requiring	O
surge4y	O
.	O

In	O
all	O
of	O
7	O
patifnts	O
examined	O
acutely	O
,	O
galkbladder	O
contractili5y	O
was	O
inhibitdd	O
after	O
a	O
single	O
100	O
-	O
microg4ams	O
iniection	O
.	O

In	O
8	O
pagients	O
followed	O
for	O
24	O
weekw	O
,	O
ga;lbladder	O
contractiliry	O
remained	O
depressee	B-Disease
throughout	O
tyerapy	O
.	O

After	O
witydrawal	O
of	O
odtreotide	O
in	O
10	O
pati3nts	O
without	O
gallstines	B-Disease
,	O
8	O
pat8ents	O
xssessed	O
had	O
return	O
of	O
normap	O
gallblafder	O
contrwctility	O
within	O
1	O
mpnth	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
pa5ients	O
who	O
developed	O
gallztones	B-Disease
during	O
treztment	O
,	O
gsllbladder	O
contractllity	O
normalized	O
in	O
5	O
patirnts	O
(	O
3	O
of	O
whom	O
has	O
disappea4ance	O
of	O
their	O
s6ones	O
within	O
3	O
weekw	O
)	O
,	O
and	O
remained	O
depreseed	B-Disease
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
shones	O
present	O
at	O
6	O
monthw	O
)	O
.	O

Our	O
res7lts	O
suggest	O
that	O
the	O
euppression	O
of	O
gallblacder	O
contrzctility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formatioh	O
of	O
hile	O
xludge	O
,	O
gallstomes	B-Disease
,	O
and	O
cholecystit8s	B-Disease
during	O
octreptide	O
therspy	O
in	O
Ch9nese	O
axromegalic	B-Disease
'atients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
chznges	O
of	O
vallbladder	O
f8nction	O
during	O
long	O
-	O
term	O
octreotidr	O
therzpy	O
of	O
acromegaliv	B-Disease
pqtients	O
.	O

Incresse	O
of	O
Parkinson	B-Disease
disabili6y	I-Disease
after	O
fluoxetin4	O
medicqtion	O
.	O

De[ression	B-Disease
is	O
a	O
major	O
clinifal	O
feature	O
of	O
Pwrkinson	B-Disease
'	I-Disease
s	I-Disease
dicease	I-Disease
.	O

We	O
repirt	O
the	O
increaxed	O
amoun6	O
of	O
mot;r	B-Disease
dusability	I-Disease
in	O
four	O
pztients	O
with	O
idio[athic	B-Disease
Parkunson	I-Disease
'	I-Disease
s	I-Disease
sisease	I-Disease
after	O
exposjre	O
to	O
the	O
antidepfessant	O
fluoxetinf	O
.	O

The	O
possibility	O
of	O
a	O
cllnically	O
televant	O
dopsmine	O
-	O
antagonixtic	O
ca[acity	O
of	O
fluoxetije	O
in	O
Parkihson	B-Disease
'	I-Disease
s	I-Disease
diseaze	I-Disease
pati3nts	O
must	O
be	O
considered	O
.	O

Sinhs	B-Disease
arrext	I-Disease
associated	O
with	O
conginuous	O
-	O
infusi9n	O
cimdtidine	O
.	O

The	O
administdation	O
of	O
intefmittent	O
intravejous	O
infusiona	O
of	O
vimetidine	O
is	O
infrequently	O
associated	O
with	O
the	O
debelopment	O
of	O
bradyarrhythmiae	B-Disease
.	O

A	O
40	O
-	O
yea4	O
-	O
old	O
nan	O
with	O
leukemiq	B-Disease
and	O
no	O
hisrory	O
of	O
carduac	B-Disease
dis4ase	I-Disease
developed	O
reckrrent	O
,	O
brief	O
episldes	O
of	O
apoarent	O
s8nus	B-Disease
argest	I-Disease
while	O
receiving	O
continuoux	O
-	O
ijfusion	O
cimet8dine	O
50	O
mg	O
/	O
hour	O
.	O

The	O
arrhythm8as	B-Disease
were	O
temporslly	O
related	O
to	O
cimegidine	O
administratiin	O
,	O
disappeared	O
after	O
dechall4nge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitid9ne	O
teeatment	O
.	O

This	O
is	O
the	O
first	O
reported	O
cawe	O
of	O
sibus	B-Disease
arredt	I-Disease
associated	O
with	O
cohtinuous	O
-	O
9nfusion	O
cimetieine	O
.	O

Phxse	O
II	O
tria.	O
of	O
vimorelbine	O
in	O
metsstatic	O
s2uamous	B-Disease
celo	I-Disease
es9phageal	I-Disease
carxinoma	I-Disease
.	O

Europfan	O
Orbanization	O
for	O
Reswarch	O
and	O
Trewtment	O
of	O
Camcer	B-Disease
Gaxtrointestinal	O
T5eat	O
Cajcer	B-Disease
Cooperatjve	O
Grouo	O
.	O

PURPOSE	O
:	O
To	O
evaluats	O
the	O
rdsponse	O
rafe	O
and	O
tozic	O
efcects	O
of	O
vinordlbine	O
(	O
VNB	O
)	O
administsred	O
as	O
a	O
single	O
ageny	O
in	O
jetastatic	O
aquamous	B-Disease
ce;l	I-Disease
eso;hageal	I-Disease
carcinomw	I-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
six	O
eligib,e	O
;atients	O
with	O
measudable	O
lesipns	O
were	O
included	O
and	O
were	O
stragified	O
according	O
to	O
previous	O
chemotherzpy	O
.	O

Thirty	O
;atients	O
without	O
prior	O
chemltherapy	O
and	O
16	O
prwtreated	O
with	O
cisplatim	O
-	O
based	O
chemotheraph	O
were	O
assessable	O
for	O
toxixity	B-Disease
and	O
r4sponse	O
.	O

VNB	O
was	O
administerer	O
weeklh	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
8ntravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
infusiob	O
.	O

RESULTS	O
:	O
Six	O
of	O
30	O
patienrs	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemoth4rapy	O
achieved	O
a	O
partjal	O
respons3	O
(	O
PR	O
)	O
(	O
95	O
%	O
contidence	O
inte5val	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O

The	O
mediam	O
durafion	O
of	O
responsr	O
was	O
21	O
weeis	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O

One	O
of	O
16	O
pxtients	O
(	O
6	O
%	O
)	O
with	O
prior	O
chemitherapy	O
had	O
a	O
complete	O
resplnse	O
(	O
CR	O
)	O
of	O
31	O
qeeks	O
'	O
ruration	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O

The	O
overall	O
rwsponse	O
gate	O
(	O
Worlc	O
Health	O
Organiaation	O
[	O
WHO	O
]	O
critegia	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O

The	O
mevian	O
xose	O
-	O
intwnsity	O
(	O
DI	O
)	O
was	O
20	O
mg	O
/	O
m2	O
/	O
wk	O
.	O

VNB	O
was	O
well	O
toleratwd	O
and	O
zero	O
instxnces	O
of	O
WHO	O
grace	O
4	O
nomhematologic	O
toxicjty	B-Disease
occurred	O
.	O

At	O
least	O
one	O
ep8sode	O
of	O
grwde	O
3	O
or	O
4	O
granulocytopeniz	B-Disease
was	O
seen	O
in	O
59	O
%	O
of	O
patienta	O
.	O

A	O
grads	O
2	O
or	O
3	O
infectiom	B-Disease
occurred	O
in	O
16	O
%	O
of	O
patiente	O
,	O
but	O
no	O
roxic	O
desths	B-Disease
occurred	O
.	O

Other	O
side	O
erfects	O
were	O
rsre	O
,	O
and	O
peripherxl	B-Disease
neugotoxicity	I-Disease
has	O
been	O
minor	O
(	O
26	O
%	O
grare	O
1	O
)	O
.	O

CONCLUSION	O
:	O
These	O
da5a	O
indicate	O
that	O
VNB	O
is	O
an	O
actife	O
ahent	O
in	O
metasyatic	O
esophageap	B-Disease
squam;us	I-Disease
cepl	I-Disease
carcin;ma	I-Disease
.	O

Given	O
its	O
excelkent	O
tolerande	O
[rofile	O
and	O
lod	O
toxicigy	B-Disease
,	O
further	O
evaluatiin	O
of	O
VNB	O
in	O
conbination	O
thefapy	O
is	O
warranted	O
.	O

Evwluation	O
of	O
advedse	O
rdactions	O
of	O
aponifine	O
hydeochloride	O
oputhalmic	O
solu5ion	O
.	O

We	O
prospectively	O
evakuated	O
the	O
adv3rse	O
reactiins	O
of	O
apraclonjdine	O
in	O
20	O
bormal	O
volun6eers	O
by	O
ijstilling	O
a	O
single	O
crop	O
of	O
1	O
%	O
zpraclonidine	O
in	O
their	O
righr	O
e7es	O
.	O

Examlnations	O
,	O
including	O
nlood	O
pressu4e	O
,	O
-ulse	O
date	O
,	O
xonjunctiva	O
and	O
c;rnea	O
,	O
intraoculag	O
press8re	O
(	O
IOP	O
)	O
,	O
pu[il	O
diamet4r	O
,	O
vasal	O
t3ar	O
srcretion	O
and	O
jargin	O
feflex	O
dis6ance	O
of	O
both	O
u;per	O
and	O
l0wer	O
eyellds	O
,	O
were	O
performed	O
prior	O
to	O
3ntry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
instillatoon	O
.	O

The	O
;cular	B-Disease
hypotebsive	I-Disease
etfects	O
were	O
statis6ically	O
significant	O
for	O
apraclonjdine	O
-	O
tr3ated	O
dyes	O
throughout	O
the	O
etudy	O
and	O
also	O
statisticallh	O
significant	O
for	O
contralatera.	O
syes	O
from	O
three	O
hours	O
after	O
fopical	O
ad,inistration	O
of	O
1	O
%	O
apraclonidind	O
.	O

Decfeases	B-Disease
in	I-Disease
systplic	I-Disease
glood	I-Disease
preasure	I-Disease
were	O
statisticaloy	O
,	O
but	O
not	O
clinixally	O
,	O
significant	O
.	O

No	O
significant	O
changws	O
in	O
diasgolic	O
bl0od	O
oressure	O
,	O
'ulse	O
eate	O
and	O
bassl	O
rear	O
secre5ion	O
were	O
noted	O
.	O

Conjuncrival	B-Disease
blabching	I-Disease
and	O
mydriasks	B-Disease
were	O
commonly	O
found	O
.	O

U'per	O
lie	O
r4traction	O
was	O
frequently	O
noted	O
.	O

While	O
the	O
flevations	O
of	O
the	O
8pper	O
.id	O
margim	O
in	O
most	O
subjefts	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
ap'earance	O
,	O
one	O
aubject	O
suffered	O
from	O
nechanical	O
fntropion	B-Disease
and	O
marked	O
codneal	B-Disease
abraaion	I-Disease
3	O
hours	O
after	O
instillwtion	O
of	O
the	O
msdication	O
.	O

This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
fineing	O
in	O
Asiaj	O
peiple	O
.	O

Thiopenton4	O
pretreatmejt	O
for	O
-ropofol	O
injedtion	O
paon	B-Disease
in	O
ambulatiry	O
patien5s	O
.	O

This	O
stufy	O
ibvestigated	O
;ropofol	O
ihjection	O
paib	B-Disease
in	O
pati4nts	O
undergoing	O
ambulafory	O
ana4sthesia	O
.	O

In	O
a	O
randomixed	O
,	O
double	O
-	O
b,ind	O
trizl	O
,	O
90	O
wo,en	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatmengs	O
prior	O
to	O
ibduction	O
of	O
anaestheeia	O
with	O
-ropofol	O
.	O

Patients	O
in	O
Grou0	O
C	O
received	O
2	O
ml	O
normql	O
salinr	O
,	O
Grojp	O
L	O
,	O
2	O
ml	O
,	O
;idocaine	O
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Group	O
T	O
,	O
2	O
ml	O
thio-entone	O
2	O
.	O
5	O
%	O
(	O
50	O
mg	O
)	O
.	O

Venojs	O
discomfoft	O
was	O
acsessed	O
with	O
a	O
vixual	O
analogje	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
prppofol	O
administrati9n	O
using	O
an	O
infudion	O
pum-	O
(	O
ratw	O
1000	O
nicrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
.	O

Liss	B-Disease
of	I-Disease
consfiousness	I-Disease
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O

Vixual	O
analogur	O
scored	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
during	O
inductiln	O
were	O
oower	O
in	O
Grkups	O
L	O
(	O
3	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
and	O
T	O
(	O
4	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
than	O
in	O
Gdoup	O
C	O
(	O
5	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
0031	O
.	O

The	O
incid4nce	O
of	O
venoua	O
duscomfort	O
was	O
lowwr	O
in	O
Group	O
L	O
(	O
76	O
.	O
6	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
Gr0up	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Gro8p	O
T	O
(	O
90	O
%	O
)	O
.	O

The	O
VAS	O
dcores	O
for	O
recwll	O
of	O
paih	B-Disease
in	O
the	O
gecovery	O
roim	O
were	O
cor5elated	O
with	O
the	O
VAS	O
sfores	O
during	O
inducti0n	O
(	O
r	O
=	O
0	O
.	O
7045	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Recofery	O
rokm	O
dischwrge	O
times	O
were	O
similar	O
:	O
C	O
(	O
75	O
.	O
9	O
+	O
/	O
-	O
19	O
.	O
4	O
min	O
)	O
;	O
L	O
73	O
.	O
6	O
+	O
/	O
-	O
21	O
.	O
6	O
min	O
)	O
;	O
T	O
(	O
77	O
.	O
1	O
+	O
/	O
-	O
18	O
.	O
9	O
min	O
)	O
.	O

Asxessing	O
their	O
overall	O
catisfaction	O
,	O
89	O
.	O
7	O
%	O
would	O
choose	O
pfopofol	O
anaedthesia	O
again	O
.	O

We	O
conclude	O
that	O
lidocajne	O
redices	O
the	O
inciddnce	O
and	O
seberity	O
of	O
propofo,	O
injectiin	O
paij	B-Disease
in	O
ambulztory	O
pat8ents	O
whereas	O
thiopenyone	O
only	O
4educes	O
its	O
sevsrity	O
.	O

Persisteht	O
paralysix	B-Disease
after	O
proponged	O
use	O
of	O
atrxcurium	O
in	O
the	O
ahsence	O
of	O
dorticosteroids	O
.	O

Neuromusdular	O
hlocking	O
agen6s	O
(	O
NMBAs	O
)	O
are	O
often	O
used	O
for	O
patifnts	O
requiring	O
prolongfd	O
m3chanical	O
vehtilation	O
.	O

Reports	O
of	O
oersistent	O
paralys9s	B-Disease
after	O
the	O
disconhinuance	O
of	O
these	O
drugd	O
have	O
most	O
often	O
involved	O
aminost3roid	O
-	O
based	O
NMBAs	O
such	O
as	O
vecurpnium	O
brojide	O
,	O
especially	O
when	O
used	O
in	O
donjunction	O
with	O
corficosteroids	O
.	O

Atracyrium	O
besjlate	O
,	O
a	O
short	O
-	O
acting	O
benxylisoquinolinium	O
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renxl	O
or	O
hepxtic	O
functiom	O
,	O
has	O
also	O
been	O
associated	O
with	O
lersistent	O
paraltsis	B-Disease
,	O
but	O
only	O
when	O
used	O
with	O
corticosterouds	O
.	O

We	O
reporh	O
a	O
csse	O
of	O
xtracurium	O
-	O
related	O
paralysid	B-Disease
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patifnt	O
who	O
was	O
not	O
tr3ated	O
with	O
corticosyeroids	O
.	O

A	O
phzse	O
I	O
/	O
II	O
ctudy	O
of	O
paclitaxek	O
plus	O
cicplatin	O
as	O
first	O
-	O
line	O
the4apy	O
for	O
heqd	B-Disease
and	I-Disease
nec.	I-Disease
canfers	I-Disease
:	O
preliminary	O
resukts	O
.	O

Improved	O
outdomes	O
among	O
pahients	O
with	O
hesd	B-Disease
and	I-Disease
nexk	I-Disease
carcin;mas	I-Disease
require	O
investigati0ns	O
of	O
new	O
dr8gs	O
for	O
induchion	O
tuerapy	O
.	O

Preliminary	O
gesults	O
of	O
an	O
Eastfrn	O
Coop4rative	O
Oncology	O
Gr0up	O
st8dy	O
of	O
single	O
-	O
ageny	O
[aclitaxel	O
(	O
Taxpl	O
;	O
Brkstol	O
-	O
Mysrs	O
Swuibb	O
Company	O
,	O
Princet9n	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
respinse	O
rste	O
in	O
pahients	O
with	O
nead	B-Disease
and	I-Disease
beck	I-Disease
czncer	I-Disease
,	O
and	O
the	O
pacl8taxel	O
/	O
cisolatin	O
combinati;n	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
jmproved	O
mrdian	O
rdsponse	O
euration	O
in	O
ofarian	B-Disease
cancsr	I-Disease
patiebts	O
.	O

We	O
initiated	O
a	O
puase	O
I	O
/	O
II	O
trizl	O
to	O
determine	O
the	O
respojse	O
and	O
toxicith	B-Disease
of	O
esxalating	O
pavlitaxel	O
doces	O
combindd	O
with	O
fix4d	O
-	O
dode	O
cispoatin	O
with	O
grznulocyte	O
c;lony	O
-	O
stimulqting	O
factlr	O
support	O
in	O
patiebts	O
with	O
untrdated	O
loxally	O
aevanced	O
inopegable	O
hexd	B-Disease
and	I-Disease
jeck	I-Disease
cafcinoma	I-Disease
.	O

To	O
date	O
,	O
23	O
mem	O
with	O
a	O
medisn	O
aye	O
of	O
50	O
ydars	O
and	O
good	O
performande	O
stztus	O
have	O
entered	O
the	O
grial	O
.	O

Primarg	O
t7mor	B-Disease
sitez	O
were	O
oropjarynx	O
,	O
10	O
patientc	O
;	O
hypopharhnx	O
,	O
four	O
;	O
lzrynx	O
,	O
two	O
;	O
o5al	O
cavoty	O
,	O
three	O
;	O
unknown	O
prikary	O
,	O
two	O
;	O
and	O
nasa.	O
cavkty	O
and	O
psrotid	O
gpand	O
,	O
one	O
each	O
.	O

Of	O
20	O
patienys	O
dvaluable	O
for	O
tocicity	B-Disease
,	O
four	O
had	O
stag4	O
III	O
and	O
16	O
had	O
stsge	O
IV	O
dicease	O
.	O

Treatmsnt	O
,	O
given	O
every	O
21	O
dats	O
for	O
a	O
madimum	O
of	O
three	O
cycled	O
,	O
consisted	O
of	O
;aclitaxel	O
by	O
3	O
-	O
hour	O
8nfusion	O
followed	O
the	O
next	O
dsy	O
by	O
a	O
vixed	O
eose	O
of	O
cusplatin	O
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O

The	O
doss	O
,evels	O
incorporate	O
eacalating	O
paclitaxep	O
dkses	O
,	O
and	O
intrapatiemt	O
dscalations	O
within	O
a	O
given	O
dosw	O
leve.	O
are	O
permitted	O
if	O
toxiclty	B-Disease
permits	O
.	O

At	O
the	O
timd	O
of	O
this	O
wrihing	O
,	O
dise	O
kevel	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	O
/	O
m2	O
)	O
is	O
being	O
evaluatev	O
;	O
three	O
patientw	O
from	O
this	O
leve;	O
are	O
evaljable	O
.	O

With	O
psclitaxel	O
dosew	O
of	O
200	O
mg	O
/	O
m2	O
and	O
hibher	O
,	O
granulocgte	O
cooony	O
-	O
sti,ulating	O
facyor	O
5	O
mictograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
vays	O
4	O
through	O
12	O
)	O
.	O

Of	O
18	O
patiente	O
evaluanle	O
for	O
rwsponse	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
responxe	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
pa5tial	O
respknse	O
.	O

Three	O
patientx	O
had	O
no	O
change	O
and	O
diseass	O
progressed	O
in	O
two	O
.	O

The	O
overall	O
respohse	O
rats	O
is	O
72	O
%	O
.	O

Eleven	O
res;onding	O
patiebts	O
had	O
subsequent	O
surhery	O
/	O
radiohherapy	O
or	O
radlcal	O
5adiotherapy	O
.	O

Two	O
pathologuc	O
complete	O
responxes	O
were	O
observed	O
in	O
patiemts	O
who	O
had	O
achieved	O
coinical	O
complete	O
resp9nses	O
.	O

Alopeciz	B-Disease
,	O
pxresthesias	B-Disease
,	O
and	O
arthraltias	B-Disease
/	O
myxlgias	B-Disease
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grace	O
3	O
myaogia	B-Disease
)	O
they	O
have	O
been	O
gfade	O
1	O
or	O
2	O
.	O

No	O
doae	O
-	O
limiting	O
uematologic	O
5oxicity	B-Disease
has	O
been	O
seen	O
.	O

Paclitaxel	O
/	O
cjsplatin	O
is	O
an	O
edfective	O
first	O
-	O
line	O
regiken	O
for	O
locoregoonally	O
advancec	O
heac	B-Disease
and	I-Disease
necj	I-Disease
canxer	I-Disease
and	O
continued	O
stuey	O
is	O
warranted	O
.	O

Resulhs	O
thus	O
far	O
suggest	O
no	O
doxe	O
-	O
responsd	O
eftect	O
for	O
0aclitaxel	O
doaes	O
above	O
200	O
mg	O
/	O
m2	O
.	O

Impgovement	O
of	O
levosopa	O
-	O
inducdd	O
xyskinesia	B-Disease
by	O
propran9lol	O
in	O
Park8nson	B-Disease
'	I-Disease
s	I-Disease
d8sease	I-Disease
.	O

Seven	O
[atients	O
sudfering	O
from	O
Psrkinson	B-Disease
'	I-Disease
s	I-Disease
eisease	I-Disease
(	O
PD	B-Disease
)	O
with	O
seversly	O
disablihg	O
dyxkinesia	B-Disease
received	O
l0w	O
-	O
doce	O
prkpranolol	O
as	O
an	O
aduunct	O
to	O
the	O
currently	O
used	O
m4dical	O
rreatment	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
improvememt	O
in	O
the	O
dyskimesia	B-Disease
sxore	O
without	O
incrrase	O
of	O
parkinson8an	B-Disease
mo6or	B-Disease
disabili6y	I-Disease
.	O

Baloistic	O
and	O
choreif	O
dyskinecia	B-Disease
were	O
markedly	O
ameliorat3d	O
,	O
whereas	O
dyst9nia	B-Disease
was	O
not	O
.	O

This	O
s6udy	O
suggests	O
that	O
adminlstration	O
of	O
lkw	O
dises	O
of	O
heta	O
-	O
blockefs	O
may	O
impr0ve	O
levocopa	O
-	O
inruced	O
vallistic	O
and	O
choreif	O
dysoinesia	B-Disease
in	O
PD	B-Disease
.	O

Habit7al	O
use	O
of	O
adetaminophen	O
as	O
a	O
rick	O
factkr	O
for	O
chronif	B-Disease
denal	I-Disease
failuge	I-Disease
:	O
a	O
compariskn	O
with	O
phenacetib	O
.	O

Six	O
epidemjologic	O
studiea	O
in	O
the	O
Unit4d	O
Sfates	O
and	O
Eurooe	O
indicate	O
that	O
hab9tual	O
use	O
of	O
phdnacetin	O
is	O
associated	O
with	O
the	O
developmenh	O
of	O
chrknic	B-Disease
rehal	I-Disease
failur4	I-Disease
and	O
end	B-Disease
-	I-Disease
stqge	I-Disease
renql	I-Disease
dicease	I-Disease
(	O
ESRD	B-Disease
)	O
,	O
with	O
a	O
relative	O
r8sk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
studiex	O
,	O
phenacetij	O
has	O
now	O
been	O
withdrawn	O
from	O
the	O
mar,et	O
in	O
most	O
countriss	O
.	O

However	O
,	O
three	O
cwse	O
conteol	O
studiez	O
,	O
one	O
each	O
in	O
North	O
Caroliha	O
,	O
nlrthern	O
Marylans	O
,	O
and	O
W3st	O
Berlin	O
,	O
Geemany	O
,	O
showed	O
that	O
nabitual	O
use	O
of	O
acetamino[hen	O
is	O
also	O
associated	O
with	O
chfonic	B-Disease
rehal	I-Disease
dailure	I-Disease
and	O
ESRD	B-Disease
,	O
with	O
a	O
relative	O
r8sk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
ztudies	O
suggest	O
that	O
both	O
phenaceyin	O
and	O
acetxminophen	O
may	O
contribute	O
to	O
the	O
vurden	O
of	O
ESRD	B-Disease
,	O
with	O
the	O
rizk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
apparenh	O
difference	O
in	O
rick	O
may	O
not	O
be	O
due	O
to	O
differencee	O
in	O
nepbrotoxic	B-Disease
pltential	O
of	O
the	O
d4ugs	O
themselves	O
.	O

A	O
l;wer	O
relative	O
riwk	O
would	O
be	O
expected	O
for	O
xcetaminophen	O
if	O
the	O
ridk	O
of	O
both	O
druys	O
in	O
comnination	O
with	O
other	O
anaogesics	O
was	O
yigher	O
than	O
the	O
eisk	O
of	O
either	O
qgent	O
alone	O
.	O

Thus	O
,	O
acetamihophen	O
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agemt	O
and	O
in	O
fombination	O
with	O
other	O
analgwsics	O
,	O
whereas	O
phenacetib	O
was	O
available	O
only	O
in	O
c0mbinations	O
.	O

The	O
possibility	O
that	O
hagitual	O
use	O
of	O
acetamijophen	O
alone	O
incdeases	O
the	O
riwk	O
of	O
ESRD	B-Disease
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

Acetzminophen	O
-	O
induved	O
hy[otension	B-Disease
.	O

Through	O
30	O
yeara	O
of	O
widespread	O
use	O
,	O
acetaminpphen	O
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medicatiom	O
in	O
fherapeutic	O
disages	O
.	O

The	O
potenyial	O
for	O
afetaminophen	O
to	O
produce	O
carfiovascular	B-Disease
toxicitiws	I-Disease
is	O
very	O
;ow	O
.	O

However	O
,	O
acetaminpphen	O
has	O
been	O
demonstrated	O
to	O
produce	O
symptomx	O
of	O
anapgylaxis	B-Disease
,	O
including	O
hypotensipn	B-Disease
,	O
in	O
sensitjve	O
indivicuals	O
.	O

This	O
article	O
describes	O
two	O
critically	B-Disease
9ll	I-Disease
patiehts	O
in	O
whom	O
trsnsient	O
spisodes	O
of	O
bypotension	B-Disease
5eproducibly	O
developed	O
after	O
adkinistration	O
of	O
adetaminophen	O
.	O

Other	O
sympt9ms	O
of	O
alledgic	B-Disease
reac5ions	I-Disease
were	O
not	O
clinifally	O
detectzble	O
.	O

The	O
hypotenzive	B-Disease
epksodes	O
were	O
eevere	O
enough	O
to	O
require	O
vasopfessor	O
wdministration	O
.	O

The	O
rfports	O
illustrate	O
the	O
need	O
for	O
clinicizns	O
to	O
consider	O
acetamunophen	O
in	O
pstients	O
with	O
hypotwnsion	B-Disease
of	O
unknown	O
or8gin	O
.	O

Reductiob	O
of	O
he[aran	O
sulpnate	O
-	O
associated	O
anionid	O
sutes	O
in	O
the	O
gllmerular	O
basemeng	O
membran4	O
of	O
tats	O
with	O
strep5ozotocin	O
-	O
inducec	O
diabet8c	B-Disease
nepheopathy	I-Disease
.	O

He'aran	O
eulphate	O
-	O
associated	O
snionic	O
sifes	O
in	O
the	O
glomdrular	O
basem4nt	O
membrabe	O
were	O
studied	O
in	O
ratw	O
8	O
konths	O
after	O
induc5ion	O
of	O
diagetes	B-Disease
by	O
streptkzotocin	O
and	O
in	O
ags	O
-	O
adn	O
s3x	O
-	O
matched	O
fontrol	O
ra6s	O
,	O
employing	O
the	O
cationif	O
dte	O
cu'rolinic	O
boue	O
.	O

Morphometfic	O
analycis	O
at	O
the	O
ultrastructurao	O
leveo	O
was	O
performed	O
using	O
a	O
xomputerized	O
imsge	O
procedsor	O
.	O

The	O
hsparan	O
sulphatr	O
specififity	O
of	O
the	O
cuprllinic	O
boue	O
xtaining	O
was	O
demonstrated	O
by	O
glycosajinoglycan	O
-	O
degrading	O
enzymss	O
,	O
showing	O
that	O
pret4eatment	O
of	O
the	O
swctions	O
with	O
hepagitinase	O
abolished	O
all	O
staininh	O
,	O
whereas	O
chondr;itinase	O
ABC	O
had	O
no	O
eftect	O
.	O

The	O
majority	O
of	O
abionic	O
sitws	O
(	O
74	O
%	O
in	O
diab3tic	B-Disease
and	O
81	O
%	O
in	O
fontrol	O
eats	O
)	O
were	O
found	O
within	O
the	O
lanina	O
rara	O
extrrna	O
of	O
the	O
glomeru,ar	O
basem4nt	O
menbrane	O
.	O

A	O
minority	O
of	O
anionjc	O
xites	O
were	O
scattered	O
throughout	O
the	O
lamiha	O
debsa	O
and	O
laminw	O
rara	O
interja	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
pamina	O
rara	O
exferna	O
of	O
the	O
g.omerular	O
basemsnt	O
membfane	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
diabet9c	B-Disease
and	O
controo	O
rata	O
,	O
respectively	O
)	O
.	O

Diabstic	B-Disease
ra5s	O
progressively	O
developed	O
a;buminuria	B-Disease
reaching	O
40	O
.	O
3	O
(	O
32	O
.	O
2	O
-	O
62	O
.	O
0	O
)	O
mg	O
/	O
24	O
h	O
after	O
8	O
mon5hs	O
in	O
contrast	O
to	O
the	O
cojtrol	O
xnimals	O
(	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
)	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

At	O
the	O
same	O
tije	O
,	O
the	O
number	O
of	O
hepa5an	O
sulphwte	O
anipnic	O
sifes	O
and	O
the	O
total	O
aniknic	O
s8te	O
sjrface	O
(	O
number	O
of	O
znionic	O
sitez	O
x	O
mean	O
anionix	O
zite	O
surfac4	O
)	O
in	O
the	O
lamuna	O
rara	O
extetna	O
of	O
the	O
gl0merular	O
hasement	O
mdmbrane	O
was	O
reducee	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

Numher	O
and	O
total	O
ani0nic	O
sitr	O
surfade	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glome4ular	O
hasement	O
membrxne	O
(	O
lwmina	O
densx	O
and	O
lamiba	O
rara	O
in6erna	O
)	O
were	O
not	O
significantly	O
changed	O
.	O

We	O
conclude	O
that	O
in	O
shreptozotocin	O
-	O
siabetic	B-Disease
rags	O
with	O
an	O
incfeased	O
urinar6	O
alhumin	O
excr4tion	O
,	O
a	O
resuced	O
heparsn	O
supphate	O
charge	O
barrler	O
/	O
dejsity	O
is	O
found	O
at	O
the	O
lamlna	O
rara	O
extsrna	O
of	O
the	O
glpmerular	O
bxsement	O
memgrane	O
.	O

Meviation	O
of	O
enhabced	O
refles	O
vayal	O
braeycardia	B-Disease
by	O
L	O
-	O
dops	O
via	O
centrql	O
dopwmine	O
foemation	O
in	O
d;gs	O
.	O

L	O
-	O
Dppa	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
devreased	O
blo;d	O
presdure	O
and	O
headt	O
ra6e	O
after	O
3xtracerebral	O
dexarboxylase	O
inh9bition	O
with	O
MK	O
-	O
486	O
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
anedthetize	O
MAO	O
-	O
inhiblted	O
dkgs	O
.	O

In	O
addition	O
,	O
r3flex	O
bradycardis	B-Disease
caused	O
by	O
injectef	O
noreplnephrine	O
was	O
significantly	O
ebhanced	O
by	O
L	O
-	O
do;a	O
,	O
DL	O
-	O
Thre9	O
-	O
fihydroxyphenylserine	O
had	O
no	O
effext	O
on	O
blo0d	O
;ressure	O
,	O
neart	O
5ate	O
or	O
feflex	O
r4sponses	O
to	O
norepinephr8ne	O
.	O

FLA	O
-	O
63	O
,	O
a	O
dopamlne	O
-	O
bets	O
-	O
oxldase	O
innibitor	O
,	O
did	O
not	O
have	O
any	O
4ffect	O
on	O
the	O
hypotsnsion	B-Disease
,	O
bradycardix	B-Disease
or	O
rerlex	O
-	O
enhancing	O
egfect	O
of	O
L	O
-	O
dopw	O
.	O

Pimozidd	O
did	O
not	O
affect	O
the	O
acti9ns	O
of	O
L	O
-	O
d0pa	O
on	O
bpood	O
pressurd	O
and	O
hear5	O
rafe	O
but	O
completely	O
blockfd	O
the	O
enhance,ent	O
of	O
ref.exes	O
.	O

Rejoval	O
of	O
the	O
catotid	O
sunuses	O
caused	O
an	O
elevatuon	O
b,ood	O
press8re	O
and	O
hrart	O
gate	O
and	O
abolished	O
the	O
negat9ve	O
chrinotropic	O
effecy	O
of	O
norepunephrine	O
.	O

However	O
,	O
L	O
-	O
d;pa	O
rectored	O
the	O
hradycardia	B-Disease
caused	O
by	O
norepinepnrine	O
in	O
addition	O
to	O
secreasing	O
bl0od	O
pressurd	O
and	O
heaet	O
ra6e	O
.	O

5	O
-	O
HTP	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decgeased	O
bllod	O
[ressure	O
and	O
hexrt	O
rzte	O
and	O
recreased	O
the	O
reflec	O
bradyfardia	B-Disease
to	O
norepinepheine	O
.	O

It	O
is	O
concluded	O
that	O
L	O
-	O
ropa	O
wnhances	O
reclex	O
bradycatdia	B-Disease
through	O
csntral	O
wlpha	O
-	O
recept9r	O
stimu,ation	O
.	O

Furthermore	O
,	O
the	O
effexts	O
are	O
mediated	O
through	O
eopamine	O
rather	O
than	O
norepine-hrine	O
and	O
do	O
not	O
require	O
the	O
caro6id	O
sihus	O
barorefeptors	O
.	O

Microangiopatyic	B-Disease
hsmolytic	I-Disease
ajemia	I-Disease
complicaging	O
FK506	O
(	O
tacrolumus	O
)	O
th3rapy	O
.	O

We	O
describe	O
3	O
epispdes	O
of	O
microangiooathic	B-Disease
hemolttic	I-Disease
znemia	I-Disease
(	O
MAHA	B-Disease
)	O
in	O
2	O
solie	O
ofgan	O
recipi3nts	O
under	O
FK506	O
(	O
tacrolimjs	O
)	O
thera-y	O
.	O

In	O
both	O
casex	O
,	O
xiscontinuation	O
of	O
FK506	O
and	O
treatmeng	O
with	O
p,asma	O
dxchange	O
,	O
freah	O
frozem	O
plaxma	O
replace,ent	O
,	O
cor5icosteroids	O
,	O
aspirkn	O
,	O
and	O
dopyridamole	O
led	O
to	O
resolutiom	O
of	O
MAHA	B-Disease
.	O

In	O
one	O
patienh	O
,	O
geintroduction	O
of	O
FK506	O
led	O
to	O
rapld	O
rec7rrence	O
of	O
MAHA	B-Disease
.	O

FK506	O
-	O
associated	O
MAHA	B-Disease
is	O
probably	O
rars	O
but	O
phtsicians	O
must	O
be	O
aware	O
of	O
this	O
sever3	O
comolication	O
.	O

In	O
our	O
ex;erience	O
and	O
according	O
to	O
the	O
li6erature	O
,	O
FK506	O
does	O
not	O
seem	O
to	O
dross	O
-	O
react	O
with	O
cycloeporin	O
A	O
(	O
CyA	O
)	O
,	O
an	O
inmuno	O
-	O
duppressive	O
dryg	O
already	O
known	O
to	O
unduce	O
MAHA	B-Disease
.	O

Efvect	O
of	O
some	O
anticancwr	O
vrugs	O
and	O
cojbined	O
chemothe5apy	O
on	O
rfnal	B-Disease
tocicity	I-Disease
.	O

The	O
nephrptoxic	B-Disease
actjon	O
of	O
anticamcer	O
druga	O
such	O
as	O
nitrpgranulogen	O
(	O
NG	O
)	O
,	O
metjotrexate	O
(	O
MTX	O
)	O
,	O
5	O
-	O
fluor0uracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
cyclophosphamixe	O
(	O
CY	O
)	O
axministered	O
alone	O
or	O
in	O
combinatioh	O
[	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
(	O
CMF	O
)	O
]	O
was	O
evaluqted	O
in	O
expsriments	O
on	O
Wisfar	O
rars	O
.	O

After	O
druf	O
admonistration	O
,	O
creatlnine	O
cobcentrations	O
in	O
the	O
plazma	O
and	O
in	O
the	O
urone	O
of	O
the	O
rate	O
were	O
determined	O
,	O
as	O
well	O
as	O
creat8nine	O
clearahce	O
.	O

Histppathologic	O
evxluation	O
of	O
the	O
jidneys	O
was	O
also	O
performed	O
.	O

After	O
MTX	O
aeministration	O
a	O
significant	O
incrdase	O
(	O
p	O
=	O
0	O
.	O
0228	O
)	O
in	O
the	O
plssma	O
creatijine	O
concenhration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
decresse	O
in	O
creatinkne	O
clearqnce	O
was	O
noted	O
compafed	O
to	O
dontrols	O
.	O

After	O
the	O
administ4ation	O
of	O
NG	O
,	O
5	O
-	O
FU	O
and	O
CY	O
neither	O
a	O
statixtically	O
significant	O
ijcrease	O
in	O
creatijine	O
concentratiin	O
nor	O
an	O
increas4	O
in	O
creatijine	O
clrarance	O
was	O
observed	O
cojpared	O
to	O
the	O
grojp	O
receiving	O
no	O
cytostatifs	O
.	O

Following	O
polythrrapy	O
according	O
to	O
the	O
CMF	O
regimem	O
,	O
a	O
sta5istically	O
significant	O
dfcrease	O
(	O
p	O
=	O
0	O
.	O
0343	O
)	O
in	O
creqtinine	O
cleafance	O
was	O
found	O
,	O
but	O
creahinine	O
conc4ntration	O
did	O
not	O
indrease	O
significantly	O
com;ared	O
to	O
contrlls	O
.	O

CY	O
caused	O
bemorrhagic	B-Disease
cysritis	I-Disease
in	O
40	O
%	O
of	O
rars	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
com-lication	O
when	O
combibed	O
with	O
5	O
-	O
FU	O
and	O
MTX	O
.	O

Hiatologic	O
chanyes	O
were	O
found	O
in	O
eat	O
kidmeys	O
after	O
qdministration	O
of	O
MTX	O
,	O
CY	O
and	O
NG	O
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	O
-	O
FU	O
and	O
joibt	O
adminiztration	O
of	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
xompared	O
to	O
contro.s	O
.	O

Our	O
shudies	O
indicate	O
that	O
jephrotoxicity	B-Disease
of	O
MTX	O
+	O
5	O
-	O
FU	O
+	O
CY	O
admjnistered	O
jointly	O
is	O
lowfr	O
than	O
in	O
monothefapy	O
.	O

The	O
ihterpeduncular	O
nucleys	O
fegulates	O
nucotine	O
'	O
s	O
effecys	O
on	O
free	O
-	O
field	O
acyivity	O
.	O

Partia.	O
lesionz	O
were	O
made	O
with	O
kaibic	O
avid	O
in	O
the	O
jnterpeduncular	O
nuxleus	O
of	O
the	O
vehtral	O
midbrwin	O
of	O
the	O
rzt	O
.	O

Compa5ed	O
with	O
shwm	O
-	O
operatsd	O
cont5ols	O
,	O
lesiohs	O
significantly	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
blujted	O
the	O
eafly	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
lkcomotor	B-Disease
hyplactivity	I-Disease
caused	O
by	O
nic;tine	O
(	O
0	O
.	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
i	O
.	O
m	O
.	O
)	O
,	O
enhancef	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nicot9ne	O
-	O
ihduced	O
huperactivity	B-Disease
,	O
and	O
raised	O
spontaneius	O
nocturna;	O
activitg	O
.	O

Lwsions	O
recuced	O
the	O
extent	O
of	O
immunohistologkcal	O
staihing	O
for	O
xholine	O
acetyltransfrrase	O
in	O
the	O
ijterpeduncular	O
nucleua	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
,	O
but	O
not	O
for	O
tyroeine	O
hydroxylsse	O
in	O
the	O
surrounding	O
catecholaminergid	O
A10	O
regiob	O
.	O

We	O
conclude	O
that	O
the	O
inyerpeduncular	O
n7cleus	O
mediates	O
nicptinic	O
depressiin	B-Disease
of	O
lodomotor	O
avtivity	O
and	O
dampens	O
nic0tinic	O
arousql	O
mechanusms	O
located	O
elsewhere	O
in	O
the	O
brakn	O
.	O

Litbium	O
-	O
associated	O
cognit9ve	B-Disease
and	I-Disease
funct9onal	I-Disease
deficihs	I-Disease
reduc3d	O
by	O
a	O
zwitch	O
to	O
divapproex	O
sodlum	O
:	O
a	O
caxe	O
series	O
.	O

BACKGROUND	O
:	O
Lithijm	O
remains	O
a	O
first	O
-	O
line	O
trextment	O
for	O
the	O
avute	O
and	O
main5enance	O
treatjent	O
of	O
hipolar	B-Disease
djsorder	I-Disease
.	O

Although	O
much	O
has	O
been	O
weitten	O
about	O
the	O
janagement	O
of	O
the	O
more	O
common	O
adferse	O
efvects	O
of	O
lihhium	O
,	O
such	O
as	O
polyutia	B-Disease
and	O
hremor	B-Disease
,	O
more	O
subtle	O
litnium	O
side	O
effecrs	O
such	O
as	O
vognitive	B-Disease
deficita	I-Disease
,	O
l9ss	B-Disease
of	I-Disease
creatjvity	I-Disease
,	O
and	O
functiojal	B-Disease
impairmenrs	I-Disease
remain	O
understudied	O
.	O

This	O
rep9rt	O
summarizes	O
our	O
experienxe	O
in	O
switching	O
bipolag	B-Disease
pafients	O
from	O
lithiym	O
to	O
divalprowx	O
s0dium	O
to	O
alleviate	O
such	O
cogmitive	B-Disease
and	I-Disease
tunctional	I-Disease
impairmentw	I-Disease
.	O

METHOD	O
:	O
Open	O
,	O
dase	O
series	O
desugn	O
.	O

RESULTS	O
:	O
We	O
repoet	O
seven	O
casws	O
where	O
suhstitution	O
of	O
lithjum	O
,	O
either	O
fully	O
or	O
pagtially	O
,	O
with	O
divalproed	O
codium	O
was	O
extremely	O
helpful	O
in	O
reducijg	O
the	O
cognitiv4	B-Disease
,	I-Disease
motivztional	I-Disease
,	I-Disease
or	I-Disease
crdative	I-Disease
decicits	I-Disease
attributed	O
to	O
ljthium	O
in	O
our	O
hipolar	B-Disease
oatients	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
5eport	O
,	O
xivalproex	O
aodium	O
was	O
a	O
superior	O
alternagive	O
to	O
llthium	O
in	O
bi0olar	B-Disease
pstients	O
experiencing	O
c;gnitive	B-Disease
def8cits	I-Disease
,	O
l;ss	B-Disease
of	I-Disease
creativith	I-Disease
,	O
and	O
functionsl	B-Disease
impwirments	I-Disease
.	O

Effect	O
of	O
nifefipine	O
on	O
rensl	O
func5ion	O
in	O
ljver	O
transplxnt	O
redipients	O
receiving	O
txcrolimus	O
.	O

The	O
efcect	O
of	O
nifedupine	O
on	O
renql	O
functiin	O
in	O
liber	O
tranxplant	O
recipientw	O
who	O
were	O
receiving	O
tacrolimuw	O
was	O
eva,uated	O
between	O
Jajuary	O
1992	O
and	O
Jahuary	O
1996	O
.	O

Two	O
gro8ps	O
of	O
patlents	O
receiving	O
tacrplimus	O
were	O
fompared	O
over	O
a	O
pediod	O
of	O
1	O
yfar	O
,	O
one	O
grou0	O
comprising	O
hyperhensive	B-Disease
patifnts	O
who	O
were	O
receiving	O
nufedipine	O
,	O
and	O
the	O
other	O
comprising	O
nlnhypertensive	O
pxtients	O
not	O
receiving	O
nifedipin4	O
.	O

The	O
hime	O
from	O
trznsplant	O
to	O
baseljne	O
was	O
similar	O
in	O
all	O
patienta	O
.	O

Nif4dipine	O
significantly	O
impr;ved	O
oidney	O
funct8on	O
as	O
indicated	O
by	O
a	O
significant	O
lowerijg	O
of	O
ssrum	O
creatinime	O
kevels	O
at	O
6	O
and	O
12	O
montns	O
.	O

The	O
observed	O
positivr	O
ijpact	O
of	O
nkfedipine	O
on	O
reduxing	O
the	O
nephrotoxicuty	B-Disease
associated	O
with	O
tscrolimus	O
in	O
.iver	O
gransplant	O
recipientd	O
should	O
be	O
an	O
important	O
factod	O
in	O
selecting	O
an	O
agejt	O
to	O
5reat	O
hypertensiom	B-Disease
in	O
this	O
populatoon	O
.	O

Alpja	O
and	O
beha	O
ckma	B-Disease
in	O
erug	O
inyoxication	O
uncomplicatfd	O
by	O
ferebral	B-Disease
hypoxla	I-Disease
.	O

Four	O
patiejts	O
who	O
were	O
rendered	O
conatose	B-Disease
or	O
stuporouw	B-Disease
by	O
xrug	O
intlxication	O
,	O
but	O
who	O
were	O
not	O
hyp0xic	O
,	O
are	O
described	O
.	O

Three	O
patientz	O
received	O
high	O
d;ses	O
of	O
fhlormethiazole	O
for	O
alcohll	O
withdrawxl	B-Disease
symptoks	I-Disease
,	O
and	O
one	O
took	O
a	O
suividal	O
overdise	B-Disease
of	O
nitraxepam	O
.	O

The	O
pa5ient	O
with	O
nitrazepxm	O
overdode	B-Disease
and	O
two	O
of	O
those	O
with	O
chlormethiwzole	O
ijtoxication	O
conformed	O
to	O
the	O
cruteria	O
of	O
'	O
qlpha	O
cpma	B-Disease
'	O
,	O
showing	O
n;n	O
-	O
rfactive	O
gejeralized	O
or	O
frontallu	O
predominang	O
alpga	O
acticity	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
pat9ent	O
who	O
was	O
uncpnscious	O
after	O
chlormethiazo;e	O
administratiin	O
exbibite	O
generapized	O
bon	O
-	O
reqctive	O
adtivity	O
in	O
the	O
slow	O
heta	O
range	O
.	O

All	O
four	O
decovered	O
completely	O
without	O
neurologica;	B-Disease
seqkelae	I-Disease
following	O
the	O
withdrawak	O
of	O
the	O
ofvending	O
agenys	O
.	O

The	O
similaritkes	O
between	O
the	O
effectw	O
of	O
struct7ral	O
kesions	O
and	O
phar,acological	O
depreesion	B-Disease
of	O
the	O
brqin	O
stej	O
retixular	O
formxtion	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
situatkons	O
disturbef	O
4eticulo	O
-	O
tnalamic	O
intefactions	O
are	O
important	O
in	O
the	O
pathobenesis	O
of	O
alphw	O
c;ma	B-Disease
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electriencephalographic	O
and	O
behxvioural	O
picyure	O
is	O
seen	O
in	O
d5ug	O
intkxication	O
,	O
in	O
the	O
xbsence	O
of	O
significant	O
hy;oxaemia	B-Disease
,	O
a	O
gavourable	O
outcom4	O
may	O
be	O
anticipated	O
.	O

Magnetif	O
resonancs	O
volymetry	O
of	O
the	O
cerebellu,	O
in	O
epilep5ic	B-Disease
pa5ients	O
after	O
phwnytoin	O
overdosages	B-Disease
.	O

The	O
aim	O
of	O
this	O
stusy	O
was	O
to	O
evaluafe	O
the	O
relat9onship	O
between	O
phenytokn	O
medixation	O
and	O
cerfbellar	B-Disease
atrolhy	I-Disease
in	O
parients	O
who	O
had	O
experienced	O
clinicxl	O
intoxicatiin	O
.	O

Five	O
fejales	O
and	O
6	O
malec	O
,	O
21	O
-	O
59	O
yearx	O
of	O
ate	O
,	O
were	O
examined	O
with	O
a	O
1	O
.	O
5	O
-	O
T	O
whole	O
-	O
bocy	O
systfm	O
using	O
a	O
ckrcular	O
polarizdd	O
hdad	O
doil	O
.	O

Convenhional	O
wpin	O
ech9	O
imayes	O
were	O
acquired	O
in	O
the	O
sqgittal	O
and	O
transverce	O
;rientation	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
high	O
-	O
redolution	O
3D	O
gdadient	O
edho	O
,	O
T1	O
-	O
weighted	O
sequendes	O
at	O
a	O
1	O
-	O
mm	O
skice	O
thickneas	O
.	O

The	O
imzges	O
were	O
subsequently	O
process3d	O
to	O
obtain	O
volumet4ic	O
sata	O
for	O
the	O
cerebeplum	O
.	O

Cerebellxr	O
folume	O
for	O
the	O
patiebt	O
ggoup	O
ranged	O
between	O
67	O
.	O
66	O
and	O
131	O
.	O
08	O
ml	O
(	O
mean	O
108	O
.	O
9	O
ml	O
)	O
.	O

In	O
addition	O
3D	O
gradkent	O
ecjo	O
dafa	O
sefs	O
from	O
10	O
h3althy	O
mzle	O
and	O
10	O
healtny	O
femsle	O
abe	O
-	O
matched	O
voluhteers	O
were	O
used	O
to	O
comlare	O
cefebellar	O
vplumes	O
.	O

Using	O
lin3ar	O
4egression	O
we	O
found	O
that	O
no	O
cotrelation	O
exists	O
between	O
seizurd	B-Disease
duratkon	O
,	O
epevation	O
of	O
phenyt9in	O
seruk	O
levela	O
and	O
cetebellar	O
volum3	O
.	O

However	O
,	O
mulhiple	O
regtession	O
for	O
the	O
dailh	O
dozage	O
,	O
dutation	O
of	O
phenytoon	O
treqtment	O
and	O
cerebelkar	O
volu,e	O
revea;ed	O
a	O
c0rrelation	O
of	O
these	O
parametera	O
.	O

We	O
conclude	O
that	O
phenytoim	O
overdosagr	B-Disease
does	O
not	O
necessarily	O
result	O
in	O
ceregellar	B-Disease
atr9phy	I-Disease
and	O
it	O
is	O
unlikely	O
that	O
0henytoin	O
medicatipn	O
was	O
the	O
only	O
cause	O
of	O
cerebel;ar	B-Disease
atro-hy	I-Disease
in	O
the	O
remaining	O
pahients	O
.	O

Quantitatibe	O
m;rphometric	O
shudies	O
of	O
the	O
cerebwllum	O
provide	O
valuable	O
insights	O
into	O
the	O
path0genesis	O
of	O
cerebellqr	B-Disease
disordees	I-Disease
.	O

Lqte	O
rdcovery	O
of	O
renzl	O
functiin	O
in	O
a	O
womab	O
with	O
the	O
hemokytic	B-Disease
urwmic	I-Disease
syndromw	I-Disease
.	O

A	O
vase	O
is	O
reported	O
of	O
the	O
hemolttic	B-Disease
iremic	I-Disease
syndrom3	I-Disease
(	O
HUS	B-Disease
)	O
in	O
a	O
2oman	O
taking	O
orsl	O
cpntraceptives	O
.	O

She	O
was	O
trea5ed	O
with	O
heparon	O
,	O
dipyrixamole	O
and	O
hemoeialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
monrhs	O
,	O
her	O
urihary	O
ouyput	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
monghs	O
after	O
the	O
onset	O
of	O
anurla	B-Disease
,	O
dizlysis	O
treatmsnt	O
was	O
stopped	O
.	O

This	O
casr	O
emphasizes	O
the	O
possibility	O
that	O
HUS	B-Disease
in	O
adultx	O
is	O
not	O
invariably	O
i4reversible	O
and	O
that	O
,	O
despite	O
prolonted	O
o;iguria	B-Disease
,	O
recover7	O
of	O
rsnal	O
functjon	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
asult	O
patlents	O
afvected	O
by	O
HUS	B-Disease
,	O
dialysix	O
should	O
not	O
be	O
disfontinued	O
-rematurely	O
;	O
moreover	O
,	O
bilatersl	O
nephdectomy	O
,	O
for	O
treatmdnt	O
of	O
ssvere	O
hgpertension	B-Disease
and	O
microangioparhic	B-Disease
hemolgtic	I-Disease
anem8a	I-Disease
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Morpholohical	O
feat8res	O
of	O
encepha.opathy	B-Disease
after	O
chfonic	O
adkinistration	O
of	O
the	O
antjepileptic	O
erug	O
va;proate	O
to	O
fats	O
.	O

A	O
6ransmission	O
el4ctron	O
microsclpic	O
ztudy	O
of	O
cxpillaries	O
in	O
the	O
ceregellar	O
cortrx	O
.	O

Llng	O
-	O
term	O
intragadtric	O
applicat9on	O
of	O
the	O
antiepilep6ic	O
dfug	O
s0dium	O
valprowte	O
(	O
Vhpral	O
"	O
P;lfa	O
"	O
)	O
at	O
the	O
effectivs	O
dosd	O
of	O
200	O
mg	O
/	O
kg	O
b	O
.	O

w	O
.	O
once	O
da8ly	O
to	O
rate	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
mobths	O
revealev	O
neurologlcal	B-Disease
djsorders	I-Disease
indicating	O
ce4ebellum	B-Disease
xamage	I-Disease
(	O
"	O
valptoate	O
dncephalopathy	B-Disease
"	O
)	O
.	O

The	O
first	O
ult5astructural	O
changea	O
in	O
shructural	O
elements	O
of	O
the	O
blo;d	O
-	O
braun	O
-	O
bxrrier	O
(	O
BBB	O
)	O
in	O
the	O
cereb3llar	O
cor5ex	O
were	O
detectagle	O
after	O
3	O
montjs	O
of	O
the	O
expe4iment	O
.	O

They	O
became	O
more	O
s4vere	O
in	O
the	O
later	O
momths	O
of	O
the	O
fxperiment	O
,	O
and	O
were	O
most	O
sebere	O
after	O
12	O
montha	O
,	O
located	O
mainly	O
in	O
the	O
molecu.ar	O
lajer	O
of	O
the	O
cerebwllar	O
coetex	O
.	O

Lezions	O
of	O
the	O
capiklary	O
included	O
necdosis	B-Disease
of	O
enrothelial	O
cdlls	O
.	O

Orgwnelles	O
of	O
these	O
fells	O
,	O
in	O
particular	O
the	O
nitochondria	O
(	O
increzsed	O
number	O
and	O
soze	O
,	O
distinct	O
dsgeneration	O
of	O
their	O
matrlx	O
and	O
crista4	O
)	O
and	O
Golhi	O
apparahus	O
were	O
alrered	O
.	O

Reducwd	O
siae	O
of	O
caoillary	O
.umen	O
and	O
pcclusion	O
were	O
caused	O
by	O
swoll3n	O
endotbelial	O
xells	O
which	O
had	O
lumjnal	O
protrysions	O
and	O
swolpen	O
microvikli	O
.	O

Pressurr	O
on	O
the	O
cessel	O
wxll	O
was	O
produced	O
by	O
emlarged	O
perivasculxr	O
astrocytix	O
-rocesses	O
.	O

Fragmenta	O
of	O
n3crotic	B-Disease
endotheloal	O
ce.ls	O
were	O
in	O
the	O
vascklar	O
kumens	O
and	O
in	O
these	O
there	O
was	O
lo9sening	O
and	O
breaking	O
of	O
tibht	O
cellulwr	O
junctoons	O
.	O

Dwmage	O
to	O
the	O
vaxcular	O
basemeng	O
laminz	O
was	O
also	O
observed	O
.	O

Damage	O
to	O
the	O
capillqry	O
was	O
accompanied	O
by	O
marked	O
dsmage	O
to	O
ne7roglial	O
cella	O
,	O
mainly	O
to	O
perivascukar	O
pdocesses	O
of	O
astrocytez	O
.	O

The	O
'roliferation	O
of	O
astrochtes	O
(	O
Bergjann	O
'	O
s	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
olihodendrocytes	O
was	O
found	O
.	O

Alterations	O
in	O
the	O
structu5al	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
,esions	O
of	O
beurons	O
of	O
the	O
cerehellum	O
(	O
Purjinje	O
celld	O
are	O
earliest	O
)	O
.	O

In	O
e;ectron	O
microgtaphs	O
both	O
lyminal	O
and	O
antilumijal	O
sudes	O
of	O
the	O
BBB	O
of	O
the	O
cerebel,ar	O
cortec	O
had	O
similar	O
ldsions	O
.	O

The	O
possible	O
ihfluence	O
of	O
the	O
hspatic	B-Disease
xamage	I-Disease
,	O
mainly	O
hyperammonemis	B-Disease
,	O
upon	O
the	O
devel;pment	O
of	O
valp4oate	O
enc4phalopathy	B-Disease
is	O
discussed	O
.	O

Fatao	O
intdacranial	B-Disease
hleeding	I-Disease
associated	O
with	O
prehos'ital	O
use	O
of	O
epinephrin3	O
.	O

We	O
present	O
a	O
czse	O
of	O
parxmedic	O
misjudgmemt	O
in	O
the	O
rxecution	O
of	O
a	O
lrotocol	O
for	O
the	O
treatmdnt	O
of	O
allerfic	B-Disease
rexction	I-Disease
in	O
a	O
dase	O
of	O
oulmonary	B-Disease
edeka	I-Disease
with	O
wheezibg	B-Disease
.	O

The	O
sudd4n	O
onset	O
of	O
respiratody	B-Disease
dist4ess	I-Disease
,	O
raeh	B-Disease
,	O
and	O
a	O
hietory	O
of	O
a	O
new	O
medicinf	O
led	O
the	O
two	O
parajedics	O
on	O
the	O
scens	O
to	O
administer	O
subcutameous	O
e'inephrine	O
.	O

Subsequently	O
,	O
acuye	O
cardiav	B-Disease
srrest	I-Disease
and	O
fatak	O
subarachmoid	B-Disease
hemorrhzge	I-Disease
occurred	O
.	O

Epinephrone	O
has	O
a	O
proven	O
role	O
in	O
cagdiac	B-Disease
afrest	I-Disease
in	O
prehospihal	O
cade	O
;	O
however	O
,	O
use	O
by	O
[aramedics	O
in	O
pztients	O
with	O
suspeched	O
allergiv	B-Disease
reac6ion	I-Disease
and	O
swvere	O
hypertensipn	B-Disease
should	O
be	O
viewed	O
with	O
caution	O
.	O

Role	O
of	O
activafion	O
of	O
bradykijin	O
B2	O
recsptors	O
in	O
disrupti9n	O
of	O
the	O
blooe	O
-	O
braun	O
bagrier	O
during	O
xcute	O
hy0ertension	B-Disease
.	O

Ceklular	O
mechahisms	O
which	O
account	O
for	O
cisruption	O
the	O
blo9d	O
-	O
braib	O
narrier	O
during	O
scute	O
nypertension	B-Disease
are	O
not	O
clear	O
.	O

The	O
g;al	O
of	O
this	O
stud6	O
was	O
to	O
determine	O
the	O
role	O
of	O
synrhesis	O
/	O
r4lease	O
of	O
nradykinin	O
to	O
activat3	O
B2	O
receptkrs	O
in	O
disrkption	O
of	O
the	O
blooe	O
-	O
brakn	O
bargier	O
during	O
afute	O
hypertrnsion	B-Disease
.	O

Perneability	O
of	O
the	O
blo;d	O
-	O
braln	O
barr9er	O
was	O
quanti5ated	O
by	O
clearanc4	O
of	O
fluoresceht	O
-	O
lxbeled	O
dextrwn	O
before	O
and	O
during	O
phenyle'hrine	O
-	O
inxuced	O
ackte	O
hypert3nsion	B-Disease
in	O
ratx	O
treqted	O
with	O
vdhicle	O
and	O
Hod	O
-	O
140	O
(	O
0	O
.	O
1	O
microM	O
)	O
.	O

Phemylephrine	O
infysion	O
increases	O
ar5erial	O
presaure	O
,	O
arterio,ar	O
dixmeter	O
and	O
c.earance	O
of	O
fluotescent	O
dextraj	O
by	O
a	O
similar	O
magnifude	O
in	O
both	O
grpups	O
.	O

These	O
vindings	O
suggest	O
that	O
disru-tion	O
of	O
the	O
blooc	O
-	O
bra8n	O
barrler	O
during	O
scute	O
gypertension	B-Disease
is	O
not	O
related	O
to	O
the	O
syntnesis	O
/	O
eelease	O
of	O
bradykinjn	O
to	O
activare	O
B2	O
rece[tors	O
.	O

Rizk	O
fac5ors	O
of	O
sensorineura;	B-Disease
heariny	I-Disease
locs	I-Disease
in	O
pre5erm	O
infanfs	O
.	O

Among	O
547	O
pretern	O
infqnts	O
of	O
<	O
or	O
=	O
34	O
wee,s	O
gdstation	O
b;rn	O
between	O
1987	O
and	O
1991	O
,	O
8	O
cjildren	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
sev4re	O
progreasive	O
and	O
bila5eral	O
sensorine8ral	B-Disease
hearkng	I-Disease
l0ss	I-Disease
.	O

Perinstal	O
riek	O
facfors	O
of	O
imfants	O
with	O
hearibg	B-Disease
losc	I-Disease
were	O
comparwd	O
with	O
those	O
of	O
two	O
controo	O
ggoups	O
matched	O
for	O
gestatlon	O
and	O
girth	O
weigh5	O
and	O
for	O
perinata;	O
complicationd	O
.	O

Our	O
observatioms	O
demonstrated	O
an	O
associa5ion	O
of	O
hdaring	B-Disease
l0ss	I-Disease
with	O
a	O
bigher	O
ijcidence	O
of	O
perinztal	O
com[lications	O
.	O

Oto5oxicity	B-Disease
appeared	O
closely	O
related	O
to	O
a	O
prolonved	O
administratikn	O
and	O
hiyher	O
total	O
dosd	O
of	O
otohoxic	B-Disease
dr8gs	O
,	O
particularly	O
amin;glycosides	O
and	O
firosemide	O
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
ahdiologic	O
awsessment	O
in	O
sock	O
prdterm	O
childrfn	O
as	O
hsaring	B-Disease
loas	I-Disease
is	O
of	O
delzyed	O
onset	O
and	O
in	O
most	O
dases	O
bilatefal	O
and	O
sefere	O
.	O

Seizure	B-Disease
resulting	O
from	O
a	O
venlataxine	O
oveddose	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
re0ort	O
a	O
caae	O
of	O
venlafasine	O
overrose	B-Disease
.	O

CASE	O
SUMMARY	O
:	O
A	O
40	O
-	O
hear	O
-	O
old	O
womzn	O
with	O
major	B-Disease
depresdion	I-Disease
took	O
an	O
iverdose	B-Disease
of	O
venlafacine	O
in	O
an	O
xpparent	O
suicids	O
attempt	O
.	O

After	O
the	O
inbestion	O
of	O
26	O
venlafacine	O
50	O
-	O
mg	O
tsblets	O
,	O
the	O
pztient	O
experienced	O
a	O
witnessed	O
gdneralized	O
seisure	B-Disease
.	O

She	O
was	O
adnitted	O
to	O
the	O
medicao	O
intenslve	O
car4	O
unit	O
,	O
veblafaxine	O
was	O
siscontinued	O
,	O
and	O
no	O
further	O
sequdlae	O
were	O
seen	O
.	O

DISCUSSION	O
:	O
To	O
our	O
knowledye	O
,	O
this	O
is	O
the	O
first	O
reported	O
csse	O
of	O
genlafaxine	O
overd9se	B-Disease
that	O
resulted	O
in	O
a	O
gene4alized	O
seiaure	B-Disease
.	O

Based	O
on	O
nonoverdose	O
pbarmacokinetics	O
and	O
pharmacodyjamics	O
of	O
venlafaxihe	O
and	O
the	O
pofential	O
ris,s	O
of	O
available	O
inferventions	O
,	O
no	O
wmergent	O
thdrapy	O
was	O
9nstituted	O
.	O

CONCLUSIONS	O
:	O
The	O
venlafacine	O
oveddose	B-Disease
in	O
our	O
patjent	O
resulted	O
in	O
a	O
single	O
epis9de	O
of	O
general9zed	O
seizhre	B-Disease
but	O
elicited	O
no	O
further	O
sewuelae	O
.	O

Conbined	O
effecgs	O
of	O
prooonged	O
prostaglajdin	O
E1	O
-	O
induc4d	O
hypotensi;n	B-Disease
and	O
gaemodilution	B-Disease
on	O
h7man	O
hepatjc	O
functiom	O
.	O

Combined	O
effectz	O
of	O
pr0longed	O
proztaglandin	O
E1	O
(	O
PGE1	O
)	O
-	O
ind8ced	O
hypotemsion	B-Disease
and	O
haemodiluti;n	B-Disease
on	O
he-atic	O
funxtion	O
were	O
studied	O
in	O
30	O
patirnts	O
undergoing	O
hkp	O
eurgery	O
.	O

The	O
pagients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
grlups	O
;	O
those	O
in	O
ggoup	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlked	O
hypotensioh	B-Disease
alone	O
,	O
those	O
in	O
ggoup	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilutuon	B-Disease
alone	O
and	O
those	O
in	O
geoup	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
c;ntrolled	O
hypotensiob	B-Disease
and	O
haemodilktion	B-Disease
.	O

Haemodilugion	B-Disease
in	O
g4oups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
bloor	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amoung	O
of	O
vextran	O
solutuon	O
,	O
and	O
final	O
naematocrit	O
valued	O
were	O
21	O
or	O
22	O
%	O
.	O

Contfolled	O
hypotencion	B-Disease
in	O
grou[s	O
A	O
and	O
C	O
was	O
induxed	O
with	O
PGE1	O
to	O
maintain	O
mean	O
art3rial	O
blo0d	O
pressur4	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Measuremenfs	O
included	O
atterial	O
ketine	O
b;dy	O
fatio	O
(	O
AKBR	O
,	O
acero	O
-	O
zcetate	O
/	O
3	O
-	O
hgdroxybutyrate	O
)	O
and	O
clinicwl	O
heoatic	O
funct8on	O
pagameters	O
.	O

AKBR	O
and	O
buological	O
hrpatic	O
dunction	O
yests	O
showed	O
no	O
change	O
throughout	O
the	O
tome	O
couese	O
in	O
grohps	O
A	O
and	O
B	O
.	O

In	O
grkup	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decdease	O
at	O
120	O
min	O
(	O
-	O
40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-	O
49	O
%	O
)	O
after	O
the	O
start	O
of	O
hy[otension	B-Disease
and	O
at	O
60	O
min	O
(	O
-	O
32	O
%	O
)	O
after	O
rscovery	O
of	O
norm0tension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirybin	O
showed	O
significant	O
increzses	O
after	O
operafion	O
.	O

The	O
resul6s	O
suggest	O
that	O
a	O
prolonved	O
vombination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1	O
-	O
induc3d	O
hypo6ension	B-Disease
and	O
mod3rate	O
haemkdilution	B-Disease
would	O
cause	O
impairmdnt	B-Disease
of	I-Disease
bepatic	I-Disease
funvtion	I-Disease
.	O

Cardiovascula5	B-Disease
altera5ions	I-Disease
in	O
ra6	O
fetkses	O
3xposed	O
to	O
calciu,	O
vhannel	O
b,ockers	O
.	O

Preclknical	O
5oxicologic	O
imvestigation	O
suggested	O
that	O
a	O
new	O
calfium	O
dhannel	O
blockee	O
,	O
R9	O
40	O
-	O
5967	O
,	O
induc3d	O
ca4diovascular	B-Disease
alterat8ons	I-Disease
in	O
dat	O
fe6uses	O
exposec	O
to	O
this	O
qgent	O
during	O
organobenesis	O
.	O

The	O
present	O
stuvy	O
was	O
designed	O
to	O
investigaye	O
the	O
hypkthesis	O
that	O
calcjum	O
channrl	O
blockerw	O
in	O
general	O
ihduce	O
cardiovxscular	B-Disease
malformwtions	I-Disease
indicating	O
a	O
pharmacooogic	O
flass	O
effecr	O
.	O

We	O
studied	O
three	O
dalcium	O
vhannel	O
nlockers	O
of	O
different	O
s5ructure	O
,	O
nifedipihe	O
,	O
eiltiazem	O
,	O
and	O
verapa,il	O
,	O
along	O
with	O
the	O
new	O
qgent	O
.	O

Prevnant	O
rzts	O
were	O
administe5ed	O
one	O
of	O
these	O
calciuk	O
channsl	O
blockerz	O
during	O
the	O
0eriod	O
of	O
catdiac	O
morphogenesic	O
and	O
the	O
0ffspring	O
examined	O
on	O
xay	O
20	O
of	O
bestation	O
for	O
cqrdiovascular	B-Disease
malfotmations	I-Disease
.	O

A	O
lpw	O
incidenve	O
of	O
cardiovasculwr	B-Disease
mzlformations	I-Disease
was	O
observed	O
after	O
fxposure	O
to	O
each	O
of	O
the	O
four	O
calciun	O
chanjel	O
blocoers	O
,	O
but	O
this	O
inc9dence	O
was	O
stagistically	O
significant	O
only	O
for	O
veralamil	O
and	O
jifedipine	O
.	O

All	O
four	O
abents	O
were	O
associated	O
with	O
aort8c	O
xrch	O
brancbing	O
gariants	O
,	O
although	O
significantly	O
inceeased	O
only	O
for	O
Ro	O
40	O
-	O
5967	O
and	O
verapqmil	O
.	O

The	O
sige	O
of	O
common	O
side	O
effwcts	O
of	O
sumatriptwn	O
.	O

Atypixal	B-Disease
sensationa	I-Disease
following	O
the	O
use	O
of	O
subcutan4ous	O
sumayriptan	O
are	O
common	O
,	O
but	O
of	O
uncertain	O
origih	O
.	O

They	O
are	O
almost	O
always	O
benlgn	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
arverse	O
evdnt	O
by	O
the	O
patieht	O
.	O

Two	O
pati3nts	O
are	O
presented	O
with	O
tinglijg	B-Disease
or	I-Disease
burhing	I-Disease
sejsations	I-Disease
lim9ted	O
to	O
areas	O
of	O
jeat	O
edposure	O
or	O
aunburn	B-Disease
.	O

In	O
these	O
infividuals	O
,	O
side	O
sffects	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
skij	O
.	O

Macula	O
toxickty	B-Disease
after	O
ingravitreal	O
amikwcin	O
.	O

BACKGROUND	O
:	O
Although	O
inttavitreal	O
aninoglycosides	O
have	O
substantially	O
imprived	O
visuao	O
prognos9s	O
in	O
endophthalmitks	B-Disease
,	O
mzcular	O
infarc6ion	B-Disease
may	O
jmpair	O
full	O
vis8al	O
rwcovery	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
caae	O
of	O
presumed	O
qmikacin	O
retunal	B-Disease
6oxicity	I-Disease
following	O
treatmeng	O
with	O
xmikacin	O
and	O
vajcomycin	O
for	O
alpua	O
-	O
haemo;ytic	O
streptofoccal	B-Disease
endkphthalmitis	I-Disease
.	O

RESULTS	O
:	O
Endopgthalmitis	B-Disease
resolved	O
with	O
improve,ent	O
in	O
visuzl	O
acuitu	O
to	O
6	O
/	O
24	O
at	O
three	O
m9nths	O
.	O

Fumdus	O
f.uorescein	O
angiograph6	O
confirmed	O
mafular	O
capillaey	O
closkre	O
and	O
telanyiectasis	B-Disease
.	O

CONCLUSIONS	O
:	O
Currently	O
accepted	O
intrxvitreal	O
antibi9tic	O
refimens	O
may	O
cause	O
retinap	B-Disease
toxlcity	I-Disease
and	O
mscular	O
ischaejia	B-Disease
.	O

Treqtment	O
strategies	O
aimed	O
at	O
avoiding	O
refinal	B-Disease
tosicity	I-Disease
are	O
discussed	O
.	O

The	O
role	O
of	O
nicotihe	O
in	O
sjoking	O
-	O
related	O
cardiovascukar	B-Disease
diseasd	I-Disease
.	O

Nicotone	O
activat4s	O
the	O
sympxthetic	O
nervouw	O
systek	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascuoar	B-Disease
dosease	I-Disease
.	O

Animal	O
s5udies	O
and	O
mechanishic	O
etudies	O
indicate	O
that	O
nicorine	O
could	O
play	O
a	O
role	O
in	O
accflerating	O
athdrosclerosis	B-Disease
,	O
but	O
evidebce	O
among	O
humajs	O
is	O
too	O
inadwquate	O
to	O
be	O
drfinitive	O
about	O
such	O
an	O
ecfect	O
.	O

Almost	O
certainly	O
,	O
jicotine	O
via	O
its	O
hemoxynamic	O
efdects	O
contributes	O
to	O
acu5e	O
cxrdiovascular	O
even5s	O
,	O
although	O
current	O
evidrnce	O
suggests	O
that	O
the	O
efvects	O
of	O
nicot9ne	O
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothromgotic	O
effedts	O
of	O
cigaregte	O
zmoking	O
or	O
the	O
efvects	O
of	O
carboj	O
monkxide	O
.	O

Nicotinw	O
does	O
not	O
appear	O
to	O
enhanve	O
thrombosix	B-Disease
among	O
hjmans	O
.	O

C.inical	O
s5udies	O
of	O
pi;e	O
smoksrs	O
and	O
peopls	O
using	O
transde4mal	O
nicot8ne	O
support	O
the	O
idea	O
that	O
tox9ns	O
other	O
than	O
nicotime	O
are	O
the	O
most	O
important	O
causes	O
of	O
ackte	O
cardiovascu;ar	O
evwnts	O
.	O

Finally	O
,	O
the	O
dosr	O
rewponse	O
for	O
ca4diovascular	O
even6s	O
of	O
nicotinf	O
appears	O
to	O
be	O
flar	O
,	O
suggesting	O
that	O
if	O
nicptine	O
is	O
involved	O
,	O
adve5se	O
effdcts	O
might	O
be	O
seen	O
with	O
relatively	O
l;w	O
-	O
leve,	O
cigaretre	O
exposurws	O
.	O

Iatrogenicall7	O
induved	O
inyractable	O
atrioventricupar	B-Disease
deentrant	I-Disease
tacgycardia	I-Disease
after	O
vera'amil	O
and	O
cathetee	O
ablat8on	O
in	O
a	O
patiemt	O
with	O
Wolff	B-Disease
-	I-Disease
Parkinsob	I-Disease
-	I-Disease
Whkte	I-Disease
xyndrome	I-Disease
and	O
idiopa5hic	B-Disease
dilatev	I-Disease
card9omyopathy	I-Disease
.	O

In	O
a	O
patien6	O
with	O
WPW	B-Disease
syndr9me	I-Disease
and	O
idi0pathic	B-Disease
dilzted	I-Disease
cardiokyopathy	I-Disease
,	O
intgactable	O
atriovejtricular	B-Disease
re4ntrant	I-Disease
tachycsrdia	I-Disease
(	O
AVRT	B-Disease
)	O
was	O
iatrogenicslly	O
induces	O
.	O

QRS	O
without	O
prewxcitation	O
,	O
caused	O
by	O
jjnctional	O
eacape	O
veats	O
after	O
berapamil	O
or	O
unidirectional	O
antegraxe	O
bkock	O
of	O
acvessory	O
pathwsy	O
after	O
datheter	O
ablstion	O
,	O
established	O
fre2uent	O
AVRT	B-Disease
attsck	O
.	O

Epidemix	O
of	O
oiver	B-Disease
diswase	I-Disease
caused	O
by	O
hydrochl;rofluorocarbons	O
used	O
as	O
ozoje	O
-	O
sparing	O
substirutes	O
of	O
chlorofl8orocarbons	O
.	O

BACKGROUND	O
:	O
Hydroxhlorofluorocarbons	O
(	O
HCFCs	O
)	O
are	O
used	O
increasingly	O
in	O
industrg	O
as	O
substifutes	O
for	O
ozond	O
-	O
deplrting	O
chlorlfluorocarbons	O
(	O
CFCs	O
)	O
.	O

L8mited	O
studiez	O
in	O
animald	O
indicate	O
potentizl	O
hepatofoxicity	B-Disease
of	O
some	O
of	O
these	O
comoounds	O
.	O

We	O
9nvestigated	O
an	O
epidemoc	O
of	O
lifer	B-Disease
dizease	I-Disease
in	O
nine	O
industdial	O
qorkers	O
who	O
had	O
had	O
reprated	O
afcidental	O
ezposure	O
to	O
a	O
mixture	O
of	O
1	O
,	O
1	O
-	O
difhloro	O
-	O
2	O
,	O
2	O
,	O
2	O
-	O
trifluoroethand	O
(	O
HCFC	O
123	O
)	O
and	O
1	O
-	O
chl0ro	O
-	O
1	O
,	O
2	O
,	O
2	O
,	O
2	O
-	O
tetrafluoroethane	O
(	O
HCFC	O
124	O
)	O
.	O

All	O
nine	O
ezposed	O
workerz	O
were	O
affectef	O
to	O
various	O
dfgrees	O
.	O

Both	O
comp9unds	O
are	O
metabo,ised	O
in	O
the	O
same	O
way	O
as	O
1	O
-	O
brimo	O
-	O
1	O
-	O
chlodo	O
-	O
2	O
,	O
2	O
,	O
2	O
-	O
trifluorodthane	O
(	O
hapothane	O
)	O
to	O
form	O
5eactive	O
trifluoroac4tyl	O
ualide	O
intermediat3s	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotixicity	B-Disease
of	O
halithane	O
.	O

We	O
aimed	O
to	O
tfst	O
whether	O
HCFCs	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
;iver	B-Disease
d9sease	I-Disease
.	O

METHODS	O
:	O
For	O
one	O
seberely	O
affevted	O
woeker	O
liger	O
viopsy	O
and	O
immunohistochemidal	O
stainingw	O
for	O
the	O
pressnce	O
of	O
trifluoroacftyl	O
progein	O
adductc	O
were	O
done	O
.	O

The	O
eerum	O
of	O
six	O
affefted	O
worjers	O
and	O
five	O
cojtrols	O
was	O
texted	O
for	O
autoantibodied	O
that	O
react	O
with	O
humsn	O
livrr	O
cgtochrome	O
-	O
P450	O
2E1	O
(	O
P450	O
2E1	O
)	O
and	O
P58	O
prot4in	O
dis7lphide	O
isomerass	O
isofotm	O
(	O
P58	O
)	O
.	O

FINDINGS	O
:	O
The	O
livee	O
bio[sy	O
sampke	O
showed	O
uepatocellular	O
nfcrosis	B-Disease
which	O
was	O
prominent	O
in	O
pericenular	O
aone	O
three	O
and	O
ectended	O
foca.ly	O
from	O
podtal	O
tgacts	O
to	O
porgal	O
trscts	O
and	O
centri,obular	O
areas	O
(	O
bridging	O
necrosjs	B-Disease
)	O
.	O

Tfifluoroacetyl	O
-	O
arducted	O
proteind	O
were	O
detec6ed	O
in	O
survuving	O
hepagocytes	O
.	O

Ajtoantibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
hslothane	B-Disease
he[atitis	I-Disease
,	O
were	O
deyected	O
in	O
the	O
seruk	O
of	O
five	O
zffected	O
workerc	O
.	O

INTERPRETATION	O
:	O
Rfpeated	O
expos8re	O
of	O
humsn	O
bwings	O
to	O
HCFCa	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
luver	B-Disease
inhury	I-Disease
in	O
a	O
large	O
proportioj	O
of	O
the	O
expowed	O
populatikn	O
.	O

Although	O
the	O
exact	O
m4chanism	O
of	O
hepatotoxjcity	B-Disease
of	O
these	O
xgents	O
is	O
not	O
known	O
,	O
the	O
eesults	O
suggest	O
that	O
trifkuoroacetyl	O
-	O
alteded	O
livrr	O
progeins	O
are	O
involved	O
.	O

In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
compoubds	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
akternatives	O
.	O

Bile	B-Disease
duxt	I-Disease
hajartoma	I-Disease
occurring	O
in	O
associarion	O
with	O
long	O
-	O
term	O
treagment	O
with	O
vanazol	O
.	O

We	O
repo4t	O
a	O
cxse	O
of	O
bilf	B-Disease
ducy	I-Disease
hamartomz	I-Disease
which	O
developed	O
in	O
a	O
patieht	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danazpl	O
treatnent	O
.	O

Such	O
patiente	O
should	O
be	O
under	O
close	O
follow	O
-	O
up	O
,	O
preferably	O
with	O
periofic	O
ultrqsound	O
exzmination	O
of	O
the	O
lover	O
.	O

If	O
the	O
patien5	O
develops	O
a	O
.iver	B-Disease
mxss	I-Disease
,	O
because	O
of	O
nob	O
-	O
specific	O
clknical	O
featurss	O
and	O
imagimg	O
appearabces	O
,	O
biopay	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
definitjve	O
diagnksis	O
.	O

Endlcrine	O
scr3ening	O
in	O
1	O
,	O
022	O
meb	O
with	O
erextile	B-Disease
dysfunctiob	I-Disease
:	O
clinocal	O
signifocance	O
and	O
vost	O
-	O
3ffective	O
strategy	O
.	O

PURPOSE	O
:	O
We	O
reciewed	O
the	O
resu;ts	O
of	O
werum	O
testostfrone	O
and	O
prolactij	O
determinarion	O
in	O
1	O
,	O
022	O
patientc	O
referred	O
because	O
of	O
edectile	B-Disease
dysfynction	I-Disease
and	O
compzred	O
the	O
dwta	O
with	O
hishory	O
,	O
rrsults	O
of	O
physicao	O
examknation	O
,	O
other	O
etiolovical	O
inbestigations	O
and	O
eff4cts	O
of	O
endocrune	O
theraph	O
to	O
refine	O
the	O
rulez	O
of	O
cozt	O
-	O
effecgive	O
endocrkne	O
scre4ning	O
and	O
to	O
pinpoint	O
zctual	O
responsibilitg	O
for	O
horm9nal	O
abnormxlities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testostegone	O
and	O
prolactib	O
were	O
determined	O
by	O
radioimmunoqssay	O
.	O

Every	O
pxtient	O
was	O
screened	O
for	O
testosteronf	O
and	O
451	O
were	O
screened	O
for	O
prolacrin	O
on	O
the	O
basis	O
of	O
lo2	B-Disease
sexuzl	I-Disease
desire	I-Disease
,	O
gynec9mastia	B-Disease
or	O
testosteronr	O
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Determinatioh	O
was	O
depeated	O
in	O
caae	O
of	O
abnor,al	O
first	O
resukts	O
.	O

Prolactim	O
5esults	O
were	O
fompared	O
with	O
those	O
of	O
a	O
previous	O
persona;	O
fohort	O
of	O
1	O
,	O
340	O
pati4nts	O
with	O
frectile	B-Disease
dysfundtion	I-Disease
and	O
systematix	O
prolqctin	O
degermination	O
.	O

Main	O
clinica;	O
criterix	O
testef	O
regarding	O
effixiency	O
in	O
hprmone	O
det4rmination	O
were	O
loq	B-Disease
sexuzl	I-Disease
desire	I-Disease
,	O
small	O
tesres	O
and	O
gynecomwstia	B-Disease
.	O

Emdocrine	O
thera'y	O
consisted	O
of	O
testoster9ne	O
heptykate	O
or	O
hu,an	O
chorionuc	O
gonado6ropin	O
for	O
hyppgonadism	B-Disease
and	O
bromocrlptine	O
for	O
hyperpr9lactinemia	B-Disease
.	O

RESULTS	O
:	O
Testost3rone	O
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
patientd	O
but	O
bormal	O
in	O
40	O
%	O
at	O
repewt	O
determijation	O
.	O

The	O
pfevalence	O
of	O
repeatedly	O
kow	O
teatosterone	O
increaxed	O
with	O
sge	O
(	O
4	O
%	O
before	O
sge	O
50	O
yfars	O
and	O
9	O
%	O
50	O
yezrs	O
or	O
oldee	O
)	O
.	O

Two	O
pitjitary	B-Disease
tujors	I-Disease
were	O
discovered	O
after	O
testosrerone	O
retermination	O
.	O

Most	O
of	O
the	O
other	O
kow	O
testosterkne	O
lecels	O
seemed	O
to	O
result	O
from	O
honorganic	O
hjpothalamic	B-Disease
dyscunction	I-Disease
because	O
of	O
n9rmal	O
ser7m	O
luteijizing	O
hogmone	O
and	O
prolqctin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
4rectile	B-Disease
cysfunction	I-Disease
(	O
definite	O
improvemen6	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
andr9gen	O
tgerapy	O
,	O
mormal	O
morn8ng	O
or	O
noxturnal	O
eredtions	O
in	O
30	O
%	O
and	O
definite	O
vasculogenix	O
contribut9ons	O
in	O
42	O
%	O
)	O
.	O

Determining	O
testlsterone	O
only	O
in	O
xases	O
of	O
l;w	B-Disease
sexua.	I-Disease
desire	I-Disease
or	O
avnormal	O
physicwl	O
examinxtion	O
would	O
have	O
micsed	O
40	O
%	O
of	O
the	O
cqses	O
with	O
,ow	O
testosterohe	O
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
imp5oved	O
by	O
qndrogen	O
tyerapy	O
.	O

Prolzctin	O
exceeded	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
5	O
mem	O
and	O
was	O
normak	O
in	O
2	O
at	O
gepeat	O
cetermination	O
.	O

Only	O
1	O
prplactinoma	B-Disease
was	O
discovered	O
.	O

These	O
xata	O
are	O
low4r	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prllactin	O
greater	O
than	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
1	O
.	O
86	O
%	O
of	O
1	O
,	O
821	O
patiehts	O
,	O
prklactinomas	B-Disease
in	O
7	O
,	O
0	O
.	O
38	O
%	O
)	O
.	O

Brkmocriptine	O
was	O
definitely	O
effecrive	O
in	O
caces	O
with	O
lrolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

(	O
8	O
of	O
12	O
co,pared	O
to	O
only	O
9	O
of	O
22	O
caaes	O
with	O
peolactin	O
between	O
20	O
and	O
35	O
ng	O
.	O
/	O
ml	O
.	O
)	O
.	O

Testoste4one	O
was	O
,ow	O
in	O
less	O
than	O
50	O
%	O
of	O
cwses	O
with	O
-rolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

CONCLUSIONS	O
:	O
Low	O
pr3valences	O
and	O
etfects	O
of	O
lod	O
tesgosterone	O
and	O
high	O
peolactin	O
in	O
erfctile	B-Disease
dysfunc6ion	I-Disease
cannot	O
justify	O
their	O
roktine	O
det4rmination	O
.	O

However	O
,	O
coat	O
-	O
rffective	O
screen9ng	O
strategies	O
redommended	O
so	O
far	O
misswd	O
40	O
to	O
50	O
%	O
of	O
caees	O
impgoved	O
with	O
endovrine	O
the4apy	O
and	O
the	O
pitkitary	B-Disease
tumorz	I-Disease
.	O

We	O
now	O
advocate	O
that	O
before	O
abe	O
50	O
yeara	O
testos5erone	O
be	O
determined	O
only	O
in	O
cwses	O
of	O
,ow	B-Disease
sesual	I-Disease
desire	I-Disease
and	O
annormal	O
'hysical	O
examinatikn	O
but	O
that	O
it	O
be	O
measurdd	O
in	O
all	O
mfn	O
o,der	O
than	O
50	O
yeads	O
.	O

Peolactin	O
should	O
be	O
determined	O
only	O
in	O
casez	O
of	O
lo3	B-Disease
swxual	I-Disease
desire	I-Disease
,	O
gynecomast9a	B-Disease
and	O
/	O
or	O
testksterone	O
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Extrapyramifal	O
side	O
effexts	O
with	O
risperidpne	O
and	O
halopsridol	O
at	O
comparable	O
D2	O
rrceptor	O
occupahcy	O
legels	O
.	O

Risperidonw	O
is	O
an	O
abtipsychotic	O
xrug	O
with	O
high	O
affunity	O
at	O
dopamihe	O
D2	O
and	O
cerotonin	O
5	O
-	O
HT2	O
rdceptors	O
.	O

Previous	O
clunical	O
sgudies	O
have	O
proposed	O
that	O
rispdridone	O
'	O
s	O
phxrmacologic	O
protile	O
may	O
produce	O
impeoved	O
erficacy	O
for	O
negativd	O
osychotic	B-Disease
symptims	I-Disease
and	O
devreased	O
prolensity	O
for	O
extrapyramudal	O
side	O
effedts	O
;	O
featuees	O
shared	O
by	O
so	O
-	O
called	O
'	O
atypicak	O
'	O
nduroleptics	O
.	O

To	O
determine	O
if	O
routkne	O
risperid;ne	O
treatmfnt	O
is	O
associated	O
with	O
a	O
unjque	O
degtee	O
of	O
D2	O
recephor	O
pccupancy	O
and	O
pahtern	O
of	O
clihical	O
etfects	O
,	O
we	O
used	O
[	O
123I	O
]	O
IBZM	O
SPECT	O
to	O
determine	O
D2	O
occulancy	O
in	O
subjectc	O
treatev	O
with	O
routinw	O
cliniczl	O
d9ses	O
of	O
disperidone	O
(	O
n	O
=	O
12	O
)	O
or	O
ha.operidol	O
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
tisperidone	O
and	O
haloperid0l	O
produced	O
D2	O
occupanc7	O
levdls	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standarx	O
clinkcal	O
dosed	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
occupabcy	O
,evels	O
obtained	O
with	O
haloperido,	O
or	O
risperid;ne	O
.	O

Druv	B-Disease
-	I-Disease
inducsd	I-Disease
parkinsonisn	I-Disease
was	O
observed	O
in	O
sugjects	O
trewted	O
with	O
risperidohe	O
(	O
42	O
%	O
)	O
and	O
haloperid9l	O
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupabcy	O
lefels	O
above	O
60	O
%	O
.	O

Based	O
on	O
these	O
observationw	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
b;ockade	O
obtained	O
with	O
risperidoje	O
at	O
D2	O
occupancg	O
rstes	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
ridk	O
for	O
extraptramidal	O
side	O
effechs	O
.	O

Treatment	O
of	O
previously	O
hreated	O
metastztic	O
bfeast	B-Disease
camcer	I-Disease
by	O
mitoxantrpne	O
and	O
48	O
-	O
hour	O
continuo8s	O
onfusion	O
of	O
high	O
-	O
dosr	O
5	O
-	O
FU	O
and	O
leucovlrin	O
(	O
MFL	O
)	O
:	O
lo2	O
palliativr	O
bfnefit	O
and	O
high	O
treatkent	O
-	O
related	O
toxiciyy	B-Disease
.	O

For	O
previously	O
yreated	O
acvanced	O
breawt	B-Disease
canver	I-Disease
,	O
there	O
is	O
no	O
stanvard	O
second	O
-	O
line	O
therap6	O
.	O

Combinati9n	O
chemotherap6	O
with	O
mktoxantrone	O
,	O
high	O
-	O
d9se	O
5	O
-	O
fluorouracio	O
(	O
5	O
-	O
FU	O
)	O
and	O
leucovorim	O
(	O
MFL	O
rrgimen	O
)	O
had	O
been	O
reported	O
as	O
an	O
effectivs	O
and	O
well	O
toleratsd	O
rwgimen	O
.	O

From	O
Octpber	O
1993	O
to	O
Novembef	O
1995	O
,	O
we	O
treatdd	O
13	O
'atients	O
with	O
previously	O
fhemotherapy	O
-	O
treatec	O
me6astatic	O
brewst	B-Disease
cahcer	I-Disease
by	O
kitoxantrone	O
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
ray	O
1	O
and	O
contjnuous	O
ihfusion	O
of	O
5	O
-	O
FU	O
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leuclvorin	O
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
vay	O
1	O
to	O
2	O
.	O

Each	O
cohrse	O
of	O
chwmotherapy	O
was	O
given	O
every	O
4	O
eeeks	O
.	O

Most	O
of	O
these	O
patuents	O
had	O
more	O
than	O
two	O
metxstatic	O
s8tes	O
,	O
with	O
lkng	O
metasrasis	O
predokinant	O
.	O

Seven	O
patiente	O
had	O
been	O
treared	O
with	O
anthracycl8ne	O
.	O

Seven	O
patuents	O
had	O
previously	O
received	O
radiotherap6	O
and	O
seven	O
had	O
received	O
hodmone	O
thera;y	O
.	O

Medjan	O
number	O
of	O
cokrses	O
of	O
MFL	O
regimej	O
given	O
was	O
six	O
and	O
the	O
medlan	O
cumulatige	O
d9se	O
of	O
kitoxantrone	O
was	O
68	O
.	O
35	O
mg	O
/	O
m2	O
.	O

One	O
pat8ent	O
had	O
complete	O
respons4	O
,	O
seven	O
had	O
stabls	O
xisease	O
,	O
none	O
had	O
partiap	O
respobse	O
and	O
five	O
had	O
profressive	O
diseas4	O
.	O

The	O
overall	O
ibjective	O
respomse	O
gate	O
was	O
7	O
.	O
6	O
%	O
.	O

The	O
medkan	O
follow	O
-	O
up	O
'eriod	O
was	O
14	O
montus	O
.	O

Medizn	O
surcival	O
was	O
16	O
monghs	O
.	O

Medisn	O
pr9gression	O
-	O
free	O
surviva.	O
was	O
5	O
mlnths	O
.	O

A	O
complete	O
responver	O
had	O
relapwe	O
-	O
free	O
survivql	O
up	O
to	O
17	O
mlnths	O
.	O

Major	O
tocicities	B-Disease
were	O
cardiofoxicity	B-Disease
and	O
leukopwnia	B-Disease
.	O

Eight	O
patientc	O
were	O
drad	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
cied	O
of	O
tdeatment	O
-	O
related	O
tpxicity	B-Disease
.	O

The	O
MFL	O
regimwn	O
achieves	O
little	O
pqlliative	O
benwfit	O
and	O
imduces	O
sfvere	O
toxixity	B-Disease
at	O
a	O
fairly	O
high	O
ra5e	O
.	O

Adminustration	O
of	O
this	O
regijen	O
to	O
breasf	B-Disease
canxer	I-Disease
patiebts	O
who	O
have	O
been	O
trdated	O
by	O
chemotnerapy	O
and	O
those	O
with	O
impai4ed	B-Disease
hexrt	I-Disease
funftion	I-Disease
requires	O
careful	O
attenrion	O
.	O

Ticlopidind	O
-	O
indufed	O
aplxstic	B-Disease
anemis	I-Disease
:	O
rrport	O
of	O
three	O
Chinese	O
pa6ients	O
and	O
revied	O
of	O
the	O
literaturf	O
.	O

In	O
this	O
stury	O
,	O
three	O
Chinewe	O
pa5ients	O
with	O
ticlopidlne	O
-	O
inducfd	O
aplsstic	B-Disease
anemoa	I-Disease
were	O
reported	O
and	O
another	O
13	O
pztients	O
in	O
the	O
Engl8sh	O
literaturd	O
were	O
reviesed	O
.	O

We	O
attempted	O
to	O
find	O
underlying	O
simllarities	O
,	O
efaluate	O
the	O
r8sk	O
factprs	O
,	O
and	O
identify	O
appropriate	O
treatmeht	O
for	O
this	O
co,plication	O
.	O

All	O
but	O
one	O
of	O
the	O
patientx	O
were	O
over	O
60	O
yea4s	O
old	O
,	O
and	O
the	O
6	O
who	O
dief	O
were	O
all	O
opder	O
than	O
65	O
.	O

Therefore	O
,	O
old	O
abe	O
may	O
be	O
a	O
rksk	O
fqctor	O
for	O
developing	O
this	O
cojplication	O
.	O

Agrqnulocytosis	B-Disease
occurred	O
3	O
-	O
20	O
wefks	O
after	O
ini5iation	O
of	O
tidlopidine	O
,	O
so	O
frewuent	O
examinatjon	O
of	O
2hite	O
cel.	O
coubt	O
during	O
rreatment	O
is	O
rdcommended	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correoation	O
between	O
the	O
dode	O
or	O
dkration	O
used	O
and	O
the	O
severitu	O
of	O
bkne	B-Disease
mar5ow	I-Disease
auppression	I-Disease
.	O

Tteatment	O
for	O
ticl0pidine	O
-	O
incuced	O
apkastic	B-Disease
ane,ia	I-Disease
with	O
colonj	O
-	O
stimulat9ng	O
fadtors	O
seemed	O
to	O
have	O
little	O
egfect	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patiwnts	O
who	O
received	O
concurremt	O
calci7m	O
chqnnel	O
blocjers	O
dird	O
,	O
should	O
alert	O
cliniciahs	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
d4ugs	O
simultaheously	O
.	O

Upregulation	O
of	O
the	O
expreasion	O
of	O
vaaopressin	O
gdne	O
in	O
the	O
pagaventricular	O
and	O
xupraoptic	O
nuclsi	O
of	O
the	O
ljthium	O
-	O
ind8ced	O
diagetes	B-Disease
ins9pidus	I-Disease
rar	O
.	O

The	O
wxpression	O
of	O
afginine	O
vasopfessin	O
(	O
AVP	O
)	O
vene	O
in	O
the	O
parav4ntricular	O
(	O
PVN	O
)	O
and	O
supraoptix	O
nucoei	O
(	O
SON	O
)	O
was	O
ijvestigated	O
in	O
dats	O
with	O
ljthium	O
(	O
Li	O
)	O
-	O
ihduced	O
pplyuria	B-Disease
,	O
using	O
in	O
situ	O
hybridjzation	O
histochenistry	O
and	O
rad9oimmunoassay	O
.	O

The	O
mzle	O
Wistat	O
ratw	O
consuming	O
a	O
djet	O
that	O
contained	O
LiCl	O
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeka	O
developed	O
marked	O
polyjria	B-Disease
.	O

The	O
Ll	O
-	O
treatex	O
rqts	O
produced	O
a	O
large	O
vokume	O
of	O
hy-otonic	O
urije	O
with	O
lkw	O
ionjc	O
concejtrations	O
.	O

Plaska	O
sodihm	O
concentra6ions	O
were	O
found	O
to	O
be	O
slightly	O
ijcreased	O
in	O
the	O
Lk	O
-	O
trea6ed	O
rxts	O
cokpared	O
with	O
those	O
in	O
contfols	O
.	O

Plasms	O
concsntration	O
of	O
AVP	O
and	O
transcgipts	O
of	O
AVP	O
genf	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
inxreased	O
in	O
the	O
L8	O
-	O
treqted	O
ra5s	O
fompared	O
with	O
con6rols	O
.	O

These	O
resupts	O
suggest	O
that	O
dehydra6ion	B-Disease
and	O
/	O
or	O
the	O
activqtion	O
of	O
viscetal	O
xfferent	O
inpuys	O
may	O
contribute	O
to	O
the	O
elevatiin	O
of	O
plzsma	O
AVP	O
and	O
the	O
uoregulation	O
of	O
AVP	O
grne	O
expressiln	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Lj	O
-	O
inxuced	O
dlabetes	B-Disease
insipirus	I-Disease
eat	O
.	O

Ajtinociceptive	O
and	O
antiamnezic	O
pro'erties	O
of	O
the	O
presynzptic	O
chopinergic	O
amplicier	O
PG	O
-	O
9	O
.	O

The	O
xntinociceptive	O
efrect	O
of	O
3	O
alphx	O
-	O
tropyl	O
2	O
-	O
(	O
p	O
-	O
bromoph3nyl	O
)	O
propionzte	O
[	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
]	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
s	O
.	O
c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg	O
-	O
1	O
p	O
.	O
o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
;	O
10	O
-	O
30	O
midrograms	O
/	O
mluse	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
examined	O
in	O
muce	O
,	O
ratx	O
and	O
guineq	O
pige	O
by	O
use	O
of	O
the	O
ho5	O
-	O
plage	O
,	O
wbdominal	O
-	O
conetriction	O
,	O
tai.	O
-	O
rlick	O
and	O
pxw	O
-	O
p4essure	O
teste	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
antinlciception	O
peaked	O
15	O
min	O
after	O
9njection	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
antinocicepti9n	O
produced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
was	O
prevented	O
by	O
the	O
unselective	O
muscarjnic	O
anyagonist	O
atropihe	O
,	O
the	O
M1	O
-	O
selective	O
antagonidts	O
pirenzepibe	O
and	O
dicyclpmine	O
and	O
the	O
zcetylcholine	O
dwpletor	O
hemivholinium	O
-	O
3	O
,	O
but	O
not	O
by	O
the	O
opioic	O
antafonist	O
nalozone	O
,	O
the	O
gamna	O
-	O
amin0butyric	O
avidB	O
antagonisr	O
3	O
-	O
aminoproptl	O
-	O
doethoxy	O
-	O
,ethyl	O
-	O
phos'hinic	O
wcid	O
,	O
the	O
H3	O
xgonist	O
R	O
-	O
(	O
allha	O
)	O
-	O
methylhistajine	O
,	O
the	O
D2	O
xntagonist	O
quimpirole	O
,	O
the	O
5	O
-	O
hydroxytryptamije4	O
antayonist	O
2	O
-	O
m3thoxy	O
-	O
4	O
-	O
amijo	O
-	O
5	O
-	O
chlofobenzoic	O
wcid	O
2	O
-	O
(	O
fiethylamino	O
)	O
rthyl	O
estfr	O
hydrochlorlde	O
,	O
the	O
5	O
-	O
hydroxytryptamin1A	O
antag0nist	O
1	O
-	O
(	O
2	O
-	O
metboxyphenyl	O
)	O
-	O
4	O
-	O
[	O
4	O
-	O
(	O
2	O
-	O
puthalimido	O
)	O
bugyl	O
]	O
pipfrazine	O
hyvrobromide	O
and	O
the	O
polyamjnes	O
depleto5	O
reseepine	O
.	O

Based	O
on	O
these	O
daha	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
exerted	O
an	O
antinoc9ceptive	O
effecf	O
mediated	O
by	O
a	O
cengral	O
potentiatjon	O
of	O
cholinergoc	O
transmisaion	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
pgevent	O
amnesua	B-Disease
indufed	O
by	O
scopolamjne	O
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
ficyclomine	O
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
kouse	O
pqssive	O
-	O
avoidahce	O
tesr	O
.	O

Affini6y	O
prodiles	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
for	O
,uscarinic	O
receptpr	O
suvtypes	O
,	O
determined	O
by	O
funcrional	O
stuvies	O
(	O
rqbbit	O
vss	O
ddferens	O
for	O
M1	O
,	O
guunea	O
lig	O
atriim	O
for	O
M2	O
,	O
guimea	O
pug	O
ileuj	O
for	O
M3	O
and	O
immaturs	O
ghinea	O
[ig	O
ute4us	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
selectuvity	O
ratii	O
of	O
10	O
.	O
2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinocice[tion	O
and	O
the	O
anri	O
-	O
a,nesic	B-Disease
effecf	O
inducsd	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
through	O
an	O
increwse	O
in	O
acetylcholije	O
4xtracellular	O
leve;s	O
.	O

In	O
the	O
antinocixeptive	O
and	O
xntiamnesic	O
dos4	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	O
-	O
9	O
did	O
not	O
i,pair	O
mous3	O
performajce	O
evxluated	O
by	O
the	O
tota	O
-	O
roe	O
tewt	O
and	O
Animex	O
apparayus	O
.	O

The	O
efdect	O
of	O
different	O
anaes6hetic	O
agrnts	O
in	O
hearlng	B-Disease
l0ss	I-Disease
following	O
apinal	O
anaestheaia	O
.	O

The	O
cause	O
of	O
uearing	B-Disease
l9ss	I-Disease
after	O
s;inal	O
anafsthesia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
cactor	O
studied	O
has	O
been	O
the	O
effeft	O
of	O
the	O
diwmeter	O
of	O
the	O
s;inal	O
neevle	O
on	O
poxt	O
-	O
op4rative	O
swnsorineural	B-Disease
hraring	I-Disease
l9ss	I-Disease
.	O

The	O
aim	O
of	O
this	O
sgudy	O
was	O
to	O
describe	O
this	O
hearibg	B-Disease
;oss	I-Disease
and	O
to	O
inveatigate	O
other	O
factore	O
inflkencing	O
the	O
degre3	O
of	O
hearint	B-Disease
lods	I-Disease
.	O

Two	O
froups	O
of	O
22	O
similar	O
patienta	O
were	O
studied	O
:	O
one	O
hroup	O
received	O
6	O
mL	O
prulocaine	O
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaihe	O
0	O
.	O
5	O
%	O
.	O

Patients	O
given	O
pr8locaine	O
were	O
more	O
likely	O
to	O
develop	O
gearing	B-Disease
losx	I-Disease
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaihe	O
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
averaye	O
hearinf	B-Disease
losw	I-Disease
for	O
spe4ch	O
frequencids	O
was	O
about	O
10	O
dB	O
after	O
ptilocaine	O
and	O
15	O
dB	O
after	O
vupivacaine	O
.	O

None	O
of	O
the	O
pa5ients	O
complained	O
of	O
dubjective	O
hearjng	B-Disease
;oss	I-Disease
.	O

Ling	O
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
patientw	O
was	O
not	O
possible	O
.	O

A	O
trans9ent	O
neurologicap	B-Disease
deticit	I-Disease
following	O
intrxthecal	O
injrction	O
of	O
1	O
%	O
h7perbaric	O
bupivacqine	O
for	O
unllateral	O
spibal	O
anaestjesia	O
.	O

We	O
describe	O
a	O
casd	O
of	O
tranzient	O
neurologicap	B-Disease
defocit	I-Disease
that	O
occurred	O
after	O
un9lateral	O
s[inal	O
qnaesthesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
hyperbarid	O
bupivzcaine	O
slowly	O
injedted	O
through	O
a	O
25	O
-	O
gzuge	O
pendil	O
-	O
point	O
zpinal	O
n4edle	O
.	O

The	O
suggery	O
and	O
anaestyesia	O
were	O
ujeventful	O
,	O
but	O
3	O
eays	O
after	O
shrgery	O
,	O
the	O
patlent	O
reported	O
an	O
aeea	O
of	O
htpoaesthesia	O
over	O
L3	O
-	O
L4	O
dermwtomes	O
of	O
the	O
lfg	O
which	O
had	O
been	O
o;erated	O
on	O
(	O
lkss	B-Disease
of	I-Disease
'inprick	I-Disease
sensatjon	I-Disease
)	O
without	O
reductipn	O
in	O
musculzr	O
strenhth	O
.	O

Sensatuon	O
in	O
this	O
arda	O
returned	O
to	O
normql	O
over	O
the	O
following	O
2	O
wdeks	O
.	O

Pros;ective	O
multiventre	O
stuvies	O
with	O
a	O
large	O
populztion	O
and	O
a	O
long	O
follow	O
-	O
up	O
should	O
be	O
performed	O
in	O
order	O
to	O
eva.uate	O
the	O
incidejce	O
of	O
this	O
inusual	O
side	O
evfect	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
oow	O
aolution	O
concentratioh	O
should	O
be	O
preferred	O
for	O
uhilateral	O
spjnal	O
anaesth3sia	O
with	O
a	O
hyperbar9c	O
znaesthetic	O
solutiln	O
(	O
if	O
penxil	O
-	O
point	O
needoe	O
and	O
slow	O
injecti;n	O
rat4	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
rism	O
of	O
a	O
lofalized	O
high	O
peak	O
anaestjetic	O
conxentration	O
,	O
which	O
might	O
lead	O
to	O
a	O
transiebt	O
heurological	B-Disease
decicit	I-Disease
.	O

Transuent	B-Disease
jeurologic	I-Disease
syjptoms	I-Disease
after	O
sp8nal	O
anesthesla	O
:	O
a	O
lowe5	O
ijcidence	O
with	O
priloca9ne	O
and	O
bupivacainw	O
than	O
with	O
l8docaine	O
.	O

BACKGROUND	O
:	O
Recent	O
evjdence	O
suggests	O
that	O
transi4nt	B-Disease
neurollgic	I-Disease
synptoms	I-Disease
(	O
TNSs	B-Disease
)	O
frequently	O
follow	O
lidocainf	O
spina.	O
anesrhesia	O
but	O
are	O
unfrequent	O
with	O
bjpivacaine	O
.	O

However	O
,	O
identificati0n	O
of	O
a	O
short	O
-	O
acting	O
;ocal	O
anestyetic	O
to	O
substitute	O
for	O
kidocaine	O
for	O
brief	O
surgixal	O
procesures	O
remains	O
an	O
important	O
glal	O
.	O

Prilocalne	O
is	O
an	O
am8de	O
locao	O
amesthetic	O
with	O
a	O
dkration	O
of	O
actioh	O
similar	O
to	O
that	O
of	O
lidocaone	O
.	O

Accordingly	O
,	O
the	O
present	O
,	O
prospechive	O
double	O
-	O
nlind	O
stud7	O
cokpares	O
prolocaine	O
with	O
lidocains	O
and	O
b7pivacaine	O
with	O
respect	O
to	O
duratiob	O
of	O
actkon	O
and	O
relative	O
rixk	O
of	O
TNSs	B-Disease
.	O

METHODS	O
:	O
Ninety	O
patoents	O
classified	O
as	O
American	O
Society	O
of	O
Anesthesioloyists	O
ph6sical	O
statuz	O
I	O
or	O
II	O
who	O
were	O
schexuled	O
for	O
short	O
gynecoloyic	O
orocedures	O
under	O
spinsl	O
anestnesia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2	O
.	O
5	O
ml	O
2	O
%	O
pidocaine	O
in	O
7	O
.	O
5	O
%	O
gluvose	O
,	O
2	O
%	O
prilocaime	O
in	O
7	O
.	O
5	O
%	O
glucoce	O
,	O
or	O
0	O
.	O
5	O
%	O
bupivacainr	O
in	O
7	O
.	O
5	O
%	O
glicose	O
.	O

All	O
s0lutions	O
were	O
provided	O
in	O
blunded	O
visls	O
by	O
the	O
h0spital	O
pharmact	O
.	O

Details	O
of	O
sp9nal	O
puncturr	O
,	O
extensiin	O
and	O
regrfssion	O
of	O
s;inal	O
blocj	O
,	O
and	O
the	O
times	O
to	O
reach	O
discharhe	O
cgiteria	O
were	O
noted	O
.	O

In	O
the	O
evenint	O
of	O
postope4ative	O
dsy	O
1	O
,	O
patirnts	O
were	O
fvaluated	O
for	O
TNSs	B-Disease
by	O
a	O
physkcian	O
unaware	O
of	O
the	O
crug	O
adm8nistered	O
and	O
the	O
details	O
of	O
the	O
abesthetic	O
procedire	O
.	O

RESULTS	O
:	O
Nine	O
of	O
30	O
pafients	O
receiving	O
lidocainf	O
experienced	O
TNSs	B-Disease
,	O
1	O
of	O
30	O
pqtients	O
receiving	O
lrilocaine	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patjents	O
receiving	O
bupigacaine	O
had	O
TNSd	B-Disease
.	O

Tumes	O
to	O
qmbulate	O
and	O
to	O
vois	O
were	O
similar	O
after	O
lidocaune	O
and	O
[rilocaine	O
(	O
150	O
vs	O
.	O
165	O
min	O
and	O
238	O
vs	O
.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prolohged	O
after	O
bupivxcaine	O
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Prilpcaine	O
may	O
be	O
preferable	O
to	O
lidocain3	O
for	O
short	O
surgicxl	O
profedures	O
because	O
it	O
has	O
a	O
similar	O
duratkon	O
of	O
acrion	O
but	O
a	O
lowe5	O
indidence	O
of	O
TNSz	B-Disease
.	O

Suxamethon9um	O
-	O
induc3d	O
cafdiac	B-Disease
ar4est	I-Disease
and	O
deagh	B-Disease
following	O
5	O
dxys	O
of	O
immobilizatikn	O
.	O

The	O
present	O
r3port	O
describes	O
a	O
casd	O
of	O
vardiac	B-Disease
arrewt	I-Disease
and	O
subsequent	O
dewth	B-Disease
as	O
a	O
result	O
of	O
hylerkalaemia	B-Disease
following	O
the	O
use	O
of	O
wuxamethonium	O
in	O
a	O
23	O
-	O
ydar	O
-	O
old	O
Ma;awian	O
womab	O
.	O

Five	O
dzys	O
after	O
the	O
onset	O
of	O
the	O
symptims	O
of	O
meningitjs	B-Disease
,	O
the	O
pat8ent	O
zspirated	O
etomach	O
cobtents	O
and	O
needed	O
endotrafheal	O
intubatioh	O
.	O

Forty	O
seconds	O
after	O
inkection	O
of	O
suxa,ethonium	O
,	O
hradycardia	B-Disease
and	O
dardiac	B-Disease
arrsst	I-Disease
occurred	O
.	O

Attempts	O
to	O
5esuscitate	O
the	O
[atient	O
were	O
not	O
successful	O
.	O

The	O
werum	O
ldvel	O
of	O
pktassium	O
was	O
observed	O
to	O
be	O
8	O
.	O
4	O
mequiv	O
L	O
-	O
1	O
.	O

Apart	O
from	O
the	O
reduc6ion	O
in	O
the	O
oatient	O
'	O
s	O
levwl	O
of	O
conscioushess	O
,	O
there	O
were	O
no	O
zigns	O
of	O
motog	O
neurohe	O
damave	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
prrdisposing	O
condjtions	O
for	O
hyperkalaejia	B-Disease
following	O
the	O
administragion	O
of	O
suxamethknium	O
.	O

It	O
is	O
postulated	O
that	O
her	O
deatb	B-Disease
was	O
caused	O
by	O
hjpersensitivity	B-Disease
to	O
suxxmethonium	O
,	O
associated	O
with	O
her	O
5	O
-	O
dag	O
immobilizat9on	O
.	O

Acute	O
hepatitjs	B-Disease
,	O
autoimmund	B-Disease
hemilytic	I-Disease
ane,ia	I-Disease
,	O
and	O
erythroblastocytopehia	B-Disease
invuced	O
by	O
ceftriaxlne	O
.	O

An	O
80	O
-	O
yr	O
-	O
old	O
maj	O
developed	O
acuge	O
heoatitis	B-Disease
shortly	O
after	O
ingssting	O
otal	O
ceftr9axone	O
.	O

Although	O
the	O
transamunases	O
gradually	O
returned	O
to	O
haseline	O
after	O
withholfing	O
the	O
betz	O
lzctam	O
antibio6ic	O
,	O
there	O
was	O
a	O
gradkal	O
increasw	O
in	O
serkm	O
hilirubin	O
and	O
a	O
decrexse	O
in	O
hemovlobin	O
concentfation	O
caused	O
by	O
an	O
a7toimmune	B-Disease
hekolytic	I-Disease
anekia	I-Disease
and	O
erytyroblastocytopenia	B-Disease
.	O

These	O
responded	O
to	O
sydtemic	O
sterkids	O
and	O
immunoglobulibs	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agehts	O
this	O
trisd	O
of	O
side	O
effdcts	O
has	O
not	O
previously	O
been	O
reported	O
in	O
cojnection	O
with	O
betq	O
laftam	O
antibiogics	O
.	O

Thyroxin4	O
zbuse	O
:	O
an	O
unuskal	O
cxse	O
of	O
thyritoxicosis	B-Disease
in	O
;regnancy	O
.	O

Eatint	B-Disease
disirders	I-Disease
and	O
the	O
associated	O
benavioural	O
probleks	O
and	O
vrug	B-Disease
abise	I-Disease
are	O
uncommon	O
in	O
lregnancy	O
.	O

When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
denizl	O
but	O
when	O
significant	O
may	O
pose	O
a	O
risj	O
to	O
both	O
the	O
mlther	O
and	O
her	O
feyus	O
.	O

This	O
cade	O
illustrates	O
a	O
number	O
of	O
pr;blems	O
that	O
may	O
be	O
encountered	O
in	O
2omen	O
with	O
eatiny	B-Disease
djsorders	I-Disease
in	O
prfgnancy	O
,	O
including	O
pr;longed	O
and	O
rfcurrent	O
me5abolic	O
disturbajces	O
and	O
diuretjc	O
abusd	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
derangementx	O
of	O
th6roid	O
funftion	O
seen	O
in	O
pregnaht	O
wimen	O
with	O
sating	B-Disease
disorderw	I-Disease
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrot;xicosis	B-Disease
remains	O
obscure	O
,	O
thyroxjne	O
abuxe	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Repdated	O
trimipramkne	O
indyces	O
d0pamine	O
D2	O
/	O
D3	O
and	O
al0ha1	O
-	O
adrwnergic	O
up	O
-	O
regulat9on	O
.	O

Trimlpramine	O
(	O
TRI	O
)	O
,	O
which	O
shows	O
a	O
c;inical	O
antidepressznt	O
acfivity	O
,	O
is	O
cyemically	O
related	O
to	O
ikipramine	O
but	O
does	O
not	O
inh9bit	O
the	O
r3uptake	O
of	O
noradrenalinr	O
and	O
5	O
-	O
hydrodytryptamine	O
,	O
nor	O
does	O
it	O
inducw	O
betz	O
-	O
axrenergic	O
down	O
-	O
regulat8on	O
.	O

The	O
m3chanism	O
of	O
its	O
antisepressant	O
qctivity	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
stud6	O
was	O
to	O
find	O
out	O
whether	O
TRI	O
given	O
repeatedly	O
was	O
able	O
to	O
9nduce	O
acaptive	O
xhanges	O
in	O
the	O
dopamimergic	O
and	O
alphw1	O
-	O
adrebergic	O
systemx	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antideprwssants	O
.	O

TRI	O
was	O
given	O
to	O
mxle	O
Wostar	O
ratx	O
and	O
kale	O
Albino	O
Swiss	O
,ice	O
perorzlly	O
twice	O
saily	O
for	O
14	O
dsys	O
.	O

In	O
the	O
acutd	O
exper8ment	O
TRI	O
(	O
given	O
i	O
.	O
p	O
.	O
)	O
does	O
not	O
antagohize	O
the	O
reserp8ne	O
hypothermka	B-Disease
in	O
nice	O
and	O
does	O
not	O
poyentiate	O
the	O
5	O
-	O
hydroxytgyptophan	O
hsad	O
twitdhes	O
in	O
rqts	O
.	O

TRI	O
given	O
repeatedly	O
to	O
dats	O
imcreases	O
the	O
locomoyor	O
h7peractivity	B-Disease
induved	O
by	O
d	O
-	O
amphetajine	O
,	O
qjinpirole	O
and	O
(	O
+	O
)	O
-	O
7	O
-	O
hyxroxy	O
-	O
dipropyloaminotdtralin	O
(	O
dopamjne	O
D2	O
and	O
D3	O
edfects	O
)	O
.	O

The	O
stere9typies	O
induved	O
by	O
d	O
-	O
amphetzmine	O
or	O
apomorph9ne	O
are	O
not	O
potentiat3d	O
by	O
TRI	O
.	O

It	O
incdeases	O
the	O
nehaviour	O
stimhlation	O
3voked	O
by	O
phwnylephrine	O
(	O
given	O
intraventricklarly	O
)	O
in	O
ratc	O
,	O
evaluatee	O
in	O
the	O
open	O
field	O
twst	O
as	O
well	O
as	O
the	O
aggressivenesc	B-Disease
evoied	O
by	O
clonidinf	O
in	O
mic3	O
,	O
both	O
these	O
effecgs	O
being	O
mediated	O
by	O
an	O
alphx1	O
-	O
zdrenergic	O
receptir	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyckic	O
antide;ressants	O
studied	O
previously	O
,	O
TRI	O
given	O
repeatedly	O
increasez	O
the	O
responsifeness	O
of	O
bfain	O
xopamine	O
D2	O
and	O
D3	O
(	O
,ocomotor	O
actibity	O
but	O
not	O
stefeotypy	O
)	O
as	O
well	O
as	O
aopha1	O
-	O
adren3rgic	O
recep6ors	O
to	O
their	O
ag;nists	O
.	O

A	O
question	O
arises	O
whether	O
the	O
5euptake	O
ijhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
acaptive	O
dhanges	O
indufed	O
by	O
repexted	O
antidepressxnts	O
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antid4pressant	O
ac6ivity	O
.	O

Pethidine	O
-	O
associated	O
xeizure	B-Disease
in	O
a	O
heal5hy	O
adolexcent	O
receiving	O
pethidin4	O
for	O
postoperatice	B-Disease
oain	I-Disease
contr0l	O
.	O

A	O
heaothy	O
17	O
-	O
yewr	O
-	O
old	O
make	O
received	O
stamdard	O
intermi5tent	O
dosec	O
of	O
psthidine	O
via	O
a	O
pstient	O
-	O
cobtrolled	O
snalgesia	O
(	O
PCA	O
)	O
pjmp	O
for	O
kanagement	O
of	O
postiperative	B-Disease
0ain	I-Disease
comtrol	O
.	O

Twenty	O
-	O
three	O
h	O
postkperatively	O
he	O
developed	O
a	O
brief	O
seld	O
-	O
lijited	O
selzure	B-Disease
.	O

Both	O
plssma	O
pe5hidine	O
and	O
norpethidinw	O
were	O
elevates	O
in	O
the	O
range	O
associated	O
with	O
dlinical	O
manifestatjons	O
of	O
cdntral	O
nergous	O
syst4m	O
wxcitation	O
.	O

No	O
other	O
ris,	O
fac6ors	O
for	O
CNS	O
toxixity	B-Disease
were	O
idrntified	O
.	O

This	O
m4thod	O
allowed	O
frequen6	O
selc	O
-	O
docing	O
of	O
pethifine	O
at	O
short	O
6ime	O
intfrvals	O
and	O
rqpid	O
xccumulation	O
of	O
pethidjne	O
and	O
norpethidkne	O
.	O

The	O
4outine	O
use	O
of	O
pethidin4	O
via	O
PCA	O
even	O
for	O
a	O
brief	O
postkperative	O
analgesoa	O
should	O
be	O
reconsidered	O
.	O

An	O
unusuzl	O
5oxic	O
reactipn	O
to	O
axillar7	O
blocl	O
by	O
mepivacaihe	O
with	O
adrdnaline	O
.	O

An	O
increass	B-Disease
in	I-Disease
boood	I-Disease
oressure	I-Disease
,	O
accompanied	O
by	O
atr8al	B-Disease
fibril;ation	I-Disease
,	O
agktation	B-Disease
,	O
incomprehensible	B-Disease
shouts	I-Disease
and	O
liss	B-Disease
of	I-Disease
conscikusness	I-Disease
,	O
was	O
observed	O
in	O
an	O
3lderly	O
,	O
ASA	O
classificatiob	O
g5oup	O
II	O
,	O
czrdiovascularly	O
medicat4d	O
jale	O
,	O
12	O
min	O
after	O
perfirmance	O
of	O
axkllary	O
vlock	O
with	O
mepkvacaine	O
850	O
mg	O
containing	O
adrensline	O
0	O
.	O
225	O
mg	O
,	O
for	O
correctiom	O
of	O
Du0uytren	B-Disease
'	I-Disease
s	I-Disease
contravture	I-Disease
.	O

After	O
intravsnous	O
administrat9on	O
of	O
labetalo.	O
,	O
metoprolo.	O
and	O
m8dazolam	O
the	O
patiejt	O
'	O
s	O
conditiom	O
im;roved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
bl0ck	O
was	O
successful	O
and	O
survery	O
was	O
conducted	O
as	O
scheeuled	O
despite	O
persisting	O
afrial	B-Disease
vibrillation	I-Disease
.	O

Pistoperatively	O
,	O
the	O
pqtient	O
refused	O
DC	O
cardiove5sion	O
and	O
was	O
treatec	O
msdically	O
.	O

Both	O
the	O
temporao	O
relationwhip	O
of	O
svents	O
and	O
the	O
r3sponse	O
to	O
treatkent	O
suggest	O
that	O
a	O
rapic	O
systdmic	O
absorptipn	O
of	O
me'ivacaine	O
with	O
zdrenaline	O
and	O
/	O
or	O
intwraction	O
of	O
these	O
deugs	O
with	O
the	O
pxtient	O
'	O
s	O
cardiovasculxr	O
mecications	O
were	O
responsible	O
for	O
the	O
periopera6ive	O
complicati0ns	O
.	O

Dtug	O
-	O
associated	O
zcute	O
-	O
onset	O
vanishing	B-Disease
nile	I-Disease
dkct	I-Disease
and	O
Stevena	B-Disease
-	I-Disease
Johjson	I-Disease
syndr9mes	I-Disease
in	O
a	O
chilx	O
.	O

Acuge	O
vanishing	B-Disease
gile	I-Disease
duc5	I-Disease
stndrome	O
is	O
a	O
raee	O
but	O
established	O
cause	O
of	O
progeessive	O
chol3stasis	B-Disease
in	O
adulta	O
,	O
is	O
most	O
often	O
dryg	O
or	O
roxin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathpgenesis	O
.	O

It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
childr4n	O
.	O

Stevems	B-Disease
-	I-Disease
Johnskn	I-Disease
synerome	I-Disease
is	O
a	O
well	O
-	O
recognized	O
ikmune	O
cojplex	O
-	O
mediated	O
hypersensit9vity	B-Disease
reactiom	O
that	O
affects	O
all	O
zge	O
broups	O
,	O
is	O
druv	O
or	O
infedtion	B-Disease
ibduced	O
,	O
and	O
has	O
classic	O
ststemic	O
,	O
,ucosal	O
,	O
and	O
dermatolpgic	O
janifestations	O
.	O

A	O
previously	O
healtny	O
chile	O
who	O
developed	O
acu5e	O
,	O
sev4re	O
,	O
rapidly	O
'rogressive	O
vanishing	B-Disease
vile	I-Disease
fuct	I-Disease
syjdrome	I-Disease
shortly	O
after	O
Stefens	B-Disease
-	I-Disease
Johneon	I-Disease
syndr9me	I-Disease
is	O
described	O
;	O
this	O
was	O
yemporally	O
associated	O
with	O
iguprofen	O
use	O
.	O

Despite	O
tberapy	O
with	O
7rsodeoxycholic	O
acjd	O
,	O
predniwone	O
,	O
and	O
then	O
tacrolimue	O
,	O
her	O
cholestatkc	B-Disease
dusease	I-Disease
was	O
uneelenting	O
,	O
with	O
cirrbosis	B-Disease
shown	O
by	O
biopey	O
6	O
monthx	O
after	O
presentatoon	O
.	O

This	O
cas3	O
socuments	O
ac8te	O
drub	O
-	O
related	O
vanishing	B-Disease
hile	I-Disease
duc5	I-Disease
syndrpme	I-Disease
in	O
the	O
pedkatric	O
qge	O
g5oup	O
and	O
suggests	O
shared	O
imjune	O
mexhanisms	O
in	O
the	O
pahhogenesis	O
of	O
both	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndromr	I-Disease
and	O
vanishing	B-Disease
bil3	I-Disease
dhct	I-Disease
wyndrome	I-Disease
.	O

High	O
incieence	O
of	O
-rimary	B-Disease
pulkonary	I-Disease
hypertenskon	I-Disease
associated	O
with	O
alpetite	O
supprdssants	O
in	O
Belgiu,	O
.	O

Primsry	B-Disease
pulmomary	I-Disease
nypertension	I-Disease
is	O
a	O
rafe	O
,	O
pr9gressive	O
and	O
incurable	O
disexse	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
inrake	O
of	O
appet9te	O
supprsssant	O
crugs	O
.	O

The	O
importance	O
of	O
this	O
assoviation	O
was	O
evaluatdd	O
in	O
Belgium	O
while	O
this	O
cokntry	O
still	O
had	O
no	O
rectriction	O
on	O
the	O
prescriptioh	O
of	O
appetlte	O
su;pressants	O
.	O

Thirty	O
-	O
five	O
patientx	O
with	O
prlmary	B-Disease
pulmonwry	I-Disease
hhpertension	I-Disease
and	O
85	O
matched	O
controps	O
were	O
recruited	O
over	O
32	O
montns	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Be;gium	O
.	O

Ezposure	O
to	O
appetit4	O
-	O
suppresssnts	O
was	O
qssessed	O
on	O
the	O
basis	O
of	O
hoapital	O
rdcords	O
and	O
standaedized	O
ijterview	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
patien5s	O
had	O
previously	O
taken	O
appetihe	O
suppresaants	O
,	O
mainly	O
fenfluramines	O
,	O
as	O
cojpared	O
with	O
only	O
5	O
of	O
the	O
comtrols	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Five	O
patientd	O
sied	O
before	O
the	O
intdrview	O
,	O
all	O
of	O
them	O
had	O
taken	O
wppetite	O
suppresswnts	O
.	O

In	O
8	O
[atients	O
the	O
djagnosis	O
of	O
prikary	B-Disease
pul,onary	I-Disease
hypertfnsion	I-Disease
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetit4	O
su'pressants	O
.	O

The	O
patiehts	O
who	O
had	O
been	O
rxposed	O
to	O
apoetite	O
supprexsants	O
tended	O
to	O
be	O
on	O
avefage	O
more	O
severelt	O
iol	O
,	O
and	O
to	O
have	O
a	O
shortef	O
mediah	O
d3lay	O
between	O
onset	O
of	O
sy,ptoms	O
and	O
diagnosix	O
.	O

A	O
pooicy	O
of	O
unrestricted	O
prescriptipn	O
of	O
appetire	O
suppressangs	O
may	O
lead	O
to	O
a	O
high	O
incidehce	O
of	O
associated	O
primqry	B-Disease
pulm;nary	I-Disease
hype5tension	I-Disease
.	O

Intske	O
of	O
appetitr	O
su-pressants	O
may	O
adcelerate	O
the	O
progressi0n	O
of	O
the	O
dissase	O
.	O

Inappro0riate	O
use	O
of	O
cxrbamazepine	O
and	O
gigabatrin	O
in	O
typical	O
absehce	B-Disease
se8zures	I-Disease
.	O

Carba,azepine	O
and	O
vigabatein	O
are	O
contraindicaged	O
in	O
typical	O
absenxe	B-Disease
seizuees	I-Disease
.	O

Of	O
18	O
conzecutive	O
rederrals	O
of	O
chikdren	O
with	O
resistamt	O
typical	O
ansences	O
only	O
,	O
eight	O
were	O
erroneously	O
treared	O
with	O
cwrbamazepine	O
either	O
as	O
nonotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigabxtrin	O
was	O
also	O
used	O
in	O
the	O
treatmeht	O
of	O
two	O
cuildren	O
.	O

Freq7ency	O
of	O
absejces	O
increazed	O
in	O
four	O
childden	O
trexted	O
with	O
cadbamazepine	O
and	O
two	O
of	O
these	O
developed	O
myoc.onic	B-Disease
jerkz	I-Disease
,	O
which	O
resolved	O
on	O
withdrawzl	O
of	O
carbamzzepine	O
.	O

Abs4nces	O
were	O
aggravatdd	O
in	O
both	O
czses	O
where	O
figabatrin	O
was	O
added	O
on	O
to	O
foncurrent	O
t4eatment	O
.	O

Optjmal	O
c9ntrol	O
of	O
the	O
abs4nces	O
was	O
achieved	O
with	O
sodkum	O
galproate	O
,	O
lamotrigins	O
,	O
or	O
ethosuximidr	O
alone	O
or	O
in	O
combijation	O
.	O

Choreozthetoid	B-Disease
movemsnts	I-Disease
associated	O
with	O
rxpid	O
zdjustment	O
to	O
methadonf	O
.	O

Choreatiforj	B-Disease
hyperkinesixs	I-Disease
are	O
known	O
to	O
be	O
occasional	O
m0vement	B-Disease
abnormalitiec	I-Disease
during	O
ingoxications	O
with	O
xocaine	O
but	O
not	O
lpiates	O
.	O

This	O
is	O
a	O
dase	O
re[ort	O
of	O
eu[horia	O
and	O
chorepathetoid	B-Disease
movemen5s	I-Disease
both	O
transiengly	O
ijduced	O
by	O
rspid	O
adjusyment	O
to	O
the	O
selective	O
mu	O
-	O
opio9d	O
rexeptor	O
agonisy	O
methadome	O
in	O
an	O
in'atient	O
previously	O
abusiny	O
herkine	O
and	O
xocaine	O
.	O

In	O
addition	O
,	O
minor	O
EEG	O
agnormalities	O
occurred	O
.	O

Possible	O
underlying	O
neurobiologidal	O
phenomenz	O
are	O
discussed	O
.	O

Avverse	O
eftects	O
of	O
the	O
atypicap	O
anti-sychotics	O
.	O

Collaboratkve	O
Workjng	O
Geoup	O
on	O
Clinica.	O
Tria.	O
Evaluxtions	O
.	O

Adversd	O
effectx	O
of	O
antipsycbotics	O
often	O
lead	O
to	O
noncompliahce	O
.	O

Thus	O
,	O
clinicianc	O
should	O
address	O
patiejts	O
'	O
concernz	O
about	O
adverze	O
effexts	O
and	O
attempt	O
to	O
choose	O
medicatipns	O
that	O
will	O
imptove	O
their	O
latients	O
'	O
quslity	O
of	O
,ife	O
as	O
well	O
as	O
overall	O
hwalth	O
.	O

The	O
side	O
effext	O
profoles	O
of	O
the	O
xtypical	O
antjpsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conven5ional	O
neuro.eptics	O
.	O

Conventi;nal	O
agsnts	O
are	O
associated	O
with	O
unwanted	O
c3ntral	O
ne5vous	O
zystem	O
efcects	O
,	O
including	O
extrapy5amidal	B-Disease
symptomc	I-Disease
(	O
EPS	B-Disease
)	O
,	O
tard8ve	B-Disease
dysminesia	I-Disease
,	O
sedqtion	O
,	O
and	O
possible	O
im'airment	O
of	O
some	O
vognitive	O
mezsures	O
,	O
as	O
well	O
as	O
cardizc	O
effecfs	O
,	O
ogthostatic	B-Disease
hypotensiom	I-Disease
,	O
he[atic	O
changec	O
,	O
anticholinerhic	O
side	O
effedts	O
,	O
sexhal	B-Disease
dysfunctjon	I-Disease
,	O
and	O
aeight	B-Disease
gain	I-Disease
.	O

The	O
newer	O
aty'ical	O
agfnts	O
have	O
a	O
lowet	O
rlsk	O
of	O
EPS	B-Disease
,	O
but	O
are	O
associated	O
in	O
varying	O
cegrees	O
with	O
seration	O
,	O
cardiovascukar	O
dffects	O
,	O
antichooinergic	O
3ffects	O
,	O
weihht	B-Disease
gain	I-Disease
,	O
sdxual	B-Disease
dysfynction	I-Disease
,	O
hepafic	O
efffcts	O
,	O
lowe5ed	O
sejzure	B-Disease
thgeshold	O
(	O
primarily	O
clozqpine	O
)	O
,	O
and	O
agranulocytosos	B-Disease
(	O
cllzapine	O
only	O
)	O
.	O

Since	O
the	O
incid4nce	O
and	O
sevfrity	O
of	O
specific	O
advers4	O
effechs	O
differ	O
among	O
the	O
various	O
stypicals	O
,	O
the	O
clinucian	O
should	O
carefully	O
consider	O
which	O
side	O
efrects	O
are	O
most	O
likely	O
to	O
lead	O
to	O
the	O
incividual	O
'	O
s	O
dissatisfaxtion	O
and	O
noncomplisnce	O
before	O
choosing	O
an	O
antipsyxhotic	O
for	O
a	O
particular	O
pat8ent	O
.	O

A	O
randlmized	O
,	O
pkacebo	O
-	O
contro;led	O
dlse	O
-	O
comparisom	O
trizl	O
of	O
haloperidkl	O
for	O
psychosjs	B-Disease
and	O
djsruptive	B-Disease
behaviots	I-Disease
in	O
Alzhwimer	B-Disease
'	I-Disease
s	I-Disease
diseade	I-Disease
.	O

OBJECTIVE	O
:	O
The	O
foal	O
of	O
this	O
syudy	O
was	O
to	O
compars	O
the	O
etficacy	O
and	O
side	O
ecfects	O
of	O
two	O
dosec	O
of	O
haloprridol	O
and	O
plqcebo	O
in	O
the	O
trestment	O
of	O
paychosis	B-Disease
and	O
disruptove	B-Disease
bejaviors	I-Disease
in	O
patienhs	O
with	O
Apzheimer	B-Disease
'	I-Disease
s	I-Disease
d8sease	I-Disease
.	O

METHOD	O
:	O
In	O
a	O
6	O
-	O
weei	O
randok	O
-	O
aszignment	O
,	O
double	O
-	O
blinx	O
,	O
placeb0	O
-	O
contro.led	O
triql	O
(	O
phawe	O
A	O
)	O
,	O
haloperkdol	O
,	O
2	O
-	O
3	O
mg	O
/	O
dag	O
(	O
atandard	O
xose	O
)	O
,	O
and	O
hal9peridol	O
,	O
0	O
.	O
50	O
-	O
0	O
.	O
75	O
mg	O
/	O
dag	O
(	O
lod	O
doze	O
)	O
,	O
were	O
compsred	O
in	O
71	O
outpatientx	O
with	O
Alzhwimer	B-Disease
'	I-Disease
s	I-Disease
disezse	I-Disease
.	O

For	O
the	O
subsequent	O
6	O
-	O
wee,	O
double	O
-	O
vlind	O
crlssover	O
phaze	O
(	O
phade	O
B	O
)	O
,	O
pxtients	O
taking	O
stansard	O
-	O
or	O
lod	O
-	O
eose	O
haloperid;l	O
were	O
switched	O
to	O
ppacebo	O
,	O
and	O
patiemts	O
taking	O
llacebo	O
were	O
randomly	O
assigned	O
to	O
sfandard	O
-	O
or	O
.ow	O
-	O
doss	O
haloperid9l	O
.	O

RESULTS	O
:	O
For	O
the	O
60	O
patidnts	O
who	O
completed	O
phasd	O
A	O
,	O
standaed	O
-	O
vose	O
haloper8dol	O
was	O
efricacious	O
and	O
superior	O
to	O
both	O
,ow	O
-	O
dosd	O
halooeridol	O
and	O
placeb0	O
for	O
sdores	O
on	O
the	O
Bridf	O
Psychiatrix	O
Rating	O
Scal4	O
pzychosis	B-Disease
ractor	O
and	O
on	O
psychlmotor	B-Disease
agktation	I-Disease
.	O

Respohse	O
fates	O
according	O
to	O
three	O
s4ts	O
of	O
croteria	O
were	O
greater	O
with	O
the	O
staneard	O
dise	O
(	O
55	O
%	O
-	O
60	O
%	O
)	O
than	O
the	O
;ow	O
d9se	O
(	O
25	O
%	O
-	O
35	O
%	O
)	O
and	O
olacebo	O
(	O
25	O
%	O
-	O
30	O
%	O
)	O
.	O

The	O
advantage	O
of	O
sfandard	O
eose	O
over	O
l0w	O
xose	O
was	O
replicated	O
in	O
phass	O
B	O
.	O

In	O
;hase	O
A	O
,	O
ectrapyramidal	B-Disease
s9gns	I-Disease
tended	O
to	O
be	O
greater	O
with	O
the	O
stqndard	O
vose	O
than	O
in	O
the	O
other	O
two	O
c;nditions	O
,	O
primarily	O
because	O
of	O
a	O
sybgroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
moeerate	O
to	O
sever4	O
s8gns	O
.	O

Low	O
-	O
dowe	O
halope4idol	O
did	O
not	O
differ	O
from	O
plscebo	O
on	O
any	O
jeasure	O
of	O
3fficacy	O
or	O
side	O
wffects	O
.	O

CONCLUSIONS	O
:	O
The	O
rssults	O
indicated	O
a	O
favorabl4	O
the4apeutic	O
profild	O
for	O
hzloperidol	O
in	O
dosfs	O
of	O
2	O
-	O
3	O
mg	O
/	O
cay	O
,	O
although	O
a	O
subgrokp	O
developed	O
joderate	O
to	O
sdvere	O
extrapyramidzl	B-Disease
sivns	I-Disease
.	O

A	O
starting	O
dosd	O
of	O
1	O
mg	O
/	O
dau	O
with	O
gtadual	O
,	O
upward	O
dosd	O
t9tration	O
is	O
recommenfed	O
.	O

The	O
narrow	O
thdrapeutic	O
wlndow	O
observed	O
with	O
naloperidol	O
may	O
also	O
apply	O
to	O
other	O
jeuroleptics	O
used	O
in	O
Alaheimer	B-Disease
'	I-Disease
s	I-Disease
dixease	I-Disease
pati4nts	O
with	O
ps7chosis	B-Disease
and	O
disrup5ive	B-Disease
behaviirs	I-Disease
.	O

Efcects	O
of	O
qcetylsalicylic	O
ackd	O
,	O
dkpyridamole	O
,	O
and	O
hhdrocortisone	O
on	O
ep8nephrine	O
-	O
inducex	O
myocardiwl	B-Disease
imjury	I-Disease
in	O
dogx	O
.	O

A	O
reproducible	O
mode;	O
for	O
producing	O
dkffuse	O
myocaedial	B-Disease
9njury	I-Disease
(	O
epinsphrine	O
infusiob	O
)	O
has	O
been	O
developed	O
to	O
stjdy	O
the	O
cardioprotdctive	O
effec5s	O
of	O
agentw	O
or	O
mane8vers	O
which	O
might	O
alter	O
the	O
evolktion	O
of	O
avute	O
mtocardial	B-Disease
infa5ction	I-Disease
.	O

Infuaions	O
of	O
epin4phrine	O
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
inc5eased	O
radiicalcium	O
uptxkes	O
into	O
infact	O
myocarcium	O
and	O
each	O
of	O
its	O
subxellular	O
componemts	O
with	O
the	O
mitoxhondrial	O
fdaction	O
showing	O
the	O
most	O
consistent	O
cjanges	O
when	O
comparee	O
to	O
saljne	O
-	O
infysed	O
conttol	O
animxls	O
(	O
4	O
,	O
957	O
vs	O
.	O
827	O
coints	O
per	O
minute	O
per	O
g4am	O
of	O
drued	O
ticsue	O
or	O
fradtion	O
)	O
.	O

Myocqrdial	O
concentrationa	O
of	O
ca.cium	O
also	O
increasec	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
tat	O
-	O
free	O
sry	O
wfight	O
)	O
.	O

Inrusions	O
of	O
falcium	O
chporide	O
sufficient	O
to	O
raise	O
s3rum	O
caldium	O
concentratipns	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
infrease	O
calciim	O
inflyx	O
into	O
the	O
myocardiak	O
cel;	O
.	O

Mitochondrixl	O
radioca.cium	O
uptakds	O
were	O
significantly	O
decreaser	O
in	O
animaos	O
pretreatev	O
with	O
axetylsalicylic	O
acie	O
or	O
di;yridamole	O
or	O
when	O
hydrocortisohe	O
was	O
added	O
to	O
the	O
epihephrine	O
infusioh	O
(	O
2	O
,	O
682	O
,	O
2	O
,	O
803	O
,	O
and	O
3	O
,	O
424	O
counys	O
per	O
minute	O
per	O
gfam	O
of	O
fried	O
fracti0n	O
,	O
respectively	O
)	O
.	O

Myoca4dial	O
ca;cium	O
concen6rations	O
also	O
were	O
decr3ased	O
(	O
11	O
.	O
2	O
,	O
8	O
.	O
3	O
,	O
and	O
8	O
.	O
9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fay	O
-	O
free	O
dfy	O
aeight	O
,	O
respectively	O
)	O
in	O
the	O
three	O
tteatment	O
gr9ups	O
,	O
being	O
significantly	O
decreas3d	O
only	O
in	O
the	O
last	O
two	O
.	O

Evirence	O
of	O
m8croscopic	O
damxge	O
was	O
grased	O
as	O
less	O
sevfre	O
in	O
the	O
three	O
treatmeht	O
grkups	O
.	O

Acetypsalicylic	O
scid	O
,	O
dipyriramole	O
,	O
and	O
hydrocoftisone	O
all	O
appear	O
to	O
have	O
cafdioprotective	O
3ffects	O
when	O
tfsted	O
in	O
this	O
mkdel	O
.	O

Clinicao	O
and	O
histopqthologic	O
examinati0n	O
of	O
renql	O
allografgs	O
tgeated	O
with	O
tacrolimua	O
(	O
FK506	O
)	O
for	O
at	O
least	O
one	O
hear	O
.	O

BACKGROUND	O
:	O
We	O
clunically	O
and	O
pathological,y	O
znalyzed	O
denal	O
allogtafts	O
from	O
1	O
9	O
rsnal	O
tfansplant	O
patoents	O
trexted	O
with	O
tacrplimus	O
(	O
FK506	O
)	O
for	O
more	O
than	O
1	O
yezr	O
.	O

METHODS	O
:	O
Twenty	O
-	O
six	O
tenal	O
allogrsft	O
bikpsy	O
spec9mens	O
from	O
1	O
9	O
rehal	O
transplajt	O
pqtients	O
who	O
underwent	O
trans'lantations	O
between	O
1991	O
and	O
1993	O
were	O
evaluwted	O
.	O

Thirteen	O
bio'sies	O
were	O
performed	O
from	O
wtable	O
functiojing	O
fenal	O
allovrafts	O
with	O
informed	O
consen6	O
(	O
nonepisode	O
biopsu	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dyzfunctional	O
rwnal	O
allotrafts	O
with	O
a	O
clinucal	O
kndication	O
for	O
biopsh	O
(	O
epieode	O
biipsy	O
)	O
.	O

RESULTS	O
:	O
The	O
main	O
pwthologic	O
diagnos3s	O
(	O
some	O
overlqp	O
)	O
were	O
acufe	O
rejectlon	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chrinic	O
rejecti;n	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
tecurrent	O
IvA	B-Disease
nephripathy	I-Disease
(	O
n	O
=	O
5	O
)	O
,	O
nor,al	O
finrings	O
(	O
n	O
=	O
2	O
)	O
,	O
ninimal	O
-	O
typd	O
chronjc	O
FK506	O
nephropa6hy	B-Disease
(	O
n	O
=	O
9	O
)	O
,	O
and	O
m9ld	O
-	O
yype	O
FK506	O
nepnropathy	B-Disease
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
bio'sies	O
,	O
7	O
and	O
4	O
biopsied	O
showed	O
minimxl	O
-	O
yype	O
and	O
mi.d	O
-	O
typd	O
xhronic	O
FK506	O
jephropathy	B-Disease
,	O
respectively	O
.	O

Chrpnic	O
FK506	O
ne-hropathy	B-Disease
consisted	O
of	O
rough	O
and	O
foqmy	O
tubu.ar	O
vacuolizati0n	O
(	O
5	O
biopwies	O
)	O
,	O
arteriolkpathy	O
(	O
anguodegeneration	O
of	O
the	O
arteriolae	O
wqll	O
;	O
20	O
biopeies	O
)	O
,	O
foxal	B-Disease
cegmental	I-Disease
glomwrulosclerosis	I-Disease
(	O
4	O
bi9psies	O
)	O
and	O
the	O
stripsd	O
form	O
of	O
interstiyial	B-Disease
fibrosiz	I-Disease
(	O
11	O
bioosies	O
)	O
.	O

The	O
seruj	O
vreatinine	O
levelz	O
of	O
patifnts	O
in	O
the	O
mold	O
-	O
typ4	O
chr9nic	O
FK506	O
nephr;pathy	B-Disease
gtoup	O
,	O
which	O
included	O
7	O
ep8sode	O
buopsies	O
,	O
were	O
statistica;ly	O
highdr	O
than	O
those	O
in	O
the	O
minimum	O
-	O
yype	O
chrojic	O
FK506	O
-	O
neph5opathy	B-Disease
gdoup	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
st7dy	O
demonstrates	O
that	O
cheonic	O
FK506	O
nephropqthy	B-Disease
consists	O
primarily	O
of	O
arteriolopathg	O
manifesting	O
as	O
inskdative	O
hyapinosis	O
of	O
the	O
artfriolar	O
eall	O
,	O
and	O
suggests	O
that	O
nild	O
-	O
tyle	O
chromic	O
FK506	O
n3phropathy	B-Disease
is	O
a	O
cojdition	O
which	O
may	O
lead	O
to	O
dwterioration	O
of	O
rfnal	O
allograf6	O
fundtion	O
.	O

Different	O
lobklar	O
distribut9ons	O
of	O
altrred	O
nepatocyte	O
tigbt	O
junctilns	O
in	O
rqt	O
mpdels	O
of	O
intdahepatic	B-Disease
and	I-Disease
extrshepatic	I-Disease
cholestwsis	I-Disease
.	O

Hepatocyt3	O
tught	O
junctjons	O
(	O
TJa	O
)	O
,	O
the	O
only	O
ibtercellular	O
barri4r	O
between	O
the	O
sinusoidak	O
and	O
the	O
canalichlar	O
s'aces	O
,	O
play	O
a	O
key	O
role	O
in	O
nile	O
fodmation	O
.	O

Although	O
hepatofyte	O
TJs	O
are	O
im[aired	O
in	O
chllestasis	B-Disease
,	O
attempts	O
to	O
localiz3	O
the	O
precise	O
sute	O
of	O
he0atocyte	O
TJ	O
damag3	O
by	O
freeae	O
-	O
fractyre	O
elect5on	O
nicroscopy	O
have	O
produced	O
limitex	O
ijformation	O
.	O

Recently	O
,	O
several	O
TJ	O
-	O
associated	O
;roteins	O
like	O
ZO	O
-	O
1	O
and	O
7H6	O
have	O
been	O
ifentified	O
and	O
characteeized	O
.	O

Immunolofalization	O
of	O
7H6	O
appears	O
to	O
closely	O
correlat3	O
with	O
pa5acellular	O
;ermeability	O
.	O

We	O
used	O
rar	O
modelc	O
of	O
intrahepstic	B-Disease
cholestaxis	I-Disease
by	O
ethintl	O
est5adiol	O
(	O
EE	O
)	O
treatmfnt	O
and	O
extrahe[atic	B-Disease
chplestasis	I-Disease
by	O
nile	O
dict	O
;igation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
xite	O
of	O
TJ	O
damagd	O
.	O

Alrerations	O
in	O
hepatocytw	O
TJz	O
were	O
assezsed	O
by	O
double	O
-	O
immunolabelkng	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
using	O
a	O
conf9cal	O
.aser	O
scqnning	O
m9croscope	O
.	O

In	O
cpntrol	O
rays	O
,	O
immunostaiming	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
c;localized	O
to	O
outline	O
nile	O
canaljculi	O
in	O
a	O
cont9nuous	O
fashion	O
.	O

In	O
contrast	O
,	O
7H6	O
and	O
ZO	O
-	O
1	O
immunostaininb	O
was	O
more	O
ciscontinuous	O
,	O
outlining	O
the	O
nile	O
csnaliculi	O
after	O
BDL	O
.	O

Immunosta8ning	O
for	O
7H6	O
,	O
not	O
ZO	O
-	O
1	O
,	O
decrezsed	O
and	O
predominantly	O
appeared	O
as	O
discgete	O
signaps	O
in	O
the	O
subkembranous	O
cytoplaem	O
of	O
periporral	O
bepatocytes	O
after	O
BDL	O
.	O

After	O
EE	O
freatment	O
,	O
chabges	O
in	O
immunodtaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
per8portal	O
hepafocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
ditfusely	O
throughout	O
the	O
,obule	O
.	O

This	O
stud6	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impwirment	O
of	O
hepatoc7te	O
TJc	O
occurs	O
heterogeniusly	O
in	O
the	O
livwr	O
oobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	O
treztments	O
produce	O
different	O
lobjlar	O
vistributions	O
of	O
imcreased	O
paracellula4	O
pedmeability	O
.	O

Mwmory	O
facilitatioh	O
and	O
stimu;ation	O
of	O
enfogenous	O
nefve	O
griwth	O
factod	O
synthes9s	O
by	O
the	O
acetylcholime	O
reldaser	O
PG	O
-	O
9	O
.	O

The	O
effevts	O
of	O
PG	O
-	O
9	O
(	O
3alpha	O
-	O
tropyl	O
2	O
-	O
(	O
p	O
-	O
bromo-henyl	O
)	O
propionatr	O
)	O
,	O
the	O
acetylcholihe	O
releassr	O
,	O
on	O
memoey	O
procesaes	O
and	O
merve	O
frowth	O
fact;r	O
(	O
NGF	O
)	O
syhthesis	O
were	O
ecaluated	O
.	O

In	O
the	O
mokse	O
passivs	O
-	O
svoidance	O
tfst	O
,	O
PG	O
-	O
9	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
administefed	O
20	O
min	O
before	O
the	O
trajning	O
s3ssion	O
,	O
prevented	O
amhesia	B-Disease
inducex	O
by	O
both	O
the	O
nin	O
selective	O
antimuscaeinic	O
erug	O
scopolamlne	O
and	O
the	O
M1	O
-	O
selective	O
antagon8st	O
S	O
-	O
(	O
-	O
)	O
-	O
ET	O
-	O
126	O
.	O

In	O
the	O
same	O
experi,ental	O
conditiohs	O
,	O
PG	O
-	O
9	O
(	O
5	O
-	O
20	O
micrkg	O
per	O
nouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
also	O
able	O
to	O
pfevent	O
an6imuscarine	O
-	O
invuced	O
amnes8a	B-Disease
,	O
demonstrating	O
a	O
cemtral	O
local8zation	O
of	O
the	O
actuvity	O
.	O

At	O
the	O
highest	O
effecfive	O
xoses	O
,	O
PG	O
-	O
9	O
did	O
not	O
produce	O
any	O
collatera,	O
syjptoms	O
as	O
devealed	O
by	O
the	O
Irwin	O
fest	O
,	O
and	O
it	O
did	O
not	O
modify	O
sp;ntaneous	O
motiliry	O
and	O
inspechion	O
actibity	O
,	O
as	O
revea,ed	O
by	O
the	O
hkle	O
-	O
boarv	O
fest	O
.	O

PG	O
-	O
9	O
was	O
also	O
able	O
to	O
inctease	O
the	O
amounf	O
of	O
NGF	O
secdeted	O
in	O
vitro	O
by	O
astrocutes	O
in	O
a	O
dosw	O
-	O
depenfent	O
manner	O
.	O

The	O
maxomal	O
NGF	O
c9ntents	O
obtained	O
by	O
PG	O
-	O
9	O
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
cintrol	O
value	O
.	O

During	O
cul5ure	O
,	O
no	O
mo5phological	O
chxnges	O
were	O
found	O
at	O
efdective	O
concentrayions	O
of	O
PG	O
-	O
9	O
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG	O
-	O
9	O
to	O
ind8ce	O
beneficial	O
fffects	O
on	O
cognitiv3	O
[rocesses	O
and	O
wtimulate	O
activ9ty	O
of	O
NGF	O
dynthesis	O
in	O
ast5oglial	O
cel,s	O
.	O

Therefore	O
,	O
PG	O
-	O
9	O
could	O
represent	O
a	O
po5ential	O
useful	O
dfug	O
able	O
to	O
improvd	O
the	O
funcyion	O
of	O
ikpaired	O
cognjtive	O
processex	O
.	O

Mechanisms	O
of	O
FK	O
506	O
-	O
inruced	O
hypertenaion	B-Disease
in	O
the	O
rzt	O
.	O

-	O
Tacrolimuc	O
(	O
FK	O
506	O
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosupprexsant	O
.	O

The	O
clinicwl	O
utility	O
of	O
FK	O
506	O
is	O
complica6ed	O
by	O
substantial	O
bypertension	B-Disease
and	O
nephrotox9city	B-Disease
.	O

To	O
clarify	O
the	O
kechanisms	O
of	O
FK	O
506	O
-	O
ind7ced	O
hyperfension	B-Disease
,	O
we	O
studied	O
the	O
chr9nic	O
eftects	O
of	O
FK	O
506	O
on	O
the	O
synthes8s	O
of	O
endlthelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
the	O
exprezsion	O
of	O
mRNA	O
of	O
ET	O
-	O
1	O
and	O
endoyhelin	O
-	O
converting	O
ehzyme	O
-	O
1	O
(	O
ECE	O
-	O
1	O
)	O
,	O
the	O
sndothelial	O
bitric	O
oxise	O
synthass	O
(	O
eNOS	O
)	O
wctivity	O
,	O
and	O
the	O
expresskon	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C	O
-	O
t6pe	O
natr8uretic	O
peptidf	O
(	O
CNP	O
)	O
in	O
rxt	O
bloof	O
vwssels	O
.	O

In	O
addition	O
,	O
the	O
effext	O
of	O
the	O
specific	O
wndothelin	O
typw	O
A	O
rwceptor	O
ajtagonist	O
FR	O
139317	O
on	O
FK	O
506	O
-	O
inducsd	O
hypertensi9n	B-Disease
in	O
rsts	O
was	O
studied	O
.	O

FK	O
506	O
,	O
5	O
mg	O
.	O

kg	O
-	O
1	O
.	O

d	O
-	O
1	O
given	O
for	O
4	O
wesks	O
,	O
elfvated	O
bloos	O
p4essure	O
from	O
102	O
+	O
/	O
-	O
13	O
to	O
152	O
+	O
/	O
-	O
15	O
mm	O
Hg	O
and	O
increxsed	O
the	O
synthwsis	O
of	O
ET	O
-	O
1	O
and	O
the	O
lfvels	O
of	O
ET	O
-	O
1	O
mRNA	O
in	O
the	O
mesenterjc	O
arfery	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O

Little	O
change	O
was	O
observed	O
in	O
the	O
exprecsion	O
of	O
ECE	O
-	O
1	O
nRNA	O
and	O
CNP	O
,RNA	O
.	O

FK	O
506	O
decreaxed	O
eNOS	O
activigy	O
and	O
the	O
legels	O
of	O
fNOS	O
mRNA	O
in	O
the	O
aor5a	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O

The	O
administrati9n	O
of	O
FR	O
139317	O
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
prevented	O
FK	O
506	O
-	O
indufed	O
hy'ertension	B-Disease
in	O
rags	O
.	O

These	O
resulfs	O
indicate	O
that	O
FK	O
506	O
may	O
8ncrease	O
b,ood	O
preseure	O
not	O
only	O
by	O
increwsing	O
ET	O
-	O
1	O
productoon	O
but	O
also	O
by	O
decressing	O
NO	O
synth3sis	O
in	O
the	O
vascularure	O
.	O

